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Abstract
Parasitic diseases such as Human African Trypanosomiasis (HAT), Chagas disease and Leish-
maniasis cause thousands of fatalities each year. Current chemotherapy is based on drugs
discovered over 60 years ago that are expensive and difficult to administer. The drug-pipeline
is virtually dry and the trickle of inhibitors that are in development are largely based on those
that are already in use. Parasite resistance to these drugs is developing, underlining the urgent
need for novel anti-parasitic drug therapies.
This study focused on the identification of novel small molecular inhibitors with anti-parasitic
activities against Trypanosoma brucei spp. (HAT), Trypanosoma cruzi spp. (Chagas disease)
and Leishmania infantum spp. (Leishmaniasis) with a particular focus on combining broad-
spectrum activity with parasite-specificity.
A two-pronged approach was used to develop an effective chemotherapy through the op-
timisation of known inhibitors of glycophosphatidylinositol (GPI)-anchor biosynthesis and im-
proving the specificity of iron chelators.
GPI anchor biosynthesis is a pathway essential for survival to all three parasites. Here, a
rhodanine-N-acetic acid derivative served as the starting point for the development of a library
of 379 thiazolidine-4-one and pyrazolone analogues. These were systematically screened
against three species of parasitic protozoa and a mammalian cell line in order to identify in-
hibitors which demonstrate low-µM anti-parasitic activity and a good selectivity profile.
Further target identification studies on the effect of these new inhibitors using in vitro as-
says confirmed inhibition of GPI anchor biosynthesis as a mode of action. This provides further
evidence that the GPI anchor is a druggable target for the development of novel anti-parasitic
agents against T. brucei, T. cruzi and L. infantum. Taken together, this work indicates that
drugs targeting one feature common to all three protozoa can provide anti-parasitic activity
with low toxicity against mammalian cells.
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1 Introduction
1.1 Parasitic diseases
Neglected parasitic diseases such as Human African Trypanosomiasis (HAT), Chagas dis-
ease and Leishmaniasis are major health threats in significant areas of the population. [1]
People affected by these parasites live mainly in the developing countries, resulting in major
health threats, as most of these diseases are fatal if untreated. [2–4] Combined, these diseases
threaten a total of 500,000 million people worldwide, of which 20 million people are actually in-
fected, and more than 100,000 of whom die annually due to diseases caused by Trypanosoma
brucei spp. (T. brucei), Trypanosoma cruzi sp. (T. cruzi) and Leishmania sp. [2–7] The current
chemotherapy is based on drugs discovered over 60 years ago to which resistance is develop-
ing. [1] The drug-pipeline is virtually empty and new drugs in development are mostly based on
established drugs, that are expensive and difficult to administer. [8–12] There is an urgent need
for new and novel anti-parasitic drug therapies.
These tropical parasitic diseases are caused by kinetoplastid protozoan parasites, such
as Trypanosoma spp. and Leishmania spp., which are characterised by the presence of mi-
tochondrial DNA contained within a kinetoplast. [13] These parasites are well adapted to the
biological environment in their hosts and have evolved different strategies to ensure survival
and rapid propagation by binary fission. [13] A particularly interesting feature is a highly dec-
orated plasma membrane that is essential for the survival of these parasites. [13] Due to sim-
ilarities in cellular biology, it is not surprising that recent genomic data showed that out of
8,000 genes in each kinetoplastid genome, more than 6,000 orthologous genes have been
found in Trypanosoma brucei, Trypanosoma cruzi and Leishmania infantum. [13] Despite these
similarities, each of these kinteplastid protozoa cause distinct human diseases transmitted by
different insect vectors. [13] Furthermore, all of these protozoa are found in different compart-
ments within their human host, complicating the discovery of a general treatment against these
parasites. [14]
T. b. gambiense and T. b. rhodesiense are the etiological origin of Human African Try-
panosomiasis (HAT). [3] In 2002, the combined fatality rate of Chagas disease and HAT was
estimated at 48,000 deaths. [3] After extensive efforts, both in vector control and patient surveil-
lance, the number of new infections has dropped below 10,000 (9878) people in 2009, with
7139 reported causes in 2010, but the actual number of infected people is estimated at 30,000,
all of whom will die from HAT if left untreated. [6] A total of 70 million people living in 36 sub-
Saharan countries are at risk of infection with HAT. [6] HAT is transmitted by the bite of an
infected tsetse fly, limiting the disease distribution to its breeding grounds. [6] Three particular
strains of T. brucei spread HAT and the animal disease Nagana; T. b. gambiense causes the
1
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severe chronic disease in human, whereas T. b. rhodesiense is responsible for the acute dis-
ease. [6] T. b. brucei is the etiological agent for animal trypanosomiasis (Nagana disease) in
domestic animals like cattle, with huge economical consequences for the country. [6] However,
animal infection by T. b. rhodesiense has also been reported and plays an essential role as a
parasite reservoir in the distribution of HAT. [15] T. b. brucei is morphologically indistinguishable
to T. b. gambiense and T. b. rhodesiense, the parasites causing HAT in humans, so serves
as a model for HAT. [16] HAT presents itself in two stages; in the first stage trypanosomes infect
subcutaneous tissue, blood and lymph, resulting in fever, joint pain and itching. [5] In the second
stage, the parasites penetrate the blood brain barrier, causing infection of the central nervous
system and manifesting neurological and psychiatric disorders, including the disturbance of
the sleep cycle, hence this disease is also known as african sleeping sickness. [5]
Chagas disease is caused by the parasite T. cruzi and is transmitted through the faeces of
an infected triatomine bug, which is involuntary smeared in bite wounds, mouth or eyes. [2] Con-
taminated food, blood transfusions, organ transplantations, passage from mother to newborn
and lab accidents are further transmission routes. [2] In the human host, T. cruzi trypomastig-
otes infect human cells, where they transform to amastigotes in order to reproduce by binary
fission. [17] Chagas disease is endemic in 26 Latin American countries, putting 25 million people
at risk of infection, of which 10 million people are estimated to be currently infected, resulting
in death of 10,000 people in 2008. [2,5] Chagas disease is curable if treatment is commenced
shortly after infection (2 months), however disease diagnosis is difficult, resulting in chronic
infection where patients develop cardiac and neurological alterations (30 % and 10 % of pa-
tients, respectively). [2] For many of these patients a heart transplant is the last life-prolonging
measure,1 however infection of the new heart is likely to reoccur. In the first two months after
infection, patients commonly present mild fever and headaches, symptoms easily associated
with bacterial or viral infections. [2] However in 50 % of the cases, skin lesions around the bite
wound of the triatomine bug are observed in combination with a purplish swelling of one eye-
lid. [2] Chagas disease is not confined to Latin American, as cases have been reported in the
United States of America, Canada and even European and Western Pacific countries, how-
ever these cases are thought to be due to increased population mobility. [2] Nevertheless, the
outbreak of Chagas disease in non-endemic countries is considered as a serious public health
challenge. [5]
The parasite Leishmania sp. causes Leishmanisasis in humans and accounts for the ma-
jority of casualties reported by these three parasitic diseases. [4] Leishmania sp. causes death
in 51,000 people living in 88 countries around the world, affecting a total of 0.2 % of the worlds
population. An estimate of 12 million people are currently infected and 1.5-2 million individuals
are newly infected annually. [3,4,7] Overall 350 million people are at risk of infection worldwide. [13]
1personal communication with physicians at the heart transplantation centre in Sao Paulo, Brazil
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Leishmaniasis is caused by the bite of an infected female sandfly, [5] transmitting the promastig-
ote form of Leishmania spp. into the human host, where the parasite transforms into the
amastigote form and infects intracellular macrophages. [8] There are 23 species of Leishma-
nia spp., of which 20-21 species cause two forms of Leishmaniasis in humans. [13,18] Visceral
Leishmaniasis is the most severe form as the parasite is found in internal organs, causing
death within 2 years if untreated. [5] Cutaneous Leishmaniasis is the common form, causing
skin ulcers and in the worst case disfigurement by destruction of the soft tissue around the
nose, mouth and throat (mucocutaneous Leishmaniasis). [5] All Leishmania spp. show different
drug sensitivities and need different drug applications, making treatment extremely difficult. [8]
In this study only one of these 23 Leishmania spp., Leishmania infantum will be the focus
for development of anti-parasitic compounds. L. infantum belongs to the class of Leishmania
donovani, [19] causing the fatal visceral Leishmaniasis in humans. [8]
1.2 Current treatment for parasitic diseases
The current treatment of HAT, Chagas disease and Leishmaniasis is based on drugs which
were developed decades ago and are difficult to administer as well as causing severe side
effects. [8,20,21]
There are currently four drugs registered for the treatment of HAT, of which three were de-
veloped more than 60 years ago. [6] For the first stage of HAT infection with T. b. gambiense and
T. b. rhodiense, Pentamidine is the front line drug. [20] Pentamidine (Figure 1) has been widely
used and although resistance is shown to be inducible in laboratory strains, no resistance has
been observed during 60 years of clinical use. [20] Suramin (Figure 1) is an alternative first line
drug, but is of limited use due to its high affinity to proteins in blood plasma (resulting in unde-
sired pharmacokinetics), furthermore resistance has also been reported. [20] The treatment of
the second stage of HAT relies on the ability of the drug to penetrate the blood-brain barrier in
order to reach parasitic compartments in humans. [20] The first line treatment is the arsenical
drug Melarsoprol (Figure 1), administered parenterally it is able to treat both T. b. gambiense
and T. b. rhodiense infections, but unfortunately treatment is also very toxic and causes death
in 5 % of patients, showing symptoms similar to arsenic poisoning. [20,22] A more recent drug,
introduced in 1990 for the treatment of stage 2 HAT caused by T. b. gambiense is Eflornithine
(Figure 1) an irreversible inhibitor of ornithine decarboxylase. [20] However, the production of
Eflornithine is very expensive and administration via intravenous injection over a course of
14 days limits its use in rural Africa. [23] Since 2009, a combination therapy of Nifurtimox and
Eflornithine is in clinical use, benefiting from the oral availability and cheap production of Nifur-
timox. [20] Cross-resistance in particular against the chronic stage of HAT has been reported in
the treatment with Melarsoprol, leaving Eflornithine, which is difficult to administer under field
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Figure 1: Current drugs against first and late stage HAT.
conditions, as the last resort. [20]
The first line treatment against Chagas disease is vector control and the screening of blood
transfusions, which has reduced the number of people at risk of infection from 100 million to 40
million people in 2003. [21] Therapeutically, Chagas disease is treated with Benznidazole and
Nifurtimox (Figure 2) which has been reported to cure 100 % of patients in the early stage.
However these drugs are less effective against the chronic stage of the disease and the ad-
verse toxic side effects (CNS toxicity and peripheral neuropathy) outweigh their beneficial ef-
fect. [2,21] Benznidazole and Nifurtimox (Figure 3) belong to the class of nitro-heterocycles, com-
monly reported to be associated with mutagenicity. [24] Indeed Benznidazole has been shown
to induce mitotic recombination events in diploid strains of Aspergillus nidulans, whereas Ni-
furtimox tested positive for mutagenesis, based on somatic mutation and recombination tests
in Drosophila melanogaster and the bacterium Salmonella typhimurium. [24,25]
The first line treatment for Leishmaniasis, both visceral and cutaneous (mucocutaneous)
forms are the pentavalent antimonial drugs Pentostam and Meglumine antimoniate (Figure 3),
both administered by parenteral injection and introduced more than 50 years ago. [8] But,
4
1 Introduction
O
O-
O
N
N
N
N+
H
S
O O
O
O-
O
N
N
N+
Benznidazole Nifurtimox
Figure 2: Current drugs against acute and chronic Chagas disease.
widespread resistance against pentavalent antimonial drugs limit their use. [8] The antimicrobial
diamidine Pentamidine (Figure 1) is used as second line drug for these resistant strains, but is
of limited use due to its toxicity. [8]
The anti-fungal polyene antibiotic Amphotericin B (Figure 3) and its lipid-formulated Am-
Biosome are highly effective drugs against antimonial resistant visceral and mucocutaneous
Leishmaniasis, however its prolonged parenteral administration (up to 28 days) and the severe
side effects for amphotericin B (nephrotoxicity) restrict their application. [8]
1.3 Current drug development
The current drug treatments against HAT, Chagas disease and Leishmaniasis are unsatis-
factory, due to resistance and severe toxic side effects. [26] There is an urgent need for novel
anti-parasitic agents in order to treat these diseases and evade resistance to established drug
therapies. [26] In the years from 1975 to 1999 less than 1 % (13 drugs) of new chemical entities
released to the market (1393 drugs) were indicated for tropical diseases (Malaria, Leishmania-
sis, Lymphatic Filariasis, Chagas disease, and Schistosomiasis). [26] Economically this reflects
the lowest investment (10.1 % of $35.3 billion) for development of drugs against tropical dis-
eases by the pharmaceutical industry. [26] The private sector and government contributions
were as low as $70 million in 1999. [26] Despite the wealth of genetic information available (the
genomes of all three protozoa have been sequenced) there has been little improvement in
the field of anti-parasitic research. [26] After a long innovation gap in the development of drugs
to treat tropical diseases, non-profit public private partnership programmes between industry
and academia have been established. (e.g. Drugs for Neglected Diseases initiative (DNDi)
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http://www.dndi.org, Medicines for Malaria Venture (MMV): http://www.mmv.org). [1]2 There are
currently no vaccines against Leishmaniasis, Chagas disease or HAT and antigenic variation
in trypanosomes will make the prospect for vaccination very unlikely, leaving chemotherapy as
the only treatment. [7,22]
The current drug treatments against HAT are considered out-dated and unacceptable, as
many drugs were developed >60 years ago and Melarsoprol fatality rates are reported to be
as high as 5 %. [20] Currently only disease control by case detection and treatment prevent an
endemic outbreak of HAT. [27] In 2009, diamidine Pafuramidine (DB289), a derivative of Pen-
tamidine, was the first drug in clinical phase III for the second stage of HAT, until liver and
renal-toxicity discontinued its development. [28,29] The related aza-analogue DB829 is currently
in preclinical development, but already shows good oral availability and was able to cure a
central nervous system (CNS) mouse model of HAT (in vitro activity 19 nM, SI > 10,000). [12]
DB829 belongs to the class of diamidines, which are readily accumulated in mM concentra-
tions within DNA-containing organelles, such as the kinetoplast or nucleus, but accumulation
was observed in acidocalcisomes, suggesting DNA binding as possible mode-of-action, al-
though accumulation in other cell compartments could contribute to the trypanocidal activ-
ity. [30,31] Moreover, aza-analogues of furamidine have been shown to cross the blood-brain
barrier through an active transport. [32] Although this is also true for other pentamidine deriva-
tives, uptake studies have shown that the pyridine-nitrogens in DB829, slow down the efflux
transporter, which clears the drug from the cerebral fluid. [32] In September 2009, the nitroim-
2Personal communication with Xavier Ding, research scientist at MMV, Cancun, Mexiko
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idazole Fexinidazole (DNDi supported) entered first human phase I trials as drug against T.
b. gambiense and T. b. rhodesiense. [11] The orally available Fexinidazole (41 % oral availabil-
ity), a derivative of Megazol, [12,30] has shown nM activity in vitro (IC50 0.16-0.93µg/mL) and
in vivo (100 mg/day/kg over 4 days or 200 mg/day/kg for 5 days, 100 % cure rate in mice, in
vitro SI >100), with promising results against both drug-sensitive and drug-resistant strains
of T. brucei spp. [11,33] Metabolic studies in mice, rats, dogs and humans have identified two
active metabolites of Fexinidazole (a sulfoxide and sulfone), which are most likely responsible
for anti-trypanosomal activity . [11,34] Fexinidazole is not a new discovery, but a re-evaluation of
a drug shown to be mutagenic as shown by Ames tests in bacteria. [11] However, further muta-
genic evaluations on human lymphocytes, mouse bone marrow cells and ex vivo unscheduled
DNA synthesis in rats showed no genotoxicity. [11] The mechanism of action is unknown, but is
proposed to involve bio-reductive activation by nitro-reductases in T. brucei, generating nitro-
anion radicals, which cause DNA damage. [35,36] In mammalian cells Fexinidazole is thought not
to be reducible under aerobic conditions, [11] however nitro-anion generation from bacteria in
humans can not be ruled out. Leishmania donovani possesses a similar type I nitro-reductase
and indeed in vitro studies with Fexinidazole in a mouse model of visceral Leishmaniasis have
shown a 98.4 % reduction of parasitaemia and complete clearance of Leishmania donovani
amastigotes from macrophages in vitro. [37]
The other drug against HAT, currently in clinical phase I, is the oxaborole SCYX-7158
(DNDi supported). [12] SCYX-7158 was discovered through the screening of a oxaborole li-
brary against T. b. rhodisiense and T. b. gambiense, which revealed a sub-µM inhibitor
(IC50 0.29µM and 0.07-0.36µM, respectively). [12,38] SCYX-7158 has been shown to actively
be transported into the brain, making SCYX-7158 a candidate for the treatment of the late
stage of HAT. [38] The mechanism of action is unknown, but SCYX-7158 has been shown to
localise near the flagella pocket region in T. brucei. [38,39] SCYX-7158 passed absorption, dis-
tribution, metabolism, and excretion (ADME) studies (55 % oral availability) and toxicity studies
(SI in vitro >100) and is currently in Phase I clinical trials by DNDi. [12,40]
A very recent example of the development of a drug against both visceral and cutaneous
Leishmaniasis is Miltefosine (Figure 5), which has been used since 2002 in India. [41] Miltefo-
sine is the first orally available treatment for Leishmaniasis and was included in the World
Health Organisation (WHO) medical repertoire in 2010. [41] Miltefosine is an analogue of phos-
phatidylcholine and was first described in 1980, independently as both an anti-cancer drug
and anti-leishmanial drug with excellent oral availability. [42,43] The mode of action in both can-
cer cells and Leishmania is considered to have a similar molecular basis, as both result in
apoptosis and disturbance of lipid-dependant cell signalling pathways. [41] Detailed studies on
the mode of action in Leishmania have shown that Miltefosine interferes with lipid metabolism
(affecting membrane composition), DNA fragmentation during apoptosis and cytochrome c
7
1 Introduction
O
NH2
N
NH2
N O
CH3
OH3C
ON
N
H2N
HN
H2N
NH
S
O O-
O
N
N
N+
F
CF3
H
N
O O
B
OH
DB289
DB829
Fexinidazole SCYX-7158
Figure 4: Current drugs in clinical development; DB289 failed clinical trials, DB829 currently
in preclinical trials, Fexinidazole and SCYX-7158 are currently in clinical phase 1.
oxidase activity in mitochondria, however the exact mode of action is unknown and multiple
targets in Leishmania spp. are proposed. [41] Miltefosine has been shown to be particularly
active against Leishmania donovani strains (EC50 3.3-4.6µM in an amastigote model of in-
fected macrophages), [41] however there is uncertainty about efficacy in L. infantum, the para-
site discussed in this study. [8] The current problem with Miltefosine medication is its high cost
of production compared to cheap antimonials, therefore several combination therapies with
Paromomycin and liposomal Amphotericin B are currently in clinical trials. [41] Miltefosine is also
currently investigated for the treatment of Chagas disease, as it shows comparable activities
to Benznidazole. [44] Although there are as yet no reported cases of Miltefosine resistant Leish-
mania, drug uptake was shown to be transporter mediated and resistance is easily induced
in laboratory strains. [41] Treatment with Miltefosine is further limited due to its teratogenicity, [8]
highlighting the need for safer and cheaper drugs for the medication of Leishmaniasis.
Sitamaquine (Figure 5), an 8-amino-quinoline derivative is the first drug developed against
the visceral form of Leishmaniasis and entered clinical trials in March 2002 (currently in clinical
phase 2b). [45–48] First reports on the efficacy of Sitamaquine have shown a 80 % cure rate of
patients, but only at doses high enough to also cause nephrotoxicity. [49] Therefore, combina-
tion therapies with Sitamaquine are currently explored to overcome liver toxicity and improve
anti-leishmanial activity. [49] The exact mode of action is unknown, however studies have indi-
cated that Sitamaquine uptake is mediated in an electrical and concentration dependant man-
ner, causing accumulation in the cytosol, [50] where it accumulates in the acidocalcisome. But
accumulation in this organelle may not responsible for anti-leishmanial activity, as activity has
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been shown against acidocalchisome null mutants in Leishmania major. [46] Currently, changes
in the membrane potential in the parasitic mitochondria and interactions with membrane lipids
are believed to be the mode-of-action. [9,46,51]
Paromomycin (Figure 5), an anti-bacterial amino-glycoside antibiotic is the latest anti-
leishmanial drug registered for visceral Leishmaniasis in India. [9] Paromomycin causes a depo-
larisation of the leishmanial mitochondrial membrane, interferes with the protein biosynthesis
(ribosomes) and causes respiratory dysfunction. [9,48] However, Paromomycin efficacy is infe-
rior to Amphotericin B, injection pains have frequently being reported and distribution problems
of Paromomycin make this drug unavailable for endemic regions. [9,48]
The anti-fungal drugs Ketoconazole, Itraconazole and Fluconazole (Figure 6) have been
assessed in various clinical trials against visceral and cutaneous Leishmaniasis with vary-
ing success rates. [8] These azole derivatives are inhibitors of the 14-α-demethylase in sterol
biosynthesis, however Leishmania spp. have the ability to survive reduced sterol availabil-
ity by using metabolised sterols from the human host, possibly explaining the variations in
clinical trials. [48,49] Inhibition of the sterol pathway and in particular 14-α-demethylase is an in-
teresting anti-parasitic target, as this pathway is conserved between L. infantum, T. cruzi and
T. brucei. [52] Indeed, the azole derivative Posaconazole (Figure 6) has been shown to inhibit
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epimastigote proliferation in T. cruzi by reducing the ergosterol synthesis, due to inhibition of
14-α-lanosterol demethylase. [21,53]
T. cruzi and other parasites are dependent on de novo synthesis of sterols, in particular
ergosterol-like 24-alkyl-sterols as found in fungi and plants, presenting essential lipid compo-
nents of membranes. [54]
Posaconazole has been shown to be more effective than Benznidazole and Nifurtimox
(in the treating both early and late stages of Chagas disease). Subsequently Posacona-
zole has recently entered clinical phase II against both stages of Chagas disease together
with other 14-α-lanosterol demethylase inhibitors, such as TAK-187 (Phase I) and Ravucona-
zole (phase 1). [55,56] These azole derivatives bind within the lanosterol binding site of 14-α-
lanosterol demethylase, where the azole-nitrogen atoms chelate the heme iron in the active
site, interrupting oxidation and substrate binding. [57]
The drugs presented to this point are all derived from those used in other clinical applica-
tions (Table 1, also shows general overview of all three parasitic diseases). In contrast, one
drug specifically designed against Chagas disease is the cysteine peptidase inhibitor K-777
(Figure 7), which has been shown to cure acute and chronic Chagas disease mouse models
and is currently in preclinical development. [10,58] The major cysteine peptidase, also known as
Cruzipain, is an essential enzyme associated with induced host tissue damage in the prolifer-
ation of the parasite and is furthermore suggested to digest human IgG proteins to escape the
host immune response. [59,60]
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Table 1: Summary of parasitic diseases discussed in this thesis and their current treatment and drugs in clinical development.
HAT Cagas Disease Leishmaniasis
Disease form First stage and late stage [5] acute phase and chronic stage [2] Visceral, cutaneous
and mucocutaneous [4]
Etiological T. b. gambiense, T. cruzi [2] 21 Leishmania sp. [3,4,7]
agent T. b. rhodesiense [3]
Host subcataneous tissue, intracellular, intracellular in
distribution blood and lymph, in cytoplasm of heart phagolysosomes
cerebral spinal fluid [6] smooth muscle, gut, CNS [17] of macrophages [8]
Vectors Tsetse fly [6] Triatumine bug [2] female sandfly [5]
Transmission bite of infected Tsetse fly [6] feces of triatumine bug, bite of infected
blood transfusion, infected sandfly [5]
organ transplantation [2]
Geographic sub-Saharan 26 Latin American [2,5] South and Central America
distribution countries in Africa [6] countries Europe, Africa, Asia [13]
Population 70,000,000 25,000,000 350,000,000
at risk people [6] people [2,5] people [13]
Infections 7,139 people [6] 10,000,000 people [2,5] 12,000,000 people [3,4,7]
Deaths 30,000 10,000 51,000
per annum people [6] people [2,5] people [3,4,7]
Current Pentamidine , Suramin, Benznidazole, Nifurtimox [24] Pentostam, Meglumine antimoniate,
chemotheraphy Melarsoprol, Eflornithine [20] Pentamidine, Amphotericin B [8]
Drugs in Nifurtimox/Eflornithine Posaconazole (phase 2) [21,53] Miltefosine (approved 2010) [41]
the pipeline DB829 (preclinical) [12] TAK-187 (phase I) [55,56] Sitamaquine (phase 2b) [45–48]
Fexinidazole (phase I) [11] Ravuconazole (phase 1) [55,56] Paromomycin (licensed in India) [9]
SCYX-7158 (Phase I) [12,38] K-777 (preclinical) [10,58] Ketoconazole, Itraconazole
Fluconazole (anti-fungal drugs) [48,49]
layout of table modified from Stuart et al. [13]
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1.4 GPI-anchor biosynthesis as a prospective drug target
Most of the drugs in the pipeline for treating HAT, Chagas disease and Leishmaniasis were
initially developed for other applications. Although this a good approach to identify drugs
quickly, [8] analysis of the kinetoplastid genome has allowed the identification of common tar-
gets essential for parasite survival which have yet to be exploited. [13] Particularly interesting
anti-parasitic targets essential for all three protozoa include biosynthetic pathways in fatty
acid biosynthesis, glycophosphatidylinositol (GPI) anchor biosynthesis, sterol biosynthesis
(ergosterol and isoprenoids), cysteine proteases, protein kinases and iron chelation ther-
apy. [13,61–63] However, the path towards broad anti-parasitic agents is difficult, as all three par-
asites are found within different compartments in the human organism and efforts to find anti-
trypanosomal agents against T. brucei and T. cruzi have been described as "frustrating". [14]
GPI-anchor biosynthesis has been shown to be essential for the survival of T. brucei, T.
cruzi and L. infantum, using chemical and or genetic approaches (Figure 8). [18,64–67] In T. bru-
cei, the GPI-anchor serves to attach essential proteins to the plasma membrane of the par-
asite, particularly the variant surface glycoprotein (VSG) protein to confer protection and the
transferrin-receptor needed for iron uptake. [69,70] T. brucei is covered in a dense-cell surface
coat of VSG proteins, [71] which undergoes constant anti-genetic variation from 1,000 immuno-
logically distinct VSG genes. [72,73] Although only one VSG gene is expressed at a time, tight
regulation of gene expression enables temporal changes in the VSG coat, allowing the para-
site to evade the human host immune system. [72,73]
The related kinetoplastid Leishmania sp. is also known to express GPI-anchored glycopro-
teins and GPI-related lipophosphoglycan and glycoinositolphospholipid structures on its sur-
face, suggesting that GPI-anchor synthesis inhibition could lead to anti-parasitic agents with
anti-trypanosomal and anti-leishmanial activity. [71] However, Leishmania mexicana has been
shown to survive without GPI-anchored glycoproteins and GPI related structures, whereas
Leishmania major displayed dependencies on these structures for survival. [71] Recently, GPI-
anchor biosynthesis inhibition in Leishmania spp. has been reviewed, highlighting the im-
portance of GPI-anchored glycoconjugates for survival and virulence and suggesting similar
targets as discussed in this thesis for T. brucei. [18] Genetic studies on a knockout T. brucei
strain deficient in TbGPI10, the gene that encodes the third mannosyltransferase (MT-III) in T.
brucei-GPI synthesis, has been shown not to be viable in the bloodstream form in vitro. [70] Al-
though, the protective coat, which is associated with the GPI-anchor, would theoretically not be
essential for T. brucei in vitro, the loss of the VSG-coat is thought to change cell-morphology
and this combined with the loss of the GPI- bound trypanosome transferrin receptor could
explain the observed trypanocidal effects. [70] In addition to genetic validations of GPI-anchor
synthesis as an anti-trypanosomal target, the enzymes involved in the GPI-anchor biosynthe-
14
1 Introduction
O
O
O
OO
PO
O
O-
OH
OH
OHHO
O
O
OO
OH
NH2
O
OH
HO
O
HO
O
O
HO
OH
O
O
HO
HO
O
O OH
OHHO
HO
HO
O
O
P
O
O
O-
HO
O
OH
HOOH OH
OH
n
n
Dol-P-Man DPMS
Dol-PGDP
GDP-Man
UDP-GlcNAc
PIUDP
MT
-1
MT-3
PI-GlcNAc
DeN
Ac
cell surface
cytoplasm
GlcNAc-T
HN
Protein
HO
MT-2
UDP-
Figure 8: Schematic representation of GPI-anchored VSG protein and key steps in the GPI-
anchor biosynthesis; MT I-III: mannosyltransferases; DPMS: dolichol-phosphate
mannose synthase; GlcNAc-T: N-acetylglucosaminyltransferase complex; DeNAc:
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sis pathway have been evaluated as potential targets for the development of anti-trypanosomal
agents. [64,74] Chemical and genetic studies confirmed inhibition of GPI anchor biosynthesis as
a validated target of the bloodstream form of T. brucei. [64,65,75] Although mammalian and try-
panosomal GPI-biosynthesis are very similar, there are essential differences which can be
exploited in potential drugs against T. brucei, T. cruzi and L. infantum. [70] The mannosylation
and acylation steps in the GPI-anchor synthesis in T. brucei, T. cruzi and L. infantum are of
particular interest, as their substrate specificity and order of action differ from the mammalian
analogues. [64] In protozoa such as T. brucei, T. cruzi and L. infantum the 2-OH of inositol is
acylated with a fatty acid after addition of the first mannose and detailed investigations have
shown that without this fatty acid, the ethanol-amine phosphate is not added to the third man-
nose residue, resulting in the loss of GPI-anchors for attachment of proteins. [64] Whereas in
mammalian cells the acylation occurs prior to the transfer of the first mannose, the differing
substrate specificities of both mammalian and T. brucei enzymes have been exploited through
the use of modified substrate analogues. [64] The first step of GPI-anchor biosynthesis is the
transfer of N-acetylglucosamine (GlcNAc) from UDP-GlcNAc to phosphatidylinositol (PI). This
step is catalysed by the N-acetylglucosaminyl transferase complex (GlcNAc-T) (Figure 8). [64]
In the consecutive step of the GPI-anchor biosynthesis, the N-acetyl group of PI-GlcNAc is re-
moved by the Zn-metalloprotease GlcNAc-PI de-N-acetylase (DeNAc). [64,76] DeNAc has been
genetically validated as a target for the development of anti-trypanosomal agents. [71] Inhibition
studies with modified substrates suggested substrate-channeling between DeNAc and MT-I
could prevent GlcN-PI from accessing the active site of MT-I. [77] This implies that successful
inhibition of DeNAc will prevent the incorporation of the tri-mannoside core structure (Fig-
ure 8 displayed in green). The incorporation of this tri-mannoside core structure is catalysed
by three mannosyltransferases MT-I-III using Dol-P-Man as the common donor substrate. [64]
Dol-P-Man is a key substrate in GPI-anchor biosynthesis, as it is used by the mannosyltrans-
ferases MTI-III and furthermore for four more mannosyltransferases for the formation of N-
linked glycans. [78–80] The formation of Dol-P-Man is catalysed by dolichol-phosphate mannose
synthase (DPMS) from dolicholphosphate (Dol-P) and the sugar-nucleotide GDP-mannose
(GDP-Man). [80] Inhibition of DPMS would prevent formation of key substrate Dol-P-Man, there-
fore it has an essential role in GPI-anchor biosynthesis and is an attractive target (Figure 8). [68]
Indeed, inhibition of DPMS by small molecular inhibitors has been shown to result in moderate
anti-trypanosomal activity in T. brucei. [68]
T. cruzi is also dependant on GPI-anchor biosynthesis to attach trans-silidases on its mem-
brane surface, allowing the parasite to invade cells and ensuring parasite survival. [66] GPI-
deficient T. cruzi amastigotes fail to develop into infective trypomastigotes within host cells, [67]
suggesting that GPI-anchor biosynthesis in T. cruzi is a valid drug target.
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1.5 Rhodanine derivatives in drug discovery
Recently, rhodanine-N-acetic acid derivatives (Figure 9) have been discovered as inhibitors of
DPMS, with possible inhibitory effects on other enzymes essential for GPI-anchor biosynthe-
sis in T. brucei. [68] However these derivatives showed no inhibitory effect on parasitic growth
at 100µM. [68] Thus further optimisation of this scaffold might be a good starting point for the
development of anti-parasitic agents. Rhodanine derivatives are known to bind to a diverse
set of targets, explaining their significant appearance in the literature (299 publications in the
years 2010-2011). [81] Consequently, this compound class has recently been classified as an
undesirable scaffold for screening against molecular targets. [82] However, there is continued
discussion about the usefulnes of the rhodanine scaffold. Supporters insist the rhodanine scaf-
fold benefits from its ability to bind to a broad range of molecular targets, [83] while others would
avoid rhodanine derivatives at any cost in a drug discovery program. [82,84] A detailed analy-
sis of the rhodanine scaffold in protein crystallographic structures, identified the thiocarbonyl
as major contributor to polar and intermolecular interactions in molecular targets. [83] Density
functional theory calculations on rhodanine derivatives have shown that the highest occupied
molecular orbital (HOMO)-orbital is localised at the exo-cyclic sulphur atom. [83] In addition, the
electrostatic potential has been calculated and mapped on the surface-accessible molecular
surface, showing localisation of a negative potential on the thiocarbonyl. [83] These calculations
give an explanation for the observed polar and intermolecular interactions of the thiocarbonyl
moiety in protein X-ray structures. [83]
However, this is not the only reason for controversy regarding their use. The exo-cyclic
double bond in rhodanine-5-benzylidene derivatives is part of a Michael acceptor system and
therefore prone to nucleophlic attack and covalent binding to molecular targets. [81–83] The abil-
ity of rhodanine derivatives to react as Michael acceptors have been shown in a X-ray structure
of hepatitis C virus (HCV) RNA polymerase NS5B with a 5-benzylidene rhodanine covalently
bound to the Cys366 residue, although pre-incubation and dilution experiments suggest re-
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versible binding in vitro. [85] Using ultra-violet spectroscopy another rhodanine derivative has
been shown to act as a Michael acceptor with dithiothreitol (DTT) under physiological con-
ditions (a decrease of absorbance, due to interruption of the conjugated aromatic system
was observed). [86] Here too, Michael acceptor reactivity was described as reversible, shown
by complete restoration of the conjugated aromatic system after exposure to oxidative con-
ditions. [86] But this experiment is questionable, as rhodanine derivatives have been found to
undergo light-induced binding to nucleophiles, which in the absence of light were found to be
of a reversible nature. [87] Alternative methods to show Michael acceptor reactivity in rhoda-
nine derivatives include the La antigen protein reactive species Nuclear Magnetic Resonance
(NMR) assay. [88] Out of 19 rhodanine compounds screened for Michael acceptor reactivity
against the human La antigen protein, an important component of the ribonucleoprotein com-
plex, [89] 8 compounds were shown to react as Michael acceptors. [90] The Michael acceptor
reaction of rhodanine with nucleophiles results in the loss of the conjugated aromatic sys-
tem, energetically disfavouring this kind of reaction, [83] which could explain the lack of general
Michael acceptor reactivity of rhodanine derivatives and the reversibility of the reaction.
A third and possible main reason for the controversial reputation of rhodanine derivatives
in screening campaigns is their interference with many biological assays due to their intense
colour and ability to chelate transition metals. [81,82] The impact of a publication on rhodanine
as Pan assay interference compounds in screening of libraries, describing rhodanine deriva-
tives as "pollutants of the scientific literature", is significant. [82] Researchers who previously
published a number of papers and reviews about the benefits of the rhodanine scaffold, prais-
ing its distinct biological activity, subsequently changed opinion and would now only use the
rhodanine scaffold in drug development combined with X-ray crystallography and even then,
only as probes. [81,82,91–96] Despite debates on the status of rhodanine derivatives as promis-
cuous binders or privileged scaffolds, many have made it successfully through clinical trials.
Epalrestat (Figure 10), is a rhodanine-N-acetic derivative with Michael acceptor system and is
currently the only available aldose reductase inhibitor against diabetic retinopathy/nephropathy
in Japan. [97]
The rhodanine class seems to be an ideal starting point to achieve inhibition of one or
multiple pathways common to T. brucei, T. cruzi and L. infantum. Rhodanine derivatives
have been reported as inhibitors of bacterial, fungal and recently parasitic glycosyltrans-
ferases, [86,92–95,98–100] making them particularly interesting for the development of inhibitors
against GPI-anchor synthesis in parasites. This is further supported by reports about rho-
danine derivatives as mimics for phosphate groups, [68,86,100–105] as many of the glycosyltrans-
ferases involved in the GPI-anchor biosynthesis have sugar nucleotide donors (GDP-Man), for
which the rhodanine-scaffold would be an ideal mimic. [68]
The rhodanine class could also potentially be an important scaffold for the development of
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Figure 10: Epalrestat, a rhodanine-N-acetic acid derivatives used against long term diabetic
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inhibitors against the sterol pathway in parasitic organisms, as they have been found to inhibit
many NAD(P)H processing enzymes, [106–110] in particular aldose reductases similar to 14-α-
demethylase CYP51. [111] Here a catechol moiety on the 5-position of the rhodanine-scaffold
has been reported as mimic for NAD(P)H in bacterial enzymes. [107,108] This combination of
a catechol motif and a rhodanine moiety has been shown to successfully inhibit type II fatty
acid biosynthesis in Plasmodium falciparum by inhibiting the enoyl acyl carrier protein reduc-
tase. [112] However none of these derivatives have been assessed for their anti-trypanosomal
and anti-leishmanial activity.
Rhodanine derivatives have been identified as inhibitors against hepatitis C virus pro-
teases, [113,114] but only with moderate activities and poor selectivity for viral proteases com-
pared to the mammalian equivalent [114]. However this could potentially be exploited, as mam-
malian protease inhibitors showed surprising selectivities and activities against the trypanosome
proteasome. [115] Therefore rhodanine derivatives might be potential candidates for inhibitors
against parasitic proteases.
The thiazolidine-2,4-dione derivative AS605240, an inhibitor of phosphoinositide 3-kinase-
γ (PI3Kγ) has been found to be as effective against cutaneous Leishmanasis as the pentava-
lent antimonial stibogluconate in Leishmania mexicana infected mice (15 mg/kg dose). [116]
Genetic knockout experiments of PI3Kγ in mice caused a suppression of parasite entry into
the phagocytes, [116] confirming the role of host PI3Kγ in parasite infection. AS605240 was
first explored against neuroblastoma, rheumatoid arthritis and systemic lupus erythematosus,
diseases affected by PI3Kγ inhibition. [117,118] But recently PI3Kγ has been suggested as target
against kinetoplastids such as T. brucei, T. cruzi and Leishmania spp. as genomic data has
identified 12 proteins belonging to the PI3Kγ protein superfamily, with some of them unique
to these parasites. [119] TbVps34, the T. brucei equivalent of PI3Kγ has been shown to be
important for membrane trafficking and Golgi segregation during binary fission. [120] Various
kinase inhibitors have been assessed for their anti-parasitic activity in vitro and in T. bru-
cei spp., T. cruzi and Leishmania major infected mice. [119] Although no benefit was conferred
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on T. cruzi and Leishmania major infected mice, T. brucei infected mice showed an extended
survival of 10.8±2.4 days. [119] Kinase inhibitors are promising starting points for combating
trypanosomal infection, [119] however the PI3Kγ inhibitor AS605240 and other thiazolidine-2,4-
dione derivatives have not yet been assessed for their anti-parasitic activity.
The rhodanine compound class has been chosen as a lead structure due to its previously
reported biological activities, in particular its ability to inhibit glycosyltransferases, such as
DPMS in the GPI-anchor biosynthesis. [68] Rhodanine and rhodanine-like compounds, such as
thiazolidine-2,4-dione and pyrazolones were among the few reported small molecular inhibitors
for glycosyltransferases. [86,92–95,98–100] The majority of glycosyltransferase inhibitors are carbo-
hydrate analogues mimicking essential transition states. [99,121] Although the use of the rhoda-
nine scaffold may pose potential problems in the drug discovery process, recent examples
have shown that this scaffold can serve as a lead for enzymes such as the tyrosyl-DNA Phos-
phodiesterase I, for which there are no alternative templates available. [122] Another potential
problem of rhodanine derivatives is selectivity towards a molecular target, but here too a recent
report on proviral (integration site for moloney murine leukemia virus) kinases have shown that
non-specific thiazolidine-2,4-dione derivatives can be optimised to be selective inhibitor candi-
dates with low nM target affinity. [123]
1.6 Iron chelation as an anti-parasitic strategy
A further main focus of this project was the investigation of iron chelation therapy against
protozoan diseases like HAT, Chagas disease and Leishmaniasis. Iron is an essential ele-
ment in all living organisms, including T. brucei, T. cruzi and L. infantum. [61–63] Iron, due to
its oxide-reductive properties and high affinity to oxygen is an important co-factor in numer-
ous enzymes, such as ribonucleotide reductase which is involved in DNA synthesis. [124,125]
The bloodstream form of T. brucei does not have a conventional respiratory chain, instead
oxidation and electron transport for energy production is carried out by the iron-dependent al-
ternative oxidase (TAO). [126] Genetic alterations of the heme binding site in TAO have validated
iron dependency for catalytic function. [127] Furthermore, the iron chelator ortho-Phenanthroline
(Figure 12) has been shown to inactivate the TAO-complex. [127] The main source of iron in T.
brucei is host transferrin, which is transported through the trypanosomal receptor for transfer-
rin uptake (TbTfR) in order to reach the interior of the parasite. [128] Intracellular amastigotes
of L. infantum salvage iron from host macrophages. [126] Whereas T. cruzi has been shown
to rely on transferrin uptake, but the exact mechanism is unknown. [126] Iron depletion in par-
asites has been shown to induce oxidative stress, prevent J-base synthesis, decrease DNA
synthesis and inevitably cause death. [126] Consequently, iron chelation has been suggested
as a potential strategy to combat infectious diseases. [126] While iron chelation would cause
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Figure 11: The bacterial siderophore Deferoxamine.
general cytotoxicity, iron chelators with possible parasite selectivity, without interfering with
the host iron status, would be of particular interest. Deferoxamine (Figure 11) is a bacterial
siderophore that has been shown to reduce parasitemia in vivo in L. infantum and T. cruzi in-
fected mice, without interfering with the host iron metabolism. [62,63] However, a complete cure
of parasitemia was not achieved, highlighting the need for novel parasite selective iron chela-
tors. [62,63] Deferoxamine has also been shown to inhibit T. brucei growth in vitro, [61] however no
in vivo studies have been performed yet. [126] Few iron chelating agents besides Deferoxamine
have been investigated as anti-parasitic agents. [126]
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ortho-Phenanthroline
Figure 12: Molecular structure of the iron chelator ortho-Phenanthroline.
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Figure 13: The iron chelating agent Deferiprone.
In this study the anti-parasitic activity of iron chelators derived from the clinically used
Deferiprone (Figure 13) were investigated. Deferiprone is an orally available iron chelator
for the treatment of thalassemia in humans. [129] Deferiprone and simple N-alkyl substituted
analogues have previously been assessed for anti-plasmodial activity against Plasmodium fal-
ciparum and showed promising activities in vivo. [130–132] But these Deferiprone derivatives also
21
1 Introduction
showed increased toxicity in mice and in vitro against mammalian K-562 cells. [130–132] Further
modification in particular on the N-1 position of Deferiprone would be an interesting starting
point for anti-parasitic activity with increased selectivity. Additionally the oral availability is
very interesting as most of the previously mentioned anti-parasitic agents relied on parenteral
administration.
1.7 Parasite life cycles
T. brucei ssp., T. cruzi (Y-strain) and L. infantum exist in different stages of the life cycle de-
pending on time of infection and host. [2–4] Individual life cycle stages differ in regards to the
metabolism and ecology of the parasite, [133] therefore it is important to screen against relevant
stages of the parasites.
Anti-parasitic activity screens against T. brucei ssp. were performed using T. brucei brucei
trypomastigotes (Figure 14) which cause the animal disease Nagana, but are not pathogenic
to humans. [16] T. b. brucei is commonly used as model for T. b. gambiense and T. b. rhodiense,
the parasite causing HAT in humans. [33,134,135] Previously the first line drug Pentamidine has
been tested against T. b. brucei, showing an anti-trypanosomal activity of 14 nM. [134] Further-
more, the anti-trypanosomal activity of Fexinidazole against T. brucei brucei (2.38±0.88µM),
T. brucei rhodesiense (2.17±0.29µM) and T. brucei gambiense (1.84±1.13µM) showed
similar activities. [33] In the same study the standard drugs Melarsoprol, Pentamidine and Dim-
inazene have been shown to have comparable anti-parasitic activity, [33] further validating that
screens against T. b. brucei are indicative for the activity against other T. brucei ssp. causing
HAT in humans.
Anti-parasitic activity screens against T. cruzi were performed using trypomastigotes (Fig-
ure 15), which are found in the mammalian host during the acute phase of Chagas disease. [136]
T. cruzi trypomastigotes are responsible for continuation of the intracellular infection and are
commonly used in anti-parasitic drug screens for Chagas disease. [17,136,137] In these screening
campaigns Benznidazole was used as a standard and reference drug (172.4µM). [137]
Anti-parasitic activity screens against L. infantum were performed using promastigotes
(Figure 16). Screening against the promastigote form reduced the cost and time for evaluation
of the anti-leishmanial activity of inhibitors. The promastigote form of T. cruzi is found extra-
cellularly in the sand fly vector and the parasites can be grown in high densities. [133] Therefore
screens against the promastigote form are very popular, [133] although metabolism and ecology
of the promastigote form differ from the amastigote stage. [133] In order to overcome this hurdle,
active compounds against the promastigote stage were assayed against growth of the intracel-
lular Leishmania amastigote form. [133] But screens against Leishmania amastigotes are very
expensive in terms of the maintenance of lab animals and varying success of infectivity with
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Figure 14: Life cycle of T. brucei in Tsetse fly and man; picture taken from
http://www.dpd.cdc.gov.
macrophages.3 It has been found that the promastigote stage is less sensitive towards small
molecular inhibitors as compared to the intracellular amastigote form. [138] Although screening
results against the promastigote form are therefore of limited value as indicator for activity
against the infective mammalian form, [138] it was chosen as fast evaluation of a large set of
inhibitors in short time. However, drugs such as Amphotericin B and Miltefosine which affect
membrane integrity have been shown to have comparable activities in the vector and mam-
malian stage of the parasite, [138] possibly validating the approach for screening of inhibitors
against Leishmania promastigotes to identify potent inhibitors of the amastigote growth.
3Personal communication with Dr. Andre Tempone
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Figure 15: Life cycle of T. cruzi in Triatomine bug and man; picture taken from
http://www.dpd.cdc.gov.
Figure 16: Life cycle of Leishmania infantum in sand fly and man; picture taken from
http://www.dpd.cdc.gov.
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The main goal of this study was the identification of novel small molecular inhibitors against the
parasitic protozoa T. brucei, T. cruzi and L. infantum. Of particular interest was the identifica-
tion of inhibitors with simultaneous activity against all three parasites and low mammalian toxi-
city. In order to identify such potential broad-spectrum and parasite-selective inhibitors, whole-
parasite cytotoxicity assays were used as primary screening assays. These anti-parasite as-
says were complemented by toxicity assays against mammalian cell lines in order to assess
the selectivity profile of inhibitor candidates.
As chemical starting points, known inhibitors of T. brucei GPI-anchor biosynthesis on the one
hand side, and known iron chelators on the other, were selected. Chemical synthesis of
analogue libraries was carried out in order to improve the anti-parasitic activity of these starting
compounds and to explore their applicability to T. cruzi and L. infantum.
Inhibitor candidates were evaluated for their activity against the bloodstream form of T. brucei
brucei. The evaluation against T. cruzi was performed with the trypomastigote form, found
in human blood, whereas the evaluation against Leishmania was executed against the pro-
mastigote form (insect vector) of L. infantum with testing of active candidates against the
amastigote form in mice macrophages.
These whole-parasite assays do not provide information about the molecular target or mode-
of-action of active compounds. It was therefore another goal of this study to carry out target
identification studies with selected inhibitors. These experiments included additional biological
assays as well as computational approaches and the development and application of chemical
probes. Results from these target identification experiments were expected to also inform the
rational design of optimized inhibitor analogues.
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3.1 Known biological activities of Rhodanine-N-acetic acid derivatives
Rhodanine-N-acetic acid derivatives are known for their broad biological activity as anti-viral,
anti-bacterial, anti-fungal, anti-malarial, anti-tumor, anti-inflammatory and cardiotonic agents. [91]
Recently, rhodanine-N-acetic acid derivatives have also been reported as anti-trypanosomal
agents against the bloodstream form of T. brucei. [68]
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Figure 17: Previous examples of rhodanine-N-acetic acid derivatives and their corresponding
thiazolidine-2,4-dione derivatives with anti-parasitic potential; X=O,S.
Rhodanine-N-acetic acid derivatives (Figure 17, 1a–d) have been reported as aldose re-
ductase and/or oxidoreductase inhibitors and in particular as NAD(P)H cofactor mimics. [106–110]
The rhodanine-N-acetic acid derivative 1a was the first rhodanine-like inhibitor discovered for
bovine aldose reductase. [106] In a different study, aldose reductase activity was explained by
the ability of rhodanine-N-acetic acid derivatives to function as a NAD(P)H cofactor mimic,
leading to the use of this compound class as a proteomic tool for oxidoreductases. [107,108]
Recently, compounds 1c and 1d have been identified as potent aldose reductase in-
hibitors. [107,110] Parasitic kinetoplastids, such as Trypanosoma ssp. and Leishmania sp. are
sensitive to oxidative stress, [139] the flavoenzyme trypanothione reductase has been validated
as essential for growth and virulence of these parasites. [140–142] Rhodanine-N-acetic acid deriva-
tives and in particular catechol derivatives that are thought to resemble the NAD(P)H cofac-
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tor, [107,108] might be very interesting candidates for inhibitors against flavoenzyme reductases
in parasites. Indeed, rhodanine-N-acetic acid derivatives have been identified as moderate
inhibitors of trypanosomal 14αdemethylase CYP51 (45µM (T. brucei)and 38µM (T. cruzi)), a
NAD(P)H dependant enzyme of the cytochrome P450 family, essential for sterol-biosynthesis
in T. cruzi and T. brucei. [111] Although, each protozoon has different sterol requirements (sterols
play a structural role in T. cruzi membrane formation and a functional role for life cycle regu-
lation in T. brucei), inhibition of 14αdemethylase CYP51 caused anti-trypanosomal activity in
both T. brucei andT. cruzi. [111] Sterol biosynthesis in trypanosomes is a particularly interesting
target as several azole CYP51 inhibitors, such as E1224, Posaconazole and Tak-187 are cur-
rently in clinical trials as anti-trypanosomal agents against Chagas disease (further details see
Chapter 1.3). [55] Rhodanine-N-acetic acid derivatives could potentially present an alternative
scaffold to these azole derivatives in order to develop new anti-trypanosomal agents against
both T. brucei and T. cruzi.
Besides their role as oxidoreductase inhibitors, rhodanine-N-acetic acid derivatives have
been studied as inhibitors for UDP-galactopyranose mutase (UGM). [86,100] UGM catalyses the
formation of UDP-galactopyranose, a precursor for the assembly of galactofuranose, which
is a key substrate for lipophosphoglycan synthesis in many pathogenic prokaryotes and pro-
tozoans, such as L. infantum and T. cruzi. [86,100] Therefore, inhibition of UGM has been sug-
gested as strategy for anti-leishmanial drugs, in particular against the visceral form of Leish-
maniasis. [100] In addition, rhodanine-N-acetic acid derivatives have been studied as inhibitors
against MurB and MurG bacterial glycosyltransferases. [101,103,143] This significant accumulation
of reports about the inhibitory activity against bacterial glycosyltransferases was hypothesised
to originate from the ability of the rhodanine moiety to function as a mimic for diphosphate
bonds of sugar nucleotide substrates. [86,100–104,143] The reported activity against glycosyltrans-
ferases and the possible ability to mimic phosphate bonds ultimately led to the discovery of
novel inhibitors for dolichol phosphate mannnose synthase (DPMS), an essential sugar nu-
cleotide glycosyltransferase in T. brucei. [68] DPMS catalyses the formation of Dolicholphos-
phate mannose (Dol-P-Man) from dolicholphosphate (Dol-P) and the sugar-nucleotide GDP-
mannose (GDP-Man). [80]
GDP-Man was proposed to have structural similarity to 5-benzylidene rhodanine-N-acetic
acid derivatives. [68] The most active DPMS inhibitor in the reported rhodanine-N-acetic acid se-
ries had a residual DPMS-activity of 10 %, however the same inhibitor only displayed moderate
anti-trypanosomal activity at 338µM. [68] In contrast, the most promising anti-trypanosomal ac-
tivity in this series was observed at 96µM, with a residual DPMS activity of only 23 %, [68]
suggesting other mode of actions for these inhibitors, as DPMS activity did not correlate
with the shown in vitro results against T. brucei. Indeed, using a free-cell assay of the Gly-
cosylphosphatidylinositol (GPI)-synthesis in T. brucei, the inhibitor with the most promising
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anti-trypanosomal activity has been shown to inhibit other enzymes in addition to DPMS in
the GPI-anchor biosynthesis, therefore possibly explaining the additional contribution to anti-
trypanosomal activity. [68]
The inhibition of one or possibly multiple steps in the described biosynthesis pathway will
interrupt the formation of GPI-anchors, having lethal effects on the bloodstream form of T.
brucei. [64] Another potential target in the GPI-anchor biosynthesis is the Zn-metalloprotease
GlcNAc-PI de-N-acetylase (DeNAc), where zinc-binding substrates have been postulated to
inhibit DeNAc. [76] Indeed, carboxylic acids or hydroxamic acid as zinc-binding groups have
been shown to inhibit DeNAc, confirming this hypothesis. [77] Coincidentally, rhodanine-N-acetic
acid derivatives have previously been identified as zinc-chelating agents and potent inhibitors
of the Anthrax-Zn-metalloproteinase. [144,145] Furthermore, rhodanine-N-acetic acid derivatives
have been studied as fungal mannosyltransferase 1 inhibitors in Candida albicans and other
bacterial UDP-glycosyl transferases. [98,99] The ability to chelate zinc and to bind numerous gly-
cosyl processing enzymes make rhodanine-N-acetic acid derivatives excellent candidates for
the development of multi-targeted inhibitors of the GPI-anchor biosynthesis pathway, particu-
larly as these derivatives have already been shown to inhibit DPMS, an early essential enzyme
in the GPI-anchor biosynthesis. [68] Recently, rhodanine-N-acetic acid derivatives have been
studied as drugs against Alzheimer’s disease (AD), inhibiting tau aggregation in the brain of
AD patients ex vivo, demonstrating their capabilities to penetrate the blood-brain barrier. [146,147]
Therefore, rhodanine-N-acetic acid derivatives, if sufficiently active against T. brucei, could po-
tentially be applied as drugs for stage 2 human african trypanosomiasis (HAT) in the central
nervous system.
Rhodanine-N-acetic acid derivatives have been found to have interesting inhibition proper-
ties against Hepatitis C Virus (HCV) chymotrypsin-like protease. [113,114] However, most of these
derivatives have been identified as unspecific inhibitors for HCV proteases and significantly
inhibit other mammalian serine proteases, such as chymotrypsin, trypsin, plasmin and elas-
tase. [113,114] This lack of specificity can potentially be exploited, as substrates with mammalian
proteasome trypsin-like activity have previously been assessed for their anti-trypanosomal
activity against T. brucei, showing interesting selectivities for T. brucei as compared to the
mammalian proteasome. [115] Therefore, it would be of interest to study rhodanine-N-acetic
derivatives with trypsin-like activity for their anti-trypanosomal potential.
Although, rhodanine-N-acetic acid derivatives show a lot of beneficial characteristics for the
development of anti-parasitic agents, several draw-backs have been reported. [82] Rhodanine
derivatives were reported to interfere with assay read-outs in colorimetric assays. [82] Indeed
coloured rhodanine derivatives have been applied as chromogenic agents to monitor bacterial
colony growth. [148,149]
Furthermore, rhodanine-N-acetic acid derivatives have been reported to undergo nonspe-
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Figure 18: Examples of rhodanine and thiazolidine-2,4-dione derivatives in clinical use
cific binding to proteins and therefore decrease their activity towards the target protein. [150] This
unspecific binding most likely occurred through Michael acceptor systems within the rhodanine
structure, making them susceptible to nucleophiles such as thiols in various proteins. [82,86]
Indeed, rhodanine derivatives have been shown to undergo Michael addition reactions with
dithiothreitol (DTT) under reducing conditions and physiological pH, however the binding to
DTT of the rhodanine-moiety was described as reversible under oxidative conditions. [86]
Besides these undesired side-effects of rhodanine derivatives, there are examples of rho-
danine derivatives or analogues which are successfully used as drugs. Rosiglitazone, Piogli-
tazone and Troglitazone represent examples of thiazolidine-2,4-dione derivatives, which are
used in the treatment of type II diabetes mellitus. [91] Epalrestat is a rhodanine derivative that
is used as aldose-reductase inhibitor for the treatment of diabetic complications. [91]
3.2 Synthesis of inhibitor library
In this chapter the synthesis of rhodanine-N-acetic acid derivatives is described. Following
these descriptions, the underlying reaction mechanism of the Knoevenagel condensation and
a possible side-reaction (Michael addition) will be discussed. Next a detailed analysis of the
underlying stereo-chemistry is presented in order to understand the formation of double bond
isomers, as well as to determine the double bond configuration of rhodanine-N-acetic acid
derivatives.
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Scheme 1: Synthesis of 5-Benzylidene rhodanine N-acetic acid derivatives 2a–j; (i) NH4OAc,
DMF, 80 ◦C, 3h (2a) or EtOH, piperidine, 80 ◦C, 3-6 h (2b–j). For substituents
R1-R4 see Table 2. [68]
Table 2: Library of rhodanine-N-acetic acid derivatives identified as inhibitors against DPMS,
see Scheme 1 for structures. [68]
# R1 R2 R3 R4
2a H H H H
2b H H H OBn
2c H H OBn H
2d Piperidine H OBn OBn
2e H OH H H
2f H H OH H
2g H H H OH
2h H H H Cl
2i H H H CN
2j H H H CCH
3.2.1 Synthesis of rhodanine-N-acetic acid derivatives
Rhodanine-N-acetic acid derivatives have been reported as inhibitors for DPMS, an essential
enzyme for GPI-anchor biosynthesis in T. brucei, T. cruzi and L. infantum. [68,151] This study
was chosen as the starting point for the synthesis of rhodanine-N-acetic acid derivatives with
anti-parasitic activity. These rhodanine-N-acetic acid derivatives were synthesised by Knoeve-
nagel condensation reaction of rhodanine-N-acetic acid and various benzaldehyde derivatives
(Scheme 1, see Table 2). [68] Different solvent systems and base catalysts have been explored
to optimise the reaction conditions and piperidine in ethanol has been identified as a preferable
system, resulting in short reaction times and simple product isolation by filtration. [68]
In order to optimise the condensation reaction further, the underlying mechanism of the
Knoevenagel reaction is studied in further detail (Chapter 3.2.2) and different reaction condi-
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tions are discussed.
3.2.2 Knoevenagel reaction
The Knoevenagel reaction, first described by Emil Knoevenagel, is a special form of the aldol
condensation reaction. [152] The Knoevenagel reaction describes the reaction of an activated
methylene compound with ketones or aldehydes in the presence of a weak base. [152,153] An
example for such an activated methylene group can be found in the rhodanine derivative 2
(Scheme 1). The methylene group in compound 2 is activated by the electron withdrawing
effect of a thio-ester and a carbonyl group. The first step of the Knoevenagel reaction is
the formation of the enolate 3a (Scheme 2), using a weak base such as piperidine. The
most common catalyst for the Knoevenagel reaction is piperidine acetate (piperidine in acetic
acid). [152]
In the proceeding step the enol 3a can either react directly with the aldehyde to form the
β-hydroxy carbonyl 3b or can react with the imine 3c. [152] Both reaction mechanisms lead to
the formation of the elimination product 3d. If the reaction proceeds via the β-hydroxy car-
bonyl 3b, it follows the Hann-Lapworth reaction mechanism. [152] Otherwise, the mechanism
follows the Knoevenagel mechanism, with the addition of the enol to the imine to form the cor-
responding β-amino intermediate. [152] In order for the reaction to proceed via the Knoevenagel
mechanism, an imine has to be formed prior to nucleophilic attack of the enol. The formation
of the imine intermediate 3c depends on the steric demands of the amine and the carbonyl
compound, as well as the concentration of amine. [154] Catalytic amounts of amine favour the
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Hann-Lapworth mechanism and the reaction proceeds over the β-hydroxy carbonyl 3b. [152]
The second common step in both mechanism is the 1,2-elimination of water or amine.
Both reactions, the nucleophilic addition and the 1,2-elimination are strongly solvent de-
pendant. [152] While the addition reaction is facilitated by solvents with high polarity, the sec-
ond step proceeds best in aprotic solvents. [152] Therefore, solvents like dimethylformamide
(DMF) would be ideal for the Knoevenagel reaction. [155] However polar protic solvents, such
as ethanol are preferable for the synthesis of rhodanine derivatives due to facile product isola-
tion by precipitation of the elimination product 3d. [68]
The elimination product 3d possesses an exo-cyclic double bond in conjugation to a car-
bonyl, this 1,4-electrophilic system is also known as a Michael acceptor system. Michael
acceptor systems are known to undergo reaction with nucleophiles, 1,4-nucleophilic addi-
tions to this αβ-unsaturated carbonyl system are therefore known as Michael addition. [152]
There is a strong correlation between the Michael acceptor reactivity and the Lewis acidity
of the Knoevenagel product. [156] The Lewis acidity and therefore Michael acceptor reactiv-
ity of neutral organic lewis acid increases with electron-withdrawing groups and planarity of
the molecule. [152] An example of an excellent Michael acceptor is displayed in Scheme 3.
This Knoevenagel product 4a, also known as Meldrum’s acid possesses two strong electron-
withdrawing carboxylic ester groups which form a planar structure. [152] Upon addition of base
to the Michael acceptor system, a labile pseudo base adduct is formed. [152] The existence
of this base adduct, also known as abadon 4b has been confirmed by NMR and UV spec-
troscopy. [152] The rhodanine-N-acetic derivative 5a can react with nucleophiles in a similar
way, but here the abadon has never been reported and the reaction proceeds to the proto-
nated form 5b (Scheme 3), as similar derivatives of 5a have been reported as reversible ac-
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ceptors of DTT under physiological conditions. [86] Furthermore, the Michael acceptor reactivity
of rhodanine-N-acetic acid derivatives has been confirmed by a X-ray structure of hepatitis C
virus RNA polymerase showing the Michael addition product of a cysteine residue covalently
attached to the rhodanine-benzylidene moiety. [85]
But the Michael acceptor reactivity of rhodanine derivative is considered to be rare, as the
conjugated aromatic system between the rhodanine core and the benzylidene moiety would be
interrupted. [83] This is even more pronounced in 5-benzylidene thiazolidine-2,4-dione deriva-
tives, where the thiocarbonyl is substituted with a carbonyl group, as there are no reports about
Michael reaction adducts. [81,83] Thiazolidine-2,4-dione derivatives have been shown to inhibit
autotaxin, which similar to hepatitis C virus RNA polymerase has a cysteine residue in its
active side, in a reversible (non-covalently) manner, as 97 % of substrate could be recovered
after enzymatic reaction with complete retention of enzymatic activity. [157]
3.2.3 Stereochemistry of the Knoevenagel reaction
The Knoevenagel reaction, depending on the nature of the substrates, can give rise to different
diastereoisomers, which differ in the configuration of the exo-cyclic double bond. In order to
understand the biological activity of rhodanine derivatives it is therefore crucial to know the
exact configuration of the double bond to differentiate both isomers.
To understand the formation of these different isomers, the reaction of a rhodanine deriva-
tive 6a (Scheme 4) and an aldehyde 6b is examined in further detail. The stereospecific
outcome of this reaction is mostly dependant on steric considerations. In the following discus-
sions, the Hann-Lapworth mechanism over the β-hydroxy intermediate will be used to explain
the different diastereoisomers. The aldol reaction between 6a and 6b can form two aldol-
products 6c and 6d. In the following elimination reaction two diastereoisomers are formed, the
E-isomer (6e) and the Z-isomer (6f). The Z-isomer 6f has been described as the thermody-
namically more stable product. [158] All reactions are reversible, so that only one diastereoiso-
mer could preferably be formed. Previous studies on the mechanism of the aldol-condensation
reaction, proposed a Zimmerman-Traxler like transition state of the rhodanine 6a and the alde-
hyde 6b. [158] In this study, the chelating agent for the electrophilic carbonyl and the enol was
suggested to be H+. [158] However, metal ions such as lithium or boron are known to be pri-
marily involved in Zimmerman-Traxler transition states. [159] The Zimmerman-Traxler transition
state is aimed at avoiding syn-pentane interactions of axial substitutents in chair-like transition
states. [159] In other words, Z-enolates react to syn-aldol product, while E-enolates lead to the
anti-aldol product. [159] In the Zimmerman-Traxler transition state of rhodanine 6a and aldehyde
6b, sodium ions are proposed as chelating agents, as sodium acetate is a commonly used as
weak base in combination with acetic acid in Knoevenagel reactions. [160,161] In the transition
states for the E-isomer 6g and the Z-isomer 6h, the syn-pentane interactions are minimised
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for the E-isomer 6g. The Z-isomer 6h shows 1,3-diaxiale interactions between R2 and NR1.
Assuming anti-periplanar elimination of water, the product 6e is formed over the intermediate
6c. The Newman-projection shows an unfavourable interaction between R2 and the carbonyl
group. This steric interaction was thought to be the reason for the formation of the thermody-
namically stable Z-isomer. [158] Following the reaction pathway starting from the Zimmerman-
Traxler transition state for the Z-isomer 6h, an aldol product is formed, which is favoured by
less steric interactions between R2 and the sulphur group. [158] Assuming the reaction proceeds
via an anti-periplanar elimination of water, a favourable hydrogen bond interaction between the
carbonyl group and the methylene proton could be hypothesised. As mentioned before, it will
be very unlikely that the reaction proceeds via strict Zimmerman-Traxler transition states, so
that regio-selectivity is mainly governed by steric interactions, which are most easily displayed
in the appropriate Newman-projection rather than cyclic transition states as proposed ear-
lier. [158] Considering only steric considerations, the Z-isomer is under less steric strain with
the R2 substituent facing towards the sulphur group. However, the introduction of additional
substituents on R2, especially hydrogen bond donors could affect the preference for formation
of the E-isomer as will be shown later in this thesis.
The stereo-configuration of the methylene (CH) proton in rhodanine derivatives is easily
determined by X-ray structure analysis or NMR spectroscopy. The chemical shift of the CH
signal in 1H-NMR or 13C-NMR spectra depends on the alkenic substituents. This observation
is particularly useful, with highly anisotropic substituents like carbonyl groups. The chemical
shifts of the CH signals can be calculated and compared to the experimentally determined
values in order to determine the stereochemistry of the products. [162] Methylene protons in
proximity to a carbonyl group are more deshielded and appear further downfield in the 1H-NMR
spectra. The Z-methylene proton chemical shift of a thiazolidine-2,4-dione derivative has been
reported to be 7.74 ppm while the E-form had a chemical shift of 7.30 ppm. [162] In the case of
di- or tri-substituted Knoevenagel products (electrophile is an aldehyde (di) or a ketone (tri)),
the 3JC=O,H coupling between the carbonyl group and the methylene proton of compounds with
known stereochemistry can be measured and then compared to unknown derivatives. [106,163]
Vicinal 3JC=O,H coupling constants between 3.7-6.8 Hz indicate the Z-isomer, while coupling
constants between 10.0-12.3 Hz are indicative for the E-isomer. [163] This approach was applied
for elucidation of the double bond configuration of pyrazolone derivatives in chapter 6.
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3.2.4 Design of rhodanine-N-acetic acid derivatives with anti-parasitic activity
Figure 19: Strategies to improve anti-trypanosomal activity of identified lead structure.
One of the most active inhibitors of T. brucei growth and the DPMS enzyme is the rhodanine-
N-acetic acid derivative 2c. [68] Compound 2c has a 5-benzylidene derivative with a benzyloxy
substituent in the meta position. This compound was chosen as lead structure for further
modifications to increase the in vitro activity. [68] The optimised rhodanine-N-acetic acid deriva-
tives have been designed according to Lipinski’s rule of five. [164] Therefore, the new derivatives
have a molecular weight less than 500 g/mol, less than 5 hydrogen-bond donors, less than 10
hydrogen-bond acceptors and an octanol-water partition coefficient logP value of less than
5. [164] The molecular weight of compound 2c is relatively low (385 g/mol), allowing further opti-
misation. The rhodanine N-acetic acid starting structure shows large scope for modifications
to improve activity (Figure 19).
Inhibitors were designed for broad anti-parasitic activity (T. brucei, T. cruzi, L. infantum).
Therefore the activity of these inhibitors as anti-trypanosomal and anti-leishminial agents was
evaluated against the whole organism. This phenotypic assay allows to screen for compounds
with broad spectrum activity, already optimized for cell membrane penetration and activity
against the whole parasites. Once compounds with interesting anti-parasitic activity are found,
further target identification via labelling experiments will allow the elucidation of the molecular
target. This target identification is essential in order to optimize activity and selectivity of in-
hibitor candidates. Rhodanine-N-acetic acid derivatives have been chosen primarily for their
previous anti-parasitic activity and in particular for their ability to act as substrates in glyco-
syltransferases for GPI-anchor biosynthesis inhibition. [68,86,111] This could potentially lead to
multiple drug targets, making resistance less likely to evolve.
In order to improve the activity of future inhibitors, modifications were carried out to as-
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Scheme 5: Synthesis of 5-Benzylidene rhodanine N-acetic acid derivatives 2a–ai; (i) EtOH,
80 ◦C; for bases used for synthesis and R1−5 substituents see Table 3.
sess the structural requirements for anti-parasitic compounds. To establish a structure activity
relationship (SAR), different 5-benzylidene substituted analogues were synthesised. This ap-
proach helped to identity electronic and spacial requirements. Next, the role of the thiocarbonyl
was assessed by substitution strategies with a carbonyl. To study the effect of the N-3-acetic
acid moiety, longer side-chain analogues were synthesised. The effect of the carboxylic acid
under physiological conditions has been studied by converting the free acid to its ester to mask
the negative charge. The role of the exo-cyclic double bond was studied by the synthesis of
saturated analogues. And lastly the influence of heterocyclic modifications in the 5-position of
the rhodanine core was examined.
3.2.5 Aromatic substitution strategies
The modification on the 5-position of the initial rhodanine-N-3-acetic acid library was not exten-
sive enough to draw conclusions about electronic or spacial requirements for activity against
the bloodstream form of T. brucei. The derivatives were synthesised via base-catalyst Kno-
evennagel condensation reactions using conventional heating (Scheme 5), [153] and piperidine
or sodium acetate as weak bases in ethanol as the solvent. The products were obtained after
simple filtration. The choice of bases seemed to have no effect on the overall yield of Knoeve-
nagel condensation products, but the use of piperidine resulted in the formation of piperidine
salts in 2d and 2y. To convert the piperidine salt to the free carboxylic acid, the salts were dis-
solved in 1 N hydrochloric acid (HCl) and the free carboxylic acids were extracted with ethyl
acetate (EtOAc). The conversion of the salt to the free acid represented a further step in the
synthesis. Whereas then using sodium acetate (NaOAc) as base, the corresponding acetate
salts were not obtained, therefore sodium acetate is the preferable base for the synthesis of
rhodanine-N-acetic acid derivatives. Furthermore, piperidine proved to be more difficult to
separate from the products and recrystallisations had to be performed or more solvent had to
be used to wash the excess piperidine in the filtration step. Sodium acetate on the other hand
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Table 3: Synthesised Rhodanine-N-acetic acid derivatives; yield; chemical shift for CH signal
(both 1H and 13C); n.a.: not available; 2a–r: piperidine as base; 2s–ae: NaOAc as
base; 2y δ in MeOD-d4 otherwise DMSO-d6, see Scheme 5.
NMR shifts of CH
# R1 R2 R3 R4 R5 yield [%] δH δC
2a H H H H H 72 7.91 134.0
2b H H H OBn H 24 7.86 134.1
2c H H OBn H H 82 7.86 134.2
2d Piperidine H OBn OBn H 54 7.74 133.5
2e H OH H H H 45 8.04 129.9
2f H H OH H H 84 7.77 134.2
2g H H H OH H 45 7.79 134.7
2h H H H Cl H 93 7.85 132.4
2i H H H CN H 78 7.91 131.4
2j H H H CCH H 87 7.85 132.5
2k H H NO2 H H 67 8.02-8.18 135.8
2l H H Br OMe H 75 7.87 n.a.
2m H H CH3 H H 76 7.85 131.7
2n H H H CH3 H 78 7.87 134.1
2o H CH3 H H H 78 7.96 139.5
2p H H CF3 H H 94 8.03 132.1
2q H H H CF3 H 73 7.99 131.7
2r H CF3 H H H 81 7.89 127.8
2s H H H SO2Me H 29 7.99 137.5
2t H H H NMe2 H 87 7.75 135.5
2u H H OH OH H 76 7.65 126.7-137.9
2v H H COOH H H 17 7.80 n.a.
2w H OH H OH H 52 7.99 n.a.
2x H CF3 H H CF3 27 7.77-8.17 n.a.
2y Piperidine H H tBu H 20 7.70 133.5
2z H H H tBu H 79 7.68 134.7
2aa H COOH H H H 15 8.79 136.0
2ab H CF3 H CF3 H 27 7.77 124.6
2ac H H H OMe H 31 7.55-7.88 n.a.
2ad H H H NHAc H 85 7.82 133.9
2ae H H CF3 H CF3 40 8.00 n.a.
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Scheme 6: Synthesis N-acetic acid thiazolidine-2,4-dione analogue; (i) DMF, 0 ◦ C to rt; (ii)
EtOH, 80 ◦ C; (iii) acetone, 70 ◦ C.
is easily removed after the first washing step in the filtration or after extraction with EtOAc. The
stereochemistry of the exo-cyclic double bond was determined by comparisons of the chemi-
cal shift of the methylene-CH signal in 1H- and 13C-NMR experiments. The chemical shifts (δH ,
δC) were in good correlation with previously reported chemical shifts for the thermodynamically
stable Z-isomer. [162,163]
3.2.6 Replacement of thiocarbonyl
Rhodanine-like compounds are known as promiscuous binders to a range of molecular tar-
gets. [83] An analysis of rhodanine derivatives in protein X-ray structures have shown that the
exo-cyclic thiocarbonyl group is involved in multiple molecular interactions such as hydrogen
bonding and electrostatic effects. [83] Although thiocarbonyl hydrogen bonds are less favoured
compared to carbonyl hydrogen bond interactions, it has been suggested that water disso-
ciation from thiocarbonyl residues is facilitated and this is a major factor in the formation of
hydrogen bonds in thiocarbonyl groups. [83] Therefore, substitution of the thiocarbonyl to a car-
bonyl group could increase the selectivity towards anti-parasitic targets through the formation
of specific hydrogen bond interactions with the carbonyl group, possibly reducing unwanted
interactions. The substitution will also reveal the importance of a exo-cyclic thiocarbonyl group
for anti-parasitic activity. The synthetic strategy towards N-acetic acid thiazolidine-2,4-dione
analogues is outlined in Scheme 6.
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Scheme 7: Synthesis of thiazolidine-2,4-dione ester derivatives 7a–k; (i) EtOH, 80 ◦C, for R1-
R3 see Table 4.
Initially, thiazolidine-2,4-dione was subjected to alkylation conditions with iodo- and bromo-
acetic acid sodium salts (X=Br,I and R=Na) in the presence of sodium hydride in DMF (Scheme 6
Method 1). The reaction protocol was adapted from Bhat et al. The solvent was substituted
with DMF for better solubility of the starting thiazolidine-2,4-dione (technical grade, 90 %). [165]
However, the alkylation did not occur under these reaction conditions and only starting material
was recovered. Using the adapted protocol with ethyl-2-bromoacetate as the alkylating agent
yielded the desired ethyl ester 7. The yield was dependant on the use of anhydrous solvents,
varying from 86-90 % after column chromatography. At the same time a different protocol was
explored for the synthesis of the ethyl ester 7 (Scheme 6 Method 2). Treating thiazolidine-2,4-
diones with potassium hydroxide in ethanol resulted in the formation of the potassium salt 8
after simple filtration in quantitative yields. [166] The following alkylation was carried out in the
presence of ethyl-2-bromoacetate to afford the product 7 in excellent yields (>98 %) after sim-
ple extraction. Both methods gave access to the ester derivative 7, but the synthesis of the free
carboxylic acid was not achieved. Instead of hydrolysing the ester under basic or acidic condi-
tions, 7 was chosen for subsequent Knoevenagel reactions with various aldehydes. The ester
7 can be seen as the pro-drug of the free carboxylic acid. Similar ester-modified compounds
have been shown to improve membrane diffusion and consequently improve anti-parasitic ac-
tivity. [167] Within the parasite, the ester derivative could be hydrolysed and release the active
free carboxylic acid, or the ester derivative binds directly to the desired target. The capability
of hydrolysing ester analogues to free acids has previously been shown in T. brucei. [167]
Derivatives of 7a–l were synthesised via Knoevenagel condensation with various ben-
zaldehydes and sodium acetate as the base (Scheme 7). The synthesised analogues 7a–l
showed improved solubility in ethanol. Because of this improved solubility only 7j and 7a were
afforded after simple filtration from ethanol, all other derivatives (7c, 7d, 7e, 7f, 7l, 7i, and 7k)
were purified by column chromatography, explaining the particularly low yields of 31 % for 7k.
The synthesis of the para-trifluoromethyl substituted derivative 7g did not succeed under these
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Table 4: Synthesised thiazolidine-2,4-dione ester derivatives 7a–k including yields and NMR
chemical shifts of CH signal (both 1H and 13C); R1-R3; yield; δC for 7k in MeOD
otherwise all δ in CDCl3; n.a.: not available.
[%] NMR shifts of CH
# R1 R2 R3 yield δH δC
7a H H H 46 7.95 n.a.
7b CH3 H H 69 8.07 132.8
7c H CH3 H 71 7.91 135.1
7d H H CH3 71 7.75 134.8
7e CF3 H H 87 8.20 130.6
7f H CF3 H 52 7.94 132.7
7g H H CF3 no reaction
7h H OBn H 88 7.86 134.6
7i H H OBn 50 7.89 134.7
7j H OBn OBn 67 7.79 134.8
7k H OH OH 31-58 7.78 136.2
conditions. TLC showed complete consumption of starting 7, but also the formation of multiple
decomposition products. All products were afforded as the Z-isomer, which was confirmed by
the chemical shifts of the methylene signal in 1H- and 13C-NMR experiments. The chemical
shifts of the CH signal were in the same range as for the corresponding rhodanine derivatives
9. A particularly interesting compound with respect to the configuration of the double bond
was the ortho-trifluoromethyl substituted derivative 7e. The chemical shift in the 1H-NMR ex-
periment for the CH-signal was further downfield at 8.20 ppm, while all other derivatives were
in the range of 7.75-8.07 ppm. The closest chemical shift was that of 7b, with a chemical shift
of 8.07 ppm. Both structures are related through substitution of the ortho-position in the 5-
benzylidene moiety. Thus, indicating that the ortho-substituent is in proximity of the CH-group,
deshielding it to appear further downfield compared to meta- and para-substituted analogues.
The three dimensional coordinates of 7e were prepared with the MOE2009.10 software
package (Merck molecular force field 94x (MMFF94x)) and distances between the CH group
and the trifluoromethyl group were calculated. The fluorine atoms of the trifluoromethyl group
are only 0.2 Å further apart from the CH-group than the carbonyl group (Figure 20). This re-
sults suggested that the trifluoro-methyl group was indeed responsible for the change of the
chemical shift in the CH-signal in the 1H- and 13C-NMR experiments. But even more remark-
able was the observation of a 5JH,F -coupling constant of 1.9 Hz, between the proton of the CH-
group and the fluorines in the trifluoromethyl (CF3) group. The intramolecular distance between
the CH-proton and the trifluoromethyl group was estimated to be 2.8 Å and therefore just out of
the van der Waals-radii of the participating fluorine and hydrogen atoms (2.7 Å). [168] However,
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Scheme 8: Synthesis of elongated N-3 sidechain linkers in rhodanine-N-acetic acid analogues
12 and 13; (i) NaOHaq, rt; (ii) HCl, 100 ◦C.
the distance measurement was only estimated, assuming a slightly shorter intramolecular dis-
tance within the van der Waals-radii would allow the overlap of the 1s orbital of the proton
and 2p orbital of the fluorine, generating a one-center molecular orbital (Figure 21). [169–171] All
atomic orbitals (the bonding and anti-bonding) will be filled, so that covalent bonds cannot be
formed. These orbital interactions might explain the observed 5JH,F coupling of 1.9 Hz. How-
ever, the exact mechanism of this long range coupling constant is unknown, but has been
shown to be dependant on the intramolecular distance between both coupling partners. [172]
Furthermore such coupling constants have previously been used to reveal intramolecular
interactions, such as hydrogen-bonds of participating groups. [173] For example fluorine-groups
participating in hydrogen-bonding to an intermolecular amide (NH) showed 5JH,F coupling con-
stants in the range of 1.7-2.0 Hz. [173] It can be concluded that a value of 1.9 Hz for the 5JH,F
coupling constant in 7e was dependant on the through space distance and or intermolecular
interaction of the hydrogen (CH) and fluorine group (CF3), thus suggesting possible hydrogen-
bonding interaction between the trifluoromethyl group and the CH moiety. Interestingly, the
13C-NMR experiment showed a similar long range 4JC,F coupling constant of 1.9 Hz between
the CH and the CF3 group.
3.2.7 Elongation of N3-sidechain
To study the influence of the N-3 side chain length, derivatives with a propionic and butyric
acid function were synthesised (Scheme 8). Therefore, a one-pot reaction sequence starting
from β-alanine or γ-aminobutyric acid was pursued. [174] The one-pot-reaction sequence was
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Figure 20: 1H- and 13C-NMR spectra of 7e showing long range coupling between CH and CF3;
the stick representation of 7e showing distances between CH and CF3 and C=O.
slightly modified in order to optimise the product isolation and yield of the reaction. Carbon
disulphide was added to an aqueous solution of the corresponding acid in the presence of
sodium hydroxide. In the following reaction sequence, bromo acetic acetate was added to
intermediate 10. The substitution product 11 is subjected to acidic conditions to catalyse the
formation of the desired five-membered heterocycles 12 and 13 (Scheme 8). The products
were afforded after recrystallization and simple filtration as red crystals. In this reaction se-
quence the chloro-acetic acetate was substituted with the corresponding bromo-derivative and
reaction times were slightly varied to allow products 12 and 13 time for the crystallisation pro-
cess, whereas in the previously published procedure, the products were afforded after column
chromatography. [174] The yields of the reaction varied from 65-80 % for 12 and 68 % for 13.
Each reaction step was accompanied with a change of colour of the reaction mixture. A bright
red colour in the last step was indicative of complete consumption of bromo acetic acetate as
confirmed by TLC.
The modified rhodanine precursors 12 and 13 were subjected to Knoevenagel condensa-
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Scheme 9: Synthesis of N-3 elongated rhodanine acid derivatives 12a–m and 13a–d; (i)
EtOH, 80 ◦C; R1-R4 substituents are declared in Table 5.
tion reaction conditions with various benzaldehydes and sodium acetate as the base (Scheme 9).
The condensation products 12a–m and 13a–d were obtained as red or yellow solids after sim-
ple filtration. The yield of the reaction varied from 19-98 %. It was striking to observe that an
ortho-substituent on the 5-benzylidene moiety in compounds 12e, 12g, 12j, and 13b resulted
in a decreased yield, ranging from 19-61 %. The only exception was compound 12b, which
although ortho-substituted had a high yield of 87 %. It is most likely that steric repulsion with
the ortho-substituent and the rhodanine moiety were responsible for the low yields.
All compounds had chemical shifts of the CH group indicating the Z-configuration, with the
only exception of compound 12j, which had a slightly lower chemical shift for δH at 7.42 ppm.
Unfortunately, the 13C chemical shift could not be measured because of the poor solubility of
12j in DMSO-d6. It would have been expected, that the chemical shift of 12j would be slightly
lower (>7.70 ppm) because of the combined deshielding of the carbonyl and the hydroxy group,
if the Z-configuration would have been present. This result indicated that the double bond in
12j might have been in the E-configuration. Indeed, the presence of a trifluoromethyl group in
ortho-position of the 5-benzylidene moiety in compounds 12e and 12g resulted in a chemical
shift of >7.70 ppm. The proximity in space of the trifluoromethyl group could be seen by a large
5JH,F -coupling of the CH- and the CF3-group (see Figure 20), confirming the Z-configuration
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Table 5: Rhodanine derivatives 12a–m and 13a–d and their R substituents, yields and chem-
ical shifts (δH,C); n.a.: not available; see Scheme 9.
[%] NMR shifts of CH [ppm]
# n R1 R2 R3 R4 yield δH δC
12a 2 H H H H 80 7.81 132.7
12b 2 CH3 H H H 87 7.88 130.3
12c 2 H CH3 H H 98 7.75 133.1
12d 2 H H CH3 H 97 7.77 133.0
12e 2 CF3 H H H 58 7.80 126.2
12f 2 H CF3 H H 69 7.92 130.7
12g 2 CF3 H H CF3 19 7.77 124.9
12h 2 H H NMe2 H 80 7.67 134.4
12i 2 H H Cl H 83 7.81 131.1
12j 2 OH H H H 21 7.42 n.a.
12k 2 H OH H H 79 7.69 133.0
12l 2 H H OH H 85 7.68 133.9
12m 2 H OH OH H 91 7.51 135.2
13a 3 H H H H 90 7.80 132.7
13b 3 CH3 H H H 61 7.88 130.4
13c 3 H CH3 H H 71 7.73 132.8
13d 3 H H CH3 H 72 7.76 132.9
of the double bond.
3.2.8 Esterification of carboxylic acid
The efficiency of carboxylic acid compounds to penetrate membranes can potentially be im-
proved by the synthesis of ester derivatives, as mentioned in section 3.2.6. [167] Derivatives of
2 were converted to esters using standard esterification conditions with N’,N’-dicyclohexylcar-
bodiimide (DCC), 4-dimethylaminopyridine (DMAP) and the desired alcohol (methanol, ethanol
or tert-butanol). Two strategies have been applied to achieve this transformation. In the first
strategy (Method A), the previous synthesised analogues 2m, 2p, 2o, and 2d were subjected
to standard esterification conditions. The yield of the reaction varied from 18-78 %. There,
compound 14f gave the lowest yield by showing only 18 % conversion to the tert-butyl es-
ter after 16 h. The trend seemed to be that the ethyl ester resulted in a higher yield (78 %),
than the methyl ester (41 %), followed by the tert-butyl ester (18 %). However, a major factor
for the decreased yield was the purification method. Derivatives 14a–h were purified by col-
umn chromatography, the major by-product of the esterification reaction was dicyclohexylurea
(DCU) and the catalyst DMAP. Both of these molecules, but in particular DCU are very unpo-
45
3 Rhodanine-N-acetic acid derivatives
N S
S
O
RO
O
O
R1
R2
R3
R=H (i)
(ii)
R=Me, Et, tBu
N S
S
O
RO
O
R1 R2
R3
n
n
R=H (i)R=Me, Et, tBu
n=1
n=2
n=3
n=1
n=2
n=3
R4
R4
18-97 %
Method B Method A
14
15
16
14a–y
15a–f
16a–i
Scheme 10: Synthesis of Ester derivatives; 14a–h: Method A; 14i–y, 15a–f, and 16c–i:
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EtOH; R and R1-R3 are declared in Table 6.
lar molecules and had similar retention times as the esters. Separation of these by-products
proved to be difficult and multiple purification steps had to be performed.
For these reasons, a second approach towards ester derivatives was investigated (Method
B). The starting rhodanine derivatives 2, 12, and 13 were converted to their esters prior to sub-
jecting them to the Knoevenagel reaction. The esterification was carried out with methanol,
ethanol and tert-butanol as the nucleophilic reagents. The esterification using ethanol yielded
the desired ethyl ester 14 in almost quantitative yields (64-99 %) after purification. Improve-
ments of the purification protocol had a significant role in increased yields. In the first purifica-
tion step, DCU is precipitated with the addition of dichloromethane to the EtOH/CHCl3 (10:1)
solution. DCU was filtered as a white solid from the crude reaction mixture, improving consec-
utive purification efforts via flash column chromatography. The ethyl ester of 14 was afforded
as yellow oil, which solidified upon exposure to air. Applying the improved purification protocol
to the crude methyl ester of 14 afforded the product in 78 % yield. Lastly, tert-butanol was used
for the esterification reaction and yielded only 17 % after purification. Similarly as described
above, the ethyl ester of 14 was afforded in the highest yield of 99 %, followed by the methyl
ester with 78 % and the tert-butyl ester with 17 %. For the following esterification reaction with
12 and 13, ethanol was chosen to afford the corresponding ethyl esters 15 and 16.
Interestingly, the yield of the esterification reaction for 12 was only 21-39 % and even pro-
longed reaction times did not affect the isolated yields. However, applying the esterification on
13 resulted in the formation of the butyl ester 16 in good yields of 72-77 %. The rhodanine es-
ter derivatives 14, 15, and 16 were subjected to various aldehydes in a Knoevenagel reaction
with NaOAc as base. The yield of the reaction ranged from 32-97 %. Impurities from the pre-
46
3 Rhodanine-N-acetic acid derivatives
Table 6: Rhodanine ester derivatives 14a–ab, 15a–f, and 16a–j; R and R1-R3; yield; chemical
shift of CH (δH,C), see Scheme 10.
[%] NMR shifts of CH [ppm]
# n R R1 R2 R3 R4 yield δsolvent δH δC
14a 1 Et H CH3 H H 53 CDCl3 7.14, 7.76 134.5, 138.7
14b 1 tBu H CH3 H H 72 CDCl3 7.75 134.3
14c 1 Me H CH3 H H 41 DMSO 7.86 n.a.
14d 1 Et H H CF3 H 69 DMSO 8.00 n.a.
14e 1 Me H H CF3 H 71 DMSO 8.00 n.a.
14f 1 tBu H OBn OBn H 18 DMSO 7.81 n.a.
14g 1 Et CH3 H H H 78 DMSO 8.00 n.a.
14h 1 tBu CH3 H H H 49 DMSO 7.99 n.a.
14i 1 Et H H H H 73 CDCl3 7.79 134.2
14j 1 tBu H H H H 77 CDCl3 7.78, 7.79 133.4, 133.9
14k 1 Et CF3 H H H 86 CDCl3 7.45, 8.05 129.4, 132.6
14l 1 Et H CF3 H H 51 CDCl3 7.79 131.8
14m 1 Et CF3 H H CF3 62 CDCl3 8.00 127.1
14n 1 Et H H CH3 H 90 CDCl3 7.77 n.a.
14o 1 Et H H tBu H 55 CDCl3 7.71 134.3
14p 1 Et OH H H H 84 CDCl3 8.19 130.1
14q 1 Et H OH H H 86 CDCl3 7.55 133.9
14r 1 Et H H OH H 89 CDCl3 7.61 134.3
14s 1 Me H OH OH H 32 MeOD 7.65 136.0
14t 1 Et H OH OH H 58 MeOD 7.55 136.0
14u 1 Et OH H OH H 86 DMSO 8.00 130.6
14v 1 Et H OBn H H 54 CDCl3 7.73 134.0
14w 1 Et H H OBn H 67 CDCl3 7.74 134.1
14x 1 Et H OBn OBn H 87 CDCl3 7.64 134.3
14y 1 Et H OMe OH OMe 64 CDCl3 7.65 134.7
15a 2 Et H H H H 72 CDCl3 7.73 133.5
15b 2 Et CH3 H H H 35 CDCl3 7.97 131.5
15c 2 Et H CH3 H H 61 CDCl3 7.72 133.9
15d 2 Et H H CH3 H 57 CDCl3 7.73 133.9
15e 2 Et H H OH H 93 CDCl3 7.61 133.8
15f 2 Et H OH OH H 52 DMSO 7.65 134.3
16a 3 Et H H H H 91 DMSO 7.80 n.a.
16b 3 Et CH3 H H H 92 CDCl3 7.94 131.0
16c 3 Et H CH3 H H 97 CDCl3 7.68 133.5
16d 3 Et H H CH3 H 55 CDCl3 7.71 133.6
16e 3 Et CF3 H H CF3 91 CDCl3 7.92-7.96 126.2
16f 3 Et OH H H H 94 CDCl3 8.29 129.6
16g 3 Et H OH H H 94 CDCl3 7.64 133.4
16h 3 Et H H OH H 71 CDCl3 7.81 132.7
16i 3 Et H OH OH H 85 CDCl3 7.62 134.1
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vious esterification reaction (DCC, DCU, or DMAP) improved yields and reaction times of the
condensation reaction. The products 14a–ab, 15a–f, and 16a–j were afforded after column
chromatography.
The ester derivatives 14a–ab, 15a–f, and 16a–j were almost all obtained as a single
stereoisomer. The chemical shift δ 7.55-8.29 ppm of the CH signal identified these molecules
as the Z-configurated diastereoisomer. The NMR spectra were recorded mainly in CDCl3, or
DMSO-d6 and MeOD-d4, if the solubility of the compound did not allow recording in CDCl3.
The usage of different deutorated solvents was useful in order to study the influence of the
solvent on the chemical shift of the CH-signal. DMSO-d6, as a dipolar aprotic solvent re-
sulted in a further deshielding (8.00 ppm) of the CH-signal in 1H-NMR experiments compared
to CDCl3 (7.75 ppm). On the other hand, MeOD-d4 resulted in a upfield-shift of the CH-signal
to 7.55 ppm. MeOD-d4, as polar-protic solvent, has the capability to form hydrogen bond inter-
actions with the CH-signal, therefore lowering the chemical shift to appear upfield.
Compounds 14a, 14j, and 14k were afforded as mixtures of the Z- and E-diastereoisomers.
Compound 14a was afforded as a mixture of predominantly the Z-isomer, in a ratio of 5:1 (Z:E).
The E-isomer had a chemical shift of the CH signal of 7.14 ppm in the 1H-NMR experiment,
while the Z-isomer, deshielded by the neighbouring carbonyl group, showed a chemical shift of
7.76 ppm. The trend was very similar in the 13C-NMR experiment, where the E-isomer had a
chemical shift of the CH-signal at 134.5 ppm, while the Z-isomer peak appeared at 138.7 ppm.
The tert-butyl ester 14j was afforded in a Z:E ratio of 3:1. The chemical shift of the Z- and E-
isomer in both 1H-NMR (Z:7.79 ppm, E:7.78 ppm) and 13C-NMR (Z:133.9 ppm, E:133.4 ppm)
experiments was very similar and less distinguished than 14a. The ethyl ester 14k showed a
Z:E ratio of 2:1 and additional long range 5JH(C),F -coupling constants. The coupling constants
in the 1H-NMR experiment showed similar values of 2.2 Hz then compared to 7e (1.9 Hz). This
is not surprising, as the distance of the trifluoromethyl group in the E-isomer was predicted to
be 2.7 Å (MOE, MacPymol-distance measuring) and therefore both isomers have the same
distance between the CH-group and the trifluoromethyl group (Figure 20). Also the 2,5-di-
trifluoromethyl derivative 14m and 16e showed a long-range 5JC,F coupling constant of 1.9 Hz,
but here only the Z-isomers (δH 7.92-8.00 ppm) have been observed. The chemical-shift of the
CH-proton in 14k showed the usual tendency, with the E-isomer having a chemical shift of the
CH-signal at 7.45 ppm, whereas the Z-isomer showing a peak further downfield at 8.05 ppm.
So far, all Knoevenagel condensation reactions yielded only the thermodynamically more
stable Z-isomer as the major product. [158] The combination of a Knoevenagel reaction followed
by an esterification (Method A: 14a) or an esterification followed by a Knoevenagel conden-
sation (Method B: 14j and 14k) gave rise to the E-isomer, but with the Z-isomer still as the
predominant product. It was interesting to observe that both methods gave access to both
isomers, however only the ethyl ester of 14 which showed impurities of the esterification re-
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Scheme 11: Racemerization of exo-cyclic double bond configuration; (i) Ph-SH, DIPEA,
toluene, 100 ◦C.
action, reacted to the corresponding E-isomer. It is thought that DMAP might be responsible
for the reaction towards to the E-isomer. DMAP could possibly attack the Michael acceptor
system and the product could isomerize and eliminate the base again to react to the corre-
sponding E-isomer. A similar type of reaction has been observed with rhodanine derivatives
and thiophenol in refluxing benzene (Scheme 11). [85]
In the previous study, a 3-amino rhodanine derivative was chosen for the reaction with
thiophenol in benzene. [85] In order to show that thiophenol does induce racimerization of the
exo-cyclic double bond in rhodanine derivatives, a similar rhodanine derivative 17a was cho-
sen for the isomerization reaction. The reaction was performed as described in the previous
study, however the solvent was substituted with toluene as a replacement for carcinogenic
benzene. Unfortunately the desired E-isomer 17b was not observed. Benzene might have
been essential for this type of reaction, or toluene may have caused the isomerization to the
Z-isomer, as described in the same study for methanol, water or buffer. [85]
3.2.9 Modification of the 3-benzyloxy group
The originally investigated rhodanine-N-acetic acid derivative (R=H, n=1, X=S, Y=O, Z=CH, A-
C=H, Figure 19) had a 3-benzyloxy-substituent on the 5-benzylidene moiety. In order to study
the importance of this 3-benzyloxy substituent, two modifications were introduced (Figure 22).
The first modification was aimed at examining the spacial requirement of the 3-benzyloxy
substituent through the synthesis of methoxy-substituted analogues. Furthermore, several
pyridine substituents were installed in the 3-benzyloxy-moiety (Figure 22, green). For the
second modification, the 3-benzyloxy substituent was replaced by a heterocyclic modification.
The N-benzylpyridine-2-amine group was chosen to replace the benzyloxy(benzene) moiety
(Figure 22, blue). The modifications on the 3-benzyloxy substituent derived from aldehydes,
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Figure 22: Retrosynthesis of improved rhodanine-N-acetic acid derivatives; R=H,Et; X=O,S;
n=1,2; Y=O,NH; Z=CH, N; A=N,C-R1, B=N,CR2, C=N,CR3.
OH
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18a–f
Scheme 12: Synthesis of modified aldehydes 18a–f (i) K2CO3, 50-90 ◦C, DMF, NaI ; A, B, C,
X see Table 7.
not commercially available. These aldehydes were synthesised by nucleophilic substitution
reactions between 3-hydroxybenzaldehyde and various benzylic chlorides (Scheme 12) with
potassium carbonate (K2CO3) as base. The reaction was carried out in DMF, a dipolar aprotic
solvent, in order to stabilise the charged intermediate of the SN2 reaction.
Although benzaldehyde 18a was commercially available, it was synthesised to test the re-
action protocol for the synthesis of the modified aldehydes 18b–f. The reaction of 3-hydroxy
benzaldehyde and benzylbromide proceeded with an excellent yield of 84 % after column
chromatography and 4 h reaction time. In the following substitution reactions benzylchloride
(Scheme 12, X=Cl) derivatives were used for the substitution reaction. Initially, aldehyde 18b
was synthesised using the reaction protocol described above (K2CO3, DMF, 90 ◦C), but after
8 h only 18 % was converted to the desired product. In order to improve the yield and possible
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Table 7: Synthesis of modified 3-benzyloxy-benzaldehyde derivatives; A,B,C,X for modified
aldehydes 18a–f; catalyst and yield, see Scheme 12.
# X A B C Temperature catalyst yield [%]
18a Br CH CH CH 90 none 84
18b
Cl CH COMe CH 90 none 15
Cl CH COMe CH 90 NaI 82
18c
Cl CH CH COMe 90 none 30-53
Cl CH CH COMe 90 NaI 85
18d Cl N CH CH 50 none 55
18e
Cl CH N CH 50 none 16
Cl CH N CH 50 NaI 59
18f
Cl CH CH N 50 none 33
Cl CH CH N 50 NaI 50
the reaction time, sodium iodide was added as a catalyst, mediating the reaction to the corre-
sponding benzyliodide derivatives. These derivatives are equipped with a good iodide leaving
group and therefore react preferably in SN2 reactions with the 3-hydroxy-benzaldehyde. In-
deed, in the presence of sodium iodide the yield of 18b improved to 82 % with similar reaction
times. The uncatalysed reaction, without sodium iodide, of 18b–f resulted in low yields of 15-
55 %. Whereas the reaction in presence of sodium iodide proceeded in high yields of 50-85 %.
The low yield of 50 % was due to decomposition of the starting pyridyl-chloride derivatives or
the aldehydes 18d–f at high temperatures over 50 ◦C.
The modified aldehydes 18a–f were subjected to Knoevenagel condensation conditions
to yield the desired derivatives 19a–i (Scheme 13). The Knoevenagel reaction proceeded
with an excellent yields of 64-94 % after column chromatography. However, the reaction with
the ethyl ester of 14 and the pyridinyl-aldehydes 18d–f did not result in the formation of the
desired product. Instead only decomposition products were observed. It was most likely
that the aldehydes decomposed under the reaction conditions and lower temperatures might
have led to the formation of products 19j–k. The reaction times of the Knoevenagel reaction
varied from 1-8 h. In particular the short reaction times of only 1 h for 19a and 19e were very
surprising, as for all previous Knoevenagel reactions an average of 4 h was observed for the
complete consumption of starting materials. The chemical shift of the CH-signal in 1H-NMR
(7.63-7.87 ppm) and 13C-NMR (133.4-134.7 ppm) experiments confirmed the formation of the
Z-isomer as the only product.
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Scheme 13: Synthesis of 3-benzyloxy-modified analogues 19a–a; (i) NaOAc, EtOH, 80 ◦C,
see Table 8.
Table 8: Synthesis of condensation products with modified 3-benzyloxybenzaldehyde deriva-
tives; R, n, X, A, B and C for 3-benzyloxy modified derivatives 19a–l; δCDCl3 , see
Scheme 13.
NMR shifts of CH [ppm]
# R n X A B C yield [ %] δH δC
19a Et 2 S CH COMe CH 82 7.66 133.4
19b Et 1 O CH COMe CH 94 7.86 134.6
19c Et 1 S CH CH COMe 64 7.63 134.0
19d Et 1 O CH CH COMe 94 7.87 134.7
19e Et 2 S CH CH COMe 80 7.65 133.4
19j Et 1 S N CH CH 30 7.65 133.6
19l Et 1 S CH N CH 38 7.66 133.7
19k Et 1 S CH CH N 50 7.64 133.5
19f H 2 S N CH CH 75 7.76 132.5
19g H 2 S CH N CH 69 7.77 132.3
19h H 2 S CH CH N 82 7.77 132.4
3.2.10 Heterocyclic modification on the 5-position of the rhodanine-N-acetic acid
For the introduction of the second modification on the 3-benzyloxy lead structure, an 3-amino-
benzylidene group was chosen to replace the benzyloxy-substiuent. The substitution of the
oxygen linker with an amino-linker might show improved activity, possibly indicating hydrogen
bond donor activity of this moiety. On the other hand the amino-benzylidene group is in theory
easily introduced by simple nucleophilic substitution of the corresponding 2-halogen-pyridine
analogues.
Initially, the introduction of the amino-benzylidene substituent should occur after Knoeve-
nagel condensation with the appropriate 2-substituted pyridine aldehyde. A good leaving group
in ortho-position next to the pyridine nitrogen was thought to facilitate nucleophilic aromatic
substitution reactions with amino-benzylidene derivatives (Scheme 14). Therefore, rhodanine-
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Scheme 14: Synthesis of heterocyclic derivatives 22a as replacement for the 3-
benzyloxygroup; (i) R=Et (14), X=Cl (20a), NaOAc, 80 ◦C, EtOH; (ii) neat ben-
zylamine, 190 ◦C, see Table 9.
Table 9: Synthesis of heterocyclic modified rhodanine-N-acetic acid derivatives; of R, X for the
synthesis of 21a–c; yield and chemical shift of CH-signal, see Scheme 14.
# R X yield [%] δDMSO−d6
21a Et Cl 20 7.88
21b H Cl no reaction
21c Et Br decomposition
22a Et NHBn no reaction
N-acetic ethyl ester (R=Et, 14) was subjected to Knoevenagel condensation condition with
2-chloro substituted isonicotinaldehyde 20a (Scheme 14). The reaction yielded the desired
Knoevenagel product 21a in moderate yields of 20 % after simple filtration. The chemical shift
of δH 7.88 ppm of the CH-signal identified the product as the Z-isomer. Attempts to synthesise
the free carboxylic analogue 21b failed and no reaction was observed. Also the attempt to
install the 2-bromo-leaving group on the pyridine moiety failed and only decomposition was
observed in the synthesis of derivative 21c. After having installed the chloro-leaving group
on the pyridine moiety of the derivative 21a, the compound was subjected to aromatic substi-
tution conditions in neat benzylamine solution. The reaction mixture was refluxed at 190 ◦C.
However, no reaction between the amino-benzylidene group and the 2-chloro-aminopyridine
21a was observed. The lack of reactivity is most likely explained by the poor chloro leaving
group compared to a bromo-substituent in 2-position of the pyridine ring. In order to repeat
the reaction with the better bromo-leaving group, the Knoevenagel reaction with the 2-bromo-
pyridine aldehyde 20b was carried out at room temperature and under a nitrogen gas protec-
tion atmosphere to prevent decomposition of the aldehyde. None of these efforts resulted in
the formation of the bromo-derivative of 21a. In order to overcome the decomposition of the
starting aldehyde 20b under Knoevenagel condensation conditions, a different strategy had
53
3 Rhodanine-N-acetic acid derivatives
N Br
O
(i)
N
OO
Br
(ii-viii)
N N
H
O
R2
R3
R4
n
R1
44-100 %
18-43 %
20b 23
25e–b
Scheme 15: Synthesis of amino-substituted aldehydes 25a–g; (i) TFA, EtOH, CHCl3, 80 ◦C,
2 h; (ii) NH2-R (neat), reflux (150-190 ◦C);(iii) Cs2CO3, DMF, NH2-R; (iv) Cs2CO3,
ACN, NH2-R; (v) NH2-R, NaOtBu; (vi) Pd(OAc)2, NaOtBu, DPPF, dioxane/toluene
(1:1); (vii) NH2-R, CuI, CsOAc, toluene, 110 ◦C; (viii) H2O, TFA, rt; for substituents
of n,R1-R4 see Table 10.
to employed. Analysing the aldedhyde 20b in closer detail identified the aldehyde functional
group as the most sensitive functional group. For this reason the aldehyde functional group
was protected as its acetal (Scheme 15). By applying this strategy the order of the reaction
could be reversed. The nucleophilic aromatic substitution reaction could be carried out prior
to the Knoevenagel reaction.
The acetylation of the aldehyde functional group was carried out in ethanol in the presence
of TFA. The reaction mixture was heated to reflux to form the full acetal in quantitative yields.
The full acetate 23 was obtained after simple basic extraction as clear oil. The crude was suf-
ficiently pure (NMR >95 %) for the following substitution reaction. Different reaction conditions
have been explored for the nucleophilic aromatic substitution of the 2-bromo-pyridine derivative
23 (Scheme 15, Table 10). At the beginning, the amination was carried out in neat benzylamine
solution at boiling point of the corresponding amine (100-190 ◦C) (method (ii) in Scheme 15).
However, the desired nucleophilic substitution did not occur and the starting material could be
recovered. Next, bases were added to increase the nucleophilicity of the benzylamine deriva-
tives. Here, caesium carbonate was used in dimethylformamide or acetonitrile, however the
substitution product was not observed and the starting materials were recovered after column
chromatography (methods (iii-iv), Scheme 15). Using sodium tert-butoxide as a strong base,
resulted in the successful formation of the desired 2-amino-pyridine 24i and 24j in moderate
yields of 21-36 % (method (v), Scheme 15). But the trifluoromethyl substituted analogue 24b
could not be synthesised under these reaction conditions. Different conditions for the substitu-
tion were explored in order to improve the nucleophilicity of the amines, but reaction yields did
not improve. A different approach for the substitution reaction was the palladium catalyst am-
ination reaction using Pd(OAc)2 as palladium source (method (vi), Scheme 15). The reaction
proceeded to the desired product 24k, but the yields were not satisfactory (18 %), reflect-
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Table 10: Synthesis of amino-substituted aldehydes, yield and method; n, R1-R4 for amino-
substituted acetals 24a–n and aldehydes 25a–g; reaction conditions used and
yields; see Scheme 15.
aldehyde
# n R1 R2 R3 R4 method yield [%] # yield [%]
24a 1 H H H CH3 (ii) no reaction
24b 1 H H H CF3 (ii) no reaction
24c 1 H H H H (ii) no reaction
24d 1 CH3 H H H (ii) no reaction
24e 2 H H H H (ii) no reaction
24f 2 H H H OH (ii) no reaction
24g 1 H H H CH3 (iii) no reaction
24h 1 H H H CH3 (iv) no reaction
24b 1 H H H CF3 (v) no reaction
24i 2 H H H H (v) 21-32 25a 44-100
24j 1 H H H CH3 (v) 36 25b 100
24k 1 H H H H (vi) 18 25c 100
24l 1 H H H CH3 (vii) 43 25f 43
24m 1 H H H CF3 (vii) n.a. 25d 100
24n 1 H H H H (vii) 65 n.a. n.a.
ing the poor reactivity of substituted aldehydes/ acetals from type 20a–b with benzylamine
derivatives. [175] In order to overcome the lack of reactivity an Ullman-type coupling reaction
with Cu(I) has been used for the formation of the acetals 24l, 24m, and 24n (Method (d) in
Scheme 15). [175] Therefore, a modified version of the amination protocol of Frey et al. has been
applied to the acetal 23. [175] Copper iodide has been used as source for Cu(I) and caesium
acetate served as the base. The reaction proceeded in excellent yields (43-65 %) and has
been chosen as the preferred approach for the synthesis of derivatives of the type 24. In all
cases, the desired 2-amino aldehydes 25a, 25b, 25c, 24l, and 25d were obtained after acidic
hydrolysis of the acetal with TFA at room temperature. Compound 26a was chosen for the
further Knoevenagel reaction with the ethyl ester of 14 (Scheme 16). The reaction proceeded
in good yields of 75 %. In addition to these heterocyclic modification several other pyridine-
carboxaldehydes, furanyl-aldehydes as well as cinnamonyl-aldehydes were chosen for the
Knoevenagel reaction with rhodanine-N-acetic acid 2 and thiazolidine-2,4-dione derivatives
and their ethyl-ester analogues 7 and 14 (Scheme 16). The yields of the reactions varied from
14-100 % and the chemical shift of the CH-signal in 1H-NMR experiments showed only forma-
tion of the thermodynamically more stable Z-isomer. [160] The chemical shift for the CH-signal
in DMSO-d6 (7.05-7.96 ppm) were observed further downfield than for CDCl3 (7.29-7.75 ppm).
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Scheme 16: Synthesis of heterocyclic derivatives 26a–j; X=S,O; R=H,Et, R1=25f, 2-pyridine,
3-pyridine, 4-pyridine, furan, cinnamonaldehyde (i) NaOAc, EtOH, 80 ◦C, see Ta-
ble 11.
Table 11: Synthesis of heterocyclic rhodanine-N-acetic acid/ ester derivatives; R1-R2 and
X of heterocyclic compounds 26a–j; yield and chemical shift of CH-signal, see
Scheme 16.
yield NMR shift of CH [ppm]
# R1 X R2 [%] δsolvent δH δC
26a Et S 25f 75 CDCl3 7.53 131.6
26b H S 2-pyridinyl 54 DMSO-d6 7.92 129.4
26c H S 3-pyridinyl 74 DMSO-d6 7.96 130.6
26d H S 4-pyridinyl 82 DMSO-d6 7.90 n.a.
26e H S phenylallylidene 20 DMSO-d6 7.71-7.75 n.a.
26f Et S 2-pyridinyl 100 CDCl3 7.67 128.6
26g Et S 3-pyridinyl 14 CDCl3 7.75 129.9
26h Et S 4-pyridinyl 28 DMSO-d6 7.05 n.a.
26i Et O 4-pyridinyl 21 CDCl3 7.29 n.a.
26j Et S 2-furanyl 38 CDCl3 7.51 119.1-119.2
3.2.11 Reduction of the exo-cyclic double bond in rhodanine-N-acetic acid derivatives
The exo-cyclic double bond within the rhodanine or thiazolidine-2,4-dione derivatives are part
of a Michael acceptor system. The double bond is conjugated to a carbonyl group, making it
potentially prone to 1,4-nucleophilic attack from biological nucleophiles such as gluthathione. [82,83]
Previous examples of nucleophilic attacks to the Michael acceptor system in rhodanine and
thiazolidine-2,4-dione derivatives have been discussed in section 3.2.2 (Scheme 3). In or-
der to study the effect of the double bond on the activity against various protozoa, a range
of saturated analogues have been synthesised. There are essentially three methods to re-
duce the double bond in rhodanine-like derivatives. [104,176,177] Derivatives with an exo-cyclic
sulphur group can be reduced by LiBH4 in the presence of pyridine or via the Hantzsch-ester
method. [104,176,177] The reported yields for the LiBH4 in pyridine reduction for rhodanine deriva-
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Scheme 17: Synthesis of reduced analogues 27a–c; for X=S, R1,2=OH,H (i) Hantzsch ester
28, activated SiO2 gel, toluene, 85 ◦C, dark; for X=O, R1,2=OH,H (i) Pd/C, H2,
dioxane, see Table 12.
Table 12: Reduction of rhodanine-N-acetic ester analogues; X and R1-R2 of reduced ana-
logues 27a–c; yield, chemical shift of CH-signal, see Scheme 17.
# X R1 R2 method yield
27a S H H (i) 67
27b O H H (ii) 98
27c O OH OH (ii) 100
tives were only 26 %. [161] For this reason, the second approach, the Hantzsch-ester reduction,
was chosen for the reduction of rhodanine derivatives. The Hantzsch ester is a milder reduc-
ing agent compared to LiBH4. [177] Compounds with an exo-cyclic carbonyl group were reduced
by catalytic hydrogenation with Pd/C and H2 (Scheme 17). The Hantzsch ester reduction of
the exo-cyclic double bond in 27a proceeded in good yields of 67 %. The reduced analogue
27a was easily purified by direct application of the crude silica to column chromatography.
The hydrogenation of the compounds from the type 7 worked very well, yielding the products
27b and 27c after simple filtration over celite.
3.2.12 Synthesis of photo-affinity label for identification of target proteins
Introduction
The rhodanine N-acedic acid inhibitors 2a–ai, the thiazolidine-2,4-dione derivatives 7a–l, their
ester analogues 14a–ab, 21a, 3-benzyloxy-modified analogues 19a–l, the heterocyclic modi-
fied analogues 26a–j and the reduced analogues 27a–c were designed as inhibitors for para-
sitic growth. Therefore all inhibitors were screened against parasitic organism and mammalian
cells to evaluate their activity and toxicity profile (Chapter 3.2.5, 3.2.6, 3.2.7, 3.2.8, 3.2.9,
3.2.10 and 3.2.11) . This approach helped in the identification of potent inhibitors against par-
asitic growth, without prior optimisation towards a specific target protein. However, in later opti-
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Figure 23: Photo-affinity label for the identification of possible targets in parasites (T. brucei, T.
cruzi, L. infantum) and mammalian cells (HL60 cells); five-membered ring (yellow):
affinity probe; red circle: photo-label group; blue circle: Click-chemistry tag.
misation steps it is important to know the molecular target protein(s) of the designed inhibitors.
In order to identify possible target proteins, a photo-affinity probe with three major compo-
nents was designed (Figure 23). The first important component was the rhodanine affinity
ligand (yellow five-membered ring, Figure 23). The affinity ligand ensures target-specificity
by tight binding to its molecular target. The second component is a UV-sensitive aromatic-
azide-tag (red circle, Figure 23). Aromatic azides are widely used in protein photo-affinity
labelling. [178] Under UV-activation (254 nm), aromatic azides from the type 29 form highly re-
active intermediates (Figure 24), [179] such as singlet nitrenes, which are converted to triplet
nitrenes at higher temperatures. [180] Otherwise at low temperatures (< 77 K), singlet nitrenes
react to ketenimines (azepine 30). These reactive intermediates, the triplet nitrenes or the
ketenimine azepines 30 can react with nucleophiles in the receptor protein which are in close
proximity. [180] The third component of the photo-affinity probe (Figure 23) is an alkyl azide
group (blue circle, Figure 23), which is stable under UV-irridation conditions. [178] This alkyl
azide served as an additional tag for the introduction of fluorescence- or biotin-probes via
Click-Chemistry reaction.
The designed probe with all three components (affinity-, photo-label, click-chemistry-group)
will be applied to protein mixtures of parasitic or mammalian origin (Figure 25). The affinity
group will provide the selectivity for the individual target protein or target proteins. After a short
incubation time, the ligand-probe receptor-protein complex will be exposed to UV-irridiation, to
promote the formation of covalent bonds between the ligand and the receptor. In the final
step click-chemistry will be applied to the covalently bonded ligand-receptor complex and an
identification tag, for example a fluorophore or biotin-moiety is introduced via the free alkyl-
azide linker of the ligand. If biotin is chosen for the tagging of the protein-ligand complex, a
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Figure 24: Reaction mechanism of aryl azides after UV-activation.
purification step via streptadivin beads can be performed, otherwise the fluorescence of the
protein-ligand-complex can directly be read from a SDS-gel.
Synthesis of the photo-affinity label probe
The synthesis of the photo-affinity probe (Figure 23) was performed according to previous
reports. [178,181] The only difference in the synthetic procedure was the introduction of a different
affinity group on the photo-label-alkylazide moiety. [181]
The bis-(2,4-dichlorophenyl) phosphorochloridate 31a was synthesised via esterification
reaction of phosphoryl trichloride and 2 eq of 2,4-dichlorophenol. [182] The product 31a was
afforded in excellent yields of 80-89 % after simple distillation (Scheme 18). [182] The major by-
Cl
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Scheme 18: Synthesis of phosphorochloridate 31; (i) magnesium turnings, rt→ 120 ◦C, 3 h at
120 ◦C, 3 h at 160 ◦C.
product of the esterification was the dichloro-monoester 31b, but this by-product was fraction-
ated by distillation and re-reacted with 2,4-dichlorophenol. The stated yield was the combined
yield of both reactions.
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Figure 25: Photo-affinity strategy to identify molecular targets; five-membered ring (yellow):
affinity probe; red circle: photo-label group; blue circle: Click-chemistry tag; green:
Alexa-Fluor 488 or biotin-tag.
The synthesis towards the photo-affinity probe 34 started from dimethyl 5-aminoisophtha-
late 33a. The diester 33a was reduced with excess lithium aluminium hydride (LiAlH4) in THF
((i) in Scheme 19).
The reduced amino-diol 33b was obtained in excellent yields of 88-98 %. The following
amino to azido transformation was performed with tert-butyl nitrite (tBuONO) and TMS-N3 in
acetonitrile to obtain the desired azido-diol 33c with a 98 % yield ((ii) in Scheme 19). The
conversion of one of the alcohols in 33c to an azide functionality was achieved by a one-pot
reaction with 31a, DMAP and sodium azide (NaN3) in dimethylformamide ((iii) in Scheme 19).
The conversion of only one of the primary alcohols was achieved by using 1.1 eq of 31a. Under
these conditions less than 10 % of the azido-diol 33c were converted to the tri-azido analogue.
The desired di-azido-alcohol 33d was afforded after column chromatography in yields of 54-
75 %. The free primary alcohol of 33d was tosylated with tosyl chloride (TsCl) and triethy-
lamine (NEt3). For this substitution, it was important to keep the reaction temperature under
0 ◦C, otherwise decomposition was observed. Tosylated di-azide 33e was afforded in moder-
ate yields of 35-76 %. The 3-benzyloxy modified aldehyde 33f was synthesised by nucleophilic
substitution reaction between 3-hydroxybenzaldehyde and the tosyl di-azide 33e. The photo-
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Scheme 19: Synthesis of photo-label-aldehyde 33f; (i) LiAlH4, THF 0 ◦C → rt, 8 h; (ii) t-
BuONO, TMS-N3, ACN, 0 ◦C → rt, 2 h; (iii) 31a, DMAP, NaN3, DMF, rt, 4 h; (iv)
Ts-Cl, NEt3, 0 ◦C, 2 h; K2CO3, DMF, 50 ◦C.
affinity aldehyde 33f was reacted with rhodanine-N-acetic ethyl ester 14 in a Knoevenagel
reaction to afford the desired photo-affinity-probe in moderate yields of 38 % (Scheme 20).
The Knoevenagel reaction was carried out at lower temperatures of 50 ◦C to ensure that the
photo-affinity label does not decompose.
N S
S
O
O
O O
NN+-N
N N+ N-
N S
S
O
O
O
(i)
38 %
14
34
33f
Scheme 20: Synthesis of rhodanine-N-acetic ethyl ester photo-affinity label 34; (i) NaOAc,
EtOH, 50 ◦C, 2 h.
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3.3 Anti-trypanosomal activity
3.3.1 AlamarBlue & MTT activity/toxicity assays
In this section the whole cell assays against trypanosomes and mammalian cells are described
in detail. The detailed description is important in order to understand the possible problems
which can arise with the screening of rhodanine compounds. Rhodanine derivatives were
mostly afforded as yellow to red solids after filtration, in solution these derivatives caused
an intense colour change in the aqueous assay media. This colour can interfere with the
assay readout, as the measured absorbance wavelengths of indicator dye and compound
absorbance could overlap. In this study, the activity of growth inhibitors was evaluated with
colorimetric assays, such as the AlamarBlue assay (Figure 26, (a)) or the MTT-assay (Fig-
ure 26, (b)). [183,184] The cell viability dye AlamarBlue was used for determination of activity
data against T. brucei and toxicity data against HL60 cells. MTT was used for the acquisition
of the activity data against T. cruzi.
AlamarBlue assay MTT assay
Figure 26: Colorimetric activity-/ toxicity assays. Left: Outline of 24 well plate assay for esti-
mation of GI50 values for T. brucei and HL60 cell growth after 72 h of incubation.
Right: Outline of 96 well plate assay for determination of GI50 values for T. cruzi
and L. infantum after 24 h of incubation.
The AlamarBlue assay is an one-step assay, which does not require any washing or extrac-
tion steps prior to read out of cell viability, as compared to the MTT analogous assay. [185] The
cell viability can be determined by simple linear correlation between cell density and the ab-
sorbance or fluorescence intensity of AlamarBlue. [183] Living cells are able to reduce the blue
AlamarBlue (also known as resazurin) to the pink resorufin (Figure 27). [183] In mammalian
cells, the reduction of resazurin is dependant on the activity of dehydrogenases in the respira-
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Figure 27: Intracellular reduction of blue resazurin to purple resorufin.
tory chain of mitochondria. [185] In T. brucei the reductions are believed to occur in the glycolytic
pathway. [185]
The activity assay for T. b. brucei TC211 was performed in a 24 well plate format (Fig-
ure 26, (a)). Therefore, T. brucei was cultured in Baltz medium supplemented with 16.7 %
heat-inactivated foetal bovine serum (FBS) at a final concentration of 104 cells in 1 mL me-
dia. Controls were performed in the presence of 0.5 % DMSO, without showing any toxic
effects. Inhibitors were tested at five concentrations (100, 10, 1, 0.1, 0.01µM) in a final DMSO-
concentration of 0.5 %. The cells were incubated for 24 h in the presence of the inhibitor prior
to addition of AlamarBlue (10 % solution). After a further 48 h the resazurin indicator dye has
been reduced by living parasites and the absorbance at 570 nm was read, using 630 nm as the
reference wavelength for the absorbance of proteins in the media. Each assay was performed
at least in duplicate with more replicates added.
As previously mentioned, AlamarBlue can also be used to monitor the viability of mam-
malian cells. Here Human myeloid leukaemia (HL60) cells were used for the evaluation of the
toxicity of anti-parasitic compounds. The cell line was first isolated from a patient with acute
promyelocytic leukemia. [186] HL60 cells are easy to maintain, grow in suspension and repro-
duce faster than normal cells, therefore they can easily be applied to high throughput assays in
order to screen for general cytotoxicity. [187,188] HL60 cells are commonly used as reference for
general cytotoxicity in drug discovery for HAT, Chagas disease [189,190] and Leishmaniasis. [191]
Screening results obtained with immortal cancer cell lines for toxicity correlate well with toxic-
ity against primary cells if the drug affects common basal functions of cells. [187,188] In general
the cytotoxicity data obtained with HL60 cells is lower compared to screening results against
primary cell lines.4
Similar to the activity assay against T. brucei, HL60 cells were seeded in 24 well plate
at a final concentration of 105 cells in 1 mL RPMI 1640 medium supplemented with 2 mM
L-glutamine and 16.7 % FBS. HL60 cells were challenged with five concentrations of each in-
hibitor over a time period of 24 h, prior to addition of AlamarBlue (10 % solution). Following
the read out procedure described for T. brucei, the absorbance at 570 nm was acquired. Al-
4oral communication with Dr. Dietmar Steverding
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Figure 28: Intracellular reduction of yellow tetrazole salt MTT to its purple formazan.
ternatively, the toxicity assay was performed in a 96 well format with a total volume of 200µL
media and a cell density of 105 cellsmL . HL60-cells were challenged with 8 different inhibitor con-
centrations (100, 50, 25, 12.5, 6.25, 3.125, 1.5625, 0.78125µM) over a period of 44 h. After
which AlamarBlue was added and the cells were incubated for another 4 h. The fluorescence
of resorufin was read at 585 nm (emission) with excitation at 570 nm. Using the fluorescence
intensity instead of the absorbance had the advantage of less interference of yellow coloured
inhibitors in the toxicity assay. Furthermore, performing the toxicity assay in a 96 well plate
allowed the screening of 2 additional drugs per plate with three additional concentrations (Fig-
ure 26).
For the evaluation of inhibitory activity against T. cruzi the MTT-assay variant was pursued.
MTT, 3-[4,5- dimethylthiazol-2-y1]-2,5-diphenyl-tetrazolium bromide is a similar indicator dye
for cell viability to AlamarBlue. Yellow tetrazolium salt (MTT) is reduced by mitochondrial en-
zymes to its purple furazan salt. The progress of this reduction can be followed by measuring
the absorbance at 550 nm. [136] The assay is performed in a 96 well plate, with T. cruzi try-
pomastigote densities of 106 cellsmL . After 24 h, MTT was added and formazan extraction was
carried out with 10 % (v/v) SDS over a time period of 18 h. The total formazan concentra-
tion and therefore the number of viable T. cruzi was obtained by measuring the absorbance
at 550 nm. Unfortunately most rhodanine inhibitors also absorbed at a similar region as the
MTT viability dye, resulting in missing activity data against T. cruzi throughout this thesis. The
AlamarBlue viability dye was not available for the whole cell assays against T. cruzi.
The minimum inhibitory concentration (MIC) for all inhibitors was determined by visual
inspection with a light microscope. The MIC is defined as the minimum drug concentration,
where all parasites or mammalian cells were lysed.
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3.3.2 Calculation of GI50-values
All assays were performed in the presence of a positive and a negative control in order to
accurately define 0 % and 100 % parasite survival. This was essential for normalisation of the
obtained absorbance or fluorescence intensity data. Here, the steps for calculation of growth
inhibition constants (GI50) are described for the arsenical drug Melarsoprol. Melarsoprol has
been evaluated against T. brucei and HL60 cell growth in the AlamarBlue assay (Figure 29,
(b)). The raw absorbance data was normalised and plotted against the logarithm of Melar-
sorpol concentrations (log(C)) (Figure 29). Growth inhibition constants GI50, the concentration
needed to reduce cell growth by 50 %, was calculated by the following equation
Y =
100
1 + 10(LogGI50−X )·HillSlope
(1)
where Y is the parasite concentration, X is log(C) and the Hill-Slope is variable. Applying
this formula in the integrated settings of Prism GraphPad v5.0a for Mac OS X resulted in
GI50-values of 1.70 nM and 1.76 nM for each individual assay. Next the average of the GI50
values together with their standard deviation was calculated (1.73±0.04 nM, MIC 10 nM). The
calculated GI50-value for Melarsoprol was very similar to previously published GI50 against T. b.
rhodesiense (1.7 nM) and T. brucei brucei (3.7 nM). [185,189] The toxicity of Melarsoprol against
HL60 cells was calculated to 14.53±1.27µM (MIC 100µM), slightly less toxic then previously
reported (3.26µM). [189] The calculated GI50 values for Melarsorpol for T. brucei and HL60 cells
not only validate the AlamarBlue assay, but also validate the chosen model for the estimation
of GI50 values. The standard drug for T. cruzi was Benznidazole and GI50 was estimated to
440.7 nM (CI95 % 406.2-478.4 nM).
3.3.3 Anti-Trypanosomal activity of rhodanine-N-acetic acid derivatives
Anti-trypanosomal activity of rhodanine-N-acetic acid derivatives 2a–ai
The previously identified DPMS inhibitors 2a–j were re-synthesised and screened against T.
brucei and T. cruzi. [68] Previously 2a–j showed activities against the bloodstream form of T.
brucei of >100µM (Table 13). [68] Therefore, it was expected that derivatives 2a–j would not
show any trypanocidal activity against the T. brucei variant TC211. However, surprisingly
compounds 2a and 2d showed activities of 56.0µM and 12.7µM, respectively. The increased
activity of the piperidine salt 2d was particularly interesting, as this derivative showed the
highest GI50-value of 492µM. [68] However, these results may reflect the poor solubility of rho-
danine derivatives in aqueous media, as previous reports had shown that salts of rhodanine-
N-acetic acids improve water solubility. [192] Alternatively, the salt adduct 2d may improve dif-
fusion through biological membranes. Improved membrane permeability would also explain
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Figure 29: Plot of log(C) against normalised parasite survivals and structure of Melarsoprol.
the relatively high toxicity (45.2µM) of the piperidine-salt 2d. Overall, activity against T. brucei
correlated well with previous results (Table 13). [68] However, the residual DPMS activity in the
previous study, generally did not correlate with its in vitro activity against T. brucei. [68] This ob-
servation indicates that the salt adduct improved the compounds ability to penetrate biological
plasma membranes. In the case of 2d, this would mean that the two very lipophilic benzylsub-
stituents facilitate the diffusion through the parasite membrane. Once inside the cytosol, 2d
can diffuse to its potential target (e.g. DPMS). In order to support the hypothesis that increased
lipophilicity improves anti-parasitic activity (Table 14), the library of rhodanine-N-acetic acid
derivatives was enlarged through the addition of lipophilic substituents such as methyl, trifluo-
romethyl or tert-butyl-groups. Initially, the activity of the starting rhodanine-N-acetic acid 2 was
assessed and was found inactive against T. brucei. Indeed, none of the derivatives showed ac-
tivity against T. brucei and T. cruzi at 100µM. Similarly to 2d, the piperidine salt of compound
2y (R4=tert-butyl) was prepared and tested. But in this case the activity of the piperidine
salt 2y and the free acid 2z did not affect trypanosomal activity. Di-trifluoromethyl substituted
derivatives 2ab and 2ae were not active at 100µM, but showed some trypanocidal activity at
the highest concentration of 100µM. Interestingly, the catechol derivative 2u (R1=OH) did not
show any anti-parasitic activity, but its slightly modified analogue 35a (R1=NH2) inhibited T.
brucei growth at GI50 17.1µM. These results suggested modifications on position N-1 to be
important for anti-trypanosomal activity. All derivatives had minimum inhibitory concentration
of >100µM.
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Table 13: Comparison of residual T. brucei DPMS activity and trypanocidal activity; Pip:
piperidine salt.
N S
S
O
R1O
O
R2 R3
R4
compounds
[%] GI50 [µM]
# R1 R2 R3 R4 DPMS(a) T. brucei (a) T. brucei T. cruzi HL60
2a H H H H 42±5 232±12 56.0±3.3 >100 >100
2b H H H OBn 10±2 338±31 >100 >100 >100
2c H H OBn H 23±3 96±5 >100 >100 >100
2d Pip H OBn OBn 20±4 492±24 12.7±0.2 n.a. 45.2±2.1
2e H OH H H 23±8 107±12 >100 >100 124.1±6.6
2f H H OH H 70±4 427±19 >100 >100 >100
2g H H H OH 90±5 345±23 >100 >100 >100
2h H H H Cl 73±6 244±17 >100 >100 >100
2i H H H CN 86±5 398±19 >100 >100 >100
2j H H H CCH 94±7 >1000 >100 >100 >100
(a) Data published by Smith et al. [68]
3.3.4 Anti-trypanosomal activity of the rhodanine moiety
It has been established, that anti-parasitic activity might vary with N-1 substitutions. In order to
further elucidate the role of the N-1-substituent on the rhodanine moiety, several N-1-modified
aliphatic acids were screened against T. brucei (Table 15, (a)). Firstly, rhodanine-N-acetic acid
2 was evaluated against T. brucei, but showed only weak anti-trypanosomal effects (around
100µM), although the exact value was not measured as it was beyond the highest concen-
tration in the screen. Furthermore, the ester derivatives 14 have been screened against T.
brucei and showed promising trypanocidal effects of GI5011.1 and 13.2µM against T. brucei.
Analogues with an elongated N-side linker (12 and 13) showed increased activity against T.
brucei with longer linker lengths. The logP values of all derivatives were calculated (MarvinS-
ketch) and compared to the anti-trypanosomal activity. With the exception of the methyl ester
analogue 14, a linear relationship between the logP value and anti-trypanosomal activity was
observed (Table 15, (b)). Although the methyl ester 14 had a logP of 0.46, its activity was
higher (11.1µM) compared to 12 (50.6µM) which had a logP value of 0.55. This result sug-
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Table 14: Anti-trypanosomal activity of rhodanine-N-acetic acid derivatives 2, 2k–ae, and 35a.
N S
S
O
R1
O
R2 R3
R4
R5
2a–ae
GI50 [µM]
# R1 R2 R3 R4 R5 T. brucei T. cruzi HL-60
2 OH n.a. n.a. n.a. n.a. >100 n.a. n.a.
2k OH H NO2 H H >100 >100 >100
2l OH H Br OMe H >100 >100 >100
2m OH H CH3 H H >100 >100 >100
2n OH H H CH3 H >100 >100 >100
2o OH CH3 H H H >100 n.a. >100
2p OH H CF3 H H >100 >100 >100
2q OH H H CF3 H >100 >100 >100
2r OH CF3 H H H >100 >100 >100
2ag OH CF3 H CF3 H >100 >100 n.a.
2s OH H H SO2Me H >100 >100 >100
2t OH H H NMe2 H >100 >100 >100
2u OH H OH OH H >100 >100 n.a.
2v OH H COOH H H >100 >100 >100
2w OH OH H OH H >100 >100 >100
2x OH CF3 H H CF3 >100 >100 >100
2y C5H11N H H tBu H >100 >100 >100
2z OH H H tBu H >100 >100 >100
2aa OH COOH H H H >100 >100 n.a.
2ab OH CF3 H CF3 H 185.6±3.54 >100 >100
2ac OH H H OMe H >100 >100 n.a.
2ad OH H H NHAc H >100 >100 >100
2ae OH H CF3 H CF3 109.7±10.61 >100 n.a.
35a(a) NH2 H OH OH H 17.7±0.1 >100 n.a.
(a) received from Prof. Dr. M. Schlitzer, Phillips University, Marburg, Germany.
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Table 15: Activity of starting rhodanine-N-acetic acid derivatives and correlation to logP
(Y=145.9-160.5·x, r2=1.0).
(a) Activity of starting rhodanine
N S
S
O
R1O
O
n
GI50 [µM]
# n R logP(a) T. brucei HL60
2 1 H 0.31 100 n.a.
14 1 Me 0.46 11.1±0.1 n.a.
12 2 H 0.55 50.6±1.2 >100
14 1 Et 0.82 13.3±0.5 >100
13 3 H 0.84 15.2±3.3 >100
(a)calculated with ChemAxxon MarvinSketch
(b) Correlation of logP and GI50 (T. brucei)
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gested that the anti-trypanosomal activity went beyond simple correlation to logP and other
factors had to be considered. Under physiological pH the analogue 12 is negatively charged,
potentially resulting in repulsion from the parasitic membrane, whereas the negative charge
in the methyl ester analogue 14 is masked, facilitating diffusion to the plasma membrane. In
the case of the ethyl ester analogue 14 and the charged analogue 13 the effect is less domi-
nant, possibly due to similar logP values (0.82 and 0.84). The two additional methylene-linker
groups might contribute more to membrane diffusion than the ethyl ester moiety. Thus in-
creased linker length and ester functionalities resulted in low µM inhibitors of T. brucei growth,
without showing toxicity against mammalian cells (HL60 cells, Table 15 (a)). The methyl and
ethyl esters 14 as well as the elongated analogue 13 cleared parasitaemia at 100µM (MIC
100µM). Therefore, it was of interest if additional substituents in position 5 of the rhodanine
moiety would further enhance their anti-parasitic activity.
3.3.5 Derivatives with elongated N-3 side-chain linkers
Increasing lipophilicity of the rhodanine-moiety led to increased potency against T. brucei (Ta-
ble 15). In this chapter, the effect of the increased linker-length of derivatives 12 and 13 was
studied. In particular their condensation products on position 5 were of interest to increase
anti-parasitic activity. And indeed, the simple condensation product of 12 and benzaldehyde
was almost 4 times as potent against T. brucei (12a, GI50 13.0µM) as the unsubstituted rhoda-
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Table 16: Anti-trypanosomal activities of derivatives with elongated side chain.
N S
S
O
HO
O
n
R1 R2
R3
R4
MIC [µM] GI50 [µM]
# n R1 R2 R3 R4 T. brucei T. brucei T. cruzi HL60
12a 2 H H H H 100 13.0±0.7 >100 >100
12l 2 H H OH H n.a. n.a. >100 >100
12k 2 H OH H H >100 >100 >100 n.a.
12m 2 H OH OH H 100 14.2±2.3 >100 >100
12h 2 H H NMe2 H >100 60.8±8.9 >100 >100
12i 2 H H Cl H >100 60.6±2.0 >100 >100
12b 2 CH3 H H H 100 13.0±0.6 >100 >100
12c 2 H CH3 H H >100 72.8±1.9 >100 >100
12d 2 H H CH3 H 100 12.3±0.9 >100 >100
12e 2 CF3 H H H 100 11.5±0.1 >100 >100
12f 2 H CF3 H H 100 13.9±1.4 >100 >100
12g 2 CF3 H H CF3 100 9.0±0.3 >100 >100
13a 3 H H H H 100 13.3±0.6 >100 >100
13b 3 CH3 H H H 100 13.0±1.6 >100 >100
13c 3 H CH3 H H 100 13.6±1.8 >100 >100
13d 3 H H CH3 H 100 16.7±0.3 >100 >100
nine precursor 12 (50.6µM, Table 16). The derivative 13a with an additional methylene-group
in the linker moiety of the rhodanine showed similar activity of GI5013.3µM against T. bru-
cei. But compared to its parent rhodanine (13, GI50 15.2µM) the condensation had only a
minor effect on the overall activity. Substitutions in ortho-position on the 5-benzylidene moi-
ety were well tolerated by methyl and trifluoromethyl groups (GI50 11.5-13.0µM). In the case
of the propyl-linked derivatives 12a–g a trifluoromethyl group in meta-position increased anti-
trypanosomal activity (GI50 13.9µM). The corresponding meta-hydroxy or meta-methyl sub-
stituted analogues were 5 times less active. It is possible, that the trifluoromethyl acts as a
hydrogen-bond acceptor through negative hyper conjugation of the aromatic pi-system, or the
bulky trifluoromethyl group might fill a liphophilic pocket within the active site of a protein (Fig-
ure 30). [193,194] It is also possible that the increased activity was merely a result of increased
solubility through the trifluoromethyl substitution. [195] Trifluoromethyl substituents are known to
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Figure 30: Possible effects of the meta-CF3 group on the activity of rhodanine derivatives.
act as hydrogen-bond acceptors, but they also have been used as replacements for isosteric
OH groups. [193,196] However, in compound 12e, the reason for increased activity cannot be
explained by mimicking hydroxyl groups, as the meta-hydroxy analogue 12k did not show any
anti-trypanosomal activity. But it was interesting to observe that anti-trypanosomal activity was
restored through installing an additional para-hydroxy substituent (12m, GI50 14.2µM). The
bis-trifluoromethyl substituted compound 12g might benefit from improved solubility and was
therefore the most active anti-parasitic compound in this series (GI50 9.0µM). [196] But other
effects of the trifluoromethyl group, such as resemblance to bulky propyl groups or hydrogen-
bond acceptor functionality or indeed attraction to electropositive regions (Asn, Glu, Arg) of
receptor sites may be responsible for increased actitivity. [195] Almost all derivatives of this se-
ries were able to lyse T. brucei in vitro at 100µM (MIC 100µM) and did not show toxicity
against mammalian HL60 cells at 100µM (Table 16).
3.3.6 N-1 ester modification and their anti-trypanosomal effect
In Table 15, a linear relationship between logP and the starting rhodanine derivatives was
observed. Following this trend, elongated N-1-sidechain rhodanines showed similar activities
to ester derivatives due to similar logP values. However, a methyl ester did not follow this trend;
although the logP (0.46) was relatively low, its activity was better than compounds with higher
logPs (0.82, 0.84). Thus far, it has been established that elongated derivatives with a free
carboxylic acid had activities against T. brucei in the range of 9.0-72.8µM. In this chapter, ester
derivatives of rhodanine-N-acetic acid were screened for their trypanocidal activity (Table 17).
Hydroxy-modified ester analogues
The most potent compound against T. brucei growth was the catechol modified ethyl ester
14t (Table 17). 14t had an activity of GI50 1.6µM against T. brucei, without showing any
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Table 17: Anti-trypanosomal activity of ester analogues and their toxicity, sorted by activity
and toxicity.
N S
S
O
R1O
O
R2 R3
R4
R5
GI50 [µM]
# R1 R2 R3 R4 R5 T. brucei SI (T. brucei) T. cruzi HL60
14t Et H OH OH H 1.6±0.1 >62.5 n.a. >100
14o Et H H tBu H 1.7±0.1 >59 >100 >100
14v Et H OBn H H 4.4±1.1 >23 >100 >100
14j tBu H H H H 9.6±0.8 >10 >100 >100
14a Et H CH3 H H 1.5±0.3 21 >100 31.0±0.8
14b tBu H CH3 H H 1.8±0.1 14 5.1±0.5 25.0±1.6
14g Et CH3 H H H 1.3±0.1 10 >100 12.7±0.9
14c Me H CH3 H H 1.3±0.1 9 >100 12.0±1.7
14h tBu CH3 H H H 5.2±0.3 9 >100 48.2±7.0
14d Et H H CF3 H 1.4±0.1 8 n.a. 11.8±0.5
14e Me H H CF3 H 1.4±0.1 7 17.4±1.1 9.9±1.8
14k Et CF3 H H H 1.4±0.1 7 n.a. 9.3±3.7
14l Et H CF3 H H 1.7±0.1 7 n.a. 11.3±3.7
14m Et CF3 H H CF3 1.8±0.1 n.a. n.a. n.a.
14w Et H H OBn H 17.0±0.9 6 >100 >100
14i Et H H H H 8.3±0.7 5 94.6±1.8 38.0±1.8
14y Et H OMe OH OMe 11.7± 1.8 3 46.6±0.5 38.1±6.4
14p Et OH H H H 1.7±0.1 2 n.a. 4.1±0.7
14s Me H OH OH H 11.1±0.1 2 n.a. 23.6±1.1
14n Et H H CH3 H 15.6±1.4 2 n.a. 29.3±8.3
14q Et H OH H H 4.8±0.9 2 n.a. 9.9±0.5
14f tBu H OBn OBn H >100 n.a. >100 n.a.
14x Et H OBn OBn H >100 >1 >100 >100
14u Et OH H OH H 1.7±0.1 n.a. 4.7±0.6 n.a.
35b Me H OH OH H 10.1±1.6 n.a. n.a. n.a.
14r Et H H OH H 17.6±0.1 n.a. >100 n.a.
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Scheme 21: Catechol reactivity to react with biological nucleophiles or cross-link proteins,
adapted scheme by Stanwell et. al [198].
toxicity against HL60 cells at 100µM. This was a surprising observation, since the analogous
catechol modified free acid 2u did not show any trypanocidal activity. The simple esterification
resulted in the transformation of an inactive compound against T. brucei growth to one of the
most active inhibitors both in terms of anti-trypanosomal activity and selectivity against HL60
cells (SI >63, Table 17). In particular the missing toxicity against HL60 cells was significant,
since similar compounds, such as the N-1-unmodified catechol rhodanine 36a (Table 41, page
152) has previously been reported as potent inhibitor of HL60 cell growth. [197] Compound 37
has been shown to inhibit oncoprotein aggregation of c-Myc Max, therefore preventing DNA
binding and leading to apoptosis in HL60 cells. [197] Indeed, 36a showed a GI50 value of 45µM
against HL60 cells growth, confirming the previously reported IC50 of 23µM. [197] The additional
substituent in position N-1 in compound 14t led to complete loss of toxicity against HL60 cell
growth, potentially showing that c-Myc Max aggregation was not inhibited. However, the ethyl
ester modification was essential for retaining the selectivity as the corresponding methyl ester
14s had only a selectivity index (SI) of 2 and displayed a ten-fold reduction in anti-parasitic
activity (GI50 11.1µM). This indicates the potential problem of catechol-containing molecules
in medicinal chemistry. [198] The cytotoxicity of catechol derivatives is believed to derive from
oxidation of the hydroxyl groups to quinones, which can react with biological nucleophiles such
as glutathione or cross-link proteins (Scheme 21). [198,199]
However, this mode-of-action cannot be generalised, as the free acid of 14t has previously
been reported as non-covalent ("affinity-based") probe for the NAD(P)H site of dehydroge-
nases. [107,108] Indeed, similar catechol derivatives showed nM activity against the NAD(P)H-
dependant enoyl acyl carrier protein reductase of Plasmodium falciparum (PfENR). [112] The
catechol moiety has been found to be essential for PfENR inhibition and thus for type II fatty
acid biosynthesis inhibition. [112] T. brucei uses a related elongase pathway for de novo synthe-
sis of myristate, an essential building block for GPI anchor biosynthesis, [200] (further details in
section 5.1) possibly explaining the low µM anti-trypanosomal activity.
A third possible mode of action was derived during the evaluation of the activity and toxicity
assays against T. brucei and HL60 cells. Stock solutions of catechol derivatives 14t, 14s, and
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35b in DMSO are distinguished by their bright yellow-orange colour. However, in aqueous
solutions these compounds were bright red. Catechol rhodanine 36a has previously been
found to form brown complexes with Fe(III) ions. [201] In addition, Mn(II) and Mg(II) formed
purple-red complexes with catechol rhodanine under basic conditions. [201] It seemed evident
that 14t, 14s, and 35b formed metal-complexes in the assay medium. Although the red colour
might have indicated Mn(II) or Mg(II) chelation, the neutral pH of the assay medium made
Fe(III) more likely.
Other hydroxy-substituted methyl and ethyl ester derivatives (14p, 14s, 14q, 14u, 35b,
14r, and 14y) showed good activity against T. brucei growth (GI50 1.7-17.6µM), however the
selectivity indices were less preferable for derivatives 14p, 14s, and 14q (SI 2). A particularly
interesting inhibitor was 14u, as it showed activity in the lower µM range for both T. brucei and
T. cruzi (GI50 1.7 and 4.7µM). The previously mentioned formation of bright red colours in the
assay medium interfered with the MTT formazan readout, therefore derivatives 14p, 35b, and
14r could not be assessed against T. cruzi, although the MIC value was 100µM.
Methyl-, trifluoromethyl- and tert-butyl-substituted benzylidene derivatives and their
trypanocidal activity
Methyl- and trifluoromethyl-substituted ester derivatives 14a–l and 14n had low µM activity
against T. brucei with GI50 values ranging from 1.3-15.6µM and had SI of 2-21. These deriva-
tives showed general cytotoxic effects against T. brucei and HL60 cells. Different ester mod-
ifications (methyl, ethyl or tert-butyl) had no effect on the activity against T. brucei or toxicity
against HL60 cells. However, modification of the ester moieties resulted in an increased activ-
ity against T. cruzi. The ethyl ester derivative 14a did not show any trypanocidal activity against
T. cruzi at 100µM, while the methyl ester substitution increased activity by a factor of 20 (GI50
5.1µM). Modification of the ester group also proved beneficial for the unsubstituted benzyli-
dene derivatives 14i and 14j. The ethyl ester modification in 14i increased activity against T.
brucei by a factor of 7 (GI50 8.3µM) compared to the free acid analogue 2a (GI50 56.0µM), but
14i also showed increased toxicity against HL60 cells (GI50 38µM). Substitution of the ethyl
to a bulky tert-butyl ester had no effect on the anti-trypansomal activity against T. brucei, but
has proven beneficial in terms of its toxicity. The tert-butyl ester derivative 14j retained activity
at GI50 9.6µM and did not show any toxicity against HL60 cells at 100µM. A similar conclu-
sion could be drawn by comparing the 5-benzylidene modifications in para position. The bulky
lipophilic trifluoromethyl derivatives 14d and 14e displayed low µM activity against T. brucei,
but also demonstrated significant toxicity against HL60 cells (SI 7). Bio-isosteric replacement
of the trifluoromethyl group (Taft E value -2.4), to the only slightly larger tert-butyl group (Taft
E value -2.78) resulted in complete loss of toxicity at 100µM against HL60 cells, while activity
against T. brucei was retained at GI50 1.7µM. [193] The retention in activity might suggest that
the trifluoromethyl group served as a lipophilic substituent in para-position of the 5-benzylidene
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moiety.
Benzyloxy-modified 5-benzylidene ester derivatives and their anti-trypanosomal activity
Benzyloxy-modified rhodanine-N-acetic acid derivatives 2b, 2c, and 2d were of particular inter-
est, as they showed promising activity against DPMS (residual activity 10-23 %), an essential
enzyme in the GPI-anchor biosynthesis. [68] It was pleasing to observe, that the 3-benzyloxy-
modified ethyl ester 14v showed low µM activity against T. brucei (GI50 4.4µM) and most
importantly did not reveal any toxicity against HL60 cells at 100µM. These results might in-
dicate a correlation between the in vitro anti-trypanosomal activity against T. brucei and the
enzymatic activity of DPMS. The ester modification could facilitate membrane diffusion, allow-
ing a higher concentration of the inhibitor to reach the enzymatic site for effective inhibition.
Interestingly the 4-benzyloxy-ethyl ester was four times less active in vitro against T. brucei,
although it showed two times better DPMS inhibition (Table 13, 10 % residual activity) than
14v (23 % residual activity). [68] However, it is not known if the active inhibitor of DPMS is
the free acid or its ester analogue. Moreover, potentially multiple targets in T. brucei could
be affected by the modified analogues 14v and 14w. The 3,4-bis-benzyloxy ester modified
analogues 14f and 14x did not demonstrate any trypanosomal activity at 100µM. These ana-
logues might have been too lipophilic to pass through the parasitic plasma membrane and
therefore demonstrate the limits of increasing lipophilicity to gain anti-trypanosomal activity.
3.3.7 Compounds with improved anti-parasitic activity identified after first generation
of optimisation
The first round of optimisations of rhodanine-N-acetic acid derivatives led to compounds with
low µM activity (GI50 1.6-14.2µM) against T. brucei and T. cruzi with low toxicity against HL60
cells (Table 18). The first class of derivatives (Class A, Table 18) was composed of the cate-
chol modified rhodanine derivatives 14t and 12m. Possible further optimisations include the
combination of an elongated side-linker and an ester functionality.
Benzyloxy-modified esters and in particular compound 14v showed good activity against
T. brucei (GI50 4.4µM) while revealing no toxicity against HL60 cells. This derivative (Class B,
Table 18) was interesting, as its parent free acid has been identified as good DPMS inhibitor. [68]
Further optimisation of this derivative would include modifications on the 3-benzyloxy moiety.
The ester derivatives 14o and 14b represent the other identified class of compounds with
improved anti-parasitic activity (Class C and D, Table 18). They had low µM activity against T.
brucei (14o and 14b) and T. cruzi (14b). Further modifications of the thiocarbonyl group in the
rhodanine moiety might improve their toxicity profile, as the carbonyl group has been shown
to undergo more specific interaction compared to the thiocarbonyl, which has a diffuse HOMO
orbital, favouring multiple polar and intermolecular interactions. [83]
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Table 18: 2nd generation inhibitor classes A-D as anti-trypanosomal agents against T. brucei
and T. cruzi.
N S
S
O
R1O
O
R3
R2n
GI50 [µM]
# Class R1 n R2 R3 T. brucei SI T. brucei T. cruzi HL60
14t
A
Et 1 OH OH 1.6±0.1 >62.5 n.a. >100
12m H 2 OH OH 14.2±2.3 >7 >100 >100
14v B Et 1 OBn H 4.4±1.1 >23 >100 >100
14o C Et 1 H tBu 1.7±0.1 >59 >100 >100
14b D tBu 1 CH3 H 1.8±0.1 14 5.1±0.5 25.0±1.6
3.3.8 Further optimisation of structure classes A,C and D
In the next round of inhibitor optimisation, the free carboxylic acid of the elongated analogues
was masked as its ethyl ester. This modification resulted in low µM active compounds for
the simple N-acetic ester modified series. The thiocarbonyl in the rhodanine was replaced
by a carbonyl group. A recent review about rhodanine derivatives suggested that this thio-
carbonyl group is a major contributor to the ubiquitous binding of rhodanine derivatives. [83]
The interactions of the thiocarbonyl group in rhodanine derivatives in protein X-ray structures
in the PDB database has been analysed and revealed that this group undergoes a significant
amount of polar and intermolecular interactions. [83] Therefore, replacement of this thiocarbonyl
might increase selectivity towards a particular target, possibly simultaneously reducing toxic-
ity against HL60 cells. The modifications on the 5-benzylidene moiety were chosen based
on previous results. Hydroxy, methyl and trifluoromethyl substituents resulted in low µM try-
panocidal compounds, if combined with an ester moiety on the N1-side of the rhodanine core
structure (Table 17). The results of the screening of these inhibitors against T. brucei, T. cruzi
and HL60 cells is summarised in Table 19. The entries in the table were sorted by increas-
ing activity against T. brucei and decreasing toxicity against HL60 cells. Not surprisingly,
the top entries of Table 19 constituted catechol derivatives (7k, 15f, and 16i). Substitution
of the thiocarbonyl did not effect activity against T. brucei. The dione derivative 7k had a
GI50of 1.4µM against T. brucei, whilst showing no toxicity against HL60 cells. Alkylation of the
3,4-dihydroxy motif with benzyl groups totally abolished anti-trypanosomal activity. This might
indicate that the catechol moiety could be involved in hydrogen bonding interactions. Alterna-
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Table 19: 3rd generation optimisation of compound classes A, C and D.
N S
X
O
O
O
R1 R2
R3
R4
n
GI50[µM]
# X n R1 R2 R3 R4 T. brucei SI T. brucei T. cruzi HL60
7k O 1 H OH OH H 1.4±0.2 >71 >100 >100
15f S 2 H OH OH H 0.9±0.1 35 n.a. 31.2±2.8
16i S 3 H OH OH H 1.4±0.3 21 n.a. 29.0±4.2
16a S 3 H H H H 7.4±5.2 >14 n.a. >100
16e S 3 CF3 H H CF3 9.5±0.1 5 >100 47.9±4.6
15a S 2 H H H H 4.5±0.3 4 >100 16.5±1.2
16f S 3 OH H H H 1.3±0.1 n.a. 10.9±0.1 n.a.
15c S 2 H CH3 H H 10.2±0.2 2 >100 17.6±2.5
15b S 2 CH3 H H H 10.6±0.3 3 >100 35.6±2.9
16b S 3 CH3 H H H 11.5±0.1 4 >100 40.5±3.3
16c S 3 H CH3 H H 12.0±1.1 3 >100 31.5±1.6
7e O 1 CF3 H H H 13.0±1.2 >8 >100 >100
15d S 2 H H CH3 H 13.1±2.4 3 >100 44.4±5.6
7f O 1 H CF3 H H 13.3±0.4 >8 >100 >100
7c O 1 H CH3 H H 14.7±1.7 >7 >100 >100
16d S 3 H H CH3 H 15.1±2.2 >7 >100 >100
7b O 1 CH3 H H H 15.2±2.3 >7 >100 >100
7d O 1 H H CH3 H 16.3±1.8 >6 >100 >100
16g S 3 H OH H H 16.8±1.0 21.4±4.2 n.a.
15e S 2 H H OH H 17.4±0.5 1 >100 9.2±2.0
7j O 1 H OBn OBn H >100 >1 n.a. >100
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tively the 3,4-benzyloxy substituent may be too bulky to be accommodated in the active site,
or it may have been too lipophilic to pass through the parasite membrane. The elongation of
the side-chain in N-1 position in the rhodanine moiety combined with the ester modification
and a catechol motif in position five resulted in the first inhibitor against T. brucei growth in the
sub-µM range. The elongated analogue 15f had a GI50 value of 0.9µM and displayed a SI of
35 towards HL60 cells. Increasing the methylene linker even further, as shown in compound
16i did not improve activity against T. brucei. Interestingly, the combination of an elongated
side chain (n=3) combined with a hydroxy substituent on the 5-benzylidene moiety resulted
in compounds 16f and 16g, which displayed moderate activities against T. cruzi (GI50 10.9-
21.4µM). However, the shorter (n=2) linker analogue did not show any activity against T. cruzi,
but toxicity in the lower µM range against HL60 (GI50 9.2µM).
Applying the elongation and esterification strategy on methyl or trifluoromethyl benzylidene
modified rhodanine derivatives did not improve their anti-parasitic activity (GI509.5-16.3µM)
or toxicity against HL60 cells (SI 2-8) compared to derivatives 14a–l. The substitution of
the thiocarbonyl to a carbonyl group improved their toxicity profile and none of the inhibitors
displayed any toxicity against HL60 cells at 100µM. But the replacement also reduced the
anti-parasitic activity by a factor of 10 (GI50 13.0-16.3µM).
Optimisation of compound class B
In the first screening of rhodanine derivatives, a 5-(benzylidene-3 benzyloxy) rhodanine-N-
acetic acid derivative (2c, Table 20) has been identified as DPMS inhibitor of T. brucei, but did
not display any activity against T. brucei in vitro. [68] The introduction of an ethyl ester moiety
as replacement for the free acid resulted in low µM activity against T. brucei (14v, Table 20).
In order to improve the anti-trypanosomal activity, various substituents on the 3-benzyloxy
moiety were introduced. Furthermore, the side-chain linker was elongated by an additional
methylene-unit, and the thiocarbonyl was substituted with a carbonyl group. Lastly prolonged
N-1-side-chain analogues with a free acid moiety were compared to ester analogues. The
assessed inhibitors are displayed in increasing order of activity against T. brucei and decreas-
ing toxicity against HL60 cells (Table 20). Indeed, substitution of the 3-benzyloxy substituent
improved activity against T. brucei by a factor of 3 compared to the unsubstituted analogue
14v. The inhibitor 19c displayed low µM activity against T. brucei (GI50 1.5µM) and only mi-
nor toxicity against HL60 cells (SI 59). The derivative 14v is equipped with a para-methoxy
substituent on the 3-benzyloxy-moiety. Using this modification and replacing the thiocarbonyl
to a carbonyl group furnished 19e, revealing a 10-fold decrease in activity against T. brucei.
Similarly, increasing the length of the N-1 side-linker in compound 19e caused a 10-fold drop
in anti-trypanosomal activity against T. brucei, this is similar to previous reports that substitu-
tion to the carbonyl group results in loss of activity. [81] It was interesting to observe that the
starting para-methoxy substituted aldehyde 18c did not display any anti-trypanosomal activity
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Table 20: Optimisation of compounds from class B, substitution of the 3-benzyloxy-
substituent.
N S
X
O
O
O O
nR
D C
B
A
O
O
D C
B
A
N S
S
O
EtO
O
N
HN
CH319c–f, 14v, 7h, 2c, and 34 18d–c 26a
GI50[µM]
# n X R A B C D T. brucei SI T. cruzi HL60
19c 1 S Et CH CH COMe CH 1.5±0.3 59 >100 88.8±8.5
14v 1 S Et CH CH CH CH 4.4±1.1 >23 >100 >100
7h 1 O Et CH CH CH CH 11.1±0.3 >9 >100 >100
19k 1 S Et CH CH N CH 1.7±0.1 9 n.a. 15.5±1.7
19j 1 S Et N CH CH CH 1.7±0.1 9 n.a. 14.7±2.7
19l 1 S Et CH N CH CH 1.7±0.1 7 n.a. 11.5±4.8
19d 1 O Et CH CH COMe CH 9.9±4.2 n.a. >100 n.a.
34 1 S Et CH CN3 CH CN3 12.9±4.6 >8 >100 >100
19b 1 O Et CH COMe CH CH 13.1±2.7 n.a. >100 n.a.
19e 2 S Et CH CH COMe CH 13.9±3.4 n.a. n.a. n.a.
19a 2 S Et CH COMe CH CH 14.8±0.4 n.a. >100 n.a.
18b n.a. CH COMe CH CH 15.5±3.0 n.a. n.a. n.a.
18e n.a. CH N CH CH 17.4±0.2 n.a. n.a. n.a.
19h 2 S H CH CH N CH 60.7±3.3 2 n.a. >100
19g 2 S H CH N CH CH 66.9±2.0 1 n.a. >100
19f 2 S H N CH CH CH 68.3±0.7 1 n.a. >100
18f n.a. CH CH N CH >100 n.a. n.a. n.a.
18d n.a. N CH CH CH >100 n.a. n.a. n.a.
18c n.a. CH CH COMe CH >100 n.a. n.a. n.a.
2c 1 S H CH CH CH CH >100 >1 >100 >100
26a not applicable 1.6±0.1 6 21.6±4.0 10.0±3.8
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at 100µM. While the analogous meta-methoxy substituted aldehyde 18b had a moderate ef-
fect on trypanosomal growth (GI5015.5µM). However, the corresponding condensation product
19a was 10-fold less active than the para-substituted analogue 19c.
The introduction of a pyridine-moiety in compounds 19k, 19j, and 19l resulted in low µM ac-
tive inhibitors of T. brucei growth (GI501.7µM). But these derivatives displayed less selectivity
between T. brucei and HL60 cells (SI 7-9), compared to the methoxy substituted derivative
19c (SI 59). Similar to the methoxy-substituted analogues, the meta-pyridine substituted alde-
hyde 18e showed moderate anti-trypanosomal activity while the ortho- and para-substituted
analogues did not display any activity against T. brucei at 100µM. The combination of a
free carboxylic acid and an elongated side-chain with the pyridine-substiution furnished com-
pounds 19h, 19g, and 19f, which displayed only moderate activity against T. brucei (GI50 60.7-
68.3µM).
Compound 34 was a protein-reactive photo-labelling probe. This probe was designed
to bind to its target protein via an aryl-azide moiety, while a second photo-stable aliphatic
azide serves as a tag for biotin or fluorophorores (such as AlexaFluor 488). It was pleasing
to observe that although relatively large azide substituents were introduced, the probe 34
retained most of its anti-trypanosomal activity (GI50 12.9µM) compared to the original lead
structure 14v (GI50 4.4µM).
In order to study the importance of the oxygen-linker in the benzyloxy-substituted ana-
logues, the heterocycle 26a was assessed for its anti-trypanosomal potential. The 5-(benzy-
lidene-3-benzyloxy) moiety has been replaced with a 2-amino(benzylidene)-pyridine group in
compound 26a. This derivative was the first inhibitor in this series to display a trypanocidal
effect both in T. brucei and T. cruzi, however the activity against T. cruzi might correlate to the
toxicity towards HL60 cells. Yet this inhibitor was a good starting point for the development for
more potent and in particular less toxic inhibitors of T. brucei and T. cruzi growth.
3.3.9 Heterocyclic modifications on position 5 of N-1-substituted rhodanine and
thiazolidine-2,4-dione derivatives
Heterocyclic analogues, such as the rhodanine-N-acetic ester derivative 26a (Table 20) has
been identified as low µM growth inhibitor of T. brucei and T. cruzi, but also displayed high tox-
icity against HL60 cells (GI50 10.0 µM). In this chapter, several 5-pyridine modifications have
been assessed for their anti-trypanosomal activity (Table 21). The most active inhibitor in this
series had a 3-pyridinyl modification on the 5-position of the rhodanine-N-acetic ester moiety.
Compounds 26g and 26f displayed anti-trypanosomal activity against T. brucei in the low µM
range (GI501.5µM) and against T. cruzi at 100µM (MIC 100µM). The exact GI50 values could
not be obtained due to interference of the derivatives with the viability dye MTT used in the
growth inhibition assay for T. cruzi. Furthermore, both inhibitors 26g and 26f possessed a
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Table 21: Heterocyclic modified rhodanine-N-acetic acid and there ester analogues.
N S
X
O
R1O
O
R2
GI50[µM]
# x R1 R2 T. brucei SI T. brucei T. cruzi HL60
26g S Et 3-pyridinyl 1.5±0.2 34 n.a. 51.5±2.5
26f S Et 2-pyridinyl 1.5±0.3 >67 n.a. >100
21a S Et 2-cl-4-pyridinyl 1.7±0.1 n.a. 6.9±0.6 n.a.
26c S H 3-pyridinyl 116.0±6.4 >1 >100 >100
26i O Et 4-pyridinyl 16.4±1.7 >6 n.a. >100
26b S H 2-pyridinyl >100 >1 >100 >100
26h S Et 4-pyridinyl >100 >1 >100 >100
26d S H 4-pyridinyl >100 >1 >100 >100
26j S Et 2-furanyl 7.4±2.1 7 n.a. 48.1±2.4
good toxicology profile (SI 34-(>67)). The anti-parasitic effect against T. brucei could already
be observed in the free carboxylic acid derivative 26c, which inhibited growth of T. brucei at
100µM by 55 % (data not shown) and resulted in a GI50 116µM. The transformation of the acid
to the ethyl ester resulted in a compound with low µM activity and a good selectivity profile.
A 4-pyridinyl-modification on position 5 of the rhodanine-N-acetic acid (26d) and ester
(26h) resulted in a complete loss of anti-trypanosomal activity against both T. brucei and T.
cruzi. However, substituting the thiocarbonyl to a carbonyl-group in compound 26i restored
some of the anti-trypanosomal activity against T. brucei (GI50 16.4 um). In addition the intro-
duction of a 2-chloro-substituent next to 4-pyridinyl-moiety restored activity. Indeed, compound
21a was equipotent against T. brucei and T. cruzi as the 2- and 3-pyridinyl substituted inhibitors
26g and 26f (GI50 1.5µM).
3.3.10 Anti-trypanosomal effect of saturated rhodanine analogues
The inhibitor with the highest anti-trypanosomal activity against T. brucei was the catechol
derivative 7k, which had a GI50 of 1.4µM against T. brucei growth and did not show any
toxicity against HL60 cells (Table 22). Similarly, the unsubstituted 5-benzylidene rhodanine-
N-acetic acid ester 14i displayed low µM activity against T. brucei (GI50 8.3 um). In order to
study the growth inhibition of these derivatives in more detail, the exo-cyclic double bond was
reduced and evaluated for their trypanocidal activity (Table 22). The double bond in rhoda-
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nine and thiazolidine-2,4-dione derivatives is part of a Michael acceptor system and therefore
susceptible to nucleophilic attack by glutathione or similar biological nucleophiles. If inhibitors
in this series could covalently bind over this Michael acceptor system to the target protein,
reduction of this double bond should abolish its activity. The reduction of the benzylidene
rhodanine-N-acetic ester 14i furnished the saturated analogue 27a. The reduction of the dou-
ble bond in derivative 27a improved its anti-trypanosomal activity towards T. brucei. This result
not only suggested that the inhibitor did not covalently bind to its target, it also revealed possi-
ble strategies to increase its anti-parasitic activity against T. brucei. It is possible that reduction
of the double bond in compound 27a increased flexibility and solubility compared to its non-
reduced analogue 14i. Substitution of the thiocarbonyl to a carbonyl functionality reduced
the anti-trypanosomal activity to 50.3µM. 27b was 50 times less active against T. brucei and
HL60 cells. These promising results on the reduction of the unsubstituted rhodanine-N-acetic
ester derivative 14i encouraged the reduction of the double bond in the cathechol derivative
7k. This thiazolidine-2,4-dione derivative was one of the most active inhibitor against T. bru-
cei growth and displayed no toxicity against HL60 cells. The reduction of the double bond
furnished a compound 11 times less active against T. brucei. However, the reduced analogue
27c still possessed a GI50 value of 16µM. It is possible that the catechol moiety in 27c is
involved in hydrogen-bonding interactions. Increased flexibility resulting from the reduction of
the double bond might weaken these interactions. Furthermore, the non-reduced analogue
7k might resemble a conformation that preferably binds to its molecular target, whereas the
reduction of the double bond results in multiple possible conformers. The only side-product of
the reduction of the rhodanine-derivatives, a Hantzsch ester 28, has been purified and tested
for anti-trypanosomal activity. The Hantzsch ester did not show any activity at 100µM on T.
cruzi growth.
3.4 Anti-leishmanial activity
The complete set of compounds, previously assessed for their anti-trypanosomal activity, were
screened against Leishmania infantum promastigotes. Initially, L. infantum promastigotes were
screened against the whole inhibitor library at a fixed concentration of 100µM in a 96 well plate
format. Each inhibitor was evaluated for its anti-leishmanial effects by visual inspection under
a light microscope. Derivatives which killed L. infantum at 100µM (MIC 100µM) were further
evaluated. These pre-selection steps narrowed the focus onto the analysis of compounds with
interesting anti-leishmanial activity to maximise efficiency during the limited time available for
the execution of these activity screens (data not shown). For compounds with MIC values
at 100µM, a complete inhibition curve was recorded using the MTT 96 well format assay
previously described (chapter 3.3.1).
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Table 22: Reduced rhodanine-N-acetic ester analogues and their anti-trypanosomal activity.
N S
X
O
O
O
H
H H
N S
X
O
O
O
27a, 27b, and 27c 14i and 7k
GI50[µM]
# X R1 R2 T. brucei SI T. brucei T. cruzi HL60
27a S H H 1.3±0.1 14 n.a. 18.1±3.6
27b O H H 50.3±4.0 >2 >100 >100
14i S H H 8.3±0.7 5 94.6±1.8 38.0±1.8
27c O OH OH 16.0±2.5 n.a. n.a.
7k O OH OH 1.4±0.2 >71 >100 >100
28 NH3C CH3
EtOOC COOEt
7k n.a. n.a. >100 n.a.
A total of 14 compounds showed anti-leishmanial effects and their GI50 values were as-
sessed (Table 23). All these derivatives displayed anti-trypanosomal activity against T. brucei
in the low µM range (GI50 0.9-16.8µM). The most active inhibitor was the rhodanine-N-acetic
tert-butyl ester derivative 14b. Derivative 14b stood out for its broad anti-parasitic activity
against T. brucei, T. cruzi and L. infantum. The GI50 of 14b against the tested protozoa was in
the range of 1.8-5.1µM and the SI ranged from 5-14. It is worth noticing that the methyl and
ethyl ester derivative of 14b displayed no activity against L. infantum, suggesting that the bulky
and lipophilic tert-butyl ester was necessary for anti-leishmanial activity. It would be possible
that a high logP-value and therefore a high lipophilicity may facilitate the uptake of the inhibitor
resulting in increased anti-leishmanial activity.
In order to analyse this hypothesis further, the logP of anti-leishmanial inhibitors (Table 23)
was plotted against their GI50 values (Figure 31). The red spots in the graph represent
hydroxy-modified inhibitors, whereas the yellow colour indicates lipophilic substituents such
as methyl, trifluoromethyl and tert-butyl groups on the 5-benzylidene moiety. The green colour
represents inhibitors of the heterocyclic modified series or derivatives with a reduced exo-
cyclic double bond. Excluding the last mentioned green labelled analogues, a negative trend
between the logP and GI50 was observed. Increasing logP values in inhibitors in this series
resulted in low µM active compounds against L. infantum.
However, with the exception of compound 14b, all inhibitors in this series were equal or
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Figure 31: Correlation of logP and increasing anti-leishmanial activity (Y=87.2-15.5·x, r2=0.4);
red: hydroxy substituted inhibitors; yellow: lipophilic; green: reduced or hetero-
cyclic modified derivative.
more toxic against HL60 cells than their anti-leishmanial activity (SI <1→>4).
It also seemed that this inhibitor series was more selective towards L. infantum and T.
brucei than against T. cruzi. Although many GI50 in Table 23 were not recorded against T.
cruzi, there MIC value was either 100 or >100µM. A MIC value in this range would result in
GI50 values in the range of 50-200µM. Inhibitors have been screened against T. cruzi, but
GI50 values could not be determined due to colorimetric interference of the inhibitor with the
MTT viability dye. However the reduced analogues could be tested, as reduction of the exo-
cyclic double bond in 27a and 27c caused a decrease in colour intensity. The reduction of
the double bond disrupts the conjugated aromatic system and therefore inhibitors appeared
less coloured in solution. The derivative 14b was also tested for its anti-leishmanial activity
against L. infantum amastigotes, as this is the standard assay for evaluation against Leish-
maniasis, [202] however these experiments were inconclusive as infection of mice macrophages
with L. infantum amastigotes failed, a common problem with this assay. [202]
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Table 23: Rhodanine- and thiazolidine-2,4-dione-N-ester derivatives with anti-leishmanial activity; logP calculated with instantchem
(ChemAxon).
N S
X
O
O
n N S
S
O
O
O
H
H H
R2 R3
R4
R5
R1O
R5
R4
27a and 27c
GI50[µM]
# n X R1 R2 R3 R4 R5 logP L. infantum SI L. infantum T. brucei T. cruzi HL60
14b 1 S tBu H CH3 H H 4.15 2.4±0.3 10 1.8±0.1 5.1±0.5 25.0±1.6
19k 1 S Et
O
N27c 3.29 16.3±6.9 1 1.7±0.1 n.a. 15.5±1.7
16e 3 S Et CF3 H H CF3 5.23 16.6±2.5 3 9.5±0.1 >100 47.9±4.6
16g 3 S Et H OH H H 3.17 18.6±10.6 n.a. 16.8±1.0 21.4±4.2 n.a.
16f 3 S Et OH H H H 3.17 20.0±1.5 n.a. 1.3±0.1 10.9±0.1 n.a.
14o 1 S Et H H tBu H 4.49 23.4±2.8 >4 1.7±0.1 >100 >100
14m 1 S Et CF3 H H CF3 3.91 28.7±1.1 n.a. 1.8±0.1 n.a. n.a.
16b 3 S Et CH3 H H H 3.98 29.9±0.9 1 11.5±0.1 >100 40.5±3.3
14p 1 S Et OH H H H 2.64 33.8±1.7 <1 1.7±0.1 n.a. 4.1±0.7
16c 3 S Et H CH3 H H 3.98 35.5±0.1 1 12.0±1.1 >100 31.5±1.6
15f 2 S Et H OH OH H 2.57 45.9±15.1 1 0.9±0.1 n.a. 31.2±2.8
16i 3 S Et H OH OH H 2.86 54.6±0.4 <1 1.4±0.3 n.a. 29.0±4.2
27a 1 S Et H H H H 3.04 73.5±5.5 <1 1.3±0.1 n.a. 18.1±3.6
27c 1 O Et H OH OH H 1.54 75.7±4.8 n.a. 16.0±2.5 n.a. n.a.
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3.5 Target identification studies
The anti-parasitic activity data to this point were obtained through whole cell activity assays.
Although this type of assay allowed the optimisation of the inhibitors in this series to low
µM activity, more insight in the molecular target(s) is needed in order to further optimise the
anti-parasitic activity. The initial objective was the identification of anti-parasitic agents with
potential activity against enzymes in the GPI-anchor biosynthesis, therefore several assays
have been designed to validate inhibition of this pathway. Two derivatives with interesting
anti-parasitic activity were chosen for further target validation studies. The first of these com-
pounds was the 3-benzyloxy rhodanine ethyl ester 14v (Table 24). This compound was cho-
sen for its low µM activity against T. brucei growth (GI50 4.4µM) and high selectivity (SI >23).
Furthermore the free acid analogue had been shown to inhibit DPMS in previous studies. [68]
The second compound was the meta-methyl rhodanine ethyl ester 14a (Table 24), which was
also chosen for its low activity against T. brucei (GI50 1.5µM). One further consideration was
that the analogous tert-butyl ester showed broad anti-parasitic activity against T. brucei, T.
cruzi and L. infantum (GI50 1.8, 5.1, 2.4µM, SI 14, 5, 10). This compound was assumed to
have a similar target than the ethyl ester analogue 14a, as activity against T. brucei was very
similar. The target identification studies were carried out on T. brucei, as this parasite was the
main focus of this study and other parasites were not accessible at this point.
3.5.1 Myristate labelling of GPI anchor biosynthesis
Introduction to myristate role in GPI anchor biosynthesis
The bloodstream form of T. brucei is covered in a dense coat of variant surface glycoproteins
(VSG), which are attached via a conserved GPI anchor to the plasma membrane of the para-
site. [69,203] This VSG coat serves as a barrier for components of the host immune system and
undergoes constant antigenetic variation, thus evading the host immune system. [70,204]
The GPI structure constitutes two myristates, that are embedded into the lipid bilayer of
the parasite membrane, anchoring the GPI-VSG construct. [69,203] Therefore, myristate has an
essential role in GPI anchor biosynthesis, as it is the sole fatty acid component integrated
within this construct in T. brucei. [205] Myristate is readily taken up from the host serum and
used in GPI-anchor biosynthesis, as has been shown by incorporation of radio-labelled [3H]-
myristate. [203,205] Myristate is incorporated within the GPI structure through both fatty acid re-
modelling of the GPI precursor and myristate exchange, although the latter was thought to
function in repair to ensure myristate incorporation. [205]
In this research study, a myristic acid analogue bearing an alkyne moiety (Figure 32) for the
introduction of a fluorescent biotin tag via Click-Chemistry was used for the metabolic labelling
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of the GPI-VSG structure in live trypanosomes. [206]5
HO
O
YnC12
Figure 32: Myristate analogue bearing an alkyne functionality for labelling with TAMRA-
fluorophore and biotin-tag, provided by Megan Wright and Dr. Ed Tate (Imperial
College London, London, UK). [206]
Effect of inhibitors 14v and 14a on myristate labelling after an incubation period of 3 h
Initially, 14v and 14a were used at a concentration slightly under the minimum inhibitory con-
centration, in oder to allow parasite survival, whilst observing the maximum effect on GPI-
anchor biosynthesis. Derivatives 14v and 14a have been chosen for this study, because of
their low µM anti-trypanosomal effect in T. brucei. T. brucei was incubated with 14v and 14a
over a time period of 3 h, after which the cells were counted and adjusted to similar con-
centrations. The myristic acid analogue YnC12 was added to the parasites and incubation
was continued for another 4 h to ensure good incorporation of the myristate analogue in the
GPI-anchor of T. brucei. After incubation, the cells were lysed and the proteins purified by
precipitation from acetone. Next, the fluorescent/ biotin-tag was introduced by Click-chemistry
between the alkyne-fatty acid analogue and the azide tag in 38 (Figure 33). This crude extract
was used without further purification and applied to a SDS gel. After fixation of the sodium
dodecyl sulphate (SDS)-gel, the in-gel fluorescence was measured under TAMRA-setting in
a fluorescence plate reader (Figure 34). Indeed, the positive control with DMSO and YnC12
showed two fluorescently labelled bands. One very intense band at a molecular weight around
50 kDa and the expected band for the GPI-VSG proteins at 57 kDa. [207] A possible explanation
for the additional band, would be that YnC12 inhibits some steps in the de novo synthesis
or recycling of GPI-VSG proteins, resulting in low-molecular weight analogues of 50 kDa with
a small proportion of YnC12 still incorporated in the full GPI-VSG construct. Previously, ra-
dioactive labelling with [3H]-myristate in the presence of tunicamycin, an inhibitor of N-linked
glycosylation, resulted in the appearance of two bands at 55 and 57 kDa, with the 55 kDa band
representing the N-linked glycosylation deficient GPI-VSG proteins. [207] In this study, the lower
band at 50 kDa might represent newly synthesised GPI-VSG proteins, where glycosylation
steps are inhibited by YnC12, whereas the weaker fluorescent band at 57 kDa represent the
5The myristic analogue YnC12 was kindly provided by Megan Wright (Research group: Prof. Dr. Ed Tate,
Imperial College London, London, UK)
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Figure 33: Tag 38 for visualisation of metabolic labelling of YnC fatty acids, provided by Megan
Wright and Dr. Ed Tate (Imperial College London, London, UK). [206]
recycled GPI-VSG proteins with all modification already in place. However, this hypothesis
requires confirmation through mass spectrometric analysis of the corresponding bands.
Next, the effect of pre-incubation with the inhibitors 14v and 14a (lane:1 and 2 in Fig-
ure 34) on myristic labelling of the GPI-anchored VSG proteins was studied. Both inhibitors
14v and 14a resulted in reduction in the fluorescent signal in the 50 kDa band, while the higher
band 57 kDa appeared at similar intensities compared to the control with DMSO only. In par-
ticular, the 3-benzyloxy derivative 14v caused a significant reduction in fluorescent signal after
only 3 h of incubation compared to the positive control. This observation was further supported
by Coomassie staining of the same gel, indicating that equal or indeed slightly more protein
was applied in lane 1 for the derivative 14v. Since T. brucei has two distinct pathways to incor-
porate myristate in the GPI-VSG structure (remodelling of fatty acids or exchange in complete
GPI-VSG constructs). [207] It might be possible that derivative 14z only inhibits de novo syn-
thesis via remodelling, possibly explaining the reduction of the fluorescent band at 50 kDa.
Coomassie staining identified the 57 kDa band as the major protein in the crude protein mix-
ture. This may explain the weak fluorescent intensity of the 57 kDa band, as only recycled
GPI-VSG proteins are myristylated. The bloodstream form of T. brucei has a high rate of en-
docytosis and is therefore able to change its VSG-coat every 12 min, [208] and this should lead
to a reduction of the 57 kDa band if only YnC12 is present as the sole source for myristate.
However YnC12 was not the sole source for myristate and this might explain the higher inten-
sity of the 57 kDa band compared to the weak fluorescence signal. The methyl derivative 14a
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in-gel fluorescence in SDS gel observed under
TAMRA settings
Coomassie-stained SDS gel
Figure 34: SDS gels after 3 h incubation with 14v and 14a; lane 1: 14v, lane 2: 14a, full gels
see Chapter 11.
also showed a reduction of the 50 kDa fluorescent band, confirmed by Coomassie staining,
but seemed to be less active than 14v. Interestingly, 14v and 14a also had low µM activ-
ity against T. brucei in vitro, suggesting that indeed GPI anchor biosynthesis inhibition could
be responsible for the anti-trypanosomal effect. Although the 3-methyl derivative 14a resulted
only in a small reduction of myristate incorporation, it was slightly more active against T. brucei
than 14v, but unfortunately it was also more toxic against mammalian cells (Figure 34).
Effect of inhibitors 14v and 14a on myristate labelling after an incubation period of 24 h
The initial experiment confirmed that the myristate analogue YnC12 is incorporated in the full
(57 kDa) GPI-VSG structure and an unknown protein (50 kDa), most likely a VSG-precursor,
as the protein was very abundant (Figure 34). However, in order to validate the labelling a
negative control with T. brucei proteins without YnC12 and the fluorescent tag 38 has been
performed. Although, a reduction of fluorescent signal for the derivatives 14v and 14a was
observed after 3 h, longer incubation times with the inhibitors have not been investigated yet.
Therefore, the initial labelling experiment was repeated with longer incubation times and an
additional negative control. The incubation time was chosen to be 24 h, as at this time ac-
tivity against the parasites was observed. Assays to determine the effective doses for the
labelling were performed against T. brucei. Next, T. brucei was incubated with concentra-
tions of inhibitors which did not display any toxicity against the parasites over a time course
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Table 24: Anti-parasitic activity of compounds chosen for target identification studies.
N S
O
S
R
EtO
O
GI50 [µM]
# R T. brucei T. cruzi L. infantum HL60
14v OBn 4.4±1.1 >100 >100 >100
14a CH3 1.5±0.3 >100 >100 31.0±0.8
of 24 h. Although the benzyloxy derivative 14v previously did not show toxicity at 50µM (MIC
100µM), reduced parasite densities were observed after 24 h. However, the number of live
trypanosomes after 24 h was still sufficient for the following labelling experiment with myristate
YnC12. Therefore, the parasite density was adjusted to 3.7x106 cellsmL and YnC12 and fresh
inhibitors (14v and 14a, respectively) were added at a final concentration of 100µM and incu-
bation was continued for another 4 h. After 4 h, parasites were lysed, proteins precipitated with
acetone and subsequently subjected to click-chemistry with the tag 38. Finally, 10µg crude
labelled protein was loaded on a SDS gel and separated. The fluorescent protein bands were
visualised under TAMRA settings and stained with Coomassie blue (Figure 35).
Pleasingly, the negative control in the absence of YnC12 did not show unspecific labelling
of the tag 38 with trypanosomal proteins. Interestingly, the Coomassie stained SDS gel
showed the same two protein bands at 50 and 57 kDa as described previously (Figure 34).
This result does suggest that most likely a GPI-VSG precursor at 50 kDa is present in the
crude protein composition in T. brucei, possibly a precursor before N-linked glycosylation. As
expected the positive control in the presence of DMSO resulted in an intense fluorescent signal
at 50 kDa, with only minor amounts of a higher 57 kDa protein band. Prolonging the incubation
time of derivative 14v from 3 h to 24 h resulted in a complete loss of the fluorescent band at
50 kDa and therefore in no incorporation of YnC12 in this GPI-VSG precursor. However, the
faint 57 kDa band still remained, further supporting that 14v inhibits incorporation of YnC12
almost solely in the precursor at 50 kDa. Indeed, the Coomassie stain did not show any rem-
nants of the 50 kDa protein, but an abundant 57 kDa band for the full GPI-VSG proteins. This
observation can be explained in the light of previous work, where VSG RNAi silencing caused
cell cycle arrest, blocking further cell devision. [209] Although T. brucei unable to synthesise
new VSG proteins could survive in vitro, an inability to vary the VSG coat led to clearance
by the immune system (in vivo). [209] Here, inhibitors of GPI anchor synthesis prevent the par-
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Figure 35: YnC12 labelling after 24 h pre-incubation with 14v and 14a; lane 1: 14v, lane 2:
14a; full gels see Chapter 11.
asite from recycling VSG proteins, but retain a minimal protective coat, which could explain
the residual 57 kDa GPI-VSG proteins for 14v in the Coomassie stained gel (Figure 35). This
previous study would explain the proposed idea that T. brucei has the ability to monitor VSG
synthesis or VSG-coverage of the cell surface. [210] VSG has been shown to have a half life time
of 33±9 h, [211] less than the time used for the evaluation of anti-trypanosomal activity (72 h) of
14v. The methyl derivative 14a also showed a significant reduction of the fluorescent intensity
of the 50 kDa protein by approximately 50 %. Coomassie staining confirmed this reduction of
the lower 50 kDa band compared to the positive control. The upper band at 57 kDa for 14a was
weakly labelled in the fluorescent channel, but Coomassie staining revealed a large amount of
57 kDa proteins.
Effects on fatty acid labelling of GPI-anchored proteins using the pentadecylic fatty acid
YnC15 and the inhibitors 14v and 14a
The metabolic labelling with the myristate analogue YnC12 resulted in incorporation into
the full (57 kDa) and partially (50 kDa) synthesised GPI-VSG proteins. The ester derivatives
14v and 14a have been shown to inhibit this incorporation, resulting in reduction and/ or loss of
GPI-VSG proteins. Next, the myristic acid probe YnC12 was exchanged with the pentadecylic
fatty-acid analogue YnC15 (Figure 36).6 T. brucei exclusively uses myristic acid for the full
GPI-VSG construct, however other fatty acids can be incorporated in GPI-precursors and will
be exchanged by myristate in the final GPI-VSG adduct. [205] Incorporation of the pentadecylic
fatty-acid analogue YnC15 could potentially answer the question if the protein band at 50 kDa
6YnC15 was kindly provided by Megan Wright and Dr. Ed Tate (Imperial College London, London, UK).
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Figure 36: Pentadecylic acid YnC15
is a fatty acid precursor of the partially synthesised GPI-VSG proteins. Therefore, T. brucei
was incubated with the derivatives 14v and 14a over a period of 24 h. After which the para-
sites were counted and subjected to metabolic labelling with the elongated fatty acid analogue
YnC15 for a further 4 h. Unfortunately, the elongated fatty acid YnC15 showed some toxicity
against T. brucei and caused cell death in combination with 14v. However, the ester analogue
14a in combination with YnC15 showed less toxicity and could further be subjected to fluores-
cent labelling with the fluorophore 38 under Click-chemistry conditions. The crude proteins of
the negative control (without YnC15), the positive control (DMSO) and 14a were separated on
a SDS gel and the bands were visualised using in-gel fluorescence and Coomassie staining
(Figure 37). The negative control in the absence of YnC15 showed minor unspecific binding of
the fluorophore 38 with proteins at 57 kDa, which is most likely the full GPI-VSG-protein band.
In contrast, labelling in the presence of YnC15 resulted in a weak additional band just below
the 57 kDa band ( 55 kDa). Coomassie staining showed the 50 kDa band for the negative and
positive control, but under in-gel fluorescence analysis these bands did not appear. It might
be possible that the additional weak band at 55 kDa is further unspecific binding of the fluo-
rophore with the GPI-VSG-construct. The inhibition with the rhodanine derivative 14a resulted
in similar protein band intensities than for the positive control with DMSO only. There were two
bands at 55 and 57 kDa with the former being very weak. Coomassie staining showed that
slightly less proteins were loaded onto the SDS gel for derivative 14a, but the staining showed
diffuse bands ranging from 50-57 kDa. In conclusion, labelling with the elongated analogue
resulted only in minor incorporation into the GPI-VSG-proteins as expected by exclusivity of
myristate in this construct. [205]
Fatty acid labelling in HL60 cells and effect of pre-incubation with selected rhodanine
inhibitors
The derivatives 14v and 14a have been shown to inhibit enzymes of the GPI-anchor biosynthe-
sis through reduction of myristate uptake into the GPI-anchor. In order to investigate the mode
of action of the derivatives 14v and 14a on HL60 cells, the myristate labelling with YnC12
was repeated in the presence of these inhibitors. In particular for derivative 14a, this was an
important question as it showed toxicity against HL60 cells at GI50 31.0µM. HL60 cells were
incubated for 24 h in the presence of 14v and 14a at inhibitor concentrations of 50 and 7.5µM
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TAMRA settings Coomassie-stained SDS gel
Figure 37: YnC15 labelling after 24 h pre-incubation with 14a; lane 1: 14a; full gels see Chap-
ter 11.
respectively. After the incubation period the cells were counted and subjected to YnC12 over
a time period of 4 h, crude proteins were precipitated and modified with a fluorophore using
Click-chemistry. In-gel fluorescence of the separated crude proteins and Coomassie staining
showed that YnC12 did not specifically label proteins in HL60 cells. In the negative control in
the absence of YnC12 the in-gel fluorescence showed a weak band at 80 kDa, Coomassie
staining on the same gel displayed only one major protein band at 80 kDa. The fluorescence
intensity of these 80 kDa band was increased in the positive control with DMSO and in the
cases for 14v and 14a, however the increasing intensity correlated with increasing amounts
of protein loaded to the gel as shown in the Coomassie stained gel (Figure 38). In conclu-
sion, fatty acid metabolism might not be affected by the derivatives 14v and 14a in HL60 cells,
suggesting a different mode of action.
3.5.2 Flow cytometry analysis of T. brucei transferrin receptors for GPI anchor
biosynthesis inhibition studies
In the previous section, inhibition of GPI anchor biosynthesis has been demonstrated to be
a possible mode-of-action of inhibitors 14v and 14a, using a myristic acid analogue to label
myristate incorporated proteins in T. brucei and observe in-gel fluorescence on SDS gels
(Figure 35). This method was excellent to identify GPI-anchor biosynthesis as possible target
of the derivatives 14v and 14a.
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Figure 38: YnC12 labelling after 24 h pre-incubation with 14aa and 14a; lane 1: 14v, lane 2:
14a; full gels see Chapter 11.
In order to further support the hypothesis, that the trypanocidal effect of 14v and 14a de-
rives from GPI-anchor synthesis inhibition, quantified and unambiguous experiments needed
to be performed. An experiment to monitor the quantified inhibition of GPI-anchor biosynthe-
sis is the use of flow-cytometry to measure the uptake of Fluorescein IsoThioCyanate (FITC)-
conjugated bovine transferrin. T. brucei like all living cells is dependant on iron for growth. [128]
The major source for iron in T. brucei is host transferrin, which is bound to the trypanosomal
receptor for transferrin uptake (TbTfR) in order to reach the interior of the parasite. [128] The
TbTf receptor shows a significant sequence similarity to VSG proteins (60-76 %) and both are
attached via a GPI anchor to the plasma-membrane of the bloodstream form of T. brucei. [128]
Thus, TbTf receptor iron uptake directly depends on GPI-anchor biosynthesis and inhibition
thereof will affect the parasites ability to uptake transferrin. Furthermore, subjecting T. brucei
to iron starvation conditions has been shown to upregulate the synthesis of GPI-anchored
TbTf receptors and indeed this up regulation could be quantified by measuring the uptake of
radioactive labelled holo-transferrin. [212] In this research study, FITC-conjugated bovine trans-
ferrin was used as direct indicator for the iron status in T. brucei and therefore the parasites
ability to synthesis GPI-anchored TbTfRs.
T. brucei was incubated with the rhodanine derivatives 14v and 14a for 24 h, after which
the media was exchanged to transferrin-free media in order to cause iron-starvation and there-
fore increased expression of TbTfRs. After 2 h of incubation, the FITC-labelled transferrin
was added and fluorescence intensity was quantified using flow-cytometry (Figure 39). The
positive control with DMSO only showed a high fluorescence intensity signal (13,874.8 FU),
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Figure 39: Mean fluorescence intensity of FITC-labelled transferrin after incubation with 1:
14v, 2: 14a.
whereas the negative control without the FITC-labelled transferrin showed a negligible mean
fluorescence (312.5 FU). Analysis of the side-scattered light showed that the majority of try-
panosomes were intact (Figure 40, SSC-A vs Fluorescent intensity) The FITC-labelled try-
panosomes were further stained with DAPI and analysed by fluorescence microscopy. The
fluorescently labelled trypanosomes showed a bright DAPI (blue) stained kinetoplast and nu-
cleus and if treated with FITC-labelled transferrin (green) an additional fluorescent signal was
detected (Figure 40). In the absence of FITC-labelled transferrin (in the negative control), no
fluorescence signal for FITC was detected under the fluorescent microscope (Figure 40).
Interestingly, the 3-benzyloxy derivative 14v resulted in a 36 % decrease in fluorescent sig-
nal compared to the positive control (Figure 39). Analysis of the side-scattered light and the
fluorescence intensity indicated lysed trypanosomes, which might explain the drop in fluores-
cent intensity. But although the number of parasites was decreased, the intact trypanosomes
showed a decrease in transferrin uptake, confirming the hypothesis that GPI-anchor is indeed
inhibited by this derivative. Indeed, further analysis under fluorescence microscopy showed
that the FITC-labelled transferrin content in parasites treated with 14v was decreased com-
pared to the positive control (Figure 41 and Figure 40, respectively). The fluorescent mi-
croscopy picture in Figure 41 shows a sample of the three different populations of T. brucei if
treated with 14v. The first type of parasite showed normal uptake of transferrin, while another
displayed no presence of the FITC fluorophore and the last type showed a lysed parasite with
diffuse DAPI staining. The observation of the second type of parasite was in agreement with
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Figure 40: Flow-cytometry analysis of cell morphology (SSC-A vs. Fluorescent intensity) and
uptake of FITC labelled transferrin; Fluorescence microscopy images with DAPI
co-staining.
the myristic acid labelling experiment, where a decreased amount of GPI-VSG proteins were
observed after incubation with 14v. In order to visualise the effects in more detail it would be
necessary to repeat the experiment with lower doses of inhibitor.
Then parasites were treated with 14a, cells with and without FITC-label were detected
under the fluorescent microscope (Figure 41). Indeed, the mean fluorescent intensity of par-
asites treated with 14a was slightly higher (10,476.3 FU) compared to treatment with 14v
(8,878.4 FU), indicating 14a weaker inhibition of the GPI-anchor biosynthesis. Treatment with
14a caused a 25 % deduction of FITC fluorescent signal compared to the positive control (Fig-
ure 39). The combination of flow-cytometry with fluorescence microscopy was very well suited
to study and quantify the influence of 14v and 14a on GPI-anchor biosynthesis.
The flow-cytometry analysis of transferrin uptake confirmed the previous experiment with
the metabolic labelling with myristate YnC12. The meta-benzyloxy ethyl ester 14v showed
the strongest inhibition of myristate incorporation and in the flow-cytometry experiment, re-
duced GPI anchor biosynthesis was confirmed by a reduced uptake of FITC-labelled transfer-
rin. The reduction in fluorescence intensity correlated directly to the expressed GPI-anchored
TbTf receptors. The meta-methyl rhodanine ethyl ester 14a showed similar results in both
assays, but was a slightly weaker inhibitor of GPI-anchor biosynthesis, as could be seen in
the flow-cytometry experiment. The two studies combined strengthened the hypothesis that
GPI-anchor synthesis was inhibited by 14v and 14a.
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Figure 41: Flow-cytometry analysis of derivatives 14v and 14a; Side-scattered light vs flu-
orescent intensity and Number of cells vs fluorescent intensity and fluorescence
microscopy pictures of treated parasites.
3.5.3 GPI cell-free radio-label assay
Introduction to cell-free GPI-synthesis assay
Initially the DPMS inhibitors in Table 2 were screened to evaluate their trypanocidal activity
against T. brucei (Table 25). [68] With the exception of the unsubstituted 5-benzylidene deriva-
tive 2a (GI50 56.0µM) none of the other inhibitors showed any effect on T. brucei growth at
100µM, although they inhibited DPMS, a validated anti-trypanosomal protein, with good to
moderate residual activities. [68] In addition to these studies a cell free-GPI synthesis assay
on trypanosome enzymes was performed.7 Briefly, radio-labelled GDP-[3H]-Man was sub-
jected to cell-free membranes of T. brucei in the presence of 1 mM of rhodanine-inhibitor. [68]
This membrane layer contains all enzymes involved in GPI anchor biosynthesis and is able
to synthesise the GPI-anchor until the substrate ethanolamine-P-Manα1-2Manα1-6Manα1-
4GlcNH2-PI. [68] Intermediates of the GPI-anchor synthesis can be extracted and separated
by high performance thin layer chromatography (HPTLC). [68] The radio-labelled intermediates
of the GPI-anchor synthesis can be visualised by fluorography and this TLC-plate can be
analysed by comparison of substrate band intensities (Table 25). [68] In order to explain GPI-
anchor synthesis in the cell-free system, individual steps will be explained in further detail
for the control (DMSO, Table 25). The first band on the HPTLC is representing Dol-P-Man,
whose synthesis is catalysed by DPMS from GDP-[3H]-Man and dolichylphosphate. A weak
7This assays were performed by Dr. Terry Smith from the University of St. Andrews, St Andrews, Scotland, UK
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intensity of this band in combination with weaker consecutive bands is indicative for DPMS
inhibition. However, frequently this band will appear with a decreased fluorescent intensity,
but is accompanied by intensive consecutive bands, indicating that the substrate Dol-P-Man
is faster consumed than re-synthesised.8 In the consecutive step the mannosyltransferase
1 (MT-1) catalyses the transfer of Dol-P-Man onto GlcNH2-PI, resulting in the formation of
the second band (M1) on the HPTLC. [65] The next mannose residue is installed by the α1-6
mannosyltransferase (MT-2) resulting in the formation of Manα1-6Manα1-4GlcNH2-PI (M2) on
the HPTLC plate. [65] The third mannose is transferred by an α1-2-mannosyl transferase from
Dol-P-Man to generate Manα1-2Manα1-6Manα1-4GlcNH2-PI (M3). [65] Next the inositol acyl-
transferase acylates M3 to generate the substrate Manα1-2Manα1-6Manα1-4GlcNH2-(acyl)PI
(aM3). [65] The final step performed by the cell-free system is the ethanol amine phosphate
transfer to form the substrate ethanolamine-P-Manα1-2Manα1-6Manα1-4GlcNH2-PI (A’) (Fig-
ure 42). Inhibition of individual enzymes by rhodanine derivatives will lead to accumulation of
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Figure 42: Substrates of cell-free GPI-synthesis assay, M1: Manα1-4GlcNH2-PI; M2:
Manα1-6Manα1-4GlcNH2-PI; M3: Manα1-2Manα1-6Manα1-4GlcNH2-PI (M3);
aM3: Manα1-2Manα1-6Manα1-4GlcNH2-(acyl)PI; A’: ethanolamine-P-Manα1-
2Manα1-6Manα1-4GlcNH2-PI.
the individual substrates of that particular enzyme and can therefore be identified by this cell-
free assay.
8Oral communication with Dr. Terry Smith, St. Andrews University
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Comparison of DPMS activity and activity in cell-free GPI-synthesis assay and in vitro
activity
A chosen subset of rhodanine-N-acetic acid derivatives was screened in this cell-free assay of
GPI-anchor synthesis in order to identify potential targets within the GPI-anchor biosynthesis
pathway. Particularly interesting were the derivatives shown in Table 25, as residual DPMS
activity data was already available. [68] The DPMS activity correlated well with the cell-free
assay, as low residual DPMS activity resulted in weak substrate bands upstream from Dol-
P-Man. The high intensity of the Dol-P-Man band might be explained by accumulation of
substrate over time, as none of the inhibitors abolished DPMS synthesis completely. This
hypothesis is supported by derivative 2f, a weak DPMS inhibitor, resulting in a diminished Dol-
P-Man band followed by a weak M1 band. While 2f inhibits DPMS weakly, less Dol-P-Man
substrate is accumulated, resulting in a weak band. However, it may also be possible that
the derivatives inhibit additionally the first mannosyltransferases MT-1 and therefore cause
decrease in subsequent substrate bands. To this point it is unclear if one or more enzymes
were inhibited by these rhodanine-N-acetic acid derivatives. However, particularly exciting was
the observation that 2c, the free acid analogue of the ester derivative 14v, which has been
shown by myristate labelling and flow cytometry analysis to inhibit GPI-anchor biosynthesis,
indeed is a good DPMS and possible MT-1 inhibitor.
It is likely, that the ester derivative has the same molecular target, as the ester moiety
potentially serves as a pro-drug and increases membrane diffusion, while being hydrolysed
within the cell. This hypothesis was supported by low µM activity of the ester derivatives
against the bloodstream form of T. brucei in vitro (Table 25). Indeed, the most promising
inhibitor was 14v as it showed a good selectivity index of SI > 23, while most of the other
ester-derivatives showed increased toxicity towards HL60 cells.
Methyl and trifluoromethyl substituted rhodanine-N-acetic acid and their activity in the
cell-free GPI-synthesis assay
Previously, the rhodanine-N-acetic ester derivative 14a has been shown by myristate labelling
and flow cytometry analysis to inhibit GPI-anchor biosynthesis. In the following research
study, the activity against isolated enzymes of the GPI-anchor synthesis is narrowed down
and should allow the identification of the molecular target(s) within the GPI-anchor biosyn-
thesis. The free carboxylic acid derivative 2m was screened in the cell-free GPI-synthesis
assay as it is assumed that the ester moiety is cleaved upon entering into the parasitic cell.
However, it may also be likely that the ester derivative is the active agent. The free acid
analogue 2m showed the strongest inhibition in this series, resulting in complete inhibition of
the first mannosyltransferase (MT-1) and possible also DPMS (Table 26). This radio-labelled
assay possibly identified the enzymes inhibited in the GPI-anchor biosynthesis, resulting in
99
3 Rhodanine-N-acetic acid derivatives
Table 25: cell-free GPI assay for rhodanine-N-acetic acid derivatives; lane 1: 2a, lane 2: 2ah,
lane 3: 2c, lane 4: 2e, lane 5: 2g, lane 6: 2f; in vitro activity against T. brucei ; Blue
highlighted bands: DPMS inhibition; Green highlighted bands: MT-1 inhibition.
N S
S
O
R1O
O
R2 R3
R4
R1=H R1=Et
GI50 [µM] GI50 [µM]
# R2 R3 R4 res. DPMS [68] [%] T. brucei # T. brucei HL60
2e OH H H 23±8 >100 14p 1.7±0.1 4.1±0.7
2c H OBn H 23±3 >100 14v 4.4±1.1 >100
2f H OH H 90±5 >100 14q 4.8±0.9 9.9±0.5
2a H H H 42±5 56.0±3.3 14i 8.3±0.7 38.0±1.8
2ah H H OBn 10±2 >100 14w 17.0±0.9 >100
2g H H OH 70±4 >100 14r 17.6±0.1 n.a.
decreased incorporation of myristate in metabolic labelling experiments and a reduction in up-
take of FITC-labelled transferrin. All three assays showed similar results, but the radio-label
assay narrowed the inhibition of GPI-anchor biosynthesis down to MT-1 and DPMS. Shift-
ing the methyl group on the 5-benzylidene moiety in para-position (2n) abolished its activity
against MT-1. There was a weak band for DPMS, but this was not indicative for DPMS inhi-
bition, as Dol-P-Man has been synthesised but was used in subsequent steps, explaining the
intense bands of consecutive substrates. Transferring the methyl substituent in ortho-position
in derivative 2o decreased MT-1 inhibition. Interestingly, in the trifluromethyl series the meta-
and para-substituted analogues showed good MT-1 inhibition, whereas the ortho substituent
did not show any inhibition of GPI-anchor synthesis. The anti-trypanosomal activity against T.
brucei in vitro correlated well with GPI-anchor synthesis inhibition. However, trifluoromethyl
substituted analogues showed increasing toxicity against HL60 cells. The most promising
candidate in this series was the meta-methyl substituted ester analogue 14a as it showed low
µM activity against T. brucei, while having a good SI of 21.
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Table 26: cell-free GPI assay for rhodanine-N-acetic acid derivative-2; lane 1: 2o, lane 2: 2m,
lane 3: 2n, lane 4: 2r, lane 5: 2p, lane 6: 2q; in vitro activity against T. brucei ; Blue
highlighted bands: DPMS inhibition; Green highlighted bands: MT-1 inhibition.
N S
S
O
R1O
O
R2 R3
R4
R1=H R1=Et
GI50 [µM] GI50 [µM]
# R2 R3 R4 T. brucei # T. brucei HL60 SI
2o CH3 H H >100 14g 1.3±0.1 12.7±0.9 10
2m H CH3 H >100 14a 1.5±0.3 31.0±0.8 21
2n H H CH3 >100 14n 15.6±1.4 29.3±8.3 2
2r CF3 H H >100 14k 1.4±0.1 9.3±3.7 7
2p H CF3 H >100 14l 1.7±0.1 11.3±3.7 7
2q H H CF3 >100 14d 1.4±0.1 11.8±0.5 8
Anti-trypanosomal rhodanine-N-acetic acid derivative with no activity in cell-free GPI-
synthesis
Interestingly, one of the most potent inhibitors against T. brucei growth in vitro did not show any
effect on enzymes of the GPI-anchor biosynthesis as is to be seen in the results of the cell-free
GPI-synthesis assay with 2u (structural analogue of 14t, Table 27). Also, the pyridine derivative
26d was inactive in the GPI-synthesis assay, whereas its structural ethyl ester analogue 26h
displayed anti-trypanosomal activity in the low µM range. The catechol derivative 14t may
inhibit oxide-reductases in parasites, as several other rhodanine-catechol derivatives have
been reported as molecular probes for bacterial NAD(P)H-dependant oxidoreductases. [107,108]
However, the exact mode of action of these derivatives is unknown at the present time, but
using the fluorescence properties of 2u in combination with native protein gels (western blots),
the molecular target could potentially be identified. [108]
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Table 27: Cell-free GPI assay for rhodanine-N-acetic acid derivatives-3; R1=H; lane 1: 2u,
lane 2: 2s, lane 3: 2h, lane 4: 26c, lane 5: 26d; in vitro activity against T. brucei ;
Blue highlighted bands: DPMS inhibition; Green highlighted bands: MT-1 inhibition.
N S
S
O
R1O
O
R2 R3
R4
R1=H R1=Et
GI50 [µM] GI50 [µM]
# R2 R3 R4 T. brucei # T. brucei HL60 SI
2u H OH OH >100 14t 1.6±0.1 >100 63
2s H H SO2Me >100 n.a.
2h H H Cl >100 n.a.
26c 3-pyridinyl >100 26g 1.5±0.2 51.5±2.5 34
26d 4-pyridinyl >100 26h >100 >100 >1
3.5.4 Target-based optimisation using homology modelling
The target identification assays discussed in the previous chapters identified DPMS and/ or
MT-1 as possible targets of the the inhibitors 14v and 14a. In particular the meta-benzyloxy
derivative 14v was interesting for DPMS inhibition, as the free acid analogue has previously
been shown to inhibit DPMS with a residual activity of 23 %. [68] In order to improve activity
against DPMS, it would be beneficial to know the exact binding mode within the active site.
However, the rational design of inhibitors against DPMS is complicated by the absence
of crystallographic data to date. DPMS with its crucial role in Dol-P-Man synthesis plays an
important role in several glycosylation pathways among eukaryotic organisms. [213] Therefore it
was not surprising to observe high sequence similarities among T. brucei, T. cruzi, L. infantum
and Saccharomyces cerevisiae (S. cerevisiae) DPMS (Figure 43). Furthermore, T. brucei
DPMS has been shown to complement a DPM deficient clone of S. cerevisiae (yeast strain
dpm1-6), causing rescue of this phenotype if grown on plates. [213]
However, features characteristic to T. brucei DPMS, such as the missing dolichol binding
site, essential for DPMS functionality in hamsters, [214] have been highlighted as possible strate-
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Figure 43: Sequence alignment of DPMS amino acid sequence of S. cerevisiae, T. brucei,
T. cruzi, L. infantum and human DPM1 using uniprot align functionality; 37 % se-
quence similarity between S. cerevisiae,T. brucei, T. cruzi, L. infantum and 69 %
similarity between T. brucei and S. cerevisiae DPMS.
gies for the development of T. brucei specific inhibitors. [213] Fluorescence resonance energy
transfer studies on S. cerevisiae DPMS in conjunction with the use of the Robetta homology
modelling server has been used to establish a structural model for yeast DPMS. [215] Taking
into consideration that S. cerevisiae DPMS shows a high sequence similarity to T. brucei (Fig-
ure 43), the primary amino acid sequence of T. brucei DPMS was submitted to the Robetta
full-chain protein structure prediction server in order to obtain a homology model, which may
help the rational improvement of the previous found rhodanine-N-acetic acid derivatives. [216]
Homology-Modelling of DPMS using Robetta
The Robetta full-chain protein structure prediction server is a fully automated tool to predict
the atomic coordinates of proteins with unknown 3D structure. [216] Starting from the primary
amino acid sequence of the unknown protein, a search for proteins with similar amino acid se-
quences is performed. [216] This initial step, classified as "Ginzu", uses BLAST and psi-BLAST
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searches to identify structural homologous proteins in the PDB database [217], generating indi-
vidual domains of the primary amino acid sequence, which can be applied to a further neural
network based search (Pcons2) [218] in order to identify further structural homologous proteins
and/or models of already predicted proteins. [216] Fragment domains, which cannot be assigned
to a homologue, are de novo modelled and assembled with all other fragments to generate
the final full-chain homology model. [216] The closest structural homologue identified by psi-
BLAST (34.10) was a mannosyl-3-phosphoglycerate synthase (MPGS) from Rubrobacter xy-
lanophilus (3F1Y). [219] Both, DPMS and MPGS both have GDP-mannose as common donor
substrate, indeed the X-ray structure of GDP-mannose bound to MPGS has already been
solved (3O3P), allowing the comparison of both GDP-binding sites of the models and the par-
ent. [219] The Robetta server generated five homology models of DPMS, based on the primary
amino acid sequence and the parent MPGS. The models were submitted to model evalua-
tion servers such as PROSA II, VERIFY_3D and ProQ, [220–222] however the results were not
conclusive and no model could be ruled out based on these results (data not shown). There-
fore, Ramachandran plots of the models were generated (Figure 44) [223] and based on these
results models 1, 3 and 5 could be eliminated as they showed disfavoured conformations of
amino acid residues. Both homology model 2 and model 4 were further evaluated as potential
models for DPMS.
Docking of the natural substrate GDP-mannose
To further evaluate the potential of these models to serve as a model for DPMS, docking simu-
lations of the natural substrate GDP-mannose were performed using Gold Suite 4.12 (CCDC,
Cambridge, UK). The binding site was defined over the whole protein and 50 docking runs
were performed. The docking poses were analysed and compared to known interactions of
GDP-mannose within the active site of yeast DPMS (Tyr12, Asp44, Asp97, Arg212), as all
these residues are conserved through all DPMS structures of T. brucei, T. cruzi, L. infantum
and S. cerevisiae, they may indicate their importance for catalytic activity. [215] The docking
simulation for GDP-mannose were carried out for all five homology models, but only homology
model 4 showed the expected interactions of GDP-mannose within the active site of the homol-
ogy model (Figure 45). Although not all interactions are displayed in the interaction diagram
in Figure 45, the ligand is placed in proximity of the expected amino acid residues. As the 3D
coordinates of the homology model for yeast DPMS were not available for comparison with
the generated homology model 4, the mannosyl-3-phosphoglycerate synthase (MPGS) from
Rubrobacter xylanophilus (3O3P) was chosen for this purpose. Therefore, homology model 4
was aligned with 3O3P, showing that many of the modelled residues were similar to the active
site of 3O3P, as can be seen Figure 46. Although many of the residues, such as the Tyr11 are
different in 3O3P, the interactions and placement of docked GDP-mannose was very similar
compared to the homology model of yeast DPMS. [215] However, this results should be han-
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Figure 44: Ramachandran plots of Robetta homology models 1-5; generated with
MOE2009.10. [223]
dled with care, as the homology model is not based on experimental evidence as compared
to the yeast DPMS homology model and the closest psi-BLAST hit showed a similarity of only
34.10 %. [215]
Docking of rhodanine-N-acetic acid derivatives
Homology model 4 has been chosen as the model for the potential DPMS structure, based
on re-docking experiments of GDP-mannose to the active site and similar molecular interac-
tions of this substrate as described for yeast DPMS. [215] In order to investigate the hypothetical
binding mode of rhodanine-N-acetic acid derivatives, three-dimensional structures were gen-
erated and energy minised using the MMF94 forcefield option in MOE2009.10. [223] One of the
most active rhodanine-N-acetic acid derivatives against DPMS was the 3-benzyloxy derivative
2c (23 % residual DPMS activity) [68], its ethyl ester analogue 14v has been shown to inhibit
GPI-anchor biosynthesis in vitro as could be observed by myristate labelling and flow cytome-
try experiments (Figure 35 and Figure 41 respectively). The energy-minimised ligand 2c was
docked into the active site of the DPMS homology model (HM 4) and consecutively compared
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Figure 45: Docking of GDP-mannose into the active site of Homology model 4 using Gold
Suite 4.12 (CCDC, Cambridge, UK) and MOE2009.10 [223] for graphical visualisa-
tion.
to the proposed binding of GDP-mannose (Figure 47). The predicted docking pose for 2c
was within the mannose and phosphate site of the previously docked GDP-mannose. The
3-benzyloxy substituent fills a small lipophilic pocket within the binding site, possible explain-
ing the structural requirements of this moiety. However, two arginine residues (Arg126 and
Arg210) contribute the most to the binding of 2c in the active site. Both residues were mod-
elled to undergo close hydrogen-bond interactions (1.9 and 2.2 Å) with carbonyl groups of the
rhodanine-moiety and the N-1-carboxylic side-chain. Interestingly, this binding mode was con-
served for other docking experiments with rhodanine-N-acetic acid derivatives independent of
the 5-benzylidene substitution (data not shown). Rhodanine derivatives were frequently de-
scribed as phosphate mimics [68,100,101,103] and this proposed binding mode would be in agree-
ment with this hypothesis. However, here the 5-benzylidene moiety would be in proximity to
the phosphate binding site, rather than the rhodanine-moiety as previously hypothesised. [100]
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Figure 46: Overlay of homology model (HM) 4 and parent mannosyl-3-phosphoglycerate syn-
thase (MPGS) from Rubrobacter xylanophilus (3F1Y); in the active site the GDP-
mannose substrate from MPGS is displayed as lines, while the re-docked substrate
for the HM 4 is shown as sticks together with active site residues of the HM.
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Next, with the assumption that the homology model for DPMS is valid, a molecular probe
for DPMS has been designed to verify the molecular target in vitro. The proposed binding
mode of this rhodanine probe 34 is shown in Figure 48. The arginine Arg126 in this proposed
binding mode undergoes hydrogen bonding interactions with the N-1-carboxylic side chain,
while the rhodanine moiety is placed in close proximity to the phosphate binding side (Asp97
and Asp99). In contrast to previous docking solutions the modified 3-benzyloxy moiety is mod-
elled to undergo pi-stacking interaction with Tyr12, a residue believed to undergo pi-stacking
interactions with the GDP-nucleotide. [215]
3.5.5 Investigation of DPMS as a possible target for rhodanine inhibitors
The final step for the target identification was to confirm binding to DPMS and to identify its
exact binding mode. Therefore a rhodanine photo-affinity probe (34) was designed with the
capability to covalently bind to proteins in close proximity upon UV-activation. In this chapter,
the experimental setup and results of this target identification study is described. The photo-
affinity probe 34 showed activity against T. brucei at GI50 12.9µM, however compared to the
unsubstituted 3-benzyloxy analogue 14v (GI50 4.4µM), the activity decreased by a factor of 3.
Both 34 and 14v did not show any toxicity against HL60 cells at 100µM. Further details about
the photo-affinity label are described in section 3.2.12. The labelling was carried out in 24 well
plates with incubation times varying from 4 to 24 h in the presence of photo-affinity probe 34
and T. brucei. Initially a tubular low-pressure mercury-vapour discharge lamp from Phillips with
a UV maximum irradiation at 365 nm, a wavelength ideally for initiation of photo-cross-linking to
proteins was used. [179] After UV-activation, the parasites were lysed and proteins precipitated
and subjected to Click-chemistry conditions with an alkyne-AlexaFluor488 tag. However, SDS-
gel analysis did not show any fluorescent tagged protein bands (results not shown). After this
initial experiment it was assumed that the photo-induced coupling to proteins is insufficient. In
order to improve the experimental setup, the experiment was repeated as described above,
but this time a portable UV-lamp at 254 nm maximum UV-irradiation was used for the photo-
cross linking of the probe and the molecular target. Furthermore, this time the fluorescent tag
was exchanged with an alkyne-biotin tag, in order to increase sensitivity by concentration of
biotin-tagged proteins with streptavidin beads. However, SDS-gel analysis after Coomassie
staining did not show any protein bands other than in the negative control without 34. It
seemed that although rhodanine derivatives are described as promiscuous binders, [82] 34 did
not interact with any proteins. As this was rather unlikely considering its biological activity, the
problem has to be the photo-cross-linking procedure. Indeed a recent communication with
Prof. Keith A. Stubbs (The University of Western Australia) suggested that 24 well plates might
not be suitable for the UV-cross linking step and that quartz spectrophotometric cuvettes might
increase efficiency of the photo-labelling step due to better light exposure. In order to increase
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Figure 47: Representative docking result of rhodanine-N-acetic acid derivatives within the ac-
tive site of homology model 4, upper figure shows the alignment of GDP-Man
(lines) with the rhodanine inhibitor (stick); lower figure shows interactions within
the active site; pictures were created with MacPymolX11 and MOE.2009.10.
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Figure 48: Interactions of rhodanine-probe within the active site of homology model 4,
overlaid with GDP-Man (lines); pictures were created with MacPymolX11 and
MOE.2009.10.
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the sensitivity even further it is planned to lyse the parasite prior to addition of the photo-affinity
probe and to initiate the cross-linking within the crude protein mixture.
3.6 Discussion
The rhodanine-N-acetic acid and the related thiazolidine-2,4-dione scaffold are an interesting
starting point for the development of broad-spectrum anti-parasitic agents. Numerous biolog-
ical applications of rhodanine and related compounds have been reported, often this scaffold
is described as privileged for its ability to undergo multiple interactions with proteins. [81,83,91,224]
However, recently rhodanine derivatives were suggested to be promiscuous binders and there-
fore it was crucial in this study to evaluate the anti-parasitic activity always based on previous
toxicity studies against HL60 cells. [82] While in many clinical applications it would be desirable
to minimise side-effects, hitting multiple targets in parasites would be beneficial, as resistance
is less likely to occur.
The investigations towards anti-parasitic agents started with a report of rhodanine-N-acetic
acid derivatives as inhibitors of trypanosomal DPMS, an essential enzyme in GPI-anchor
biosynthesis in T. brucei. [68] However none of these derivatives inhibited DPMS completely
(at best 10 % residual activity) or showed trypanocidal activity beyond ED50 96µM. [68] Various
derivatives of the previously found inhibitors were synthesised in order to increase in vitro anti-
parasitic activity. A synthetically interesting derivative was the ortho-trifluoromethyl derivative
7e (Figure 49), as it showed a long range 5JH,F coupling constant of 1.9 Hz in 1H-NMR and
13C-NMR experiments. This long range coupling is most likely explained via orbital interactions
(Figure 49) of the 1s orbital of H and the 2p orbital of F through-space. The long range coupling
was used to determine the double bond configuration as the thermodynamically more stable
Z-isomer. [162] The interaction of the trifluoromethyl group and the CH group and therefore the
5JH,F coupling could potentially be used as diagnostic tool for the measurement of intermolec-
ular interaction of 7e and a target protein. Where disruption of the coupling would indicate
binding of the protein towards the probe. A similar experiment has been performed previously
with a 5-fluoropyrimidine substituted RNA, where the 5JF ,H long-range coupling was diagnos-
tic for nucleic acid conformations. [225] Isomerisation of the exo-cyclic double bond could be
induced via a reaction sequence of esterification followed by a Knoevenagel reaction, giving
access to various E- and Z-isomer mixtures with the Z-isomer as major product. This racemi-
sation was most likely DMAP induced, as traces of DMAP have been observed.
Various modifications on the 5-benzylidene moiety in rhodanine-N-acetic acid derivatives
have been explored, but none of these modifications resulted in improved anti-parasitic activity
(GI50 >100). Modifications on the N-3 position of the rhodanine scaffold, such as elongation of
the side-linker, have been identified as essential for low µM activity against T. brucei ((GI50 9.0-
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Figure 49: Long-range 5JH,F coupling observed in compound 7e, possible induced by non-
bonded orbital interactions
72.8µM). Particularly remarkable was the effect of the esterification of the free carboxylic acid,
resulting in low µM active compounds against T. brucei and T. cruzi (GI50 1.3-17.6µM and 4.7-
94.6µM respectively), whereas the free carboxylic analogues showed no activity at 100µM.
Reduction of the exo-cyclic double bond increased anti-trypanosomal activity, suggesting that
Michael acceptor reactivity might not be part of the mode-of-action of these inhibitors.
Of particular interest were the rhodanine-N-acetic ester and thiazolidine-2,4-dione ana-
logues displayed in Figure 50, as they showed low µM activity and selectivity against para-
sites.
The rhodanine-N-acetic ester derivatives 14b and 14v (Figure 50) both showed low µM ac-
tivity against parasites, but furthermore the parent free carboxylic acid analogue of 14v has
been shown to inhibit DPMS, an essential enzyme in the GPI-anchor biosynthesis. [68] Fur-
ther modifications on the benzyloxy-substituent in 14v increased anti-trypanosomal activity,
but also toxicity against HL60 cells. The meta-methyl substituted tert-butyl ester 14b showed
broad anti-parasitic activity in the lower µM range against T. brucei, T. cruzi and L. infan-
tum (GI50 1.8, 5.1 and 2.4µM respectively).
The para-tert-butyl derivative 14o (Figure 50) showed excellent anti-trypanosomal activity
against T. brucei at GI50 1.7µM, moderate activity at GI50 23.4µM against L. infantum and no
activity against T. cruzi.
A 2-pyridinyl substituent on position 5 of the rhodanine moiety resulted in trypannocidal
activity against T. brucei and T. cruzi (GI50 1.5µM and MIC 100µM respectively) and had
good selectivity indices for T. brucei (SI >67).
The ethyl esters of the meta-methyl (14a) and 3-benzyloxy (14v) derivatives were chosen
for further mode-of-action studies. Using a myristic acid probe in combination with a fluores-
cent tag, allowed the identification of GPI-anchor biosynthesis as possible target, indicated by
decreasing intensities of GPI-anchored proteins using in-gel fluorescence. In order to further
evaluate GPI-anchor biosynthesis as potential target, flow cytometry experiments with FITC-
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Figure 50: Rhodanine-N-acetic derivatives and analogues identified as promising anti-
parasitic lead structures
labelled transferrin were performed on trypanosomes treated with 14a and 14v. These deriva-
tives caused a reduction of transferrin uptake compared to control cells, most likely mediated
by decreasing amounts of GPI-anchored TbTf receptors. 14v caused a 1.6 fold reduction of
transferrin uptake, whereas 14a caused a 1.3 fold reduction, possible accounting for their try-
panocidal activity in vitro. Fluorescence microscopy showed trypanosomes with diminished or
missing FITC-labelled transferrin, confirming the FACS analysis experiment and missing up-
take through GPI-anchored transferrin receptors. Lastly, cell-free assays of GPI-anchor syn-
thesis in T. brucei were performed and revealed DPMS and/or the first mannosyltransferase
(MT-1) as potential targets for 14v and 14a. 14a was the stronger inhibitor, resulting in total
vanishing of GPI-anchor intermediates after the synthesis of Dol-P-Man on HPTLC plates.
Analysis of logP and activity data against L. infantum showed that lipophilic substituents
increased anti-parasitic activity. In the case of 14a, this might explain the lack of activity of
the ethyl ester, while the tert-butyl ester 14b was active in the µM range against L. infantum.
It may be possible that increased lipophilicity aids plasma membrane diffusion, in this case
14b might have been the first GPI-anchor biosynthesis inhibitor with broad activity against all
three protozoa. The next logical step to confirm this hypothesis would be screening against
enzymes of the GPI-anchor biosynthesis in T. cruzi and L. infantum. An indirect confirma-
tion would be the synthesis of a tert-butyl ester analogue of the 3-benzyloxy derivative 14v,
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as the increased lipophilicity might aid membrane diffusion and possible result in low µM ac-
tivity against L. infantum. Alternatively the N-3 side chain could be elongated to increase
lipophilicity. In order to further optimise the anti-parasitic activity and to confirm the molec-
ular target, a photo-affinity probe has been designed, where two azides, a photo-activalible
aromatic azide and an aliphatic azide for fluophore-tagging, were attached to the 3-benzyloxy-
moiety of 14v. However, attempts to identify the target protein failed, most likely due to missing
photo-reactivity of the probe with the target in 24 well plates. Once the reaction conditions are
optimised and cross-labelling between the probe and the target protein occur, further mass
spectrometry studies would help to identify the protein-sequence, the mass and potentially the
amino-acid residues where the labelling occurred.
Another interesting class of rhodanine and thiazolidine-2,4-dione derivatives had a cat-
echol moiety on position 5. The derivatives 14t, 15f, and 7k were among the most potent
inhibitors of T. brucei growth (GI50 0.9-1.6µM). 14ab also showed anti-leishmanial activity at
GI50 45.9µM, but unfortunately high toxicity against HL60 was also observed (GI50 31.2µM).
However, 14t and its thiazolidine-2,4-dione analogue 7k showed no toxicity against HL60 at
100µM. The free acid of 14t, 2u showed no activity against any enzymes of the GPI-anchor
biosynthesis, suggesting a different mode-of-action. 2u has previously been reported as probe
for many dehydrogenases, possible by mimicking the cofactor NAD(P)H. [107,108] The aldose re-
ductase 14-αdemethylase CYP51 plays an important role in sterol synthesis in T. brucei, T.
cruzi and possible L. infantum. [111] It would be possible that 14t and 7k act as inhibitors for
this or similar NAD(P)H dependent enzymes in parasites, explaining their low µM activity. A
possible strategy to confirm this hypothesis would be the use of in-gel protein-affinity binding of
2u. A similar strategy has been employed previously, where 2u has been shown to be a weak
fluorophore, and this property in combination with target-affinity has led to the identification of
lactate dehydrogenase isozymes and 1-deoxy-D-xylulose-5-phosphate reductoisomerase as
targets of 2u in Escherichia coli. [108] Therefore in future experiments, crude protein extracts of
T. brucei would be separated on a Western-blot gel, this gel would be stained with 2u, washed
with buffer and the fluorescent proteins visualised (λex=465 nm, λem=535 nm emission). [108]
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3.7 Summary
130 rhodanine-N-acetic and related analogues have been synthesised and screened against
T. brucei, T. cruzi and L. infantum in a whole cell activity assay.
At the same time all 130 derivatives were screened against HL60 cells for evaluation of toxicity
against mammalian cells.
77 out of 130 derivatives were able to completely kill T. brucei in vitro at 100µM (MIC 100µM),
a further 25 of them showed trypanocidal effects at 10µM (MIC 10µM).
27 out of 130 derivatives killed T. cruzi at 100µM (MIC 100µM).
8 out of 130 derivatives killed L. infantum at 100µM (MIC 100µM).
6 out of 130 derivatives showed anti-parasitic activity against T. brucei, T. cruzi and L. infan-
tum in the whole cell activity screen, but only one compound (14b) had a good activity and se-
lectivity profile. This tert-butyl ester analogue 14b showed broad anti-parasitic activity against
T. brucei, T. cruzi and L. infantum (GI50 1.8, 5.1 and 2.4µM, SI 14, 5 and 10 respectively).
Primary whole organism phenotypic screens allowed identification of inhibitors with low µM anti-
parasitic activity (GI50 0.9-17.6µM) and good selectivity (SI >62.5 - 2).
Target identification studies, comprising metabolic labelling with myristate analogues, flow cy-
tometry with FITC-labelled transferrin and cell-free radio-label assays for GPI-synthesis in T.
brucei allowed the identification of GPI-anchor synthesis as potential target, with DPMS and/
or MT-1 as molecular targets.
Taken together, these results provide further evidence that GPI anchor biosynthesis is a drug-
able target for the development of novel anti-parasitic agents.
Catechol modified rhodanine-N-acetic ester analogues have been identified in a whole cell
assay as low-µM growth inhibitors of T. brucei (GI50 0.9-1.4µM, SI 21 - >75) with no activity in
GPI-anchor biosynthesis and with unknown mode-of-action.
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4 N-allyl rhodanine derivatives
4.1 Background on previous biological activities of N-allyl rhodanine
and N-allyl thiazolidine-2,4-dione derivatives
The following introduction serves as an overview of previous reports about N-allyl rhodanine
and related analogues. Previous biological studies on these inhibitor classes might have a
similar effect in parasitic protozoa and therefore it is important to know about their mode-of-
action in other organisms (Figure 51).
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Figure 51: Examples of previously N-allyl rhodanine and N-allyl thiazolidine-2,4-dione deriva-
tives.
N-allyl rhodanine and N-allyl thiazolidine-2,4-dione derivatives represent a compound class,
which exhibits a broad activity spectrum and a low toxicity profile. [114,226–233] N-allyl rhodanine
derivatives from type 39a have been described as anti-microbial agents, with activity against
gram-positive bacteria including multi-drug resistant strains. [226,227] Compound 39a has fur-
thermore been reported as an inhibitor of bacterial RNA polymerase and did not show any
toxicity against growth of chinese hamster ovary cells, Candida albicans or Aspergillus fumi-
gatus. [226,231,232] However, a recent study on the inhibitory effect of 39a and similar analogues
showed inhibition of multiple enzymes in bacteria, such as malate dehydrogenase and chy-
motrypsin in addition to RNA polymerase. [229] Using biomolecular approaches (bacterial mu-
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tants exhibiting luciferase activity upon inhibition of particular targets), it was revealed that 39a
inhibit DNA biosynthesis and has membrane damaging effects. [229] Consequently, 39a was
considered unattractive as an inhibitor of bacterial RNA polymerase. [229] These studies indi-
cate that rhodanine-N-allyl derivatives could also exhibit DNA damaging effects in parasites.
Furanyl rhodanine derivatives 39b and 39c have been reported as inhibitors of the non-
structural protein 3 in Hepatitis C virus (HCV NS3). [114] Although 39b and 39c are inhibitors
against HCV NS3, they also showed activity against other serine proteases, namely chy-
motrypsin and plasmin. [114] Furthermore, furanyl rhodanine derivatives 39d have been shown
to inhibit Sortase A, a trans-peptidase essential to attach surface proteins in Staphylococus
aureus. [230]
Also the N-allyl thiazolidine-2,4-dione scaffold shows interesting pharmacological activ-
ity. Compound 39e has been reported as an inhibitor of Autotaxin, a phosphodiesterase
thought to have implications for tumor progression, metastasis, inflammation and fibrotic dis-
eases. [157] Compound 39e has further been shown not to exhibit Michael addition reactivity to
Autotaxin. [157]
The pyrazole N-allyl thiazolidine-2,4-dione derivative 39f has been studied for its anti-in-
flammatory and anti-neurotoxicity profile, showing that in particular NAD(P)H oxidase inhibition
is effected. [233] This hybrid molecule further showed no toxicity in animals at 300 mg/kg. [233]
Recently thiazolidine-2,4-dione derivatives have been assessed as inhibitors against β-
ketoacyl carrier protein synthase. [228] While there have been reports of N-allyl rhodanine and
N-allyl thiazolidine-2,4-dione derivatives as anti-bacterials, anti-viral, anti-inflammatory and
anti-toxicity agents, there are no reports about their anti-parasitic activity. [114,226–233] However,
a patent about the use of these analogues as anti-parasitic agents against Toxoplasma gondii
has been filed. [234]
Rhodanine-N-allyl derivatives and analogues exhibit broad biological activity and were cho-
sen as interesting candidates for the development as broad-spectrum anti-parasitic agents, as
relatively little is yet known about their anti-trypanosomal and anti-leishmanial properties. Fur-
thermore, it was of interest to compare this compound class with the rhodanine-N-acetic acid
derivatives for their GPI anchor biosynthesis inhibition activity. The reported toxicity profile
suggested low toxicity, [226,231,232] but DNA damaging effects in bacteria were reported. [229]
4.2 Synthesis of inhibitor library
In this chapter the synthesis of N-allyl rhodanine and N-allyl thiazolidine-2,4-dione derivatives
as anti-parasitic agents is described.
The general molecular structure of N-allyl rhodanine and thiazolidine-2,4-dione derivatives
is shown in Figure 52. This scaffold has large scope for modifications in order to improve
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Figure 52: Synthetic strategy for N-allyl rhodanine and N-allyl thiazolidin-2,4-one derivatives
as anti-parasitic agents; X=O,S; A,B,C: variable aromatic substitution.
anti-parasitic activity. Therefore several aromatic substitutions (A,B,C=N or CR) on the 5-
position of this scaffold have been persued (Figure 52). But also modifications on the exo-
cyclic thiocarbonyl (X=S,O) have been explored. Furthermore, the influence of the exo-cyclic
double bond was examined through the synthesis of saturated analogues.
4.2.1 Aromatic Substitution
The rhodanine derivatives were synthesised starting from N-allyl rhodanine 40, which was
subjected to Knoevenagel condensation reactions with various benzaldehyde derivatives in
the presence of sodium acetate as the base (Scheme 22). The Knoevenagel reaction resulted
in the formation of the desired 5-benzylidene modified N-allyl rhodanine derivatives 40a–ae in
good yields of 10-100 %.
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Scheme 22: Knoevenagel condensaion reaction of N-allyl rhodanine derivatives; (i) NaOAc,
ethanol, 80 ◦C; for R1-R3 substitutions see Table 28, see Table 28.
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All products crystallised from the ethanol reaction mixture and were afforded by simple fil-
tration, thus the yield of the reaction was dependant on the ability to form crystals. NMR analy-
sis of the CH-signal in the N-allyl rhodanine derivatives 40a–ae showed only the Z-isomer (δH
7.57-8.08 ppm, δC 128.6-135.3 ppm) of the exo-cyclic double bond. The configuration of the
double bond was further validated by an X-ray structure of 40ac. The X-ray structure showed
the Z-configuration of the double bond (Figure 53). Molecules of 40ac were stacked above
each other, with the rhodanine core being in a plane of the 5-benzylidene moiety. The alter-
nate arrangement of 40ac along the stacked columns showed a slight offset in their alignment
in the planes (Figure 53). The N-allyl group orientated in two distinct orientations alongside
these planes. The crystal structure of 40ac most likely represents a general representation of
the crystal packing in compounds of the type 40a–ae, explaining their tendency to form crys-
tals. Although similar packing might be expected in other types of rhodanine derivatives, no
other derivatives showed as facile crystallisation properties.
Another interesting observation in the 1H- and 13C-NMR spectra of 40e (Table 28) was
a 5JH(C),F -coupling constant of 1.9 Hz. This phenomenon was previously observed with sim-
ilar rhodanine analogues in this research study (Chapter 3.2.5). The nature and underlying
mechanism of the long-range coupling is discussed in Figure 20.
4.2.2 Replacement of the Thiocarbonyl X=O
The thiocarbonyl group in rhodanine derivatives have been shown to be in part responsible
for their versatile ability to bind to different proteins (see also Chapter 3.2.6). [83] Replacement
of this group has previously been shown in this study to decrease toxicity against HL60 cells
in rhodanine-N-acetic acid derivatives (Chapter 3.3.8). The replacement of the thiocarbonyl
by a carbonyl group might potentially increase target selectivity and may result in decreased
toxicity.
Synthesis of the N-allyl thiazolidine-2,4-dione precursor
The N-allyl or N-propargyl thiazolidine-2,4-dione derivatives 41 and 42 were synthesised start-
ing from thiazolidine-2,4-dione. Two strategies have been chosen for the synthesis of substi-
tuted thiazolidine-2,4-dione derivatives 41 and 42 (Scheme 23, refnallyldionesynthesistable).
The first approach was nucleophilic substitution of thiazolidine-2,4-dione with allyl- or propar-
gyl alcohol using Mitsonobu reaction conditions (method (i) in Scheme 23, Table 29). In the
first reaction sequence the active reagent of the Mitsonobu reaction has to be prepared by
addition of di-tert-butylazodicarboxylate (DEAD) to a -78 ◦C cooled solution of triphenylphos-
phine (PPh3) in anhydrous THF. In the consecutive step, the thiazolidine-2,4-dione and the
corresponding alcohol were added and the reaction mixture was stirred subsequently at room
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Figure 53: View of stacking of 40ac along the b axis. The X-ray structure was kindly recorded
by Dr. David Hughes (UEA, Norwich, UK).
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Table 28: Knoevenagel condensation reaction of N-allyl rhodanine derivatives; R1-R3 for
rhodanine N-allyl derivatives 40a–ae; yield and chemical shift of CH-signal, see
Scheme 22.
[%] NMR chemical shifts of CH-signal [ppm]
# R1 R2 R3 R4 yield δsolvent δH δC
40a H H H H 31 CDCl3 7.74 133.4
40b CH3 H H H 100 CDCl3 7.98 131.2
40c H CH3 H H 49 CDCl3 7.70 133.7
40d H H CH3 H 82 DMSO-d6 7.81 133.2
40e CF3 H H H 22 CDCl3 8.01 128.6
40f H CF3 H H 50 CDCl3 7.73 131.0
40g H H CF3 H 70 CDCl3 7.73 130.9
40h H H Cl H 53 CDCl3 7.67 131.9
40i H H CN H 57 CDCl3 7.68 130.0
40j H H CCH H 49 CDCl3 7.69 132.0
40k H Br OMe H 66 CDCl3 7.79 129.6
40l H Br F H 52 CDCl3 7.61 130.2
40m H NO2 H H 21 CDCl3 7.75 129.6
40n H H Nme H 32 CDCl3 7.68 n.a.
40o H H NHAc H 52 CDCl3 7.69 129.7
40p OH H H H 87 CDCl3 8.20 130.3
40q H OH H H 45 CDCl3 7.67 133.0
40r H H OH H 50 CDCl3 7.69 133.5
40s OH H OH H 47 CDCl3 8.08 131.1
40t H OH OH H 15 MeOD-d4 7.57 135.3
40u H OMe OH OMe 78 DMSO-d6 7.74 134.6
40v H H SO2Me H 42 CDCl3/DMSO-d6 7.72 130.0
40w H H CHO H 27 CDCl3 7.62 n.a.
40x H OBn H H 10 CDCl3 7.69 133.2
40y H H OBn H 69 CDCl3 7.69 133.4
40z H OBn OBn H 51 CDCl3 7.60 133.6
40aa H H B(OH)2 H decompostion
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Scheme 23: Synthesis of N-allyl thiazolidine-2,4-dione derivative 41 and anlogue 42; (i) allyl
or propargyl alcohol, PPh3, DEAD, -78 grad C→ rt, THF; (ii) allyl bromide, NaH,
0 ◦C→ rt, DMF; for substituents of X and R see Table 29, see Table 29.
Table 29: Synthesis of N-allyl thiazolidine-2,4-dione derivative; X and R for synthesis of 41
and 42; methods and yields, see Scheme 23.
# x R Method yield [%]
41 OH CHCH2 (i) 84
41 Br CHCH2 (ii) 62-86
42 OH CCH (i) 98
temperature. The products were obtained after column chromatography as clear oils and in
good yields of 84-98 %. The second approach was the base-catalysed nucleophilic substi-
tution with allyl bromide and thiazolidine-2,4-dione in the presence of sodium hydride (NaH)
(method (ii) in Scheme 23). The reaction was carried out in DMF and under a nitrogen gas
atmosphere. The yields of 62-67 % were slightly decreased compared to the Mitsunobu ap-
proach, but the reaction procedure was facilitated, as no reagents needed to be formed prior
to reacting the substrates and the reaction could be carried out under ice-cooling compared to
cooling to -78 ◦C. In summary, both methods were suitable for the formation of the precursors
41 and 42.
Knoevenagel reaction of thiazolidine-2,4-dione analogue 41 with benzaldehyde deriva-
tives
The N-allyl thiazolidine-2,4-dione precursor 41 was subjected to various benzaldehyde deriva-
tives in a Knoevenagel condensation reaction (Scheme 24). The condensation products were
afforded in yields of 13-88 % mostly as white solids. The replacement of the thiocarbonyl group
resulted in a complete loss of the previous yellow to red colour of the rhodanine analogue. The
purification method of the previous reaction protocol for rhodanine derivatives needed to be
adjusted, as most of the products 41a–m did not precipitate from ethanol. However, alterna-
tive purification via extraction and column chromatography succeeded in the isolation of the
desired products 41a–m (Table 30). The low yield of the reaction might correspond to im-
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Scheme 24: Synthesis of N-allyl thiazolidine-2,4-dione derivates 41a–m and 42; (i) NaOAc,
80 ◦C, EtOH; for substitutions of R1-R4 see Table 30.
proved water-solubility of the condensation products and therefore loss of product during the
extraction process. The carbonyl group in thiazolidine-2,4-dione derivatives can form specific
hydrogen-bonds to water molecules, which need to be disrupted, prior to binding to a molec-
ular target, thus potentially leading to more target selectivity. [83] In contrast the analogous
thiocarbonyl derivatives undergoes less specific hydrogen bonds with water and desolvatation
is facilitated. [83]
Compounds 41a and 41e (Table 30) showed a long-range 5JH(C),F -coupling of 1.5-1.9 Hz
(discussed previously in chapter 4.2.1). The coupling constant of 1.5 Hz for 41e is slightly
lower compared to the previous observed long-range couplings of 1.9-2.0 Hz. This decrease
is most likely due to the electron-withdrawing effect of the other trifluoromethyl group in the
5-benzylidene-residue. All products 41a–m were afforded as the Z-double bond isomer as
confirmed by the chemical shift of the CH-signal in 1H- and 13C-NMR experiments. The chem-
ical shifts were between 7.74-8.23 ppm depending on the deutorated solvent used and were
in the same region as observed with all other analogues in Z-configuration.
4.2.3 Introduction of 5-benzylidene-3-benzyloxy- and heterocyclic modifications on the
N-allyl rhodanine 40 and thiazolidine-2,4-dione derivatives 41 and 42
In this chapter, the synthesis of condensation products, bearing heterocyclic modification on
position 5 of the rhodanine or thiazolidine-2,4-dione moiety, is described. Furthermore, modifi-
cations on the 5-benzylidene-3-benzyloxy-substituent were explored and the condensation of
non-aromatic aldehydes and difunctionalised aromatic aldehyde derivatives were investigated.
The installation of further modifications on position 5 of the thiazolidine-4-one moiety possible
helps the identification of compounds with improved anti-parasitic activity. In particular hete-
rocyclic aldehydes have different electronic properties, such as charge or the ability to interact
in hydrogen bonding than compared to simple benzylidene motifications. In a structure activity
relationship study this important information would be invaluable.
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Table 30: Synthesis of N-allyl thiazolidine-2,4-dione derivates; R1-R4 for derivatives 41a–m
and 42; yield and NMR chemical shift of CH-signal, see Scheme 24.
[%] NMR of CH-signal [ppm]
# R1 R2 R3 R4 yield δsolvent δH δC
41a CF3 H H H 35 CDCl3 8.18 129.7
41b H CF3 H H 14 CDCl3 7.92 132.0
41c H H CF3 H 66 CDCl3 7.91 132.0
41d H CF3 H CF3 no product
41e CF3 H CF3 H 25 CDCl3 8.01 129.9
41f OH H H H 19 MeOD-d4 8.27 130.6
41g H OH H H 35 CDCl3 7.85 133.9
41h H H OH H 46 CDCl3 7.86 134.2
41i H OH OH H 13 MeOD-d4 7.74 135.6
41m OH H OH H 15 MeOD-d4 8.23 131.0
41j H OBn H H 88 CDCl3 7.83 133.9
41k H H OBn H 88 CDCl3 7.84 133.8
41l H OBn OBn H 72 CDCl3 7.75 134.0
Initially, simple pyridine-carboxaldehyde derivatives were subjected to 40, 41, and 42 in a
Knoevenagel condensation reaction (Scheme 25). The products 43a, 43b, 43c, 44a, and 45a
(Table 31) were obtained in yields of 23-91 % after column chromatography. The chemical
shift δH of the CH-signal (7.62-7.83 ppm) indicated the formation of the thermodynamically
more stable Z-configuration of the double bond. [158] Next, 2-halogen-substituted pyridinecar-
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R1=CHCH2, X=S
R1=CHCH2, X=O
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Scheme 25: Synthesis of modified N-allyl rhodanine and thiazolidine-2,4-dione derivatives; (i)
NaOAc, 80 ◦C, EtOH, see Table 31.
boxaldehyde derivatives were reacted with 40. The 2-chloro-substituted pyridine derivative
43d (Table 31) was afforded in good yields of 44 %, while reaction of the 2-bromo-analogue
resulted only in the formation of decomposition products. This observation was very similar to
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Table 31: Synthesis of modified N-allyl rhodanine and thiazolidine-2,4-dione derivatives; X,
R1-R2; yields and chemical shift of CH-signal of modified N-allyl rhodanines and
thiazolidine-2,4-dione derivatives, see Scheme 25.
[%] NMR shift of CH-signal [ppm]
# X R1 R2 yield δsolvent δH δC
43a S Allyl 2-pyridinyl 91 CDCl3 7.62 128.0
43b S Allyl 3-pyridinyl 47 CDCl3 7.71 128.7
43c S Allyl 4-pyridinyl 42 CDCl3 7.62 129.2
44a O Allyl 4-pyridine 23 CDCl3 7.79 130.6
45a O Propagyl 4-pyridine 26 CDCl3 7.83 131.3
43d S Allyl 2-chloropyridinyl 44 CDCl3 7.55 n.a.
43e S Allyl 2-bromopyridine no product
43f S Allyl 25c N
HN Bn
54 CDCl3 7.41 n.a.
43g S Allyl 25g
N
HN
CH3 32 CDCl3 7.49 131
43h S Allyl 25a N
HN
Bn
no product
43i S Allyl 18c
O
OCH3 90 CDCl3 7.69 133.4
43j S Allyl 33f
O
N3
N3
66 CDCl3 7.17 n.a.
43k S Allyl hexanol no reaction
43l S Allyl
NS
O
S
R1
16 DMSO-d6 7.82-7.84 n.a.
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the condensation reaction with the rhodanine-N-acetic ethyl ester 14, as no product could be
isolated in both cases after column chromatography (Scheme 14).
Previously, 2-amino-substituted aldehydes were synthesised to explore their structure ac-
tivity relationship in comparison to 5-benzylidene-3-benzyloxy substituents (NHBn vs. OBn)
and simple pyridine derivatives (Scheme 15). The aldehydes 25a, 25c, and 25g were re-
acted with 40. The 2-aminobenzyl aldehydes 25c and 25g led to the formation of the desired
products 43f and 43g (Table 31) in yields of 32-54 %. In contrast, the 2-amino aldehyde 25a
(NHCH2Bn) did not react with 40 and only starting materials were recovered.
In order to explore the anti-parasitic effect of 5-benzylidene-3-benzyloxy modified N-allyl
rhodanine derivatives, the modified 3-benzyloxy benzaldehyde 18c was subjected to Knoeve-
nagel reaction conditions with 40. The condensation product 43i (Table 31) was isolated in
very good yields of 90 %.
To study the anti-parasitic effect of 3-benzyloxy- and 2-amino- pyridines modified N-allyl
rhodanine 43f, 43g, and 43i (Table 31), a photo-affinity probe was introduced to the 3-benzyloxy-
modification. The synthesis of this photo-affinity probe is described in Scheme 19. The Kno-
evenagel reaction was carried out under lower temperatures of 50 ◦C, to prevent decomposi-
tion of the newly formed product 43j and the starting aldehyde 33f. The photo-affinity probe for
N-allyl rhodanine 43j was obtained in yields of 66 % after simple filtration. The spectroscopic
analysis (1H-NMR) showed a chemical shift of the CH-signal at δH 7.17 ppm in CDCl3. A chem-
ical shift that up-field would indicate the E-configuration of the exo-cyclic double bond. Due to
poor solubility of 43j in CDCl3, MeOH-d4 and DMSO-d6, further NMR spectroscopic analysis
to reveal the double bond configuration could not be performed. Because of its poor solubility
it was not expected, that the photo-affinity label would be active against living parasites and
no further studies on the double bond configuration were pursued.
The aliphatic aldehyde 5-hydroxypentanal did not react to the desired condensation prod-
uct 43k (Table 31). The Knoevenagel reaction proceeded to a mixture of products, but no
product was obtained after column chromatography.
Previously, terephthalaldehyde was reacted with N-allyl rhodanine to obtain 40w as a 1:1
mixture of aldehyde and mono-condensated product. Here, two equivalents of N-allyl rhoda-
nine 40 (Table 31) were used for the condensation reaction. The reaction proceeded to the
desired bis-condensation product 43l in poor yields of 16 %. The bis-substituted product 43l
was very poorly soluble, so synthesis was of minor importance and the reaction conditions
were not optimised any further.
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4.2.4 Reduction of the exo-cyclic double bond in N-allyl thiazolidine-2,4-dione
derivatives
N-Allyl thiazolidine-2,4-dione derivatives are potentially prone to react with biological nucle-
ophiles such as gluthathione. [82] The nucleophile could react with the Michael acceptor sys-
tem and could covalently bind to the exo-cyclic double bond. Previous reports suggested that
thiazolidine-2,4-dione derivatives were less reactive towards Michael addition reactions. [157]
In order to exclude the possibility of covalent binding, it was desirable to reduce the double
bond and compare the activity profile of both the saturated and unsaturated thiazolidine-2,4-
dione derivatives. The reduction of thiazolidine-2,4-dione derivatives could easily be achieved
by catalytic hydrogenation with Pd/C as the catalyst. Therefore, compound 41h was subjected
to catalytic hydrogenation conditions to yield the reduced analogue 46a (Scheme 26).
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41h 46a
Scheme 26: Synthesis of reduced N-allyl thiazolidine-2,4-dione analogue 46a; (i) Pd/C, H2
(30 psi), dioxane.
However, under these conditions also the allyl double bond of 41h was reduced together
with the double bond. Although the full reduction in 46a was expected, sometimes the catalytic
hydrogenation can give unpredicted outcomes. One such example was the hydrogenation
product 47a. Compound 47a was synthesised starting from the unsubstituted thiazolidine-2,4-
dione and 4-benzyloxybenzaldehyde in a Knoevenagel condensation reaction. The resulting
Knoevenagel product was subjected to catalytic hydrogenation with Pd/C at 30 psi H2. Sur-
prisingly the 4-benzyl protecting group was not cleaved during the catalytic hydrogenation
(Scheme 27, R1=H, R2=Bn). Consequently, alternative strategies towards reduced N-allyl
thiazolidine-2,4-dione derivatives were explored. The reduced catechol derivative 47b was
synthesised via a Knoevenagel reaction of catechol benzaldehyde and thiazolidine-2,4-dione.
The condensation product was subjected to catalytic hydrogenation to afford the reduced ana-
logue 47b in quantitative yield. In order to introduce the N-allyl function, compound 47b was
reacted in a Mitsonobu reaction with allyl alcohol, but unfortunately the desired product could
not be obtained via this route and only starting material was recovered. Therefore the deriva-
tive 46a was used as a model compound for the comparison of the reduced versus the non-
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Scheme 27: Alternative strategy toward reduced N-allyl thiazolidine-2,4-dione derivatives; (i)
NaOAc, 80 ◦C, EtOH; (ii) Pd/C, 30 psi H2, dioxane; (iii) allyl-alcohol, PPh3, DEAD,
THF, -78 ◦C→ rt.
reduced analogue.
4.3 Anti-parasitic activity
4.3.1 Whole cell activity assay: simple N-allyl rhodanine derivatives
The biological activity against parasitic protozoa such as T. brucei, T. cruzi and L. infan-
tum were assessed with the colorimetric and/or fluorometric viability dyes MTT and Alamar-
Blue, as previously described in chapter 3.3.1.
Initially, N-allyl rhodanine 40 and its Knoevenagel condensation products 40a–ae were
screened for their activity as anti-parasitic agents. At the same time toxicity assays were
performed to assess their toxicity against mammalian HL60 cells (Table 32).
The starting N-allyl rhodanine 40 had no effect on parasitic growth in T. brucei, but showed
toxicity against HL60 cells (GI50 75.6µM). However, the simple introduction of a benzyl group
(40a) in position 5 of the rhodanine moiety led to a complete loss of toxicity at 100µM. Al-
though, 40a did not show any effect on parasitic growth in T. brucei, T. cruzi or L. infantum,
the introduction of hydroxy substituents on the 5-benzylidene moiety led to low µM inhibitors
against T. brucei (40t) and moderate inhibitors against T. cruzi (40r). The inhibitor 40t had
a catechol motif on the benzylidene moiety. Similar catechol modifications in rhodanine-N-
acetic ester derivatives (Table 16, Table 17, Table 18, Table 19 and Table 22) resulted in low
µM inhibitors against T. brucei growth (GI50 0.9-14.2µM) and moderate activity against L. in-
fantum (GI50 45.9-75.7µM). Derivative with only one hydroxy substituent in meta- (40q) or in
para-position (40r) were 43- and 13-times less active against T. brucei than the catechol mod-
ified analogue with a meta- and para-substituent. However, the introduction of a para-hydroxy
substituent in 40r resulted in moderate activities against T. brucei and T. cruzi (GI50 15.1-
27.8µM). 40r was the only inhibitor in this initial series to display activity against T. cruzi. N-allyl
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Table 32: Anti-parasitic activity of N-allyl rhodanine derivatives; SI refers to T. brucei activity.
N S
S
O
N S
S
O
R1 R2
R3
R4
40 40a–ae
GI50 [µM]
# R1 R2 R3 R4 T. brucei T. cruzi L. infantum HL60
40 338.7±2.6 n.a. n.a. 75.6±15.1
40t H OH OH H 1.2±0.1 n.a. >100 >100
40e CF3 H H H 1.7±0.1 >100 22.4±0.1 69.1±4.3
40p OH H H H 1.5±0.3 >100 >100 11.2±3.5
40f H CF3 H H 3.7±1.2 >100 >100 15.1±1.3
40l H Br F H 10.7±0.2 >100 >100 12.3±1.9
40v H H SO2Me H 11.0±0.6 >100 >100 20.8±8.5
40b CH3 H H H 12.4±0.4 >100 >100 81.0±2.9
40c H CH3 H H 12.9±0.8 >100 >100 81.0±2.3
40u H OMe OH OMe 13.9±0.9 n.a. n.a. >100
40s OH H OH H 14.0±1.1 n.a. >100 >100
40m H NO2 H H 14.6±0.5 >100 >100 18.3±2.2
40x H OBn H H 14.9±3.2 >100 >100 >100
40r H H OH H 15.1±2.9 27.8±1.9 >100 >100
40o H H NHAc H 16.3±0.5 >100 >100 17.9±2.5
40ad H H CH3 H 16.5±1.9 >100 >100 >100
40n H H NMe2 H 17.5±0.2 n.a. n.a. >100
40i H H CN H 41.3±4.6 >100 >100 67.4±0.4
40q H OH H H 52.1±1.3 >100 >100 80.2±3.1
40w H H CHO H 52.4±2.7 >100 >100 >100
40a H H H H >100 >100 >100 >100
40g H H CF3 H >100 >100 >100 >100
40y H H OBn H >100 >100 >100 >100
40z H OBn OBn H >100 >100 >100 >100
40h H H Cl H >100 >100 >100 >100
40j H H CCH H >100 >100 >100 >100
40k H Br OMe H >100 >100 >100 >100
40d H H tBu H n.a. n.a. n.a. >100
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rhodanine derivatives with a ortho- and para-hydroxy modification (40s) showed moderate ac-
tivity against T. brucei, while the mono-ortho analogue 40p was as potent (GI50 1.5µM) as the
previous identified catechol modified derivative 40t. The ortho-hydroxy group might serve as
a hydrogen-bond acceptor, as the ortho-trifluoromethyl substituted analogue 40e was equipo-
tent against T. brucei growth. Furthermore, 40e was the only compound in this series to inhibit
L. infantum growth at GI50 22.4µM, while showing only moderate toxic against HL60 cells
(GI50 69.1µM) than the analogues hydroxy modified derivative 40p (GI50 11.2µM).
Substitutions of the meta position of the 5-benzylidene moiety with trifluoromethyl, methyl,
methoxy, bromo and benzyloxy substitutions resulted in GI50 values of 3.7-14.9µM against T.
brucei. However, large substituents in para-position (trifluoromethyl, benzyloxy, methoxy and
tert-butyl groups) caused complete loss of anti-parasitic activity at 100µM.
4.3.2 Replacement of the thiocarbonyl
In order to further optimise activity of N-allyl rhodanine derivatives, the thiocarbonyl was re-
placed by a carbonyl group. This modification resulted in an improved toxicity profile in the
rhodanine-N-acetic ester series (described in Chapter 3.3.8).
The best inhibitor of the first screening of rhodanine-N-allyl derivatives against T. brucei, T.
cruzi and L. infantum had an activity of 1.2µM and displayed no toxicity against mammalian
HL60 cells at 100µM. Replacing the thiocarbonyl group with a carbonyl group, decreased
the activity of this catechol modified thiazolidine-2,4-dione derivative 41i by a factor of 4 and
an increased toxicity against HL60 cells was observed (GI50 83.4µM, see Table 33). The
ortho- and para-dihydroxy modified analogue 41m displayed similar activity against T. brucei
(GI50 8.6µM) than its thiocarbonyl derivative 40s. Both, the dione-modified analogue 41m
and the rhodanine derivative 40s were non-toxic against HL60 cells at 100µM. The meta
hydroxy modified derivative 41g was 4 times as active against T. brucei (GI50 12.9µM) than its
thiocarbonyl analogue 40q. The para-hydroxy modified thiazolidine-2,4-dione analogue 41h
was more than 4 times less active against T. brucei and T. cruzi than its rthodanine analogue
40r. Particularly interesting was the ortho-hydroxy modified thiazolidine-2,4-dione analogue
41f, which showed good activity against both T. brucei and T. cruzi (GI50 15.7-49.4µM). The
parent thiocarbonyl analogue 40p was 10 fold more active against T. brucei, the selectivity SI
7 was relatively low towards T. brucei in comparison to HL60 cells. Additionally, compound
40p did not show any activity against T. cruzi, whereas 41f was moderately active.
A similar trend was observed in the trifluoromethyl series of the thiazolidine-2,4-dione
derivatives. The meta-trifluoromethyl dione derivative 41b (GI50 14.4µM) was 4 fold less
active against T. brucei , but did not show any toxicity against HL60 cells, compared to the
analogous rhodanine derivative (GI50 15.1µM). Ortho- and para-ditrifluoromethyl substituted
thiazolidine-2,4-diones, such as 41e were 10fold less active against T. brucei than the mono-
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Table 33: N-allyl thiazolidine-2,4-dione derivatives and their anti-parastic activity.
N S
O
O
R1 R2
R3
R4
GI50 [µM]
# R1 R2 R3 R4 T. brucei SI T. cruzi L. infantum HL60
41i H OH OH H 5.0±0.6 17 n.a. >100 83.4±0.3
41m OH H OH H 8.6±0.4 >12 n.a. n.a. >100
41g H OH H H 12.9±0.4 >8 >100 >100 >100
41e CF3 H CF3 H 14.2±3.2 n.a. >100 59.2±6.0 n.a.
41b H CF3 H H 14.4±1.1 >7 >100 >100 >100
41f OH H H H 15.7±0.1 >6 49.4±4.6 >100 >100
41j H OBn H H 16.0±1.9 n.a. >100 >100 n.a.
41c H H CF3 H 50.8±4.0 >2 >100 >100 >100
41h H H OH H 58.2±6.4 >2 n.a. n.a. >100
41l H OBn OBn H >100 >1 >100 >100 >100
41k H H OBn H >100 >1 >100 >100 >100
ortho trifluoromethyl substituted rhodanine derivative 40e. However, both the dione 41e and
the rhodanine derivative 40e displayed activity against L. infantum, indicating the importance
of a ortho-trifluoromethyl substituent. A para-trifluoromethyl substituent in the dione series
(41c) showed a 4 fold decreased activity against T. brucei and T. cruzi.
As expected from first screening results of rhodanine derivatives, bulky 4-benzyloxy deriva-
tives, such as in compounds 41l and 41k did not show any effect on parasitic growth at
100µM. Whereas the 3-benzyloxy analogue 41j retained all of its activity against T. bru-
cei (GI50 16.0µM) then the thiocarbonyl (GI50 14.9µM) was replaced by a carbonyl group.
4.3.3 Modification of the 3-benzyloxy-substitutent
The N-allyl thiazolidine-2,4-dione derivative 41j was the only derivative to retain its activity
against T. brucei, if the thiocarbonyl group was replaced by a carbonyl group, whereas in
general a decrease in activity by a factor 4-10 was observed. This outstanding observation
led to further investigations of the importance of the 3-benzyloxy-substituent for anti-parasitic
activity. Substitutions on the 3-benzyloxysubstituent in compounds 43i and 43j decreased
anti-parasitic activity compared the unsubstituted analogue 40x (Table 34). However, if the
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3-benzyloxy moiety was replaced by a 3-amino-benzyl group in the pyridine rhodanine deriva-
tives 43f and 43g activity against T. brucei was retained (GI50 12.7-15.0µM) from its parent
derivative 40x. But the modifications in 43f and 43g did not improve potency, as they showed
increased toxicity against HL60 cells (GI50 48.6-72.6µM). The derivative 43g was also inter-
esting for its activity against L. infantum (GI50 46.1µM). The additional methyl group in meta-
position of the 3-benzyloxy-substituent increased activity against L. infantum and decreased
toxicity against HL60 cells, compared to the analogue without this methyl substituent.
Table 34: Activity of 3-benzyloxy modified N-allyl rhodanine derivatives.
N S
S
O
O
D C
B
A
N S
S
O
N
HN
D C
B
A
40x, 43i, and 43j 43f and 43g
GI50 [µM]
# A B C D T. brucei SI T. cruzi L. infantum HL60
40x CH CH CH CH 14.9±3.2 7 >100 >100 >100
43f CH CH CH CH 12.7±0.5 4 >100 >100 48.6±7.1
43g CH CH CCH3 CH 15.0±1.6 5 >100 46.1±2.2 72.6±22.1
43i CH CH COCH3 CH 60.1±10.7 2 >100 >100 >100
43j CH CN3 CH CN3 >100 n.a. >100 >100 n.a.
4.3.4 Heterocyclic modified N-allyl rhodanine and thiazolidine-2,4-dione derivatives
The 2-amino-pyridinyl-derivative 43g in the previous chapter showed good activity against T.
brucei (GI50 15.0µM) and T. cruzi (GI50 46.1µM). The derivative 43g has been used to
explore anti-parasitic activity of 3-benzyloxy-modified rhodanine derivatives (Table 34). Al-
though structurally similar to 5-benzylidene-3-benzyloxy-substituents, additional effects of the
4-pyridinyl function in compound 43g could not be excluded. Therefore, additional rhodanine
and thiazolidine-2,4-dione derivatives bearing various heterocyclic modifications in position 5
have been tested for their anti-parasitic activity (Table 35). Indeed, the results of the screening
of pyridinyl-derivatives showed that 4-pyridinyl modifications resulted in low µM activity against
T. brucei growth (GI50 1.5-4.2µM). But these 4-pyridinyl derivative also showed high toxicity
against HL60 cells. The 4-pyridinyl rhodanine derivative 43c showed the highest toxicity of a
GI50 4.5µM against HL60 cells. However the introduction of an additional chloro-substituent
in 2-position of the pyridinyl-moiety decreased toxicity to GI50 11.0µM, without affecting anti-
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Table 35: Activities of heterocyclic modified N-allyl rhodanine and thiazolidine-2,4-dione
derivatives.
N S
X
O
R143g
GI50 [µM]
# X R1 T. brucei T. cruzi L. infantum HL60
43d S 2-chloropyridin-4-yl 1.5±0.1 >100 >100 11.0±1.7
43b S 3-pyridinyl 1.5±0.2 >100 >100 29.3±0.1
43c S 4-pyridinyl 1.5±0.2 n.a. >100 4.5±0.1
44a O 4-pyridinyl 4.2±0.2 >100 >100 63.7±1.3
43a S 2-pyridinyl >100 >100 >100 >100
43l S benzylidene-4-(5-rhodanine-N-Allyl) n.a. >100 >100 n.a.
trypanosomal activity against T. brucei. The replacement of the thiocarbonyl group in the ana-
logue 44a decreased toxicity even further to GI50 63.7µM, however also the anti-trypanosomal
activity was slightly decreased to GI50 4.2µM. Shifting the nitrogen in meta position in the 3-
pyridinyl derivative 43b resulted in equal potent anti-trypanosomal agents against T. brucei
and only moderate toxicity (GI50 29.3µM). Interestingly, the 2-pyridinyl-derivative 43a showed
no anti-trypanosomal activity at 100µM.
The bis-benzylidene-N-allyl rhodanine derivative 43l did not show any parasitic activity nor
toxicity. However its activity evaluation was compromised due to insufficient solubility, resulting
in precipitation under assay conditions with 0.5 % DMSO.
4.3.5 Effect of saturated N-propyl thiazolidine-2,4-dione derivative on
anti-trypanosomal activity; reactivity assay towards glutathione
Attempts to synthesis a reduced N-allyl rhodanine derivative failed and the N-propyl thiazolidine-
2,4-dione derivative 46a was used to study the effect of a reduced double bond on anti-
trypanosomal activity (Table 36). The reduced analogue 46a showed no anti-trypanosomal
activity at 100µM, whereas its unsaturated precursor 41h displayed moderate activity against
T. brucei. This result may indicate, that the exo-cyclic double bond contributes towards the anti-
parasitic activity. The reduction of the double bond increases flexibility and allows the molecule
to adapt different conformations, possible reducing binding affinity towards the molecular tar-
get. But the double bond may also be involved in covalent binding towards biological nu-
cleophiles, such as glutathione over its Michael acceptor system. For the following research
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Table 36: Anti-trypanosomal activity of saturated N-propyl thiazolidine-2,4-dione derivative.
X
SN
O
O
R1
OH
GI50 [µM]
# R1 X tb hl
41h allyl CH 58.2±6.4 >100
46a propyl CH2 >100 >100
study, the derivatives 43b and 43a have carefully been chosen for analysis of glutathione re-
activity (Table 37). Compound 43b possesses a low µM activity against T. brucei, whereas
Table 37: Glutathione reactivity of 43b and 43a measured by reaction with DTNB measured
in 10 % DMSO in PBS.
N
SN
S
O N
SN
S
O
43b 43a
GI50 [µM] RC50 [µM] against GSH
# T. brucei 8min 15 min 42 min 50 min
Acrolein n.a. 210.9±15.7 196.8±18.5 172.5±6.4 83.7±7.8
43b 1.5±0.2 >2000 1642 803.1 552.2
43a >100 >2000 >2000 >2000 >2000
43a did not show anti-parasitic activity. Furthermore, the nitrogen in the 3-pyridinyl would pos-
itively contribute towards Michael acceptor reactivity, as the nitrogens electronegativity results
in a partially positive charge on the alkenyl-carbon atom, thus favouring possible addition of
glutathione to the Michael acceptor system. This positive contribution is abandoned in 43a, as
the nitrogen partially changes the polarity of the alkenyl-carbon.
The reactivity towards glutathione was assessed by a published procedure using the El-
manns reagent for measuring residual glutathione in solution. [235] The reaction was carried
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out in 10 % DMSO, to overcome the poor solubility of 43b and 43a, and PBS to ensure a
buffered solution and physiological relevant conditions. Initially, the known Michael accep-
tor acrolein was screened for its ability to react with glutathione. It was pleasing to observe
that the use of PBS-buffer instead of phosphate buffer had no influence on the reactivity
constant for acrolein (RC50 83.7µM), correlating well with previously published results (RC50
84.5µM). [235] In contrast to the previous published procedure, the RC50 values presented in
this study were obtained in a 96 well plate assay format. Unfortunately, the absorbance of the
5,5’-dithiobis-(2-nitrobenzoic acid) (DTNB)-glutathione adduct at 412 nm interfered with the
bright yellow coloured analogues 43b and 43a. However, at lower concentrations the back-
ground absorbance of the inhibitors was decreased, compared to the intense signal of the
DTNB-glutathione adduct. For the evaluation of RC50 values for 43b and 43a, the absorbance
of the inhibitor was measured prior to addition of DTNB and was subtracted from the final
absorbance intensity. Indeed, the anti-trypanosomal inhibitor, which also showed moderate
toxicity against HL60 cells (GI50 29.3µM), reacted with glutathione and a RC50 of 552.2µM
was measured. Although this concentration is much higher than concentrations used in the
activity screens (100µM), it might explain 43b general cytotoxicity against T. brucei and HL60
cells. The 2-pyridinyl analogue 43a displayed no reactivity towards glutathione at 2 mM, pos-
sible explaining its missing anti-trypanosomal activity. It might be possible that the reactivity of
these inhibitor against glutathione is reversible as it has previously been observed for similar
derivatives in a UV-based assay. [86] The assay for glutathione reactivity, used in this study is an
endpoint assay, as DTNB addition results in consumption of all remaining glutathione. How-
ever, reversibility of the reaction with glutathione similarly as described by others is likely, as
irreversible binding should led to general cytotoxicity. However, 43b did not show any activity
against T. cruzi or L. infantum (GI50 >100).
4.4 Target identification studies
4.4.1 Myristate labelling of GPI anchor biosynthesis using YnC12
The previous analysed rhodanine-N-acetic ester derivatives 14v and 14a showed strong in-
hibitory effects on the incorporation of myristic acid derivative YnC12 in T. brucei, most likely by
inhibition of DPMS and/or the first mannosyltransferase as shown by a cell-free GPI-synthesis
assay (Chapter 3.5.1 and 3.5.3). In this experiments, the analogous N-allyl rhodanine series
(Table 38) was assessed for their ability to inhibit incorporation of the myristic acid YnC12 in
GPI-VSG proteins. Therefore, T. brucei was incubated with the N-allyl derivatives 40x and 40c
for 3 h, before parasite density was adjusted to equal amounts for both inhibitors and YnC12
was added. T. brucei was incubated for a further 4 h to ensure incorporation of the myristic
acid in the GPI-anchor. Next, the crude proteins were precipitated and the fluorescent tag 38
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Table 38: Anti-parasitic activity of chosen N-allyl rhodanine derivatives.
N S
O
S
R
GI50 [µM]
# R T. brucei T. cruzi L. infantum HL60
40x OBn 14.9±3.2 >100 >100 >100
40c CH3 12.9±0.8 >100 >100 81.0±2.3
was introduced via Click-chemistry, followed by visualisation of fluorescent protein bands on a
SDS-gel (Figure 54).
The positive control in the presence of DMSO and YnC12 showed a strong fluorescent
band at 50 kDa and a wide weak band at 57 kDa. As discussed previously it is assumed
that the intense protein band at 50 kDa may represent a GPI-VSG precursor protein, which
may not be fully glycosylated (Chapter 3.5.3). The allyl-derivative 40x with a 3-benzyloxy
substituent reduced the intensity of the 50 kDa band by about 50 %. However, in comparison
to the analogous rhodanine-N-acetic ester derivative 14v the effect of 40x to inhibit myristate
incorporation was reduced after incubation of 3 h. The methyl substituted N-allyl derivative 40c
showed comparable results to the analogous rhodanine-N-acetic ester 14a, as both showed
only weak inhibition of YnC12 incorporation. Although, the fluorescent signal bands appeared
reduced in Figure 54 for 40c, Coomassie staining showed that a smaller quantity of protein
was loaded to the SDS gel, explaining the reduced fluorescent intensity.
YnC12 labelling after 24 h incubation with 40x and 40c
The allyl-derivative 40x had a moderate effect on incorporation of the myristic acid analogue
YnC129 in T. brucei after an incubation period of 3 h, as can be seen in Figure 54. The
meta methyl substituted allyl derivative 40c did not show any effect on myristate incorporation
in GPI-VSG-proteins. In order to study the inhibition effect of 40x and 40c over a longer
time period, the incubation time with T. brucei was increased to 24 h. After 24 h incubation
with compound 40c an increase in toxicity against T. brucei was observed, although earlier
activity assays against T. brucei did not show any toxicity at this inhibitory concentration.
Therefore, 40c could not be evaluated for its inhibitory effect on YnC12 labelling in the GPI
bound VSG proteins. However, the remaining 3-benzyloxy derivative 40x did not show any
9YnC12 was kindly provided by Megan Wright and Dr. Ed Tate (Imperial College London, London, UK).
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in-gel fluorescence in SDS gel observed under
TAMRA settings
Coomassie-stained SDS gel
Figure 54: SDS gels after 3 h incubation with 40x and 40c; lane 1: 40x, lane 2: 40c, full gels
see Chapter 11.
anti-trypanosomal effects after 24 h and labelling with YnC12 was performed. After lysis of the
parasites and the introduction of the tamra-fluorophore 38, the proteins were separated on a
SDS gel and analysed by in-gel fluoresence and Coomassie staining.
The inhibitor 40x resulted in a significant reduction of incorporation of YnC12 in the GPI
bound VSG proteins (Figure 55). However the rhodanine-N-acetic ester analogue 14v showed
a complete inhibition of YnC12 incorporation, suggesting that the N-allyl functionality caused
the reduction in activity and therefore suggesting that a carboxylic moiety is preferable for
inhibiting YnC12 incorporation in T. brucei.
YnC15 labelling in T. brucei and influence of N-allyl derivatives
The inhibitory effect of derivative 40c on YnC12 incorporation in T. brucei could not be studied
after 24 h due to increased trypanocidal effects. Unfortunately, these experiments could not
be repeated at lower concentrations of 40c and YnC12, as all of the myristic acid analogue
YnC12 had been used. However, in order to overcome this problem, the pentadecylic fatty
acid analogue YnC1510 was used in combination with lower concentration of 40c.
Indeed, after 24 h of incubation with T. brucei, a decrease in anti-trypanosomal activity
was observed and labelling with YnC15 could be performed with both 40x and 40c treated
trypanosomes. However, the corresponding gel (Figure 55) showed only unspecific binding of
10YnC15 was kindly provided by Megan Wright (Prof. Dr. Ed Tate, Imperial College London, London, UK).
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in-gel fluorescence with TAMRA setting Coomassie-staining;
Figure 55: SDS gels after 24 h incubation with 40x; lane 1: 40x, full gels see Chapter 11.
the tamra-fluorophore with trypanosomal proteins in the negative control (absence of YnC15)
and all treated trypanosome cultures. Therefore confirming the specificity of myristate incor-
poration in GPI-anchor bound VSG proteins. [203,205]
YnC15 labelling in HL60 cells and influence of N-allyl derivatives 40x and 40c
After showing that 40x inhibited incorporation of the mysristic acid analogue YnC12 in the GPI
bound VSG proteins in T. brucei, studies on the effect of YnC12 in HL60 cells were performed.
Therefore, T. brucei was incubated with the derivatives 40x and 40c for 24 h, after which cells
were lysed, proteins tagged with the tamra-fluorophore 38 via Click-chemistry and visualised
on a SDS gel using in-gel fluorescence and Coomassie staining. The negative control, which
was performed in the absence of YnC12 showed unspecific binding of the tamra-fluorophore
with HL60 proteins (Figure 57). The same unspecific binding was observed in proteins treated
with YnC12 and inhibitors (DMSO, 40x and 40c).
This experiment could not provide an answer about the molecular target in HL60 cells
of the N-allyl-derivatives 40x and in particular 40c, as this derivative showed toxicity at GI50
81.0µM against HL60 cells.
4.4.2 Flow cytometry analysis of T. brucei transferrin receptors for indication of GPI
anchor biosynthesis inhibition
The trypanosomal transferrin receptor (TbTfR) is bound through a GPI-anchor to the plasma
membrane of T. brucei, [128] therefore transferrin uptake was established as a measure of GPI-
bound-transferrin receptors (Chapter 3.5.2). The uptake of transferrin can be quantified by the
138
4 N-allyl rhodanine derivatives
in-gel fluorescence in SDS gel observed under
TAMRA settings Coomassie-stained SDS gel
Figure 56: YnC15 SDS gels after 24 h incubation with 40x and 40c; lane 1: 40x, lane 2: 40c
full gels see Chapter 11.
in-gel fluorescence in SDS gel observed under
TAMRA settings
Coomassie-stained SDS gel
Figure 57: YnC12 SDS gels after 24 h incubation with 40x and 40c in HL60 cells; lane 1: 40x,
lane 2: 40c full gels see Chapter 11.
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use of FITC-labelled transferrin in combination with flow cytometry.
In this study, T. brucei was incubated with the N-allyl rhodanine derivatives 40x and 40c
over a period of 24 h. Next, the trypanosomes were cultured in transferrin deprived media for
another 4 h, causing an up-regulation of TbTf receptors and therefore increasing the uptake of
FITC-labelled transferrin in the consecutive step. [212] In the final step after 4 h, FITC-labelled
transferrin was added and the uptake in T. brucei was measured by flow cytometry. The mean
fluorescence intensity was measured and plotted in Figure 58.
Figure 58: Mean fluorescence intensity of FITC-labelled transferrin after incubation with 1:
40x, 2: 40c.
Indeed the previous observation, that the 3-benzyloxy derivative 40x inhibited uptake of the
myrisitic acid analogue YnC12 in GPI bound VSG proteins, was confirmed by a decrease in
mean fluorescence intensity. In contrast, the meta-methyl derivative 40c did not show any de-
crease in the mean fluorescence intensity, indicating that GPI-bound TbTf receptor synthesis
in T. brucei was not effected. This observation was in agreement with previous experiments
with the myristic acid analogue YnC12 after 3 h of pre-incubation with 40c. The myristate
labelled GPI-VSG protein expression was similar to trypanosomes treated with DMSO only,
indicating that 40c did not inhibit GPI-anchor synthesis in GPI bound VSG proteins.
In addition to these experiments, fluorescence microscopy was performed in order to lo-
calise the FITC labelled transferrin in T. brucei. Therefore, trypanosomes, treated with DMSO,
absence of FITC-labelled tranferrin, 40x and 40c were co-stained with DAPI and analysed
by fluorescence microscopy (Figure 59). The control experiments were discussed in chapter
3.5.2. The inhibitor 40c showed a high FITC-fluorophore intensity, similar to the positive con-
140
4 N-allyl rhodanine derivatives
Figure 59: Flow cytometry analysis of derivatives 40x and 40c; Side-scattered light vs flu-
orescent intensity and Number of cells vs fluorescent intensity and fluorescence
microscopy pictures of treated parasites.
trol with DMSO only (left upper blue graph in Figure 59) and morphological analysis with flow
cytometry showed only intact trypanosomes (right upper plot Figure 59). As expected, flu-
orescence microscopy showed trypanosomes where the kinetoplast and nucleus were DAPI
stained (blue in Figure 59) and an intense signal from the FITC fluorophore (green in Fig-
ure 59).
In contrast, the 3-benzyloxy derivative 40x showed a low fluorescence intensity for FITC
labelled transferrin (left blue graph in Figure 59), therefore fluorescence microscopy showed
trypanosomes with intense DAPI signal and two types of FITC-fluorophore accumulations.
Trypanosomes missing and weak FITC fluorophore intensities are most likely deficient in GPI-
anchor biosynthesis.
Interestingly the myristate labelling and transferrin uptake experiments showed that the
meta-benzyloxy-derivative 40x in the N-allyl rhodanine series was as potent in inhibiting GPI-
anchor biosynthesis than did the corresponding 3-benzyloxy N-acetic ester analogue 14v. In
contrast, the meta-methyl derivative 40c was ineffective in GPI anchor biosynthesis, while the
corresponding meta-methyl N-acetic ester analogue showed weak inhibition of GPI anchor
biosynthesis in T. brucei.
Also this observation could be confirmed with the myristic acid labelling experiment, as
there was no reduction in fluorescent labelled GPI-VSG-proteins. But even more interesting is
the effect of compound 40x, the structural analogue to 14v. Pre-incubation with 40x resulted
in a 50 % reduction of uptake of transferrin. The FM pictures showed a reduction in fluorescent
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intensity for the treated parasites. And indeed only one kind of population could be observed.
Also these results are in agreement with previous experiments on the myristic acid labelling
results, suggesting GPI-anchor biosynthesis inhibition.
From these experiments it can be concluded that the studied inhibitor classes of 14v, 14a
and 40x, 40c are most likely inhibitors of the GPI anchor biosynthesis. The question of the
exact molecular target remained and is elucidated in Chapter 4.4.3.
4.4.3 GPI cell-free radio-label assay
In order to confirm the hypothesis that the 3-benzyloxy derivative 40x is active in GPI anchor
synthesis in T. brucei, a cell-free assay was performed.11 Further details on the assay are
described in chapter 3.5.3. Briefly, this assay was performed with radioactive labelled [3H]-
GDP-mannose and assay results are displayed in form of radioactive-labelled GPI synthesis
substrates on a HPTLC. [68] The intensity of the substrate bands on these HPTLC plate allow
interpretation of potential targets in the GPI-anchor biosynthesis. [68]
Initially, the 3-benzyloxy derivative together with other benzyloxy-modified and trifluoromethyl
substituted rhodanine-N-allyl derivatives in this study were assessed for their ability to inhibit
enzymatic steps in the cell-free GPI synthesis assay (Table 39). Indeed, the 3-benzyloxy
derivative 40x showed a weak inhibition of the M1 substrate band, suggesting inhibition of
the first mannosyltransferase as potential target. However, the decrease in substrate intensity
of M1 could be a synergistic effect of DPMS and MT-1 inhibition as previously described in
chapter 3.5.3. Furthermore, 40x has been shown to inhibit T. brucei growth at GI50 14.9µM,
without showing toxicity against HL60 cells.
The 4-benzyloxy derivative 40y showed a very weak decrease in the Dol-P-Man substrate
band and the following M1 band, compared to the positive control with DMSO only. However,
40y did not show anti-trypanosomal activity in vitro, suggesting that this derivative is possibly
not reaching the molecular target, or that the inhibition effect was too weak to cause trypanoci-
dal activity. In contrast, rhodanine-N-allyl derivatives with a trifluoromethyl substituent in ortho-
and meta-position showed low µM activity against T. brucei in vitro (GI50 1.7 and 3.7µM re-
spectively) and moderate activity against L. infantum in vitro. But these derivatives did not
show any inhibition of enzymes involved in the cell-free GPi-synthesis, indicating that other
mode-of-actions are responsible for their anti-trypanosomal activity.
Anti-trypanosomal N-allyl rhodanine derivatives and activity against GPI-anchor syn-
thesis
In this study, pyridine-substituted rhodanine-N-allyl derivatives have been identified as low µM
inhibitors against T. brucei growth in vitro (Table 40).
11This assays were performed by Dr. Terry Smith from the University of St. Andrews, St Andrews, Scotland, UK
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Table 39: cell-free GPI assay results for N-allyl rhodanine derivatives-1; line 1: 40x, line 2:
40y, line 3: 40z, line 4: 40e, line 5: 40f, line 6: 40g; in vitro activity against T.
brucei ; Blue highlighted bands: DPMS inhibition; Green highlighted bands: MT-1
inhibition.
N S
S
O
R1 R2
R3
GI50 [µM]
# R1 R2 R3 T. brucei T. cruzi L. infantum HL60
40x H OBn H 14.9±3.2 >100 >100 >100
40y H H OBn >100 >100 >100 >100
40z H OBn OBn >100 >100 >100 >100
40e CF3 H H 1.7±0.1 >100 22.4±0.1 69.1±4.3
40f H CF3 H 3.7±1.3 >100 >100 15.1±1.3
40g H H CF3 >100 >100 >100 >100
In order to identify the mode-of-action of these derivatives, derivatives 43a, 43b, and 43c
were assessed for their ability to inhibit enzymes of the GPI-anchor synthesis in T. brucei us-
ing a cell-free radio-label assay. The 2-pyridinyl derivative 43a did not show inhibitory activity
in this assay, however these results were not surprising, as no trypanocidal activity against
T. brucei in vitro was observed. The 3-pyridinyl derivative 43b showed a reduction in the
Dol-P-Man and the M1 substrate bands, however all subsequent GPI-intermediate appeared
as intense bands, suggesting that Dol-P-Man and M1 was synthesised but consumed in later
reaction steps. Based on this experiment no conclusions about GPI-synthesis inhibition can
be drawn. However, 43b has also been shown to react with gluthathione under physiological
relevant conditions (Table 37) and 43b also displayed moderate toxicity against HL60 cells,
suggesting possible un-selective binding to biological nucleophiles as mode-of-action. The 4-
pyridinyl derivative 43c displayed no activity in the cell-free GPI-synthesis assay, but showed a
high toxicity against HL60 cells, possible indication similar Michael acceptor reactivity than dis-
played for derivative 43b. In addition to these pyridine derivative several 5-benzylidene modi-
fied rhodanine-N-allyl derivative with low µM activity against T. brucei have been screened in
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Table 40: Cell-free GPI assay results for N-allyl rhodanine derivatives-2; line 1: 43a, line 2:
43b, line 3: 43c, line 4: 40v, line 5: 40h, line 6: 40i, line 7: 40m; in vitro activ-
ity against T. brucei ; Blue highlighted bands: DPMS inhibition; Green highlighted
bands: MT-1 inhibition.
N S
S
O
R1 R2
R3
GI50 [µM]
# R1 R2 R3 T. brucei T. cruzi L. infantum HL60
43a 2-pyridinyl >100 >100 >100 >100
43b 3-pyridinyl 1.5±0.2 >100 >100 29.3±0.1
43c 4-pyridinyl 1.5±0.2 n.a. >100 4.5±0.1
40v H H SO2Me 11.0±0.6 >100 >100 20.8±8.5
40h H H Cl >100 >100 >100 >100
40i H H CN 41.3±4.6 >100 >100 67.5±0.4
40m H NO2 H 14.6±0.5 >100 >100 18.3±2.2
the cell-free GPI-synthesis assay (Table 40). None of these inhibitors showed any inhibitory
activity against GPI-synthesis in this cell-free assay. But although these derivatives showed
low µM activity against T. brucei, they also showed toxicity against HL60 cells. In all cases an
electron-withdrawing group (SO2Me, Cl, CN, NO2) was present, suggesting that these groups
may lead to general toxic derivatives, both against T. brucei and HL60 cells. Taking into ac-
count that N-allyl rhodanine derivatives have been shown to interfere with DNA synthesis in
bacteria, [229] this might be an alternative mode-of-action and possible explanation for their low
selectivity profiles.
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4.5 Discussion
The N-allyl rhodanine derivatives studied in this research project showed interesting anti-
parasitic properties against T. brucei, but only moderate activities against T. cruzi and L.
infantum. In particular three sub-classes displayed interesting ativity as anti-trypanosomal
agents.
The most interesting inhibitors discovered in this series were derivatives with a 3-benzyloxy-
substitutent on the 5-benzylidene-moiety of the N-allyl rhodanine or N-allyl thiazolidine-2,4-
dione scaffold. The inhibitors showed promising anti-trypanosomal activity against T. brucei
in vitro (GI50 14.9-60.1) and had an excellent selectivity profile, as they showed no toxicity
against HL60 cells at 100µM. Interestingly, replacement of the thiocarbonyl group in the rho-
danine moiety retained anti-trypanosomal activity as compared to other modifications, there
modifications of the thiocarbonyl group resulted in reduced anti-trypanosomal activity. The
mode of anti-trypanosomal activity of these derivatives has been investigated in this study and
these experiments suggested that GPI anchor biosynthesis and in particular the essential en-
zymes DPMS and MT-1 were inhibited by this subclass of rhodanine-N-allyl derivatives. This
observation was further more significant as a similar 3-benzyloxy substituted N-acetic acid
rhodanine showed similar mode-of-actions, but was 3 times more active against T. brucei in
vitro. This observation showed that a 3-benzyloxy-substituent is important for inhibitory effects
against DPMS and/or the first mannosyltransferase in the GPI-anchor biosynthesis pathway.
In order to validate DPMS inhibition as target by this substance subclass, a photo-affinity
probe similar to the one described in chapter 3.5.5 has been designed and screened for its anti-
trypanosomal activity. However, this photo-label-probe 43j was insoluble in aqueous media
and most likely therefore lost its anti-trypanosomal activity. The 3-benzyloxy-modification is
a promising lead structure and further modification thereof might improve anti-trypanosomal
activity.
The most potent anti-trypanosomal agent with a GI50 of 1.2µM was the catechol modified
N-allyl rhodanine derivative 40t. This subclass was particular interesting for its low toxicity
against HL60 cells (GI50 >100µM). Similarly to the 3-benzyloxy-modification, substitution of
the thiocarbonyl did not decrease anti-trypanosomal activity and the corresponding N-allyl
thiazolidine-2,4-dione derivative retained its anti-trypanosomal activity at GI50 5.0µM, while
showing only moderate toxicity against HL60 cells (SI 17). The exact mode-of-action of this
subclass is unknown, but similar catechol modified rhodanine derivatives were reported as
probes for dehydrogenases. [108]
Pyridinyl-substituted N-allyl rhodanine derivatives showed low µM activity (GI50 1.5µM)
against T. brucei, but unfortunately this modifications also displayed increased toxicity against
HL60 (GI50 4.5-29.3µM). In order to decrease the observed toxicity the thiocarbonyl was re-
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placed by a carbonyl group and indeed, this 4-pyridinyl derivative 44a retained most of its
anti-trypanosomal activity (GI50 4.2µM) and displayed reduced toxicity against HL60 cells
(GI50 63.7µM). As these derivatives did not show activity against enzymes in the GPI anchor
synthesis, alternative mode-of-actions such as general Michael acceptor reactivity were in-
vestigated. Indeed, the 3-pyridinyl N-allyl rhodanine-derivative 43b reacted with gluthathione
under physiological conditions (PBS buffer pH 7.4), however its reactive dose was relatively
high with 552.2µM, compared to the very reactive Michael acceptor acrolein (83.7µM), sug-
gesting that only a small quantity of 43b will effectively be covalently bound to glutathione in
vitro. This small quantity most likely does not account for its low anti-trypanosomal activity and
therefore validating further attempts to optimise this subclass for its anti-trypanosomal activity.
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4.6 Summary
89 N-allyl rhodanine and thiazolidine-2,4-dione derivatives have been synthesised and screened
for anti-parasitic activity against T. brucei, T. cruzi and L. infantum.
29 out of 89 N-allyl derivatives were able to kill T. brucei at 100µM (MIC 100µM), while a
further 6 compounds showed trypanocidal effects at 10µM (MIC 10µM).
5 out of 89 N-allyl derivatives killed T. cruzi at 100µM (MIC 100µM).
2 out of 89 N-allyl derivatives killes L. infantum at 100µM (MIC 100µM).
No derivative showed inhibitory effects against all three parasites.
The whole cell phenotypic screening of N-allyl derivatives identified promising low µM anti-
trypanosomal (GI50 1.2-14.9µM, SI 7 - >83) inhibitors with low toxicity against mammalian
cells.
Target identification showed that with the exception of a meta-benzyloxy derivative 40x GPI-
anchor biosynthesis was not affected by this compound class.
The meta-benzyloxy substituted N-allyl rhodanine derivative 40x showed low µM activity against
T. brucei (GI50 14.9µM, SI >7). This derivative has been shown with metabolic labelling exper-
iments, flow cytometry analysis and a cell-free radio-label assay to inhibit GPI-anchor biosyn-
thesis in vitro and particularly to inhibit DPMS and/ or MT-1.
Further mode-of-action studies showed that a 3-pyridinyl derivative reacted as Michael ac-
ceptor with glutathione as nucleophile (RC50 552.2µM), but the reactivity towards biological
nucleophiles was very mild compared to acrolein (RC50 83.7µM).
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5 Rhodanine and thiazolidine-2,4-dione derivatives
This chapter analyses rhodanine and thiazolidine-2,4-dione derivatives and their analogues
for their anti-parasitic activity. Therefore previous anti-parasitic biological applications or anti-
parasitic related studies are reported. Furthermore, it was of interest to test active inhibitors
of this series against enzymes of the GPI-anchor biosynthesis and compare these results to
previous inhibitors in this thesis.
5.1 Rhodanine derivatives with an anti-parasitic application compared
to structurally related inhibitors that had been reported previously
Numerous biological studies on rhodanine and thiazolidine-2,4-dione derivatives have been
reported. This introduction gives an overview of rhodanine and thiazolidine-2,4-dione deriva-
tives reported to have anti-parasitic activity to date (Figure 60).
N S
S
O
O
O
O
N S
X
O
R1
O
R2
HN S
O
O
N
N
N S
S
O
OH
H3C
H3C
OH
R1=H X=O,S
R1=NH2 X=S
49
5051
52 53
Figure 60: Examples of previous rhodanine and thiazolidine-2,4-dione derivatives and their
biological application with relevance towards anti-parasitic agents; R2=variable.
Compounds of type 49 have been studied for their inhibitory effects on Phosphoinositide
3-Kinase γ (PI3Kγ). [236] PI3Kγ is crucial in mediating leukocyte chemotaxis and mast cell de-
grannulation. [236] Therefore, it has been targeted for possible application as anti-inflammatory
or auto-immune drugs. [236] Compound 50 has been found to be a potent inhibitor for PI3Kγ
with no immediate toxicity in mice at 500 µg/g and has further been shown to have a tumor-
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static effect in PI3Kγ exhibiting tumour cells and in tumour infected mice. [117] Furthermore, 50
and therefore PI3Kγ inhibition has been assessed for its role in parasite invasion and disease
progression in cutaneous leishmaniasis. [116] It has been proposed that inhibition of PI3Kγ
would be as effective as the drug Stibogluconate. [116] PI3K activity has also been observed
to play a critical role in host cell invasion by T. cruzi. [237] However, derivatives of 49 and 50
have never been tested against parasitic protozoa, such as T. brucei, T. cruzi and L. chagasi.
The above findings suggested that selective inhibitors of PI3Kγ could potentially be active as
broad-spectrum anti-parasitic agents.
Compounds of type 51 and 52 have been shown to be potent inhibitors against Plasmod-
ium falciparum Enoyl-Acyl Carrier Protein Reductase (ACP). [112] The type II fatty acid synthase
(P. falciparum) and elongase pathway (T. brucei) have been validated for the development for
drugs against both Malaria and Human African Trypanosomiasis (HAT). [112,200] The etiological
organism of HAT, T. brucei has a high demand for myristic acid in the GPI anchor biosynthe-
sis. [200] The myristic acid for the GPI anchor biosynthesis is partially salvaged from the host
and de novo synthesised using the elongase pathway. [200] Inhibitors of this pathway could pre-
vent incorporation of myristic acid in the GPI anchor. T. brucei is dependant on numerous GPI
anchored proteins, such as the transferrin receptor and the VSG proteins. [65,128] Therefore,
GPI anchor biosynthesis is essential for the survival of the bloodstream form of T. brucei. [65]
Compounds 51 and 52 have never been assessed for their activity against T. brucei, T. cruzi
or L. chagasi.
Compound 53 was identified as a moderate inhibitor against M. tuberculosis growth, how-
ever, its macrophage toxicity was higher than the activity against M. tuberculosis. [238] Besides
this biological application, there is very little known about rhodanine derivatives of type 53.
Therefore, it would be very interesting to study this compound class for potential anti-parasitic
use.
A further motivation was to study possible GPI anchor inhibition activity of this compound
classes and compare them to previous results in this research project.
5.2 Synthesis of inhibitor library
In this chapter the synthesis of rhodanine derivatives with potential anti-parasitic effect is de-
scribed. In the effort to synthesize anti-parasitic agents against T. brucei, T. cruzi and L.
infantum simple 5-benzylidene modified rhodanine, thiazoidine-2,4-dione, N-amino rhodanine,
N-phenyl rhodanine were investigated (blue box in Figure 61).
These derivatives were subjected to the Knoevenagel reaction to afford 5-modified ana-
logues (R3, magenta box in Figure 61). Various benzylidene moieties were explored in 5-
position, as well as modified pyridinyl substituents. Furthermore, unsubstituted rhodanine
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Figure 61: Strategy towards synthesis of rhodanine and thiazolidine-2,4-dione derivatives and
analogues with anti-parasitic activity.
derivatives were modified on the thiocarbonyl function via alkylation with ethyl 2-bromoacetate,
benzyl-bromide (R5=Bn) or methyl or ethyl iodide (R5=H, CH3). Otherwise the thiocarbonyl was
substituted with an amino-acetic methyl ester- or piperidine-moiety. Or in the simplest case,
the thiocarbonyl was replaced with a carbonyl group (green box in Figure 61). In particular
the latter replacement to a carbonyl group is of interest, as previous results in this thesis have
shown, that this replacement resulted in reduced toxicity against HL60 cells and therefore
might reduce promiscuous binding as reported for the thiocarbonyl group (see also Chapters
3.2.6, 4.2.2 and 3.3.8 for further explanation for the replacement of the thiocarbonyl). [83] Lastly,
the exo-cyclic double bond in rhodanine 5-benzylidene or thiazolidine-2,4-dione 5-benzylidene
derivatives was reduced (red box in Figure 61).
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5.2.1 Synthesis of 5-benzylidene modified rhodanine and thiazolidine-2,4-dione
derivatives R1=H, R2=S,O and R3=Aryl
Unsubstituted rhodanine derivatives 36a–ag were synthesised in a Knoevenagel reaction with
various benzaldehyde derivatives (Scheme 28). The yield of the reaction varied from 10-
HN S
X
O
O
R1
R2
R3
R4
(i)
HN S
X
O
R1 R2
R3
R4
X=S
X=O
X=S
X=O
36
48
36a–ag
48a–v
10-93 %
Scheme 28: Synthesis of rhodanine and thiazolidine-2,4-dione derivatives 36a–ag and 48a–v;
(i) NaOAc, 80 ◦C, EtOH; for substitutions of X and R1-R4 see Table 41, Table 42.
93 %. All rhodanine derivatives were synthesised on a parallel synthesiser in individual tubes.
For this reason the reactions were not optimised for each single product, thus explaining the
lower yields. The reaction was carried out over a time period of 4-5 h, at which TLC showed
complete consumption of starting material. The crude reaction mixtures were filtered and
washed with ethanol to obtain the desired unsubstituted 5-benzylidene rhodanine derivatives
36a–ag in moderate yields. The products 36a–ag were analysed by NMR spectroscopy to
elucidate the configuration of the exo-cyclic double bond. The chemical shift for the CH-signal
in 1H-NMR experiments varied from δH 7.16-8.21 ppm. The Z-configuration of the double
bond is assigned by comparing the chemical shifts of the CH-signal with previous synthesised
analogues. Usually, the thermodynamically more stable Z-isomer appears at lower fields,
because of deshielding of the CH-signal from the neighbouring carbonyl function. [158,162] The
reported chemical shift of similar unsubstituted rhodanine derivatives was 7.30 ppm for the E-
isomer and 7.74 ppm for the Z-isomer, where chemical shifts were measured in DMSO-d6. [162]
If previously published chemical shifts were to be used for the assignment of double bond
configurations, only derivative 36v would be assigned with an E-configurated double bond,
with all other derivatives in a Z-configuration. However, derivatives 36j and 36o were actually
obtained as mixtures of E- and Z-configurated products (Table 41), allowing the differentiation
between both isomers. Both chemical shifts for the E- and the Z-configurated double bond
appeared downfield at δH 7.56-7.99 ppm for the E- and δ 7.70-8.21 ppm for the Z-isomer. In
both cases there was a strong electron-withdrawing substituent (36j : CN; 36o : NO2), that
most likely shifted the CH-signal further downfield. Therefore, it is very difficult to assign
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Table 41: Synthesis of rhodanine and thiazolidine-2,4-dione derivatives; X, R1-R4 for rhoda-
nine derivatives 36a–ag; yield and chemical shift of CH-signal; δ were recorded in
DMSO-d6, if not stated otherwise; (a) CDCl3; (b) MeOD-d4; n.a.: not available, see
Scheme 28.
NMR shift of CH-signal in [ppm]
# X R1 R2 R3 R4 yield [%] δH δC
36b S H H H H 25 7.67 131.6
36c S CH3 H H H 23 7.74 129.3
36d S H CH3 H H 90 7.60 131.8
36e S H H CH3 H 78-86 7.58 131.7
36f S CF3 H H H 73 7.65-7.73 131.2
36g S H CF3 H H 42 8.00 129.5
36h S H H CF3 H 37-78 7.71 129.5
36i S H H Cl H 63 7.61(a) n.a.
36j S H H CN H 30 7.56(E), 7.70(Z) 129.1(Z), 133.7(E)
36k S H Br F H 24 7.51 125.7
36l S H Br OMe H 16 7.61 n.a.
36m S H H NHAc H 22 7.57 n.a.
36n S H H NMe2 H 10 7.53 n.a.
36o S H NO2 H H 35 7.99(Z), 8.21(E) 129.0
36p S H H SO2Me H 12 7.73 n.a.
36q S H H CHO H 32 7.67 n.a.
36r S OH H H H 67 7.84 126.9
36s S H OH H H 68 7.53 131.8
36t S H H OH H 25 7.57 132.5
36u S OH H OH H 15 7.97(b) n.a.
36a S H OH OH H 14 7.47 132.8
36v S H OMe OH OMe 93 7.16 125.4
36w S H OBn H H 44 7.62 131.5
36y S H H OBn H 41-89 7.62 131.7
36z S H OBn OBn H 23 7.52(a) 133.7
36ab S H H tBu H 78 7.52 130.7
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the double bond configuration only based on the chemical shift of the CH-signal. The best
way would be to calculate each chemical shift based on their chemical environment. But
generally, it can be assumed that the thermodynamically more stable Z-isomer is formed as
the major product of the Knoevenagel reaction. [158] The low chemical shift for 36v is most
likely explained by the two electron-donating methoxy groups in the aromatic ring. In the case
of the E- and Z- mixtures in compounds 36j and 36o, there was a considerable difference
in the chemical shift of the E- and Z-isomer (∆>0.2 ppm). The Z/E-isomer-ratio for 36j was
5:1, whereas the ratio for 36o was 10:1. The higher isomerisation rate for 36j is most likely
explained by a electron withdrawing CN-group in para position in the 5-benzylidene moiety
(Figure 62). The electron-withdrawing group in para position could stabilise the resonance
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Figure 62: Resonance Structure of 36j and possible isomerisation mechanism.
structure of 36j (Resonance-36j, Figure 62). The conjugated aromatic system is interrupted
and racemisation can occur. Steric hindrance of the 5-benzylidene group and the carbonyl
moiety are most likely the cause for the excess of the Z-isomer (Scheme 4). whereas in the
case of 36o, a similar resonance structure can not be formed. However, in the case of 36o
electrostatic interactions between the carbonyl-group and the meta nitro-group could cause
the formation of the E-isomer, although steric restrains would favour the formation of the Z-
isomer (Figure 63). In comparison to 36j this means that the isomer ratio is determined by
the formation of the Knoevenagel product. The Knoevenagel reaction intermediate for the
E-isomer of 36o is shown as a Newman-projection (Figure 63). An electrostatic interaction
between the carbonyl and the nitro-group would change the equilibrium slightly towards the
formation of the E-isomer (Scheme 4).
The analogues thiazolidine-2,4-dione derivatives 48a–v were obtained as a single regio-
isomer (Table 42). The chemical shift of the CH-signal was δH 7.11-8.13 ppm. The chemical
shift was dependant on the substitution of the aromatic ring, such that trifluoromehtyl sub-
stituent led to a down-field shift of the CH-signal. Based on the chemical shifts, it can be
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Table 42: Synthesis of thiazolidine-2,4-dione derivatives; X, R1-R4 for thiazolidine-2,4-dione
derivatives 48a–v; yield and chemical shift of CH-signal; δ were recorded in DMSO-
d6, if not stated otherwise; (a) CDCl3; (b) MeOD-d4; n.a.: not available; see
Scheme 28.
NMR shift of CH-signal in [ppm]
# X R1 R2 R3 R4 yield [%] δH δC
48o O H H H H 42 7.29 127.5
48a O CH3 H H H 31 7.89 129.6
48b O H CH3 H H 45 7.84(a) n.a.
48c O H H CH3 H 24 7.54(b) n.a.
48d O CF3 H H H 16 8.13(a) 133.5
48e O H CF3 H H 45 7.93 130
48f O H H CF3 H 15 7.87 129.8
48g O OH H H H 38 8.02 127
48h O H OH H H 31 7.43 127.2
48i O H H OH H 15 7.52(b) n.a.
48j O OH H OH H no product
48p O H OH OH H 46 7.11 123.1
48k O H OMe OH OMe 47 7.21 123.2
48l O H OBn H H 76 7.35 129.9
48m O H H OBn H 38 7.74 131.1
48n O H OBn OBn H 29 7.70(a) 134.6(a)
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Figure 63: Formation of the E-isomer of 36o shown in Newman-Projection.
assumed that only the thermodynamically more stable Z-isomer was formed. [163]
Another interesting observation was the missing 5JH,F -long range coupling of compounds
36f and 48d. Analogous derivatives which were substituted on the N-3-position showed a long
range coupling of the CH-signal and the trifluoromethyl group (Figure 20).
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5.2.2 Synthesis of 5-benzylidene modified 3-amino rhodanine derivatives R1=NH2,
R2=S and R3=Aryl
N-amino rhodanine derivatives 54a–ab (Scheme 29, Table 43) were synthesised via Knoeve-
nagel reaction. The reaction was tolerated by a broad range of substituted benzaldehydes,
however aldehydes substituted with labile groups such as boronic acid (54y), methyl sulfoxide
(54z) or di-aldehydes (54aa) failed to react and no condensation product could be obtained.
Otherwise, the reaction yielded the desired products in good yields of 10-79 %. The chemical
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Scheme 29: Synthesis of 5-benzylidene modified N-amino rhodanine derivatives 54a–ab; (i)
NaOAc, 80 ◦C, EtOH, see Table 43.
shift of the CH-signal in the 1H-NMR experiment was in the range of δH 7.52-8.96 ppm, while
unsubstituted derivatives had a chemical shift around δH 7.70-7.90 ppm. Only the Z-isomer
has been observed for the condensation reaction with N-amino rhodanine and various ben-
zaldehydes. Particularly interesting was 54p as it showed a chemical shifts of the CH-signal
at δH 8.96 ppm and δC 158.7 ppm. This was the first example, where the CH-signal was that
far downfield, it could be possible that the ortho OH substituent of the 5-benzylidene moi-
ety undergoes hydrogen-bond interactions with the carbonyl group, bringing the CH-signal in
very close proximity to the carbonyl and the hydroxy group. The combined deshielding of the
hydroxy group and the carbonyl group could account for the signal appearing at 8.96 ppm.
5.2.3 Synthesis of 5-benzylidene modified N-phenyl rhodanine derivatives R1=Ph,
R2=S and R3=Aryl
N-phenyl rhodanine derivatives 55a–z were synthesised using the standard Knoevenagel con-
ditions with NaOAc and various benzaldehydes in ethanol at 80 ◦C (Scheme 30). The prod-
ucts were obtained mostly after simple filtration in good yields of 10-93 % (Table 44). But
the chosen reaction conditions were not tolerated with trifluoromethyl substituted aldehydes
(55t–v), aldehydes bearing labile functional groups such as methyl sulfoxide and di-aldehydes
(55s and 55y), nor with the di-halogen or di-hydroxy benzaldehydes (55w and 55x).
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Table 43: Synthesis of 5-benzylidene modified N-amino rhodanine derivatives; R1-R4 for N-
amino rhodanine derivatives 54a–ab; yield and chemical shift of CH-signal, see
Scheme 29.
NMR shift of CH-signal [ppm]
# R1 R2 R3 yield [%] δsolvent δH δC
54a H H H 79 DMSO-d6 7.86 133.5
54b CH3 H H 32 DMSO-d6 7.93 131.2
54c H CH3 H 70 DMSO-d6 7.81 133.5
54d H H CH3 74 DMSO-d6 7.81 133.5
54e CF3 H H 12 MeOD-d4 8.19 n.a.
54f H CF3 H 78 DMSO-d6 7.98 131.4
54g H H CF3 41 CDCl3 7.82 130.7-132.1
54h H H Cl 50 DMSO-d6 7.86 132
54i H Br F 79 DMSO-d6 7.85 131.6
54j H Br OMe 34 DMSO-d6 7.82 132.0
54k H H CCH 28 DMSO-d6 7.86 132.1
54l H H CN 42 DMSO-d6 7.90 130.9
54m H NO2 H 69 DMSO-d6 8.04 n.a.
54n H H NHAc 68 DMSO-d6 7.73-7.78 133.4
54o H H NMe2 21 DMSO-d6 7.74 135.0
54p OH H H 65 DMSO-d6 8.96 158.7
54q H OH H 32 DMSO-d6 7.74 133.7
54r H H OH 31 DMSO-d6 7.74 133.7
54s OH H OH 55 DMSO-d6 7.97 130.0
54t H OH OH 14 MeOD-d4 7.67 n.a.
54u H H OMe 62 DMSO-d6 7.82 133.7
54v H OBn H 10 CDCl3 6.97-7.52 n.a.
54w H H OBn 63 DMSO-d6 7.82 133.7
54x H OBn OBn 31 DMSO-d6 7.76 133.7
54y H H B(OH)2 no product
54z H H SO2Me 32 DMSO-d6 8.85 n.a.
54aa H H CHO no product
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Table 44: Synthesis of 5-benzylidene modified N-phenyl rhodanine derivatives; R1-R4 for N-
phenyl rhodanine derivatives 55a–z; yield and chemical shift of CH-signal, see
Scheme 30.
[%] NMR shift of CH-signal [ppm]
# R1 R2 R3 yield δsolvent δH δC
55a H H H 60 CDCl3 7.80 133.6
55b CH3 H H 17 CDCl3 8.02 131.4
55c H CH3 H 32 CDCl3 7.78 133.9
55d H H CH3 47 CDCl3 7.78 133.9
55e H H Cl 46 CDCl3 7.74 n.a.
55f H H CCH 18 CDCl3 7.76 n.a.
55g H H CN 57 CDCl3 7.75 n.a.
55h H Br OMe 36 CDCl3 7.67 n.a.
55i H H NHAc 34 DMSO-d6 7.77 132.6
55j H H NMe2 10 CDCl3 7.03(E), 7.73(Z) 134.9 (Z)
55k H NO2 H 19 CDCl3 7.81 n.a.
55l OH H H 12 MeOD-d4 8.17 n.a.
55m H OH H 15 CDCl3 7.73 n.a.
55n H H OH 23 DMSO-d6 7.76 n.a.
55o H OH OH 78 DMSO-d6 7.66 133.9
55p H OBn H 93 CDCl3 7.75 133.2
55q H H OBn 21 CDCl3 7.75 133.6
55r H OBn OBn 60 CDCl3 7.59 133.8
55s H H SO2Me no product
55t CF3 H H no product
55u H CF3 H no product
55v H H CF3 no product
55w H Br F no product
55x OH H OH no product
55y H H CHO no product
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Scheme 30: Synthesis of 5-benzylidene modified N-phenyl rhodanine derivatives 55a–z, (i)
NaOAc, 80 ◦C, EtOH, see Table 44.
The chemical shift of the CH-signal was almost diagnostic for N-phenyl rhodanine deriva-
tives 55a–z with chemical shift of 7.70-7.80 indicated the thermodynamically more stable Z-
isomer, whereas the chemical shift of the corresponding E-isomer was observed at 7.03 ppm
(55j). The E-isomer was obtained in a mixture of 1:4 E to Z ratio. This E to Z ratio could
possibly be explained trough the electron-donating dimethylamino group. The electrons could
be delocalised over the whole aromatic system (Figure 64), stabilising the negative charge
through the carbonyl group in the rhodanine moiety. However there was no mixture of isomers
observed, when the N-substituent was an allyl or acetic acid function. Therefore, it seems
that an additional delocalisation of electron over the N-3-substituent is responsible for the iso-
merization (Figure 64). A possible resonance structure would involve a positive charge on the
phenyl-amino substituent and a negative charge on the thiocarbonyl, stabilising all charges
leading to the double bond isomerization (Figure 64). The equilibrium of this racemization
should favour the Z-isomer because of steric clashes with the carbonyl group and the benzyli-
dene moiety (Scheme 4, p. 35).
5.2.4 Synthesis of 5-benzylidene-3-benzyloxy- and heterocyclic-modified rhodanine
56a–d, thiazolidine-2,4-dione, N-amino rhodanine 58a–i and N-phenyl rhodanine
59a–c derivatives.
Initially, the rhodanine and thiazolidine-2,4-dione derivatives were subjected to pyridine car-
boxaldehyde in the presence of NaOAc as a weak base (Scheme 31, Table 45).
This condensation reaction resulted in the synthesis of the pyridinyl-rhodanine derivatives
56a, 56b, and 56c in good yields of 50-59 % (Table 45). In contrast, the N-amino and N-
phenyl substituted rhodanine derivatives yielded only the 2-pyridinyl-derivatives 58d and 59c,
whereas in the case of the 3- or 4-pyridinylaldehydes no product was obtained. It was possible
that the aldehydes and/ or the products decomposed under the reaction conditions used, while
2-pyridinyl-aldehyde was more stable to temperatures of 80 ◦C. The 2-pyridinyl derivative 59c
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Table 45: Synthesis of heterocyclic and 3-benzyloxy modified rhodanine derivatives; X, R1-R2
of 3-benzyloxy- and heterocyclic-modified rhodanine 56a–d, thiazolidine-2,4-dione
57a–d, N-amino rhodanine 58a–i and N-phenyl rhodanine 59a–c derivatives; yield
and chemical shift of the CH-signal in DMSO-d6, Scheme 31.
[%] NMR shift of CH-signal [ppm]
# X R1 R2 yield δH δC
56a S H 4-pyridinyl 50- 96 7.57 n.a.
56b S H 3-pyridinyl 52 7.61 125.7
56c S H 2-pyridinyl 59 7.68 127.5
56d S H O
OCH3
85 7.59 131.3
57a O H 91 7.50 126.8
57b O H 4-pyridinyl 48 7.67 n.a.
57c O H 3-pyridinyl 53 7.56 123.3
57d O H 2-pyridinyl 24 7.54 n.a.
58a S NH2 CH2Cl no product
58b S NH2 4-pyridinyl no product
58c S NH2 3-pyridinyl no product
58d S NH2 2-pyridinyl 57 7.87 128.8
58e S NH2 (CH2)4OH no product
58f S NH2
N no product
58g S NH2 CH(CH3)2 no product
58h S NH2 NH2 no product
58i S NH2 H no product
59a S Ph 4-pyridinyl no product
59b S Ph 3-pyridinyl no product
59c S Ph 2-pyridinyl 72 8.85 149.6
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Figure 64: Resonance structures of 55j to explain high Z/E isomer ration.
showed a very low field chemical shift of 8.85 ppm for the CH-signal. Similarly high values
of 7.87-7.68 ppm for CH-signal in the presence of the 2-pyridinyl-group have been observed
in the rhodanine derivatives 58d and 56c. The values for the CH-signal of 3- and 4-pyridinyl
derivatives appeared at lower field at 7.57-7.61 ppm. It is possible that the 2-pyridinyl group
in rhodanine derivatives performed a hygrogen-bonding interaction with the carbonyl-group
and the CH-signal, resulting in a closer proximity of the CH to the two electronegative groups.
A similar phenomena was observed in the case of the rhodanine derivative 54p, which was
modified with a 2-hydroxy aryl group in position 5 and had a chemical shift of the CH-signal
at 8.96 ppm. It seemed that this interaction did not occur in thiazolidine-2,4-dione derivatives
57d, 57c, and 57b, which had very similar CH chemical shifts of 7.54-7.67 ppm. All products
were obtained as a single regio-isomer, which was most likely the Z-configurated double bond
isomer. Attemps to introduce aliphatic substituents on position 5 on the N-amino rhodanine
moiety failed and no products could be obtained under the reaction conditions used.
5.2.5 Alkylation of the thiocarbonyl in rhodanine derivatives R2=SMe, SEt, SBn,
thio-acetic ester
Rhodanine derivatives, where the thiocarbonyl was substituted with alkyl groups were syn-
thesised by nucleophilic substitution with alkyl-halides. These derivatives were of interest for
their previous biological activity against M. tubercolosis growth, [238] but also to study the effect
of thiocarbonyl alkylation on the anti-parasitic activity of this inhibitor class. Particularly the
introduction of a acetic ester functionality was interesting, as N-acetic ester derivatives have
been identified as good inhibitors of DPMS and/ or the first mannosyltransferase in the GPI-
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Scheme 31: Synthesis of heterocyclic and 3-benzyloxy modified rhodanine 56a–d,
thiazolidine-2,4-dione 57a–d, N-aminorhodanine 58a–i and N-phenyl rhodanine
59a–c derivatives; (i) NaOAc, 80 ◦C, EtOH, see Table 45.
anchor biosynthesis in T. brucei, while having low µM activity against T. brucei, T. cruzi and L.
infantum (Chapter 3.7). The substitution to a N-allyl functionality has been shown to decrease
both DPMS and/ or MT-1 inhibition as well as in vitro anti-trypaosnomal activity (Chapter 4.6).
Therefore it was of interest to study the effect on shifting this essential functional group onto
the thiocarbonyl position.
The reaction was carried out in the presence of a strong base, such as sodium hydroxide
(NaOH). The NaOH deprotonates the rhodanine 36 and forms the sodium salt of the rhoda-
nine 60a–b, which now readily reacted with electrohiles such as alkyl-halides (Figure 65).
This reaction can easily be visualised by the nucleophilic attack of 60b and alkyl-halides
HN S
S
O
N S
S
O
Na
N S
S
O
(i)
Na
X
R N S
S
O
R
36 60a 60b 61
Figure 65: Electrophilic substitution of the thiocarbonyl group in rhodanine derivatives; (i)
NaOH, see Scheme 32.
to form the alkylated thiocarbonyl 61 (Figure 65). Two strategies towards the synthesis of
rhodanine-5-benzylidene derivatives, where the thiocarbonyl was alkylated by various aliphatic
substituents, were employed. In the first approach (Method A (i), Scheme 32), rhodanine
was subjected to Knoevenagel reactions with various benzaldehyde derivatives. In the sub-
sequent step the condensation products were subjected to alkylating agents (Conditions (ii),
Scheme 32). While in the second method (Method B, Scheme 32), the alkylation of the thio-
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carbonyl was carried out prior to the condensation reaction.
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Scheme 32: Two approaches towards alkylated thiocarbonyl derivatives; (i) Benzaldehyde
derivatives, NaOAc, 80 ◦C, EtOH; (ii) NaOHaq (2 %), R4-halide, see Figure 65.
Method A: Knoevenagel reaction followed by Alkylation
Ortho-, meta- or para-trifluoromethyl substituted rhodanine derivatives 36f, 36g, and 36h were
reacted with methyl iodide or benzyl bromide in the presence of NaOH as base (Scheme 33).
The alkylation proceeded in good yields of 46-57 % and the products were obtained after
HN S
S
O
R1 R2
R3
R4X
(i) N S
S
O
R1 R2
R3
R4
46-57 %
62a–f
Scheme 33: Alkylation of the thiocarbonyl group in benzylidene rhodanine derivatives; (i)
NaOHaq (2 %), see Table 46.
simple filtration. The chemical shift of the CH-signal in alkylated derivatives 62a–f varied
between δH 4.96-8.14 ppm. The alkylation of the thiocarbonyl group resulted in a change of
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the steric demands of the rhodanine-moiety, most likely allowing the Knoevenagel reaction
to proceed via the E-isomer transition state (Scheme 4). This is clearly shown in Table 46,
the smaller the alkylation substiutent R4, the bigger the ratio between E- and Z-isomer. But
Table 46: Alkylation of the thiocarbonyl group in benzylidene rhodanine derivatives; X, R1-R4
for alkylation products 62a–f, yields and chemical shift of CH-signal, 62c and 62f in
DMSO-d6, all other in CDCl3, see Scheme 33.
NMR shift of CH-signal [ppm]
# X R1 R2 R3 R4 yield [%] E:Z ratio δH δC
62a I CF3 H H CH3 48 0:1 8.14(Z) 131.2(Z)
62b I H CF3 H CH3 46 3:4 5.25(E), 7.81(Z) n.a.
62c I H H CF3 CH3 48 10:1 4.96(E), 7.94(Z) 54.0(E)
62d Br CF3 H H Bn 46 0:1 8.13(Z) 131.5
62e Br H CF3 H Bn 54 0:1 7.85(Z) 133.9
62f Br H H CF3 Bn 57 1:1 5.46(E), 7.96(Z) 57.5(E), 133.3(Z)
the steric considerations are not enough to explain the E:Z ratio. As described previously,
the trifluoromethyl group is able to interact with the CH and the carbonyl-group (Figure 20).
This interaction can be quantified by the long-range 5JH(C),F -coupling of the CH-signal and the
trifluoromethyl group (Figure 20). Here, for the first time, this interaction could be brought into
connection with the formation of double bond regio-isomers. An ortho-trifluoromethyl group
interacts over space with the CH-group, establishing a preference for the Z-isomer. The further
away the trifluoromethyl group in relation to the CH-group the greater the amount of E-isomer.
In the para-trifluoromethyl substituted derivative 62c the interaction can not be established
and as a result the E-isomer occurred almost exclusively (ratio E:Z 10:1). However, if the R4
group has a higher steric demand, as it is seen with the benzyl-group in 62d, 62e, and 62f,
the Z-isomer was favoured. The trifluoromethyl substituent and the steric demanding benzyl
group both favour the Z-configuration over the E-isomer. Steric considerations on its own led
to a formation of E:Z in a 1:1 ratio, as can be seen with 62f. Here the trifluoromethyl group
in para-position and therefore does not contribute to the formation of Z-isomer any longer.
Compounds 62a–f were ideal for the study of factors important for the formation of double
bond isomers in rhodanine derivatives. But the chemical shift of the CH-signal for the E-
isomer, suggested aliphatic characteristics, as the δH was around 4.96-5.46 ppm and the δC
was 54.0-57.5 ppm. It was unclear as how this might effected the double bond isomerisation,
so the above mentioned observation might only account for these types of derivatives.
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Method B: Alkylation prior to Knoevenagel reaction
The alkylation of rhodanine derivatives was achieved by subjecting rhodanine 36 to various
alkylating agents under slightly basic conditions (Scheme 34). Initially, the reaction conditions
HN S
S
O
X R1
(ii)
(i) N S
S
O
R1
R1=COOMe or COOEt
(iii)
33-90 %
33-90 %
X=I, R1=H
X=I R1=COONa
X=Br, R1=COOEt
X=I, R1=COOEt
R1=H
R1=COOH
36
64a
66
64
65
63 63a
Scheme 34: (i) 2 % NaOH(aq), 16 h, rt; (ii) NaI, dark, acetone; (iii) DCC, DMAP, EtOH or MeOH,
CHCl3, rt.
were validated by using ethyl iodide as the alkylating agent. [239] The reaction proceeded to
the desired alkylation product 63a with a 90 % yield after re-cystrallisation from methanol. [239]
After the validation of the reaction protocol, sodium iodoacetic acid 64 was subjected to rho-
danine 36. The alkylation occurred in moderate yields of 33 % after re-crystallisation from
methanol. However, in order to obtain products which have previously been reported as anti-
tuberculosis agents (53 in Figure 60), the free carboxylic ester needed to be transformed to
its ester. [238] Here the previous protocol (Scheme 10) with DCC, DMAP and alcohol was ap-
plied to transform the free carboxylic ester of 64a to its ethyl or methyl ester. However this
resulted in decomposition products and no product could be isolated. An alternative strategy
to the ester was employed. Performing the alkylation with the iodoacetate 66 would yield the
desired ester in only one reaction step. But iodo ester 66 first had to be synthesised, start-
ing from ethyl 2-bromoacetate 65. The Finkelstein reaction between ethyl 2-bromoacetate 65
and sodium iodide in the dark yielded the desired iodo-substrate in excellent yields of 98 %,
as confirmed by NMR and mass spectrometric analysis. The substitution product 66 was re-
acted with rhodanine 36 under NaOH catalysis, but these slightly basic conditions resulted in
complete hydrolsys after 12 h.
This lack of success in the synthesis of S-modified acetic ester derivatives, meant that
other approaches were subsequently investigated. One such approach was the pre-activation
of the rhodanine precursor 36 with NEt3 (Scheme 35). [240] Treating rhodanine 36 with NEt3
results in the formation of its triethylamine salt 68. The base activated precursor 68 was
easily alkylated by chloro- or bromo-alkyls. [240] Here, ethyl 2-bromoacetate 65 was used as
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Scheme 35: Synthesis of S-modified acetic ester analogues; (i) NEt3, isopropanol, 100 ◦C; (ii)
65, acetone, 70 ◦C; (iii) NaOAc, EtOH, 80 ◦C.
the alkylating agent for 68. The alkylation product 69 was afforded in excellent yields of 93-
97 % after re-crystallisation.
In the consecutive step, the alkylated product 69 was subjected to various aromatic aldehy-
des in a Knoevenagel condensation reaction. The condensation products 69a–l were afforded
after simple filtration and were analysed by NMR and mass spectrometry (Table 47). While
1H- and 13C-NMR identified the products, the mass spectrometric analysis of compounds
69b, 69c, 69d, and 69e showed in addition to the molecular mass peak (M) another M+100
peak. It is likely, that under the conditions of the ionisation an adduct or different product was
formed during spectrometric analysis. The instability in the mass analysis might also explain
the overall low yield of the Knoevenagel reaction of 10-54 % for the benzylidene derivatives
69a–j. The reaction with the 2-furanyl-aldehyde proceeded well and 84 % of product were
isolated after filtration. The alkyl-ester derivative 69a was analysed by mass spectrometry,
but the Knoevenagel reaction yielded only traces of the desired product. The chemical shift
of the CH-signal δH was between 7.00-8.05 ppm for all derivatives. Compound 69h was ob-
tained as a 1:1 mixture of E/Z-isomers, so it would seem that the formation of both isomers
is facilitated if the thiocarbonyl group is alkylated. It is reasonable to assume that compounds
69d, 69e, 69f, 69g, and 69j were obtained as the E-isomer as the only product. Compounds
69b and 69c were difficult to compare in these series, as the spectres were recorded in
CDCl3, as other compounds were recorded in DMSO-d6. The CH-signal of previous NMR-
experiments showed that the chemical shift is solvent dependant. However, in the 13C-NMR
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Table 47: Synthesis of S-modified acetic ester analogues; R1-R3 for alkylation products 69a–l;
yield and chemical shift of the CH-signal.
NMR shift of CH-signal [ppm]
# R1 R2 R3 yield [%] δsolvent δH δC
69a CH3 H H n.a. n.a. n.a. n.a.
69b H CH3 H 30 CDCl3 7.81 134.6
69c H H CH3 33 CDCl3 7.80 134.4
69d H OBn H 21 DMSO-d6 7.32 130.0-136.9
69e H H OBn 10 DMSO-d6 7.33 126.4
69f H OBn OBn 14 DMSO-d6 7.27 127.7
69g H OH H 16 DMSO-d6 7.00-7.05 121.0
69h H H OH 14 DMSO-d6 7.29(E), 7.79(Z) 127.0(E), 136.5(Z)
69i OH H OH 54 MeOD-d4 8.05 n.a.
69j H OH OH 12 DMSO-d6 7.20 127.9
69k OH H H no product
69l 2-furanyl 84 DMSO-d6 7.71 121.6
the changes in chemical shift were smaller and indeed the values of 123.6-134.4 ppm for com-
pounds 69b and 69c were very similar to the reference chemical shift δC 136.5 ppm of 69h.
5.2.6 Replacement of thiocarbonyl group in rhodanine derivatives R2=NH-acetic ester
or N-piperidyl
The alkylated thiocarbonyl derivatives 69a–l have been shown to be unstable towards mass
spectrometric analysis (Chapter 5.2.5). Indeed, the thio-alkyl group in derivatives of 69 were
known to be good leaving groups. [240] This thio-alkyl group can be substituted with primary
amines in a nucleophilic substitution reaction. [240] In order to show this experimentally, 69 was
reacted with glycine methyl ester (NH2-Gly-OMe) in the presence of N,N-diisopropylethylamine
(DIPEA) as a base (Scheme 36). The amino substituted derivative 70 was obtained in excellent
yields of 88-93 %. In the consecutive step 70 was reacted with 4-chloro-benzaldehyde in the
presence of sodium acetate in methanol. Interestingly, the ethyl ester 70 was transformed to
its methyl ester under Knoevenagel condensation conditions in methanol. The product 70a
was obtained in 70 % yield after column chromatography.
The nucleophilic substitution of the thiocarbonyl group in rhodanine derivatives can also be
achieved in a one-pot reaction sequence. [241] Therefore, rhodanine is reacted with piperidine
and benzaldehyde in the presence of catalytic amounts of glacial acetic acid (Scheme 37).
The products were obtained in good yields of 23-68 % after simple filtration. This was an
interesting experiment, because the initial found reaction conditions for the Knoevenagel re-
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Scheme 36: (i) NH2-Gly-OMe, DIPEA, EtOH, 80 ◦C; (ii) 4-chloro-benzaldehyde, NaOAc,
EtOH, 80 ◦C.
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Scheme 37: Synthesis of thiocarbonyl substituted analogues; (i) AcOH, EtOH, 80 ◦C.
action were piperidine in ethanol. [68] Similar thiocarbonyl substitution reaction as well as the
alkylation of N-modified rhodanine derivatives have previously been reported. [242,243] However,
attempts to repeat this claim failed (Scheme 38). N-allyl rhodanine 40 did not react with ethyl
2-bromoacetate towards the salt 71, instead only starting materials were isolated. This sug-
gests that these particular side reactions with N-substituted rhodanine derivatives are not very
likely to occur.
N S
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40 71
Scheme 38: Attempts to alkylate N-substituted rhodanine derivatives; (i) 70 ◦C, acetone.
168
5 Rhodanine derivatives
5.2.7 Reduction of double-bond in rhodanine and thiazolidine-2,4-dione derivatives
R1=H, NH2, R2=O,S, R3=Aryl
Representative compounds 36ad, 36b, 36i, 54a, 54a, 54a, and 54h were chosen for the re-
duction of the exo-cyclic double bond. Similar derivatives in the N-acetic acid or N-allyl series
showed low µM activity against T. brucei and reduction of analogous derivatives was therefore
of interest in this series. The exo-cyclic double bond gives the molecule an essentially planar
structure and is also part of a Michael acceptor system. Reduction of the double bond could
be beneficial in terms of increased solubility by disruption of the planar configuration and loss
of activity as a potential Michael acceptor. The reduction of rhodanine derivatives is com-
plicated by the presence of a thiocarbonyl (S1) and carbonyl group. Catalytic hydrogenation
would result in catalyst poisoning by the sulphur atoms contained in the rhodanine moiety. [244]
Indeed, catalytic hydrogenation with Pd/C and high H2 pressure is used for the removal of the
thiocarbonyl group, although a a huge excess (300 eq) of Pd/C had to be used in the previ-
ous study to remove the thiocarbonyl. [244] There are only few general methods reported for
the reduction of rhodanine and thiazolidine-2,4-dione derivatives. [176] One of these methods
uses LiBH4 and pyridine for the selective reduction of the double bond, without reduction of
the carbonyl group. [176] Another reduction procedure uses the Hantzsch ester as mild reducing
agent for the exo-cyclic double bond. [177] Initially, the first procedure with LiBH4 and pyridine
as the reducing agent was used for the reduction of the double bond in anhydrous THF. The
reducing agent was proposed to be the pyridine-borane complex 72 (Scheme 39). [176] The
pyridine played a critical role for the selective reduction of the double bond, as in its absence
unspecified mixtures were reported. [176] 1H- and 13C-NMR studies showed that pyridine does
not undergo any interaction with the starting rhodanine or thiazolidine-2,4-dione, leaving only
the complexation to LiBH4 as an explanation for the regioselective reduction. Similar pyridine
complexes have been reported with lithium aluminium hydride. [176]
The reduction was carried out first using NaBH4, LiCl and pyridine in anhydrous THF, for
the in situ formation of LiBH4 (Scheme 39). However, only compound 36b was reduced to the
desired product 36ac and this reaction only proceeded in moderate yields of 55 %. In all other
cases only starting material and the pyridine-boron complex 73 could be recovered from the
reaction mixture after purification by flash column chromatography. The pyridine complex 73
has previously been reported to be ineffective in the reduction of rhodanine or thiazolidine-2,4-
dione derivatives. [176]
In the original procedure, N-1 substituted analogues have also been successfully reduced
using LiBH4-pyridine procedure. [176] In order to study the effect of N-1 substitution, the N-Allyl
rhodanine derivative 40ae (3-pyridine as 5-substituent) was used for the reduction with LiBH4
and pyridine. However, only starting materials could be recovered. Taking the lengthy reaction
protocol and the low reduction efficieny together, a different approach using the Hantzsch ester
169
5 Rhodanine derivatives
N S
S
O X
R2
(i)
R1
B
N
N N
N
Li
N S
S
O X
R2
R1
N
B HH H
R1=H, X=N, R2=H
R1=H, X=N, R2=H
R1=H, X=CH, R2=H
R1=H, X=CH, R2=H
R1=H, X=CH, R2=Cl
R1=H, X=CH, R2=Cl
R1=NH2, X=CH, R
2=H
R1=NH2, X=CH, R
2=H
R1=NH2, X=CH, R
2=Cl
R1=NH2, X=CH, R
2=Cl
no reaction
no reaction
no reaction
no reaction
36ad
36b
36i
54a
54h
36ad–i and 54a–h
73
72
36ac
55 %
Scheme 39: Reduction of the exo-cyclic double bond in rhodanine derivatives; (i) NaBH4, LiCl,
pyridine, THF.
28 as a mild reducing agent was pursued. [177] The reduction was carried out with the Hantzsch
ester in the presence of activated SiO2 solubilised in toluene in the dark. [177] SiO2 controls
the regioselectivity of the reduction and is postulated to have a dual role in the reduction
mechanism. Firstly, it could act as an acid catalyst and secondly as an adsorbent for the
Hantzsch ester and the substrate, bringing them in close proximity. [177]
Compound 36y was subjected to the Hantzsch ester reduction protocol (Scheme 40).
The reaction was completed within 16 h and yielded the product 36ae with the reduced
Hantzsch ester 74 as the only side product. The Rf values of 36ae and 74 were very similar,
and multiple purifications attempts via flash column chromatography (Hexane/EtOAc 8:2 and
DCM) had to be performed, thus explaining the low yield of 46 %.
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36y 36ae
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Scheme 40: Reduction of exo-cyclic double bond using the Hantzsch-ester approach; (i)
Hantzsch ester, activated SiO2, toluene, dark, 110 ◦C.
5.3 Anti-parasitic activity
The activity of inhibitors has been assessed as previously described in Chapter 3.3.1
5.3.1 Anti-trypanosomal and anti-leishmanial activity of unsubstituted rhodanine
derivatives
Initially, the starting material (rhodanine) was assessed for its activity against T. brucei. The
starting material did not show any activity against T. brucei, T. cruzi or L. infantum. Similar
results were obtained for the screening of the simple condensation product with benzalde-
hyde, however the derivative (36b) displayed toxicity against HL60 cells at GI50 95.3µM (Ta-
ble 48). Screening a variety of different substituted 5-benzylidene moieties a weak trend of
anti-trypanosomal activity against T. brucei and the logP value has been discovered (Fig-
ure 66). Compounds following this trend, where a high logP value resulted in a decreased
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Figure 66: Rhodanine derivatives, their anti-parasitic activity and correlation to logP (Y=85.9-
14.0·x, r2=0.3).
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Table 48: Anti-parasitic activity of rhodanine derivatives.
HN S
S
O
R1 R2
R3
R4
GI50[µM]
# R1 R2 R3 R4 logp T. brucei T. cruzi L. inf. HL60
36 0.61 >100
36z H OBn OBn H 5.87 10.7±0.2 n.a. >100 38.2±2.7
36e H H CH3 H 3.25 12.3±0.2 >100 >100 >100
36w H OBn H H 4.31 13.1±0.9 12.4±0.2 >100 53.8±0.2
36a H OH OH H 2.13 13.3±1.1 >100 >100 45.0±9.3
36h H H CF3 H 3.62 13.9±0.4 >100 >100 48.0±3.6
36g H CF3 H H 3.62 13.9±1.7 n.a. >100 >100
36k H Br F H 3.65 14.6±2.7 23.7±3.5 >100 70.8±3.1
36ab H H tBu H 4.28 16.3±2.3 n.a. n.a. 25.7±0.3
36r OH H H H 2.44 46.2±2.1 n.a. >100 >100
36y H H OBn H 4.31 49.0±4.8 >100 >100 76.8±9.9
36d H CH3 H H 3.25 52.1±8.0 >100 >100 >100
36t H H OH H 2.44 52.4±0.6 n.a. >100 >100
36s H OH H H 2.44 69.2±13.7 >100 >100 n.a.
36p H H SO2Me H 1.58 69.3±8.9 >100 >100 >100
36j H H CN H 2.6 72.5±8.3 >100 >100 91.7±6.3
36v H OMe OH OMe 2.12 73.4±20.5 n.a. n.a. >100
36q H H CHO H 2.45 78.6±9.2 >100 >100 n.a.
36i H H Cl H 3.34 >100 >100 >100 59.8±6.2
36m H H NHAc H 1.98 >100 >100 >100 >100
36l H Br OMe H 3.35 >100 >100 >100 90.0±7.3
36u OH H OH H 2.13 >100 >100 >100 >100
36n H H NMe2 H 2.85 >100 >100 >100 >100
36o H NO2 H H 2.14 >100 >100 >100 >100
36b H H H H 2.74 >100 >100 >100 95.3±3.3
36f CF3 H H H 3.62 >100 24.9±4.8 >100 87.5±8.4
36c CH3 H H H 3.25 >100 >100 >100 >100
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anti-trypanosomal activity, are located close to the line drawn in Figure 66. However, there are
a few exceptions from this linear correlation. The first exception is not surprising and arose
from the catechol modified rhodanine analogue 36a, this modification has previously been
shown for rhodanine-N-acetic acid derivatives to result in low-µM activity (see Chapter 3.7).
The other group of rhodanine derivatives not following this trend comprise of meta-substituted
analogues (CH3, CF3, OBn). However, these derivatives are in close proximity to the line
drawn in Figure 66, resulting in 36a as the outlier of this trend.
Therefore most lipophilic compound, such as the 3,4-bis-benzyloxy moiety (36z), displayed
a GI50 of 10.7µM against T. brucei. However, also other lipophilic substitutions such as
methyl, trifluoromethyl, fluoro, bromo or tert-butyl groups showed good anti-trypanosomal ac-
tivity against T. brucei (GI50 12.3-16.3µM). Particularly interesting was the 3-benzyloxy mod-
ified compound 36w as it displayed similar activity against T. cruzi and T. brucei. But it is
likely that other derivatives, such as the bis-benzyloxy 36z, the trilfuoromethyl 36g and tert-
butyl 36ab derivative may show similar activities against T. cruzi, as they had a MIC value of
100µM. The exact GI50 value could not be measured due to interference with MTT.
Although this first series of inhibitors showed interesting anti-trypanosomal activity they
were relatively toxic towards HL60 cells (GI50 25.7-91.7µM) and showed no activity against
L. infantum.
The catechol modified analogue 36a represented an exception from the logP versus GI50
correlation. Although it has a low logP, it displayed a GI50 of 13.3µM against T. brucei. But this
result was not surprising, as similar catechol modified rhodanine analogues resulted in low µM
active compounds against T. brucei (Chapter 4.3 and 3.3). But in contrast to previous results
the derivative 36a displayed a relatively high toxicity towards HL60 cells (GI50 45µM).
Analogues with a hydrogen bond acceptor moiety (SO2Me, CF3, CN, OBn, NHAc, OMe,
NMe2) in para-position of the benzylidene moiety were characteristic for their weak anti-parasitic
activity (GI50 >100µM).
Analogues with an ortho-hydroxy group (36r) showed moderate activity against T. cruzi,
while an ortho-trifluoromethyl group led to increased activity against T. cruzi (GI50 24.9µM).
5.3.2 Strategies to decrease toxicity by screening of thiazolidine-2,4-dione derivatives
against parasitic protozoa
Previous unsubstituted rhodanine derivatives showed promising anti-trypanosomal activity, but
also possessed toxicity against HL60 cells (Table 48). In order to improve the toxicity profile
the thiocarbonyl in the rhodanine moiety was substituted by a carbonyl group. Indeed, the
resulting thiazolidine-2,4-dione derivatives did not show toxicity against HL60 cells at 100µM
(Table 49). The anti-trypanosomal activity still correlated with the logP of the derivatives, such
that compounds with a high logP value showed improved anti-trypanosomal activity against
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Table 49: Anti-parasitic activity of thiazolidine-2,4-dione derivatives.
HN S
O
O
R1 R2
R3
R4
GI50[µM]
# R1 R2 R3 R4 logp T. brucei T. cruzi L. infantum HL60
48e H CF3 H H 2.73 12.7±1.3 n.a. >100 >100
48f H H CF3 H 2.73 15.3±2.1 53.2±0.7 >100 >100
48n H OBn OBn H 4.98 15.7±2.5 >100 >100 >100
48b H CH3 H H 2.36 65.9±17.9 >100 >100 >100
48a CH3 H H H 2.36 70.8±15.5 >100 >100 >100
48l H OBn H H 3.42 87.6±2.2 45.3±0.8 >100 >100
48m H H OBn H 3.42 >100 >100 >100 >100
48d CF3 H H H 2.73 >100 >100 >100 >100
48c H H CH3 H 2.36 >100 >100 >100 >100
48o H H H H 1.85 >100 >100 >100 >100
48g OH H H H 1.55 >100 >100 >100 >100
48h H OH H H 1.55 >100 >100 >100 >100
48i H H OH H 1.55 >100 >100 >100 >100
48p H OH OH H 1.24 >100 n.a. n.a. >100
48k H OMe OH OMe 1.23 >100 n.a. n.a. >100
T. brucei. The meta- and para-trifluoromethyl substituted compounds 48e and 48f retained
their activity against T. brucei, and additional 48f showed moderate activity against T. cruzi.
Replacement of the thiocarbonyl in compound 48f led to a loss of toxicity compared to the
rhodanine analogue 36h.
Also the lipophilic 3,4-bis-benzyloxy modified thiazolidine-2,4-dione derivative 48n was as
active as the rhodanine 36z (GI50 15.7µM). The 3-benzyloxy-substituted analogue, although
still trypanocidal against T. brucei and T. cruzi, lost most of its activity (GI50 87.6 and 45.3µM).
The 4-benzyloxy-substituted thiazolidine-2,4-dione derivative 48m did not display any activity
against T. brucei anymore.
Particularly interesting was the observation that all hydroxy substituted thiazolidine-2,4-
dione did not show anti-parasitic activity at 100µM. This was surprising, as the catechol mod-
ification independently from the rhodanine or thiazolidine-2,4-dione moiety so far always re-
sulted in low µM active inhibitors against T. brucei.
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In conclusion, the substitution strategy did improve the toxicity profile of lipophilic inhibitors
48e, 48f, and 48n and retained anti-parasitic activity against T. brucei.
5.3.3 Anti-parasitic activity of N-phenyl rhodanine derivative
The rhodanine and thiazolidine-2,4-dione libraries screened against T. brucei, T. cruzi and L.
infantum, showed a dependency of logP for anti-parasitic activity (Table 48 and Table 49). In
order to exploit this dependency lipophilic N-phenyl rhodanine derivatives were evaluated for
their anti-parasitic activity (Table 50). Initially, the starting N-phenyl rhodanine was evaluated
for its anti-trypanosomal activity against T. brucei. N-phenyl rhodanine 55 showed a weak
trypanocidal activity against T. brucei at GI50 122.3µM. The unsubstituted condensation prod-
uct 55a did not display anti-parasitic activity at 100µM. However the introduction of hydroxy
groups in meta- and para-position of the 5-benzylidene moiety resulted in moderate activity
against T. brucei (GI50 52.5-72.3µM). Shifting the hydroxy group in ortho-position resulted in
low µM active inhibitors against both T. brucei and T. cruzi (13.2 and 6.8µM). But installa-
tion of a catechol moiety further improved the anti-trypanosomal activity of 35d. Replacement
of the thiocarbonyl group to a carbonyl group had no influence on the activity against T. bru-
cei, but decreased toxicity of 55o to >100µM, compared to the ortho-hydroxy derivative 55l
(GI50 50.7µM). The acetylation of the free hydroxy groups furnished compound 35e, which
had the lowest anti-trypanosomal activity against T. cruzi in these series (GI50 0.8µM). Modi-
fications in R1, such as the dihydro-indene derivative 35c were well tolerated and did not affect
anti-parasitic activity against T. brucei.
Modifications other than hydroxy groups were not tolerated on the 5-benzylidene moiety
and these derivatives showed no anti-parasitic activity at 100µM.
5.3.4 Anti-parasitic activity of N-amino rhodanine derivatives
So far it has been established that lipophilicity in rhodanine (Table 48) and thiazolidine-2,4-
dione (Table 49) derivatives played a critical role on their anti-parasitic activity, however too
lipophilic derivatives such as in the phenyl rhodanine series (Table 50) showed demished
activity, if other than hydroxy modifications were introduced on the 5-benzylidene moiety. In
this chapter, the more polar N-amino rhodanine derivatives have been evaluated for their anti-
parasitic activity (Table 51). Firstly, the starting N-amino rhodanine was screened against its
anti-trypanosomal activity against T. brucei, 54 showed no activity at 100µM (GI50 117.9µM).
The most promising inhibitors against T. brucei growth was the ortho- and meta-hydroxy
derivatives 54p and 54q (GI50 12.9 and 19.3µM), as they showed no toxicity against HL60
cells at 100µM. Although, the bis-hydroxy substituted analogues 54s and 54t showed similar
activities (GI50 12.8 and 17.5µM), they showed toxicity against HL60 cells.
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Table 50: Screening results of N-phenyl rhodanine derivatives against T. brucei, T. cruzi and
L. infantum.
N S
X
O
R2 R3
R4
R1
GI50[µM]
# X R1 R2 R3 R4 T. brucei T. cruzi L. infantum HL60
55 S Ph 122.3±2.2 n.a. n.a. n.a.
35c O H OH OH 1.4±0.1 >100 >100 n.a.
35d S Ph H OH OH 4.7±0.9 n.a. >100 n.a.
55o O Ph H OH OH 5.5±0.5 n.a. >100 >100
35e O Ph H OAc OAc 7.3±1.1 0.8±0.1 >100 n.a.
55l S Ph OH H H 13.2±1.7 6.8±1.3 >100 50.7±6.4
55n S Ph H H OH 52.4±6.2 >100 >100 37.7±2.5
55b S Ph CH3 H H 62.4±2.0 >100 >100 >100
55m S Ph H OH H 72.3±8.5 n.a. >100 32.6±5.0
55e S Ph H H Cl >100 >100 >100 >100
55g S Ph H H CN >100 >100 >100 >100
55f S Ph H H CCH >100 >100 >100 >100
55i S Ph H H NHAc >100 >100 >100 >100
55h S Ph H Br OMe >100 >100 >100 >100
55j S Ph H H NMe2 >100 >100 >100 >100
55k S Ph H NO2 H >100 >100 >100 >100
55c S Ph H CH3 H >100 >100 >100 >100
55d S Ph H H CH3 >100 >100 >100 >100
55r S Ph H OBn OBn >100 >100 >100 >100
55a S Ph H H H >100 >100 >100 >100
55q S Ph H H OBn >100 >100 >100 >100
55p S Ph H OBn H >100 >100 >100 >100
35a–k have been provided by Prof. Dr. M. Schlitzer, Phillips-Universitat, Marburg, Germany.
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Table 51: Anti-parasitic activity of N-amino rhodanine derivatives.
N S
S
O
R1 R2
R3
H2N
GI50 [µM]
# R1 R2 R3 T. brucei T. cruzi L. infantum HL60
54 117.9±23.9 n.a. n.a. n.a.
54p OH H H 12.9±0.8 >100 >100 >100
54s OH H OH 12.8±2.2 >100 >100 57.0±6.6
54g H H CF3 13.0±2.0 >100 >100 51.0±0.9
54k H H CCH 14.2±2.5 >100 >100 >100
54j H Br OMe 16.8±4.4 >100 >100 >100
54t H OH OH 17.5±0.2 n.a. >100 82.8±10.1
54q H OH H 19.3±7.3 >100 >100 >100
54n H H NHAc 21.0±4.9 >100 >100 >100
54l H H CN 47.2±11.3 >100 >100 >100
54m H NO2 H 48.0±3.4 >100 >100 >100
54w H H OBn 58.3±14.6 >100 >100 >100
54f H CF3 H 69.7±29.6 n.a. n.a. n.a.
54v H OBn H >100 n.a. n.a. n.a.
54r H H OH >100 >100 >100 >100
54o H H NMe2 >100 >100 >100 >100
54u H H OMe >100 >100 >100 >100
54b CH3 H H >100 >100 >100 >100
54c H CH3 H >100 >100 >100 >100
54d H H CH3 >100 >100 >100 >100
54x H OBn OBn >100 >100 >100 >100
54a H H H >100 >100 >100 >100
54i H Br F >100 >100 >100 >100
54h H H Cl >100 >100 >100 >100
54e CF3 H H >100 >100 >100 n.a.
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Large lipophilic substituents (CF3, CCH, OMe, NHAc) led to improved activity against T.
brucei (GI50 13.0-21.0µM). Other modifications displayed in Table 51 showed no activity
against parasitic protozoa.
5.3.5 Heterocyclic modifications on rhodanine and thiazolidine-2,4-dione derivatives
and their anti-parasitic activity
A broad range of various benzylidene modifications have been explored in this research
project. In this chapter, several heterocyclic modifications have been investigated for their
anti-parasitic activity (Table 52). Pyridinyl groups in position 5 of the rhodanine or thiazolidine-
Table 52: Anti-parasitic activity of heterocyclic modified analogues.
N S
X
O
R1
R2
N S
N
O
R1
R2
35f
GI50 [µM]
# R1 X R2 T. brucei T. cruzi L. infantum HL60
48q H O 3-pyridinyl 45.1 >100 >100 >100
54ab NH2 S 2-pyridinyl 47.5±2.5 12.1±1.5 >100 82.5±5.0
48r H O 2-pyridinyl 87.3 >100 >100 >100
36ad H S 2-pyridinyl >100 >100 >100 >100
55z Ph S 2-pyridinyl >100 >100 >100 >100
36af H S 3-pyridinyl >100 >100 >100 >100
48s H O 4-pyridinyl >100 >100 >100 n.a.
36ag H S 4-pyridinyl >100 >100 >100 >100
35f HO35f n.a. see R1 >100 >100 >100 n.a.
35a–k were kindly donated by Prof. Dr. Schlitzer, Phillips-Universitat, Marburg, Germany
2,4-dione derivatives resulted only in moderate activity against T. brucei (GI50 45.1-87.3µM).
Particularly interesting was the N-amino rhodanine 54ab, which was substituted with a 2-
pyridinyl moiety. 54ab showed anti-trypanosomal activity against both T. brucei and T. cruzi,
with a preference against the last (GI50 12.1µM). This derivative displayed toxicity against
HL60 cells at GI50 82.5µM. The unsubstituted thiazolidine-2,4-dione analogue 48r was less
toxic against HL60 cells (GI50 >100µM), but also displayed a deminished activity against both
T. brucei and T. cruzi. However, the thiazolidine-2,4-dione derivative 48q, where the 2-pyridinyl
was substituted by a 3-pyridinyl moiety, regained its anti-trypanosomal activity against T. brucei
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compared to 54ab. Other combination, such as a phenyl-group in N-1 position and various
rhodanine and thiazolidine-2,4-dione derivatives with other pyridinyl-moities than mentioned
above displayed no activity against parasitic protozoa.
5.3.6 Anti-trypanosomal effects of 3-benzyloxy modified rhodanine and
thiazolidine-2,4-diones
The 3-benzyloxy-substituted rhodanine derivative 36w showed interesting anti-trypanosomal
activity. In this chapter, it was shown that introduction of an additional methoxy-group in para-
position of the 3-benzyloxy moiety (36x, Table 53) led to decreased trypanocidal activities
against T. brucei. Similarly, in the thiazolidine-2,4-dione modification this additional substituent
showed no improvement in anti-trypanosomal activity. The best inhibitor in this series re-
mained the rhodanine derivative 36w.
Table 53: Anti-trypanosomal effect of 3-benzoloxy modifications.
OSHN
X
O
R1
O
R1
O
18c
GI50 [µM]
# X R1 T. brucei HL60
36w S CH 13.1±0.9 53.8±0.2
36x S OMe 57.9±12.3 79.6±13.3
48t O OMe 67.0±30.6 >100
48l O CH 87.6 ppm 2.2 >100
18c OMe >100 n.a.
5.3.7 Activity of reduced rhodanine and thiazolidine-2,4-dione derivatives against T.
brucei, T. cruzi and L. infantum
The 5-benzylidene rhodanine derivative 36b did not show anti-trypanosomal activity at 100µM,
however its reduced analogue 36ac was active against T. brucei, at a GI50 of 13.3µM (Ta-
ble 54). Similarly reduction of the exo-cyclic double bond in the 4-benzyloxy rhodanine deriva-
tive 36y improved activity against T. brucei by a factor of 4 and furthermore did not display
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toxicity against HL60 cells. The reduction of the double bond in thiazolidine-2,4-dione deriva-
tives in this series did not improve anti-trypanosomal activity.
Table 54: Anti-parasitic activity of reduced rhodanine and thiazolidine-derivatives in compari-
son to their unsaturated analogues.
Z
SHN
X
O
R1
R2
GI50 [µM]
# Z X R1 R2 T. brucei T. cruzi L. infantum HL60
36ac CH2 S H H 13.3 n.a. n.a. n.a.
75a CH2 S H OBn 11.7±0.2 >100 >100 >100
36y CH S H OBn 49.0±4.8 >100 >100 76.8±9.9
36b CH S H H >100 >100 >100 95.3±3.3
48m CH O H OBn >100 >100 >100 >100
48u CH2 O H OBn >100 >100 >100 n.a.
48p CH O OH OH >100 n.a. n.a. >100
48v CH2 O OH OH >100 n.a. n.a. n.a.
5.3.8 Modifications of the thiocarbonyl and anti-parasitic activity
5-Benzylidene rhodanine derivatives showed moderate activity against T. brucei and T. cruzi,
if the benzylidene moiety was modified with lipophilic substituents (OBn, CH3, CF3), other-
wise substituents showed a decrease in trypanosomal activity (Table 48). In this chapter, this
trend was further examined, by focussing on lipophilic substituents in position 5 and modifi-
cations on the thiocarbonyl, such as alkylation or substitution with amino-groups (Table 55).
This compound series is particularly interesting, as alkylation of the thiocarbonyl group re-
sulted in racemisation of the exo-cyclic double bond, so that both E and Z isomers could be
tested in varying ratios against their molecular target in parasites. One such example was
the methylated thiocarbonyl derivative 62c as it was composed as 10:1 mixture of E to Z dou-
ble bond isomers. Usually, the thermodynamic more stable Z-isomer was obtained and was
screened for their anti-parasitic activity. [162] 62c showed low anti-trypanosomal activity against
T. brucei (GI50 13.6µM) and T. cruzi (GI50 9.3µM). Whereas the rhodanine-analogue 36h did
not display activity against T. cruzi at 100µM. The anti-trypanosomal activity against T. bru-
cei was similar for both derivatives. Similarly, compounds 62f, 69h, and 62b were obtained
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Table 55: Anti-parasitic activity of S-modified and S-substituted rhodanine analogues.
SHN
X
O
R2
R3
R1
GI50 [µM]
# X R1 R2 R3 T. brucei T. cruzi L. infantum HL60
69f SCH2CO2Et H OBn OBn 10.3±0.5 n.a. n.a. n.a.
62d SBn CF3 H H 13.1±0.3 n.a. n.a. n.a.
62f SBn H H CF3 13.4±0.1 n.a. >100 n.a.
69e SCH2CO2Et H H OBn 13.4±2.1 n.a. >100 >100
62c SMe H H CF3 13.6±0.1 9.3±0.8 >100 31.9±0.3
69a SCH2CO2Et CH3 H H 14.8±1.2 >100 >100 >100
69c SCH2CO2Et H H CH3 15.8±1.3 n.a. n.a. >100
69b SCH2CO2Et H CH3 H 15.8±2.0 n.a. >100 >100
62e SBn H CF3 H 15.8±2.2 n.a. n.a. n.a.
70b Npiperidinyl H H H 17.6 >100 >100 >100
70c Npiperidinyl H OH OH 18.2 >100 >100 >100
69l SCH2CO2Et 2-furanyl 63.5±9.5 >100 >100 56.6±11.1
69d SCH2CO2Et H OBn H 65.9±3.2 n.a. n.a. >100
69h SCH2CO2Et H H OH 97.1±13.7 >100 >100 >100
62a SMe CF3 H H >100 >100 >100 n.a.
62b SMe H CF3 H >100 n.a. n.a. n.a.
69g SCH2CO2Et H OH H >100 >100 >100 n.a.
69j SCH2CO2Et H OH OH >100 >100 >100 >100
70a NHCH2CO2Me H H Cl 24.0 >100 >100 1.6±0.1
in almost 1:1 ratios of both E and Z isomer. However, 62b displayed a decrease in activity
against T. brucei, whereas 62f and 62b showed similar activity values. All other derivatives
screened in this series possessed a Z-configurated double-bond. With the exception of deriva-
tives 70c and 69d, analogues 69f, 62d, 62c, 62e, and 69e retained their anti-trypanosomal
activity against T. brucei, as compared to their rhodanine analogues.
In conclusion, modifications on the thiocarbonyl, such as alkylation and substitution did not
improve anti-trypanosomal activity. Substitution of the thiocarbonyl to an amino-acetic ester
moiety in compound 70a resulted in high toxicity against HL60 cells and only moderate activity
against T. brucei.
181
5 Rhodanine derivatives
5.4 Target identification studies
5.4.1 GPI cell-free radio-label assay
In order to analyse the mode-of-action of rhodanine, N-amino rhodanine and N-phenyl rho-
danine derivatives, a cell-free GPI synthesis assays was performed to assess their ability to
inhibit enzymes within the GPI-anchor biosynthesis in T. brucei.12 The assay is described in
further detail in chapter 3.5.3.
GPI-inhibition of rhodanine derivatives
Initially selected rhodanine derivatives were evaluated for their ability to inhibit enzymes in the
GPI-anchor biosynthesis using a cell-free GPI-synthesis assay. The derivatives have been
chosen on the basis of previous N-acetic acid and N-allyl rhodanine derivatives which showed
activity against enzymes of the GPI anchor biosynthesis.
Particularly interesting in this series was the 3-benzyloxy rhodanine derivative 36w, as it
was the first example of a derivative inhibiting MT-1 and possible DPMS, as could be seen by
a diminished substrate band for Dol-P-Man and M1 (Table 56), and resulted in low µM activity
against both T. brucei and T. cruzi in vitro (GI50 13.1 and 12.4µM respectively). But this
derivative also showed an increased toxicity against HL60 cells (GI50 53.8µM), compared to
its N-acetic acid (GI50 >100µM) or N-allyl- rhodanine derivative (GI50 100µM).
Rhodanine derivatives with an ortho methyl or trifluoromethyl group (36c and 36f) were
shown to be very good MT-1 inhibitors, as the substrate band for M1 and all subsequent GPI-
substrates disappeared in the cell free GPI synthesis assay. The trifluoromethyl derivative
36f showed moderate activity against T. cruzi (GI50 24.9µM), but did not display any activity
against T. brucei or L. infantum. The methyl derivative 36c, although a strong inhibitor of T.
brucei MT-1 did not show anti-trypanosomal activity at 100µM.
The rhodanine derivatives with a para-hydroxy group 36t displayed good inhibitory activity
against DPMS in the cell-free GPI synthesis assay. 36t had moderate activity against T. brucei
(GI5052.4µM) and T. cruzi (MIC 100µM). Benzylation of the para-hydroxy group in derivative
36y resulted in loss of its inhibitory function against enzymes of the GPI-synthesis assay,
however its anti-trypanosomal activity against T. brucei was retained at GI50 49.0µM. But
this derivative also displayed an increased toxicity against HL60 cells (76.8µM), making it
unattractive for further development.
A steric fluorine group in para position in combination with a meta bromo substituent in
derivative 36k resulted in a weak inhibitor for T. brucei MT-1 with low µM activity against both
T. brucei and T. cruzi (GI50 14.6 and 23.7µM respectively). But the toxicity of this derivative
was similar to the para-benzyloxy modified analogue (GI50 70.8µM). Pyridinyl substituted rho-
12This assays were performed by Dr. Terry Smith from the University of St. Andrews, St Andrews, Scotland, UK
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Table 56: cell-free GPI assay for rhodanine derivatives; line 1: 36c, line 2: 36f, line 3: 36t, line
4: 36w, line 5: 36y, line 6: 36k, line 7: 36ad, line 8: 36af; in vitro activity against
T. brucei ; Blue highlighted bands: DPMS inhibition; Green highlighted bands: MT-1
inhibition.
HN S
S
O
R1 R2
R3
GI50 [µM]
# R1 R2 R3 T. brucei T. cruzi L. infantum HL60
36c CH3 H H >100 >100 >100 >100
36f CF3 H H >100 24.9±4.8 >100 87.5±8.4
36t H H OH 52.4±0.6 n.a. >100 >100
36w H OBn H 13.1±0.9 12.4±0.2 >100 53.8±0.2
36y H H OBn 49.0±4.8 >100 >100 76.8±9.9
36k H Br F 14.6±2.7 23.7±3.5 >100 70.8±3.1
36ad 2-pyridinyl >100 >100 >100 >100
36af 3-pyridinyl >100 >100 >100 >100
danine derivatives showed no activity in the cell-free GPI-synthesis assay or against parasites
in vitro.
Particularly interesting was the cross-parasitic activity against T. brucei and T. cruzi of rho-
danine derivatives. The cell-free GPI-synthesis assay suggests that GPI-biosynthesis might
be responsible for anti-trypanosomal effects in vitro.
GPI synthesis inhibition by N-amino rhodanine derivatives
Rhodanine derivatives have been shown in the previous chapter, to be good inhibitors of MT-
1 and/or DPMS, possible explaining the low µM anti-trypanosomal activity against T. brucei
and T. cruzi (Table 56). In this chapter, the effect of N-amino substitution of the rhodanine
moiety on GPI-synthesis was investigated using a cell-free GPI-synthesis assay. The deriva-
tives were chosen based on their anti-trypanosomal activity against T. brucei, as many of the
derivatives in Table 56 did not show anti-trypanosomal activity at 100µM. However, although
many of the chosen N-amino rhodanine derivatives showed good anti-trypanosomal activity
(GI50 12.8-58.3µM), they did not inhibit enzymes in the cell-free GPI-synthesis assay (Ta-
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Table 57: cell-free GPI assay for N-amino rhodanine derivatives-1; line 1: 54a, line 2: 54q,
line 3: 54r, line 4: 54s, line 5: 54v, line 6: 54w, line 7: 54u; in vitro activity against
T. brucei ; Blue highlighted bands: DPMS inhibition; Green highlighted bands: MT-1
inhibition.
N S
S
O
H2N
R1 R2
R3
GI50 [µM]
# R1 R2 R3 T. brucei T. cruzi L. infantum HL60
54a H H H >100 >100 >100 >100
54q H OH H 19.3±7.3 >100 >100 >100
54r H H OH >100 >100 >100 >100
54s OH H OH 12.8±2.2 >100 >100 57.0±6.6
54v H OBn H >100 n.a. n.a. n.a.
54w H H OBn 58.3±14.6 >100 >100 >100
54u H H OMe >100 >100 >100 >100
ble 57, Table 58). Although the ortho methyl substituted amino-derivative 54b did not display
anti-trypanosomal activity at 100µM, 54b showed an absence A’ band in the GPI-synthesis
assay, thus suggesting inhibition of the ethanol-amine-phosphate transferase. This was rather
interesting as the ortho-methyl rhodanine analogue 36c was identified as very good inhibitor
of MT-1, the introduction of the additional amino-substituent caused inhibition of a complete
different enzyme in the cell-free GPI synthesis assay. However, both the rhodanine (36c)
and N-amino rhodanine (54b) derivative displayed no activity against T. brucei, T. cruzi or L.
infantum in vitro.
GPI activity of phenyl rhodanine derivatives
Rhodanine derivatives and in particular N-acetic acid rhodanine derivatives have been iden-
tified as inhibitors of the GPI-anchor biosynthesis in T. brucei using a cell-free GPI synthe-
sis assay. In order to study the importance of the N-1 substituent on GPI-anchor inhibition,
N-phenyl rhodanine derivatives were assessed for their ability to inhibit enzymes in the GPI-
anchor synthesis. However, none of the derivatives screened in the cell-free GPI synthesis
showed inhibitory effects of enzymes within the ensemble of the GPI-anchor (Table 59).
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Table 58: cell-free GPI assay for N-amino rhodanine derivatives-2; line 1: 54b, line 2: 54c,
line 3: 54d, line 4: 54i, line 5: 54h, line 6: 54l, line 7: 54ab; in vitro activity against
T. brucei ; Blue highlighted bands: DPMS inhibition; Green highlighted bands: MT-1
inhibition.
N S
S
O
H2N
R1 R2
R3
GI50 [µM]
# R1 R2 R3 T. brucei T. cruzi L. infantum HL60
54b CH3 H H >100 >100 >100 >100
54c H CH3 H >100 >100 >100 >100
54d H H CH3 >100 >100 >100 >100
54i H Br F >100 >100 >100 >100
54h H H Cl >100 >100 >100 >100
54l H H CN 47.2±11.3 >100 >100 >100
54ab 2-pyridinyl 47.5±2.5 12.1±1.5 >100 82.5±5.0
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Table 59: cell-free GPI assay for N-phenyl rhodanine derivatives; line 1: 54b, line 2: 54c, line
3: 54d, line 4: 54i, line 5: 54h, line 6: 54l, line 7: 54ab; in vitro activity against T.
brucei ; Blue highlighted bands: DPMS inhibition; Green highlighted bands: MT-1
inhibition.
N S
S
O
R1 R2
R3
GI50 [µM]
# R1 R2 R3 T. brucei T. cruzi L. infantum HL60
55q H H OBn >100 >100 >100 >100
55r H OBn OBn >100 >100 >100 >100
55z 2-pyridinyl >100 >100 >100 >100
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5.5 Discussion
Rhodanine derivatives in this study have been identified as good anti-trypanosomal agents.
Interestingly compared to N-acetic acid (ester) and N-allyl rhodanine derivatives, which were
mostly active against T. brucei, N-unsubstituted rhodanine showed broad activity against both
T. brucei and T. cruzi. Although many GI50 for T. cruzi could not be measured due to inter-
ference with the viability dye MTT, N-unsubstituted analogues showed MIC values of 100µM
against T. cruzi growth. But N-unsubstituted rhodanine derivatives also showed increased
toxicity against HL60 cells (GI50 25.7-91.7µM, Table 48). The activity against T. brucei of
the unsubsituted rhodanines showed a correlation to the derivatives logP values (Figure 66).
However, besides this observation, the structure activity relationship of the 5-benzylidene sub-
stituents was difficult to interpret as no clear trend could be observed in the screened series
of unsubstituted rhodanine derivatives. Substitution of the thiocarbonyl to a carbonyl group
in the thiazolidine-2,4-dione derivatives caused a decrease in anti-trypanosomal activity (Ta-
ble 49). Substitution of the meta-benzyloxy substituent on the 5-benzylidene moiety did not
improve anti-parasitic activity, as compared to the corresponding N-acetic rhodanine ester
derivatives (Table 53). Reduction of the exo-cyclic double bond in the para-benzyloxy rhoda-
nine derivative 36y improved anti-trypanosomal activity against T. brucei by a factor of 4 and
furthermore decreased toxicity against HL60 cells to GI50 >100µM (Table 54), suggesting that
these derivatives do not undergo un-selective Michael acceptor binding to biological nucle-
ophiles such as glutathione. On the contrary, the reduction of the double bond might have
improved the solubility of the rhodanine derivative due to increased flexibility and in conclusion
caused an improvement in anti-parasitic activity against T. brucei.
Since the 5-benzylidene moiety showed limited information on a possible structure activ-
ity relationship, further modifications on the rhodanine moiety itself were carried out. One
such modification was alkylation of the thiocarbonyl with various alkylating agents (Table 55).
Particular interesting was the observation of racemisation of the exo-cyclic double bond con-
figuration if the thiocarbonyl was subjected to alkylating agents (Table 46 and Table 47). In-
terestingly, these alkylated analogues showed comparable activities against T. brucei and T.
cruzi (GI50 9.3-65.9µM) than the not alkylated analogues. However, introduction of an amino-
acetic ester group resulted in high toxicity against HL60 cells (GI50 1.6 um).
Amino substitution of the N1-group in rhodanine moiety resulted in compounds with good
activity against T. brucei (GI50 12.9-69.7µM) and a good selectivity profile (SI 2-8, Table 51).
However, this modification also caused decreased activity against T. cruzi and did not im-
prove overall anti-parasitic activity, leading to the conclusion that an amino-modification on the
rhodanine-N1-moiety was not favourable. Therefore, the lipophilic phenyl group was chosen
for N-1 substitution. Indeed this modification in combination with a catechol motif on the 5-
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benzylidene moiety resulted in the most active anti-trypanosomal agents in this series, with
activity against both T. brucei and T. cruzi. Interestingly the acetylated catechol thiazolidine-
2,4-dione derivative 35e showed sub-µM activity against T. cruzi and µM activity against T.
brucei (Table 50). Larger indene-modification on the N-1 position improved activity against T.
brucei, if a catechol motif was present.
N-phenyl substituted rhodanine derivatives with other modifications than hydroxy groups
on the 5-benzylidene moiety showed no anti-parasitic activity.
In order to determine the possible mode-of-action of the rhodanine derivatives discussed
in this chapter, cell-free GPI synthesis were performed to identify possible inhibitors of the
GPi-anchor biosynthesis.13 Further details on the assay are described in chapter 3.5.3 The
unsubstituted rhodanine series was found to inhibit the first mannosyltransferase and DPMS
of the cell-free GPI-synthesis assay (Table 56). Particularly interesting were derivatives with
a ortho methyl or trifluoromethyl substituent, as they showed very strong inhibition effects on
the first mannosyltransferase in T. brucei, but did not show any activity against T. brucei in
vitro. The trifluoromethyl substituted derivative 36f, a strong inhibitor of the first mannosyl-
transferase, showed moderate activity against T. cruzi (GI50 24.9µM). Whereas the methyl
analogue showed no effect on T. cruzi growth, but retaining this methyl substituent and substi-
tuting the N-1 position with an amino-group resulted in a strong inhibitor for the ethanol-amine-
phosphate transferase, an enzyme very late in GPI-anchor biosynthesis (Table 58). Other
N-amino substituted rhodanine and N-phenyl amino rhodanine derivatives did not show any
effect on enzymes of the cell-free GPI-synthesis assay.
The rhodanine and thiazolidine-2,4-dione series discussed in this chapter were very inter-
esting for their anti-trypanosomal activity against both T. brucei and T. cruzi. They displayed
good selectivity and further modifications could improve anti-parasitic activity. However, the
alkylation strategy of the thiocarbonyl group generates good leaving groups for the attack of
biological nucleophiles and indeed mass spectrometric analysis showed potential adducts with
this compound class, so that this modification should not be pursued.
5.6 Summary
128 rhodanine, thiazolidine-2,4-dione derivatives and alkylation products have been synthe-
sised and evaluated for anti-parasitic activity in a whole cell activity assay against T. brucei, T.
cruzi and L. infantum.
30 out of 128 derivatives showed trypanocidal activity at 100µM (MIC 100µM) against T.
brucei, while 2 showed a MIC value of 10µM.
13This assays were performed by Dr. Terry Smith from the University of St. Andrews, St Andrews, Scotland, UK
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22 out of the 30 compounds active against T. brucei showed anti-parasitic effects against T.
cruzi at 100µM (MIC 100µM).
None of the 128 compounds showed any activity against L. infantum at 100µM.
Primary whole cell phenotypic screening of rhodanine, N-amino rhodanine, N-phenyl rhoda-
nine and thiazolidine-2,4-dione derivatives, as well as their alkylation products showed promis-
ing anti-trypanosomal activity against both T. brucei and T. cruzi (GI50 1.4-16.3µM, SI 4-18).
Target identification assays on selected derivatives identified rhodanine derivatives as partic-
ular promising derivatives for inhibitors of GPI-anchor biosynthesis in T. brucei. A rhodanine-3-
benzyloxy derivative showed good in vitro activities against both T. brucei and T. cruzi (GI50 13.1,
12.4µM, SI 4), while a cell-free radio-label assay showed very strong DPMS inhibition by this
derivative.
Target identification studies on N-amino rhodanine derivatives identified the first small molecu-
lar inhibitor of ethanol-amine-phosphate transferase, a late enzyme in the GPI-anchor biosyn-
thesis. But the same derivative did not show any activity in the whole cell assay against
parasites in vitro.
N-phenyl rhodanine derivatives did not show any anti-parasitic activity in the whole cell as-
say and against isolated enzymes of the GPI-anchor biosynthesis. However, if the N-phenyl
rhodanine moiety is conjugated to a catechol group, low µM activity against T. brucei (GI501.4-
7.3µM, SI 18) was observed.
Alkylation of the thiocarbonyl group resulted in inhibitors with good to moderate activity against
T. brucei, but characterisation by mass spectrometry resulted in adducts of molecular weight +
100 Da, suggesting possible substitution reactivity of this inhibitor series. For this reason, this
approach should not be pursued.
Replacing the rhodanine scaffold with a thiazolidine-2,4-dione moiety resulted in decreased
toxicity against HL60 cells, while anti-trypanosomal activity was retained.
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6 Pyrazolone derivatives
Pyrazolone derivatives (Figure 67) have been chosen as alternative inhibitor template to re-
place the thiazolidine-4-one moiety in rhodanine and thiazolidine-2,4-dione inhibitors. In the
following introduction reasons for the need of an alternative template are described and the
choice of the pyrazolone template is explained.
6.1 Introduction
Rhodanine have been shown in this study (Chapters 3.5.3, 4.4.3 and 5.4.1) to inhibit DPMS
and the first MT-1 transferase in the GPI-anchor biosynthesis. Rhodanine inhibitors have been
identified as low µM anti-parasitic compounds with promising selectivity profile in this study.
However, the rhodanine inhibitor class has potential drawbacks, such as the ability to bind
to many molecular targets, therefore compromising its selectivity profile. [82] Furthermore, rho-
danine derivative have been shown to undergo light-induced covalent binding interactions, [87]
and are potentially prone to nucleophilic attack on their Michael acceptor system. [82]
Although the rhodanine derivatives in this study have shown promising anti-parasitic ac-
tivity, some of these compounds in particular the unsubstituted rhodanine derivatives showed
also an increased toxicity against HL60 cells. In order to improve this selectivity profile, the
pyrazolone scaffold (Figure 67) was investigated as possible replacement of the rhodanine-
moiety. Indeed, screening campaigns against bacterial sugar nucleotide transferases have
N
N
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R
R
R
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Figure 67: Pyrazolone derivatives as alternative inhibitor template.
identified similar 3-methylpyrazolone derivatives alongside rhodanine and thiazolidine-2,4-dione
derivatives as potential inhibitors, justifying the use of this alternative scaffold for anti-parasitic
glysosyltransferases. [101,245] Furthermore, virtual screening identified all three substance classes
(pyrazolone derivatives, rhodanine and thiazolidine-2,4-dione) as inhibitors of a bacterial GT-
Pase, [246] possibly supporting their resemblance to nucleobases (XDP with X=U,A,G) and
phosphate mimics.
Pyrazolone derivatives are structurally very similar to rhodanine and thiazolidine-2,4-dione
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derivative, they possess the same number of hydrogen-bond acceptors (2 donors) as the cor-
responding rhodanine and thiazolidine-2,4-dione derivatives and constitute of a similar molec-
ular scaffold with a joined five- and six-membered ring system. Pyrazolone derivatives are
joined by a Michael acceptor system to a benzylidene moiety. Similarly to rhodanine and
thiazolidine-2,4-dione derivatives, this Michael acceptor system is susceptible towards thiol
reactivity, but thiol reactivity for pyrazolone derivatives with the endoplasmic reticulum oxidase
1 in yeast has been reported to be selective and reversible. [247]
Furthermore, pyrazolone derivatives have been studied as inhibitors for c-Met kinase activ-
ity. [248] Similarly, rhodanine and thiazolidine-2,4-dione derivatives have been found as inhibitors
of the kinase PI3Kγ (Chapter 5.1), [117,236] a potentially target for the development of anti-
leishmanial and anti-trypanosomal agents. [116,237] The previous biological studies suggested
resemblance of the pyrazolone derivatives to the rhodanine class, as they showed similar ac-
tivities against similar molecular targets. [101,245]
6.2 Synthesis of inhibitor library
6.2.1 Synthetic strategies towards anti-parasitic pyrazolone derivatives
The pyrazolone derivatives in this study had the general structure displayed in Figure 68.
Modification on the pyrazole-core were introduced over the R1 and the R2-substituent. In
the R1 position two different aryl moieties have been introduced. An unsubstituted aryl-
substituent (R=Ph) was introduced over phenyl hydrazine as reactant, whereas the corre-
sponding meta-carboxylic acid aryl was introduced through 3-hydrazinylbenzoic acid. The
unsubstituted (R=H) analogue was synthesised with hydrazine as reactant. In position R2,
substituted benzene-derivatives, furanyl- or other heterocyclic modification such as pyridines
were introduced. Lastly, the double bond displayed in red was reduced.
The pyrazolone derivatives were synthesised via two synthetic approaches (Scheme 41,
Route A or B). In the first approach (Route A) the hydrazine 76 is reacted with 77 in refluxing
acetic acid (HOAc) to afford the pyrazolone 78 (Scheme 41, green arrows, conditions (i)), [249]
which can exist as its keto or enol-form. The pyrazolone 78 is purified and subsequently re-
acted with various benzaldehydes in the presence of NaOAc in HOAc (Scheme 41, conditions
(ii)). Alternatively (Route B), the reagents can be combined in a one-pot reaction to obtain the
desired 79 under microwave irradiation (Scheme 41, conditions (iii)).
6.2.2 Stereochemistry of pyrazole derivatives
The Knoevenagel reaction between pyrazolone 78 and various benzaldehydes can lead to two
diastereoisomers (Figure 69). The isomers differ from each other through the configuration
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Figure 68: Synthethic strategies towards pyrazole-derivatives with anti-parasitic activity.
of the exo-cyclic double bond. Pyrazole derivatives were reported to preferentially react to its
Z-isomer in Knoevenagel condensation reactions. [152,250]
Two strategies are used to differentiate between both isomers with the aid of NMR spectros-
copy. [152,250] It has been observed that the chemical shift of the benzylidene-protons appeared
further downfield, if in proximity to the carbonyl function, as can be seen in the Z-configuration
of the double bond (Figure 69, blue).
A further NMR experiment to distinguish between Z- and E-isomer is the nuclear Over-
hauser effect spectroscopy (NOESY) experiment. Here the proximity in space between the
methyl group and the CH-moiety in the Z-configuration was measured. In the absence of a
methyl group 13C gated experiments can be performed to elucidate the double bond configura-
tion (Figure 69, orange). The 3JC,H-coupling between the carbonyl group and the C-H-proton
in rhodanine and rhodanine-like compounds have been reported between 5.52-7.21 Hz for the
cis configuration and 10.0-12.3 Hz for the trans-configuration. [106,163]
In this study NOESY experiments were performed for the correct assignment of the double
bond configuration. Additionally, 13C-CH-coupled experiments were performed, there specif-
ically the gated coupling of the carbonyl and the CH-proton was measured. These tools al-
lowed the assignment of the exo-cyclic double bond configuration. The assignment of the
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Scheme 41: Two approaches pyrozole-derivatives; (i) HOAc, reflux; (ii) NaOAc, HOAc; (iii)
MWI 5 min, 420 W.
double bond configuration is essential for later structure activity relationship analysis. Different
isomers could have different affinities towards a molecular target.
6.2.3 Synthesis of pyrazolone derivatives via Route A
Following the synthetic strategy outlined in Scheme 41, aryl hydrazine (R1=H or COOH) was
reacted with ethyl acetoacetate in acetic acid at 110 ◦C. [251] The condensation reaction yielded
the cyclised products 80 and 81 in excellent yield of 81-97 % after column chromatography.
The product was afforded as its keto form and no traces of the enol-form was seen in the
NMR. However, the 3-benzoic acid analogue 81 was obtained as the enol form, as confirmed
in the 1H-NMR by the absence of the CH2 signal and a signal further down field correspond-
ing to the CH-proton of the enol form. N-phenyl pyrazole 80 was subjected to various ben-
zaldehyde derivatives in the presence of sodium acetate as weak base (Scheme 42). These
reaction conditions failed to produce the desired condensation product for 50 % of the used
benzaldehyde derivatives. In all these cases, no product could be obtained after column chro-
matography and one side-products were purified. However, in the other 50 % of the cases the
reaction yielded the desired condensation products 80a–f after filtration in moderate yields of
13-80 %. The assignment of the double bond configuration was achieved with NOESY-NMR
experiments for compounds 80a, 80e, and 80f. The NOESY experiment showed a cross-
coupling of the methyl group in the pyrazolone core structure and the CH-double bond proton,
therefore confirming the formation of the Z-isomer as the major product. This observation
is agreement with previous studies, suggesting that the pyrazolone derivatives of the type
80a–an (Table 60) form preferably the Z-isomer. [250] Compound 80c was afforded as a 1:1
mixture of Z and E isomer. The chemical shift of the Ar-6-H proton in the Z-configuration ap-
193
6 Pyrazolone derivatives
Figure 69: Z- and E-isomer of pyrazolone derivatives and their structural elucidation with NMR
spectroscopy; green: NOESY; blue: δH of CH signal or H-6 on benzylidene-moiety;
orange: 3JC,H coupling measurements.
peared further downfield δH 8.42 ppm in the 1H-NMR experiment due to the proximity of the
de-shielding carbonyl-group than the corresponding E-isomer δH 7.08-7.89 ppm. The signal
for the CH-proton of the E-isomer appeared further downfield δH 8.11 ppm due to proximity
of the carbonyl group compared to the Z-isomer δH 7.69-7.75 ppm. The assignment of the Z-
configuration was further supported by a long-range 5JC,F coupling of 1.8 Hz for the CH-proton
in the E-configuration. However, the 5JC,F -coupling for the Z-isomer was not found, as there
was a overlap with other aromatic protons up-field in the 1H-NMR. But it would be expected to
see the long-range coupling only in the E-isomer, while in the Z-isomer the CH-proton and the
CF3 group are not in proximity any longer. In order to confirm this, the molecular structures
of the E- and Z-isomer were generated with MOE2009.10 and the 3D coordinates were calcu-
lated after MMF94-forcefield optimisation (Figure 70). The generated 3D-structures suggested
an intramolecular distance of 2.96 Å for the E-isomer, therefore explaining the observed long-
range 5JC,F of 1.8 Hz (Figure 70, (b)). Whereas in the generated structure for the Z-isomer, the
distance between the trifluoromethyl group and the CH-proton was 4.85-5.10 Å. However, the
distance between the CH-proton and the methyl group was calculated to be only 2.52-2.53 Å,
explaining the observed NOE effect in compounds 80a, 80e, and 80f (Figure 70). It is possible
that the trifluoromethyl group interacted as hydrogen bond acceptor with the CH-proton and
caused the racemisation towards the E- and Z-isomer.
The remaining two products 80b and 80d were assigned the Z-configuration of the double
bond based on the chemical shifts of the CH- and Ar-CH-signal. 80b and 80d showed a
chemical shift δH 7.80-7.96 ppm for the CH-proton, while the Ar-CH signals in proximity to the
carbonyl group appeared further downfield at 8.41-9.35 ppm. This values were similar to the
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Scheme 42: Synthesis of pyrazolone derivatives through synthetic Route A; (i) Ehtylaceto ac-
etate, HOAc, 110 ◦C; (ii) NaOAc, EtOH, 110 ◦C; see Table 60.
ones observed for the Z-isomer of 80c (δCH 7.69-7.75 ppm, δArCH 8.42 ppm).
In summary, route A was suitable for the synthesis of pyrazolone derivatives, but the iso-
lated yields and possible side-products made the investigation for improved methods neces-
sary. For the corresponding aryl-pyrazolone 81 a different approach was employed for the
condensation reaction with benzaldehyde derivatives.
6.2.4 Synthesis of pyrazolone derivatives via Route B
The alternative approach over route B was carried out under solvent free microwave irradiation
of the aryl-hydrazine, ethyl aceto-acetate and various benzaldehyes. The reaction was carried
out in a domestic microwave at 400-420 W at reaction times between 2-5 min. The yield of
the reaction was slightly better compared to compounds obtained via Route A (Scheme 42).
The microwave assisted one-pot three-component reaction with 3-hydrazinylbenzoic acid pro-
duced the condensation product 81a–l in good yields of 13-80 % (Scheme 43, Table 61).
Derivatives 81h, 81i, 81j, and 81k could not be isolated. The major product for compounds
81j and 81k was the Schiff base of the reaction of 3-hydrazinylbenzoic acid and the corre-
sponding aldehyde as confirmed by NMR spectroscopy. The one-pot reaction sequence using
phenyl hydrazine yielded only the product 80m in good yields of 60 %. The reactions with any
other aldehyde resulted in the formation of multiple products. It is possible that the starting
aldehydes decomposed during microwave irradiation over a prolonged period, however reduc-
ing the reaction times from 5 min to 2-3 min (80n, 80p, and 80q) did not succeed in the desired
product formation. All condensation products 81a–g and 80m were obtained as a single iso-
mer. The chemical shift of the CH-sginal δH 7.60-7.84 ppm and the Ar-CH δH 8.09-8.71 ppm
confirmed the formation of the Z-isomer as the only product in the one-pot reaction sequence.
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Table 60: Synthesis of pyrazolone derivatives through synthetic Route A; R1=H and R2-R3 for
pyrazole derivatives; yields and spectral analysis of double bond configuration; see
Scheme 42.
yield NMR spectra for DB-configuration
# R2 R3 R4 [%] δ NOE δCH δAr−H
80a H NO2 H 13 DMSO-d6 Z 8.02 9.61
80b H CH3 H 14 DMSO-d6 n.a. 7.80 8.41-8.45
80c CF3 H H 15 CDCl3 n.a. 7.69-7.75(Z) 8.42(Z)
8.11(E) 7.08-7.89(E)
80d OH H OH 31 DMSO-d6 n.a. 7.96 9.35
80e H OBn OBn 46 DMSO-d6 Z 7.73 8.9
80f H H OH 80 DMSO-d6 Z 7.7 8.64
80g H OH H no product
80h OH H H no product
80i H H CH3 no product
80j CH3 H H no product
80k H CF3 H no product
80l H H OMe no product
The reaction of 3-hydrazinylbenzoic acid, 2-carboxylic-benzaldehyde or 3-nitro benzalde-
hyde and excess ethyl aceto-acetate resulted in the formation of the Schiff-base product 82
(Scheme 44). In order to investigate the possible side-reaction in the microwave assisted one-
pot three component reaction, ethyl-aceto acetate was reacted with 3-hydroxy-benzaldehyde
in HOAc in the presence of NaOAc to catalyse the reaction. However, no reaction was ob-
served. Although, method B improved the yields of the reaction towards pyrazolone deriva-
tives, the formation of side-products was observed and phenyl-hydrazine were less tolerated.
Therefore further optimisations were carried out for the synthesis of pyrazolone derivatives.
6.2.5 Improved reaction conditions for pyrazolone derivatives
The microwave assisted synthesis was not further optimised, because of the frequent side-
reactions.
The reaction of ethyl 3-oxobutanoate with 3-hydroxy benzaldehyde did not yield any side
product 83 (Scheme 44). These results and the good yields in the formation of the pyrazolone
precursors 80 and 81 encouraged the use of HOAc as catalyst and solvent for the Knoevenagel
reaction in the second step of the reaction sequence. The synthesis of pyrazolone derivatives
was performed in a sequential one-pot reaction. The reaction was carried out in two steps. In
the first step the pyrazolone precursor for the Knoevenagel reaction was synthesised via con-
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(a) Z-isomer (b) E-isomer
Figure 70: Measurement of distances of CH-proton and CF3-group in E-isomer and CH-proton
and CF3 and CH3-group in Z-isomer using MOE2009.10.
densation of phenyl hydrazine or 3-benzoic acid hydrazine and ethyl-aceto acetate in HOAc.
The reaction was stirred overnight (16 h), until which the starting material were completely
converted to the desired phenylpyrazolone 80 or 3-benzoic acid pyrazolone 81. In the follow-
ing step, 1.5 eq. of benzaldehyde derivative were added and the reaction mixture was stirred
until TLC showed complete consumption of 80 or 81. The products were obtained in com-
bined yields over two sequential steps of 15-93 % (??). The new reaction conditions resulted
in higher yields and were tolerated by a broad range of benzaldehyde derivatives without the
formation of side-products. Only compounds 80t and 80u could not be isolated under these
reaction conditions. In the cases of 80t and 80v this might have been due to steric hindrance
of the ortho substituent in the benzaldeyde moiety.
All products 80w–v and 81m–n showed the preferred Z-double bond configuration as the
major product (Table 62).
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Scheme 43: Synthesis of pyrazolone derivatives using route B; microwave assistant one-pot
three component reaction; (i) Microwave-irridation (domestic), 400-420 W, 5 min.
Table 61: Synthesis of pyrazolone derivatives using route B; R1-R4 for pyrazolone derivatives
81a–k and 80s; yields; section time and spectral analysis of double bond configura-
tion; δH in DMSO-d6.
NMR spectra for DB
# R1 R2 R3 R4 R-time yield NOE δCH δArCH
[min] [%] [ppm] [ppm]
81a COOH H OBn OBn 5 13 Z 7.75 8.21
81b COOH H Br OMe 5 24 n.a. 7.79 8.57
81c COOH H OBn H 5 25 n.a. 7.84 8.09
81d COOH H H CN 5 45 n.a. 7.83 8.64
81e COOH H H OH 5 64 n.a. 7.71 8.60-8.66
81f COOH H H OBn 5 72 n.a. 7.79 8.71
81g COOH H H NMe2 5 80 Z 7.60 8.65
81h COOH H H tBu 5 no product
81i COOH H H SO2Me 5 no product
81j COOH COOH H H 5 schiff base
81k COOH H NO2 H 5 schiff base
80m H H H OH 5 60 Z 7.70 8.64
80n H H OH H 2 no product
80o H CF3 H H 5 no product
80p H H OH H 5 no product
80q H H OH H 3 no product
80r H H H OBn 5 no product
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Scheme 44: Side-reaction in the microwave assisted one-pot reaction; (i) ethyl acetoacetate,
2-carboxylic acid-benzaldehyde (R1=COOH) or 3-nitro-benzaldehyde (R1=H,
R2=NO2), MWI, 400 W, 5 min; (ii) 3-hydroxy-benzaldehyde, NaOAc, HOAc.
N
H
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N N CH3
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R3R4
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15-93 %
Scheme 45: Improved reaction conditions towards pyrazolone derivatives; (i) ethyl 3-
oxobutanoate, HOAc, 110 ◦C; (ii) benzaldehyde derivatives, HOAc.
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Table 62: Improved reaction conditions towards pyrazolone derivatives; R1-R5 for pyrazolone derivatives; yield; chemical shift δH for
CH and 6-Ar-CH for double bond configuration.
[%] NMR spectra for DB conf. [ppm]
# R1 R2 R3 R4 R5 yield δ NOE δCH δArCH
80w H H H OMe H 15 DMSO-d6 Z 7.71 8.71
80x H H H Ph H 16 CDCl3 n.a. 7.39-7.45 8.61
80y H H H CN H 22 DMSO-d6 n.a. 7.85-7.90 8.61-8.65
80z H H H Cl H 24 DMSO-d6 n.a. 7.83 8.61
80aa H H H SO2Me H 44 DMSO-d6 n.a. 7.95 8.68
80ab H H Br OMe H 46 DMSO-d6 Z 7.75 9.24
80ac H CF3 H H H 48 CDCl3 n.a. 7.62-7.65 8.37
80ad H H Br F H 57 DMSO-d6 Z 7.84 9.20
80ae H H CF3 H H 62 DMSO-d6 Z 7.85-7.89 9.07
80af H H OBn H H 62 CDCl3 Z 7.15(E), 7.22(Z) 6.98-7.89(E), 8.54(Z)
80ag H H OMe OH OMe 72 DMSO-d6 n.a. 7.72 8.29
80ah H H H H H 82 CDCl3 Z/E 7.27(Z), 7.92(E) 7.88(E), 8.37-8.41(Z)
80ai H H OH H H 89 CDCl3 n.a. 7.33-7.43 8.52
80aj H H H CF3 H 93 DMSO-d6 n.a. 7.07 8.31
80ak H H OH OH H 87 CDCl3 Z 7.34 9.19
80t H CF3 H H H no product
80al H H H CH3 H no product
80am H H H NMe2 H 56 CDCl3 n.a. 7.15 8.48
80v H OH H H H no product
81m COOH OH H H H 13 DMSO-d6 n.a. 8.07 9.07
81o COOH H Br F H 58 DMSO-d6 Z 7.86 9.17
81p COOH H H H H 78 DMSO-d6 Z 7.84 8.58
81n COOH H H OBn H 64 DMSO-d6 n.a. 7.78 8.70
200
6 Pyrazolone derivatives
The double bond configuration of compounds 80w, 80ab, 80ad, 80ae, 80ak, 81o, and 81p
was determined by NOESY-NMR experiments. All these derivatives showed a cross peak of
the methyl group in proximity to the CH-proton in the NOESY spectra. These Z-isomers had
a chemical shift of the 6-Ar-CH-proton of δH 8.58-9.24 ppm due to the de-shielding effect of
the neighbouring carbonyl group. Whereas the chemical shift of the CH-double bond proton is
shifted towards higher fields δH 7.34-7.89 ppm. The chemical shifts of both the 6-Ar-CH- and
CH-proton were compared with the remaining derivatives and the Z-configuration could be as-
signed. The chemical shifts of the 6-Ar-CH-proton in derivatives 80x, 80y, 80z, 80aa, 80ac,
80ag, 80ai, 80am, 81m, and 81n (Table 62) were δ 8.29-9.07 ppm and therefore in a similar
range as previous observed aromatic CH-protons in proximity to a carbonyl group. The chem-
ical shift of the CH-proton was δH 7.39-8.07 ppm and therefore were similar to Z-configurated
isomers, further supporting the Z-configuration. Compounds 80af and 80ah were afforded as
mixtures of both Z- and E-isomer. The NMR spectra were recorded in CDCl3 and the chem-
ical shifts appeared therefore at slightly higher field compared to spectra recorded in DMSO-
d6. Both compounds were analysed by NOESY-NMR experiments and Z- and E-configuration
were confirmed by cross peaks of the methyl and CH-proton for the Z-configuration and methyl
and Ar-CH-proton cross peaks for the E-configuration. Compound 80af was afforded as a mix-
ture of isomers in a ratio of 5.5:1 (Z:E-isomer). It was most likely that steric hindrance of the
3-benzyloxy group was responsible for the racemisation. In the case of compound 80ah the
isomeric ratio was 6:1 (Z:E-isomer) and the absence of any substituents might be the reason
for the racemisation. However, in both cases the Z-isomer was obtained as the major product.
The derivative 80z was chosen for additional experiments to verify the Z-configuration of
the double bond. The configuration of the Z-isomer was confirmed by NOESY and H-Jres
experiments (Figure 71 (a)). Initially, NOESY-experiments were performed to show the Z-
configuration of the double bond (Figure 71 (b)). The NOESY spectra showed the expected
cross peak between the methyl and the CH-proton. Next, HBMC-experiments were performed
to show the coupling of the CH-proton over multiple bonds in 80z (Figure 71, (c)). In the
HMBC-experiment the long range coupling of the CH-proton to the carbonyl function is visible.
To quantify the long-range coupling of the CH-double-bond proton and the carbonyl group, a
H-Jres-experiment was performed (Figure 71 (d)). The H-Jres experiment is a gated-13C-1H-
NMR coupling experiment, here the experiment is tuned to suppress all the signals except
the signal of the CH-proton and the coupled 13C-nuclei. The splitting at 161.4 ppm for the
carbonyl function was measured to be 3JCH,C=O = 5.7 Hz. This relatively small coupling constant
was surprising, as rhodanine derivatives with a cis-configurated double bond showed coupling
constants of 10.0-12.3 Hz (Chapter 6.2.2). [106,163] Attempts to find reference values for the long
range coupling of the CH-double bond proton and the carbonyl group were unsuccessful. The
double bond configuration is most conveniently determined by the chemical shift of the 6-Ar-
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(a) Overview of 80z (b) NOESY-Experiment
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(c) HMBC-Experiment (d) H-Jres Experiment
Figure 71: 2D-NMR Experiments for confirmation of the Z-configuration of double bond in 80z.
CH-shift in 1H-NMR experiments. [250] Therefore, it would be plausible that the 3JCH.C=O coupling
of 5.7 Hz would indicate the Z-configuration. The control experiment with the E-isomer was
not performed, as access to the 700 MHz NMR was limited and the Z-configuration could
undoubtedly be determined by other NMR experiments. But it would be expected that the
coupling constant would be smaller than 5.7 Hz.
6.2.6 Synthesis of ester-analogues of 81e
It has previously been reported that esterification of carboxylic acid could improve membrane
permeability and efficiency of drugs in parasites. [167] The beneficial aspect of the ester modifi-
cation in thiazolidine-2,4-dione derivatives was described in chapter 3.2.6.
In order to study the importance of this ester modification in pyrazolone derivatives, at-
tempts were made to synthesis the ester derivative 84a via standard esterification conditions,
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using DCC, DMAP in ethanol (Scheme 46). However, the esterification of the free carboxylic
acid in 81e failed and only starting material was recovered.
N N
COOH
O
HO
(i)
N N
COOEt
O
HO
81e 84a
Scheme 46: Esterification reaction of 81e; (i) DCC, DMAP, EtOH.
6.2.7 Reduction of exo-cyclic double bond in pyrazolone derivatives
Pyrazolones of the type 80ak have an exo-cyclic double bond, which is in conjugation with
the neighbouring carbonyl-group. This arrangement of conjugated double bond is possibly
prone to 1,4-addition of nucleophiles to the carbonyl- and or double bond in pyrazolones.
This Michael acceptor reactivity could potentially be a problem for compound selectivity and
toxicity. Compound 80ak could potentially bind nonselectively to biological nucleophiles (such
as glutathione) or could covalently bind to multiple proteins with low affinity. In order to study
the binding mode, the double bond in 80ak was reduced (Scheme 47). The reduced analogue
can be assessed for anti-parasitic activity and then compared to the activity of the parent non-
reduced 80ak. A drop in activity of the reduced analogue might be explained through a loss of
covalent binding or through steric considerations, as the reduction of the double bond will led
to an increase in flexibility.
The double bond in 80ak was reduced under catalytic hydrogenation, and the reduced
product 85a was obtained as the enol form. The 1H-NMR and 13C-NMR spectra showed no
signal for the keto form, the CH-proton and the carbonyl signal were missing and the 13C-NMR
showed an additional un-saturated tertiary carbon-signal.
6.2.8 Synthesis of heterocyclic modified pyrazole derivatives
Pyrazolone derivatives have been studied as inhibitors of bacterial glycosyltransferases, [101,245]
a particularly good µM-molar inhibitor (1µM) against the bacterial heptosyltansferase WaaC,
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Scheme 47: Reduction of pyrazole derivative 80ak; (i) Pd/C, H2, dioxane.
had a furanyl substituent in position 4 of the pyrazolone moiety. [245] It was assumed that this
furanyl pyrazolone might also inhibit glycosyltransferases involved in the GPI-anchor biosyn-
thesis in parasites.
In this chapter, the synthesis of a similarly modified analogue is described, starting from
the synthesis of the modified aldehyde for the Knoevenagel reaction. The corresponding alde-
hyde was synthesised via Suzuki cross coupling reaction between phenyl-boronic acid and
bromo-furanyl-carbaldehyde. The C-C coupling reaction afforded the desired product 86 in
moderate yields of 39 % (Scheme 48). The modified furanyl carbaldehyde 86 and various
O
O
Br
B OHHO (i)
O
O
39 %
86
Scheme 48: Synthesis of furanyl-carbaldehyde 86; (i) Pd(PPh3)4, K2CO3(aq), DMF, 110 ◦C.
other heteroaromatic-aldehydes were subjected to the improved sequential one-pot reaction
procedure, described in Chapter 6.2.5 (Scheme 49,Table 63). The reaction of 86 and 3-
benzoic-acid hydrazine and ethyl-aceto-acetate in HOAc failed and no product was obtained
after column chromatography. However, the unsubstituted analogue 88a produced the de-
sired condensation product in excellent yields of 92 %. The double bond configuration was
determined with NOESY experiments and through comparison with chemical shifts of the Ar-
CH-proton in the Z-configuration. NOESY experiments showed a cross-peak between the
methyl and CH-protons and the chemical shift of the furanyl-CH in proximity to the carbonyl
was δH 8.64 ppm, thus indicating the Z-configuration of the double bond.
Attempts to subject various pyridine-carboxaldehydes to the one-pot reaction failed and no
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Scheme 49: Synthesis of heterocyclic modified pyrazolone derivatives; (i) ethyl-aceto acetate,
HOAc, 110 ◦C; (ii) benzaldehyde derivatives, HOAc.
Table 63: Synthesis of heterocyclic modified pyrazolone derivatives; R1-R2 for heterocyclic
modified pyrazolone; yield and NMR Experiments for configuration of double bond.
NMR for DB conf [ppm]
# R1 R2 yield [%] δ NOE δCH δArCH
87a COOH
O
Ph no product
88a H
O
92 DMSO-d6 Z 7.71 8.64
88b H N no product
88c H
N
no product
88d H
N
no product
products could be isolated (Table 63).
6.2.9 Synthesis of N-1 aliphatic modified pyrazolone
The previous N-1 aryl modified pyrazolone analogues 80a–an and 81a–q are potentially very
lipophilic and might undergo unspecific binding to proteins. Lipophilicity can be quantified
through measuring the partition coefficient in octanol and water. This partition coefficient, also
known as logP, can be calculated by bioinformatic tools. Here, the logP has been calculated
using the weighted logP function in MarvinSketch (Figure 72). The logP value for the N-1
benzoic acid derivatives 81p was predicted to be logP 3.24, whereas the predicted value for the
N-1 unsubstituted pyrazolone derivative 89a was only logP 1.70. It would be very interesting
to assess the activity of unsubstituted analogues, both in terms of lower logP values and
lower molecular weights. N-1-unsubstituted analogues with a high anti-parasitic activity would
give more opportunities for modifications, such as the introduction of additional substituents or
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Figure 72: Calculated logP values using MarvinSketch (weighted method for calculation: VG,
klogP, phys = 1.
bulkier substituents on the C-4-pyrazolone position.
The aliphatic acetic acid ester modification in 90a was calculated to have a logP value of
1.90, slightly higher than that of the unsubstituted analogue 89a. If the ester was to be hydrol-
ysed, the logP would be 1.40. As described previously in Chapter 3.2.6, the higher logP value
of 1.70 could facilitate the diffusion through membranes. Once in the cell the free-acids can
benefit both from better water solubility (logP 1.40) and possible specific interactions with the
target protein(s). The precusors for the synthesis of N-1-modified pyrazolone derivatives were
synthesised as outlined in Scheme 50. Hydrazine 76 was reacted with ethyl-aceto-acetate in
HOAc to afford the precursor 89 in quantative yields after simple filtration (Scheme 50).
The N-1-acetic ester modified analogue 90 was synthesised by reaction of the unsubsti-
tuted pyrazolone precursor 89 with ethyl 2-bromoacetate and NaH in DMF. The substitution
product 90 was afforded in moderate yields of 30 % after column chromatography. 1H-NMR
spectral analysis of 90 confirmed the products enol-form, as well as substitution of the N-1 ni-
trogen. The NOESY experiment did not show any cross peak between the pyrazolone methyl
substituent and the ester moiety, thus suggesting N-1 substitution (Scheme 50).
The unsubstituted and ester modified pyrazolone precursors 89 and 90 were subjected to
Knoevenagel reaction conditions with benzaldehyde derivatives (Scheme 51). Initially, the con-
densation reaction was carried out with the unsubstituted pyrazolone 89, 4-methylbenzaldehyde
and NaOAc as base and in ethanol at 80 ◦C. However under these conditions no reaction was
observed and only starting material was recovered. In an attempt to activate the substrates,
the solvent was substituted to HOAc and the reaction mixture was heated to 110 ◦C (Table 64).
But the reaction did not proceed and no conversion of starting materials was observed. The
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Scheme 50: Synthesis of N-1unsubstituted pyrazolone precursor 89 and ester analogue 90;
(i) ethyl aceto-acetate, HOAc, 110 ◦C; (ii) NaH, ethyl 2-bromoacetate, DMF, 0 ◦→
rt.
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R1=CH2COOEt
89b–c
90b
Scheme 51: Knoevenagel condensation reaction of N-1-aliphatic modified pyrazolone; (i)
NaOAc, EtOH, 80 ◦C; (ii) NaOAc, HOAc, 110 ◦C; (iii) HOAc, 110 ◦C.
reaction with the 3-methylbenzaldehyde, the unsubstituted pyrazolone 89 in HOAc at 110 ◦C
also failed to produce the desired condensation products. Next, the aldehyde was substituted
to 4-chlorobenzaldehyde, as this aldehyde proved to be reactive in the Knoevenagel reac-
tion of phenyl- or phenyl-3-benzoic acid pyrazolone derivatives. The reaction conditions with
NaOAc in HOAc at 110 ◦C were chosen for the condensation reaction, but no product was
obtained. The N-acetic acid ester analogue 90 was subjected to similar conditions with 4-
chlorobenzaldehyde and sodium acetate in ethanol at 80 ◦C. Similar to previous attempts, the
condensation product was not obtained. All reactions used the pyrazolone precursor in its enol
form, so it might be that stronger bases are necessary to catalyse the condensation reaction
with benzaldehyde derivatives. Another possibility would have been to substitute the solvent
with DMF to stabilise the intermediates in the Knoevenagel reaction. The addition of TiCl4
might also catalyse the reaction further and might lead to product formation. [152] However, due
to time constrains none of these alternatives could be investigated.
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Table 64: Knoevenagel condensation reaction of N-1-aliphatic modified pyrazolone deriva-
tives; R1-R4 for N-1-substituted pyrazolone derivatives (Scheme 51); method of
preparation and yield.
# R1 R2 R3 R4 method yield [%]
89b H H H CH3 (i) no reaction
89d H H H CH3 (iii) no reaction
89e H H CH3 H (ii) no reaction
89c H H H Cl (iii) no reaction
90b CH2COOEt H H Cl (i) no reaction
6.3 Anti-parasitic activity
The anti-parasitic activity against T. brucei, T. cruzi and L. infantum was evaluated with the
activity assays described in chapter 3.3.1.
6.3.1 Anti-parasitic activity of phenyl pyrazolones
Initially, the starting phenyl pyrazolone derivative 80 was evaluated for its anti-parasitic activity.
The derivative 80 showed no activity on T. brucei, T. cruzi nor L. infantum at 100µM, however
it displayed some toxicity against HL60 cells (GI50 151.7µM).
The substitution product with benzaldehyde (80ah) was afforded as mixture of Z and E
double bond isomers (ratio 6:1 Z to E). The condensation product 80ah showed improved anti-
trypanosomal activity (GI50 15.5µM) compared to the starting pyrazolone 80. Furthermore,
80ah displayed an improved toxicity profile, as it did not show cytotoxicity against HL60 cells
at 100µM. The majority of substitutions on the 4-benzylidene moiety resulted in GI50 values
of 12.4-17.3µM (Table 65). As for the T. brucei activity there was no clear trend, however the
toxicity of the derivatives correlated well to the logP value. Therefore an increased logP value
resulted in increased toxicity against HL60 cells in compounds 80ad, 80a, 80z, 80e, 80ac,
80aj, 80ak, and 80ab. Interestingly, the ortho- and para- dihydroxy derivative 80d displayed
no activity against T. brucei, indicating a possible preference for hydrogen bond acceptors or
large lipophilic substituents, as the ortho-trifluoromethyl derivative 80ac was active in the low
µM range (GI50 15.4µM) against T. brucei. This observation is further supported by low µM
activity (GI50 17.1µM) of the para-hydroxy derivative 80f. Another interesting exception of
the low µM activity of pyrazolone derivatives, was the para-dimethylamino derivative 80am.
Comparing this substituent to other para-substituted analogues with low µM activity showed
that positive charged substituent (under physiological pH) resulted in loss of anti-trypanosomal
activity. Whereas large substituents, such as benzyl, phenyl and trifluoromethyl showed low
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µM activity against T. brucei. Furthermore, acceptor groups (CN, SO2Me, OMe) were well
tolerated and resulted in active reagents against T. brucei growth.
Heterocyclic modification, such as a furanyl group in derivative 88a deminished anti-trypa-
nosomal activity. The only derivative with moderate activity again L. infantum was compound
80ac, however its high toxicity against HL60 cells (GI50 41.6µM) resulted in an undesirable
toxicity profile.
Table 65: Anti-parasitic activity of phenyl pyrazolones derivatives.
N
N
O
CH3
R1
R2
R3R4
GI50 [µM]
# R1 R2 R3 R4 T. brucei T. cruzi L. infantum HL60 logP
80 >100 >100 >100 151.7±8.3 1.53
80ag H OMe OH OMe 12.4±0.1 >100 >100 >100 2.96
80ad H Br F H 12.5±1.0 n.a. >100 40.3±4.6 4.49
80y H H CN H 12.7±0.6 n.a. n.a. 91.8±4.0 3.44
80a H NO2 H H 13.0±0.1 n.a. >100 71.1±4.3 3.52
80af H OBn H H 13.6±0.3 n.a. n.a. n.a. 5.15
80x H H Ph H 13.7 n.a. >100 20.7 5.23
80ae H CF3 H H 14.4±1.2 n.a. >100 94.2±0.5 4.46
80z H H Cl H 14.4±1.3 n.a. >100 67.8±1.8 4.19
80e H OBn OBn H 15.1±0.5 >100 >100 31.0±6.7 6.71
80aa H H SO2Me H 15.2 n.a. >100 >100 2.42
80ac CF3 H H H 15.4±1.9 n.a. 63.6±1.8 41.6±4.7 4.46
80w H H OMe H 15.5±1.8 >100 >100 >100 3.42
80aj H H CF3 H 15.5±2.8 n.a. >100 48.7±6.1 4.46
80ah H H H H 15.5±3.2 >100 >100 >100 3.58
80f H H OH H 17.1±5.3 >100 >100 >100 3.28
80ak H OH OH H 17.3±0.1 n.a. n.a. 47.3±8.9 2.97
80ab H Br OMe H 17.3±0.6 >100 >100 51.9±3.6 4.19
80ai H OH H H 27.5±13.9 >100 >100 n.a. 3.28
88a 2-furanyl 60.6±4.7 n.a. n.a. >100 2.64
80am H H NMe2 H 64.8±10.0 n.a. n.a. >100 3.69
80d OH H OH H >100 >100 >100 >100 2.97
209
6 Pyrazolone derivatives
6.3.2 Anti-parasitic activity of 3-benzoic acid pyrazolones
Previous phenyl pyrazolone derivatives showed promising anti-trypanosomal activity against
T. brucei (GI50 12.4-17.3µM), however they also displayed toxicity against HL60 cells, re-
sulting in low SI towards T. brucei. In order to increase selectivity, 3-benzoic acid pyra-
zolones were evaluated for their anti-parasitic activity. Although structurally very similar to
previous pyrazolone inhibitors in this chapter, the additional carboxylic acid function may al-
ter toxicity towards HL60 cells by introducing a substituent which could undergo other than
lipophilic or pi-stacking interactions. Indeed, derivatives 81a and 81b showed decreased toxic-
ity against HL60 cells (GI50 >100µM), compared to their analogues 80e and 80ab (GI50 31.0
and 51.9µM). However, only the bis-benzyloxy derivative 81a retained its anti-trypanosomal
activity against T. brucei, while the bromo-methoxy derivative 81b showed no effect on T. bru-
cei growth at 100µM. Interestingly, the 4-para-hydroxy derivative 81e also showed no activity
against T. brucei at 100µM, although its phenyl-analogue 80f had a GI50 of 17.1µM. None of
the inhibitors showed any activity again L. infantum at 100µM.
Table 66: Anti-parasitic activity of 3-benzoic acid pyrazole derivatives.
N
N
O
CH3
R1
R2
R3R4
O
HO
GI50 [µM]
# R1 R2 R3 R4 T. brucei T. cruzi L. infantum HL60
81p H H H H 11.7±0.2 n.a. n.a. >100
81o H Br F H 12.8±0.2 >100 >100 >100
81f H H OBn H 13.7±0.1 >100 >100 >100
81c H OBn H H 14.2±2.0 n.a. >100 29.7±0.1
81a H OBn OBn H 14.3±3.5 n.a. >100 79.8±7.0
81e H H OH H >100 >100 >100 >100
81b H Br OMe H >100 >100 >100 >100
81g H H NMe2 H >100 >100 >100 n.a.
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6.3.3 Anti-trypanosomal effect of the reduction of the exo-cyclic double bond in
pyrazolone derivatives
The exo-cyclic double bond of the catechol pyrazolone 80ak (Table 67) was reduced and the
racemic mixture was evaluated for its anti-parasitic activity. A broad range of different sub-
stituted pyrazolones showed anti-trypanosomal activity in the lower µM range against T. bru-
cei (Table 65), while showing low selectivity then screened against mammalian HL60 cells.
Therefore, it may be possible that these inhibitors bind covalently to biological targets over their
Michael acceptor system and therefore displaying general cytotoxicity. However, reduction of
the double in derivative 85a (Table 67) did not effect its anti-trypanosomal activity, nor its toxic-
ity against HL60 cells. This promising results validated the use of pyrazolones as anti-parasitic
agents and further modification can be carried out to improve their anti-parasitic activity and
toxicity towards HL60 cells. The retention of activity might suggest that pyrazolone derivatives
are less susceptible to Michael addition reactions.
Table 67: Anti-trypanosomal effect on the reduction of the exo-cyclic double bond.
N
N
O
CH3
X
OH
OH
GI50 [µM]
# X T. brucei HL60
85a CH2 16.4±0.1 51.1±1.5
80ak CH 17.3±0.1 47.3±8.9
6.4 Discussion
Pyrazolones are a promising class of inhibitors for the development of anti-parasitic agents, in
particular against T. brucei. While substitutions on position 4 of the pyrazolone ring showed
only minor alterations in their anti-trypanosomal activity (Table 65), the modification on the N-1
substituent improved selectivity without affecting trypanocidal activity (Table 66). The reduc-
tion of the exo-cyclic double bond did not affect its anti-trypanosomal activity, suggesting that
covalent binding to the Michael acceptor system are less likely to occur in these inhibitor se-
ries. However, further optimisation of these promising compounds are necessary to increase
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anti-parasitic activity. The phenyl pyrazolone derivatives 80a–an showed considerable toxicity
against HL60 cells, the best inhibitor 80ag had a selectivity index of >8 for T. brucei, while
showing no toxicity against HL60 cells at 100µM. The introduction of a 3-benzoic acid motif in
position 1 resulted in improved selectivity for compound 81a compared to its phenyl pyrazole
analogue 80e.
6.5 Summary
33 pyrazolone derivatives have been synthesised and evaluated against T. brucei, T. cruzi and
L. infantum in a whole cell activity assay.
24 out of 33 derivatives were able to kill T. brucei at 100µM (MIC 100µM).
10 of the 24 active inhibitors against T. brucei growth also showed anti-trypanosomal effects
against T. cruzi at 100µM (MIC 100µM).
None of the derivatives showed any effect on L. infantum growth at 100µM.
The whole cell activity screen was able to identify anti-trypanosomal inhibitors with good ac-
tivity against T. brucei and T. cruzi (GI50 11.7-64.8µM, SI 2 - >9).
The meta-benzyloxy modified pyrazolone showed promising anti-trypanosomal activity (GI50 13.6-
14.2µM), possibly indicating GPI-anchor biosynthesis inhibition, as all other meta-benzyloxy
modified analogues in this thesis showed activity against enzymes in the GPI-anchor biosyn-
thesis. But also increased toxicity against HL60 was observed (SI 2).
Scaffold replacement from a rhodanine to a pyrazolone moiety resulted in a loss of anti-
parasitic activity. However, the toxicity in pyrazolone derivatives is also reduced.
In particular the N-1 substituent influenced anti-trypanosomal activity and less liphophilic sub-
stituents like aliphatic carboxylic acid might be a good starting point for improvement of anti-
parasitic activity.
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7.1 Introduction
Iron is an ubiquitous element for growth in all living organisms, as such it is also essential
for growth of T. brucei, T. cruzi and L. infantum. [61–63] Iron, due to its redox properties and
high affinity for oxygen, plays an important role in numerous biological processes. [124] Con-
sequently, iron chelation has been suggested as a potential strategy to combat infectious
diseases. [126]
The bacterial siderophore Deferoxamine (Figure 73) is a hexa-dentate iron-chelator with
weak anti-parasitic activity. [61–63] T. brucei, T. cruzi and L. infantum have been shown to have
a high sensitivity for the iron chelator Deferoxamine, resulting in reduced parasitemia at con-
centration which did not interfere with the host iron metabolism. [61–63] Deferoxamine has been
studied in mouse models of visceral Leishmaniasis and acute and chronic Chagas disease,
causing a reduction in parasite burden but no cure was observed. [63] However, the clinical
application of Deferoxamine is compromised due to its poor oral availability. [252]
A more promising iron chelator is the orally available Deferiprone (Figure 73). [253]
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O
CH3
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Figure 73: Iron chelators and their Fe(III)-complexes.
Deferiprone belongs to the class of hydroxypyridin-4-one and has a high affinity for Fe(III).
Hydroxypyridin-4-one derivatives form a neutral 3:1 complex with Fe(III), where each hydroxy-
piridin-4-one is bi-dentate bound to Fe(III) (Figure 73). [253] Deferiprone comprises a lower
molecular weight of 139.15 g/mol than Deferoxamine (560.68 g/mol) and therefore might have
a higher diffusion rate through cellular plasma membranes. [253]
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Deferiprone and similar hydroxypyridin-4-one (HPO) derivatives have previously been as-
sessed as anti-malarial agents against P. falciparum. [130–132] In particular, the N-1 position has
been modified and these derivatives were evaluated for their anti-plasmodial activity and tox-
icity to mice or mammalian cells (K-562 cells). [130–132] Several aliphatic and carboxylic acid
functionalities have been introduced in position N-1, but all derivatives showed only moderate
activities (IC50 53-650µM) against P. falciparum. [131,132] However, anti-plasmodial activity of
these derivatives correlated well their the lipophilicity, as increasing chain-lengths improved
activity. [132] However, all derivatives showed also a significant toxicity against mammalian
cells. [131,132]
Acidocalcisomes are important cellular storage compartments for essential elements like
Ca(II), Fe(III) and Zn(II), as the free elements could cause the formation of radical species,
thus killing T. brucei, T. cruzi and L. infantum. [126,254] The 8-amino-quinoline Sitamaquine (Fig-
ure 5, p. 9), currently in clinical trials against visceral Leishmaniasis has been shown to ac-
cumulate within acidocalcisomes, although it has been shown not to be associated with its
anti-leishmanial activity (Chapter 1). [46] Molecules, which accumulate within acidocalcisomes
are consequently of particular interest, as combined with the ability to chelate iron, would
deprive these parasite from essential iron for its metabolic processes, leading to disruption
of signal transduction and gene regulation. [254] Chloroquine (Figure 74), the parent analogue
of Sitamaquine, has previously been shown to accumulate in acidic compartments of pro-
cyclic trypomastigotes of T. brucei and consequently inhibited the uptake of essential lipids for
growth. [255] But the role of chloroquine is even more ubiquitous, as it is taken up into acidic
acidocalcisomes of Leishmania donovani promastigotes, causing alkalisation thereof and re-
sulting in parasite death. [256]
This encouraging observation led to the synthesis of chloroquine (CQ) conjugated HPO
molecules, designed to accumulate within the acidocalcisome of protozoa. Here, a 4-amino-
quinoline ring system was conjugated over the N-1 position to the HPO core (Figure 74).
These CQ-HPO conjugates were designed to possess pKa values which allow accumulation of
the lysosomotropic chloroquine moiety into acidic compartments in parasites. [255,256] All basic
HPO-CQ derivatives posses three pKa values. Where, pKa1 corresponds to the protonation of
the 4-oxo group, pKa2 to the deprotonation of the nitrogen in the quinoline ring and pKa3 to the
dissociation of the proton from the 3-hydroxyl group (Figure 75). [257–259] The pKa values have
been estimated to be pKa1 3 and pKa3 10 based on similar substituted HPO derivatives. [259]
The pKa3 value was estimated based on the substituent in position 7 in CQ derivatives. [258]
Electron-withdrawing substituents such as chlorine (X=Cl) lower pKa3 to 7.6 (compared to
the unsubstituted analogue (X=H) pKa3 8.0). [258] Under physiological pH (pH 7.4), the major
species of the CQ-HPO conjugate exists in the neutral form 91c, facilitating membrane diffu-
sion. The pH in the acidic compartments in T. brucei is estimated to be between pH 4.6 -
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Figure 74: Conjugation strategy towards improved anti-parasitic HPO derivatives.
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Figure 75: HPO-CQ at different pH values; X=Cl or H
5.6. [255], favouring the protonation state of 91b and therefore trapping the charged analogue
within these acidic compartments.
In order to evaluate HPO derivatives against T. brucei, T. cruzi and L. infantum, modifica-
tions on the N-1 substituent were studied. Of particular interest were N-1 substituents with
a CQ-like moiety, designed to accumulate within acidic compartments in parasites, possibly
showing diminished toxicity towards mammalian cells.
Similar chloroquine conjugation strategies have previously been studied as anti-parasitic
agents against Malaria, Leishmaniasis, and Trypanosomiasis. [260] However, the previous chloro-
quine moieties were conjugated to an organo-metallic functionality, there a synergistic effect
of lipophilicity and basicity from the CQ-moiety and toxicity from the organometallic complex
led to low µM in vitro activity (IC500.9-10.3µM). [260]
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The activity of the CQ-HPO conjugates in this study was evaluated against a broad range
of protozoa, including T. brucei, T. cruzi, L. infantum and their mode-of-action was analysed.
7.2 Synthesis of iron chelating agents
7.2.1 Previous synthesis of HPO iron chelators
This section describes the general synthetic strategy towards simple N-1 alkyl substituted
HPO iron chelators as reported in the literature. [261] This synthetic strategy is explained in
detail because the synthesis of novel HPO-CQ conjugates followed a similar strategy.
Simple N-1-substituted HPO derivatives have previously been synthesised starting from
maltol 92a. [261] In the first step, the hydroxy-group in maltol was protected as its benzyl ether
(Scheme 52, (i)). Therefore maltol was subjected to benzyl bromide in the presence of
NaOH (90 % in water). [261] Subsequently, the benzyl protected maltol 92b was conjugated
to various primary amines under base-catalysed double Michael addition reaction conditions
(Scheme 52, (ii)). [261] In the final step of the reaction sequence the benzyl protection group
of the double Michael addition product 93 was cleaved under acidic hydrolysis or catalytic hy-
drogenation to afford the final HPO iron chelator 94 (Scheme 52, (iii)). [261] Simple N-1 alkyl
substituted HPO derivatives were provided by Prof. Robert Hider (KCL, London, UK).
O CH3
O
OR
(ii)
N CH3
O
OBn
R1
(iii) or (iv)(i) R=H
R=Bn
92a
92b
93
94
Scheme 52: Synthesis of simple N-1-substituted HPO derivatives as reported in the literature;
R1=alkyl; (i) NaOH, MeOH (90 % in water), 100 ◦C; (ii) NaOH, pH 12, EtOH (50 %
aqueous solution), 100 ◦C; (iii) HCl (6 N), 100 ◦C; (iv) Pd/C, H2, EtOH (aq, pH 1).
7.2.2 Synthesis of CQ-HPO conjugated derivatives
The novel CQ-HPO conjugated iron chelators were synthesised analogously to previously
reported N-1-modifications of HPO derivatives. [261] The key step of the synthesis was a double
Michael addition reaction between various amines and the benzyl protected maltol 92b. Two
routes have been pursued for the synthesis of the CQ-HPO conjugates.
216
7 Iron chelating agents - hydroxypyridinones
In the first route (Route A, Scheme 53), the amino linker was installed onto the chloroquine
fragment 95 prior to double Michael addition to 92b. 4,7-Dichloroquinoline 95 was reacted with
excess diaminobutane in neat solution at 160-180 ◦C (Scheme 53, (i)). The desired amino-
quinoline 96 was afforded after re-crystallisation from methanol and diethyl ether as white
crystals in good yields of 62 %. Alternatively, the amino-quinoline could be obtained after col-
umn chromatography of the crude reaction mixture, although the excess of 1,4-diaminobutane
decreased the yield to 52 %.
N
O
OR2
CH3
NH
N R1
Cl
NCl
HN
NCl
NH2
4
N
O
OR2
CH3
H2N 4
O
O
OR2
CH3
(i)
(iv)
(ii)
(v)
4
ROUTE A
ROUTE B
(vi) or (vii)
PRODUCT
(iii)
R2=H
R2=Bn
R1=Cl, R2=Bn
R1=Cl, R2=H
R1-R2=H
52-62 % 50-74 %
54-59 %
95 96
97
98a
98b
92a
92b 99
Scheme 53: Synthesis of CQ-HPO conjugate derivatives; Reagents and conditions: (i) 1,4-
diaminobutane (5 equiv.), 160-180 ◦C, 18h; (ii) 92b, 2 N NaOH, pH 13, aqueous
EtOH (25 %), reflux, 12h; (iii) NaOH (1.1 eq.), BnBr (1.1 eq.), aq. MeOH (50 %),
reflux, 6h; (iv) 1,4-diaminobutane (1 equiv.), 10 N NaOH, pH 13, reflux, 18h; (v)
95, (1 equiv.), DMSO, 100-110 ◦C, 12h; (vi) 6N HCl, reflux, 2h; (vii) 5% Pd/C, H2,
ethanol, aq. HCl.
The amino-quinoline 96 was subjected to double Michael addition reaction with the benzyl
protected maltol 92b (Scheme 53, (ii)). The reaction was carried out in aqueous ethanol
(25 % H2O) in the presence of catalytic amounts of NaOH. The base-catalysed double Michael
addition reaction was pH sensitive. Therefore it was crucial to adjust the pH to 13 in order
to improve the yield of reaction to 74 %. In the final step of the reaction towards the novel
HPO-CQ conjugates, the precursor 97 was debenzylated under acidic hydrolysis in 6N HCl(aq)
(Scheme 53, (vi)). The desired CQ-HPO conjugated iron chelator 98a (R1=Cl, R2=H) was
afforded as its chloride salt, which was filtered, washed with acetone and recrystallised to
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obtain the product 98a in good yields of 54-59 %.
Alternatively, the double Michael addition can be executed prior to linking the amino-
residue to the quinoline moiety (Route B, Scheme 53). Initially, maltol was protected with ben-
zyl bromide in aqueous methanol ((v/v), 50 %) to yield 92b in good yields of 81 % (Scheme 53,
(iii)). 92b was subjected to 1,4-diaminobutane to give access to the double Michael addition
product 99 in good yields of 50 % (Scheme 53, (iv)). The amino-HPO 99 was conjugated to
the quinoline moiety by nucleophilic substitution with 4,7-dichloroquinoline (Scheme 53, (v)).
This alternative access to 97 gave a lower yield of only 20 % compared to Route A. The final
deprotection of the benzyl group was achieved through catalytic hydrogenation (Scheme 53,
(vii)), which also cleaved the 7-chloro substituent on the quinoline moiety. The desired iron
chelator product (R1-R2=H) 98b was obtained in quantitative yields after deprotection.14
In order to compare the activity of the novel CQ-HPO conjugates to previous simple N-
alkyl modified analogues, several iron chelators have been kindly donated by Prof. Robert
Hider (King’s College London, London, UK) (Table 68). Simple N-alkyl HPO derivatives are
synthesised under the same double Michael addition reaction between benzyl-protected maltol
92b and various primary amines. [261]
Table 68: Simple N-Alkyl HPO derivatives provided by Prof. Robert Hider (King’s College
London, London, UK).
(a)
N
O
OH
R
CH3
(b)
# R
101a CH3
101b (CH2)7CH3
101c (CH2)9CH3
101d (CH2)2NH2
7.3 Anti-parasitic activity
The iron-chelators were screened against T. brucei, T. cruzi trypomastigotes and L. infantum
promastigotes using the activity assays described previously in chapter 3.3.1.
14The final iron chelating agent 100a was synthesised by Karin Pleban and the synthesis described in this
alternative approach was only carried out until the protected analogue 97 (Prof. Hider group, KCL, London,
UK)
218
7 Iron chelating agents - hydroxypyridinones
7.3.1 Anti-parasitic activity of simple aliphatic N-1-substitution of the HPO moiety
The simplest iron chelator 101a, also known as Deferiprone, was substituted with a methyl
group in N-1 position of the HPO core. 101a did not display any anti-parasitic activity at
100µM. However, substituting the N-1 aliphatic side chain to a octanyl (101b) or decanyl
(101c) aliphatic substituent not only increased lipophilicity, but also cytotoxicity. The iron-
chelators 101b and 101c displayed anti-parasitic activity against T. brucei, T. cruzi and L. in-
fantum (GI50 0.7-3.7µM), but were also toxic against HL60 cells (GI50 6.3-13.4µM). Although,
these HPO derivatives displayed general cytotoxicity against both parasitic and mammalian
cells, they may possess great potential, if selectivity of these derivatives towards parasites
could be improved.
Table 69: Anti-parasitic activity of simple N-alkyl modified HPO derivatives.
N
O
OH
R
CH3
GI50 [µM]
# R T. brucei SI T. brucei T. cruzi L. infantum HL60
101c (CH2)9CH3 1.4±0.1 5 0.9±0.1 0.7±0.1 6.3±0.2
101b (CH2)7CH3 3.7±0.2 4 3.0±0.3 3.2±0.4 13.4±2.6
101a CH3 >100 >1 >100 >100 >100
101d (CH2)2NH2 >100 >1 >100 >100 >100
7.3.2 Improved selectivity through CQ conjugation strategy
Initially, the amino-quinoline precursor 96 was evaluated for its anti-parasitic activity. 96 dis-
played moderate activity against T. brucei, T. cruzi and L. infantum while showing no toxicity
against HL60 cells 100µM (Table 70). Conjugation of 96 with HPO improved anti-parasitic
activity in T. brucei and T. cruzi, resulting in low µM inhibitors (GI50 3.6-27.1µM) compared to
CQ activity alone. However in L. infantum the CQ-conjugation resulted in a decreased activity
for 98a. Removal of the 7-chloro substituent on the quinoline moiety in compound 98b resulted
in complete loss of activity in L. infantum and T. cruzi at 100µM. Interestingly, anti-parasitic
activity against T. brucei was retained at GI50 7.6µM.
Although 98b is more basic than 98a, as can be concluded by the substitution in position
7 in the quinoline ring, it was less active against T. brucei, T. cruzi and L. infantum. [258] In-
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deed, the pka values of 98b and 98a have been experimentally determined to be 7.90 and
7.77 respectively.15 Therefore, the fraction of membrane permeable CQ-HPO conjugates (un-
protonated) is relatively small according to the Henderson-Hasselbalch equation (98a: 30 %,
98b: 24 %) at physiological pH (7.4). Although the membrane-permeable fractions were rel-
atively small, they were still 3 times better than for chloroquine itself (pka:8.5, 7.4 %) at pH
7.4. However, optimisation of the quinoline pKa could potentially improve anti-parasitic activ-
ity in this series. For example substitution of the 7-chloro to a nitro group would make these
derivatives more acidic (pka 6.28) [258], therefore improving their membrane permeability.
However, the weak activity of 98b suggested other factors responsible for the weak anti-
parasitic activity against T. cruzi and L. infantum.
Table 70: CQ-conjugated iron chelator and their anti-parasitic activity.
HN
NCl
NH2
4
N
O
OH
CH3
NH
N R1
4
98a and 98b 96
GI50 [µM]
# R T. brucei SI T. brucei T. cruzi L. infantum HL60
98a Cl 3.6±0.9 14 6.5±0.1 27.1±7.0 50.5±0.9
98b H 7.6±0.4 >13 >100 >100 >100
96 n.a. 15.8±1.3 >6 39.2±4.1 42.4±4.8 >100
CQ 14.5±1.3 >6 12.8±2.9 3.6±0.1 >100
7.4 Target identification studies
7.4.1 Transferrin uptake in T. brucei
The CQ moiety in derivatives 98a and 98b have been designed to selectively accumulate
within parasitic compartments, while the HPO fragment chelates essential Fe(III), causing iron
starvation of the protozoa. In order to validate this mode-of-action, the effect of 98a was
15Personal Communication with Prof. Hider, King’s College London, 2012
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Figure 76: Mean Fluorescene Intensity of fluorescein labelled transerrin recorded by flow-
cytometry using a DB Accuri C6 flow-cytometer.
studied in live trypanosomes. T. brucei is known to up-regulate transferrin receptor (TbTfR)
expression if suffering from iron deprivation. [212]Therefore, TbTfR can be used as an indicator
for iron starvation in T. brucei. [212] In order to quantify the uptake of transferrin, T. brucei was
pre-incubated with the iron-chelator 98a for 24 h. After this incubation time the parasites should
have increased the number of TbTf receptors, if indeed suffering from iron starvation. Next,
T. brucei was deprived from transferrin the main Fe(III) source by washing with transferrin-
free Baltz-medium. Incubation with fluorescein-labelled transferrin allowed the quantification
of transferrin-uptake by measuring of the mean fluorescence intensity with flow-cytometry (Fig-
ure 76). Iron starvation by the known iron chelator Deferoxamine resulted in an increase of
transferrin uptake by a factor of 2 as compared to treatment with DMSO only. The uptake
of fluorescence labelled tranferrin for 98a was increased by a factor of 1.6, suggesting iron
starvation as possible contributor to trypanocidal activity of CQ-HPO conjugates in T. brucei.
7.4.2 Fe(III) saturation experiments
Measuring the uptake of fluorescence labelled transferrin after pretreatment of the CQ-HPO
conjugate 98a suggested Fe(III) chelation at least in part as contributor to trypanocidal ac-
tivity against T. brucei. In order to further support the hypothesis that iron chelation is the
major mode-of-action of CQ-HPO conjugates T. brucei was treated with pre-saturated 98a in
FeCl3 solution (1:3 ratio). Similar experiments have been carried out for confirming iron chela-
tion in Deferoxamine as major contributor to anti-trypanosomal activity. [262] It was assumed,
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that the CQ-HPO-Fe(III) complex would still be able to penetrate the parasitic membrane, as
HPO-Fe(III) complexes do not have a formal charge and are known to cross through liposome
membranes. [253] Saturation of the CQ-HPO iron chelator with FeCl3 solution resulted in a com-
plete loss of trypanocidal activity against T. brucei consistent with the hypothesis that iron
chelation is the major mode-of-action of CQ-HPO conjugates 98a and 98b. The excess Fe(III)
ions most likely scavenge all the free iron chelator, leaving enough iron for parasite survival.
7.5 Discussion
Iron chelation is a good strategy for the development of novel anti-parasitic agents. Simple
N-1 alkyl substituted HPO derivatives 101a–d are generally cytotoxic against parasites and
mammalian cells. In contrast, the CQ-HPO show selectivity against parasitic protozoa, while
being only moderate toxic against HL60 cells. The activity of the CQ-HPO 98a against T. bru-
cei and T. cruzi is improved compared to the parent Deferifprone 101a and CQ alone, thus
suggesting a synergistic effect between the HPO and CQ fragments. Flow-cytometry experi-
ments suggested iron-chelation was at least in part responsible for anti-trypanosomal activity
of the CQ-HPO conjugate 98a. Furthermore, saturation of the iron chelator 98a with FeCl3
resulted in a complete loss of trypanocidal activity, supporting the theory of iron chelation as
mode-of-action. The novel CQ-HPO conjugates are promising leads for the development of
more potent anti-parasitic agents. Changing the acidity of the quinone nitrogen might fur-
ther improve membrane permeability of these derivatives and therefore increase anti-parasitic
activity. Substitution of the quinoline nitrogen could result in a smaller percentage of the proto-
nated iron-chelator conjugate and therefore could facilitate diffusion through the plasma mem-
brane. A further experiment would be the localisation of the drug target within the parasites.
Due to the basic pH of the HPO-CQ conjugated iron chelators, accumulations within acidic
compartments such as acidocalcisome are possible. In order to confirm the accumulation of
the HPO-CQ iron chelators a ligand displacement assay could be performed. Previously, the
fluorescent probe Lysotracker Green, which accumulates in acidic organelles in live cells, was
shown to be displaced by the chloroquine analogue Sitamaquine by alkalysation of this com-
partment in Leishmania. [46] A similar experiment could be performed with the HPO-CQ iron
chelators in this study, as the pH of this derivatives should be basic enough to displace Lyso-
tracker Green, if accumulated within the acidocalcisome of T. brucei, T. cruzi or L. infantum.
However, even without knowing the exact compartment of accumulation, the experiments in
this study have shown, that iron chelation is a possible major contributor to the anti-parasitic
activity.
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7.6 Summary
1 iron HPO-CQ conjugated iron chelator (102a) has been synthesised.
8 derivatives have been assessed in a whole cell activity assay for anti-parasitic activity against
T. brucei, T. cruzi and L. infantum.
Simple N-alkyl substituted HPO iron chelators showed low µM activity against all three proto-
zoa (GI50 0.7-3.7µM, SI 4-9), but also high toxicity against HL60 cells.
The HPO-CQ conjugated iron chelator 98a (R7=Cl) retained low µM activity against T. brucei,
T. cruzi and L. infantum (GI50 3.6, 6.5 and 27.1µM, SI 14, 8, 2 respectively), but displayed
improved selectivity.
The replacement of the chloro-substituent in position 7 of the quinone moiety in the HPO-CQ
iron chelator (R7=H) abolished activity against T. cruzi and L. infantum, while activity against
T. brucei was reduced by a factor of 2 (GI50 7.6µM, SI 13).
Mode-of-action studies with the HPO-CQ iron chelator 98a, using flow- cytometry have shown
an upregulation of TbTf receptors, indicating iron starvation as major course of anti-trypanosomal
activity in T. brucei. [212] Further iron saturation studies abolished anti-trypanosomal activity in
vitro, thus supporting iron chelation as a possible mode-of-action.
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8 Conclusion and outlook
The aim of this research study was to identify small molecular inhibitors with anti-parasitic
activity against T. brucei, T. cruzi and L. infantum. Therefore whole cell phenotypic screening
assays were performed to identify and optimise promising candidates, leading to low µM active
inhibitors with good selectivity. Particular interesting targets studied in this thesis were GPI-
anchor biosynthesis and iron chelation therapy.
The development of anti-parasitic agents against enzymes involved in GPI-anchor biosyn-
thesis started with a lead structure (Figure 77), known to be a good inhibitor of DPMS in T.
brucei. [68] Although rhodanine-N-acetic acid derivatives were identified as small molecular in-
hibitors able to inhibit DPMS in T. brucei, the in vitro trypanocidal effect was negligible (ED50
96µM), compared to for example melarsoprol (1.7 nM). Therefore several modifications on
this molecular scaffold were performed and their anti-parasitic activity was assessed in whole
parasite activity assays against T. brucei, T. cruzi and L. infantum.
Analysis of the 379 thiazolidine-4-one and related pyrazole-5-one derivatives revealed a
trend between the anti-trypanosomal activity and the N-3 substitution (Figure 77). There-
fore derivatives carrying a N-carboxylic acid/ester or a N-allyl functional group showed low
µM activity, whereas N-unsubstituted, N-amino or N-phenyl-substitution resulted in moderate
activities against parasites. Scaffold replacement with a pyrazole-5-one moiety resulted in
moderate inhibition of parasitic growth. However, there were some interesting exceptions from
this general trend, such as a catechol or a benzylidene 3-benzyloxy motif in position 5 of the
thiazolidine-4-one scaffold.
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Figure 77: Overview of rhodanine and rhodanine-like compounds with anti-parasitic activity, highlighted structures were analysed for
their mode-of-action.
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In the case of the catechol moiety, exactly the opposite trend was observed, where the
catechol moiety was essential for low µM activity, while the thiazolidine-4-one moiety had a
secondary role. Careful analysis of the logP values of all catechol derivatives elucidated a
trend to the trypanocidal activity (Table 71), where an increased logP resulted in low-µM ac-
tivity.
Compound 55o was particular interesting as it has previously been identified as nM in-
hibitor of enoyl acyl carrier protein reductase (IC50 35.6 nM), an essential enzyme in the fatty
acid synthesis II pathway, with in vitro activity against P. falciparum (IC50 0.75µM). [263] How-
ever, T. brucei, T. cruzi and L. infantum do not have a fatty acid synthesis II pathway, in-
stead these parasites salvage lipids from their hosts through an elongase (ELO) pathway. [264]
Elongation of fatty acids in these parasites involves the action of two flavin-cofactor depen-
dant reductases (β-Ketoacyl-CoA reductase and Trans-2-enoyl-CoA reductase). [264] Catechol
rhodanine derivatives, previously been shown to mimic the NAD(P)H cofactor substrate and
therefore described as a "privileged scaffold for dehydrogenases", [107,108,265] would be poten-
tial inhibitors of the reductases in the ELO pathway. T. brucei is particularly dependant on de
novo synthesis of myristate for the incorporation of the protective GPI-anchored VSG-proteins,
which are essential for survival of the bloodstream form of T. brucei. [64,264] Also T. cruzi and L.
infantum are dependant on an ELO pathway to express lipid-functionalized proteins, respon-
sible for virulence, on their plasma membrane. [264] A possible strategy to monitor inhibition
of the ELO-pathway as mode-of-action in living parasites would be the measurement of de
novo synthesised myristate. This can potentially indirectly be achieved by the incubation of
T. brucei in myristate-free media, inducing de novo synthesis of myristate for GPI-anchored
VSG protein incorporation. One such GPI-anchored protein is the transferrin receptor of T.
brucei, responsible for iron uptake via host-transferrin. The amount of uptake of FITC-labelled
transferrin would be a measure for successful myristate incorporation in the GPI-anchored
TbTf receptor.Inhibitors of the ELO-pathway would reduce the de novo synthesis of myristate
and consequently lead to a reduction of GPI-anchored TbTf receptors, reducing the uptake of
FITC-labelled transferrin. This could potentially be quantified by flow-cytometry analysis. This
experiment would be analogous to the previously described experiments with DPMS and/or
MT-1 inhibitors (Chapter 3.5.2).
Alternatively, an in-gel-affinity approach as described in Chapter 3.6 could be pursued.
There the fluorescent catechol rhodanine-N-acetic acid 2u could be applied to a western blot
gel, washed and the remaining 2u could be visualised via fluorescence. But this is not the
only possible target for this kind of catechol derivative. Recently, catechol modified rhodanine
derivatives have been studied as tyrosyl-DNA phosphodiesterase I inhibitors with µM activ-
ity (IC50 2.6µM). [122] Interestingly Furamidine, the active reagent of the prodrug DB-289 (re-
cently in clinical phase III against HAT until development was discontinued due to liver and
226
8 Conclusion and outlook
Table 71: Importance of catechol-modified inhibitors on antitrypanosomal activity.
OH
OH
GI50 [µM]
# R logP T. brucei T. cruzi L. infantum HL60
35c
N S
O
O
4.13 1.4±0.1 >100 >100 n.a.
35g
N S
O
S
4.08 5.7±0.1 >100 20.7±7.4 n.a.
55o
N S
O
S
4.01 4.7±0.9 n.a. >100 n.a.
35h
N S
O
O
3.12 5.6±0.8 n.a. >100 n.a.
40t
N S
O
S
3.09 1.2±0.1 n.a. >100 >100
80ak
N N CH3
O 2.97 17.3±0.1 n.a. n.a. >100
35i NH
O
2.96 11.0±0.6 >100 >100 n.a.
35j N
O
CH3 2.89 4.6±0.8 >100 >100 n.a.
16i
N S
O
SEtO
O 2.86 1.35±0.3 n.a. 54.6±0.4 29.0±4.2
35k N
O
CH3 2.83 5.2±0.1 >100 >100 n.a.
15f
N S
O
SO
EtO
2.57 0.9±0.1 n.a. 45.9±15.1 31.2±2.8
14t
N S
O
S
O
EtO
2.34 1.6±0.1 n.a. n.a. >100
70c
N S
O
N
2.25 18.2 >100 >100 >100
41i
N S
O
O
2.20 5.0±0.6 n.a. >100 83.4±0.3
69j
N S
O
S
O
OEt
2.18 >100 >100 >100 >100
36a
HN S
O
S
2.13 13.3±1.1 >100 >100 45.0±9.3
12m
N S
O
S
HO
O
2.07 14.2±2.3 >100 >100 >100
14s
N S
O
SMeO
O 1.98 10.1±1.6 >100 >100 23.6±1.1
54t
N S
O
S
H2N
1.84 17.5±0.2 n.a. >100 82.8±10.1
2u
N S
O
SO
HO 1.83 >100 >100 >100
7k
N S
O
OO
EtO 1.45 1.4±0.2 >100 >100 >100
48p
HN S
O
O
1.24 >100 n.a. n.a. >100
35a
N S
O
SH2N
O 1.03 17.7±0.1 >100 >100 n.a.
35a–k were provided by Prof. Dr. Schlitzer, Germany.
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renal-toxicity [28,29]), has been shown to be an inhibitor for tyrosyl-DNA phosphodiesterase I in
humans and therefore have potential as anti-cancer therapy. [266]
These results imply that catechol modified rhodanine derivatives could potentially have
a similar mode-of-action to those previously described for Pentamidine analogues. If this
hypothesis is correct, then this would be significant, as Pentamidine analogues suffer from
drug-resistance through loss of the P2 transporter in trypanosomes, which is essential for
drug-uptake of Pentamidine and Melarsoprol. [32] The diverse chemical scaffold of the catechol
rhodanine could suggest a different drug transporter mechanism, possibly counter-acting re-
sistance in T. brucei. Pentamidine analogues are not only excellent anti-trypanosomal agents,
but are ideal to study drug accumulation though their fluorescent properties. [267] Also the cat-
echol rhodanine-N-acetic acid derivative 2u has been identified as weak fluorophore, [108] and
depending on the possible accumulation of this fluorophore in cellular compartments of T. bru-
cei, flow cytometry could be used to quantify the uptake in live trypanosomes and fluorescence
microscopy might be used to localise these cellular compartments. A localisation close to
the kinetoplast or nucleus would suggest a mode-of-action similar to Furamidine. [267] Besides
these possible advantages, catechol rhodanine derivatives are potentially also toxic to hu-
mans, as a study has shown that the catechol-rhodanine scaffold bound to many NAD(P)H de-
pendant liver-proteins. [265] But studies on catechol derivatives, described in this thesis showed
that toxicity against HL60 cells depended on the type of rhodanine-scaffold used and in par-
ticular on the N-3 substitution of the rhodanine-moiety, implying that these inhibitors could be
designed to be parasite specific. At this point no conclusion about the molecular target of
catechol modified analogues can be drawn, but this compound class is very interesting for its
anti-trypanosomal activity and high selectivity (Table 71).
In the case of the benzylidene-3-benzyloxy substituent, activity against parasites was ob-
served to be similar to the catechol moiety. The benzylidene-3-benzyloxy modification resulted
in low µM activity against T. brucei, indendependent from N-3-substitution of thiazolidine-4-one
scaffold. Interestingly, scaffold replacement with a pyrazole-5-one moiety still resulted in good
anti-trypanosomal activity (GI50 13.6 and 13.7µM). Furthermore, the benzylidene-3-benzyloxy
rhodanine, N-allyl rhodanine and N-acetic acid rhodanine, have been shown in a radio-active
HPTLC GPI-synthesis assay to inhibit the first mannosyltransferase and/or DPMS. Compar-
ing the substrate band intensities of these HPTLC plates showed that the rhodanine-N-acetic
acid derivative (GI50 1.7µM) was the most active inhibitor of DPMS and/ or MT-1, then the
rhodanine-N-allyl (GI50 14.9µM), followed by the rhodanine derivative (GI50 13.1 (T. brucei)
and 12.4µM (T. cruzi)). Metabolic labelling with myristate analogues revealed that the 3-
benzyloxy rhodanine-N-acetic ester and the rhodanine-N-allyl rhodanine derivative inhibited
incorporation of myristate in the GPI-VSG-proteins. With the aid of flow cytometry and FITC-
labelling this inhibition could be quantified by a 1.6 and 2.7 fold reduction of transferrin uptake
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respectively. However, the reduction with the rhodanine-N-acetic ester analogue is more sig-
nificant, as could be seen in reduced FITC accumulations under the fluorescence microscope
and using the metabolic labelling approach, resulting in a total abolishment of the myristate-
VSG-proteins at 50 kDa. The rhodanine-N-acetic ester derivative showed trypanocidal activity
at the chosen inhibitory concentration, resulting in reduced cell numbers and consequently an
higher average of fluorescence signal, as fluorophore could accumulate within lysed cell com-
partments (see FM pictures Figure 41 and Figure 59). In an attempt to identify the molecular
target, a homology model of DPMS was used to design a photo-affinity probe to identify the
molecular target and potentially to identify active side residues via mass spectrometry.
The most interesting rhodanine derivative identified in this study was the 3-methyl benzyli-
dene rhodanine-N-acetic tert-butyl ester 14b, as it showed low µM activity against T. brucei, T.
cruzi and L. infantum (GI501.6, 5.1 and 2.4µM, SI 14, 5, 10). Detailed mode-of-action studies
for this derivative have been performed. The rhodanine-N-acetic ester derivative 14a showed
about 50 % reduction of labelled myristate-GPI-proteins, whereas the rhodanine-N-allyl deriva-
tive 40x showed only about 25 % reduction, conferring GPI-biosynthesis as molecular target in
both cases. The quantified FITC-labelled transferrin uptake showed a reduction in uptake by a
factor of 1.3 for the rhodanine-N-acetic ester, whereas the rhodanine-N-allyl derivative did not
show any reduction, supporting the previous results from the metabolic labelling with myristate
analogues that GPI-synthesis is inhibited. The cell-free GPI-synthesis assay showed that the
rhodanine-N-acetic acid derivative 2m was a strong inhibitor of the first mannosyltransferase
and possibly DPMS. Interestingly, only the tert-butyl ester 14b was active against L. infantum,
while the corresponding ethyl ester 14a did not show any anti-leishmanial activity at 100µM.
It may be possible that the bulky and lipophilic tert-butyl ester is necessary to pass through
the parasite plasma membrane, as a comparison of anti-leishmanial activity and logP in this
study has shown that high logP values resulted in low µM anti-leishmanial activity. In order to
confirm this hypothesis, several more tert-butyl ester analogues would need to be synthesised
and screened against L. infantum. Particularly interesting would be the synthesis of the tert-
butyl ester of the benzylidene-3-benzyloxy rhodanine-N-acetic acid, as the free acid (or ethyl
ester) has already been shown to inhibit the same molecular targets in the GPI-biosynthesis
in T. brucei (metabolic labelling (Figure 35), flow cytometry (Figure 39) and radio-labelling of
GPI-substrates (Table 25)).
Rhodanine-N-allyl derivatives have been shown not to inhibit enzymes of the GPI-anchor
biosynthesis in T. brucei in a cell-free GPI-synthesis assay. Instead, the 3-pyridinyl N-allyl
rhodanine derivative has been shown to undergo unspecific binding over its Michael accep-
tor system to glutathione. Using the Ellman’s reagent, this binding could be quantified to
a reactivity constant RC50, where half of the Michael acceptor reacted with glutathione, at
552.2µM after 50 min. Over longer time periods this reactivity could account for the low anti-
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trypanosomal activity (GI50 1.5µM). But Michael acceptor reactivity in previous studies with
rhodanine and thiazolidine-2,4-dione derivatives described the Michael addition reaction as
reversible. [85,86] The mode-of-action is unknown to this point, but Michael acceptor reactivity
alone seems unlikely, as selectivity against parasites compared to mammalian HL60 cells has
been observed.
In conclusion, GPI-anchor biosynthesis is a good target for the development of anti-parasitic
agents, although it seems to be difficult to identify inhibitors which are active against all three
parasites. In particular the carboxylic ester thiazolidine-4-one derivatives have great potential
for the development of more active inhibitors against parasite growth.
In the search for broad anti-parasitic agents against HAT, Chagas disease and Leishma-
niasis, iron chelation was studied as potential therapy. In this research study, oral available
iron chelators from the 4-Hydroxy-pyridinone (HPO) class were studied for their anti-parasitic
activity against T. brucei, T. cruzi and L. infantum. The results were compared to the bacterial
iron-chelator Deferoxamine and showed significant improvements in clearing parasitaemia in
vitro, but increased toxicity against HL60 was also observed. In order to improve selectiv-
ity, the HPO moiety was conjugated to an amino-chloroquine moiety, similar to chloroquine,
which is known to accumulate within acidic compartments like acidocalcisomes in T. brucei,
T. cruzi and L. infantum. [46,254,254–256] These acidocalcisomes are important storage compart-
ments for Zn2+, Ca2+ and Fe3+, [254] making them attractive targets for iron-chelating agents.
Indeed, the chloroquine conjugated HPO iron chelator 98a showed low µM activity against
T. brucei and T. cruzi (GI50 3.6 and 6.5µM, SI 14 and 8) and moderate activity against L.
infantum (GI50 27.1µM, SI 2). Interestingly, substitution of the 7-quinoline substituent from a
chlorine to a hydrogen, abolished activity in T. cruzi and L. infantum, while anti-trypanosomal
activity against T. brucei was retained at GI50 7.6µM (SI >13). Studies on the mode-of-action
in T. brucei showed that trypanosomal transferrin receptors (TbTfR) were over expressed if
subjected to the iron chelator 98a, suggesting that T. brucei was indeed deprived of iron. [212]
Saturation experiments with FeCl3 abolished anti-trypanosomal activity. Although this could
potentially just mean that the Fe(III)-complex with the CQ-HPO conjugate prevent membrane
diffusion, studies on similar HPO-Fe(III) complexes have shown membrane diffusion capabili-
ties, [253] conferring iron starvation as potential major contributor to anti-trypanosomal effects.
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9.1 Reagents, Materials and Equipment
All chemical reagents were purchased from commercial sources and were used as received,
unless otherwise noted. Dry solvents were obtained commercially or dried under standard
procedures. The reactions were carried out under normal atmosphere unless otherwise stated
in the procedure. Aqueous solutions and aqueous reaction solutions were prepared from Milli-
Q water. For analytical applications such as HPLC, solvents and reagents of analytical purity
had been used. The compounds were purified by flash chromatography and characterized by
1H-NMR, 13C-NMR, ESI-MS, HRMS-MS and TLC. Flash chromatography: Columns were
packed wet and the separation was carried out under 1 bar. 1H, 13C and 31P-NMR: Spectras
were recorded at 298 K on a Varian VXR 400 S spectrometer at 400 MHz, a Bruker Avance
DPX-300 at 300 MHz, a Bruker BioSpin at 400 MHz. Chemical shifts (δ) are reported in ppm
and coupling constants (J) in Hz. The signals are calibrated on the residual signals of CD3OD,
DMSO-d6 or CDCl3 (4.87 (49.00), 2.50 (39.52), 7.26 (77.16) respectively). High Resolution
Electrospray Ionization Mass Spectrometry: ESI-MS and HRMS-MS were performed on a
LTQ Orbitrap XL or on a Finnigan MAT 900 XLT mass spectrometer at the EPSRC National
Mass Spectrometry Service Centre, Swansea. Thin Layer Chromatography (TLC): TLC
was performed on precoated aluminium plates (Silica Gel 60 F254, Merck). Compounds were
visualized by exposure to UV light (254/365 nm) or by staining with Ninhydrin/Molobdic acid/
KMnO4 solution. Analytical HPLC was carried out on a PerkinElmer Series 200 machine
equipped with a SupelcosilTM LC-18-T column (5 µm, 25 cm x 4.6 mm), a column oven (set
to 35 ◦C), and a diode array detector. Compound purity was determined under the following
conditions: 0-100 % MeOH over 60 mins (flow rate: 1 mL/min); detection wavelengths: 280
and 354 nm.
9.2 General Procedures for Synthesis of 5-Benzylidene rhodanine
N-acetic acid derivatives 2a–ai
Rhodanine N-acetic acid (1.0 eq), corresponding benzaldehyde (1.1-1.5 eq) and piperidine (1-
2 drops) or sodium acetate (1.0 eq) were dissolved in ethanol or methanol. The reaction mix-
ture was stirred at 80 ◦C for 2-16 h. Upon cooling a yellow to orange solid precipitated and was
filtered and washed with ethanol or methanol.
[(5Z)-4-oxo-5-(phenylmethylidene)-2-sulfanylidene- 1,3-thiazolidin-3-yl] acetic acid 2a [268]
Reaction time: 2 h; Purification: Filtration from methanol; Yield: 71 mg of yellow solid (0.25
mmol, 72 %); 1H-NMR (400 MHz, DMSO-d6) δ= 4.75 (s, 2 H, CH2), 7.51-7.60 (m, 3 H, 3xAr-
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CH), 7.65-7.71 (m, 2 H, 2xAr-CH), 7.91 (s, 1 H, CH), 13.47 (s(br), 1 H, COOH) ppm; 13C-
NMR (400 MHz, DMSO-d6) δ= 45.1 (CH2), 121.9 (Ar-C), 129.6 (Ar-CH), 130.8 (Ar-CH), 131.3
(Ar-CH), 132.8 (Ar-C), 134.0 (CH), 166.4 (C=O), 167.3 (COOH), 193.3 (C=S) ppm; HPLC-
Analysis (Method B): 93 %, Rt = 17.7 min.
[(5Z)-5-[4-(benzyloxy)phenyl]methylidene-4-oxo-2- sulfanylidene-1,3-thiazolidin-3-yl] acetic acid
2b [68]
Reaction time: 4 h; Purification: Filtration from methanol; Yield: 52 mg of yellow solid (0.13
mmol, 24 %); 1H-NMR (400 MHz, DMSO-d6) δ= 4.73 (s, 2 H, CH2), 5.21 (s, 2 H, CH2), 7.21 (d,
2 H, 3JH,H = 8.8 Hz, 3,5-Ar-CH), 7.32-7.49 (m, 5 H, 5xAr-CH), 7.65 (d, 2 H, 3JH,H = 8.8 Hz, 2,6-
Ar-CH), 7.86 (s, 1 H, CH), 13.32 (s)br), 1 H, COOH) ppm; 13C-NMR (400 MHz, DMSO-d6) δ=
45.0 (CH2), 69.6 (CH2), 116.0 (3,5-Ar-CH), 118.6 (Ar-C), 125.6 (Ar-C), 127.9 (Ar-CH), 128.1
(Ar-CH), 128.5 (Ar-CH), 133.1 (2,6-Ar-CH), 134.1 (CH), 136.4 (Ar-C), 162.3 (C=O), 167.4
(COOH), 193.1 (C=S) ppm; ESI-MS m/z (%) = 384.0 [M−H]− (100 %), 769.1 [2M−H]− (73 %);
HPLC-Analysis (Method B): 93 %, Rt = 17.7 min.
[(5Z)-5-[3-(benzyloxy)phenyl]methylidene-4-oxo-2- sulfanylidene-1,3-thiazolidin-3-yl] acetic acid
2c [68]
Reaction time: 2 h; Purification: Filtration from ethanol; Yield: 311 mg of yellow solid (0.81
mmol, 82 %); 1H-NMR (400 MHz, DMSO-d6) δ= 4.73 (s, 2 H, CH2), 5.19 (s, 2 H, CH2), 7.20
(dd, 1 H, 3,4JH,H = 8.3, 2.5 Hz, 4-Ar-CH), 7.23-7.26 (m, 1 H, 6-Ar-CH), 7.28-7.30 (m, 1 H, 2-
Ar-CH), 7.32-7.37 (m, 1 H, Ar-CH), 7.38-7.43 (m, 2 H, 2xAr-CH), 7.46-7.52 (m, 2 H, 3xAr-
CH), 7.86 (s, 1 H, ) 13.54 (s(br), 1 H, COOH) ppm; 13C-NMR (400 MHz, DMSO-d6) δ= 45.1
(CH2), 69.5 (CH2), 116.6 (2-Ar-CH), 118.1 (4-Ar-CH), 122.3 (Ar-C), 123.0 (6-Ar-CH), 127.8
(Ar-CH), 128.0 (Ar-CH), 128.5 (Ar-CH), 130.7 (Ar-CH), 133.8 (Ar-C), 134.2 (CH), 136.6 (Ar-
C), 158.8 (Ar-C), 166.3 (C=O), 167.3 (COOH), 193.2 (C=S) ppm; ESI-MS m/z (%) = 343.1
[M+H]+ (90 %), 365.0 [M+Na]+ (30 %), 702.1 [2M+NH4]+ (100 %), 707.1 [2M+Na]+ (50 %),
1044.2 [3M+NH4]+ (30 %), 1049.1 [3M+Na]+ (20 %); HR-MS m/z = 343.0573 [M+H]+ (calcu-
lated: 343.0569); HPLC-Analysis (Method B): 100 %, Rt = 20.2 min.
[(5Z)-5-[3,4-bis(benzyloxy)phenyl]methylidene-4- oxo-2-sulfanylidene-1,3-thiazolidin-3-yl] ace-
tic
acid 2d [68]
Reaction time: 2 h; Purification: Filtration from methanol; Yield: 403 mg of yellow solid
(0.70 mmol, 54 %); 1H-NMR (400 MHz, DMSO-d6) δ= 1.48-1.56 (m, 2 H, Piperidine-CH2),
1.57-1.66 (m, 4 H, Piperdine-CH2), 2.95 (t, 4 H, 3JH,H = 6.0 Hz, Piperidine-CH2), 4.57 (s, 2 H,
CH2COOH), 5.22 (s, 2 H, CH2), 5.24 (s, 2 H, CH2), 7.22-7.49 (m, 13 H, 13xAr-CH), 7.74 (s,
1 H, CH), 9.06 (s(br), 1 H, NH) ppm; 13C-NMR (400 MHz, DMSO-d6) δ= 21.8 (Piperidine-
CH2), 22.2 (2xPiperidine-CH2), 43.5 (2xPiperidine-CH2), 46.2 (CH2COOH), 69.9 (CH2), 70.1
(CH2), 114.2 (Ar-CH), 115.9 (Ar-CH), 119.4 (Ar-C), 125.4 (Ar-C), 125.9 (Ar-CH), 127.6 (2xAr-
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CH), 128.0 (Ar-CH), 128.5 (2xAr-CH), 133.5 (CH), 136.6 (Ar-C), 136.8 (Ar-C), 148.3 (Ar-C),
150.9 (Ar-C), 166.6 (C=O), 167.4 (COOH), 193.1 (C=S) ppm; ESI-MS m/z (%) = 490.1 [M−H]−
(100 %), 981.5 [2M−H]− (25 %); HPLC-Analysis (Method B): 96 %, Rt = 21.4 min.
[(5Z)-5-[(2-hydroxyphenyl)methylidene]-4-oxo-2- sulfanylidene-1,3-thiazolidin-3-yl] acetic acid
2e [68]
Reaction time: 2 h; Purification: Filtration from methanol; Yield: 202 mg of red solid (0.68
mmol, 45 %); 1H-NMR (400 MHz, DMSO-d6) δ= 4.73 (s, 2 H, CH2), 6.95-7.01 (m, 2 H, 2xAr-
CH), 7.35-7.41 (m, 2 H, 2xAr-CH), 8.04 (s, 1 H, CH), 10.84 (s(br), 1 H, OH), 13.45 (s(br), 1 H,
COOH) ppm; 13C-NMR (400 MHz, DMSO-d6) δ= 45.0 (CH2), 116.4 (Ar-C), 119.8 (Ar-C) 120.1
(Ar-CH), 120.3 (Ar-CH), 129.7 (Ar-CH), 129.9 (CH) 133.4 (Ar-CH), 157.7 (Ar-C), 166.6 (C=O),
167.4 (COOH), 193.8 (C=S) ppm; HPLC-Analysis (Method B): 100 %, Rt = 20.2 min.
[(5Z)-5-[(3-hydroxyphenyl)methylidene]-4-oxo-2- sulfanylidene-1,3-thiazolidin-3-yl] acetic acid
2f [68]
Reaction time: 3 h; Purification: Filtration from methanol; Yield: 205 mg of red solid (0.69
mmol, 84 %); 1H-NMR (400 MHz, DMSO-d6) δ= 4.71 (s, 2 H, CH2), 6.93 (d, 1 H, 3JH,H =
7.9 Hz, 4-Ar-CH), 7.01 (s, 1 H, 2-Ar-CH), 7.09 (d, 1 H, 3JH,H = 7.4 Hz, 6-Ar-CH), 7.35 (dd,
1 H, 3JH,H = 7.9, 7.4 Hz, 5-Ar-CH), 7.77 (s, 1 H, CH) ppm; 13C-NMR (400 MHz, DMSO-d6)
δ= 45.1 (CH2), 116.5 (2-Ar-CH), 118.7 (4-Ar-CH), 121.7 (Ar-C), 122.2 (6-Ar-CH), 130.7 (5-Ar-
CH), 134.0 (Ar-C), 134.2 (CH), 158.1 (Ar-C), 166.4 (C=O), 167.4 (COOH), 193.3 (C=S) ppm;
ESI-MS m/z (%) = 294.0 [M−H]− (79 %), 589.0 [2M−H]− (100 %); HPLC-Analysis (Method
B): 93 %, Rt = 15.8 min.
[(5Z)-5-[(4-hydroxyphenyl)methylidene]-4-oxo-2- sulfanylidene-1,3-thiazolidin-3-yl] acetic acid
2g [268]
Reaction time: 2 h; Purification: Filtration from methanol; Yield: 176 mg of red solid (0.60
mmol, 45 %); 1H-NMR (400 MHz, DMSO-d6) δ= 4.72 (s, 2 H, CH2), 6.95 (d, 2 H, 3JH,H =
8.7 Hz, 3,5-Ar-CH), 7.54 (d, 2 H, 3JH,H = 8.7 Hz, 2,6-Ar-CH), 7.79 (s, 1 H, CH) ppm; 13C-NMR
(400 MHz, DMSO-d6) δ= 45.0 (CH2), 115.9 (Ar-C), 116.7 (3,5-Ar-CH), 123.9 (Ar-C), 133.6
(2,6-Ar-CH), 134.7 (CH), 160.9 (Ar-C), 166.5 (C=O) 167.4 (COOH), 193.1 (C=S) ppm; ESI-MS
m/z (%) = 294.0 [M−H]− (100 %); HR-MS m/z = 293.9898 [M−H]− (calculated: 293.9900);
HPLC-Analysis (Method B): 97 %, Rt = 16.9 min.
[(5Z)-5-[(4-chlorophenyl)methylidene]-4-oxo-2- sulfanylidene-1,3-thiazolidin-3-yl] acetic acid 2h [268]
Reaction time: 2 h; Purification: Filtration from methanol; Yield: 804 mg of red solid (2.56
mmol, 93 %); 1H-NMR (400 MHz, DMSO-d6) δ= 4.71 (s, 2 H, CH2), 7.60 (d, 2 H, 3JH,H =
8.6 Hz, 3,5-Ar-CH), 7.66 (d, 2 H, 3JH,H = 8.6 Hz, 2,6-Ar-CH), 7.85 (s, 1 H, CH), 13.71 (s(br), 1 H,
COOH) ppm; 13C-NMR (400 MHz, DMSO-d6) δ= 45.3 (CH2), 122.6 (3,5-Ar-CH), 129.6 (Ar-C),
131.7 (Ar-C), 132.3 (2,6-Ar-CH), 132.4 (CH), 135.9 (Ar-C), 166.3 (C=O), 167.3 (COOH), 192.9
(C=S) ppm; ESI-MS m/z (%) = 312.0 [M−H]− (100 %), 626.9 [2M−H]− (57 %); HPLC-Analysis
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(Method B): 99 %, Rt = 18.8 min.
[(5Z)-5-[(4-cyanophenyl)methylidene]-4-oxo-2- sulfanylidene-1,3-thiazolidin-3-yl] acetic acid 2i [68]
Reaction time: 8 h; Purification: Filtration from ethanol; Yield: 744 mg of yellow solid (2.44
mmol, 78 %); 1H-NMR (400 MHz, DMSO-d6) δ= 4.70 (s, 2 H, CH2), 7.81 (d, 2 H, 3JH,H =
6.6 Hz, 2,6-Ar-CH), 7.91 (s, 1 H, CH), 7.98 (d, 2 H, 3JH,H = 6.6 Hz, 3,5-Ar-CH) ppm; 13C-
NMR (400 MHz, DMSO-d6) δ= 45.5 (CH2), 112.6 (Ar-C), 118.3 (CN), 125.5 (Ar-C), 131.0
(2,6-Ar-CH), 131.4 (CH), 133.1 (3,5-Ar-CH), 137.1 (Ar-C), 166.3 (C=O), 167.2 (COOH), 192.7
(C=S) ppm; ESI-MS m/z (%) = 303.0 [M−H]− (88 %), 607.0 [2M−H]− (100 %); HPLC-Analysis
(Method B): 99 %, Rt = 18.8 min.
[(5Z)-5-[(4-ethynylphenyl)methylidene]-4-oxo-2- sulfanylidene-1,3-thiazolidin-3-yl] acetic acid
2j [68] Reaction time: 6 h; Purification: Filtration from ethanol; Yield: 872 mg of yellow solid
(2.87 mmol, 87 %); 1H-NMR (400 MHz, DMSO-d6) δ= 4.46 (s, 1 H, CCH), 4.68 (s, 2 H, CH2),
7.62 (d, 2 H, 3JH,H = 8.6 Hz, 2,6-Ar-CH), 7.65 (d, 2 H, 3JH,H = 8.6 Hz, 3,5-Ar-CH), 7.85 (s,
1 H, CH), 13.48 (s(br), 1 H, COOH) ppm; 13C-NMR (400 MHz, DMSO-d6) δ= 45.5 (CH2),
83.0 (CCH), 84.0 (CCH), 123.0 (Ar-C), 124.0 (Ar-C), 130.9 (3,5-Ar-CH), 132.5 (CH), 132.6
(2,6-Ar-CH), 133.1 (Ar-C), 166.4 (C=O), 167.3 (COOH), 192.9 (C=S) ppm; ESI-MS m/z (%) =
302.0 [M−H]− (100 %), 605.0 [2M−H]− (100 %); HR-MS m/z = 301.9956 [M−H]− (calculated:
301.9951); HPLC-Analysis (Method B): 100 %, Rt = 18.4 min.
[(5Z)-5-[(3-nitrophenyl)methylidene]-4-oxo-2- sulfanylidene-1,3-thiazolidin-3-yl] acetic acid 2k [268]
Reaction time: 4 h Purification: Filtration from ethanol; Yield: 673 mg of red solid (2.08
mmol, 67 %); 1H-NMR (400 MHz, DMSO-d6) δ= 4.76 (s, 2 H, CH2), 7.80-7.89 (m, 1 H, 5-
Ar-CH), 8.02-8.18 (m, 2 H, 6-Ar-CH, CH), 8.30-8.39 (m, 1 H, 4-Ar-CH), 8.53 (s, 1 H, 2-Ar-
CH), 13.53 (s(br), 1 H, COOH) ppm; 13C-NMR (400 MHz, DMSO-d6) δ= 45.1 (CH2), 124.8
(Ar-C), 125.1 (4-Ar-CH), 125.3 (2-Ar-CH), 131.1 (5-Ar-CH), 131.5 (6-Ar-CH), 134.4 (Ar-C),
135.8 (CH), 148.3 (Ar-C), 166.1 (C=O), 167.2 (COOH), 192.7 (C=S) ppm; ESI-MS m/z (%) =
323.0 [M−H]− (100 %), 647.0 [2M−H]− (100 %); HR-MS m/z = 322.9806 [M−H]− (calculated:
322.9802); HPLC-Analysis (Method B): 100 %, Rt = 17.1 min.
[(5Z)-5-[(3-bromo-4-methoxyphenyl)methylidene]-4- oxo-2-sulfanylidene-1,3-thiazolidin-3-yl] ace-
tic acid 2l [269]
Reaction time: 8 h; Purification: Filtration from ethanol; Yield: 569 mg of yellow solid (1.47
mmol, 75 %); 1H-NMR (400 MHz, DMSO-d6) δ= 3.95 (s, 3 H, OCH3), 4.74 (s, 2 H, CH2), 7.32
(d, 1 H, 3JH,H = 8.8 Hz, 5-Ar-CH), 7.67 (dd, 1 H, 3,4JH,H = 8.8, 2.3 Hz, 6-Ar-CH), 7.87 (s, 1 H,
CH), 7.97 (d, 1 H, 4JH,H = 2.3 Hz, 2-Ar-CH) ppm; ESI-MS m/z (%) = 387.9 [M−H]− (100 %),
774.8 [2M−H]− (100 %), 796.8 [2M+Na−2H]− (65 %); HR-MS m/z = 385.9169 [M−H]− (calcu-
lated: 385.9162); HPLC-Analysis (Method B): 95 %, Rt = 15.4 min.
[(Z)-2-(5-(3-methylbenzylidene)-4-oxo-2-thioxothiazolidin-3-yl)] acetic acid 2m [160]
Reaction time: 6 h; Purification: Filtration from ethanol; Yield: 476 mg of yellow solid (1.62
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mmol, 76 %); 1H-NMR (400 MHz, DMSO-d6) δ= 2.39 (s, 3 H, CH3), 4.74 (s, 2 H, CH2), 7.35-
7.39 (m, 1 H, Ar-CH), 7.45-7.48 (m, 3 H, 3 x Ar-CH), 7.85 (s, 1 H, CH); 13.50 (s(br), 1 H,
COOH) ppm; 13C-NMR (400 MHz, DMSO-d6) δ= 19.4 (CH3), 45.0 (CH2), 123.4 (Ar-C), 127.0
(Ar-CH), 127.8 (Ar-CH), 131.1 (Ar-CH), 131.2 (Ar-CH), 131.7 (CH), 131.9 (Ar-C), 139.5 (Ar-C),
166.1 (C=O), 167.3 (COOH), 193.7 (C=S) ppm; ESI-MS m/z (%) = 294.0 [M+H]+ (100 %), 311.1
[M+NH4]+ (85 %); HR-MS m/z = 294.0256 [M+H]+ (calculated: 294.0253); HPLC-Analysis
(Method B): 98 %, Rt = 18.8 min.
[(Z)-2-(5-(4-methylbenzylidene)-4-oxo-2-thioxothiazolidin-3-yl)] acetic acid 2n [268]
Reaction time: 6 h; Purification: Filtration from ethanol; Yield: 541 mg of yellow solid (1.84
mmol, 78 %); 1H-NMR (400 MHz, DMSO-d6) δ= 2.38 (s, 3 H, CH3), 4.74 (s, 2 H, CH2), 7.39
(d, 2 H, 3JH,H = 8.0 Hz, 3,5-Ar-CH), 7.58 (d, 2 H, 3JH,H = 8.0 Hz, 2,6-Ar-CH), 7.87 (s, 1 H, CH);
13.48 (s(br), 1 H, COOH) ppm; 13C-NMR (400 MHz, DMSO-d6) δ= 21.2 (CH3), 45.0 (CH2),
120.6 (Ar-C), 130.1 (Ar-C), 130.2 (3,5-Ar-CH), 130.9 (2,6-Ar-CH), 134.1 (CH), 141.9 (Ar-C),
166.4 (C=O), 167.3 (COOH), 193.2 (C=S) ppm; ESI-MS m/z (%) = 294.0 [M+H]+ (100 %), 311.1
[M+NH4]+ (85 %); HR-MS m/z = 294.0257 [M+H]+ (calculated: 294.0253); HPLC-Analysis
(Method B): 98 %, Rt = 18.8 min.
[(Z)-2-(5-(2-methylbenzylidene)-4-oxo-2-thioxothiazolidin-3-yl)] acetic acid 2o
Reaction time: 6 h; Purification: Filtration from ethanol; Yield: 634 mg of yellow solid (2.16
mmol, 78 %); 1H-NMR (400 MHz, DMSO-d6) δ= 2.43 (s, 3 H, Ar-CH3), 4.74 (s, 2 H, CH2),
7.35-7.47 (m, 4 H, 4xAr-CH), 7.96 (s, 1 H, CH), 13.50 (s(br), 1 H, COOH) ppm; 13C-NMR
(400 MHz, DMSO-d6) δ= 19.4 (Ar-CH3), 45.0 (CH2), 123.4 (Ar-C), 127.0 (Ar-CH) 127.8 (Ar-
CH), 131.1 (Ar-C), 131.2 (Ar-CH), 131.7 (Ar-CH), 131.9 (Ar-C), 139.5 (CH), 166.1 (C=O),
167.3 (COOH), 193.7 (C=S) ppm; ESI-MS m/z (%) = 294.0 [M+H]+ (100 %), 311.1 [M+NH4]+
(85 %), 717.0 [2M+Na]+ (90 %); HR-MS m/z = 294.0258 [M+H]+ (calculated: 294.0253). HR-
MS m/z = 365.0239 [M+NH4]+ (calculated: 365.0236); HPLC-Analysis (Method B): 97 %, Rt =
18.6 min.
[(Z)-2-(4-oxo-2-thioxo-5-(3-(trifluoromethyl)benzylidene)thiazolidin-3-yl)] acetic acid 2p [270]
Reaction time: 2 h; Purification: Filtration from ethanol; Yield: 361 mg of yellow solid (1.04
mmol, 94 %); 1H-NMR (400 MHz, DMSO-d6) δ= 4.76 (s, 2 H, CH2), 7.81 (at, 1 H, 3JH,H =
7.8 Hz, 5-Ar-CH), 7.89 (d, 1 H, 3JH,H = 7.8 Hz, 4-Ar-CH), 7.93 (d, 1 H, 3JH,H = 7.8 Hz, 6-Ar-
CH), 8.03 (s, 1 H, CH), 8.09 (s, 1 H, 2-Ar-CH), 13.51 (s(br), 1 H, COOH) ppm; 13C-NMR
(400 MHz, DMSO-d6) δ= 45.1 (CH2), 123.7 (q, 1JC,F = 272.7 Hz, CF3), 124.1 (Ar-C), 127.3
(q, 3JC,F = 3.7 Hz, 4-Ar-CH), 127.8 (q, 3JC,F = 4.0 Hz, 2-Ar-CH), 130.1 (q, 2JC,F = 32.3 Hz, 3-Ar-
C), 130.7 (5-Ar-CH) 132.1 (CH), 133.3 (6-Ar-CH), 133.9 (Ar-C), 166.2 (C=O), 167.2 (COOH),
192.9 (C=S) ppm; ESI-MS m/z (%) = 348.0 [M+H]+ (40 %), 365.0 [M+NH4]+ (100 %), 370.0
[M+Na]+ (30 %), HR-MS m/z = 365.0239 [M+NH4]+ (calculated: 365.0236); HPLC-Analysis
(Method B): 99 %, Rt = 18.8 min.
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(Z)-2-(4-oxo-2-thioxo-5-(4-(trifluoromethyl)benzylidene)thiazolidin-3-yl) acetic acid 2q [270]
Reaction time: 3 h; Purification: Filtration from ethanol; Yield: 643 mg of yellow solid (1.85
mmol, 73 %); 1H-NMR (400 MHz, DMSO-d6) δ= 4.75 (s, 2 H, CH2), 7.89 (d, 2 H, 3JH,H =
8.8 Hz, 2,6-Ar-CH), 7.92 (d, 2 H, 3JH,H = 8.8 Hz, 3,5-Ar-CH), 7.99 (s, 1 H, CH), 13.76 (s(br),
1 H, COOH) ppm; 13C-NMR (400 MHz, DMSO-d6) δ= 45.4 (CH2), 123.8 (q, 1JC,F = 272.0 Hz,
CF3), 124.9 (Ar-C), 126.2 (q, 3JC,F = 3.5 Hz, 3,5-Ar-CH) 130.2 (q, 2JC,F = 33.3 Hz, 4-Ar-C),
131.2 (2,6-Ar-CH), 131.7 (CH), 136.7 (Ar-C), 166.3 (C=O), 167.3 (COOH), 192.9 (C=S) ppm;
ESI-MS m/z (%) = 348.0 [M+H]+ (40 %), 365.0 [M+NH4]+ (100 %), 717.0 [2M+Na]+ (90 %); HR-
MS m/z = 365.0239 [M+NH4]+ (calculated: 365.0236); HPLC-Analysis (Method B): 100 %,
Rt = 19.2 min.
(Z)-2-(4-oxo-2-thioxo-5-(2-(trifluoromethyl)benzylidene)thiazolidin-3-yl) acetic acid 2r
Reaction time: 4 h; Purification: Filtration from ethanol; Yield: 721 mg of yellow solid (2.08
mmol, 81 %); 1H-NMR (400 MHz, DMSO-d6) δ= 4.75 (s, 2 H, CH2), 7.74 (t, 1 H, 3JH,H =
7.6 Hz, 5-Ar-CH), 7.78 (d, 1 H, 3JH,H = 7.6 Hz, 6-Ar-CH), 7.89 (t, 1 H, 3JH,H = 7.6 Hz, 4-Ar-
CH), 7.89 (s, 1 H, CH), 7.95 (d, 1 H, 3JH,H = 7.6 Hz, 3-Ar-CH), 13.55 (s(br), 1 H, COOH) ppm;
13C-NMR (400 MHz, DMSO-d6) δ= 45.1 (CH2), 123.8 (q, 1JC,F = 274.3 Hz, CF3), 127.0 (q,
3JC,F = 5.3 Hz, 3-Ar-CH), 127.3 (Ar-C), 127.8 (CH), 128.0 (q, 2JC,F = 29.0 Hz, 2-Ar-C), 129.6 (6-
Ar-CH), 130.9 (Ar-C), 131.0 (5-Ar-CH) 133.6 (4-Ar-CH), 165.8 (C=O), 167.2 (COOH), 193.2
(C=S) ppm; ESI-MS m/z (%) = 348.0 [M+H]+ (40 %), 365.0 [M+NH4]+ (100 %); HR-MS m/z =
365.0237 [M+NH4]+ (calculated: 365.0236); HPLC-Analysis (Method B): 100 %, Rt = 18.4 min.
(Z)-2-(5-(4-(methylsulfonyl)benzylidene)-4-oxo-2-thioxothiazolidin-3-yl) acetic acid 2s
Reaction time: 6 h; Purification: Filtration from ethanol; Yield: 167 mg of yellow solid (0.47
mmol, 29 %); 1H-NMR (400 MHz, DMSO-d6) δ= 4.75 (s, 2 H, CH2), 7.93 (d, 2 H, 3JH,H = 8.5 Hz,
2,4-Ar-CH), 7.99 (s, 1 H, CH), 8.08 (d, 2 H, 3JH,H = 8.5 Hz, 1,5-Ar-CH); 13C-NMR (300 MHz,
DMSO-d6) δ= 45.2 (CH2, CH3), 125.4 (Ar-C or Ar-CH), 128.0 (Ar-C or Ar-CH), 131.3 (Ar-C
or Ar-CH), 131.7 (Ar-C or Ar-CH), 137.5 (CH), 141.9 (Ar-C or Ar-CH), 166.3 (C=O), 166.3
(COOH), 193.01 (C=S); ESI-MS m/z (%) = 358.0 [M+H]+ (25 %) 375.0 [M+NH4]+ (100 %), 380.0
[M+Na]+ (20 %); HR-MS m/z = 375.0140 [M+NH4]+ (calculated: 375.0138); HPLC-Analysis
(Method B): 91 %, Rt = 13.9 min.
(Z)-2-(5-(4-(dimethylamino)benzylidene)-4-oxo-2-thioxothiazolidin-3-yl) acetic acid 2t [268]
Reaction time: 6 h; Purification: Filtration from ethanol; Yield: 375 mg of yellow solid (1.16
mmol, 87 %); 1H-NMR (400 MHz, DMSO-d6) δ= 3.06 (s, 6 H, 2 x CH3), 4.72 (s, 2 H, CH2), 6.85
(d, 2 H, 3JH,H = 8.8 Hz, 2,4-Ar-CH), 7.51 (d, 2 H, 3JH,H = 8.8 Hz, 1,5-Ar-CH), 7.75 (s, 1 H, CH);
13C-NMR (300 MHz, DMSO-d6) δ= 45.0 (CH2, CH3), 112.3 (2,4-Ar-CH), 119.7 (Ar-C), 133.5
(1,5-Ar-CH), 135.5 (CH), 152.1 (Ar-C), 161.9 (Ar-C), 166.4 (C=O), 167.5 (COOH), ESI-MS
m/z (%) = 323.1 [M+H]+ (100 %), 345.0 [M+Na]+ (15 %), 645.1 [2M+H]+ (10 %); HR-MS m/z =
323.0522 [M+H]+ (calculated: 323.0519); HPLC-Analysis (Method B): 91 %, Rt = 13.9 min.
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(Z)-2-(5-(3,4-dihydroxybenzylidene)-4-oxo-2-thioxothiazolidin-3-yl) acetic acid 2u [92]
Reaction time: 6 h; Purification: Filtration from ethanol; Yield: 189 mg of red solid (0.61
mmol, 76 %); 1H-NMR (400 MHz, DMSO-d6) δ= 4.43 (s, 2 H, CH2), 6.89 (d, 1 H, 3JH,H = 8.0 Hz,
3-Ar-CH), 7.03 (dd, 1 H, 3,4JH,H = 8.1, 2.2 Hz, 4-Ar-CH), 7.04 (d, 1 H, 4JH,H = 2.2 Hz, 1-Ar-CH),
7.65 (s, 1 H, CH); 13C-NMR (300 MHz, DMSO-d6) δ= 43.52 (CH2), 100.2 (Ar-C or Ar-CH),
124.4 (Ar-C or Ar-CH), 126.7 (Ar-C or Ar-CH), 128.5 (Ar-C or Ar-CH), 129.1 (Ar-C or Ar-CH),
137.9 (Ar-C or Ar-CH), 149.8 (Ar-C or Ar-CH), 151.3 (Ar-C or Ar-CH), 166.8 (C=O), 167.5
(COOH), 199.9 (C=S); ESI-MS m/z (%) = 312.0 [M+H]+ (100 %), 329.0 [M+NH4]+ (30 %), 640.0
[2M+NH4]+ (30 %); HR-MS m/z = 311.9999 [M+H]+ (calculated: 311.9995); HPLC-Analysis
(Method B): 99 %, Rt = 16.1 min.
(Z)-4-((3-(carboxymethyl)-4-oxo-2-thioxothiazolidin-5-ylidene)methyl) benzoic acid 2v [270]
Reaction time: 4 h; Purification: Filtration from ethanol; Yield: 29 mg of yellow (0.09 mmol,
17 %); 1H-NMR (400 MHz, DMSO-d6) δ= 4.38 (s, 2 H, CH2), 7.64-7.69 (m, 2 H, 2xAr-CH),
7.80 (s, 1 H, CH), 8.01 (d, 2 H, 3JH,H = 7.4 Hz, 2xAr-CH) ppm; APCI-MS m/z (%) = 324.0 [M+H]+
(100 %); HR-MS m/z = 323.9995 [M+H]+ (calculated: 323.9995); HPLC-Analysis (Method B):
84 %, Rt = 16.0 min.
(Z)-2-(5-(2,4-dihydroxybenzylidene)-4-oxo-2-thioxothiazolidin-3-yl) acetic acid 2w [92]
Reaction time: 7 h; Purification: Filtration from ethanol; Yield: 153 mg of red solid (0.49
mmol, 52 %); 1H-NMR (400 MHz, DMSO-d6) δ= 4.71 (s, 2 H, CH2), 6.42-6.46 (m, 2 H, 3,4-Ar-
CH), 7.24 (d, 1 H, 4JH,H = 8.5 Hz, 1-Ar-CH), 7.99 (s, 1 H, CH), 10.47 (s, 1 H, OH), 10.83 (s, 1 H,
OH); ESI-MS m/z (%) = 312.0 [M+H]+ (100 %), 640.0 [2M+NH4]+ (40 %); HR-MS m/z = 311.9998
[M+H]+ (calculated: 311.9995); HPLC-Analysis (Method B): 84 %, Rt = 16.0 min.
[(5Z)-5-[2,5- bis(trifluoromethyl)phenyl]methylidene-4-oxo-2- sulfanylidene-1,3-thiazolidin-3-yl]
acetic acid 2x
TLC Rf = 0.4 (DCM/EtOAc 3:1); Reaction time: 4 h; Purification: Filtration from ethanol;
Yield: 58 mg of yellow solid (0.14 mmol, 27 %); 1H-NMR (400 MHz, DMSO-d6) δ= 4.36 (s,
2 H, CH2), 7.77-7.80 (m, 1 H, Ar-CH), 8.01 (s, 1 H, Ar-CH), 8.10 (d, 1 H, 3JH,H = 8.4 Hz, Ar-
CH), 8.17 (d, 1 H, 3JH,H = 8.4 Hz, Ar-CH) ppm; ESI-MS m/z (%) = 414.0 [M−H]− (100 %), 828.9
[2M−H]− (6 %); HPLC-Analysis (Method B): 82 %, Rt = 18.6 min.
[(5Z)-5-[2,4- bis(trifluoromethyl)phenyl]methylidene-4-oxo-2- sulfanylidene-1,3-thiazolidin-3-yl]
acetic acid 2ag
ESI-MS m/z (%) = 414.0 [M−H]− (100 %), 850.9 [2M2Na−2H]− (100 %); HR-MS m/z = 413.9702
[M−H]− (calculated: 413.9699); HPLC-Analysis (Method B): 94 %, Rt = 20.5 min.
Piperidinium (Z)-2-(5-(4-tert-butylbenzylidene)-4-oxo-2-thioxothiazolidin-3-yl) acetate 2y
TLC Rf = 0.2 (DCM/MeOH 9:1); Reaction time: 16 h; Purification: Filtration from ethanol;
Yield: 96 mg of yellow solid (0.23 mmol, 20 %); 1H-NMR (400 MHz, MeOD) δ= 1.33 (s, 9 H,
3xCH3), 1.62-1.69 (m, 2 H, 3-Pip-CH2), 1.72-1.79 (m, 4 H, 2x2-Pip-CH2), 3.09 (t, 4 H, JH,H =
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5.7 Hz, 2x1-Pip-CH2), 4.62 (s, 2 H, CH2), 7.50 (d, 2 H, 3JH,H = 8.5 Hz, 2xAr-CH), 7.56 (d,
2 H, 3JH,H = 8.5 Hz, 2xAr-CH), 7.70 (s, 1 H, CH) ppm; 13C-NMR (400 MHz, MeOD) δ= 23.1
(3-Pip-CH2), 23.8 (2x2-Pip-CH2), 31.5 (3xCH3), 35.9 (CCH3), 45.7 (2x1-Pip-CH2), 48.4 (CH2),
123.9 (Ar-C), 127.5 (2xAr-CH), 131.7 (2xAr-CH), 132.2 (Ar-C), 133.5 (CH), 155.7 (Ar-C), 169.0
(C=O), 172.8 (COOH), 195.2 (C=S) ppm; HPLC-Analysis (Method B): 97 %, Rt = 20.7 min.
(Z)-2-(5-(4-tert-butylbenzylidene)-4-oxo-2-thioxothiazolidin-3-yl) acetic acid 2z
Compound 2y was extracted between 1 N HCl (15 mL) and EtOAc (3x15 mL), dried over
MgSO4, filtered and concentrated to afford the analogues free acid. TLC Rf = 0.1 (DCM/MeOH
9:1); Yield: 32 mg of yellow solid (0.10 mmol, 79 %); 1H-NMR (400 MHz, MeOD) δ= 1.28 (s,
9 H, 3xCH3), 4.74 (s, 2 H, CH2), 7.44 (d, 2 H, 3JH,H = 8.4 Hz, 2xAr-CH), 7.51 (d, 2 H, 3JH,H =
8.4 Hz, 2xAr-CH), 7.68 (s, 1 H, CH) ppm; 13C-NMR (400 MHz, MeOD) δ= 31.4 (3xCH3), 36.0
(CCH3), 45.7 (CH2), 122.8 (Ar-C), 127.6 (2xAr-CH), 131.9 (2xAr-CH), 134.7 (CH), 156.1 (Ar-
C), 168.4 (C=O) 169.3 (C=OOH) 194.9 (C=S) ppm.
2-[(5Z)-3-(carboxymethyl)-4-oxo-2-sulfanylidene- 1,3-thiazolidin-5-ylidene]methyl benzoic acid
2aa [271]
TLC Rf = 0.1 (DCM/MeOH 9:1); Reaction time: 4 h; Purification: Filtration from ethanol;
Yield: 26 mg of yellow solid (0.08 mmol, 15 %); 1H-NMR (400 MHz, DMSO-d6) δ= 4.29 (s,
2 H, CH2), 7.34-7.41 (m, 3 H, 3xAr-CH), 7.71-7.75 (m, 1 H, Ar-CH), 8.79 (s, 1 H, CH), ppm; 13C-
NMR (400 MHz, DMSO-d6) δ= 48.2 (CH2), 121.7 (Ar-C), 127.2 (Ar-CH), 128.3 (Ar-CH), 129.8
(Ar-CH), 131.8 (Ar-CH), 136.0 (CH), 143.7 (Ar-C), 166.6 (C=O), 194.2 (C=S) ppm; ESI-MS
m/z (%) = 322.0 [M−H]− (100 %), 644.0 [2M−H]− (55 %); HR-MS m/z = 321.9851 [M−H]− (cal-
culated: 321.9849); HPLC-Analysis (Method B): 97 %, Rt = 16.3 min.
(Z)-2-(5-(2,4-bis(trifluoromethyl)benzylidene)-4-oxo-2-thioxothiazolidin-3-yl) acetic acid 2ab
TLC Rf = 0.6 (DCM/MeOH 9:1); Reaction time: 4 h; Purification: Filtration from ethanol;
Yield: 58 mg of yellow solid (0.14 mmol, 27 %); Yield: 84 mg of yellow solid (0.20 mmol, 39 %);
1H-NMR (400 MHz, DMSO-d6) δ= 4.30 (s, 2 H, CH2), 7.77 (q, 1 H, 5JH,F = 2.3 Hz, CH), 7.98
(d, 1 H, 3JH,H = 8.1 Hz, 5-Ar-CH), 8.21 (s, 1 H, 3-Ar-CH), 8.25 (d, 1 H, 3JH,H = 8.1 Hz, 6-Ar-CH)
ppm; 13C-NMR (400 MHz, DMSO-d6) δ= 48.0 (CH2), 124.4 (3-Ar-CH) 124.6 (CH), 130.7 (5-
Ar-CH), 130.8 (6-Ar-CH), 166.0 (C=O), 166.1 (COOH), 192.7 (C=S) ppm; APCI-MS m/z (%) =
416.0 [M+H]+ (100 %), 433.0 [M+NH4]+ (20 %); ESI-MS m/z (%) = 414.0 [M−H]− (100 %), 829.0
[2M−H]− (100 %); 850.9 [2M+Na−2H]− (100 %); HR-MS m/z = 413.9701 [M−H]− (calculated:
413.9699); HR-MS m/z = 413.9702 [M−H]− (calculated: 413.9699); HR-MS m/z = 415.9845
[M+H]+ (calculated: 415.9844); HPLC-Analysis (Method B): 85 %, Rt = 20.2 min.
[(5Z)-5-[(4-methoxyphenyl)methylidene]-4-oxo-2- sulfanylidene-1,3-thiazolidin-3-yl] acetic acid
2ac [272]
Reaction time: 4 h Purification: Filtration from methanol; Yield: 174 mg of yellow solid (0.56
mmol, 31 %); 1H-NMR (400 MHz, DMSO-d6) δ= 2.08 (s, 3 H, CH3) 4.48 (s, 2 H, CH2) 7.55-
238
9 Methods
7.88 (m, 5 H, 4xAr-CH, CH) 10.37 (s, 1 H, COOH) ppm; HPLC-Analysis (Method B): 91 %,
Rt = 15.6 min.
(Z)-2-(5-(4-acetamidobenzylidene)-4-oxo-2-thioxothiazolidin-3-yl) acetic acid 2ad
Reaction time: 4 h; Purification: Filtration from ethanol; Yield: 587 mg of yellow solid (1.75
mmol, 85 %); 1H-NMR (400 MHz, DMSO-d6) δ= 2.09 (s, 1 H, CH3), 4.74 (s, 2 H, CH2), 7.64
(d, 2 H, 3JH,H = 8.9 Hz, 2,6-Ar-CH), 7.78 (d, 2 H, 3JH,H = 8.9 Hz, 3,5-Ar-CH), 7.82 (s, 1 H, CH),
10.36 (s, 1 H, NH), 13.46 (s(br), 1 H, COOH) ppm; 13C-NMR (400 MHz, DMSO-d6) δ= 24.2
(CH3), 45.0 (CH2), 119.2 (Ar-C), 119.3 (3,5-Ar-CH), 127.2 (Ar-C), 132.2 (2,6-Ar-CH), 133.9
(CH), 142.1 (Ar-C), 166.5 (C=O), 167.4 (C=O), 169.0 (COOH), 193.2 (C=S) ppm; ESI-MS
m/z (%) = 337.0 [M+H]+ (100 %), 354.1 [M+NH4]+ (65 %), 690.1 [2M+NH4]+ (20 %); HR-MS m/z
= 337.0315 [M+H]+ (calculated: 337.0311); ESI-MS m/z (%) = 335.0 [M−H]− (100 %), 671.0
[2M−H]− (15 %); HPLC-Analysis (Method B): 100 %, Rt = 17.1 min.
(Z)-2-(5-(3-bromo-4-fluorobenzylidene)-4-oxo-2-thioxothiazolidin-3-yl) acetic acid 2ai
Reaction time: 6 h; Purification: Filtration from ethanol; Yield: 234 mg of yellow solid (0.62
mmol, 74 %); 1H-NMR (400 MHz, DMSO-d6) δ= 4.75 (s, 2 H, CH2), 7.59 (at, 1 H, 3JH,H(F) =
8.6 Hz, 5-Ar-CH), 7.71 (ddd, 1 H, 3,4JH,H(F) = 8.6, 4.7, 2.3 Hz, 6-Ar-CH), 7.91 (s, 1 H, CH),
8.10 (dd, 1 H, 4JH,H(F) = 6.7, 2.3 Hz, 2-Ar-CH) ppm; 13C-NMR (400 MHz, DMSO-d6) δ= 45.1
(CH2), 109.4 (d, 2JC,F = 21.6 Hz, 3-Ar-C), 117.9 (5-Ar-CH), 123.2 (Ar-C), 131.4 (CH), 131.4 (d,
4JC,F = 8.1 Hz, 6-Ar-CH), 136.4 (2-Ar-CH), 158.1 (Ar-C), 166.2 (C=O), 167.3 (COOH), 192.9
(C=S) ppm; ESI-MS m/z (%) = 774.8 [2M+Na]+ (95 %); HR-MS m/z = 397.8926 [M+Na]+ (calcu-
lated: 397.8927), 421.8721 [M−H+2Na]+ (calculated: 421.8725), 774.7931 [2M+Na]+ (calcu-
lated: 774.7941), 796.7750 [2M−H + 2Na]+ (calculated: 796.7761); HPLC-Analysis (Method
B): 92 %, Rt = 18.0 min.
(Z)-2-(5-(3,5-bis(trifluoromethyl)benzylidene)-4-oxo-2-thioxothiazolidin-3-yl) acetic acid 2ae
TLC Rf = 0.6 (DCM/MeOH 9:1); Reaction time: 4 h; Purification: Filtration from ethanol;
Yield: 86 mg of yellow solid (0.21 mmol, 40 %); 1H-NMR (400 MHz, DMSO-d6) δ= 4.32 (s, 2 H,
CH2), 8.00 (s, 1 H, CH), 8.24-8.28 (m, 3 H, 3xAr-CH) ppm; ESI-MS m/z (%) = 414.0 [M−H]−
(100 %), 829.0 [2M−H]− (100 %); HR-MS m/z = 413.9699 [M−H]− (calculated: 413.9699);
HPLC-Analysis (Method B): 94 %, Rt = 20.7 min.
9.3 General Procedures for Synthesis of 5-Benzylidene
thiazolidine-2,4-diones N-acetic ester derivatives 7a–l
Method 1: Alkylation of Thiazolidine-2,4-diones
Thiazolidine-2,4-diones (1.0 eq) was dissolved in minimum of dry DMF (2-5 mL) and NaH
(1.0 eq) were added under ice cooling. The reaction mixture was stirred for 10 min and ethyl
bromo acetate (1.0 eq) were added drop wise at 0 ◦C. The reaction was stirred at rt for 4 h or
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until TLC shows complete consumption of starting Thiazolidine-2,4-diones. Next, the reaction
was quenched with water (10 mL), extracted with EtOAc (3x10 mL), dried over MgSO4, filtered
and concentrated. Purification by flash column chromatography afforded ethyl 2-(2,4-dioxo-
1,3-thiazolidin-3-yl) acetate 7 [273] as a clear oil. TLC Rf = 0.1 (Hexane/EtOAc 9:1); Reaction
time: 3 h; Yield: 450 mg of white solid (2.21 mmol, 86 %); Yield: 1423 mg of clear oil (7.00
mmol, 88 %); Yield: 3120 mg of clear oil (15.35 mmol, 90 %); Purification: Flash-Chroma-
tography Hexane/ EtOAc 8:2 (Rf = 0.2); 1H-NMR (400 MHz, CDCl3) δ= 1.26 (t, 3 H, 3JH,H =
7.1 Hz, CH3), 4.02 (s, 2 H, CH2), 4.19 (q, 2 H, 3JH,H = 7.1 Hz, CH2CH3), 4.30 (s, 2 H, CH2)
ppm; 13C-NMR (400 MHz, CDCl3) δ= 14.1 (CH3), 33.9 (CH2), 42.2 (CH2), 62.2 (CH2), 166.3
(C=O), 170.8 (C=O), 171.2 (C=O) ppm; APCI-MS m/z (%) = 204.0 [M+H]+ (100 %); HR-MS m/z
= 204.0321 [M+H]+ (calculated: 204.0325).
Method 2: Alkylation of Thiazolidine-2,4-diones
Thiazolidine-2,4-diones (1325 mg, 10.18 mmol) was dissolved in 10 mL ethanol, potassium hy-
droxide (571 mg, 10.18 mmol) was added. The reaction mixture was stirred 1 h at 70 ◦C. Upon
cooling 2,4-dioxo-1,3-thiazolidin-3-ide potassium salt 8 [274] precipitated from the solution. The
white solid was filtered and washed with acetone. Yield: 1113 mg of white solid (7.17 mmol,
100 %); Purification: Filtration from ethanol, washing with acetone. The crude potassium salt
8 (1.0 eq) was dissolved in 15 mL acetone. Ethyl bromo-acetate was added and the reaction
mixture was heated 70 ◦C for 4 h. A white solid (KBr) crushed out and was filtered and washed
with acetone. The crude was concentrated and extracted between water (10 mL) and EtOAc
(3x10 mL). The combined organic fractions were dried over MgSO4, filtered and concentrated.
Crude 7 was pure enough for consecutive reactions. Yield: 346 mg of clear oil (1.70 mmol,
100 %); Yield: 205 mg of white solid (1.01 mmol, 100 %).
General Procedure for Knoevenagel condensation reaction
Ethyl 2-(2,4-dioxothiazolidin-3-yl) acetate 7 (1.0 eq), benzaldehyde derivatives (1.1-1.5 eq) and
sodium acetate were dissolved in 10 mL ethanol. The reaction mixture was stirred at 80 ◦C until
TLC showed complete consumption of starting 7. The products were purified as described in
the individual sections.
Ethyl 2-[(5Z)-2,4-dioxo-5-(phenylmethylidene)-1,3- thiazolidin-3-yl] acetate 7a [275]
TLC Rf = 0.6 (Hexane/EtOAc 8:2); Reaction time: 4 h; Purification: Filtration from ethanol;
Yield: 324 mg of white solid (1.11 mmol, 46 %); 1H-NMR (400 MHz, CDCl3) δ= 1.30 (t, 3 H,
3JH,H = 7.1 Hz, CH3), 4.25 (q, 2 H, 3JH,H = 7.1 Hz, CH2CH3), 4.48 (s, 2 H, CH2), 7.43-7.55 (m,
5 H, 5xAr-CH), 7.95 (s, 1 H, CH) ppm.
Ethyl 2-[(5Z)-5-[(2-methylphenyl)methylidene]-2,4-dioxo-1,3-thiazolidin-3-yl] acetate 7b
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TLC Rf = 0.6 (Hexane/EtOAc 8:2); Reaction time: 16 h; Purification: Flash-Chromatography
Hexane/EtOAc 9:1 (Rf = 0.4), DCM; Yield: 211 mg of white solid (0.69 mmol, 69 %); 1H-NMR
(400 MHz, CDCl3) δ= 1.23 (t, 3 H, 3JH,H = 7.1 Hz, CH3), 2.36 (s, 3 H, Ar-CH3), 4.17 (q, 2 H,
3JH,H = 7.1 Hz, CH2CH3), 4.40 (s, 2 H, CH2), 7.17-7.28 (m, 3 H, 3xAr-CH), 7.37-7.40 (m, 1 H,
1xAr-CH), 8.07 (s, 1 H, CH) ppm; 13C-NMR (400 MHz, CDCl3) δ= 14.2 (CH3), 20.0 (Ar-CH3),
42.1 (CH2), 62.3 (CH2), 122.6 (Ar-C), 126.7 (Ar-CH), 127.7 (Ar-CH), 130.7 (Ar-CH), 131.2 (Ar-
CH), 132.3 (Ar-C), 132.8 (CH), 139.3 (Ar-C) 165.5 (C=O), 166.4 (C=O), 168.0 (COOEt) ppm;
ESI-MS m/z (%) = 306.1 [M+H]+ (100 %), 323.1 [M+NH4]+ (35 %), 328.1 [M+Na]+ (25 %), 344.0
[M+K]+ (10 %), 628.2 [2M+NH4]+ (100 %), 633.1 [2M+Na]+ (60 %), 649.1 [2M+K]+ (15 %); HR-
MS m/z = 306.0798 [M+H]+ (calculated: 306.0795); HPLC-Analysis (Method B): 85 %, Rt =
19.6 min.
Ethyl 2-[(5Z)-5-[(3-methylphenyl)methylidene]-2,4- dioxo-1,3-thiazolidin-3-yl] acetate 7c
TLC Rf = 0.6 (Hexane/EtOAc 8:2); Reaction time: 16 h; Purification: Flash-Chromatography
Hexane→ Hexane/EtOAc 95:5 (Rf = 0.2), ; Yield: 82 mg of white solid (0.27 mmol, 71 %); 1H-
NMR (400 MHz, CDCl3) δ= 1.30 (t, 3 H, 3JH,H = 7.1 Hz, CH2CH3), 2.41 (s, 3 H, CH3), 4.25 (q,
2 H, 3JH,H = 7.1 Hz, CH2CH3), 4.48 (s, 2 H, CH2), 7.25-7.28 (m, 1 H, Ar-CH), 7.31-7.40 (m, 3 H,
3xAr-CH), 7.91 (s, 1 H, CH) ppm; 13C-NMR (400 MHz, CDCl3) δ= 14.2 (CH2CH3), 21.6 (CH3)
42.3 (CH2), 62.3 (CH2CH3), 120.9 (Ar-C), 127.5 (Ar-CH), 129.3 (Ar-CH), 131.2 (Ar-CH), 131.8
(Ar-CH), 133.2 (Ar-C), 135.1 (CH), 139.2 (Ar-C), 165.8 (C=O), 166.4 (C=O), 167.8 (COOEt)
ppm; ESI-MS m/z (%) = 306.1 [M+H]+ (100 %), 323.1 [M+NH4]+ (45 %), 633.1 [2M+Na]+ (15 %);
HR-MS m/z = 306.0798 [M+H]+ (calculated: 306.0795); HPLC-Analysis (Method B): 98 %,
Rt = 18.5 min.
Ethyl 2-[(5Z)-5-[(4-methylphenyl)methylidene]-2,4-dioxo-1,3-thiazolidin-3-yl] acetate 7d [165]
TLC Rf = 0.6 (Hexane/EtOAc 8:2); Reaction time: 16 h; Purification: Flash-Chromatogra-
phy Hexane/EtOAc 95:5 (Rf = 0.1); Yield: 211 mg of white solid (0.69 mmol, 71 %); 1H-NMR
(400 MHz, CDCl3) δ= 1.14 (t, 3 H, 3JH,H = 7.1 Hz, CH2CH3), 2.25 (s, 3 H, CH3), 4.09 (d,
2 H, 3JH,H = 7.1 Hz, CH2CH3), 4.32 (s, 2 H, CH2), 7.13 (d, 2 H, 3JH,H = 8.2 Hz, 2,6-Ar-CH),
7.26 (d, 2 H, 3JH,H = 8.2 Hz, 3,5-Ar-CH), 7.75 (s, 1 H, CH) ppm; 13C-NMR (400 MHz, CDCl3)
δ= 14.2 (CH2CH3), 21.7 (Ar-CH3), 42.2 (CH2), 62.2 (CH2CH3), 119.8 (Ar-C), 130.1 (2,6-Ar-
CH), 130.4 (3,5-Ar-CH), 130.5 (Ar-C), 134.8 (CH), 141.6 (Ar-C), 165.8 (C=O), 166.4 (C=O),
167.7 (C=OOEt) ppm; ESI-MS m/z (%) = 306.1 [M+H]+ (100 %), 323.1 [M+NH4]+ (60 %), 628.2
[2M+NH4]+ (25 %); HR-MS m/z = 306.0798 [M+H]+ (calculated: 306.0795); HPLC-Analysis
(Method B): 98 %, Rt = 18.5 min.
Ethyl 2-[(5Z)-2,4-dioxo-5-[2-(trifluoromethyl)phenyl]methylidene-1,3-thiazolidin-3-yl] acetate 7e
TLC Rf = 0.4 (Hexane/EtOAc 8:2); Reaction time: 8 h; Purification: Flash-Chromatography
Hexane/EtOAc 9:1 (Rf = 0.3), loaded in DCM; Yield: 143 mg of white solid (0.40 mmol, 87 %);
1H-NMR (400 MHz, CDCl3) δ= 1.31 (t, 3 H, 3JH,H = 7.1 Hz, CH3), 4.26 (q, 2 H, 3JH,H = 7.1 Hz,
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CH2CH3), 4.48 (s, 2 H, CH2), 7.52-7.57 (m, 1 H, 4-Ar-CH), 7.62-7.70 (m, 2 H, 5,6-Ar-CH), 7.78
(d, 1 H, 3JH,H = 7.8 Hz, 3-Ar-CH), 8.20 (q, 1 H, 5JH,F = 1.9 Hz, CH) ppm; 13C-NMR (400 MHz,
CDCl3) δ= 14.2 (CH3), 42.3 (CH2), 62.4 (CH2CH3), 123.7 (q, 1JC,F = 274.1 Hz, CF3), 126.1
(Ar-C), 126.9 (q, 3JC,F = 5.4 Hz, 3-Ar-CH), 129.0 (6-Ar-CH), 129.9 (q, 2JC,F = 30.7 Hz, 2-Ar-
C), 130.1 (4-Ar-CH), 130.6 (q, 4JC,F = 1.9 Hz, CH), 132.1 (q, 3JC,F = 1.7 Hz, 1-Ar-C), 132.5
(5-Ar-CH), 164.8 (C=O), 166.3 (C=O), 167.3 (COOEt) ppm; ESI-MS m/z (%) = 360.1 [M+H]+
(100 %), 377.1 [M+NH4]+ (60 %), 382.0 [M+Na]+ (30 %), 741.1 [2M+Na]+ (100 %); HR-MS m/z
= 360.0519 [M+H]+ (calculated: 360.0512); HPLC-Analysis (Method B): 98 %, Rt = 18.8 min.
Ethyl 2-[(5Z)-2,4-dioxo-5-[3-(trifluoromethyl)phenyl]methylidene-1,3-thiazolidin-3-yl] acetate 7f
TLC Rf = 0.5 (Hexane/EtOAc 8:2); Reaction time: 72 h; Purification: Flash-Chromatography
Hexane/EtOAc 9:1 (Rf = 0.3), loaded in DCM; Yield: 160 mg of yellow solid (0.45 mmol, 52 %);
1H-NMR (400 MHz, CDCl3) δ= 1.30 (t, 3 H, 3JH,H = 7.1 Hz, CH3), 4.25 (q, 2 H, 3JH,H = 7.1 Hz,
CH2CH3), 4.49 (s, 2 H, CH2), 7.60-7.63 (m, 1 H, 5-Ar-CCH), 7.68-7.71 (m, 2 H, 4,6-Ar-CH),
7.75 (s, 1 H, 2-Ar-CC), 7.94 (s, 1 H, CH) ppm; 13C-NMR (400 MHz, CDCl3) δ= 14.2 (CH3), 42.4
(CH2), 62.4 (CH2CH3), 123.5 (Ar-C), 123.7 (q, 1JC,F = 272.8 Hz, CF3), 127.1 (q, 3JC,F = 3.9 Hz,
2 or 4-CH), 127.2 (q, 3JC,F = 3.7 Hz, 2 or 4-CH), 130.0 (5-Ar-CH), 132.0 (q, 2JC,F = 32.9 Hz,
3-Ar-CCF3), 132.7 (CH), 132.8 (6-Ar-CH), 134.0 (Ar-C), 165.4 (C=O), 166.2 (C=O), 166.9
(COOEt) ppm; ESI-MS m/z (%) = 360.1 [M+H]+ (90 %), 377.1 [M+NH4]+ (100 %), 382.0 [M+Na]+
(12 %), 736.1 [2M+H]+ (11 %), 741.1 [2M+Na]+ (18 %); HPLC-Analysis (Method B): 98 %,
Rt = 18.8 min.
Ethyl 2-[(5Z)-5-[3-(benzyloxy)phenyl]methylidene-2,4-dioxo-1,3-thiazolidin-3-yl] acetate 7h [276]
TLC Rf = 0.5 (Hexane/EtOAc 8:2); Reaction time: 4 h; Purification: Flash-Chromatogra-
phy Hexane/EtOAc 9:1 (Rf = 0.3), loaded in DCM; Yield: 430 mg of white solid (1.08 mmol,
88 %); 1H-NMR (400 MHz, CDCl3) δ= 1.28 (t, 3 H, 3JH,H = 7.1 Hz, CH3), 4.23 (q, 2 H, 3JH,H =
7.1 Hz, CH2CH3), 4.45 (s, 2 H, CH2), 5.09 (s, 2 H, CH2), 7.03-7.06 (m, 2 H, 2,4-Ar-CH), 7.09 (d,
1 H, 3JH,H = 8.1 Hz, 6-Ar-CH), 7.30-7.45 (m, 6 H, 6xAr-CH), 7.86 (s, 1 H, CH) ppm; 13C-NMR
(400 MHz, CDCl3) δ= 14.1 (CH3), 42.2 (CH2), 62.2 (CH2CH3), 70.2 (CH2), 116.0 (2-Ar-CH),
117.8 (4-Ar-CH), 121.4 (Ar-C), 123.1 (6-Ar-CH), 127.5 (2xAr-CH), 128.3 (Ar-CH), 128.8 (2xAr-
CH), 130.4 (Ar-CH), 134.4 (Ar-C), 134.6 (CCH), 136.4 (Ar-C), 159.2 (Ar-C), 165.5 (C=O),
166.3 (C=O), 167.4 (COOEt) ppm; ESI-MS m/z (%) = 398.1 [M+H]+ (100 %), 415.1 [M+NH4]+
(24 %), 420.1 [M+Na]+ (4 %), 812.2 [2M+NH4]+ (13 %); HPLC-Analysis (Method B): 99 %,
Rt = 20.3 min.
Ethyl 2-[(5Z)-5-[4-(benzyloxy)phenyl]methylidene-2,4-dioxo-1,3-thiazolidin-3-yl] acetate 7i
TLC Rf = 0.7 (Hexane/EtOAc 8:2); Reaction time: 8 h; Purification: Filtration from Ethanol;
Yield: 245 mg of white solid (0.62 mmol, 50 %); 1H-NMR (400 MHz, CDCl3) δ= 1.30 (t,
3 H, 3JH,H = 7.1 Hz, CH2), 4.25 (q, 2 H, 3JH,H = 7.1 Hz, CH2CH3), 4.48 (s, 2 H, CH2), 5.14
(s, 2 H, CH2), 7.07 (d, 2 H, 3JH,H = 8.8 Hz, 3,5-Ar-CH), 7.33-7.46 (m, 5 H, 5xAr-CH), 7.48 (d,
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2 H, 3JH,H = 8.8 Hz, 2,6-Ar-CH), 7.89 (s, 1 H, CH) ppm; 13C-NMR (400 MHz, CDCl3) δ= 14.2
(CH3), 42.2 (CH2), 62.3 (CH2CH3), 70.4 (CH2), 115.8 (3,5-Ar-CH), 118.2 (Ar-C), 126.1 (Ar-C),
127.6 (2xAr-CH), 128.5 (Ar-CH), 128.9 (2xAr-CH) 132.5 (2,6-Ar-CH), 134.7 (CH), 136.2 (Ar-
C), 160.9 (Ar-C), 165.9 (Ar-C=O), 166.5 (C=O), 167.8 (COOEt) ppm; ESI-MS m/z (%) = 398.1
[M+H]+ (100 %), 415.1 [M+NH4]+ (21 %), 420.1 [M+Na]+ (6 %), 812.2 [2M+NH4]+ (34 %), 817.2
[2M+Na]+ (3 %); HPLC-Analysis (Method B): 99 %, Rt = 20.3 min.
Ethyl 2-[(5Z)-5-[3,4-bis(benzyloxy)phenyl]methylidene-2,4-dioxo-1,3-thiazolidin-3-yl] acetate 7j
TLC Rf = 0.5 (Hexane/EtOAc 8:2); Reaction time: 16 h; Purification: Filtration from ethanol;
Yield: 200 mg of white solid (0.40 mmol, 67 %); 1H-NMR (400 MHz, CDCl3) δ= 1.29 (t, 3 H,
3JH,H = 7.1 Hz, CH3), 4.23 (q, 2 H, 3JH,H = 7.1 Hz, CH2), 4.45 (s, 2 H, CH2), 5.23, 5.25 (0,
s H, ,J = CH2, ) 6.97-7.09 (m, 3 H, 3xAr-CH), 7.31-7.48 (m, 11 H, 11xAr-CH), 7.79 (s, 1 H,
CH) ppm; 13C-NMR (400 MHz, CDCl3) δ= 14.3 (CH3), 42.2 (CH2), 62.3 (CH2CH3), 71.1
(OCH2), 71.4 (OCH2), 114.3 (Ar-CH), 116.0 (Ar-CH), 118.5 (Ar-C), 125.6 (Ar-CH), 126.4
(Ar-C), 127.3 (3xAr-CH), 128.8 (Ar-CH), 128.9 (2xAr-CH), 134.8 (CH), 136.5 (Ar-C), 136.6
(Ar-C), 149.0 (Ar-C), 151.4 (Ar-C), 166.4 (C=O), 167.6 (C=O) ppm; ESI-MS m/z (%) = 504.1
[M+H]+ (100 %), 521.2 [M+NH4]+ (75 %), 526.1 [M+Na]+ (40 %), 542.1 [M+K]+ (10 %), 1024.3
[2M+NH4]+ (100 %), 1029.3 [2M+Na]+ (40 %), 1045.2 [2M+K]+ (10 %); HR-MS m/z = 504.1469
[M+H]+ (calculated: 504.1475).
Ethyl 2-[(5Z)-5-[(3,4-dihydroxyphenyl)methylidene]-2,4-dioxo-1,3-thiazolidin-3-yl] acetate 7k
TLC Rf = 0.1 (CHCl3/MeOH/HOAc 96:3:1); Reaction time: 1 h; Purification: Flash-Chroma-
tography CHCl3/MeOH/HOAc 95:4:1 (Rf = 0.2); Yield: 465 mg of white solid (1.44 mmol,
58 %); Yield: 202 mg of white solid (0.62 mmol, 31 %); 1H-NMR (400 MHz, MeOD) δ=
1.26 (t, 3 H, 3JH,H = 7.1 Hz, CH3), 4.21 (q, 2 H, 3JH,H = 7.1 Hz, CH2), 4.44 (s, 2 H, CH2),
6.85 (d, 1 H, 3JH,H = 8.2 Hz, 5-Ar-CH), 6.95 (d, 1 H, 3,4JH,H = 2.1, 8.2 Hz, 6-Ar-CH), 7.00
(d, 1 H, 4JH,H = 2.1 Hz, 2-Ar-CH), 7.73 (s, 1 H, CH) ppm; 1H-NMR (400 MHz, CDCl3) δ=
1.31 (t, 3 H, 3JH,H = 7.1 Hz, CH3), 4.26 (q, 2 H, 3JH,H = 7.1 Hz, CH2CH3), 4.48 (s, 2 H, CH2),
5.70 (s(br), 1 H, OH), 5.95 (s(br), 1 H, OH), 6.95 (d, 1 H, 3JH,H = 8.5 Hz, 5-Ar-CH), 6.98-7.03
(m, 2 H, 2,6-Ar-CH), 7.78 (s, 1 H, CH) ppm; 13C-NMR (400 MHz, MeOD) δ= 14.4 (CH3),
42.9 (CH2), 63.1 (CH2CH3), 116.9 (5-Ar-CH), 117.6 (2-Ar-CH), 125.7 (6-Ar-CH), 126.2 (Ar-C),
136.2 (CH), 147.1 (Ar-C), 150.1 (Ar-C), 167.1 (Ar-C), 168.4 (C=O), 169.0 (C=O) ppm; ESI-MS
m/z (%) = 324.1 [M+H]+ (100 %), 341.1 [M+NH4]+ (20 %), 664.1 [2M+NH4]+ (25 %); HR-MS m/z
= 324.0540 [M+H]+ (calculated: 324.0536); HPLC-Analysis (Method B): 95 %, Rt = 14.3 min.
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9.4 General procedure for 3-(4-oxo-2-sulfanylidene-1,3-thiazolidin-3- yl)
propanoic/ butanoic acid 12 and 13
β-alanine or γ-aminobutyric acid (30 mmol), carbon disulphide (30 mmol) and sodium acetate
(30 mmol) were dissolved in 100 mL water. The reaction mixture was stirred 16 h at rt, after
which bromo acetic acetate (30 mmol) were added. The reaction mixture turned red, while
stirring was continued for another 3 h at rt. The mixture was acidified by addition of 30 mL
HCl (6 N). The resulting red suspension was stirred 16 h at 100 ◦C. Upon cooling red crys-
tals formed and were filtered then washed with water. The crude was concentrated and re-
crystallized from HClaq. 3-(4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl) propanoic acid 12 [277]
Purification: Re-crystallisation from HClaq; Yield: 8165 mg of red crystals (39.78 mmol,
80 %); Yield: 1655 mg of red crystals (8.06 mmol, 72 %); Yield: 3988 mg of red crystals
(19.43 mmol, 65 %); 1H-NMR (400 MHz, CDCl3) δ= 2.76 (t, 2 H, 3JH,H = 7.6 Hz, β-CH2), 4.00
(s, 2 H, CH2), 4.30 (t, 2 H, 3JH,H = 7.6 Hz, α-CH2) ppm; 1H-NMR (400 MHz, DMSO-d6) δ=
2.48-2.54 (m, 2 H, α-CH2), 4.03-4.08 (m, 2 H, β-CH2), 4.22 (s, 2 H, CH2), 12.5 (s(br), 1 H,
COOH) ppm; 13C-NMR (400 MHz, DMSO-d6) δ= 30.6 (α-CH2), 36.0 (CH2), 39.6 (β-CH2),
171.8 (C=O), 174.3 (COOH), 203.0 (C=S) ppm; ESI-MS m/z (%) = 204.0 [M−H]− (100 %);
HPLC-Analysis (Method B): 98 %, Rt = 8.4 min.
4-(4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl)butanoic acid 103butycooh [278]
TLC Rf = 0.4 (Hexane/EtOAc/HOAc 1:1:0.01); Purification: Re-crystallisation from HClaq;
Yield: 4461 mg of yellow solid (20.34 mmol, 68 %); 1H-NMR (400 MHz, DMSO-d6) δ= 1.79
(ap, 2 H, 3JH,H = 7.0, 7.4 Hz, β-CH2), 2.25 (t, 2 H, 3JH,H = 7.4 Hz, γ-CH2), 3.90 (t, 2 H, 3JH,H =
7.0 Hz, α-CH2), 4.22 (s, 2 H, CH2), 12.12 (s, 1 H, COOH) ppm; 13C-NMR (400 MHz, DMSO-d6)
δ= 21.9 (CH2), 30.9 (CH2), 35.9 (CH2), 43.3 (CH2), 173.8 (C=O), 174.6 (COOH), 203.5 (C=S)
ppm; ESI-MS m/z (%) = 218.0 [M−H]− (100 %).
Knoevenagel condensation of 12 and 13 with various benzaldehydes: Derivatives
12a–m and 13a–d
Compound 12 or 13 (1.0 eq), the benzaldehyde derivatives (1.1-1.5 eq) and sodium acetate
(1.0 eq) were dissolved in 5-10 mL ethanol. The reaction mixture was stirred at 80 ◦C for 2-
16 h. Upon cooling a precipitate formed and was filtered then washed with ethanol.
3-[(5Z)-4-oxo-5-(phenylmethylidene)-2-sulfanylidene-1,3-thiazolidin-3-yl] propanoic acid 12a [279]
TLC Rf = 0.6 (Hexane/EtOAc/HOAc 1:1:0.01); Reaction time: 4 h; Purification: Filtration
from ethanol; Yield: 287 mg of orange solid (0.98 mmol, 80 %); 1H-NMR (400 MHz, DMSO-
d6) δ= 2.33-2.39 (m, 2 H, β-CH2), 4.13-4.19 (m, 2 H, α-CH2), 7.49-7.59 (m, 3 H, 3xAr-CH),
7.62-7.66 (m, 2 H, 2xAr-CH), 7.81 (s, 1 H, CH) ppm; 13C-NMR (400 MHz, DMSO-d6) δ=
32.8 (β-CH2), 41.5 (α-CH2), 122.6 (Ar-C), 129.5 (2xAr-CH), 130.6 (2xAr-CH), 130.9 (Ar-CH),
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132.7 (CH), 133.1 (Ar-C), 166.8 (C=O), 172.4 (COOH), 193.2 (C=S) ppm; ESI-MS m/z (%) =
292.0 [M−H]− (100 %), 585.0 [2M−H]− (100 %), 607.0 [2M+Na−2H]− (20 %); HR-MS m/z =
292.0113 [M−H]− (calculated: 292.0108); HPLC-Analysis (Method B): 98 %, Rt = 18.4 min.
3-[(5Z)-5-[(2-methylphenyl)methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl] propanoic
acid 12b [280]
TLC Rf = 0.4 (Hexane/EtOAc/HOAc 1:1:0.01); Reaction time: 2h; Purification: Filtration
from ethanol Yield: 326 mg of orange solid (1.06 mmol, 87 %); 1H-NMR (400 MHz, DMSO-
d6) δ= 2.22-2.27 (m, 2 H, β-CH2), 2.43 (s, 3 H, CH3), 4.11-4.17 (m, 2 H, α-CH2), 7.34-7.43
(m, 4 H, 4xAr-CH), 7.88 (s, 1 H, CH) ppm; 13C-NMR (400 MHz, DMSO-d6) δ= 19.5 (CH3),
34.3 (β-CH2), 42.5 (α-CH2), 124.2 (Ar-C), 126.9 (Ar-CH), 127.8 (Ar-CH), 130.3 (CH), 130.8
(Ar-CH), 131.2 (Ar-CH), 132.1 (Ar-C), 139.2 (Ar-C), 166.6 (C=O), 172.8 (COOH), 193.7 (C=S)
ppm; ESI-MS m/z (%) = 306.0 [M−H]− (100 %), 613.1 [2M−H]− (71 %); ESI-MS m/z (%) = 306.0
[M−H]− (54 %), 613.1 [2M−H]− (100 %); HPLC-Analysis (Method B): 96 %, Rt = 19.3 min.
3-[(5Z)-5-[(3-methylphenyl)methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl] propanoic
acid 12c [280]
TLC Rf = 0.4 (Hexane/EtOAc/HOAc 1:1:0.01); Reaction time: 3.5 h; Purification: Filtration
from ethanol; Yield: 367 mg of yellow solid (1.19 mmol, 98 %); 1H-NMR (400 MHz, DMSO-d6)
δ= 2.28-2.34 (m, 2 H, β-CH2), 2.38 (s, 3 H, CH3), 4.12-4.18 (m, 2 H, α-CH2), 7.31-7.36 (m,
1 H, Ar-CH), 7.41-7.46 (m, 3 H, 3xAr-CH), 7.75 (s, 1 H, CH) ppm; 13C-NMR (400 MHz, DMSO-
d6) δ= 20.9 (CH3), 33.6 (β-CH2), 42.0 (α-CH2), 122.5 (Ar-C), 127.9 (Ar-CH), 129.4 (Ar-CH),
131.0 (Ar-CH), 131.7 (Ar-C), 132.8 (Ar-CH), 133.1 (CH), 138.9 (Ar-C), 166.8 (C=O), 172.6
(COOH), 193.3 (C=S) ppm; ESI-MS m/z (%) = 306.0 [M−H]− (100 %), 613.1 [2M−H]− (52 %);
HPLC-Analysis (Method B): 97 %, Rt = 17.6 min.
3-[(5Z)-5-[(4-methylphenyl)methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl] propanoic
acid 12d [280]
TLC Rf = 0.5 (Hexane/EtOAc/HOAC 1:1:0.01); Reaction time: 3 h; Purification: Filtration
from ethanol; Yield: 363 mg of yellow solid (1.18 mmol, 97 %); 1H-NMR (400 MHz, DMSO-d6)
δ= 2.36 (s, 3 H, CH3), 2.42-2.48 (m, 2 H, β-CH2), 4.14-4.20 (m, 2 H, α-CH2), 7.37 (d, 2 H,
3JH,H = 8.2 Hz, 3,5-Ar-CH), 7.54 (d, 2 H, 3JH,H = 8.2 Hz, 2,6-Ar-CH), 7.77 (s, 1 H, CH) ppm;
13C-NMR (400 MHz, DMSO-d6) δ= 21.2 (CH3), 32.3 (β-CH2), 41.1 (α-CH2), 121.3 (Ar-C),
130.2 (3,5-Ar-CH), 130.3 (Ar-C), 130.8 (2,6-Ar-CH), 133.0 (CH), 141.5 (Ar-C), 166.8 (C=O)
172.2 (COOH), 193.2 (C=S) ppm; ESI-MS m/z (%) = 306.0 [M−H]− (86 %), 613.1 [2M−H]−
(100 %); HPLC-Analysis (Method B): 98 %, Rt = 19.5 min.
3-[(5Z)-4-oxo-2-sulfanylidene-5-[2-(trifluoromethyl)phenyl]methylidene-1,3-thiazolidin-3-yl] pro-
panoic acid 12e
TLC Rf = 0.3 (Hexane/EtOAc/HOAc 6:4:0.01); Reaction time: 4 h; Purification: Filtration
from ethanol; Yield: 257 mg of yellow solid (0.71 mmol, 58 %); 1H-NMR (400 MHz, DMSO-d6)
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δ= 2.23-2.30 (m, 2 H, β-CH2), 4.11-4.17 (m, 2 H, α-CH2), 7.68-7.75 (m, 2 H, 4,6-Ar-CH), 7.80
(q, 1 H, 5JH,F = 1.9 Hz, CH), 7.87 (at, 1 H, 3JH,H = 7.6, 7.7 Hz, 5-Ar-CH), 7.92 (d, 1 H, 3JH,H =
7.7 Hz, 3-Ar-CH) ppm; 13C-NMR (400 MHz, DMSO-d6) δ= 34.1 (β-CH2), 42.5 (α-CH2), 123.9
(q, 1JC,F = 274.2 Hz, CF3), 126.2 (CH), 127.0 (q, 3JC,F = 5.7 Hz, 3-Ar-CH), 127.7 (Ar-C), 128.1
(Ar-C), 129.5 (6-Ar-CH), 130.8 (4-Ar-CH), 131.2 (Ar-C), 133.6 (5-Ar-CH), 163.3 (C=O), 172.7
(COOH), 193.2 (C=S) ppm; ESI-MS m/z (%) = 360.0 [M−H]− (100 %), 721.0 [2M−H]− (100 %);
HR-MS m/z = 359.9974 [M−H]− (calculated: 359.9981); HPLC-Analysis (Method B): 96 %,
Rt = 11.8 min.
3-[(5Z)-4-oxo-2-sulfanylidene-5-[3-(trifluoromethyl)phenyl]methylidene-1,3-thiazolidin-3-yl] pro-
panoic acid 12f
TLC Rf = 0.5 (DCM/MeOH/HOAc 9:1:0.01); Reaction time: 2 h; Purification: Filtration from
ethanol; Yield: 305 mg of yellow solid (0.84 mmol, 69 %); 1H-NMR (400 MHz, DMSO-d6) δ=
2.26-2.32 (m, 2 H, β-CH2), 4.12-4.18 (m, 2 H, α-CH2), 7.79 (at, 1 H, 3JH,H = 7.8 Hz, 5-Ar-CH),
7.84-7.91 (m, 2 H, 4,6-Ar-CH), 7.92 (s, 1 H, CH), 8.04 (s(br), 1 H, 2-Ar-CH) ppm; 13C-NMR
(400 MHz, DMSO-d6) δ= 33.7 (β-CH2), 42.2 (α-CH2), 124.9 (4 or 6-Ar-CH), 127.5 (2-Ar-CH),
130.7 (CH and 4-Ar-CH), 133.2 (4 or 6-Ar-CH), 134.2 (Ar-C), 166.7 (C=O), 172.5 (COOH),
192.8 (C=S) ppm; ESI-MS m/z (%) = 360.0 [M−H]− (100 %), 721.0 [2M−H]− (100 %); HR-
MS m/z = 359.9976 [M−H]− (calculated: 359.9981); HPLC-Analysis (Method B): 94 %, Rt =
18.8 min.
3-[(5Z)-5-[2,5-bis(trifluoromethyl)phenyl]methylidene-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]
propanoic acid 12g
TLC Rf = 0.6 (DCM/MeOH/HOAc 9:1:0.01); Reaction time: 2 h; Purification: Filtration from
ethanol; Yield: 98 mg of yellow solid (0.23 mmol, 19 %); 1H-NMR (400 MHz, DMSO-d6) δ=
2.18-2.24 (m, 2 H, β-CH2), 4.10-4.16 (m, 2 H, α-CH2), 7.77 (q, 1 H, 5JH,F = 2.1 Hz, CH), 7.99
(s, 1 H, 6-Ar-CH), 8.10 (d, 1 H, 3JH,H = 8.3 Hz, 4-Ar-CH), 8.16 (d, 1 H, 3JH,H = 8.3 Hz, 5-Ar-
CH) ppm; 13C-NMR (400 MHz, DMSO-d6) δ= 34.3 (β-CH2), 42.7 (α-CH2), 124.9 (CH), 125.9
(6-Ar-CH), 127.4 (4-Ar-CH), 128.4 (5-Ar-CH) ppm; ESI-MS m/z (%) = 428.0 [M−H]− (100 %),
857.0 [M−H]− (20 %); HPLC-Analysis (Method B): 84 %, Rt = 19.5 min.
3-[(5Z)-5-[4-(dimethylamino)phenyl]methylidene-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl] pro-
panoic acid 12h [281]
TLC Rf = 0.3 (Hexane/EtOAc/HOAc 6:4:0.01); Reaction time: 4 h; Purification: Filtration
from ethanol; Yield: 330 mg of red solid (0.98 mmol, 80 %); 1H-NMR (400 MHz, DMSO-d6)
δ= 2.36-2.42 (m, 2 H, β-CH2), 3.04 (s, 6 H, 2xCH3), 4.13-4.18 (m, 2 H, α-CH2), 6.83 (d, 2 H,
3JH,H = 9.1 Hz, 3,5-Ar-CH), 7.46 (d, 2 H, 3JH,H = 9.1 Hz, 2,6-Ar-CH), 7.67 (s, 1 H, CH) ppm;
13C-NMR (400 MHz, DMSO-d6) δ= 32.8 (β-CH2), 39.6 (N(CH3)2), 41.2 (α-CH2), 112.3 (3,5-
Ar-CH), 114.1 (Ar-C), 119.9 (Ar-C), 133.2 (2,6-Ar-CH), 134.4 (CH), 151.9 (Ar-C), 166.8 (C=O),
172.3 (C=OOH), 192.4 (C=S) ppm; ESI-MS m/z (%) = 335.1 [M−H]− (100 %), 671.1 [2M−H]−
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(58 %); HPLC-Analysis (Method B): 99 %, Rt = 21.2 min.
3-[(5Z)-5-[(4-chlorophenyl)methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]propanoic
acid 12i
TLC Rf = 0.5 (Hexane/EtOAc/HOAc 1:1:0.01); Reaction time: 4 h; Purification: Filtration
from ethanol; Yield: 333 mg of yellow solid (1.02 mmol, 83 %); 1H-NMR (400 MHz, DMSO-d6)
δ= 2.13-2.20 (m, 2 H, β-CH2), 4.08-4.14 (m, 2 H, α-CH2), 7.62 (d, 2 H, 3JH,H = 8.7 Hz, 2,6-
Ar-CH), 7.67 (d, 3 H, 3JH,H = 8.7 Hz, 3,5-Ar-CH), 7.81 (s, 1 H, CH) ppm; 13C-NMR (400 MHz,
DMSO-d6) δ= 34.6 (β-CH2), 42.7 (α-CH2), 129.6 (2,6-Ar-CH), 131.1 (CH), 132.0 (Ar-C), 132.2
(3,5-Ar-CH), 135.5 (Ar-C), 166.8 (C=O), 171.9 (C=S) ppm; ESI-MS m/z (%) = 326.0 [M−H]−
(100 %), 653.0 [2M−H]− (80 %), 674.9 [2M+Na−H]− (100 %); HR-MS m/z = 325.9724 [M−H]−
(calculated: 325.9718); HPLC-Analysis (Method B): 81 %, Rt = 17.5 min.
3-[(5Z)-5-[(2-hydroxyphenyl)methylidene]-4-oxo-2- sulfanylidene-1,3-thiazolidin-3-yl] propano-
ic acid 12j [281]
Reaction time: 2 h; Purification: Filtration from ethanol; Yield: 35 mg of red solid (0.11 mmol,
21 %); 1H-NMR (400 MHz, DMSO-d6) δ= 2.15-2.25 (m, 2 H, β-CH), 3.16-3.26 (m, 2 H, α-CH),
6.92-7.38 (m, 4 H, 4xAr-CH), 7.42 (s, 1 H, CH) ppm; ESI-MS m/z (%) = 308.0 [M−H]− (100 %),
617.0 [2M−H]− (100 %), 639.0 [2M+Na−2H]− (95 %); HR-MS m/z = 308.0062 [M−H]− (calcu-
lated: 308.0057).
3-[(5Z)-5-[(3-hydroxyphenyl)methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl] propanoic
acid 12k [280]
TLC Rf = 0.3 (Hexane/EtOAc/HOAc 6:4:0.01); Reaction time: 4 h; Purification: Filtration
from ethanol; Yield: 300 mg of yellow solid (0.97 mmol, 79 %); 1H-NMR (400 MHz, DMSO-
d6) δ= 2.21-2.29 (m, 2 H, β-CH2), 4.10-4.18 (m, 2 H, α-CH2), 6.88-6.95 (m, 1 H, 4-Ar-CH),
7.00-7.07 (m, 2 H, 2,6-Ar-CH), 7.28-7.36 (m, 1 H, 5-Ar-CH), 7.69 (s, 1 H, CH) ppm; 13C-NMR
(400 MHz, DMSO-d6) δ= 34.3 (β-CH2), 42.5 (α-CH2), 116.5 (2 or 6-Ar-CH), 118.5 (4-Ar-CH),
121.6 (Ar-C), 122.3 (2,6-Ar-CH), 130.5 (5-Ar-CH), 133.0 (CH), 134.2 (Ar-C), 158.5 (Ar-C),
166.9 (C=O), 172.7 (COOH), 193.3 (C=S) ppm; ESI-MS m/z (%) = 308.0 [−HM-]100 (; %) HR-
MS m/z = 308.0051 [M−H]− (calculated: 308.0057); HPLC-Analysis (Method B): 100 %, Rt =
16.6 min.
3-[(5Z)-5-[(4-hydroxyphenyl)methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl] propanoic
acid 12l [280]
TLC Rf = 0.3 (Hexane/EtOAc/HOAc 6:4:0.01); Yield: 320 mg of yellow solid (1.03 mmol,
85 %); Reaction time: 4 h; Purification: Filtration from ethanol; 1H-NMR (400 MHz, DMSO-
d6) δ= 2.31-2.37 (m, 2 H, β-CH2), 4.12-4.18 (m, 2 H, α-CH2), 6.85 (d, 2 H, 3JH,H = 8.7 Hz, 3,5-
Ar-CH), 7.45 (d, 2 H, 3JH,H = 8.7 Hz, 2,6-Ar-CH), 7.68 (s, 1 H, CH) ppm; 13C-NMR (400 MHz,
DMSO-d6) δ= 33.0 (β-CH2), 41.4 (α-CH2), 117.0 (3,5-Ar-CH), 133.4 (2,6-Ar-CH), 133.9 (CH),
166.9 (C=O), 172.4 (COOH), 192.8 (C=S) ppm; ESI-MS m/z (%) = 308.0 [−HM-]100 (; %) HR-
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MS m/z = 308.0060 [M−H]− (calculated: 308.0057); HPLC-Analysis (Method B): 60 %, Rt =
16.6 min.
3-[(5Z)-5-[(3,4-dihydroxyphenyl)methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl] propa-
noic acid 12m [280]
TLC Rf = 0.1 (Hexane/EtOAc 1:1); Reaction time: 4 h; Purification: Filtration from ethanol;
Yield: 361 mg of red solid (1.11 mmol, 91 %); 1H-NMR (400 MHz, DMSO-d6) δ= 2.36-2.42
(m, 2 H, β-CH2), 4.12-4.18 (m, 2 H, α-CH2), 6.50-6.61 (m, 1 H, 5-Ar-CH), 6.79-6.86 (m, 1 H,
2-Ar-CH), 6.98 (dd, 1 H, 3,4JH,H = 2.4, 8.5 Hz, 6-Ar-CH), 7.51 (s, 1 H, CH) ppm; 13C-NMR
(400 MHz, DMSO-d6) δ= 33.0 (β-CH2), 41.2 (α-CH2), 114.2 (2-Ar-CH), 116.9 (5-Ar-CH),
129.2 (6-Ar-CH), 135.2 (CH) ppm; ESI-MS m/z (%) = 324.0 [M−H]− (100 %), 649.0 [2M−H]−
(18 %); HPLC-Analysis (Method B): 94 %, Rt = 15.1 min.
4-[(5Z)-4-oxo-5-(phenylmethylidene)-2-sulfanylidene-1,3-thiazolidin-3-yl] butanoic acid 13a [282]
TLC Rf = 0.7 (Hexane/EtOAc/HOAc 1:1:0.01); Reaction time: 4 h; Purification: Filtration
from ethanol; Yield: 317 mg of orange solid (1.03 mmol, 90 %); 1H-NMR (400 MHz, DMSO-
d6) δ= 1.83 (p, 2 H, 3JH,H = 7.5 Hz, β-CH2) 2.11 (t, 2 H, 3JH,H = 7.5 Hz, γ-CH2), 4.05 (t, 2 H,
3JH,H = 7.5 Hz, α-CH2), 7.48-7.58 (m, 3 H, 3xAr-CH), 7.62-7.66 (m, 2 H, 2xAr-CH), 7.80 (s,
1 H, CH) ppm; 13C-NMR (400 MHz, DMSO-d6) δ= 23.0 (β-CH2), 33.2 (γ-CH2), 44.3 (α-CH2),
122.6 (Ar-C), 129.5 (Ar-CH), 130.7 (Ar-CH), 130.9 (Ar-CH), 132.7 (CH), 133.1 (Ar-C), 167.1
(C=O), 174.4 (COOH), 193.6 (C=S) ppm; ESI-MS m/z (%) = 306.0 [M−H]− (100 %), 613.0
[2M−H]− (100 %); HR-MS m/z = 306.0258 [M−H]− (calculated: 306.0264); HPLC-Analysis
(Method B): 100 %, Rt = 18.7 min.
4-[(5Z)-5-[(2-methylphenyl)methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]butanoic
acid 13b [283]
TLC Rf = 0.1 (Hexane/EtOAc/HOAc 6:4:0.01); Reaction time: 3 h; Purification: Filtration
from ethanol; Yield: 222 mg of yellow solid (0.69 mmol, 61 %); 1H-NMR (400 MHz, DMSO-d6)
δ= 1.77-1.86 (m, 2 H, β-CH2), 2.02-2.08 (m, 2 H, γ-CH2), 4.01-4.07 (m, 2 H, α-CH2), 7.34-
7.44 (m, 4 H, 4xAr-CH), 7.88 (s, 1 H, CH) ppm; 13C-NMR (400 MHz, DMSO-d6) δ= 19.5 (CH3)
23.4 (β-CH2), 33.8 (γ-CH2), 44.5 (α-CH2), 124.1 (Ar-C), 126.9 (Ar-CH) 127.8 (Ar-CH), 130.4
(CH) 130.8 (Ar-CH), 131.2 (Ar-CH), 132.1 (Ar-C), 139.3 (Ar-C), 166.7 (C=O), 174.6 (COOH),
194.0 (C=S) ppm; ESI-MS m/z (%) = 320.0 [M−H]− (100 %), 641.1 [2M−H]− (25 %), 663.1
[2M+Na−H]− (10 %); HR-MS m/z = 320.0413 [M−H]− (calculated: 320.0421); HPLC-Analysis
(Method B): 98 %, Rt = 19.5 min.
4-[(5Z)-5-[(3-methylphenyl)methylidene]-4-oxo-2- sulfanylidene-1,3-thiazolidin-3-yl] butanoic
acid 13c [283]
TLC Rf = 0.5 (Hexane/EtOAc/HOAc 6:4:0.01); Reaction time: 3 h; Purification: Filtration
from ethanol; Yield: 259 mg of red solid (0.81 mmol, 71 %); 1H-NMR (400 MHz, DMSO-d6)
δ= 1.72-1.95 (m, 2 H, ) 2.09-2.24 (m, 2 H, ) 2.37 (s, 3 H, Ar-CH3), 3.97-4.12 (m, 2 H, α-CH2),
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7.27-7.53 (m, 4 H, 4xAr-CH), 7.73 (s, 1 H, CH) ppm; 13C-NMR (400 MHz, DMSO-d6) δ= 20.9
(CH3), 22.7 (β-CH2), 32.5 (γ-CH2), 44.1 (α-CH2), 122.3 (Ar-C), 127.9 (Ar-CH), 129.4 (Ar-CH),
131.1 (Ar-CH), 131.7 (Ar-CH), 132.8 (CH), 133.0 (Ar-C), 138.9 (Ar-C), 167.1 (C=O), 174.4
(COOEt), 193.6 (C=S) ppm; ESI-MS m/z (%) = 320.0 [M−H]− (100 %); HR-MS m/z = 320.0419
[M−H]− (calculated: 320.0421); HPLC-Analysis (Method B): 99 %, Rt = 19.8 min.
4-[(5Z)-5-[(4-methylphenyl)methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl] butanoic
acid 13d [283]
TLC Rf = 0.4 (Hexane/EtOAc/HOAc 6:4:0.01); Reaction time: 3 h; Purification: Filtration
from ethanol; Yield: 265 mg of red solid (0.82 mmol, 72 %); 1H-NMR (400 MHz, DMSO-d6) δ=
1.77-1.86 (m, 2 H, β-CH2), 2.07-2.14 (m, 2 H, γ-CH2), 2.36 (s, 3 H, CH3), 4.04 (t, 2 H, 3JH,H =
7.1 Hz, α-CH2), 7.36 (d, 2 H, 3JH,H = 8.2 Hz, 3,5-Ar-CH), 7.53 (d, 2 H, 3JH,H = 8.2 Hz, 2,6-Ar-
CH), 7.76 (s, 1 H, CH) ppm; 13C-NMR (400 MHz, DMSO-d6) δ= 21.2 (CH3), 23.1 (β-CH2),
33.2 (γ-CH2), 44.3 (α-CH2), 121.3 (Ar-C), 130.2 (3,5-Ar-CH), 130.4 (Ar-C), 130.8 (2,6-Ar-CH),
132.9 (CH), 141.4 (Ar-C), 167.1 (C=O, COOH) 193.5 (C=S) ppm; ESI-MS m/z (%) = 320.0
[M−H]− (34 %), 641.1 [2M−H]− (100 %); HPLC-Analysis (Method B): 99 %, Rt = 19.8 min.
9.5 General Procedure for the synthesis of ester derivatives
14a–ab, 15a–f, and 16a–j
Method 1: Knoevennagel condensation followed by esterification reaction
Rhodanine N-Acetic acid derivatives 14, 15, and 16 (1.0 eq), DCC (1.5 eq) and DMAP (0.3 eq)
were dissolved in methanol, ethanol or tert-butanol. The reaction mixture was stirred at rt for
16 h or until TLC showed complete consumption of starting material. The crude was filtered
and washed with DCM. The filtrate was concentrated and purified by flash column chromatog-
raphy.
(E,Z)-ethyl 2-(5-(3-methylbenzylidene)-4-oxo-2-thioxothiazolidin-3-yl) acetate 14a
Z to E 5:1 TLC Rf = 0.1 (Cyclohexane/EtOAc 9:1); Reaction time: 16 h; Purification: Flash-
Chromatography Cyclohexane/EtOAc 9:1 (Rf = 0.1); Yield: 36 mg of yellow solid (0.11 mmol,
53 %); spectra for Z-isomer 1H-NMR (400 MHz, DMSO-d6) δ= 1.21 (t, 3 H, 3JH,H = 7.1 Hz,
CH3), 2.39 (s, 3 H, CH3), 4.17 (q, 2 H, 3JH,H = 7.1 Hz, CH2), 4.84 (s, 2 H, CH2), 7.36-7.42 (m,
1 H, Ar-CH), 7.44-7.53 (m, 3 H, 2xAr-CH), 7.88 (s, 1 H, CH) ppm; E and Z isomer 1:5 1H-NMR
(400 MHz, CDCl3) δ= 1.28 (t, 3 H, 3JH,H = 7.1 Hz, E-CH3), 1.29 (t, 3 H, 3JH,H = 7.1 Hz, Z-CH3),
2.39 (s, 3 H, E-CH3), 2.42 (s, 3 H, Z-CH3), 4.22 (q, 2 H, 3JH,H = 7.1 Hz, E-CH2CH3), 4.24 (q,
2 H, 3JH,H = 7.1 Hz, Z-CH2CH3), 4.82 (s, 2 H, E-CH2), 4.85 (s, 2 H, Z-CH2), 7.14 (s, 1 H, E-
CH), 7.27 (d, 1 H, 3JH,H = 7.4 Hz, E,Z-Ar-CH) 7.30-7.35 (m, 2 H, 2xE,Z-Ar-CH), 7.35-7.41 (m,
2 H, E,Z-Ar-CH), 7.76 (s, 1 H, Z-CH), 7.76-7.78 (m, 1 H, E-Ar-CH), 7.81 (d, 1 H, JH,H = 7.7 Hz,
E-Ar-CH) ppm; 13C-NMR (400 MHz, CDCl3) δ= 14.3 (CH3), 21.6 (Ar-CH3), 45.0 (CH2), 62.2
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(CH2CH3), 122.5 (Z-Ar-C), 128.1 (Z-Ar-CH), 128.5 (E-Ar-CH), 128.9 (E-Ar-CH), 129.4 (Z-Ar-
CH), 131.5 (Z-Ar-CH), 132.1 (Z-Ar-CH), 133.3 (Z-Ar-C), 134.5 (Z-CH), 138.7 (E-CH), 139.4
(Z-Ar-C), 166.0 (C=O), 167.3 (COOEt), 193.3 (C=S) ppm; ESI-MS m/z (%) = 322.1 [M+H]+
(100 %), 339.1 [M+NH4]45 (; %) HR-MS m/z = 322.0568 [M+H]+ (calculated: 322.0566); HPLC-
Analysis (Method B): 98 %, Rt = 16.1 min; HPLC-Analysis : 98 %, Rt = 20.6 min.
(Z)-tert-butyl 2-(5-(3-methylbenzylidene)-4-oxo-2-thioxothiazolidin-3-yl) acetate 14b
TLC Rf = 0.1 (Cyclohexane/EtOAc 9:1); Reaction time: 4 h; Purification: Flash-Chroma-
tography Cyclohexane/EtOAc 9:1 (Rf = 0.1); Yield: 50 mg of yellow solid (0.14 mmol, 72 %);
1H-NMR (400 MHz, DMSO-d6) δ= , 1.41 (s, 9 H, OC(CH3)3), 2.39 (s, 3 H, CH3), 4.73 (s, 2 H,
CH2), 7.36-7.39 (m, 1 H, Ar-CH), 7.44-7.50 (m, 3 H, 3xAr-CH), 7.87 (s, 1 H, CH) ppm; 1H-NMR
(400 MHz, CDCl3) δ= 1.47 (s, 9 H, 3xCH3), 2.42 (s, 3 H, CH3), 4.76 (s, 2 H, CH2), 7.25-7.29 (m,
1 H, Ar-CH), 7.30-7.34 (m, 2 H, 2xAr-CH), 7.35-7.42 (m, 1 H, Ar-CH), 7.75 (s, 1 H, CH) ppm;
13C-NMR (400 MHz, CDCl3) δ= 21.6 (CH3), 28.1 (3xCH3), 45.7 (CH2), 83.4 (C(CH3)3), 122.6
(Ar-C), 128.1 (Ar-CH), 129.4 (Ar-CH), 131.4 (Ar-CH), 132.0 (Ar-CH), 133.4 (Ar-C), 134.3 (CH),
139.4 (Ar-C), 164.9 (C=O), 167.4 (COOtBu), 193.5 (C=S) ppm; ESI-MS m/z (%) = 350.1 [M+H]+
(100 %), 367.1 [M+NH4]+ (85 %), 372.1 [M+Na]+ (10 %); HR-MS m/z = 367.1147 [M+NH4]+ (cal-
culated: 367.1145); HR-MS m/z = 350.0883 [M+H]+ (calculated: 350.0879); HPLC-Analysis
(Method B): 98 %, Rt = 20.6 min.
(Z)-methyl 2-(5-(3-methylbenzylidene)-4-oxo-2-thioxothiazolidin-3-yl) acetate 14c
TLC Rf = 0.1 (Cyclohexane/EtOAc 9:1); Reaction time: 16 h; Purification: Flash-Chroma-
tography Cyclohexane/EtOAc 9:1 (Rf = 0.1); Yield: 25 mg of yellow solid (0.08 mmol, 41 %);
1H-NMR (400 MHz, DMSO-d6) δ= 2.38 (s, 3 H, CH3), 3.71 (s, 3 H, Ar-CH3), 4.86 (s, 2 H,
CH2), 7.33-7.40 (m, 1 H, Ar-CH), 7.42-7.50 (m, 3 H, 3xAr-CH), 7.86 (s, 1 H, CH) ppm; ESI-MS
m/z (%) = 308.0 [M+H]+ (100 %), 325.0 [M+NH4]+ (90 %), 330.0 [M+Na]+ (25 %), 346.0 [M+K]+
(10 %), 632.1 [2M+NH4]+ (60 %), 637.1 [2M+Na]+ (100 %), 653.1 [2M+K]+ (70 %); HR-MS m/z
= 308.0414 [M+H]+ (calculated: 308.0410); HPLC-Analysis (Method B): 98 %, Rt = 21.7 min.
(Z)-ethyl 2-(4-oxo-2-thioxo-5-(4-(trifluoromethyl)benzylidene)thiazolidin-3-yl) acetate 14d
TLC Rf = 0.1 (Cyclohexane/EtOAc 9:1); Reaction time: 16 h; Purification: Flash-Chromato-
graphy Cyclohexane/EtOAc 9:1 (Rf = 0.1); Yield: 36 mg of yellow solid (0.10 mmol, 69 %); 1H-
NMR (400 MHz, DMSO-d6) δ= 1.21 (t, 3 H, 3JH,H = 7.0 Hz, CH3), 4.18 (q, 2 H, 3JH,H = 7.0 Hz,
CH2), 4.85 (s, 2 H, CH2), 7.90 (d, 2 H, 3JH,H = 8.5H˙z, 3,5-Ar-CH), 7.93 (d, 2 H, 3JH,H = 8.5 Hz,
2,6-Ar-CH), 8.00 (s, 1 H, CH) ppm; EI-MS m/z (%) = 375.0 [M]+ (100 %), 202.0 [fragment]+
(100 %); ESI-MS m/z (%) = 391.3 [M+NH4]+ (100 %), 773.0 [2M+Na]+ (100 %); HR-MS m/z =
375.0208 [M]+ (calculated: 375.0211); HR-MS m/z = 773.0312 [2M+Na]+ (calculated: 773.0314);
HPLC-Analysis (Method B): 99 %, Rt = 20.5 min.
(Z)-methyl 2-(4-oxo-2-thioxo-5-(4-(trifluoromethyl)benzylidene)thiazolidin-3-yl) acetate 14e
TLC Rf = 0.1 (Cyclohexane/EtOAc 9:1); Reaction time: 16 h; Purification: Flash-Chroma-
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tography Cyclohexane/EtOAc 9:1 (Rf = 0.1); Yield: 36 mg of yellow solid (0.10 mmol, 71 %);
1H-NMR (400 MHz, DMSO-d6) δ= 3.71 (s, 3 H, OCH3), 4.88 (s, 2 H, CH2), 7.86-7.95 (m, 4 H,
4xAr-CH), 8.00 (s, 1 H, CH) ppm; ESI-MS m/z (%) = 378.0 [M+NH4]+ (100 %), 400.0 [M+K]+
(50 %); EI-MS m/z (%) = 361.0 [M]+ (100 %), 202.0 [fragment]+ (100 %). HR-MS m/z = 361.0046
[M]+ (calculated: 361.0054). HR-MS m/z = 378.0078 [M+NH4]+ (calculated: 379.0392); HPLC-
Analysis (Method B): 99 %, Rt = 20.5 min.
(Z)-tert-butyl 2-(5-(3,4-bis(benzyloxy)benzylidene)-4-oxo-2-thioxothiazolidin-3-yl) acetate 14f
TLC Rf = 0.6 (DCM); Reaction time: 16 h; Purification: Flash-Chromatography DCM (Rf = 0.6);
Yield: 10 mg of yellow solid (0.02 mmol, 18 %); 1H-NMR (400 MHz, DMSO-d6) δ= 1.41 (s, 9 H,
OC(CH3)3), 4.70 (s, 2 H, CH2), 5.24 (s, 2 H, OCH2Ph), 5.26 (s, 2 H, OCH2Ph), 7.26-7.50 (m,
13 H, 13xAr-CH), 7.81 (s, 1 H, CH) ppm; EI-MS m/z (%) = 547.1 [M]+ (100 %), 456.1 [fragment]+
(25 %), 400.1 [fragment]+ (15 %), 91.0 [fragment]+ (100 %). HR-MS m/z = 547.1478 [M]+ (cal-
culated: 547.1487); HPLC-Analysis (Method B): 94 %, Rt = 19.9 min.
Ethyl 2-[(5Z)-5-[(2-methylphenyl)methylidene]-4- oxo-2-sulfanylidene-1,3-thiazolidin-3-yl] ace-
tate 14g
TLC Rf = 0.6 (DCM); Reaction time: 16 h; Purification: Flash-Chromatography DCM (Rf = 0.6);
Yield: 50 mg of yellow solid (0.16 mmol, 78 %); 1H-NMR (400 MHz, DMSO-d6) δ= 1.07-1.33
(m, 3 H, CH3), 2.45 (s, 3 H, Ar-CH3), 4.06-4.26 (m, 2 H, CH2CH3), 4.84 (s, 2 H, CH2), 7.28-
7.52 (m, 4 H, 4xAr-CH), 8.00 (s, 1 H, CH) ppm; ESI-MS m/z (%) = 322.1 [M+H]+ (100 %), 339.1
[M+NH4]+ (45 %); HR-MS m/z = 322.0571 [M+H]+ (calculated: 322.0566); HPLC-Analysis
(Method B): 99 %, Rt = 20.4 min.
(Z)-tert-butyl 2-(5-(2-methylbenzylidene)-4-oxo-2-thioxothiazolidin-3-yl) acetate 14h
TLC Rf = 0.7 (DCM); Yield: 34 mg of yellow solid (0.10 mmol, 49 %); Reaction time: 16 h;
Purification: Flash-Chromatography DCM (Rf = 0.7); 1H-NMR (400 MHz, DMSO-d6) δ= 1.42
(s, 9 H, OC(CH3)3), 2.45 (s, 3 H, Ar-CH3), 4.73 (s, 2 H, CH2), 7.37-7.49 (m, 4 H, 4xAr-CH),
7.99 (s, 1 H, CH) ppm; ESI-MS m/z (%) = 350.1 [M+H]+ (100 %), 367.1 [M+NH4]+ (60 %), 716.2
[2M+NH4]+ (100 %), 721.1 [2M+Na]+ (40 %), 737.1 [2M+K]+ (10 %); HR-MS m/z = 350.0883
[M+H]+ (calculated: 350.0879); HR-MS m/z = 367.1145 [M+NH4]+ (calculated: 367.1145);
HPLC-Analysis (Method B): 99 %, Rt = 20.4 min.
Method 2: Esterification followed by Knoevenagel condensation
The free carboxylic acid derivatives 2, 12, and 13 (1.0 eq), DCC (1.5 eq) and DMAP (0.3 eq)
were dissolved in alcohol (methanol, ethanol or tert-butanol). The reaction mixture is stirred at
rt for 4 h or until TLC showed complete consumption of starting material. After 1 h the reaction
mixture turns from yellow to red. The reaction mixture was concentrated to half its’ reaction
volume, the DCU was filtered and washed with DCM. The crude was concentrated and purified
by flash column chromatography. The ester derivatives 14, 15, and 16 (1.0 eq), benzaldehyde
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derivatives (1.1-1.5 eq) and sodium acetate were dissolved in ethanol (5-10 mL). The reaction
mixture was continued to stir at 80 ◦C for 2 h or until TLC showed complete consumption of
starting material. The majority of products were purified by flash column chromatography. The
individual purification method is stated for each compound below.
Methyl 2-(4-oxo-2-sulfanylidene-1,3-thiazolidin-3- yl) acetate : Methyl ester of 14 [284]
TLC Rf = 0.2 (Hexane/EtOAc 8:2); Reaction time: 16 h; Purification: Flash-Chromatography
Hexane/EtOAc 8:2 (Rf = 0.2), DCM; Yield: 4600 mg of yellow oil (22.41 mmol, 78 %); 1H-NMR
(400 MHz, CDCl3) δ= 3.69 (s, 3 H, CH3), 4.03 (s, 2 H, CH2), 4.65 (s, 2 H, CH2) ppm; 13C-NMR
(400 MHz, CDCl3) δ= 35.7 (CH2), 44.7 (CH2), 52.8 (CH3), 166.3 (C=O), 173.1 (COOMe),
200.7 (C=S) ppm.
Ethyl 2-(4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl) acetate: Ethyl ester of 14 [285]
TLC Rf = 0.3 (Hexane/EtOAc 8:2); Reaction time: 16 h; Purification: Flash-Chromatogra-
phy Hexane/EtOAc 8:2 (Rf = 0.3), DCM; Yield: 1220 mg of red oil (5.56 mmol, 97 %); Yield:
1121 mg of red oil (5.11 mmol, 98 %); Yield: 1121 mg of red oil (5.11 mmol, 98 %); 1H-NMR
(400 MHz, CDCl3) δ= 1.29 (t, 3 H, 3JH,H = 7.1 Hz, CH3), 4.08 (s, 2 H, CH2), 4.23 (q, 2 H,
3JH,H = 7.1 Hz, CH2CH3), 4.72 (s, 2 H, CH2) ppm13C-NMR (400 MHz, CDCl3) δ= 14.2 (CH3),
35.7 (CH2), 45.0 (CH2), 62.2 (CH2), 165.9 (C=O), 173.2 (COOEt), 200.6 (C=S) ppm; ESI-MS
m/z (%) = 241.2 [M+Na]+ (100 %). EI-MS m/z (%) = 219.1 [M]+ (100 %), 173.0 [fragment]+ (45 %),
147.0 [fragment]+ (45 %), 118.0 [fragment]+ (85 %), 72.0 [fragment]+ (100 %), 6.07 [fragment]+
(100 %); HR-MS m/z = 219.0016 [M]+ (calculated: 219.0018); HPLC-Analysis (Method B):
99 %, Rt = 9.9 min.
tert-Butyl 2-(4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl) acetate: tert-Butyl ester of 14
TLC Rf = 0.8 (DCM/MeOH/AcOH 9:1:0.01); Reaction time: 16 h; Purification: Flash-Chroma-
tography Hexane/EtOAc 8:2 → 7:3 (Rf = 0.4, 0.4); Yield: 225 mg of yellow oil (0.91 mmol,
17 %); 1H-NMR (400 MHz, CDCl3) δ= 1.46 (s, 9 H, 3xCH3), 4.09 (s, 2 H, CH2), 4.60 (s,
2 H, CH2) ppm; 13C-NMR (400 MHz, CDCl3) δ= 28.0 (3xCH3), 74.6 (CH2), 83.2 (CH2), 164.8
(C=O), 173.2 (COOtBu), 200.8 (C=S) ppm.
Ethyl 3-(4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl)propanoate: Ethyl ester of 15 [286]
TLC Rf = 0.6 (Hexane/EtOAc 1:1); Reaction time: 16 h; Yield: 256 mg of yellow oil (1.10
mmol, 41 %); Yield: 775 mg of yellow oil (3.32 mmol, 45 %); Yield: 5133 mg of yellow solid
(22.00 mmol, 86 %) Yield: 1036 mg of yellow oil (4.44 mmol, 91 %); Yield: 347 mg of yellow
oil (1.49 mmol, 31 %); Yield: 439 mg of yellow oil (1.88 mmol, 39 %); Purification: Flash-
Chromatography Hexane/EtOAc 8:2 (Rf = 0.3); 1H-NMR (400 MHz, CDCl3) δ= 1.24 (t, 3 H,
3JH,H = 7.1 Hz, CH3), 2.67 (t, 2 H, 3JH,H = 7.5 Hz, α-CH2), 3.99 (s, 2 H, CH2), 4.12 (q, 2 H,
3JH,H = 7.1 Hz, CH2CH3), 4.28 (t, 2 H, 3JH,H = 7.5 Hz, β-CH2) ppm; 13C-NMR (400 MHz, CDCl3)
δ= 14.2 (CH3), 31.2 (α-CH2), 35.5 (CH2), 40.2 (β-CH2), 61.1 (CH2CH3), 170.5 (C=O), 173.6
(COOEt), 200.9 (C=S) ppm;
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Ethyl 4-(4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl)butanoate: Ethyl ester of 16 [287]
TLC Rf = 0.6 (Hexane/EtOAc/HOAc 6:4:0.01); Yield: 816 mg of orange oil (3.30 mmol, 72 %);
Yield: 2083 mg of orange solid (8.42 mmol, 77 %) Reaction time: 16 h; Purification: Flash-
Chromatography Hexane/EtOAc 9:1→ 8:2 (Rf = 0.3, 0.4), loaded in DCM; 1H-NMR (400 MHz,
CDCl3) δ= 1.25 (t, 3 H, 3JH,H = 7.1 Hz, CH3), 1.98 (p, 2 H, 3JH,H = 7.3 Hz, β-CH2), 2.35 (t, 2 H,
3JH,H = 7.3 Hz, γ-CH2), 3.96 (s, 2 H, CH2), 4.05 (t, 2 H, 3JH,H = 7.3 Hz, α-CH2), 4.12 (q, 2 H,
3JH,H = 7.1 Hz, CH2CH3) ppm; 13C-NMR (400 MHz, CDCl3) δ= 14.3 (CH3), 22.2 (β-CH2), 31.6
(γ-CH2) 35.4 (CH2), 44.0 (α-CH2), 60.7 (CH2CH3), 172.6 (C=O), 174.0 (COOEt), 201.4 (C=S)
ppm.
Ethyl 2-[(9H-fluoren-9-ylmethoxy)carbonyl] amino-acetate [288]
Starting was Fmoc-Gly-OH TLC Rf = 0.5 (Hexane/EtOAc 6:4); Reaction time: 16 h; Purifi-
cation: Flash-Chromatography Hexane/EtOAc 9:1 → 8:2 (Rf = 0.2); Yield: 979 mg of white
solid (3.01 mmol, 90 %); 1H-NMR (400 MHz, CDCl3) δ= 1.22 (t, 3 H, 3JH,H = 7.1 Hz, CH3),
3.92 (d, 2 H, 3JH,H = 5.5 Hz, CH2COOEt), 4.13-4.20 (m, 3 H, CH2CH3, CH-Fmoc), 4.34 (d, 2 H,
3JH,H = 7.1 Hz, CH2-Fmoc), 7.24 (at, 2 H, 3JH,H = 7.4, 7.5 Hz, Ar-CH), 7.33 (at, 2 H, 3JH,H = 7.4,
7.5 Hz, Ar-CH), 7.53 (d, 2 H, 3JH,H = 7.4 Hz, Ar-CH), 7.70 (d, 2 H, 3JH,H = 7.5 Hz, Ar-CH) ppm;
HPLC-Analysis (Method B): 99 %, Rt = 12.7 min.
Ethyl 2-[(5Z)-4-oxo-5-(phenylmethylidene)-2-sulfanylidene-1,3-thiazolidin-3-yl] acetate 14i [289]
TLC Rf = 0.6 (Hexane/EtOAc 8:2); Reaction time: 16 h; Purification: Filtration from ethanol;
Yield: 175 mg of yellow solid (0.57 mmol, 50 %); Yield: 255 mg of yellow solid (0.30 mmol,
73 %); 1H-NMR (400 MHz, CDCl3) δ= 1.29 (t, 3 H, 3JH,H = 7.1 Hz, CH3), 4.25 (q, 2 H, 3JH,H =
7.1 Hz, CH2CH2), 4.86 (s, 2 H, CH2), 7.45-7.55 (m, 5 H, 5xAr-CH), 7.79 (s, 1 H, CH) ppm; 13C-
NMR (400 MHz, CDCl3) δ= 14.3 (CH3), 45.0 (CH2), 62.2 (CH2CH3), 122.9 (Ar-C), 129.6 (Ar-
CH), 130.9 (Ar-CH), 131.1 (Ar-CH), 133.3 (Ar-C), 134.2 (CH), 166.0 (C=O), 167.3 (COOEt),
193.2 (C=S) ppm; ESI-MS m/z (%) = 308.0 [M+H]+ (100 %), 330.0 [M+Na]+ (25 %), 637.1
[2M+Na]+ (10 %); HR-MS m/z = 308.0415 [M+H]+ (calculated: 308.0410); ESI-MS m/z (%) =
308.0 [M+H]+ (79 %), 325.1 [M+NH4]+ (16 %), 330.0 [M+Na]+ (84 %), 632.1 [2M+NH4]+ (6 %),
637.1 [2M+Na]+ (100 %); HPLC-Analysis (Method B): 96 %, Rt = 19.8 min.
tert-Butyl 2-[(5Z)-4-oxo-5-(phenylmethylidene)-2- sulfanylidene-1,3-thiazolidin-3-yl] acetate 14j
TLC Rf = 0.3 (Hexane/EtOAc 9:1); Purification: Re-crystallisation from ethanol; Yield: 234
mg of yellow crystals (0.70 mmol, 77 %); 1:3 mixture of E:Z isomer: 1H-NMR (400 MHz,-
CDCl3) δ= 1.47 (s, 9 H, 6xCH3), 4.77 (s, 2 H, Z-CH2), 4.84 (s, 2 H, E-CH2), 7.43-7.55 (m, 5 H,
10xAr-CH), 7.78 (s, 1 H, Z-CH), 7.79 (s, 1 H, E-CH) ppm; 13C-NMR (400 MHz, CDCl3) δ= 28.1
(6xCH3), 45.2 (E-CH2), 45.7 (Z-CH2), 83.4 (C(CH3)3), 123.0 (Ar-C), 129.5 (Ar-CH), 130.8 (Ar-
CH), 131.0 (Ar-CH), 133.4 (Z-CH), 133.9 (E-CH), 164.9 (Z-C=O), 165.6 (E-C=O), 167.3 (E/Z-
COOtBu), 193.2 (E-C=S), 193.3 (Z-C=S) ppm; ESI-MS m/z (%) = 336.1 [M+H]+ (48 %), 353.1
[M+NH4]+ (51 %), 358.1 [M+Na]+ (30 %), 688.2 [2M+NH4]+ (37 %), 693.1 [2M+Na]+ (52 %);
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HPLC-Analysis (Method B): 98 %, Rt = 20.9 min.
(E/Z)-ethyl 2-(4-oxo-2-thioxo-5-(2-(trifluoromethyl)benzylidene)thiazolidin-3-yl) acetate 14k
TLC Rf = 0.8 (DCM); Yield: 45 mg of yellow solid (0.12 mmol, 86 %); Reaction time: 16 h; Pu-
rification: Flash-Chromatography DCM (Rf = 0.8); mixture of Z to E (2:1) 1H-NMR (400 MHz,
CDCl3) δ= 1.26 (t, 3 H, 3JH,H = 7.1 Hz, CH2CH3), 1.30 (t, 3 H, 3JH,H = 7.1 Hz, CH2CH3), 4.21
(q, 2 H, 3JH,H = 7.1 Hz, CH2CH3), 4.26 (q, 2 H, 3JH,H = 7.1 Hz, CH2CH3), 4.73 (s, 2 H, CH2),
4.86 (s, 2 H, CH2), 7.45 (q, 1 H, 5JH,F = 2.2 Hz, E-CH), 7.48-7.74 (m, 7 H, 7xAr-CH), 7.79 (d,
1 H, 3JH,H = 7.8 Hz, Ar-CH), 8.05 (q, 1 H, 5JH,F = 2.2 Hz, Z-CH) ppm; 13C-NMR (400 MHz,
CDCl3) δ= 14.2 (2xCH3), 44.8 (CH2), 45.0 (CH2), 62.2 (CH2CH3), 62.3 (CH2CH3), 126.0 (Ar-
CH), 127.0 (Ar-CH), 127.1 (Ar-CH), 127.7 (Ar-C), 129.3 (Ar-CH), 129.4 (E-CH), 129.7 (Ar-C),
130.3 (Ar-CH), 131.3 (Ar-CH), 132.1 (Ar-CH), 132.6 (Z-CH) 133.0 (Ar-C), 165.9 (C=O), 166.3
(C=O), 193.0 (2xC=S) ppm; ESI-MS m/z (%) = 376.0 [M+H]+ (100 %), 393.1 [M+NH4]+ (50 %),
773.0 [2M+Na]+ (5 %); HR-MS m/z = 376.0287 [M+H]+ (calculated: 376.0283); HPLC-Analysis
(Method B): 98 %, Rt = 21.8 min.
(Z)-ethyl 2-(4-oxo-2-thioxo-5-(3-(trifluoromethyl)benzylidene)thiazolidin-3-yl) acetate 14l
TLC Rf = 0.6 (DCM); Reaction time: 16 h; Purification: Flash-Chromatography DCM (Rf = 0.6);
Yield: 27 mg of yellow solid (0.07 mmol, 51 %); 1H-NMR (400 MHz, CDCl3) δ= 1.30 (t, 3 H,
3JH,H = 7.1 Hz, OCH2CH3), 4.25 (q, 2 H, 3JH,H = 7.1 Hz, OCH2CH3), 4.87 (s, 2 H, CH2),
7.61-7.76 (m, 4 H, 4xAr-CH), 7.79 (s, 1 H, CH) ppm; 13C-NMR (400 MHz, CDCl3) δ= 14.3
(CH3), 45.1 (CH2), 62.3 (CH2CH3) 123.6 (q, 1JC,F = 272.9 Hz, CF3) 125.1 (Ar-C) 127.3 (q,
3JC,F = 3.7 Hz, Ar-CH), 127.4 (q, 3JC,F = 3.9 Hz. Ar-CH), 130.1 (Ar-CH), 131.8 (CH), 132.1 (q,
2JC,F = 33.0 Hz, 3-Ar-C), 133.2 (Ar-CH), 134.1 (Ar-C), 165.8 (C=O), 167.0 (COOEt), 192.3
(C=S) ppm; ESI-MS m/z (%) = 376.0 [M+H]+ (50 %), 393.1 [M+NH4]+ (60 %), 398.0 [M+Na]+
(20 %), 768.1 [2M+NH4]+ (60 %), 773.0 [2M+Na]+ (100 %), 789.0 [2M+K]+ (30 %); HR-MS m/z =
376.0287 [M+H]+ (calculated: 376.0283); HPLC-Analysis (Method B): 100 %, Rt = 20.5 min.
Ethyl 2-[(3E)-3-[2,5-bis(trifluoromethyl)phenyl]methylidene-2-oxo-5-sulfanylidenepyrrolidin-1-yl]
acetate 14m
TLC Rf = 0.8 (Hexane/EtOAc 9:1); Reaction time: 30m˙in; Purification: Flash-Chromatogra-
phy Hexane/EtOAc 95:5 (Rf = 0.3); Yield: 303 mg of yellow solid (0.71 mmol, 62 %); 1H-NMR
(400 MHz, CDCl3) δ= 1.31 (t, 3 H, 3JH,H = 7.1 Hz, CH3) 4.27 (q, 2 H, ,JH,H = 7.1 Hz, CH2CH3)
4.87 (s, 2 H, CH2), 7.82 (d, 1 H, 3JH,H = 8.2 Hz, 4-Ar-CH), 7.87 (s, 1 H, 6-Ar-CH), 7.95 (d,
1 H, 3JH,H = 8.2 Hz, 3-Ar-CH), 8.00 (q, 1 H, 5JH,F = 1.9 Hz, CH) ppm; 13C-NMR (400 MHz,
CDCl3) δ= 14.2 (CH3), 45.1 (CH2Ar) 62.4 (CH2CH3), 122.9 (q, 1JC,F = 273.3 Hz, CF3), 123.0
(q, 1JC,F = 274.6 Hz, CF3), 126.1 (q, 3JC,F = 3.7 Hz, 6-Ar-CH), 126.9 (q, 3JC,F = 3.6 Hz, 4-Ar-
CH), 127.1 (q, 4JC,F = 1.9 Hz, CH), 127.8 (q, 3JC,F = 5.4 Hz, 3-Ar-CH), 129.7 (Ar-C) 132.9 (q,
2JC,F = 30.5 Hz, Ar-CCF3), 133.3 (q, 4JC,F = 1.4 Hz, Ar-C), 134.9 (q, 2JC,F = 33.5 Hz, Ar-CCF3),
165.7 (C=O), 166.1 (COOEt), 191.9 (C=S) ppm; ESI-MS m/z (%) = 444.0 [M+NH4]+ (69 %);
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HPLC-Analysis (Method B): 84 %, Rt = 20.9 min.
(Z)-ethyl 2-(5-(4-methylbenzylidene)-4-oxo-2-thioxothiazolidin-3-yl) acetate 14n
TLC Rf = 0.6 (DCM); Reaction time: 3 h; Purification: Flash-Chromatography DCM (Rf = 0.6);
Yield: 58 mg of yellow solid (0.18 mmol, 90 %); 1H-NMR (400 MHz, CDCl3) δ= 1.29 (t, 3 H,
3JH,H = 7.1 Hz, OCH2CH3), 2.42 (s, 3 H, Ar-CH3), 4.24 (q, 2 H, 3JH,H = 7.1 Hz, OCH2CH3),
4.86 (s, 2 H, CH2)7.302dH,H8.1 Hz03,5-Ar-CH3, 7.42 (d, 2 H, 3JH,H = 8.1 Hz, 2,6-Ar-CH), 7.77
(s, 1 H, CH) ppm; ESI-MS m/z (%) = 322.1 [M+H]+ (100 %); HR-MS m/z = 322.0571 [M+H]+
(calculated: 322.0566); HPLC-Analysis (Method B): 100 %, Rt = 20.4 min.
(Z)-ethyl 2-(5-(4-tert-butylbenzylidene)-4-oxo-2-thioxothiazolidin-3-yl) acetate 14o
TLC Rf = 0.4 (Cyclohexane/EtOAc 9:1); Reaction time: 4 h; Purification: Flash-Chroma-
tography Cyclohexane/EtOAc 9:1 (Rf = 0.4), DCM; Yield: 18 mg of yellow solid (0.05 mmol,
55 %); 1H-NMR (400 MHz, CDCl3) δ= 1.22 (t, 3 H, 3JH,H = 7.1 Hz, CH3), 1.28 (s, 9 H, 3xCH3),
4.17 (q, 2 H, 3JH,H = 7.1 Hz, CH2), 4.79 (s, 2 H, CH2), 7.39 (d, 2 H, 3JH,H = 8.5 Hz, 2xAr-CH),
7.45 (d, 2 H, 3JH,H = 8.5 Hz, 2xAr-CH), 7.71 (s, 1 H, CH) ppm; 13C-NMR (400 MHz, CDCl3) δ=
14.2 (CH3), 31.2 (3xCH3), 45.0 (CH2), 62.2 (CH2CH3), 126.6 (2xArCH), 130.6 (Ar-C), 130.9
(2xArCH), 134.3 (CH), 155.1 (Ar-C), 166.1 (Ar-C), 167.4 (C=O), 193.3 (C=S) ppm; ESI-MS
m/z (%) = 364.1 [M+H]+ (68 %), 744.2 [M+NH4]+ (29 %); HPLC-Analysis (Method B): 99 %,
Rt = 22.1 min.
Ethyl 2-[(5Z)-5-[(2-hydroxyphenyl)methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]
acetate 14p
TLC Rf = 0.6 (CHCl3/EtOAc 9:1); Reaction time: 16 h; Purification: Flash-Chromatography
CHCl3/EtOAc 1:0→ 9:1 (Rf = 0.6); Yield: 210 mg of yellow solid (0.65 mmol, 84 %); 1H-NMR
(400 MHz, CDCl3) δ= 1.34 (t, 3 H, 3JH,H = 7.1 Hz, CH3), 4.31 (q, 2 H, 3JH,H = 7.1 Hz, CH2CH3),
4.89 (s, 2 H, CH2), 6.83 (d, 1 H, 3JH,H = 8.2 Hz, 3-Ar-CH), 6.94 (at, 1 H, 3JH,H = 7.5, 7.8 Hz,
5-Ar-CH), 7.16 (d, 1 H, 3JH,H = 7.8 Hz, 6-Ar-CH), 7.25-7.30 (m, 1 H, 4-Ar-CH), 7.48 (s(br),
1 H, OH), 8.19 (s, 1 H, CH) ppm; 13C-NMR (400 MHz, CDCl3) δ= 14.2 (CH3), 45.0 (CH2),
62.8 (CH2CH3), 116.5 (3-Ar-CH), 120.6 (Ar-C), 121.1 (5-Ar-CH), 121.2 (Ar-C), 129.7 (6-Ar-
CH), 130.1 (CH), 133.1 (4-Ar-CH), 156.8 (Ar-C), 167.6 (C=O, COOEt), 193.9 (C=S) ppm;
ESI-MS m/z (%) = 324.0 [M+H]+ (91 %), 341.1 [M+NH4]+ (17 %), 664.1 [2M+NH4]+ (100 %),
669.1 [2M+Na]+ (6 %); HPLC-Analysis (Method B): 99 %, Rt = 18.2 min.
Ethyl 2-[(5Z)-5-[(3-hydroxyphenyl)methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl] ace-
tate 14q
TLC Rf = 0.3 (CHCl3/EtOAc 9:1); Reaction time: 3 h; Purification: Flash-Chromatography
CHCl3/EtOAc 9:1 (Rf = 0.3), CHCl3; Yield: 317 mg of yellow solid (0.98 mmol, 86 %); 1H-
NMR (400 MHz, CDCl3) δ= 1.23 (t, 3 H, 3JH,H = 7.1 Hz, CH3), 4.29 (q, 2 H, 3JH,H = 7.1 Hz,
CH2CH3), 4.88 (s, 2 H, CH2), 6.84-6.87 (m, 1 H, 2-Ar-CH)6.871ddH,H2.3, 7.8 Hz4-Ar-CH3,4,
7.00 (d, 1 H, 3JH,H = 7.7 Hz, 6-Ar-CH), 7.30 (at, 1 H, 3JH,H = 7.7, 7.8 Hz, 5-Ar-CH), 7.55 (s, 1 H,
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CH) ppm; 13C-NMR (400 MHz, CDCl3) δ= 14.2 (CH3), 45.0 (CH2), 62.6 (CH2CH3), 117.2 (2-
Ar-CH), 118.4 (4-Ar-CH), 123.0 (Ar-C), 123.4 (6-Ar-CH), 130.7 (5-Ar-CH), 133.9 (CH), 134.6
(Ar-C), 156.7 (Ar-C), 166.8 (C=O) 167.3 (COOEt), 193.2 (C=S) ppm; ESI-MS m/z (%) = 324.0
[M+H]+ (38 %), 341.1 [M+NH4]+ (16 %), 346.0 [M+Na]+ (6 %), 664.1 [2M+NH4]+ (13 %), 669.1
[2M+Na]+ (12 %); HPLC-Analysis (Method B): 99 %, Rt = 18.2 min.
Ethyl 2-[(5Z)-5-[(4-hydroxyphenyl)methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl] ace-
tate 14r
TLC Rf = 0.1 (Hexane/EtOAc 8:2); Reaction time: 6 h; Purification: Flash-Chromatography
Hexane/EtOAc 7:3 (Rf = 0.3); Yield: 330 mg of red crystals (1.02 mmol, 89 %); 1H-NMR (400
MHz, MeOD) δ= 1.27 (t, 3 H, 3JH,H = 7.1 Hz, CH3), 4.22 (q, 2 H, 3JH,H = 7.1 Hz, CH2CH3),
4.85 (s, 2 H, CH2), 6.93 (d, 2 H, 3JH,H = 8.7 Hz, 2,6-Ar-CH), 7.47 (d, 2 H, 3JH,H = 8.7 Hz, 3,5-
Ar-CH), 7.74 (s, 1 H, CH) ppm; 13C-NMR (400 MHz, MeOD) δ= 14.4 (CH3), 45.8 (CH2), 63.0
(CH2CH3),/ 117.6 (2,6-Ar-CH), 119.4 (Ar-C), 126.0 (Ar-C), 134.5 (3,5-Ar-CH), 135.6 (CH),
162.2 (Ar-C), 167.9 (C=O), 168.5 (COOEt), 194.9 (C=S) ppm; 1H-NMR (400 MHz, CDCl3)
δ= 1.32 (t, 3 H, 3JH,H = 7.1 Hz, CH3), 4.27 (q, 2 H, 3JH,H = 7.1 Hz, CH2CH3), 4.88 (s, 2 H,
CH2), 5.97 (s(br), 1 H, OH), 6.90 (d, 2 H, 3JH,H = 8.6 Hz, 2,6-Ar-CH), 7.34 (d, 2 H, 3JH,H =
8.6 Hz, 3,5-Ar-CH), 7.61 (s, 1 H, CH) ppm; 13C-NMR (400 MHz, CDCl3) δ= 14.2 (CH3), 45.0
(CH2), 62.5 (CH2CH3), 116.7 (2,6-Ar-CH), 126.0 (Ar-C), 133.3 (3,5-Ar-CH), 134.3 (CH), 158.7
(Ar-C), 166.8 (C=O), 167.4 (COOEt), 193.1 (C=S) ppm; 1H-NMR (400 MHz, DMSO-d6) δ=
1.20 (t, 3 H, 3JH,H = 7.1 Hz, CH3), 4.17 (q, 2 H, 3JH,H = 7.1 Hz, CH2CH3), 4.82 (s, 2 H, CH2),
6.95 (d, 2 H, 3JH,H = 8.7 Hz, 2,6-Ar-CH), 7.56 (d, 2 H, 3JH,H = 8.7 Hz, 3,5-Ar-CH), 7.82 (s, 1 H,
CH), 10.57 (s(br), 1 H, OH) ppm; ESI-MS m/z (%) = 341.2 [M+NH4]+ (20 %); HPLC-Analysis
(Method B): 90 %, Rt = 18.1 min.
Methyl 2-[(5Z)-5-[(3,4- dihydroxyphenyl)methylidene]-4-oxo-2-sulfanylidene- 1,3-thiazolidin-3-
yl] acetate 14s
TLC Rf = 0.2 (CHCl3/MeOH/HOAc 97:2:1); Reaction time: 4 h; Purification: Filtration from
ethanol; Yield: 35 mg of yellow solid (0.11 mmol, 32 %); 1H-NMR (400 MHz, CDCl3) δ= 3.79
(s, 3 H, CH3), 4.87 (s, 2 H, CH2), 6.94 (d, 1 H, 3JH,H = 8.1 Hz, Ar-CH), 6.96-7.03 (m, 2 H, 2xAr-
CH), 7.64 (s, 1 H, CH) ppm; 1H-NMR (400 MHz, MeOD) δ= 3.76 (s, 3 H, CH3), 4.86 (s, 2 H,
CH2), 6.89 (d, 1 H, 3JH,H = 8.1 Hz, 5-Ar-CH), 6.97-7.03 (m, 2 H, 2,6-Ar-CH), 7.65 (s, 1 H, CH)
ppm; 13C-NMR (400 MHz, MeOD) δ= 45.6 (CH2), 53.2 (OCH3), 117.1 (5-Ar-CH), 117.9 (2-
Ar-CH), 119.2 (Ar-C), 126.5 (6-Ar-CH), 136.0 (CH), 147.4 (Ar-C), 150.8 (Ar-C), 168.4 (C=O),
175.3 (COOMe), 194.8 (C=S) ppm; HPLC-Analysis (Method B): 95 %, Rt = 15.8 min.
Ethyl 2-[(5Z)-5-[(3,4-dihydroxyphenyl)methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]
acetate 14t
TLC Rf = 0.6 (CHCl3/MeOH 9:1); Reaction time: 4 h; Purification: Flash-Chromatography
DCM/EtOAc 9:1 (Rf = 0.1); Yield: 192 mg of yellow solid (0.57 mmol, 58 %); 1H-NMR (400
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MHz, CDCl3) δ= 1.32 (t, 3 H, 3JH,H = 7.1 Hz, CH3), 4.27 (q, 2 H, 3JH,H = 7.1 Hz, CH2CH3), 4.87
(s, 2 H, CH2), 5.98 (s(br), 1 H, OH), 6.28 (s(br), 1 H, OH), 6.91-7.00 (m, 2 H, 5,6-Ar-CH), 7.26
(s, 1 H, CH), 7.59 (s, 1 H, 2-Ar-CH) ppm; 1H-NMR (400 MHz, MeOD) δ= 1.25 (t, 3 H, 3JH,H =
7.1 Hz, CH3), 4.20 (q, 2 H, 3JH,H = 7.1 Hz, CH2CH3), 4.78 (s, 2 H, CH2), 6.85 (d, 1 H, 3JH,H =
8.2 Hz, 5-Ar-CH), 6.93 (dd, 1 H, 3,4JH,H = 2.1, 8.2 Hz, 6-Ar-CH), 6.96 (d, 1 H, 4JH,H = 2.1 Hz,
2-Ar-CH), 7.55 (s, 1 H, CH) ppm; 13C-NMR (400 MHz, MeOD) δ= 14.4 (CH3), 45.7 (CH2)
63.0 (CH2CH3), 117.1 (5-Ar-CH), 117.9 (2-Ar-CH), 119.1 (Ar-C), 126.4 (Ar-C), 126.6 (6-Ar-
CH), 136.0 (CH), 147.2 (Ar-C), 150.6 (Ar-C), 167.9 (C=O), 168.4 (COOEt), 194.6 (C=S) ppm;
ESI-MS m/z (%) = 340.0 [M+H]+ (100 %), 357.1 [M+NH4]+ (15 %), 696.1 [2M+NH4]+ (20 %); HR-
MS m/z = 340.0312 [M+H]+ (calculated: 340.0308); HPLC-Analysis (Method B): 95 %, Rt =
14.3 min.
Ethyl 2-[(5Z)-5-[(2,4-dihydroxyphenyl)methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]
acetate 14u
TLC Rf = 0.2 (CHCl3/MeOH/HOAc 95:4:1); Reaction time: 1 h; Purification: Flash-Chroma-
tography CHCl3/MeOH/HOAc 95:4:1 (Rf = 0.2); Yield: 342 mg of yellow solid (1.01 mmol,
86 %); 1H-NMR (400 MHz, DMSO-d6) δ= 1.20 (t, 3 H, 3JH,H = 7.1 Hz, CH3), 4.16 (q, 2 H,
3JH,H = 7.1 Hz, CH2CH3), 4.80 (s, 2 H, CH2), 6.42-6.46 (m, 2 H, 3,5-Ar-CH), 7.25 (d, 1 H,
3JH,H = 8.4 Hz, 6-Ar-CH), 8.00 (s, 1 H, CH), 10.47 (s, 1 H, OH), 10.83 (s, 1 H, OH) ppm; 13C-
NMR (400 MHz, DMSO-d6) δ= 14.0 (CH3), 44.9 (CH2), 61.6 (CH2CH3), 102.5 (3-Ar-CH), 109.2
(5-Ar-CH), 111.8 (Ar-C), 114.8 (Ar-C), 130.6 (CH), 132.0 (6-Ar-CH), 160.2 (Ar-C), 163.1 (Ar-
C), 166.2 (C=O), 166.6 (COOEt), 193.4 (C=S) ppm; ESI-MS m/z (%) = 340.0 [M+H]+ (100 %),
696.1 [2M+NH4]+ (41 %); HPLC-Analysis (Method B): 66 %, Rt = 17.4 min.
Ethyl 2-[(5Z)-5-[3-(benzyloxy)phenyl]methylidene-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]
acetate 14v
TLC Rf = 0.6 (Hexane/EtOAc 8:2); Reaction time: 2 h; Purification: Re-crystallisation from
ethanol; Yield: 145 mg of yellow crystals (0.35 mmol, 54 %); 1H-NMR (400 MHz, CDCl3)
δ= 1.29 (t, 3 H, 3JH,H = 7.1 Hz, CH3), 4.24 (q, 2 H, 3JH,H = 7.1 Hz, CH2CH3), 4.85 (s, 2 H,
CH2COOEt), 5.13 (s, 2 H, CH2-Ar), 7.06-7.14 (m, 3 H, 3xAr-CH), 7.35-7.47 (m, 6 H, 6xAr-CH),
7.73 (s, 1 H, CH) ppm; 13C-NMR (400 MHz, CDCl3) δ= 14.2 (CH3), 45.0 (CH2COOEt), 62.2
(CH2CH3), 70.4 (CH2Ar), 116.2 (Ar-CH), 118.2 (Ar-CH), 123.2 (Ar-C), 123.8 (Ar-CH), 127.6
(Ar-CH), 128.4 (Ar-CH), 128.9 (Ar-CH), 130.6 (Ar-CH), 134.0 (CH), 134.6 (Ar-C), 136.4 (Ar-
C), 159.4 (Ar-C), 166.0 (C=O), 167.2 (COOEt), 193.2 (C=S) ppm; ESI-MS m/z (%) = 414.1
[M+H]+ (100 %), 431.1 [M+NH4]+ (33 %), 436.1 [M+Na]+ (4 %); HPLC-Analysis (Method B):
99 %, Rt = 21.6 min.
Ethyl 2-[(5Z)-5-[4-(benzyloxy)phenyl]methylidene-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]
acetate 14w
TLC Rf = 0.6 (Hexane/EtOAc 8:2); Reaction time: 2 h; Purification: Re-crystallisation from
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ethanol; Yield: 340 mg of yellow crystals (0.82 mmol, 67 %); 1H-NMR (400 MHz, CDCl3)
δ= 1.29 (t, 3 H, 3JH,H = 7.1 Hz, CH3), 4.24 (q, 2 H, 3JH,H = 7.1 Hz, CH2CH3), 4.86 (s, 2 H,
CH2COOEt), 5.14 (s, 2 H, CH2Ar), 7.08 (d, 2 H, 3JH,H = 8.8 Hz, 2,6-Ar-CH), 7.33-7.45 (m, 5 H,
5xAr-CH), 7.48 (d, 2 H, 3JH,H = 8.8 Hz, 3,5-Ar-CH), 7.74 (s, 1 H, CH) ppm; 13C-NMR (400 MHz,
CDCl3) δ= 14.3 (CH3), 45.0 (CH2COOEt), 62.2 (CH2CH3), 70.4 (CH2Ar), 116.0 (2,6-Ar-CH),
119.9 (Ar-C), 126.3 (Ar-C), 127.6 (Ar-CH), 128.5 (Ar-CH) 128.9 (Ar-CH) 133.0 (3,5-Ar-CH),
134.1 (CH), 136.1 (Ar-C), 161.2 (Ar-C), 166.1 (C=O), 167.4 (COOEt), 193.2 (C=S) ppm;
ESI-MS m/z (%) = 414.1 [M+H]+ (100 %), 436.1 [M+Na]+ (40 %), 452.0 [M+K]+ (15 %), 844.2
[2M+NH4]+ (100 %), 849.1 [2M+Na]+ (95 %), 865.1 [2M+K]+ (70 %); HR-MS m/z = 414.0828
[M+H]+ (calculated: 414.0828); HPLC-Analysis (Method B): 99 %, Rt = 21.6 min.
Ethyl 2-[(5Z)-5-[3,4-bis(benzyloxy)phenyl]methylidene-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-
yl] acetate 14x
TLC Rf = 0.3 (Hexane/EtOAc 8:2); TLC Rf = 0.5 (DCM); Reaction time: 1 h; Purification:
Filtration from Ethanol; Yield: 513 mg of yellow solid (0.99 mmol, 87 %); Yield: 21 mg of yellow
solid (0.04 mmol, 40 %); 1H-NMR (400 MHz, DMSO-d6) δ= 1.20-1.23 (m, 3 H, OCH2CH3), 4.16
(q, 2 H, 3JH,H = 7.0 Hz, OCH2), 4.82 (s, 2 H, CH2)5.242s00OCH2Ph, 5.26 (s, 2 H, OCH2Ph),
7.25-7.49 (m, 13 H, 13xAr-CH), 7.82 (s, 1 H, CH) ppm; 1H-NMR (400 MHz, CDCl3) δ= 1.28 (t,
3 H, 3JH,H = 7.1 Hz, CH3), 4.23 (q, 2 H, 3JH,H = 7.1 Hz, CH2CH3), 4.84 (s, 2 H, CH2), 5.24 (s, 2 H,
CH2Ar), 5.25 (s, 2 H, CH2Ar), 6.99 (d, 1 H, 3JH,H = 8.4 Hz, 5-Ar-CH), 7.02 (d, 1 H, 4JH,H = 1.7 Hz,
2-Ar-CH), 7.08 (dd, 1 H, 3,4JH,H = 1.7, 8.4 Hz, 6-Ar-CH), 7.30-7.50 (m, 10 H, 10xAr-CH), 7.64
(s, 1 H, CH) ppm; 13C-NMR (400 MHz, CDCl3) δ= 14.3 (CH3), 45.0 (CH2), 62.2 (CH2CH3),
71.1 (CH2), 71.4 (CH2), 114.3 (5-Ar-CH), 116.1 (2-Ar-CH), 120.2 (Ar-C), 126.3 (6-Ar-CH),
127.3 (4xAr-CH), 127.4 (2xAr-CH), 128.3 (4xAr-CH) 128.9 (2xAr-C), 134.3 (CH), 136.4 (Ar-C),
149.1 (Ar-C), 151.7 (Ar-C), 166.1 (C=O), 167.3 (COOEt), 193.1 (C=S) ppm; ESI-MS m/z (%) =
520.1 [M+H]+ (100 %), 537.2 [M+NH4]+ (75 %); HR-MS m/z = 520.1247 [M+H]+ (calculated:
520.1242); HPLC-Analysis (Method B): 98 %, Rt = 18.4 min.
Ethyl 2-[(5Z)-5-[(4-hydroxy-3,5-dimethoxyphenyl)methylidene]-4-oxo-2-sulfanylidene-1,3-thiazoli-
din-3-yl] acetate 14y
TLC Rf = 0.6 (CHCl3/MeOH 1:0.05); Reaction time: 16 h; Purification: Flash-Chromatogra-
phy Toluene/MeOH 9:1 (Rf = 0.3); Yield: 279 mg of red solid (0.73 mmol, 64 %); 1H-NMR (400
MHz, CDCl3) δ= 1.29 (t, 3 H, 3JH,H = 7.1 Hz, CH3), 3.94 (s, 6 H, 2xOCH3), 4.24 (q, 2 H, 3JH,H =
7.1 Hz, CH2CH3), 4.85 (s, 2 H, CH2), 6.71 (s, 2 H, 2,6-Ar-CH), 7.65 (s, 1 H, CH) ppm; 13C-NMR
(400 MHz, CDCl3) δ= 14.2 (CH3), 44.9 (CH2), 56.5 (2xOCH3), 62.1 (CH2CH3), 108.0 (2,6-Ar-
CH), 119.7 (Ar-C) 124.7 (Ar-C), 134.7 (CH), 138.1 (Ar-C), 147.6 (3,5-Ar-C), 166.0 (C=O),
167.1 (COOEt), 192.8 (C=S) ppm; ESI-MS m/z (%) = 384.1 [M+H]+ (20 %), 784.1 [2M+NH4]+
(19 %), 789.1 [2M+Na]+ (3 %); HPLC-Analysis (Method B): 99 %, Rt = 22.6 min.
Ethyl 3-[(5Z)-4-oxo-5-(phenylmethylidene)-2-sulfanylidene-1,3-thiazolidin-3-yl] propanoate 15a [286]
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TLC Rf = 0.3 (Hexane/EtOAc 8:2); Reaction time: 16 h; Purification: Flash-Chromatography
DCM (Rf = 0.1); Yield: 211 mg of yellow solid (0.66 mmol, 72 %); 1H-NMR (400 MHz, CDCl3)
δ= 1.26 (t, 3 H, 3JH,H = 7.1 Hz, CH3), 2.73-2.78 (m, 2 H, β-CH2), 4.15 (q, 2 H, 3JH,H = 7.1 Hz,
CH2CH3), 4.39-4.45 (m, 2 H, α-CH2), 7.42-7.51 (m, 5 H, 5xAr-CH), 7.73 (s, 1 H, CH) ppm; 13C-
NMR (400 MHz, CDCl3) δ= 14.2 (CH3), 31.5 (β-CH2), 40.1 (α-CH2), 61.1 (CH2CH3), 122.8
(Ar-C), 129.4 (2xAr-CH), 130.8 (2xAr-CH), 130.9 (Ar-CH), 133.3 (Ar-C), 133.5 (CH), 167.5
(C=O), 170.5 (COOEt), 193.1 (C=S) ppm; ESI-MS m/z (%) = 322.1 [M+H]+ (100 %), 344.0
[M+Na]+ (3 %), 660.1 [2M+NH4]+ (11 %); HPLC-Analysis (Method B): 99 %, Rt = 20.4 min.
Ethyl 3-[(5Z)-5-[(2-methylphenyl)methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl] propa-
noate 15b
TLC Rf = 0.7 (Hexane/EtOAc 8:2); Reaction time: 30 min; Purification: Re-crystallisation
from ethanol; Yield: 100 mg of orange crystals (0.30 mmol, 35 %); 1H-NMR (400 MHz, CDCl3)
δ= 1.27 (t, 3 H, 3JH,H = 7.1 Hz, CH3), 2.47 (s, 3 H, Ar-CH3), 2.77 (t, 2 H, 3JH,H = 7.6 Hz,
β-CH2), 4.16 (q, 2 H, 3JH,H = 7.1 Hz, CH2CH3), 4.44 (t, 2 H, 3JH,H = 7.6 Hz, α-CH2), 7.25-
7.37 (m, 3 H, 3,4,5-Ar-CH), 7.41 (d, 1 H, 3JH,H = 7.5 Hz, 6-Ar-CH), 7.97 (s, 1 H, CH) ppm;
13C-NMR (400 MHz, CDCl3) δ= 14.3 (CH3), 20.2 (Ar-CH3), 31.6 (β-CH2), 40.1 (α-CH2), 61.1
(CH2CH3), 124.2 (Ar-C), 126.9 (Ar-CH), 128.2 (6-Ar-CH), 131.0 (Ar-CH), 131.4 (Ar-CH), 131.5
(CH), 132.5 (Ar-C), 139.7 (Ar-C), 167.4 (C=O), 170.6 (COOEt), 193.8 (C=S) ppm; ESI-MS
m/z (%) = 336.1 [M+H]+ (100 %), 353.0 [M+NH4]+ (7 %), 358.1 [M+Na]+ (42 %), 688.3 [M+NH4]+
(13 %), 693.1 [2M+Na]+ (33 %); HPLC-Analysis (Method B): 99 %, Rt = 21.0 min.
Ethyl 3-[(5Z)-5-[(3-methylphenyl)methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl] propa-
noate 15c
TLC Rf = 0.4 (Hexane/EtOAc 9:1); Reaction time: 30 min; Purification: Filtration from
ethanol; Yield: 132 mg of yellow solid (0.39 mmol, 61 %); 1H-NMR (400 MHz, CDCl3) δ=
1.26 (t, 3 H, 3JH,H = 7.1 Hz, CH3), 2.42 (s, 3 H, Ar-CH3), 2.76 (t, 2 H, 3JH,H = 7.6 Hz, β-CH2),
4.15 (q, 2 H, 3JH,H = 7.1 Hz, CH2CH3), 4.44 (t, 2 H, 3JH,H = 7.6 Hz, α-CH2), 7.25-7.29 (m, 1 H,
4-Ar-CH), 7.29-7.33 (m, 2 H, 2,6-Ar-CH), 7.35-7.40 (m, 1 H, 5-Ar-CH) 7.72 (s, 1 H, CH) ppm;
13C-NMR (400 MHz, CDCl3) δ= 14.3 (CH3), 21.6 (Ar-CH3), 31.6 (β-CH2), 40.1 (α-CH2), 61.1
(CH2CH3), 122.6 (Ar-C), 128.1 (2 or 6-Ar-CH), 129.4 (5-Ar-CH), 131.4 (2 or 6-Ar-CH), 131.9
(4-Ar-CH), 133.4 (Ar-C). 133.9 (CH), 139.4 (Ar-C), 167.7 (C=O), 170.6 (COOEt), 193.4 (C=S)
ppm; ESI-MS m/z (%) = 336.1 [M+H]+ (100 %), 353.1 [M+NH4]+ (6 %), 358.1 [M+Na]+ (22 %),
688.2 [2M+NH4]+ (23 %), 693.1 [2M+Na]+ (11 %); HPLC-Analysis (Method B): 99 %, Rt =
21.0 min.
Ethyl 3-[(5Z)-5-[(4-methylphenyl)methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl] propa-
noate 15d
TLC Rf = 0.4 (Hexane/EtOAc 9:1); Reaction time: 30 min; Purification: Filtration from
ethanol; Yield: 122 mg of yellow solid (0.36 mmol, 57 %); 1H-NMR (400 MHz, CDCl3) δ=
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1.26 (t, 3 H, 3JH,H = 7.1 Hz, CH3), 2.41 (s, 3 H, Ar-CH3), 2.76 (t, 2 H, 3JH,H = 7.5 Hz, β-
CH2), 4.15 (q, 2 H, 3JH,H = 7.1 Hz, CH2CH3), 4.43 (t, 2 H, 3JH,H = 7.5 Hz, α-CH2) 7.29 (d,
2 H, 3JH,H = 8.1 Hz, 3,5-Ar-CH), 7.40 (d, 2 H, 3JH,H = 8.1 Hz, 2,6-Ar-CH), 7.73 (s, 1 H, CH)
ppm; 13C-NMR (400 MHz, CDCl3) δ= 14.3 (CH3), 21.8 (Ar-CH3), 31.6 (β-CH2), 40.1 (α-CH2),
61.1 (CH2CH3), 121.6 (Ar-C), 130.3 (3,5-Ar-CH), 130.7 (Ar-C), 131.0 (2,6-Ar-CH), 133.9 (CH),
170.6 (COOEt), 193.3 (C=S) ppm; ESI-MS m/z (%) = 336.1 [M+H]+ (100 %), 358.1 [M+Na]+
(35 %), 688.2 [2M+NH4]+ (5 %); HR-MS m/z = 336.0728 [M+H]+ (calculated: 336.0723); HPLC-
Analysis (Method B): 99 %, Rt = 21.2 min.
Ethyl 3-[(5Z)-5-[(4-hydroxyphenyl)methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl] pro-
panoate 15e
TLC Rf = 0.3 (CHCl3/EtOAc 9:1); Reaction time: 1 h; Purification: Flash-Chromatography
CHCl3/EtOAc 9:1 (Rf = 0.3); Yield: 334 mg of red solid (0.99 mmol, 93 %); 1H-NMR (400
MHz, CDCl3) δ= 1.28 (t, 3 H, 3JH,H = 7.2 Hz, CH3), 2.77 (t, 2 H, 3JH,H = 7.3 Hz, β-CH2), 4.17
(q, 2 H, 3JH,H = 7.2 Hz, CH2CH3), 4.44 (t, 2 H, 3JH,H = 7.3 Hz, α-CH2), 6.91 (d, 2 H, 3JH,H =
8.6 Hz, 2,6-Ar-CH), 7.33 (d, 2 H, 3JH,H = 8.6 Hz, 3,5-Ar-CH), 7.61 (s, 1 H, CH) ppm; 13C-
NMR (400 MHz, CDCl3) δ= 14.2 (CH3), 31.7 (β-CH2), 40.2 (α-CH2), 61.3 (CH2CH3), 116.7
(2,6-Ar-CH), 119.7 (Ar-C), 126.1 (Ar-C), 133.2 (3,5-Ar-CH), 133.8 (CH), 158.6 (Ar-C), 167.8
(C=O), 171.0 (COOEt), 193.2 (C=S) ppm; ESI-MS m/z (%) = 338.1 [M+H]+ (100 %), 355.1
[M+NH4]+ (5 %), 360.0 [M+Na]+ (10 %), 692.1 [2M+NH4]+ (24 %), 696.1 [2M+Na]+ (12 %);
HPLC-Analysis (Method B): 90 %, Rt = 18.8 min.
Ethyl 3-[(5Z)-5-[(3,4-dihydroxyphenyl)methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]
propanoate 15f
TLC Rf = 0.2 (CHCl3/MeOH/AcOH 96:3:1); Reaction time: 2 h; Purification: Flash-Chroma-
tography CHCl3/MeOH/AcOH 96:3:1 (Rf = 0.1); Yield: 195 mg of yellow solid (0.55 mmol,
52 %); 1H-NMR (400 MHz, DMSO-d6) δ= 1.16 (t, 3 H, 3JH,H = 7.1 Hz, CH3), 2.69 (t, 2 H,
3JH,H = 7.4 Hz, β-CH2), 4.04 (q, 2 H, 3JH,H = 7.1 Hz, CH2CH3), 4.25 (t, 2 H, 3JH,H = 7.4 Hz,
α-CH2), 6.89 (d, 1 H, 3JH,H = 8.0 Hz, 5-Ar-CH), 7.03-7.05 (m, 1 H, 2-Ar-CH), 7.05 (dd, 1 H,
3,4JH,H = 2.2, 8.0 Hz, 6-Ar-CH), 7.65 (s, 1 H, CH) ppm; 13C-NMR (400 MHz, DMSO-d6) δ= 14.0
(CH3), 31.0 (β-CH2), 40.1 (α-CH2), 60.4 (CH2CH3), 116.5 (5-Ar-CH), 116.7 (2-Ar-CH), 117.3
(Ar-C), 124.4 (Ar-C), 125.4 (6-Ar-CH), 134.3 (CH), 146.2 (Ar-C), 149.6 (Ar-C), 166.8 (C=O),
170.2 (C=OOEt), 193.2 (C=S) ppm; HPLC-Analysis (Method B): 97 %, Rt = 17.6 min.
Ethyl 4-[(5Z)-4-oxo-5-(phenylmethylidene)-2- sulfanylidene-1,3-thiazolidin-3-yl] butanoate 16a [287]
TLC Rf = 0.5 (Hexane/EtOAc 8:2); Reaction time: 1 h; Purification: Filtration from ethanol;
Yield: 310 mg of yellow solid (0.92 mmol, 91 %); 1H-NMR (400 MHz, DMSO-d6) δ= 1.17
(t, 3 H, 3JH,H = 7.1 Hz, CH3), 1.92 (ap, 2 H, 3JH,H = 7.1, 7.0 Hz, β-CH2), 2.38 (t, 2 H, 3JH,H =
7.1 Hz, γ-CH2), 4.03 (q, 2 H, 3JH,H = 7.1 Hz, CH2CH3), 4.07 (t, 2 H, 3JH,H = 7.0 Hz, α-CH2),
7.48-7.66 (m, 5 H, 5xAr-CH), 7.80 (s, 1 H, CH) ppm; ESI-MS m/z (%) = 336.1 [M+H]+ (100 %),
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353.1 [M+NH4]+ (19 %); HPLC-Analysis (Method B): 98 %, Rt = 20.8 min.
Ethyl 4-[(5Z)-5-[(2-methylphenyl)methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl] buta-
noate 16b TLC Rf = 0.5 (Hexane/EtOAc 8:2); Reaction time: 1 h; Purification: Flash-
Chromatography hexane/EtOAc 9:1 (Rf = 0.2); Yield: 320 mg of yellow solid (0.92 mmol,
92 %); Yield: 270 mg of yellow solid (0.77 mmol, 77 %); 1H-NMR (400 MHz, CDCl3) δ= 1.27
(t, 3 H, 3JH,H = 7.1 Hz, CH2CH3), 2.07 (p, 2 H, 3JH,H = 7.4 Hz, β-CH2), 2.40 (t, 2 H, 3JH,H =
7.4 Hz, γ-CH2), 2.46 (s, 3 H, CH3), 4.14 (q, 2 H, 3JH,H = 7.1 Hz, CH2CH3), 4.20 (t, 2 H, 3JH,H =
7.4 Hz, α-CH2), 7.25-7.35 (m, 3 H, 3xAr-CH), 7.38-7.41 (m, 1 H, 6-Ar-CH), 7.94 (s, 1 H, CH)
ppm13C-NMR (400 MHz, CDCl3) δ= 14.3 (CH2CH3), 20.0 (CH3), 22.5 (β-CH2), 31.6 (γ-CH2),
43.7 (α-CH2), 60.6 (Ar-C), 126.8 (Ar-CH), 128.1 (6-Ar-CH), 130.8 (Ar-CH), 131.0 (CH), 131.2
(Ar-CH), 132.4 (Ar-C), 139.5 (Ar-C), 167.6 (C=O), 172.5 (COOEt), 194.0 (C=S) ppm; HPLC-
Analysis (Method B): 98 %, Rt = 21.7 min.
Ethyl 4-[(5Z)-5-[(3-methylphenyl)methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl] buta-
noate 16c TLC Rf = 0.5 (Hexane/EtOAc 8:2); Reaction time: 16 h; Purification: Flash-
Chromatography Hexane/EtOAc 9:1 (Rf = 0.2); Yield: 340 mg of yellow solid (0.97 mmol,
97 %); Yield: 321 mg of yellow solid (0.92 mmol, 92 %); 1H-NMR (400 MHz, CDCl3) δ= 1.26 (t,
3 H, 3JH,H = 7.1 Hz, CH2CH3), 2.07 (p, 2 H, 3JH,H = 7.4 Hz, β-CH2), 2.40 (t, 2 H, 3JH,H = 7.4 Hz,
γ-CH2), 2.41 (s, 3 H, CH3), 4.14 (q, 2 H, 3JH,H = 7.1 Hz, CH2CH3), 4.19 (t, 2 H, 3JH,H = 7.4 Hz,
α-CH2), 7.24-7.39 (m, 4 H, 4xAr-CH), 7.68 (s, 1 H, CH) ppm; 13C-NMR (400 MHz, CDCl3)
δ= 14.3 (CH2CH3), 21.5 (CH3), 22.5 (β-CH2), 31.6 (γ-CH2), 43.8 (α-CH2), 60.7 (CH2CH3),
122.7 (Ar-C), 128.0 (Ar-CH), 129.3 (Ar-CH), 131.3 (Ar-CH), 131.8 (Ar-CH), 133.3 (Ar-C), 133.5
(CH), 139.3 (Ar-C), 167.9 (C=O), 172.5 (C=OOEt), 193.6 (C=S) ppm; ESI-MS m/z (%) = 350.1
[M+H]+ (100 %), 716.2 [2M+NH4]+ (46 %); HPLC-Analysis (Method B): 100 %, Rt = 21.6 min.
Ethyl 4-[(5Z)-5-[(4-methylphenyl)methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl] buta-
noate 16d TLC Rf = 0.5 (Hexane/EtOAc 8:2); Reaction time: 1 h; Purification: Filtration from
ethanol; Yield: 193 mg of yellow solid (0.55 mmol, 55 %); Yield: 247 mg of yellow crystals
(0.71 mmol, 71 %); 1H-NMR (400 MHz, CDCl3) δ= 1.26 (t, 3 H, 3JH,H = 7.1 Hz, CH2CH3),
2.07 (p, 2 H, 3JH,H = 7.4 Hz, β-CH2), 2.39 (t, 2 H, 3JH,H = 7.4 Hz, γ-CH2), 2.41 (s, 3 H, CH3),
4.14 (q, 2 H, 3JH,H = 7.1 Hz, CH2CH3), 4.20 (t, 2 H, 3JH,H = 7.4 Hz, α-CH2), 7.29 (d, 2 H,
3JH,H = 8.2 Hz, 3,5-Ar-CH), 7.40 (d, 2 H, 3JH,H = 8.2 Hz, 2,6-Ar-CH), 7.71 (s, 1 H, CH) ppm;
13C-NMR (400 MHz, CDCl3) δ= 14.4 (CH2CH3) 21.8 (CH3), 22.6 (β-CH2), 31.7 (γ-CH2), 43.9
(α-CH2), 60.8 (CH2CH3), 121.8 (Ar-C) 130.3 (3,5-Ar-CH), 130.8 (Ar-C), 130.9 (2,6-Ar-CH),
133.6 (CH), 141.9 (Ar-C), 168.1 (C=O), 172.6 (COOEt), 193.7 (C=S) ppm; ESI-MS m/z (%) =
350.1 [M+H]+ (100 %), 372.1 [M+Na]+ (7 %), 716.2 [2M+NH4]+ (44 %), 721.2 [2M+Na]+ (7 %);
HPLC-Analysis (Method B): 98 %, Rt = 21.6 min.
Ethyl 4-[(5Z)-5-[2,5-bis(trifluoromethyl)phenyl]methylidene-4-oxo-2-sulfanylidene-1,3-thiazolidin-
-3-yl] butanoate 16e
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TLC Rf = 0.3 (Hexane/EtOAc 9:1); Reaction time: 1 h; Purification: Flash-Chromatography
Hexane/EtOAc 95:5 (Rf = 0.2); Yield: 431 mg of yellow solid (0.91 mmol, 91 %); 1H-NMR (400
MHz, CDCl3) δ= 1.28 (t, 3 H, 3JH,H = 7.1 Hz, CH3), 2.09 (p, 2 H, 3JH,H = 7.2 Hz, β-CH2), 2.42 (t,
2 H, 3JH,H = 7.1 Hz, γ-CH2), 4.16 (q, 2 H, 3JH,H = 7.1 Hz, CH2CH3), 4.22 (t, 2 H, 3JH,H = 7.1 Hz,
α-CH2), 7.81 (d, 1 H, 3JH,H = 8.2 Hz, 4-Ar-CH), 7.85 (s, 1 H, 6-Ar-CH), 7.92-7.96 (m, 2 H, 3-Ar-
CH and CH) ppm; 13C-NMR (400 MHz, CDCl3) δ= 14.3 (CH3), 22.5 (β-CH2), 31.6 (γ-CH2),
44.1 (α-CH2), 60.8 (CH2CH3), 122.9 (q, 1JC,F = 273.3 Hz, CF3), 123.0 (q, 1JC,F = 274.6 Hz,
CF3), 126.1 (q, 3JC,F = 3.6 Hz, 6-Ar-CH), 126.2 (q, 5JC,F = 1.9 Hz, CH) 126.7 (q, 3JC,F = 3.6 Hz,
4-Ar-CH), 127.8 (q, 3JC,F = 5.5 Hz, 3-Ar-CH), 129.9 (Ar-C), 132.8 (q, 2JC,F = 32.0 Hz, Ar-C),
133.5 (q, 4JC,F = 1.3 Hz, Ar-C), 134.8 (q, 2JC,F = 33.6 Hz, Ar-C), 166.8 (C=O), 172.5 (COOEt),
192.3 (C=S) ppm; ESI-MS m/z (%) = 472.1 [M+H]+ (73 %), 489.0 [M+NH4]+ (100 %), 960.1
[2M+NH4]+ (51 %); HPLC-Analysis (Method B): 97 %, Rt = 15.1 min.
Ethyl 4-[(5Z)-5-[(2-hydroxyphenyl)methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl] bu-
tanoate 16f
TLC Rf = 0.3 (Hexane/EtOAc 7:3); Reaction time: 4 h; Purification: Flash-Chromatography
Hexane/EtOAc 8:2 (Rf = 0.2); Yield: 330 mg of yellow solid (0.94 mmol, 94 %); 1H-NMR (400
MHz, CDCl3) δ= 1.27 (t, 3 H, 3JH,H = 7.1 Hz, CH3), 2.10 (ap, 2 H, 3JH,H = 7.4, 7.1 Hz, β-CH2),
2.43 (t, 2 H, 3JH,H = 7.4 Hz, γ-CH2), 4.15 (q, 2 H, 3JH,H = 7.1 Hz, CH2CH3), 4.23 (t, 2 H, 3JH,H =
7.1 Hz, α-CH2), 6.93 (d, 1 H, 3JH,H = 8.1 Hz, 3-Ar-CH), 7.00 (at, 1 H, 3JH,H = 7.6 Hz, 5-Ar-CH),
7.32 (atd, 1 H, 3,4JH,H = 8.1, 1.4 Hz, 4-Ar-CH), 7.37 (dd, 1 H, 3,4JH,H = 8.1, 1.4 Hz, 6-Ar-CH),
8.29 (s, 1 H, CH) ppm; 13C-NMR (400 MHz, CDCl3) δ= 14.3 (CH3), 22.6 (β-CH2), 31.7 (γ-
CH2), 43.9 (α-CH2), 61.0 (CH2CH3), 116.6 (3-Ar-CH), 121.1 (Ar-C), 121.3 (5-Ar-C), 121.9 (Ar-
C), 129.6 (CH), 129.8 (6-Ar-CH) 132.9 (4-Ar-CH), 156.5 (Ar-C), 168.8 (C=O), 173.0 (COOEt),
194.0 (C=S) ppm; ESI-MS m/z (%) = 352.1 [M+H]+ (100 %), 369.1 [M+NH4]+ (16 %), 374.0
[M+Na]+ (2 %), 720.1 [2M+NH4]+ (67 %), 725.1 [2M+Na]+ (5 %); HPLC-Analysis (Method B):
92 %, Rt = 20.0 min.
Ethyl 4-[(5Z)-5-[(3-hydroxyphenyl)methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl] bu-
tanoate 16g
TLC Rf = 0.3 (CHCl3/MeOH/HOAc 97:2:1); Reaction time: 4 h; Purification: Flash-Chroma-
tography CHCl3/MeOH/HOAc 97:2:1 (Rf = 0.3); Yield: 329 mg of yellow solid (0.94 mmol,
94 %); 1H-NMR (400 MHz, CDCl3) δ= 1.27 (t, 3 H, 3JH,H = 7.1 Hz, CH3), 2.03-2.12 (m, 2 H,
β-CH2), 2.42 (t, 2 H, 3JH,H = 7.4 Hz, γ-CH2), 4.13-4.21 (m, 4 H, α-CH2, CH2CH3), 6.93-6.99
(m, 2 H, 2,4-Ar-CH), 7.03 (d, 1 H, 3JH,H = 7.6 Hz, 6-Ar-CH), 7.33 (at, 1 H, 3JH,H = 7.9 Hz, 5-
Ar-CH), 7.64 (s, 1 H, CH) ppm; 13C-NMR (400 MHz, CDCl3) δ= 14.3 (CH3), 22.6 (β-CH2),
31.7 (γ-CH2), 43.8 (α-CH2), 61.1 (CH2CH3), 117.0 (2-Ar-CH), 118.5 (4-Ar-CH), 123.1 (Ar-C),
123.3 (6-Ar-CH), 130.7 (5-Ar-CH), 133.4 (CH), 134.7 (Ar-C), 156.8 (Ar-C), 168.1 (C=O), 173.2
(COOEt), 193.5 (C=S) ppm; ESI-MS m/z (%) = 352.1 [M+H]+ (37 %), 369.1 [M+NH4]+ (8 %),
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374.0 [M+Na]+ (19 %), 703.1 [2M+H]+ (100 %), 720.2 [2M+NH4]+ (18 %), 725.1 [2M+Na]+
(27 %); HPLC-Analysis (Method B): 91 %, Rt = 19.3 min.
Ethyl 4-[(5Z)-5-[(4-hydroxyphenyl)methylidene]-4- oxo-2-sulfanylidene-1,3-thiazolidin-3-yl] bu-
tanoate 16h
TLC Rf = 0.3 (CHCl3/MeOH/HOAc 97:2:1); Reaction time: 1 h; Purification: Filtration from
ethanol; Yield: 145 mg of yellow solid (0.41 mmol, 71 %); 1H-NMR (400 MHz, DMSO-d6) δ=
1.17 (t, 3 H, 3JH,H = 7.1 Hz, CH3), 1.92 (p, 2 H, 3JH,H = 7.0 Hz, β-CH2), 2.38 (t, 2 H, 3JH,H =
7.2 Hz, γ-CH2), 4.03 (q, 2 H, 3JH,H = 7.1 Hz, CH2CH3), 4.08 (t, 2 H, 3JH,H = 6.9 Hz, α-CH2),
7.55 (d, 2 H, 3JH,H = 7.5 Hz, 2xAr-CH), 7.65 (d, 2 H, 3JH,H = 7.5 Hz, 2xAr-CH), 7.81 (s, 1 H,
CH) ppm; 13C-NMR (400 MHz, DMSO-d6) δ= 14.1 (CH3), 21.9 (CH2), 30.8 (CH2), 43.6 (CH2),
59.9 (CH2), 122.6 (Ar-C), 129.5 (2xAr-CH), 130.6 (2xAr-CH), 131.0 (Ar-C), 132.7 (CH), 167.2
(C=O), 172.2 (COOEt), 193.8 (C=S) ppm; HPLC-Analysis (Method B): 99 %, Rt = 20.9 min.
Ethyl 4-[(5Z)-5-[(3,4-dihydroxyphenyl)methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]
butanoate 16i
TLC Rf = 0.3 (Hexane/EtOAc 8:2); Reaction time: 1 h; Purification: Flash-Chromatogra-
phy CHCl3/MeOH/HOAc 96:3:1 (Rf = 0.1); Yield: 150 mg of yellow solid (0.41 mmol, 85 %);
1H-NMR (400 MHz, MeOD) δ= 1.14 (t, 3 H, 3JH,H = 7.1 Hz, CH3), 1.93 (ap, 2 H, 3JH,H = 6.8,
7.2 Hz, β-CH2), 2.29 (t, 2 H, 3JH,H = 7.2 Hz, γ-CH2), 4.00 (q, 2 H, 3JH,H = 7.1 Hz, CH2CH3),
4.08 (t, 2 H, 3JH,H = 6.8 Hz, α-CH2), 6.78 (d, 1 H, 3JH,H = 8.1 Hz, 5-Ar-CH), 6.86-6.92 (m, 2 H,
2,6-Ar-CH), 7.50 (s, 1 H, CH) ppm; 1H-NMR (400 MHz, DMSO-d6) δ= 1.16 (H,H, t H, ,J7.1 Hz =
CH3, 3) 1.91 (ap, 2 H, JH,H = 6.8, 7.2 Hz, β-CH2), 2.36 (t, 2 H, 3JH,H = 7.2 Hz, γ-CH2), 4.02
(q, 2 H, 3JH,H = 7.1 Hz, CH2CH3), 4.07 (t, 2 H, 3JH,H = 6.8 Hz, α-CH2), 6.89 (d, 1 H, 3JH,H =
8.1 Hz, 5-Ar-CH), 7.02-7.06 (m, 2 H, 2,6-Ar-CH), 7.62 (s, 1 H, CH) ppm; 13C-NMR (400 MHz,
DMSO-d6) δ= 14.1 (CH3), 21.9 (CH2), 30.9 (CH2), 43.5 (CH2), 59.9 (CH2), 116.5 (Ar-C or
Ar-CH), 116.7 (Ar-C or Ar-CH), 117.5 (Ar-C or Ar-CH), 124.4 (Ar-C or Ar-CH), 125.4 (Ar-C or
Ar-CH), 134.1 (CH), 146.1 (Ar-CH), 149.6 (Ar-C), 167.2 (C=O), 172.2 (COOEt), 193.6 (C=S)
ppm; ESI-MS m/z (%) = 368.1 [M+H]+ (100 %), 752.1 [2M+NH4]+ (41 %), 757.1 [2M+Na]+ (6 %);
HPLC-Analysis (Method B): 98 %, Rt = 20.9 min.
4-[(5Z)-5-[(4-hydroxy-3,5- dimethoxyphenyl)methylidene]-4-oxo-2- sulfanylidenethiolan-3-yl]
butanoic acid 16j
ESI-MS m/z (%) = 406.0 [M+Na]+ (100 %); HPLC-Analysis (Method B): 86 %, Rt = 16.5 min.
9.6 General procedure for the synthesis of modified benzyloxy
benzaldehydes 18a–f and their condensation products 19a–l
3-Hydroxy benzaldehyde (1.0 eq), the corresponding benzylchloride (1.1 eq), potassium car-
bonate (1.0 eq) and sodium iodide (1.1 eq) were dissolved in anhydrous DMF. The reaction
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mixture was stirred at 90 ◦C (50 ◦C for pyridine benzylchloride derivatives) until TLC showed
complete consumption of starting material. The crude was concentrated and the remaining
yellow oil was extracted between H2O (20 mL) and EtOAc (3x25 mL). The combined organic
fractions were washed with brine, dried over MgSO4, filtered and concentrated. The crude
extract was purified by flash column chromatography to obtain the desired modified benzy-
loxybenzaldehydes 18a–f. In the consecutive reaction the aldehydes 18b–f were subjected
to Knoevenagel condensation conditions. Aldehydes 18b–f (1.0 eq), sodium acetate (1.0 eq)
and various rhodanine/ thiazolidine-2,4-dione derivatives (1.0 eq) were dissolved in ethanol
(5-10 mL). The reaction mixture was stirred at 80 ◦C, until TLC showed complete consumption
of starting material. The condensation products 19a–l were obtained after re-crystallisation or
column chromatography.
3-(benzyloxy)benzaldehyde 18a [290]
TLC Rf = 0.6 (Hexane/EtOAc 8:2); Reaction time: 4 h; Purification: Flash-Chromatography
Hexane/EtOAc 95:5 (Rf = 0.1); Yield: 1462 mg of white solid (6.89 mmol, 84 %); 1H-NMR (400
MHz, CDCl3) δ= 5.11 (s, 2 H, CH2), 7.22-7.26 (m, 1 H, Ar-CH), 7.31-7.49 (m, 8 H, 8xAr-CH),
9.96 (s, 1 H, CHO) ppm; 13C-NMR (400 MHz, CDCl3) δ= 70.3 (CH2), 113.3 (Ar-CH), 122.3
(Ar-CH), 123.8 (Ar-CH), 127.7 (Ar-CH), 128.3 (Ar-CH), 128.8 (Ar-CH), 130.2 (Ar-CH), 136.4
(Ar-C), 137.9 (Ar-C), 159.4 (Ar-C), 192.2 (CHO) ppm;
3-[(3-methoxyphenyl)methoxy] benzaldehyde 18b
TLC Rf = 0.3 (Hexane/EtOAc 8:2); Reaction time: 8 h; Purification: Flash-Chromatography
Hexane/EtOAc 8:2 (Rf = 0.3), loaded in DCM; Yield: 1628 mg of clear oil (6.72 mmol, 82 %);
Yield: 60 mg of clear oil (0.25 mmol, 15 %) (without NaI); 1H-NMR (400 MHz, CDCl3) δ= 3.71
(s, 3 H, OCH3), 4.99 (s, 2 H, CH2), 6.78 (dd, 1 H, 3,4JH,H = 2.4, 8.1 Hz, Ar-CH), 6.88-6.90 (m,
1 H, Ar-CH), 6.92 (d, 1 H, 3JH,H = 7.8 Hz, Ar-CH), 7.13-7.16 (m, 1 H, Ar-CH), 7.21 (at, 1 H,
3JH,H = 7.8 Hz, Ar-CH), 7.32-7.39 (m, 3 H, 3xAr-CH), 9.86 (s, 1 H, CHO) ppm; 1H-NMR (400
MHz, CDCl3) δ= 3.82 (s, 3 H, OCH3), 5.10 (s, 2 H, CH2), 6.88 (dd, 1 H, 3,4JH,H = 2.3, 8.2 Hz,
4’-Ar-CH), 6.98-7.00 (m, 1 H, 2’-Ar-CH), 7.02 (d, 1 H, 3JH,H = 7.5 Hz, 6’-Ar-CH), 7.25 (adt, 1 H,
3,4JH,H = 1.8, 1.9, 7.7 Hz, 4-Ar-CH), 7.31 (at, 1 H, 3JH,H = 7.5, 8.2 Hz, 5’-Ar-CH), 7.44 (at, 1 H,
3JH,H = 7.7 Hz, 5-Ar-CH), 7.46-7.49 (m, 2 H, 2,6-Ar-CH), 9.97 (s, 1 H, CHO) ppm; 13C-NMR
(400 MHz, CDCl3) δ= 55.4 (CH3), 70.2 (CH2), 113.1 (2’-Ar-CH), 113.4 (2-Ar-CH) 113.8 (4’-Ar-
CH), 119.8 (6’-Ar-CH), 122.3 (4-Ar-CH), 123.8 (6-Ar-CH), 129.9 (5’-Ar-CH), 130.3 (5-Ar-CH),
137.9 (Ar-C), 138.0 (Ar-C), 159.4 (Ar-C), 160.0 (Ar-C), 192.2 (CHO) ppm; APCI-MS m/z (%) =
260.1 [M+NH4]100 (, %) 243.1 [M+H]+ (20 %); HR-MS m/z = 260.1281 [M+NH4]+ (calculated:
260.1281).
3-[(4-methoxyphenyl)methoxy]benzaldehyde 18c [291]
TLC Rf = 0.6 (Hexane/EtOAc 8:2); Reaction time: 6 h; Purification: Flash-Chromatography
Hexane/EtOAc 9:1 (Rf = 0.1); Yield: 211 mg of white solid (0.87 mmol, 53 %) (without NaI)
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Yield: 66 mg of white solid (0.27 mmol, 30 %) (without NaI); Yield: 1688 mg of white solid
(6.97 mmol, 85 %) (with addition of NaI); 1H-NMR (400 MHz, CDCl3) δ= 3.75 (s, 3 H, CH3),
4.98 (s, 2 H, CH2), 6.86 (d, 2 H, 3JH,H = 8.6 Hz, 2’,6’-Ar-CH), 7.17 (adt, 1 H, 3,4JH,H = 2.4, 7.2 Hz,
4-Ar-CH), 7.30 (d, 2 H, 3JH,H = 8.6 Hz, 3’,5’-Ar-CH), 7.35-7.41 (m, 3 H, 2,5,6-Ar-CH), 9.90
(s, 1 H, CHO) ppm; 13C-NMR (400 MHz, CDCl3) δ= 55.5 (CH3), 70.2 (CH2), 113.3 (Ar-CH),
114.2 (2’,6’-Ar-CH) 122.4 (4-Ar-CH), 123.8 (Ar-CH), 128.4 (Ar-C), 129.5 (3’,5’-Ar-CH), 130.2
(Ar-CH), 137.9 (Ar-C), 159.5 (Ar-C), 159.8 (Ar-C), 192.3 (CHO) ppm; EI-MS m/z (%) = 242.0
[M]+ (100 %), 121.0 [fragment]+ (100 %); HR-MS m/z = 242.0933 [M]+ (calculated: 242.0937);
HPLC-Analysis (Method B): 98 %, Rt = 15.1 min.
3-(pyridin-2-ylmethoxy)benzaldehyde 18d [292]
TLC Rf = 0.1 (Toluene/EtOAc 9:1); Reaction time: 16 h; Purification: Flash-Chromatography
Toluene/EtOAc 9:1 (Rf = 0.1); Yield: 194 mg of white solid (0.91 mmol, 55 %) (without catalyst);
1H-NMR (400 MHz, CDCl3) δ= 5.20 (s, 2 H, CH2), 7.17-7.20 (m, 1 H, 5-Pyr-CH), 7.21 (ddd,
1 H, 3,4JH,H = 7.8, 2.7, 1.6 Hz, 6-Ar-CH), 7.39 (at, 1 H, 3JH,H = 7.8 Hz, 5-Ar-CH), 7.41-7.43 (m,
2 H, 2,4-Ar-CH), 7.45 (d, 1 H, 3JH,H = 7.7 Hz, 3-Pyr-CH), 7.67 (atd, 1 H, 3,4JH,H = 7.7, 1.8 Hz,
4-Pyr-CH), 8.55 (d(br), 1 H, 3JH,H = 4.7 Hz, 6-Pyr-CH), 9.90 (s, 1 H, CHO) ppm; 13C-NMR
(400 MHz, CDCl3) δ= 70.8 (CH2), 114.2 (2 or 4-Ar-CH), 121.7 (3-Pyr-CH), 121.9 (5-Pyr-CH
or 6-Ar-CH), 123.1 (5-Pyr-CH or 6-Ar-CH), 123.7 (2 or 4-Ar-CH), 130.4 (5-Ar-CH), 137.4 (4-
Pyr-CCH), 138.0 (Ar-C), 149.3 (6-Pyr-CH), 156.5 (Ar-C), 159.1 (Ar-C), 192.1 (underlineCHO)
ppm; APCI-MS m/z (%) = 214.1 [M+H]+ (100 %); HR-MS m/z = 214.0858 [M+H]+ (calculated:
214.0863).
3-(pyridin-3-ylmethoxy)benzaldehyde 18e [293]
TLC Rf = 0.2 (Cyclohexane/EtOAc 7:3); Reaction time: 16 h; Purification: Flash-Chromato-
graphy Cyclohexane/EtOAc 7:3 (Rf = 0.2); Yield: 201 mg of white solid (0.94 mmol, 59 %) (with
NaI); Yield: 136 mg of white solid (0.64 mmol, 16 %) (without catalyst); APCI-MS m/z (%) =
214.1 [M+H]+ (100 %), 427.16 [2M+H]+ (20 %); HR-MS m/z = 214.0860 [M+H]+ (calculated:
214.0863).
3-(pyridin-4-ylmethoxy)benzaldehyde 18f
TLC Rf = 0.2 (Cyclohexane/EtOAc 6:4); Reaction time: 16 h; Purification: Flash-Chromato-
graphy Cyclohexane/EtOAc 6:4 (Rf = 0.2); Yield: 175 mg of white solid (0.82 mmol, 50 %) (with
NaI); Yield: 1068 mg of white solid (5.01 mmol, 33 %) (without catalyst); 1H-NMR (400 MHz,
CDCl3) δ= 5.09 (s, 2 H, CH2), 7.19 (ddd, 1 H, 3,4JH,H = 7.5, 2.0, 2.0 Hz, 6-Ar-CH), 7.32 (d, 2 H,
3JH,H = 5.9 Hz, 3,5-Pyr-CH), 7.37-7.39 (m, 1 H, 2-Ar-CH), 7.39-7.47 (m, 2 H, 4,5-Ar-CH), 8.57
(d, 2 H, 3JH,H = 5.9 Hz, 2,6-Pyr-CH), 9.91 (s, 1 H, CHO) ppm; 13C-NMR (400 MHz, CDCl3) δ=
68.4 (CH2), 112.9 (2-Ar-CH), 121.7 (3,5-Pyr-CH), 122.2 (6-Ar-CH), 124.5, 130.5 (4,5-Ar-CH),
138.0 (Ar-C), 145.9 (Ar-C), 150.0 (2,6-Pyr-CH), 158.8 (Ar-C), 192.0 (CHO) ppm; APCI-MS
m/z (%) = 214.1 [M+H]+ (100 %); HR-MS m/z = 214.0862 [M+H]+ (calculated: 214.0863).
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Ethyl 3-[(5Z)-5-(3-[(3-methoxyphenyl)methoxy]phenylmethylidene)-4-oxo-2-sulfanylidene-1,3-
thiazolidin-3-yl] propanoate 19a
TLC Rf = 0.3 (Hexane/EtOAc 9:1); Reaction time: 1 h; Purification: Flash-Chromatography
Hexane/EtOAc 9:1 (Rf = 0.3), loaded in DCM; Yield: 240 mg of yellow solid (0.52 mmol, 82 %);
1H-NMR (400 MHz, CDCl3) δ= 1.26 (t, 3 H, 3JH,H = 7.1 Hz, CH3), 2.74 (t, 2 H, 3JH,H = 7.6 Hz,
β-CH2), 3.82 (s, 3 H, OCH3), 4.14 (q, 2 H, ,JH,H = CH2CH3, 3) 4.40 (t, 2 H, 3JH,H = 7.6 Hz,
α-CH2), 5.08 (s, 2 H, CH2), 6.87 (dd, 1 H, 3,4JH,H = 8.2, 2.3 Hz, 4-Ar-CH), 6.98-7.00 (m, 1 H,
2-Ar-CH), 7.00-7.03 (m, 2 H, 2’,4’-Ar-CH), 7.03-7.09 (m, 2 H, 6,6’-Ar-CH), 7.31 (at, 1 H, 3JH,H =
7.9 Hz, 5-Ar-CH), 7.37 (at, 1 H, 3JH,H = 7.9 Hz, 5’-Ar-CH), 7.66 (s, 1 H, CH) ppm; 13C-NMR
(400 MHz, CDCl3) δ= 14.2 (CH3), 31.5 (β-CH2), 40.1 (α-CH2), 55.4 (OCH3), 61.1 (CH2CH3),
70.1 (CH2Ar), 112.9 (2-Ar-CH), 113.7 (4-Ar-CH), 116.1 (2’ or 4’-Ar-CH), 118.1 (6 or 6’-Ar-CH),
119.6 (2’ or 4’-Ar-CH) 123.1 (Ar-C), 123.7 (6 or 6’-Ar-CH), 129.9 (5-Ar-CH), 130.5 (5’-Ar-
CH), 133.4 (CH), 134.6 (Ar-C), 138.0 (Ar-C). 159.3 (Ar-C), 160.0 (Ar-C), 167.4 (C=O), 170.5
(COOEt), 193.1 (C=S) ppm; ESI-MS m/z (%) = 458.1 [M+H]+ (100 %), 475.1 [M+NH4]+ (30 %),
480.1 [M+Na]+ (50 %), 932.2 [2M+NH4]+ (75 %), 937.2 [2M+Na]+ (100 %), 953.16 [2M+K]+
(10 %); HR-MS m/z = 458.1096 [M+H]+ (calculated: 458.1090); HPLC-Analysis (Method B):
87 %, Rt = 22.2 min.
Ethyl 2-[5-(4-[(3- methoxyphenyl)methoxy]phenylmethyl)-2,4-dioxo-1,3- thiazolidin-3-yl] acetate
19b
TLC Rf = 0.2 (Hexane/EtOAc 8:2); Reaction time: 8 h; Purification: Flash-Chromatography
Hexane/EtOAc 8:2 (Rf = 0.2); Yield: 405 mg of white solid (0.94 mmol, 94 %); 1H-NMR (400
MHz, CDCl3) δ= 1.29 (t, 3 H, 3JH,H = 7.1 Hz, CH3), 3.81 (s, 3 H, OCH3), 4.23 (q, 2 H, 3JH,H =
7.1 Hz, CH2CH3), 4.45 (s, 2 H, CH2), 5.07 (s, 2 H, Ar-CH2), 6.87 (d, 1 H, 3JH,H = 8.3 Hz, 4-
Ar-CH), 6.97-7.06 (m, 4 H, 2,2’,6.6’-Ar-CH), 7.09 (d, 1 H, 3JH,H = 7.3 Hz, 4’-Ar-CH), 7.30 (at,
1 H, 3JH,H = 7.9 Hz, 5-Ar-CH), 7.37 (at, 1 H, 3JH,H = 8.4 Hz, 5’-Ar-CH), 7.86 (s, 1 H, CH) ppm;
13C-NMR (400 MHz, CDCl3) δ= 14.1 (CH3), 42.2 (OCH3), 55.3 (CH2), 62.2 (CH2CH3), 70.1
(CH2Ar), 112.9 (6 or 6’-Ar-CH), 113.6 (4-Ar-CH), 116.0 (2 or 2’-Ar-CH), 117.8 (2 or 2’-Ar-CH),
119.6 (6 or 6’-Ar-CH), 121.4 (Ar-C) 123.2 (4’-Ar-CH), 129.9 (5-Ar-CH), 130.4 (5’-Ar-CH), 134.4
(Ar-C), 134.6 (CH), 138.0 (Ar-C), 159.2 (Ar-C), 160.0 (Ar-C), 165.5 (C=O), 166.3 (C=O), 167.4
(COOEt) ppm; HPLC-Analysis (Method B): 96 %, Rt = 20.1 min.
Ethyl 2-[(5Z)-5-(3-[(4-methoxyphenyl) methoxy] phenylmethylidene)-4-oxo-2-sulfanylidene-1,3
thiazolidin-3-yl] acetate 19c
TLC Rf = 0.1 (Hexane/EtOAc 9:1); Reaction time: 4 h; Purification: Flash-Chromatography
Hexane/EtOAc 9:1 (Rf = 0.1); Yield: 68 mg of yellow solid (0.15 mmol, 64 %); 1H-NMR (400
MHz, CDCl3) δ= 1.21 (t, 3 H, 3JH,H = 7.1 Hz, CH3), 3.74 (s, 3 H, OCH3), 4.16 (q, 2 H, 3JH,H =
7.1 Hz, CH2CH3), 4.76 (s, 2 H, CH2), 4.95 (s, 2 H, CH2), 6.85 (d, 2 H, 3JH,H = 8.7 Hz, 3,5’-Ar-
CH), 6.96 (s, 1 H, 2-Ar-H), 6.95-7.00 (0, m H, ,J = 6-Ar-H, ) 7.00 (at, 1 H, 3JH,H = 7.6 Hz, 5-Ar-
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CH), 7.29 (d, 2 H, 3JH,H = 8.7 Hz, 2,6’-Ar-H), 7.31 (d, 1 H, 3JH,H = 7.6 Hz, 4-Ar-H), 7.63 (s, 1 H,
CH) ppm; 13C-NMR (400 MHz, CDCl3) δ= 14.2 (CH3), 44.9 (CH2), 55.4 (OCH3), 62.2 (CH2)
70.1 (CH2CH3), 114.2 (3,5’-Ar-CH), 116.1 (2-Ar-CH), 118.2 (6-Ar-CH), 123.0 (Ar-C), 123.7
(5-Ar-CH), 128.3 (2,6’-Ar-CH), 129.3 (Ar-C), 130.5 (Ar-C), 134.0 (CH), 134.5 (Ar-C), 159.4
(Ar-C), 159.7 (Ar-C), 165.9 (C=O), 167.1 (COOEt), 193.1 (C=S) ppm; ESI-MS m/z (%) = 461.1
[M+NH4]+ (100 %); HR-MS m/z = 461.0892 [M+NH4]+ (calculated: 461.0881); HPLC-Analysis
(Method B): 100 %, Rt = 21.5 min.
Ethyl 2-[(5Z)-5-(3-[(4- methoxyphenyl) methoxy] phenyl methylidene)-2,4- dioxo-1,3-thiazoli-
din-3-yl] acetate 19d
TLC Rf = 0.2 (Hexane/EtOAc 8:2); Reaction time: 8 h; Purification: Flash-Chromatography
Hexane/EtOAc 8:2 (Rf = 0.2); Yield: 401 mg of white solid (0.94 mmol, 94 %); 1H-NMR (400
MHz, CDCl3) δ= 1.29 (t, 3 H, 3JH,H = 7.1 Hz, CH3), 3.81 (s, 3 H, OCH3), 4.24 (q, 2 H, 3JH,H =
7.1 Hz, CH2CH3), 4.47 (s, 2 H, CH2), 5.03 (s, 2 H, CH2Ar), 6.93 (d, 2 H, 3JH,H = 8.7 Hz, 3’,5’-Ar-
CH), 7.03-7.08 (m, 2 H, 2,4-Ar-CH), 7.10 (d, 1 H, 3JH,H = 7.8 Hz, 6-Ar-CH), 7.36 (d, 2 H, 3JH,H =
8.7 Hz, 2’,6’-Ar-CH), 7.34-7.40 (m, 1 H, 5-Ar-CH), 7.87 (s, 1 H, CH) ppm; 13C-NMR (400 MHz,
CDCl3) δ= 14.2 (CH3), 42.2 (CH2), 55.4 (OCH3), 62.3 (CH2CH3), 70.1 (CH2Ar), 114.2 (3’,5’-
Ar-CH), 116.0 (2-Ar-CH), 117.9 (4-Ar-CH), 121.4 (Ar-C), 123.1 (6-Ar-CH), 128.4 (Ar-C), 129.3
(2’,6’-Ar-CH), 130.3 (5-Ar-CH), 130.4 (Ar-C), 134.4 (Ar-C), 134.7 (CH), 159.3 (Ar-C), 166.3
(C=O), 167.5 (C=O), 171.3 (COOEt) ppm; ESI-MS m/z (%) = 428.1 [M+H]+ (53 %), 445.1
[M+NH4]+ (100 %), 855.2 [2M+H]+ (2 %), 872.3 [2M+NH4]+ (59 %); HPLC-Analysis (Method
B): 86 %, Rt = 20.1 min.
Ethyl 3-[(5Z)-5-(3-[(4-methoxyphenyl)methoxy]phenylmethylidene)-4-oxo-2-sulfanylidene-1,3-thia-
zolidin-3-yl] propanoate 19e
TLC Rf = 0.4 (Hexane/EtOAc 8:2); Reaction time: 1h; Purification: Flash-Chromatogra-
phy Hexane/EtOAc 9:1 (Rf = 0.2), loaded in DCM; Yield: 275 mg of yellow solid (0.60 mmol,
0.80 %); 1H-NMR (400 MHz, CDCl3) δ= 1.25 (t, 3 H, 3JH,H = 7.1 Hz, CH3), 2.74 (t, 2 H, 3JH,H =
7.6 Hz, β-CH2), 3.81 (s, 3 H, OCH3), 4.14 (q, 2 H, 3JH,H = 7.1 Hz, CH2CH3), 4.39 (t, 2 H, 3JH,H =
7.6 Hz, α-CH2), 5.02 (s, 2 H, CH2), 6.92 (d, 2 H, 3JH,H = 8.7 Hz, 3’,5’-Ar-CH), 7.00-7.02 (m, 1 H,
2-Ar-CH), 7.02-7.08 (m, 2 H, 4,6-Ar-CH), 7.36 (d, 2 H, 3JH,H = 8.7 Hz, 2’,6’-Ar-CH), 7.36 (at,
1 H, 3JH,H = 7.9 Hz, 5-Ar-CH), 7.65 (s, 1 H, CH) ppm; 13C-NMR (400 MHz, CDCl3) δ= 14.2
(CH3), 31.4 (β-CH2), 40.0 (α-CH2), 55.3 (OCH3), 61.0 (CH2CH3), 70.0 (CH2), 114.1 (3’,5’-Ar-
CH), 116.1 (Ar-CH), 118.0 (Ar-CH), 123.0 (Ar-C), 123.6 (Ar-CH), 128.3 (Ar-C), 129.2 (2’,6’-Ar-
CH), 130.4 (5-Ar-CH), 133.4 (CH) 134.5 (Ar-C), 159.3 (Ar-C), 159.6 (Ar-C), 167.4 (C=O), 170.4
(COOEt) 193.0 (C=S) ppm; ESI-MS m/z (%) = 458.1 [M+H]+ (8 %); HPLC-Analysis (Method
B): 87 %, Rt = 22.0 min.
Ethyl 2-[(5Z)-4-oxo-5-[3-(pyridin-2-ylmethoxy)phenyl]methylidene-2-sulfanylidene-1,3thiazolid-
in-3-yl] acetate 19j
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TLC Rf = 0.1 (CHCl3/EtOAc 9:1); Reaction time: 4 h; Purification: Flash-Chromatography
CHCl3/EtOAc 9:1 (Rf = 0.1); Yield: 30 mg of yellow solid (0.07 mmol, 30 %); 1H-NMR (400
MHz, CDCl3) δ= 1.22 (t, 3 H, 3JH,H = 7.1 Hz, CH3), 4.17 (q, 2 H, 3JH,H = 7.1 Hz, CH2CH3), 4.78
(s, 2 H, CH2), 5.08 (s, 2 H, CH2), 6.98 (s, 1 H, 2-Ar-CH), 6.97-7.00 (m, 1 H, ,J = 6-Ar-CH, ) 7.08
(d, 1 H, 3JH,H = 7.6 Hz, 4-Ar-CH), 7.34 (d, 2 H, 3JH,H = 6.4 Hz, 4,5-Pyr-CH), 7.31-7.37 (m, 1 H,
5-Ar-CH), 7.65 (s, 1 H, CH), 8.59 (s(br), 2 H, ); 13C-NMR (400 MHz, CDCl3) δ= 14.2 (CH3),
45.0 (CH2), 62.2 (CH2CH3) 68.4 (CH2), 116.1 (2-Ar-CH), 117.8 (6-Ar-CH), 121.7 (4,5-Pyr-
CH), 123.5 (Ar-C), 124.2 (4-Ar-CH), 130.7 (5-Ar-CH), 133.6 (CH), 134.8 (Ar-C), 146.0 (Ar-C),
149.9 (3,6-Pyr-CH), 158.7 (Ar-C), 165.9 (C=O), 167.1 (COOH), 192.8 (C=S) ppm; APCI-MS
m/z (%) = 415.1 [M+H]+ (100 %); EI-MS m/z (%) = 414.0 [M]+ (100 %), 241.0 [fragment]+ (100 %),
91.9 [fragment]+ (50 %); HR-MS m/z = 415.0772 [M+H]+ (calculated: 415.0781); HPLC-Analysis
(Method B): 99 %, Rt = 16.3 min.
Ethyl 2-[(5Z)-4-oxo-5-[3-(pyridin-3-ylmethoxy)phenyl]methylidene-2-sulfanylidene-1,3-thiazolidin-
3-yl] acetate 19l
TLC Rf = 0.1 (CHCl3/EtOAc 9:1); Reaction time: 4 h; Purification: Flash-Chromatography
CHCl3/EtOAc 9:1 (Rf = 0.1); Yield: 38 mg of yellow solid (0.09 mmol, 38 %); 1H-NMR (400
MHz, CDCl3) δ= 1.22 (t, 3 H, 3JH,H = 7.1 Hz, CH3), 4.17 (q, 2 H, 3JH,H = 7.1 Hz, CH2CH3), 4.78
(s, 2 H, CH2), 5.07 (s, 2 H, CH2), 7.00 (s(br), 1 H, 2-Ar-CH), 6.98-7.02 (m, 1 H, 6-Ar-CH) 7.07
(d, 1 H, 3JH,H = 7.9 Hz, 4-Ar-CH), 7.28-7.33 (m, 1 H, 5-Ar-CH), 7.35 (at, 1 H, 3JH,H = 7.8 Hz, 5-
Pyr-CH), 7.66 (s, 1 H, CH), 7.75 (d, 1 H, 3JH,H = 7.8 Hz, 4-Pyr-CH), 8.56 (s(br), 1 H, 6-Pyr-CH),
8.65 (s(br), 1 H, 2-Pyr-CH) ppm; 13C-NMR (400 MHz, CDCl3) δ= 14.2 (CH3), 45.0 (CH2), 62.2
(CH2CH3), 67.8 (CH2), 116.2 (2-Ar-CH), 117.9 (6-Ar-CH), 123.4 (5-Ar-CH), 124.1 (4-Ar-CH),
130.7 (5-Pyr-CH), 133.7 (CH), 134.7 (Ar-C), 135.6 (4-Pyr-CH), 148.8 (2-Pyr-CH), 149.6 (6-
Pyr-CH), 158.9 (Ar-C), 165.9 (C=O), 167.1 (C=OOEt), 192.9 (C=S) ppm; APCI-MS m/z (%) =
415.1 [M+H]+ (100 %); HR-MS m/z = 415.0774 [M+H]+ (calculated: 415.0781); HPLC-Analysis
(Method B): 99 %, Rt = 16.3 min.
Ethyl 2-[(5Z)-4-oxo-5-[3-(pyridin-4-ylmethoxy)phenyl]methylidene-2-sulfanylidene-1,3-thiazoli-
din-3-yl] acetate 19k
TLC Rf = 0.2 (Toluene/EtOAc 9:1); Reaction time: 4 h; Purification: Flash-Chromatography
Toluene/EtOAc 9:1 (Rf = 0.2); Yield: 50 mg of yellow solid (0.12 mmol, 50 %); 1H-NMR (400
MHz, CDCl3) δ= 1.21 (t, 3 H, 3JH,H = 7.1 Hz, CH3), 4.16 (q, 2 H, 3JH,H = 7.1 Hz, CH2CH3), 4.77
(s, 2 H, CH2), 5.07 (s, 2 H, CH2), 6.97 (s, 1 H, 2-Ar-CH), 6.95-7.00 (m, 1 H, ,J = 6-Ar-CH, )
7.06 (d(br), 1 H, 3JH,H = 7.7 Hz, 4-Ar-CH), 7.31 (d, 2 H, 3JH,H = 4.7 Hz, 2,4-Pyr-CH), 7.34 (at,
1 H, 3JH,H = 7.7 Hz, 5-Ar-CH), 7.64 (s, 1 H, CH), 8.58 (d, 2 H, 3JH,H = 4.7 Hz, 1,5-Pyr-CH) ppm;
13C-NMR (400 MHz, CDCl3) δ= 14.2 (CH3), 44.9 (CH2), 62.2 (CH2CH3), 68.4 (CH2), 116.1 (2-
Ar-CH), 117.8 (6-Ar-CH), 121.6 (2,4-Pyr-CH), 123.4 (Ar-C), 124.1 (4-Ar-CH), 130.7 (5-Ar-CH),
133.5 (CH), 134.7 (Ar-C), 145.7 (Ar-C), 150.1 (1,5-Pyr-CH), 158.7 (Ar-C), 165.9 (C=O), 167.1
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(COOH), 192.8 (C=S) ppm; APCI-MS m/z (%) = 415.1 [M+H]+ (100 %); HR-MS m/z = 415.0772
[M+H]+ (calculated: 415.0781); HPLC-Analysis (Method B): 99 %, Rt = 14.9 min.
3-[(5Z)-4-oxo-5-[3-(pyridin-2-ylmethoxy)phenyl]methylidene-2-sulfanylidene-1,3-thiazolidin-3-yl]
propanoic acid 19f
TLC Rf = 0.3 (Hexane/EtOAc 1:1); Reaction time: 4 h; Purification: Filtration from ethanol;
Yield: 205 mg of yellow solid (0.51 mmol, 75 %); 1H-NMR (400 MHz, DMSO-d6) δ= 2.38-
2.43 (m, 2 H, β-CH2), 4.13-4.20 (m, 2 H, α-CH2), 5.25 (s, 2 H, CH2), 7.19 (dd, 1 H, 3,4JH,H =
2.4, 8.0 Hz, 6-Ar-CH), 7.22 (d, 1 H, 3JH,H = 8.1 Hz, 4-Ar-CH), 7.24-7.26 (m, 1 H, 2-Ar-CH),
7.36 (dd, 1 H, 3,4JH,H = 5.0, 7.7 Hz, 4-Pyr-CH), 7.47 (at, 1 H, 3JH,H = 8.0, 8.1 Hz, 5-Ar-CH),
7.53 (d, 1 H, 3JH,H = 7.8 Hz, 6-Pyr-CH) 7.76 (s, 1 H, CH), 7.84 (atd, 1 H, 3,4JH,H = 1.7, 7.7,
7.8 Hz, 5-Pyr-CH), 8.59 (d, 1 H, 3JH,H = 5.0 Hz, 3-Pyr-CH) ppm; 13C-NMR (400 MHz, DMSO-
d6) δ= 32.6 (β-CH2), 41.3 (α-CH2), 70.5 (CH2), 116.3 (2-Ar-CH), 117.8 (6-Ar-CH), 121.8
(6-Pyr-CH), 123.1 (4-Ar-CH, 4-Pyr-CH), 130.7 (5-Ar-CH), 132.5 (CH), 134.4 (Ar-C), 137.1 (5-
Pyr-CH), 149.2 (3-Pyr-CH), 156.3 (Ar-C), 158.6 (Ar-C), 166.7 (C=O), 172.4 (COOH), 193.2
(C=S) ppm; ESI-MS m/z (%) = 399.0 [M−H]− (100 %); HR-MS m/z = 399.0468 [M−H]− (calcu-
lated: 399.0479); HPLC-Analysis (Method B): 99 %, Rt = 17.0 min.
3-[(5Z)-4-oxo-5-[3-(pyridin-3-ylmethoxy)phenyl]methylidene-2-sulfanylidene-1,3-thiazolidin-3-yl]
propanoic acid 19g
TLC Rf = 0.3 (Hexane/EtOAc 1:1); Reaction time: 4 h; Purification: Filtration from ethanol;
Yield: 192 mg of yellow solid (0.48 mmol, 69 %); 1H-NMR (400 MHz, DMSO-d6) δ= 2.38-2.43
(m, 2 H, β-CH2), 4.13-4.20 (m, 2 H, α-CH2), 5.23 (s, 2 H, CH2), 7.17-7.23 (m, 2 H, 4,6-Ar-CH),
7.27-7.29 (m, 1 H, 2-Ar-CH), 7.44 (ddd, 1 H, 3,4JH,H = 0.6, 4.8, 7.8 Hz, 5-Pyr-CH), 7.49 (at,
1 H, 3JH,H = 8.0 Hz, 5-Ar-CH), 7.77 (s, 1 H, CH), 7.90 (dt, 1 H, 3,4JH,H = 1.9, 7.8 Hz, 6-Pyr-CH),
8.56 (dd, 1 H, 3,4JH,H = 1.6, 4.8 Hz, 4-Pyr-CH), 8.70 (ad, 1 H, 4JH,H = 1.6, 1.9 Hz, 2-Pyr-CH)
ppm; 13C-NMR (400 MHz, DMSO-d6) δ= 32.7 (β-CH2), 41.4 (α-CH2), 67.2 (CH2), 116.6 (2-
Ar-CH), 117.8 (6-Ar-CH), 123.0 (Ar-C), 123.1 (4-Ar-CH), 123.7 (5-Pyr-CH), 130.8 (5-Ar-CH),
132.3 (CH), 132.5 (Ar-C), 134.5 (6-Pyr-CH), 135.8 (Ar-C), 149.2 (2-Pyr-CH), 149.3 (4-Pyr-
CH), 158.6 (Ar-C), 166.7 (C=O), 172.5 (C=OOEt), 193.2 (C=S) ppm; ESI-MS m/z (%) = 399.0
[M−H]− (100 %); HR-MS m/z = 399.0469 [M−H]− (calculated: 399.0479); HPLC-Analysis
(Method B): 99 %, Rt = 17.0 min.
3-[(5Z)-4-oxo-5-[3-(pyridin-4-ylmethoxy)phenyl]methylidene-2-sulfanylidene-1,3-thiazolidin-3-yl]
propanoic acid 19h
TLC Rf = 0.3 (Hexane/EtOAc 1:1); Reaction time: 4 h; Purification: Filtration from ethanol;
Yield: 201 mg of yellow solid (0.50 mmol, 82 %); 1H-NMR (400 MHz, DMSO-d6) δ= 2.29-
2.35 (m, 2 H, β-CH2), 4.12-4.18 (m, 2 H, α-CH2), 5.27 (s, 2 H, CH2), 7.19 (dd, 1 H, 3,4JH,H =
2.2, 8.1 Hz, 6-Ar-CH), 7.23 (d, 1 H, 3JH,H = 8.1 Hz, 4-Ar-CH), 7.25-7.27 (m, 1 H, 2-Ar-CH),
7.45-7.52 (m, 3 H, 5-Ar-CH,2,6-Pyr-CH), 7.77 (s, 1 H, CH), 8.59 (d, 1 H, 3JH,H = 6.0 Hz, 3,5-
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Pyr-CH) ppm, 13C-NMR (400 MHz, DMSO-d6) δ= 32.9 (β-CH2), 41.5 (α-CH2), 67.6 (CH2),
116.4 (2-Ar-CH), 117.7 (6-Ar-CH), 121.8 (2,6-Pyr-CH), 123.1 (4-Ar-CH), 123.2 (Ar-C), 130.7
(5-Ar-CH), 132.4 (CH), 134.5 (Ar-C), 145.7 (Ar-C), 149.7 (3,5-Pyr-CH), 158.3 (C=O), 166.7
(COOH), 193.1 (C=S) ppm; ESI-MS m/z (%) = 399.0 [M−H]− (100 %), 799.1 [2M−H]− (7 %);
HPLC-Analysis (Method B): 97 %, Rt = 13.5 min.
9.7 General procedure for the synthesis of 2-amino substituted pyridine
carboxaldehyde derivatives 25a–g
Synthesis of the rhodanine condensed precursor 21a
The ethyl ester of 14 (44 mg, 0.20 mmol) and 2-chloroisonicotinaldehyde (31 mg, 0.22 mmol)
were dissolved in ethanol (3 mL) and stirred under reflux for 48 h, until TLC (DCM, Rf 0.4)
showed complete consumption of starting material. A yellow solid precipitated was filtered,
washed with ethanol and dried in vacuo to afford 21a as yellow solid (24 mg, 35 %).
(Z)-ethyl 2-(5-((2-chloropyridin-4-yl)methylene)-4-oxo-2-thioxothiazolidin-3-yl) acetate 21a
Reaction time: 16 h; TLC Rf = 0.4 (DCM); Purification: Filtration from ethanol; Yield: 14
mg of yellow solid (0.04 mmol, 20 %); 1H-NMR (400 MHz, DMSO-d6) δ= 1.21 (t, 3 H, 3JH,H =
7.1 Hz, OCH2CH3), 4.17 (q, 2 H, 3JH,H = 7.1 Hz, OCH2CH3), 4.85 (s, 2 H, CH2), 7.60 (d, 1 H,
3JH,H = 5.2 Hz, 4-Ar-CH), 7.81 (s, 1 H, 6-Ar-CH), 7.88 (s, 1 H, CH), 8.59 (d, 1 H, 3JH,H = 5.2 Hz,
3-Ar-CH) ppm; ESI-MS m/z (%) = 343.0 [M+H]+ (100 %), 707.0 [2M+Na]+ (15 %); HR-MS m/z =
342.9976 [M+H]+ (calculated: 342.9972); HPLC-Analysis (Method B): 92 %, Rt = 20.0 min.
General Procedure for the Synthesis of Acetal 23
2-bromoisonicotinaldehyde 20b (1.0 eq) was dissolved in EtOH/CHCl3 (1:1, 1 mL) and TFA
(1.0 eq) was added. The reaction mixture was heated under reflux for 4.5 h, until TLC (hex-
ane/EtOAc 9:1, Rf 0.4) showed complete consumption of starting material. The excess of TFA
was neutralised with aqueous NaHCO3aq (sat.), extracted with DCM (3 x 5 mL). The combined
organic layers were dried over MgSO4, filtered and concentrated. The product can optionally
be purified by flash chromatography, but the crude is satisfactory to proceed with the synthesis.
2-bromo-4-(diethoxymethyl)pyridine 23
TLC Rf = 0.4 (Hexane/EtOAc 9:1); Reaction time: 4 h; Purification: Flash-Chromatography
Hexane/EtOAc 9:1→ 8:2 (Rf = 0.1, 0.2); Yield: 565 mg of clear oil (2.74 mmol, 51 %); 1H-NMR
(400 MHz, CDCl3) δ= 1.17 (t, 6 H, JH,H = 7.0 Hz, (CH2CH3)2), 3.43-3.55 (m, 4 H, 2xCH2CH3),
5.38 (s, 1 H, CH), 7.27 (ddd, 1 H, 3,4JH,H = 5.1, 1.3, 0.6 Hz, 4-Ar-CH), 7.53 (dd, 1 H, 4JH,H = 0.6,
1.3 Hz, 2-Ar-CH), 8.28 (d, 1 H, 3JH,H = 5.1 Hz, 5-Ar-CH) ppm; ESI-MS m/z (%) = 260.0 [M+H]+
(100 %); HR-MS m/z = 260.0281 [M+H]+ (calculated: 260.0285). 13C-NMR (400 MHz, CDCl3)
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δ= 15.2 (CH3), 61.4 (CH2CH3), 99.0 (CH), 120.9 (6-Ar-CH), 126.3 (2-Ar-CH), 142.6 (Ar-C),
150.2 (5-Ar-CH), 150.8 (Ar-C) ppm;
crude 23 after simple extraction:
TLC Rf = 0.2 (Hexane/EtOAc 9:1); Yield: 115 mg of clear oil (0.44 mmol, 82 %); Yield: 202
mg of clear oil (0.78 mmol, 71 %); Yield: 565 mg of clear oil (2.74 mmol, 51 %); Yield: 204 mg
of clear oil (0.78 mmol, 91 %); Yield: 252 mg of clear oil (0.97 mmol, 88 %); Yield: 201 mg
of clear oil (0.77 mmol, 80 %); Reaction time: 2.5-4.5 h; 1H-NMR (400 MHz, CDCl3) δ= 1.25
(t, 3 H, 3JH,H = 7.1 Hz, CH3), 1.26 (t, 3 H, 3JH,H = 7.1 Hz, CH3), 3.52-3.62 (m, 4 H, 2xCH2CH3),
5.46 (s, 1 H, CH), 7.34-7.37 (m, 1 H, 6-Ar-CH), 7.61 (s, 1 H, 2-Ar-CH), 8.34-8.38 (m, 1 H, 5-Ar-
CH) ppm; 1H-NMR (400 MHz, CDCl3) δ= , 1.11 (t, 6 H, 3JH,H = 7.1 Hz, 2xCH3), 3.38-3.50 (m,
4 H, 2xCH2), 5.34 (s, 1 H, CH), 7.23 (d, 1 H, 3JH,H = 5.0 Hz, Pyr-CH), 7.47 (s, 1 H, Pyr-CH),
8.22 (d, 1 H, 3JH,H = 5.0 Hz, Pyr-CH) ppm.
NaOtBu catalysed amination approach to compounds of the class 25
Representative Procedure for the Synthesis:
Acetal 23 (100 mg, 0.38 mmol) was dissolved in toluene (2 mL) and sodium-tert-butoxide (150
mg, 1.56 mmol), 2-phenylethanamine (191µL, 2.52 mmol) were added. The reaction mixture
was stirred under reflux for 48 h, until TLC (hexane,EtOAc 8:2, Rf 0.1) showed no change in
the consumption of starting material (approx. 50 % conversion). The mixture was concen-
trated and extracted between brine and EtOAc (3 x 5m˙L). The combined organic layers were
dried over MgSO4, filtered and concentrated. Purification by column chromatography (hex-
ane/EtOAc 8:2, Rf 0.1) afforded 4-(diethoxymethyl)-N-phenethylpyridin-2-amine 24i (36 mg,
32 %) as a clear oil. The acetal 24i was dissolved in H2O (0.74 mL) and TFA (3 mL). The
reaction mixture was stirred until TLC showed complete cleavage of acetal groups. The re-
action mixture was neutralised with NaHCO3 (sat, aq). The crude was extracted with DCM
(4x5m mL), dried over MgSO4, filtered and concentrated. The crude was purified by flash
column chromatography to afford the aldehyde 25a.
4-(diethoxymethyl)-N-phenethylpyridin-2-amine 24i
TLC Rf = 0.1 (hexane/EtOAc 8:2); Reaction time: 16 h; Purification: Flash-Chromato-
graphy hexane/EtOAc 8:2 (Rf = 0.1); Yield: 36 mg of clear oil (0.12 mmol, 32 %); Yield:
24 mg of clear oil (0.08 mmol, 21 %); 1H-NMR (400 MHz, CDCl3) δ= 1.25 (t, 6 H, 3JH,H =
7.1 Hz, (OCH2CH3)2), 2.94 (t, 2 H, 3JH,H = 7.0 Hz, CH2CH2Ph), 3.50-3.66 (m, 6 H, (OCH2CH3)2,
CH2CH2Ph), 4.63 (t(br), 1 H, 3JH,H = 5.4 Hz, NH), 5.39 (s, 1 H, CH), 6.52 (s, 1 H, 2-Ar-CH), 6.68
(dd, 1 H, 3,4JH,H = 1.3, 5.3 Hz, 4-Ar-CH), 7.22-7.36 (m, 5 H, 5xAr-CH), 8.08 (dd, 1 H, 3,4JH,H =
0.6, 5.3 Hz, 6-Ar-CH) ppm;
2-(phenethylamino)isonicotinaldehyde 25a
TLC Rf = 0.1 (CHCl3/ EtOAc 9:1); Reaction time: 2 h; Purification: Flash-Chromatography
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CHCl3/EtOAc 9:1 (Rf = 0.1); Yield: 12 mg of white solid (0.05 mmol, 44 %); Yield: 18 mg of
white solid (0.08 mmol, 100 %); 1H-NMR (400 MHz, CDCl3) δ= 2.88 (t, 2 H, 3JH,H = 6.9 Hz,
CH2CH2Ph), 3.56 (dt, 2 H, 3JH,H = 6.0, 6.9 Hz, CH2CH2Ph), 4.74 (t(br), 1 H, 3JH,H = 6.0 Hz,
NH), 6.66 (s, 1 H, 2-Ar-CH), 6.89 (dd, 1 H, ,JH,H = 1.3 Hz, 5.1 Hz, 3,4) 7.13-7.28 (m, 5 H, 5xAr-
CH), 8.22 (d, 1 H, 3JH,H = 5.1 Hz, 5-Ar-CH), 9.85 (s, 1 H, CHO) ppm; APCI-MS m/z (%) = 227.1
[M+H]+ (100 %); HR-MS m/z = 227.1172 [M+H]+ (calculated: 227.1179).
4-(diethoxymethyl)-N-(4-methylbenzyl)pyridin-2-amine 24j
TLC Rf = 0.4 (DCM/EtOAc 9:1); Reaction time: 6.5 h; Purification: Flash-Chromatogra-
phy hexane/EtOAc 9:1 (Rf = 0.1), ; Yield: 36 mg of white solid (0.12 mmol, 34 %); 1H-NMR
(400 MHz, CDCl3) δ= 1.14 (t, 6 H, 3JH,H = 7.1 Hz, (OCH2CH3)2), 2.26 (s, 3 H, Ar-CH3), 3.38-
3.59 (m, 4 H, (OCH2CH3)2), 4.40 (d, 2 H, 3JH,H = 5.7 Hz, CH2Ph), 4.80 (t(br), 1 H, 3JH,H =
5.7 Hz, NH), 5.29 (s, 1 H, CH), 6.44 (s, 1 H, 2-Ar-CH), 6.61 (d, 1 H, 3JH,H = 5.3 Hz, 4-Ar-CH),
7.07 (d, 2 H, 3JH,H = 7.9 Hz, 2’,6’-Ar-CH), 7.18 (d, 2 H, 3JH,H = 7.9 Hz, 3’,5’-Ar-CH), 8.02 (d, 1 H,
3JH,H = 5.3 Hz, 5-Ar-CH) ppm; ESI-MS m/z (%) = 301.2 [M+H]+ (100 %); HR-MS m/z = 301.1914
[M+H]+ (calculated: 301.1911).
2-(4-methylbenzylamino)isonicotinaldehyde 25b
TLC Rf = 0.6 (DCM/EtOAc 8:2); Reaction time: 2 h; Purification: Extraction between NaHCO3
(aq.,10 mL) and DCM (3x10 mL). Yield: 6.4 mg of clear oil (0.03 mmol, 100 %); 1H-NMR
(400 MHz, CDCl3) δ= 2.28 (s, 3 H, Ar-CH), 4.45 (d, 2 H, 3JH,H = 5.1 Hz, CH2Ar), 5.26 (s(br),
1 H, NH), 6.70 (s, 1 H, 2-Ar-CH), 6.92 (d, 1 H, 3JH,H = 5.0 Hz, 4-Ar-CH), 7.09 (d, 2 H, 3JH,H =
7.6 Hz, 3’,5’-Ar-CH), 7.19 (d, 2 H, 3JH,H = 7.6 Hz, 2’,6’-Ar-CH), 8.23 (d, 1 H, 3JH,H = 5.0 Hz,
5-Ar-CH), 9.84 (s, 1 H, CHO) ppm; ESI-MS m/z (%) = 227.1 [M+H]+ (100 %); HR-MS m/z =
227.1180 [M+H]+ (calculated: 227.1179).
Palladium catalyst amination approach to compounds of the class 25
The acetal 23 (100 mg, 0.38 mmol), Pd(OAc)2 (8.4 mg, 3.8·10−2 mmol), sodium-tert-butoxide
(52 mg, 0.54 mmol) and DPPF (4.2 mg, 7.6·10−2 mmol) were dissolved in dioxane/toluene (1:1,
5 mL). The reaction mixture was stirred under reflux for 12 h, until TLC (hexane/EtOAc 8:2, Rf
0.1) showed complete consumption of starting material. After concentration and extraction
between brine (3 mL) and EtOAc (3 x 5 mL), the crude product was dried over MgSO4, filtered
and concentrated. Purification by flash chromatography (hexane/EtOAc 8:2, Rf 0.1) afforded
the amino actual 24k (20 mg, 18 %) as a white solid. The acetal 24k (20 mg, 0.07 mmol)
was dissolved in water (0.75 mL) and TFA (3 mL) and the reaction mixture was stirred for 4 h,
until TLC (DCM/MeOH 9:1, Rf 0.3) showed complete consumption of starting material. The
excess of TFA was neutralised with saturated aqueous NaHCO3 solution and the mixture was
extracted with DCM (4 x 5 mL). The combined organic layers were dried over MgSO4, filtered
and dried in vacuo to afford 2-(benzylamino)isonicotinaldehyde 25e (15.0 mg, 100 %) as a
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yellow solid.
N-benzyl-4-(diethoxymethyl)pyridin-2-amine 24k
TLC Rf = 0.1 (hexane/EtOAc 8:2); Reaction time: 16 h; Purification: Flash-Chromato-
graphy hexane/EtOAc 8:2 (Rf = 0.1); Yield: 20 mg of white solid (0.07 mmol, 18 %); 1H-
NMR (400 MHz, CDCl3) δ= 1.12 (t, 6 H, 3JH,H = 7.0 Hz, (OCH2CH3)2), 3.37-3.53 (m, 4 H,
(OCH2CH3)2), 4.44 (d, 2 H, 3JH,H = 5.6 Hz, CH2Ph), 4.90 (t(br), 1 H, 3JH,H = 5.6 Hz, NH), 5.27
(s, 1 H, CH), 6.44 (s, 1 H, 2-Ar-CH), 6.60 (d, 1 H, 3JH,H = 5.2 Hz, 4-Ar-CH), 7.15-7.29 (m, 5 H,
5xAr-CH), 8.00 (d, 1 H, 3JH,H = 5.2 Hz, 5-Ar-CH) ppm;
2-(benzylamino)isonicotinaldehyde 25e
TLC Rf = 0.3 (DCM/ MeOH 9:1); Yield: 19 mg of yellow solid (0.09 mmol, 100 %); Reaction
time: 4 h; Purification: Extraction between NaHCO3aq (10 mL) and DCM (3x10 mL). 1H-NMR
(400 MHz, CDCl3) δ= 4.49 (s, 2 H, CH2), 6.38 (s(br), 1 H, NH), 6.74 (s, 1 H, 2-Ar-CH), 6.91
(dd, 1 H, 3,4JH,H = 1.3, 5.3 Hz, 4-Ar-CH), 7.15-7.29 (m, 5 H, 5xAr-CH), 8.13 (d, 1 H, 3JH,H =
5.3 Hz, 5-Ar-CH), 9.81 (s, 1 H, CHO) ppm; ESI-MS m/z (%) = 213.1 [M+H]+ (100 %); HR-MS
m/z = 213.1023 [M+H]+ (calculated: 213.1022).
Ullman-type, Copper catalyst Amination
Acetal 23 (1.0 eq), the corresponding benzyl amine derivative (5 eq), and CsOAc (1.1 eq) were
dissolved in 3 mL toluene. The reaction mixture was degassed for 5 min and CuI (1.1 eq) was
added under N2 atmosphere. The reaction mixture turned green. The crude was stirred at
110 ◦C and another 5 eq of benzyl amine derivative were added. The stirring was continued
until TLC showed complete consumption of starting 23. The crude was quenched with NH4Claq
(5 mL, sat). The reaction mixture turned blue. The aqueous phase was extracted with toluene
(5x 5 mL). The combined organic layers were dried over MgSO4, filtered and concentrated.
Purification by flash chromatography affords the desired amino acetal class 24. The acetal
was cleaved under acid hydrolysis as described above to afford the aldehyde 25f.
4-(diethoxymethyl)-N-[(4- methylphenyl)methyl]pyridin-2-amine 24l
TLC Rf = 0.1 (Cyclohexane/EtOAc 9:1); Reaction time: 16 h Purification: Flash-Chromato-
graphy Cyclohexane/EtOAc 9:1 (Rf = 0.1); Yield: 55 mg of yellow oil (0.18 mmol, 43 %); 1H-
NMR (400 MHz, CDCl3) δ= 1.18 (t, 6 H, 3JH,H = 7.1 Hz, 2xCH3), 2.30 (s, 3 H, CH3), 3.42-3.58
(m, 4 H, 2xCH2CH3), 4.42 (d, 2 H, 3JH,H = 5.6 Hz, CH2NH), 5.16 (t, 1 H, 3JH,H = 5.6 Hz, NH),
5.32 (s, 1 H, CH), 6.48 (s, 1 H, 3-Pyr-CH), 6.64 (d, 1 H, 3JH,H = 5.3 Hz, 5-Pyr-CH), 7.09 (d, 2 H,
3JH,H = 7.8 Hz, 2xAr-CH), 7.21 (d, 2 H, 3JH,H = 7.8 Hz, 2xAr-CH), 8.04 (d, 1 H, 3JH,H = 5.3 Hz, 6-
Pyr-CH) ppm; 13C-NMR (400 MHz, CDCl3) δ= 15.2 (2xCH3), 21.2 (CH3), 46.3 (CH2NH), 61.2
(2xCH2), 100.2 (CH), 104.8 (3-Pyr-CH), 111.4 (5-Pyr-CH), 127.6 (2xAr-CH), 129.4 (2xAr-CH),
136.0 (Ar-C), 136.9 (Ar-C), 148.4 (6-Pyr-CH), 149.1 (Ar-C), 158.9 (Ar-C) ppm;
2-(4-Methylbenzylamino)isonicotinaldehyde 25f
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TLC Rf = 0.1 (Hexane/EtOAc 8:2); Reaction time: 4 h; Purification: Flash-Chromatogra-
phy hexane/EtOAc 8:2 (Rf = 0.1); Yield: 61 mg of yellow oil (0.27 mmol, 100 %); 1H-NMR
(400 MHz, CDCl3) δ= 2.33 (s, 3 H, CH2), 4.51 (d, 2 H, 3JH,H = 5.5 Hz, CH2), 5.46 (s(br), 1 H,
NH), 6.76 (s, 1 H, 2-Pyr-H), 6.96 (d, 1 H, 3JH,H = 5.1 Hz, 4-Pyr-H), 7.15 (d, 2 H, 3JH,H = 7.9 Hz,
2xAr-H), 7.25 (d, 2 H, 3JH,H = 7.9 Hz, 2xAr-H), 8.26 (d, 1 H, 3JH,H = 5.1 Hz, 5-Pyr-H) 9.89 (s,
1 H, CHO); 13C(DEPT)-NMR (400 MHz, CDCl3) δ= 21.1 (CH3), 46.1 (CH2), 106.4 (2-Pyr-CH),
111.0 (4-Pyr-CH), 127.4 (2xAr-CH), 129.4 (2xAr-CH), 149.6 (5-Pyr-CH), 192.2 (CHO) ppm;
N-benzyl-4-(diethoxymethyl)pyridin-2-amine 24k
TLC Rf = 0.1 (Hexane/EtOAc 8:2); Reaction time: 16 h; Purification: Flash-Chromatogra-
phy hexane/EtOAc 8:2 (Rf = 0.1), loaded in DCM; Yield: 403 mg of white solid (1.41 mmol,
65 %); 1H-NMR (400 MHz, CDCl3) δ= 1.20 (t, 6 H, 3JH,H = 7.1 Hz, 2xCH3), 3.44-3.60 (m, 4 H,
2xCH2CH3), 4.50 (d, 2 H, 3JH,H = 5.7 Hz, CH2NH), 5.25 (t(br), 1 H, 3JH,H = 5.7 Hz, NHCH2),
5.34 (s, 1 H, CH), 6.51 (s, 1 H, 2-Ar-CH), 6.67 (dd, 1 H, 3,4JH,H = 5.3, 1.1 Hz, 6-Ar-CH), 7.21-
7.36 (m, 5 H, 5xAr-CH), 8.04 (d, 1 H, 3JH,H = 5.3 Hz, 5-Ar-CH) ppm; 13C-NMR (400 MHz,
CDCl3) δ= 15.2 (2xCH3), 46.4 (CH2NH), 61.1 (2xCH2CH3), 100.2 (CH), 104.7 (2-Ar-CH),
111.4 (6-Ar-CH), 127.2 (Ar-CH), 127.5 (Ar-CH), 128.6 (Ar-CH), 139.2 (Ar-C), 148.3 (5-Ar-CH),
149.0 (Ar-C), 159.0 (Ar-C) ppm.
2-(4-(trifluoromethyl)benzylamino)isonicotinaldehyde 25d
TLC Rf = 0.3 (Hexane/EtOAc 7:3); Reaction time: 2.5 h; Purification: Flash-Chromatogra-
phy Cyclohexane/EtOAc 7:3 (Rf = 0.2); Yield: 17 mg of yellow crystals (0.08 mmol, 100 %);
1H-NMR (400 MHz, CDCl3) δ= 4.67 (d, 2 H, 3JH,H = 6.0 Hz, Bn-CH2), 5.41 (t(br), 1 H, 3JH,H =
6.0 Hz, NH), 6.79 (s, 1 H, 3-Pyr-CH), 7.01 (dd, 1 H, 3,4JH,H = 5.1, 1.2 Hz, 5-Pyr-CH), 7.48
(d, 2 H, 3JH,H = 8.2 Hz, 2xAr-CH), 7.60 (d, 2 H, 3JH,H = 8.2 Hz, 2xAr-CH), 8.31 (d, 1 H, 3JH,H =
5.1 Hz, 6-Pyr-CH), 9.92 (s, 1 H, CHO) ppm; 13C-NMR (400 MHz, CDCl3) δ= 45.8 (CH2), 106.7
(3-Pyr-CH), 111.9 (5-Pyr-CH), 125.8 (Ar-C), 125.9 (q, 3JC,F = 3.8 Hz, 2xAr-CH), 127.6 (2xAr-
CH), 130.0 (Ar-C), 142.8 (Ar-C), 143.8 (Ar-C), 149.5 (6-Pyr-CH), 159.1 (Ar-C), 192.0 (CHO)
ppm;
9.8 General procedure for the Synthesis of heterocyclic derivatives
26a–j
The derivatives 26a–j were synthesised under standard Knoevenagel condensation conditions
as described previously. Compounds 2, 14, and 7 (1.0 eq), the heterocyclic aldehyde (1.1 eq)
and sodium acetate (1.0 eq) were dissolved in ethanol and stirred at 80 ◦C under TLC showed
complete consumption of starting material.
[(5Z)-4-oxo-5-(pyridin-2-ylmethylidene)-2- sulfanylidene-1,3-thiazolidin-3-yl]acetic acid 26b [192]
Reaction time: 8 h; Purification: Filtration from ethanol; Yield: 105 mg of yellow solid (0.37
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mmol, 54 %); 1H-NMR (400 MHz, DMSO-d6) δ= 4.74 (s, 2 H, CH2), 7.47 (ddd, 1 H, 3,4JH,H =
6.8, 4.8, 2.4 Hz, 4-Pyr-CH), 7.92 (s, 1 H, CH), 7.92-8.03 (m, 2 H, 5,6-Pyr-CH), 8.82 (d, 1 H,
3JH,H = 4.8 Hz, 3-Pyr-CH), 13.43 (s(br), 1 H, COOH) ppm; 13C-NMR (400 MHz, DMSO-d6)
δ= 44.6 (CH2), 124.4 (4-Pyr-CH), 126.2 (Ar-C), 128.5 (6-Pyr-CH), 129.4 (CH), 137.8 (5-Pyr-
CH) 149.6 (3-Pyr-CH), 150.9 (Ar-C), 166.5 (C=O), 167.4 (COOH), 199.7 (C=S) ppm; ESI-MS
m/z (%) = 281.0 [M+H]+ (100 %); HR-MS m/z = 281.0052 [M+H]+ (calculated: 281.0049); HPLC-
Analysis (Method B): 99 %, Rt = 16.1 min.
(Z)-2-(4-oxo-5-(pyridin-3-ylmethylene)-2-thioxothiazolidin-3-yl)acetic acid 26c [192]
Reaction time: 6 h; Purification: Filtration from ethanol; Yield: 232 mg of yellow solid (0.83
mmol, 74 %); 1H-NMR (400 MHz, DMSO-d6) δ= 4.76 (s, 2 H, CH2), 7.60 (dd, 1 H, 3,4JH,H = 8.1,
4.7 Hz, 4-Ar-CH), 7.96 (s, 1 H, CH), 8.04 (ddd, 1 H, 3JH,H = 1.2, 1.7, 8.0 Hz, 3-Ar-CH), 8.68 (dd,
1 H, 3,4JH,H = 1.2, 4.7 Hz, 5-Ar-CH), 8.92 (d, 1 H, 4JH,H = 1.7 Hz, 1-Ar-CH), 13.52 (s(br), 1 H,
COOH) ppm; 13C-NMR (400 MHz, DMSO-d6) δ= 45.1 (CH2), 124.0 (4-Ar-CH), 124.4 (Ar-C),
129.0 (Ar-C), 130.6 (CH), 136.6 (3-Ar-CH), 151.2 (5-Ar-CH), 152.0 (1-Ar-CH), 166.2 (C=O),
167.3 (COOH), 192.9 (C=S) ppm; ESI-MS m/z (%) = 281.0 [M+H]+ (100 %), 583.0 [2M+Na]+
(10 %); HR-MS m/z = 281.0052 [M+H]+ (calculated: 281.0049); HPLC-Analysis (Method B):
99 %, Rt = 12.2 min.
[(5Z)-4-oxo-5-(pyridin-4-ylmethylidene)-2- sulfanylidene-1,3-thiazolidin-3-yl]acetic acid 26d [192]
Reaction time: 6 h; Purification: Filtration from ethanol; Yield: 284 mg of yellow solid (1.01
mmol, 82 %); 1H-NMR (400 MHz, DMSO-d6) δ= 4.63 (s, 2 H, CH2), 7.47 (ddd, 1 H, 3,4JH,H =
6.2, 4.8, 6.2 Hz, 4-Ar-CH), 7.90 (s, 1 H, CH), 7.94-8.01 (m, 2 H, 2,3-Ar-CH), 8.82 (dd, 1 H,
3,4JH,H = 4.8, 1.2 Hz, 5-Ar-CH); ESI-MS m/z (%) = 281.0 [M+H]+ (100 %), 303.0 [M+Na]+ (25 %);
HR-MS m/z = 281.0052 [M+H]+ (calculated: 281.0049); HPLC-Analysis (Method B): 99 %,
Rt = 12.2 min.
[(5Z)-4-oxo-5-[(2E)-3-phenylprop-2-en-1-ylidene]-2- sulfanylidene-1,3-thiazolidin-3-yl] acetic acid
26e [289]
Reaction time: 4 h; Purification: Filtration from ethanol; Yield: 32 mg of yellow solid (0.10
mmol, 20 %); 1H-NMR (400 MHz, DMSOd6) δ= ; 4.54 (s, 2 H, CH2), 7.14 (dd, 1 H, 3JH,H =
15.2, 11.6 Hz, CH), 7.41-7.48 (m, 3 H, 4xAr-CH), 7.58 (d, 1 H, 3JH,H = 11.6 Hz, CH), 7.71-7.75
(m, 2 H, Ar-CH, CH) ppm; ESI-MS m/z (%) = 304.0 [M−H]− (100 %); HR-MS m/z = 304.0105
[M−H]− (calculated: 304.0108); HPLC-Analysis (Method B): 82 %, Rt = 18.6 min.
(Z)-ethyl 2-(5-((2-(4-methylbenzylamino)pyridin-4-yl)methylene)-4-oxo-2-thioxothiazolidin-3-yl)
acetate 26a
TLC Rf = 0.5 (Hexane/EtOAc 7:3); Reaction time: 6 h; Purification: Flash-Chromatography
DCM→ DCM/EtOAc 9:1 (Rf = 0.1); Yield: 45 mg of yellow solid (0.11 mmol, 75 %); 1H-NMR
(400 MHz, CDCl3) δ= 1.29 (t, 3 H, 3JH,H = 7.2 Hz, CH3), 2.35 (s, 3 H, Ar-CH3), 4.23 (q, 2 H,
3JH,H = 7.2 Hz, CH2), 4.49 (d, 2 H, 3JH,H = 5.6 Hz, CH2), 4.83 (s, 2 H, CH2), 5.30 (t(br), 1 H,
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3JH,H = 5.6 Hz, NH), 6.33 (s, 1 H, 2-Pyr-CH), 6.64 (dd, 1 H, 3,4JH,H = 5.3, 1.5 Hz, 4-Pyr-CH),
7.17 (d, 2 H, JH,H = 8.0 Hz, 2xAr-CH), 7.27 (d, 2 H, JH,H = 8.0 Hz, 2xAr-CH), 7.53 (s, 1 H, CH),
8.19 (d, 1 H, 3JH,H = 5.3 Hz, 5-Pyr-CH) ppm; 13C-NMR (400 MHz, CDCl3) δ= 14.1 (OCH2CH3),
21.2 (Ar-CH3), 44.8 (NCH2COOEt), 46.2 (CH2NH), 62.2 (OCH2CH3), 106.7 (2-Pyr-CH), 112.9
(4-Pyr-CH), 127.3 (2xAr-CH), 129.6 (2xAr-CH), 131.6 (CH), 149.4 (5-Pyr-CH) ppm; ESI-MS
m/z (%) = 428.1 [M+H]+ (100 %); HR-MS m/z = 428.1098 [M+H]+ (calculated: 428.1097); HPLC-
Analysis : 99.9 %, Rt = 29.9 min.
Ethyl 2-[(5Z)-4-oxo-5-(pyridin-2-ylmethylidene)-2-sulfanylidene-1,3-thiazolidin-3-yl] acetate 26f
TLC Rf = 0.3 (Hexane/EtOAc 6:4); Reaction time: 4 h; Purification: Re-crystallisation from
ethanol; Yield: 395 mg of yellow crystals (1.28 mmol, 100 %); 1H-NMR (400 MHz, CDCl3) δ=
1.28 (t, 3 H, 3JH,H = 7.1 Hz, CH3), 4.23 (q, 2 H, 3JH,H = 7.1 Hz, CH2CH3), 4.87 (s, 2 H, CH2), 7.29
(ddd, 1 H, 3,4JH,H = 0.9, 4.8, 7.6 Hz, 4-Pyr-CH), 7.56 (d, 1 H, 3JH,H = 7.8 Hz, 6-Pyr-CH), 7.67 (s,
1 H, CH), 7.79 (adt, 1 H, 3,4JH,H = 1.7, 7.6, 7.8 Hz, 5-Pyr-CH), 8.78 (d, 1 H, 3JH,H = 4.5 Hz, 3-
Pyr-CH) ppm; 13C-NMR (400 MHz, CDCl3) δ= 14.3 (CH3), 44.6 (CH2), 62.1 (CH2CH3), 123.8
(4-Pyr-CH), 127.5 (6-Pyr-CH), 128.6 (CH), 137.1 (5-Pyr-CH), 145.6 (Ar-C), 149.7 (3-Pyr-CH),
151.7 (Ar-C), 161.3 (C=O), 166.1 (C=O) ppm; ESI-MS m/z (%) = 309.0 [M+H]+ (100 %), 331.0
[M+Na]+ (5 %), 617.1 [2M+H]+ (25 %); HR-MS m/z = 309.0364 [M+H]+ (calculated: 309.0362);
HPLC-Analysis (Method B): 100 %, Rt = 18.7 min.
Ethyl 2-[(5Z)-4-oxo-5-(pyridin-3-ylmethylidene)-2-sulfanylidene-1,3-thiazolidin-3-yl] acetate 26g
TLC Rf = 0.1 (Hexane/EtOAc 8:2); Reaction time: 2 h; Purification: Filtration from ethanol;
Yield: 31 mg of yellow solid (0.10 mmol, 14 %); 1H-NMR (400 MHz, CDCl3) δ= 1.29 (t, 3 H,
3JH,H = 7.1 Hz, CH3), 4.24 (q, 2 H, 3JH,H = 7.1 Hz, CH2CH3), 4.86 (s, 2 H, CH2), 7.45 (dd,
1 H, 3JH,H = 4.8, 8.0 Hz, 5-Pyr-CH), 7.75 (s, 1 H, CH), 7.78-7.82 (m, 1 H, 6-Pyr-CH), 8.66 (dd,
1 H, 3,4JH,H = 1.4, 4.8 Hz, 4-Pyr-CH), 8.79 (d, 1 H, 4JH,H = 2.2 Hz, 2-Pyr-CH) ppm; 13C-NMR
(400 MHz, CDCl3) δ= 14.2 (CH3), 45.1 (CH2), 62.3 (CH2CH3), 124.2 (5-Pyr-CH), 125.4 (Ar-C),
129.4 (Ar-C), 129.9 (CH), 136.5 (6-Pyr-CH), 151.2 (4-Pyr-CH), 152.1 (2-Pyr-CH), 165.8 (C=O),
166.9 (COOEt), 192.0 (C=S) ppm; ESI-MS m/z (%) = 309.0 [M+H]+ (100 %), 639.0 [2M+Na]+
(10 %); HR-MS m/z = 309.0365 [M+H]+ (calculated: 309.0362); HPLC-Analysis (Method B):
99 %, Rt = 15.7 min.
Ethyl 2-[(5Z)-4-oxo-5-(pyridin-4-ylmethylidene)-2-sulfanylidene-1,3-thiazolidin-3-yl] acetate 26h
TLC Rf = 0.2 (CHCl3/EtOAc 7:3); Reaction time: 16 h; Purification: Flash-Chromatography
CHCl3/EtOAc 7:3 → 6:4 (Rf = 0.2); Yield: 85 mg of yellow solid (0.28 mmol, 28 %); 1H-NMR
(400 MHz, DMSO-d6) δ= 1.25 (t, 3 H, 3JH,H = 7.1 Hz, CH3), 4.21 (q, 2 H, 3JH,H = 7.1 Hz, CH2),
7.05 (s, 1 H, CCH), 7.55 (d, 2 H, 3JH,H = 5.6 Hz, 2,6-Ar-CH), 8.60 (d, 2 H, 3JH,H = 5.6 Hz,
3,5-Ar-CH) ppm; HPLC-Analysis (Method B): 94 %, Rt = 18.6 min.
Ethyl 2-[(5Z)-2,4-dioxo-5-(pyridin-4- ylmethylidene)-1,3-thiazolidin-3-yl] acetate 26i
TLC Rf = 0.2 (CHCl3/MeOH 95:5); Reaction time: 16 h; Purification: Flash-Chromatography
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CHCl3/MeOH 95:5 (Rf = 0.2); Yield: 84 mg of white solid (0.29 mmol, 21 %); 1H-NMR (400
MHz, CDCl3) δ= 1.24 (t, 3 H, 3JH,H = 7.1 Hz, CH3), 4.11 (s, 2 H, CH2), 4.18 (q, 2 H, 3JH,H =
7.1 Hz, CH2CH3), 7.27 (d, 2 H, 3JH,H = 5.9 Hz, 2xPyr-CH), 8.55 (d, 2 H, 3JH,H = 5.9 Hz, 2xPyr-
CH) ppm; 13C-NMR (400 MHz, CDCl3) δ= 14.3 (CH3), 41.8 (CH2), 61.9 (CH2CH3), 122.0
(2xPyr-CH), 142.3 (Ar-C), 150.4 (2xPyr-CH), 164.9 (C=O), 170.0 (C=O), 207.2 (COOEt) ppm;
APCI-MS m/z (%) = 293.1 [M+H]+ (60 %); textbfHR-MS APCI m/z = 293.0586 [M+H]+ (calcu-
lated: 293.0591) ; HPLC-Analysis (Method B): 85 %, Rt = 19.6 min.
Ethyl 2-[(5Z)-5-(furan-2-ylmethylidene)-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl] acetate 26j [289]
TLC Rf = 0.6 (Hexane/EtOAc 8:2); Reaction time: 4 h; Purification: Re-crystallisation from
ethanol; Yield: 138 mg of yellow crystals (0.46 mmol, 38 %); 1H-NMR (400 MHz, CDCl3) δ=
1.28 (t, 3 H, 3JH,H = 7.1 Hz, CH3), 4.23 (q, 2 H, 3JH,H = 7.1 Hz, CH2CH3), 4.83 (s, 2 H, CH2),
6.60 (dd, 1 H, 3JH,H = 1.8, 3.5 Hz, 4-Ar-CH), 6.86 (d, 1 H, 3JH,H = 3.5 Hz, 3-Ar-CH), 7.51 (s, 1 H,
CH), 7.72 (d, 1 H, 3JH,H = 1.8 Hz, 5-Ar-CH) ppm; 13C-NMR (400 MHz, CDCl3) δ= 14.2 (CH3),
44.9 (CH2), 62.1 (CH2CH3), 113.7 (4-Ar-CH), 119.1 (CH or 3-Ar-CH), 119.2 (CH or 3-Ar-CH),
120.7 (Ar-C), 147.4 (5-Ar-CH), 150.1 (Ar-C), 166.1 (C=O), 167.0 (COOEt), 194.3 (C=S) ppm;
ESI-MS m/z (%) = 298.0 [M+H]+ (100 %), 320.0 [M+Na]+ (20 %), 617.0 [2M+Na]+ (10 %); HR-
MS m/z = 298.0205 [M+H]+ (calculated: 298.0202); HPLC-Analysis (Method B): 98 %, Rt =
18.1 min.
9.9 General Procedure for the reduction of rhodanine 14 and
thiazolidine-2,4-dione derivatives 7
Hantzsch ester reduction
The rhodanine derivative 14i (1.0 eq), Hantzsch ester 28 (1.3 eq) and activated SiO2 (heat
activated 120 ◦C for 5 h, 1 g/mmol) were dissolved in anhydrous toluene. The reaction mixture
was stirred under a N2 gas atmosphere at 85 ◦C for 24 h in the dark. After TLC showed
complete consumption, the reaction mixture was concentrated, leaving the crude loaded on
SiO2. The product was purified by flash chromatography to afford the reduced analogue 27a.
Ethyl 2-(5-benzyl-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl)acetate 27a
TLC Rf = 0.1 (Hexane/EtOAc 9:1); Reaction time: 16 h; Purification: Flash-Chromatography
DCM (Rf = 0.4); Yield: 173 mg of white solid (0.56 mmol, 67 %); 1H-NMR (400 MHz, CDCl3)
δ= 1.27 (t, 3 H, 3JH,H = 7.1 Hz, CH3), 3.08 (dd, 1 H, 2,3JH,H = 14.0, 10.5 Hz, E-CHH), 3.62 (dd,
1 H, 2,3JH,H = 14.0, 4.0 Hz, Z-CHH), 4.21 (q, 2 H, 3JH,H = 7.1 Hz, CH2CH3), 4.53 (dd, 1 H, 3JH,H =
10.5, 4.0 Hz, CH), 4.69 (s, 2 H, CH2) 7.21-7.36 (m, 5 H, 5xAr-CH) ppm; 13C-NMR (400 MHz,
CDCl3) δ= 14.2 (CH3), 38.7 (CH2CH), 44.9 (CH2), 53.2 (CH), 62.1 (CH2CH3), 127.8 (Ar-
CH), 129.0 (4xAr-CH), 136.0 (Ar-C), 165.9 (C=O), 175.2 (COOEt), 199.8 (C=S) ppm; ESI-MS
m/z (%) = 310.1 [M+H]+ (100 %), 327.1 [M+NH4]+ (85 %); HPLC-Analysis (Method B): 94 %,
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Rt = 18.1 min.
Catalytic hydrogenation of 27b and 27c on Pd/C (10 % on charcoal)
The thiazolidine-2,4-dione derivative (1.0 eq) was dissolved in dioxane (10-15 mL). Pd/C (xx eq)
were added and the reaction mixture was placed in a hydrogenation chamber at 30 psi H2. The
reaction mixture was shaken, until pressure valve equilibrated at a stable position, but for at
least 4 h. The reaction mixture was filtered through celite and washed with EtOAc. The filtrate
was concentrated and the products are afforded as white solids.
Ethyl 2-(5-benzyl-2,4-dioxo-1,3-thiazolidin-3-yl) acetate 27b
Reaction time: 8 h; 1H-NMR (400 MHz, CDCl3) δ= Yield: 320 mg of white solid (1.09 mmol,
98 %); 1.28 (t, 3 H, 3JH,H = 7.1 Hz, CH3), 3.07 (dd, 1 H, 2,3JH,H = 14.0, 10.5 Hz, E-CHH), 3.63
(dd, 1 H, 2,3JH,H = 14.0, 3.9 Hz, Z-CHH), 4.21 (q, 2 H, 3JH,H = 7.1 Hz, CH2CH3), 4.31 (s, 2 H,
CH2), 4.53 (dd, 1 H, 3JH,H = 10.5, 3.9 Hz, CH), 7.22-7.36 (m, 5 H, 5xAr-CH) ppm; 13C-NMR
(400 MHz, CDCl3) δ= 14.1 (CH3), 39.1 (E,Z-CHH), 42.1 (CH2), 52.0 (CH), 62.2 (CH2CH3),
127.7 (Ar-CH), 129.0 (2xAr-CH), 129.1 (2xAr-CH), 136.1 (Ar-C), 166.3 (C=O), 170.5 (C=O),
173.3 (COOEt) ppm; HPLC-Analysis (Method B): 98 %, Rt = 16.3 min.
Ethyl 2-5-[(3,4-dihydroxyphenyl)methyl]-2,4-dioxo- 1,3-thiazolidin-3-ylacetate 27c
Reaction time: 4 h; Yield: 348 mg of white solid (1.07 mmol, 100 %); 1H-NMR (400 MHz,
CDCl3) δ= 1.27 (t, 3 H, 3JH,H = 7.1 Hz, CH3), 2.93 (dd, 1 H, 2,3JH,H = 14.1, 10.1 Hz, E-CHH),
3.44 (dd, 1 H, 2,3JH,H = 14.1, 3.9 Hz, Z-CHH), 4.21 (q, 2 H, 3JH,H = 7.1 Hz, CH2CH3), 4.32 (s,
2 H, CH2), 4.47 (dd, 1 H, 3JH,H = 10.1, 3.9 Hz, CH), 6.59 (dd, 1 H, 3,4JH,H = 8.1, 1.8 Hz, 6-Ar-
CH), 6.70 (d, 1 H, 4JH,H = 1.8 Hz, 2-Ar-CH), 6.76 (d, 1 H, 3JH,H = 8.1 Hz, 5-Ar-CH) ppm; 13C-
NMR (400 MHz, CDCl3) δ= 14.0 (CH3), 38.1 (E,Z-CH2), 42.1 (CH2), 52.3 (C), 62.5 (CH2CH3),
115.6 (5-Ar-CH), 116.0 (2-Ar-CH), 121.4 (6-Ar-CH), 128.4 (Ar-C), 143.6 (Ar-C), 144.2 (Ar-C),
166.9 (C=O), 171.2 (C=O), 173.7 (COOEt) ppm; ESI-MS m/z (%) = 343.1 [M+NH4]+ (100 %),
668.2 [2M+NH4]+ (25 %), 673.1 [2M+Na]+ (100 %); HR-MS m/z = 326.0701 [M+H]+ (calculated:
326.0693); HPLC-Analysis (Method B): 97 %, Rt = 11.5 min.
9.10 Synthesis of N-allyl rhodanine and thiazolidine-2,4-dione
derivatives
Synthesis of N-Allyl rhodanine derivatives 40a–ae with different 5-benzylidene moieties
N-Allyl rhodanine 40 (1.0 eq), benzaldehyde derivatives (1.1-1.5 eq) and sodium acetate (1.0 eq)
are dissolved in ethanol (5-10 mL). The reaction mixture is stirred at 80 ◦C until TLC showed
complete consumption of starting material. The products are purified by recrystallisation from
ethanol or column chromatography.
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(Z)-3-allyl-5-benzylidene-2-thioxothiazolidin-4-one 40a [294]
TLC Rf = 0.7 (DCM); Reaction time: 1.5 h; Purification: Re-crystallisation from methanol;
Yield: 50 mg of yellow crystals (0.19 mmol, 31 %); 1H-NMR (400 MHz, DMSO-d6) δ= 4.65
(ddd, 2 H, 3,4JH,H = 5.2, 1.6 Hz, CH2), 5.14 (ddd, 1 H, 3,4JH,H = 17.2, 2.9, 1.6 Hz, E-Allyl-CH2),
5.29 (ddd, 1 H, 3,4JH,H = 10.4, 2.9, 1.6 Hz, Z-Allyl-CH2), 5.85 (ddt, 1 H, 3,4JH,H = 17.2, 10.4,
5.2 Hz, Allyl-CH), 7.51-7.61 (m, 3 H, 3 x Ar-CH), 7.64-7.70 (m, 2 H, 2 x Ar-CH), 7.85 (s, 1 H,
C-H); 1H-NMR (400 MHz, CDCl3) δ= 4.75 (dt, 2 H, 3,4JH,H = 5.8, 1.2 Hz, CH2), 5.26 (ddd, 1 H,
3,4JH,H = 10.3, 2.5, 1.4 Hz, CHH), 5.30 (ddd, 1 H, 3,4JH,H = 17.2, 2.5, 1.4 Hz, CHH), 5.87 (ddt,
1 H, 3JH,H = 17.2, 10.3, 5.8 Hz, CH), 7.42-7.53 (m, 5 H, 5xAr-CH), 7.74 (s, 1 H, CH) ppm;
13C-NMR (400 MHz, CDCl3) δ= 46.5 (CH2), 119.5 (CH2), 123.1 (Ar-C), 129.5 (Ar-CH), 129.6
(Allyl-CH), 130.8 (Ar-CCH), 130.9 (Ar-C or Ar-CCH), 133.4 (CH), 133.5 (Ar-C), 167.6 (C=O),
193.1 (C=S) ppm; ESI-MS m/z (%) = 262.0 [M+H]+ (100 %); HR-MS m/z = 262.0357 [M+H]+
(calculated: 262.0355); HPLC-Analysis (Method B): 99 %, Rt = 21.4 min.
(Z)-3-allyl-5-(2-methylbenzylidene)-2-thioxothiazolidin-4-one 40b
Reaction time: 1 h; Purification: Re-crystallisation from methanol; Yield: 78 mg of yellow
crystals (0.28 mmol, 100 %); 1H-NMR (400 MHz, CDCl3) δ= 2.48 (s, 3 H, CH3), 4.76 (dt, 2 H,
3,4JH,H = 5.8, 1.3 Hz, CH2), 5.28 (ddd, 1 H, 3,4JH,H = 10.2, 2.3, 1.2 Hz, CHH), 5.32 (ddd, 1 H,
3,4JH,H = 17.1, 2.3, 1.2 Hz, CHH), 5.89 (ddt, 1 H, 3JH,H = 17.1, 10.2, 5.8 Hz, CH), 7.26-7.37
(m, 3 H, 3xAr-CH), 7.41-7.45 (m, 1 H, 1xAr-CH), 7.98 (s, 1 H, CH) ppm; ESI-MS m/z (%) =
13C-NMR (400 MHz, CDCl3) δ= 20.0 (CH3), 46.4 (CH2), 119.4 (CH2), 126.7 (Ar-CH), 128.1
(Ar-CH), 129.6 (Ar-CH), 130.8 (Ar-CH), 131.2 (CH, Ar-CH) ppm; 276.1 [M+H]+ (100 %); HR-
MS m/z = 276.0515 [M+H]+ (calculated: 276.0511); HPLC-Analysis : 99.9 %, Rt = 37.7 min;
HPLC-Analysis (Method B): 100 %, Rt = 22.0 min.
(Z)-3-allyl-5-(3-methylbenzylidene)-2-thioxothiazolidin-4-one 40c
TLC Rf = 0.6 (DCM/hexane 6:4); Reaction time: 3 h; Purification: Re-crystallisation from
ethanol; Yield: 34 mg of yellow crystals (0.12 mmol, 49 %); 1H-NMR (400 MHz, CDCl3)
δ= 2.40 (s, 3 H, CH3), 4.74 (dt, 2 H, 3,4JH,H = 5.8, 1.3 Hz, CH2), 5.25 (ddd, 1 H, 3,4JH,H =
10.3, 2.3, 1.1 Hz, CHH), 5.29 (ddd, 1 H, 3,4JH,H = 17.2, 2.5, 1.3 Hz, CHH), 5.86 (ddt, 1 H,
3JH,H = 17.2, 10.3, 5.8 Hz, Allyl-CH), 7.25 (d, 1 H, 3JH,H = 7.8 Hz, Ar-CH), 7.28-7.32 (m,
2 H, 2xAr-CH) 7.36 (at, 1 H, ,JH,H = 7.8 Hz, 5-Ar-CH3, 7.70 (s, 1 H, CH) ppm; 13C-NMR
(400 MHz, CDCl3) δ= 21.6 (CH3), 46.5 (CH2), 119.5 (Allyl-CH2), 122.8 (Ar-C), 128.0 (Ar-
CH), 129.4 (5-Ar-CH), 129.7 (Allyl-CH), 131.4 (Ar-CH), 131.9 (Ar-CH), 133.4 (A)r-C) 133.7
(CH), 139.3 (Ar-C), 167.6 (C=O), 193.3 (C=S) ppm; APCI-MS m/z (%) = 276.0 [M+H]+ (100 %);
GCEI-MS m/z (%) = 275.0 [M]+ (100 %), 260.0 [fragment]+ (50 %), 148.0 [fragment]+ (100 %),
8.2 [fragment]+ (100 %); GCCI-MS m/z (%) = 276.0 [M+H]+ (100 %); HR-MS m/z = 276.0509
[M+H]+ (calculated: 276.0511); HPLC-Analysis (Method B): 100 %, Rt = 22.0 min.
(Z)-3-allyl-5-(4-methylbenzylidene)-2-thioxothiazolidin-4-one 40ad [295]
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Reaction time: 1 h; Purification: Re-crystallisation from methanol; Yield: 43 mg of yellow
crystals (0.16 mmol, 54 %); 1H-NMR (400 MHz, CDCl3) δ= 2.35 (s, 3 H, CH3), 4.69 (dt, 2 H,
3,4JH,H = 5.8, 1.3 Hz, CH2), 5.20 (ddd, 1 H, 3,4JH,H = 10.2, 2.4, 1.2 Hz, CHH), 5.25 (ddd, 1 H,
3,4JH,H = 17.1, 2.6, 1.4 HZ, CHH), 5.82 (ddt, 1 H, 3JH,H = 17.1, 10.2, 5.8 Hz, Allyl-CH), 7.23
(d, 2 H, 3JH,H = 8.2 Hz, 2xAr-CH), 7.35 (d, 2 H, 3JH,H = 8.2 Hz, 2xAr-CH), 7.66 (s, 1 H, CH)
ppm; 13C-NMR (400 MHz, CDCl3) δ= 21.8 (CH3), 46.5 (CH2), 119.4 (Allyl-CH2), 121.8 (Ar-C),
129.7 (Allyl-CH), 130.3 (2xAr-CH), 130.7 (ArC), 130.9 (2xAr-CH), 133.6 (CH), 141.8 (Ar-C),
167.7 (C=O), 193.1 (C=S) ppm; APCI-MS m/z (%) = 276.0 [M+H]+ (100 %); GCEI-MS m/z (%) =
275.0 [M]+ (100 %), 260.0 [fragment]+ (45 %), 148.0 [fragment]+ (100 %); GCCI-MS m/z (%) =
276.0 [M+H]+ (100 %); HR-MS m/z = 276.0512 [M+H]+ (calculated: 276.0511); HPLC-Analysis
(Method B): 100 %, Rt = 32.1 min.
(Z)-3-allyl-2-thioxo-5-(2-(trifluoromethyl)benzylidene)thiazolidin-4-one 40e
TLC Rf = 0.8 (DCM); Reaction time: 4 h; Purification: Filtration from methanol; Yield: 47
mg of yellow solid (0.14 mmol, 22 %); 1H-NMR (400 MHz, CDCl3) δ= 4.75 (dt, 2 H, 3,4JH,H =
5.9, 1.3 Hz, CH2), 5.28 (ddd, 1 H, 3,4JH,H = 10.2, 2.2, 1.1 Hz, CHH), 5.33 (ddd, 1 H, 3,4JH,H =
17.1, 2.5, 1.4 Hz, CHH), 5.87 (ddt, 1 H, 3JH,H = 17.1, 10.2, 5.9 Hz, Allyl-CH), 7.54 (at, 1 H,
3JH,H = 7.8, 7.7 Hz, 5-Ar-CH), 7.60 (d, 1 H, 3JH,H = 7.5 Hz, 3-Ar-CH), 7.66 (at, 1 H, 3JH,H = 7.7,
7.5 Hz, 4-Ar-CH), 7.78 (d, 1 H, 3JH,H = 7.8 Hz, 6-Ar-CH), 8.01 (q, 1 H, 5JH,F = 1.8 Hz, CH) ppm;
13C-NMR (400 MHz, CDCl3) δ= 46.7 (CH2), 119.9 (Allyl-CH2), 123.7 (q, 1JC,F = 274.1 Hz, CF3),
127.0 (q, 3JC,F = 5.5 Hz, 6-Ar-CH), 127.9 (Ar-C), 128.6 (q, 4JC,F = 2.0 Hz, CH), 129.3 (3-Ar-CH),
129.5 (Allyl-CH), 130.0 (q, 2JC,F = 30.6 Hz, 1-Ar-C), 130.2 (5-Ar-CH), 132.2 (q, 4JC,F = 1.6 Hz,
Ar-C), 132.5 (4-Ar-CH), 166.7 (C=O), 192.9 (C=S) ppm; EI-MS m/z (%) = 329.1[M]+ (100 %),
314.1 [fragment]+ (30 %), 202.1[fragment]+ (35 %), 86.1 [fragment]+ (60 %), 84.1 [fragment]+
(90 %), 48.9 [fragment]2 (100 %); HR-MS m/z = 329.0147 [M]+ (calculated: 329.0156); HPLC-
Analysis (Method B): 97 %, Rt = 21.1 min.
(Z)-3-allyl-2-thioxo-5-(3-(trifluoromethyl)benzylidene)thiazolidin-4-one 40f
TLC Rf = 0.9 (DCM); Reaction time: 4 h; Purification: Re-crystallisation from ethanol; Yield:
114 mg of yellow crystals (0.35 mmol, 50 %); 1H-NMR (400 MHz, CDCl3) δ= 4.75 (dt, 2 H,
3,4JH,H = 5.9, 1.3 Hz, CH2), 5.27 (ddd, 1 H, 3,4JH,H = 10.3, 2.3, 1.2 Hz, CHH), 5.31 (ddd, 1 H,
3,4JH,H = 17.2, 2.6, 1.4 Hz, CHH), 7.63 (aq, 1 H, 3,4JH,H = 7.6 Hz, 5-Ar-CH), 7.67 (d, 1 H,
3,4JH,H = 7.6 Hz, 4-Ar-CH), 7.69 (d, 1 H, 3,4JH,H = 7.6 Hz, 6-Ar-CH), 7.73 (s, 2 H, CH,2-Ar-CH)
ppm; 13C-NMR (400 MHz, CDCl3) δ= 46.7 (CH), 119.8 (Allyl-CH2) 123.7 (q, 1JC,F = 272.7 Hz,
CF3) 125.4 (Ar-C) 127.1 (q, 3JC,F = 3.7 Hz, 6-Ar-CH), 127.3 (q, 3JC,F = 3.9 Hz, 2-Ar-CH), 129.5
(Allyl-CH), 130.1 (5-Ar-CH), 131.0 (CH), 132.1 (q, 3JC,F = 32.8 Hz, 1-Ar-C), 133.2 (4-Ar-CH),
134.3 (Ar-C), 167.3 (C=O), 192.2 (C=S) ppm; 1H-NMR (400 MHz, DMSO-d6) δ= 4.65 (dt, 2 H,
3,4JH,H = 5.2, 1.6 Hz, CH2), 5.15 (ddd, 1 H, 3,4JH,H = 17.2, 2.9, 1.7 Hz, E-Allyl-CH2), 5.19 (ddd,
1 H, 3,4JH,H = 10.4, 2.7, 1.4 Hz, Z-Allyl-CH2), 5.85 (ddt, 1 H, 3,4JH,H = 17.2, 10.4, 5.2 Hz, Allyl-
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CH), 7.80 (t, 1 H, 3JH,H = 7.8 Hz, 4-Ar-CH), 7.86-7.93 (m, 2 H, 3,5-Ar-CH), 7.97 (s, 1 H, CH),
8.07 (s, 1 H, 1-Ar-CH) ppm; EI-MS m/z (%) = 329.0 [M]+ (100 %), 314.0 [fragment]+ (15 %),
202.0 [fragment]+ (100 %), 7.7 [fragment]+ (100 %); HR-MS m/z = 329.0150 [M]+ (calculated:
329.0156); HPLC-Analysis (Method B): 98 %, Rt = 21.7 min.
(Z)-3-allyl-2-thioxo-5-(4-(trifluoromethyl)benzylidene)thiazolidin-4-one 40g
TLC Rf = 0.9 (DCM); Reaction time: 4 h; Purification: Re-crystallisation from ethanol; Yield:
140 mg of yellow crystals (0.43 mmol, 70 %); 1H-NMR (400 MHz, CDCl3) δ= 4.75 (dt, 2 H,
3,4JH,H = 5.9, 1.3 Hz, CH2), 5.27 (ddd, 1 H, 3,4JH,H = 10.2, 2.3, 1.1 Hz, CHH), 5.31 (ddd, 1 H,
3,4JH,H = 17.1, 2.4, 1.3 Hz, CHH), 5.86 (ddt, 1 H, 3JH,H = 17.1, 10.2, 5.9 Hz, Allyl-CH), 7.60
(d, 2 H, 3JH,H = 8.3 Hz, 2xAr-CH), 7.73 (d, 2 H, 3JH,H = 8.3 Hz, 2xAr-CH), 7.73 (s, 1 H, CH)
ppm; 1H-NMR (400 MHz, DMSO-d6) δ= 4.64-4.68 (m, 2 H, CH2), 5.15 (ddd, 1 H, 3,4JH,H =
17.2, 2.9, 1.7 Hz, E-Allyl-CH2), 5.19 (ddd, 1 H, 3,4JH,H = 10.4, 2.7, 1.4 Hz, Z-Allyl-CH2), 5.85
(ddt, 1 H, 3,4JH,H = 17.2, 10.4, 5.2 Hz, Allyl-CH), 7.86 (m, 5 H, CH,4 x Ar-CH); 13C-NMR
(400 MHz, CDCl3) δ= 46.7 (CH2), 119.8 (Allyl-CH2), 123.6 (q, 1JC,F = 272.5 Hz, CF3), 126.0
(Ar-C), 126.4 (q, 4JC,F = 3.8 Hz, 2,6-Ar-CH), 129.4 (Allyl-CH), 130.7 (3,5-Ar-CH), 130.9 (CH),
132.0 (q, 3JC,F = 33.0 Hz,1-Ar-CCF3), 136.7 (Ar-C), 167.3 (C=O), 192.2 (C=S) ppm; EI-MS
m/z (%) = 329.1 [M]+ (100 %), 314.1 [fragment]+ (75 %), 202.1 [fragment]+ (100 %); HR-MS m/z
= 329.0151 [M]+ (calculated: 329.0156); HPLC-Analysis (Method B): 100 %, Rt = 21.6 min.
(5Z)-5-[(4-tert-butylphenyl)methylidene]-3-(prop-2- en-1-yl)-2-sulfanylidene-1,3-thiazolidin-4-one
40d
TLC Rf = 0.9 (DCM/EtOAc 9:1); Reaction time: 4 h; Purification: Re-crystallisation from
ethanol; Yield: 240 mg of yellow solid (0.76 mmol, 82 %); 1H-NMR (400 MHz, DMSO-d6) δ=
1.30 (s, 9 H, 3xCH3), 4.65 (d, 2 H, 3JH,H = 5.2 Hz, CH2), 5.11-517 (m, 1 H, E-CHH), 5.17-5.21
(m, 1 H, Z-CHH), 5.80-5.90 (m, 1 H, Allyl-CH), 7.59 (s, 4 H, 4xAr-CH), 7.81 (s, 1 H, CH) ppm;
13C-NMR (400 MHz, DMSO-d6) δ= 30.8 (3xCH3), 34.9 (C(CH3)3), 46.1 (CH2), 117.9 (Allyl-
CH2), 121.3 (Ar-C), 126.5 (2xAr-CH), 130.3 (Allyl-CH, Ar-C), 130.7 (2xAr-CH), 133.2 (CH),
154.3 (Ar-C), 166.7 (C=O), 193.1 (C=S) ppm; ESI-MS m/z (%) = 318.1 [M+H]+ (100 %); HPLC-
Analysis (Method B): 100 %, Rt = 23.1 min.
(Z)-3-allyl-5-(4-chlorobenzylidene)-2-thioxothiazolidin-4-one 40h [295]
Reaction time: 4 h; Purification: Re-crystallisation from ethanol; Yield: 97 mg of yellow
crystals (0.33 mmol, 53 %); 1H-NMR (400 MHz, CDCl3) δ= 4.74 (dt, 2 H, 3,4JH,H = 5.8, 1.3 Hz,
CH2), 5.26 (ddd, 1 H, 3,4JH,H = 10.3, 2.5, 1.4 Hz, CHH), 5.30 (ddd, 1 H, 3,4JH,H = 17.2, 2.5,
1.4 Hz, CHH), 5.86 (ddt, 1 H, 3JH,H = 17.2, 10.3, 5.8 Hz, CH), 7.42 (d, 2 H, 3JH,H = 8.8 Hz, 2xAr-
CH), 7.46 (d, 2 H, 3JH,H = 8.8 Hz, 2xAr-CH), 7.67 (s, 1 H, CH) ppm; 1H-NMR (400 MHz, DMSO-
d6) δ= 4.65 (dt, 2 H, 3,4JH,H = 5.2, 1.6 Hz, CH2), 5.17 (ddd, 1 H, 3,4JH,H = 17.2, 2.9, 1.5 Hz,
E-Allyl-CH2), 5.20 (ddd, 1 H, 3,4JH,H = 10.4, 2.8, 1.3 Hz, Z-Allyl-CH2), 5.85 (ddt, 1 H, 3,4JH,H =
17.2, 10.4, 5.2 Hz, Allyl-CH), 7.63 (ddd, 2 H, 3,4JH,H = 8.7, 2.1, 1.8, 2,4-Ar-CH), 7.69 (ddd, 2 H,
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3,4JH,H = 8.7, 2.1, 1.8, 1,5-Ar-CH), 7.84 (s, 1 H, CH) ppm; 13C-NMR (400 MHz, CDCl3) δ= 46.6
(CH2), 119.6 (Allyl-CH2), 123.7 (C), 129.5 (Allyl-CH), 129.8 (3, 5-ArCH), 131.7 (4-Ar-C), 131.8
(2,6-ArCH), 131.9 (CH), 137.1 (1-ArC), 167.5 (C=O), 192.4 (C=S); ppm; ESI-MS m/z (%) =
318.0 [M+Na]+ (100 %), 613.0 [2M+Na]+ (100 %); HR-MS m/z = 317.9789 [M+Na]+ (calculated:
317.9785); HPLC-Analysis : 99.9 %, Rt = 38.3 min.
(Z)-4-((3-allyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)benzonitrile 40i [296]
Reaction time: 4 h; Purification: Re-crystallisation from ethanol; Yield: 107 mg of orange
crystals (0.37 mmol, 57 %); 1H-NMR (400 MHz, CDCl3) δ= 4.74 (d, 2 H, 3JH,H = 5.8 Hz, CH2),
5.24-5.33 (m, 2 H, Allyl-CH2), 5.84 (ddt, 1 H, 3JH,H = 17.1, 10.3, 5.8 Hz, Allyl-CH), 7.58 (d,
2 H, 3JH,H = 8.2 Hz, 2xAr-CH), 7.68 (s, 1 H, CH), 7.76 (d, 2 H, 3JH,H = 8.2 Hz, 2xAr-CH) ppm;
13C-NMR (400 MHz, CDCl3) δ= 46.7 (CH2), 113.6 (CN), 118.1 (Allyl-CH2), 119.8 (Ar-C), 127.0
(Ar-C), 129.3 (Allyl-CH), 130.0 (CH), 130.7 (2xAr-CH), 133.0 (2xAr-CH), 137.5 (Ar-C), 167.1
(C=O), 191.6 (C=S) ppm; 1H-NMR (400 MHz, DMSO-d6) δ= 4.63-4.68 (m, 2 H, CH2), 5.12-
5.23 (m, 2 H, E(Z)-Allyl-CH2), 5.79-5.91 (m, 1 H, Allyl-CH), 7.82 (d, 2 H, 3JH,H = 7.1 Hz, 2,4-Ar-
CH), 7.88 (s, 1 H, CH), 8.00 (d, 2 H, 3JH,H = 7.1 Hz, 1,5-Ar-CH); ppm; EI-MS m/z (%) = 286.1
[M]+ (100 %), 271.0 [fragment]+ (15 %), 159.0 [fragment]+ (80 %), 98.1 [fragment]+ (40 %),
41.0 [fragment]+ (95 %), 39.0 [fragment]+ (100 %); HR-MS m/z = 286.0231 [M]+ (calculated:
286.0235); HPLC-Analysis (Method B): 99 %, Rt = 19.5 min.
(Z)-3-allyl-5-(4-ethynylbenzylidene)-2-thioxothiazolidin-4-one 40j
Reaction time: 4 h; Purification: Filtration from ethanol; Yield: 86 mg of red solid (0.30
mmol, 49 %); 1H-NMR (400 MHz, CDCl3) δ= 3.26 (s, 1 H, CCH), 4.74 (dt, 2 H, 3,4JH,H = 5.8,
1.3 Hz, CH2), 5.26 (ddd, 1 H, 3,4JH,H = 10.3, 2.3, 1.2 Hz, CHH), 5.30 (ddd, 1 H, 3,4JH,H = 17.2,
2.6, 1.4 Hz, CHH), 5.86 (ddt, 1 H, 3JH,H = 17.2, 10.3, 5.8 Hz, CH), 7.45 (d, 2 H, 3JH,H = 8.4 Hz,
2xAr-CH), 7.58 (d, 2 H, 3JH,H = 8.4 Hz, 2xAr-CH), 7.69 (s, 1 H, CH) ppm; 1H-NMR (400 MHz,
DMSO-d6) δ= 4.49 (s, 1 H, Acetylen-CH), 4.64 (dt, 2 H, 3,4JH,H = 5.2, 1.6 Hz, CH2), 5.14 (ddd,
1 H, 3,4JH,H = 17.2, 2.8, 1.6 Hz, E-Allyl-CH2), 5.19 (ddd, 1 H, 3,4JH,H = 10.4, 2.7, 1.3 Hz, Z-Allyl-
CH2), 5.84 (ddt, 1 H, 3,4JH,H = 17.2, 10.4, 5.2 Hz, Allyl-CH), 7.62-7.68 (m, 4 H, 4 x Ar-CH),
7.83 (s, 1 H, CH) ppm; 13C-NMR (400 MHz, CDCl3) δ= 46.6 (CH2), 80.5 (CCH), 83.0 (CCH),
119.6 (CH2), 124.1 (Ar-C), 124.6 (Ar-C), 129.6 (CH), 130.5 (2xAr-CH), 132.0 (CH), 133.1
(2xAr-CH), 133.6 (Ar-C), 167.5 (C=O), 192.5 (C=S) ppm; EI-MS m/z (%) = 285.1 [M]+ (100 %),
158.1 [fragment]+ (100 %); ESI-MS m/z (%) = 286.0 [M+H]+ (100 %), 308.0 [M+Na]+ (60 %); HR-
MS m/z = 285.0272 [M]+ (calculated: 285.0282); HR-MS m/z = 286.0358 [M+H]+ (calculated:
286.0355); HPLC-Analysis : 99.9 %, Rt = 37.4 min; HPLC-Analysis (Method B): 99 %, Rt =
19.5 min.
(Z)-3-allyl-5-(3-bromo-4-methoxybenzylidene)-2-thioxothiazolidin-4-one 40k
Reaction time: 4 h; Purification: Re-crystallisation from ethanol; Yield: 147 mg of yellow
crystals (0.40 mmol, 66 %); 1H-NMR (400 MHz, DMSO-d6) δ= 3.94 (s, 3 H, OCH3), 4.62-
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4.66 (m, 2 H, CH2), 5.13 (ddd, 1 H, 3,4JH,H = 17.2, 2.8, 1.6 Hz, E-Allyl-CH2), 5.18 (ddd, 1 H,
3,4JH,H = 10.4, 2.7, 1.3 Hz, Z-Allyl-CH2), 5.84 (ddt, 1 H, 3,4JH,H = 17.2, 10.4, 5.2 Hz, Allyl-CH),
7.30 (d, 1 H, 3JH,H = 8.7 Hz, 3-Ar-CH), 7.64 (dd, 1 H, 3,4JH,H = 8.7, 2.2 Hz, 4-Ar-CH), 7.79
(s, 1 H, CH), 7.93 (d, 1 H, 4JH,H = 2.2 Hz, 1-Ar-CH); ppm; 1H-NMR (400 MHz, CDCl3) δ=
3.96 (s, 3 H, OCH3), 4.73 (dt, 2 H, 3,4JH,H = 5.8, 1.3 Hz, CH2), 5.25 (ddd, 1 H, 3,4JH,H = 10.3,
2.3, 1.2 Hz, CHH), 5.29 (ddd, 1 H, 3,4JH,H = 17.2, 2.6, 1.4 Hz, CHH), 5.86 (ddt, 1 H, 3JH,H =
17.2, 10.3, 5.8 Hz, CH), 6.98 (d, 1 H, 3JH,H = 8.6 Hz, 3-Ar-CH), 7.42 (dd, 1 H, 3,4JH,H = 8.6,
2.2 Hz, 4-Ar-CH), 7.59 (s, 1 H, CH), 7.68 (d, 1 H, 4JH,H = 2.2 Hz, 6-Ar-CH) ppm; 13C-NMR
(400 MHz, CDCl3) δ= 46.5 (CH2), 56.7 (OCH3), 112.3 (3-Ar-CH), 113.0 (Ar-C), 119.5 (CH2),
121.6 (Ar-C), 127.4 (Ar-C), 129.6 (Allyl-CH), 131.5 (4-Ar-CH and CH), 135.7 (6-Ar-CH), 157.9
(Ar-CBr), 167.5 (C=O), 192.5 (C=S) ppm; ESI-MS m/z (%) = 372.0 [M+H]+ (100 %); HR-MS m/z
= 369.9570 [M+H]+ (calculated: 369.9566); HPLC-Analysis (Method B): 98 %, Rt = 21.9 min.
(Z)-3-allyl-5-(3-bromo-4-fluorobenzylidene)-2-thioxothiazolidin-4-one 40l
TLC Rf = 0.9 (DCM); Reaction time: 3 h; Purification: Re-crystallisation from methanol;
Yield: 54 mg of yellow crystals (0.15 mmol, 52 %); 1H-NMR (400 MHz, CDCl3) δ= 4.74 (dt,
2 H, 3,4JH,H = 5.8, 1.3 Hz, CH2), 5.27 (ddd, 1 H, 3,4JH,H = 10.3, 2.2, 1.1 Hz, CHH), 5.30 (ddd, 1 H,
3,4JH,H = 17.1, 2.4, 1.3 Hz, CHH), 5.86 (ddt, 1 H, 3JH,H = 17.1, 10.3, 5.8 Hz, Allyl-CH), 7.23 (at,
1 H, 3JH,F = 8.4 Hz, 6-Ar-CH), 7.43 (ddd, 1 H, 3,4JH,F(H) = 8.4, 4.5, 2.2 Hz, 5-Ar-CH), 7.61 (s, 1 H,
CH), 7.70 (dd, 1 H, 3,4JH,F(H) = 6.4, 2.2 Hz, 3-Ar-CH) ppm; 13C-NMR (400 MHz, CDCl3) δ= 46.6
(CH2), 110.7 (2JC,F = 21.8 Hz, 2-ArCBr), 117.7 (2JC,F = 23.1 Hz, 6-ArCH), 119.7 (Allyl-CH2),
124.4 (4JC,F = 2.7 Hz, 4-ArC), 129.5 (Allyl-CH), 130.2 (CH), 131.2 (3JC,F = 7.9 Hz, 5-ArCH, Ar-
C), 135.7 (3JC,F = 0.8 Hz, 3-ArCH) 160.1 (1JC,F = 255.2 Hz, 1-ArCF) 167.3 (C=O), 192.1 (C=S)
ppm; EI-MS m/z (%) = 358.9 [M]+ (100 %), 343.9 [M-O]+ (100 %), 231.9 [fragment]+ (100 %);
HR-MS m/z = 356.9282 [M]+ (calculated: 356.9293); HPLC-Analysis : 99 %, Rt = 37.6 min.
(Z)-3-allyl-5-(3-nitrobenzylidene)-2-thioxothiazolidin-4-one 40m [297]
Reaction time: 4 h; Purification: Re-crystallisation from ethanol; Yield: 41 mg of red crystals
(0.13 mmol, 21 %); 1H-NMR (400 MHz, CDCl3) δ= 4.76 (dt, 2 H, 3,4JH,H = 5.9, 1.3 Hz, CH2),
5.28 (ddd, 1 H, 3,4JH,H = 10.3, 2.2, 1.1 Hz, CHH), 5.32 (ddd, 1 H, 3,4JH,H = 17.1, 2.5, 1.4 Hz,
CHH), 5.86 (ddt, 1 H, 3JH,H = 17.1, 10.3, 5.9 Hz, Allyl-CH), 7.69 (at, 1 H, 3JH,H = 8.2, 7.9 Hz,
5-Ar-CH), 7.75 (s, 1 H, CH), 7.80 (ddd, 1 H, 3,4JH,H = 7.9, 1.8, 1.0 Hz, 4-Ar-CH), 8.29 (ddd, 1 H,
3,4JH,H = 8.2, 2.1, 1.0 Hz, 6-Ar-CH), 8.36 (at, 1 H, 4JH,H = 2.1, 1.8 Hz, 2-Ar-CH) ppm; 1H-NMR
(400 MHz, DMSO-d6) δ= 4.66 (dt, 2 H, 3,4JH,H = 5.2, 1.6 Hz, CH2), 5.15 (ddd, 1 H, 3,4JH,H =
17.2, 2.9, 1.6 Hz, E-Allyl-CH2), 5.19 (ddd, 1 H, 3,4JH,H = 10.4, 2.8, 1.4 Hz, Z-Allyl-CH2), 5.85
(ddt, 1 H, 3,4JH,H = 17.2, 10.4, 5.2 Hz, Allyl-CH), 7.85 (t, 1 H, 3JH,H = 8.1 Hz, 4-Ar-CH), 8.01
(s, 1 H, CH), 8.06 (ddd, 1 H, 3,5JH,H = 8.1, 1.7 0.7 Hz, 3-Ar-CH), 8.33 (ddd, 1 H, 3,4,5JH,H = 8.1,
2.1, 0.7 Hz, 5-Ar-CH), 8.52 (dd, 1 H, 4JH,H = 2.1, 1.7 Hz, 1-Ar-CH) ppm; 13C-NMR (400 MHz,
CDCl3) δ= 46.7 (CH2), 119.9 (Allyl-CH2), 124.8 (6-Ar-CH), 124.9 (2-Ar-CH), 126.7 (Ar-C),
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129.4 (Allyl-CH), 129.6 (CH), 130.6 (5-Ar-CH), 135.1 (Ar-C), 135.6 (4-Ar-CH), 148.9 (Ar-C),
167.2 (C=O), 191.6 (C=S) ppm; ESI-MS m/z (%) = 307.0 [M+H]+ (100 %), 324.0 [M+NH4]+
(60 %); HR-MS m/z = 307.0209 [M+H]+ (calculated: 307.0206); HPLC-Analysis : 99.9 %, Rt =
29.1 min; HPLC-Analysis (Method B): 100 %, Rt = 21.6 min.
(5Z)-5-[4-(dimethylamino)phenyl]methylidene-3- (prop-2-en-1-yl)-2-sulfanylidene-1,3-thiazolidin-
4- one 40n [298]
Reaction time: 4 h; TLC Rf = 0.6 (toluene/EtOAc 9:1); Purification: Flash-Chromatogra-
phy toluene (Rf = 0.2); Yield: 61 mg of purple crystals (0.20 mmol, 32 %); Purification: Re-
crystallisation from ethanol; Yield: 853 mg of red solid (2.80 mmol, 97 %); 1H-NMR (400
MHz, CDCl3) δ= 3.09 (s, 6 H, 2xCH3), 4.73-4.77 (m, 2 H, CH2), 5.22-5.26 (m, 1 H, Z-CHH),
5.26-5.32 (m, 1 H, E-CHH), 5.82-5.94 (m, 1 H, Allyl-CH), 6.75 (d, 2 H, 3JH,H = 9.0 Hz, 3,5-Ar-
CH), 7.41 (d, 2 H, 3JH,H = 9.0 Hz, 2,6-Ar-CH), 7.68 (s, 1 H, CH) ppm; ESI-MS m/z (%) = 305.1
[M+H]+ (100 %), 609.1 [2M+H]+ (15 %); HR-MS m/z = 305.0776 [M+H]+ (calculated: 305.0777);
HPLC-Analysis (Method B): 98 %, Rt = 21.9 min.
(Z)-N-(4-((3-allyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)phenyl) acetamide 40o
TLC Rf = 0.1 (DCM); Reaction time: 2 h; Purification: Filtration from methanol; Yield: 48 mg
of yellow solid (0.15 mmol, 52 %); 1H-NMR (400 MHz, CDCl3) δ= 2.22 (s, 3 H, CH3), 4.75 (dt,
2 H, 3,4JH,H = 5.8, 1.3 Hz, CH2), 5.25 (ddd, 1 H, 3,4JH,H = 10.3, 2.3, 1.2 Hz, CHH), 5.30 (ddd,
1 H, 3,4JH,H = 17.2, 2.6, 1.4 Hz, CHH), 5.87 (ddt, 1 H, 3JH,H = 17.2, 10.3, 5.8 Hz, CH), 7.34
(s(br), 1 H, NH), 7.47 (d, 2 H, 3JH,H = 8.7 Hz, 2xAr-CH), 7.65 (d, 2 H, 3JH,H = 8.7 Hz, 2xAr-CH),
7.69 (s, 1 H, CH) ppm; 13C-NMR (400 MHz, CDCl3) δ= 25.0 (CH3), 46.5 (CH2), 119.5 (Allyl-
CH2), 120.0 (2xAr-CH), 121.6 (Ar-C), 129.1 (Ar-C), 129.7 (Allyl-CH), 132.1 (2xAr-CH), 132.8
(CH), 140.3 (Ar-C), 167.7 (C=O), 192.9 (C=S) ppm; ESI-MS m/z (%) = 319.1 [M+H]+ (100 %),
341.0 [M+Na]+ (75 %); HR-MS m/z = 319.0574 [M+H]+ (calculated: 319.0569); HPLC-Analysis
: 100 %, Rt = 33.9 min; HPLC-Analysis (Method B): 100 %, Rt = 18.3 min.
(Z)-3-allyl-5-(2-hydroxybenzylidene)-2-thioxothiazolidin-4-one 40p [297]
TLC Rf = 0.1 (DCM); Reaction time: 2.5 h; Purification: Re-crystallisation from H2O; Yield:
70 mg of yellow crystals (0.25 mmol, 87 %); 1H-NMR (400 MHz, CDCl3) δ= 4.76 (dt, 2 H,
3,4JH,H = 5.9, 1.3 Hz, CH2), 5.26 (ddd, 1 H, 3,4JH,H = 10.2, 2.3, 1.3 Hz, Z-Allyl-CH2), 5.30 (ddd,
1 H, 3,4JH,H = 17.1, 2.3, 1.3 Hz, E-Allyl-CH2), 5.88 (ddt, 1 H, 3JH,H = 17.1, 10.2, 5.9 Hz, Allyl-
CH), 6.19 (s(br), 1 H, OH), 6.91 (d, 1 H, 3JH,H = 8.4 Hz, 3-Ar-CH), 7.01 (at, 1 H, 3JH,H = 7.6 Hz,
5-Ar-CH), 7.32 (dd, 1 H, 3JH,H = 7.6, 8.4 Hz, 4-Ar-CH), 7.39 (d, 1 H, 3JH,H = 7.6 Hz, 6-Ar-CH),
8.20 (s, 1 H, CH) ppm; 13C-NMR (400 MHz, CDCl3) δ= 47.2 (CH2), 117.1 (5-ArCH), 118.9
(Allyl-CH2), 121.1 (3-ArCH), 121.9 (Ar-C), 122.4 (Ar-C), 130.3 (CH), 130.8 (2-ArCH), 131.3
(Allyl-CH), 133.9 (4-ArCH), 159.1 (Ar-C), 168.8 (Ar-C), 173.0 (C=O), 195.2 (C=S) ppm; 1H-
NMR (400 MHz, MeOD) δ= 4.71 (dt, 2 H, 3,4JH,H = 5.7,1.4 Hz, CH2), 5.20 (ddd, 1 H, 3,4JH,H =
10.1, 2.6, 1.3 Hz, CHH), 5.21 (ddd, 1 H, 3,4JH,H = 17.4, 2.6, 1.3 Hz, CHH), 5.87 (ddt, 1 H,
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3JH,H = 17.4, 10.1, 5.6 Hz, CH), 6.89 (d, 1 H, 3JH,H = 8.2 Hz, 5-Ar-CH), 6.94 (at, 1 H, 3JH,H = 7.8,
7.4 Hz, 3-Ar-CH), 7.30 (at, 1 H, 3JH,H = 8.2, 7.4 Hz, 4-Ar-CH), 7.35 (d, 1 H, 3JH,H = 7.8 Hz, 2-
Ar-CH), 8.12 (s, 1 H, CH) ppm; 13C-NMR (400 MHz, MeOD) δ= 47.2 (CH2), 117.1 (5-Ar-CH),
118.9 (Allyl-CH2), 121.1 (3-Ar-CH), 121.9 (Ar-C), 130.3 (CH), 130.8 (2-Ar-CH), 131.3 (Allyl-
CH), 133.9 (4-Ar-CH), 159.1 (Ar-C), 168.8 (Ar-C), 173.0 (C=O), 195.2 (C=S) ppm; APCI-MS
m/z (%) = 278.0 [M+H]+ (100 %); HR-MS m/z = 278.0303 [M+H]+ (calculated: 278.0304); HPLC-
Analysis : 99.9 %, Rt = 34.0 min.
(Z)-3-allyl-5-(3-hydroxybenzylidene)-2-thioxothiazolidin-4-one 40q
TLC Rf = 0.1 (DCM); Reaction time: 4 h; Purification: Flash-Chromatography DCM (Rf = 0.1);
Yield: 36 mg of yellow solid (0.13 mmol, 45 %); 1H-NMR (400 MHz, CDCl3) δ= 1 (, ( , H H,
7JH = „ 0J4.75 = 2, H,H Hz, 5.8, 1.3 Hz)CH23,4, 5.21 (s(br), 1 H, OH), 5.26 (ddd, 1 H, 3,4JH,H =
10.3, 2.4, 1.2 Hz, Z-Allyl-CH2), 5.30 (ddd, 1 H, 3,4JH,H = 17.1, 2.4, 1.2 Hz, E-Allyl-CH2), 5.87
(ddd, 1 H, 3JH,H = 17.1, 10.3, 5.8 Hz, CH), 6.93 (dd, 1 H, 3,4JH,H = 8.0, 2.4 Hz, 4-Ar-CH),
6.96 (at, 1 H, 3,4JH,H = 2.4, 2.4 Hz, 2-Ar-CH), 7.09 (d, 1 H, 3JH,H = 8.0 Hz, 6-Ar-CH), 7.36 (at,
1 H, 3JH,H = 8.0, 8.0 Hz, 5-Ar-CH), 7.67 (s, 1 H, CH) ppm; 13C-NMR (400 MHz, CDCl3) δ= ,
46.6 (CH2), 117.1 (2-Ar-CH), 118.2 (4-Ar-CH), 119.6 (Alken-CH2), 123.5 (6-Ar-CH), 123.6 (C),
129.6 (Alken-CH), 130.8 (5-Ar-CH), 133.0 (CH), 134.9 (C), 156.3 (C), 167.6 (C), 193.0 (CHO)
ppm; EI-MS m/z (%) = 277.0 [M]+ (100 %), 262.0 [fragment]+ (70 %), 150.0 [fragment]+ (100 %);
HR-MS m/z = 277.0225 [M]+ (calculated: 277.0226); HPLC-Analysis : 99.9 %, Rt = 33.9 min.
(Z)-3-allyl-5-(4-hydroxybenzylidene)-2-thioxothiazolidin-4-one 40r [299]
TLC Rf = 0.1 (DCM/hexane 1:1); Reaction time: 4 h; Purification: Flash-Chromatography
DCM/Hexane 1:1 (Rf = 0.1); Yield: 49 mg of red solid (0.18 mmol, 50 %); 1H-NMR (400 MHz,
CDCl3) δ= 4.71-4.78 (m, 2 H, CH2), 5.23-5.33 (m, 2 H, Allyl-CH2), 5.53 (s, 1 H, OH), 5.87 (ddt,
1 H, 3JH,H = 17.2, 10.4, 5.2 Hz, Allyl-CH), 6.95 (d, 2 H, 3JH,H = 8.3 Hz, 2,6-Ar-CH), 7.42 (d,
2 H, 3JH,H = 8.3 Hz, 3,5-Ar-CH), 7.69 (s, 1 H, CH) ppm; 13C-NMR (400 MHz, CDCl3) δ= 46.5
(CH2), 116.7 (2,6-Ar-CH), 119.4 (Allyl-CH2), 120.2 (Ar-C), 126.4 (Ar-C) 129.7 (Allyl-CH), 133.2
(3,5-Ar-CH), 133.5 (CH), 158.3 (Ar-C), 167.9 (C=O), 193.1 (C=S) ppm; EI-MS m/z (%) = 277.0
[M]+ (100 %), 262.0 [fragment]+ (40 %), 150.0 [fragment]+ (100 %); HR-MS m/z = 277.0226 [M]+
(calculated: 277.0231); HPLC-Analysis : 91 %, Rt = 38.1 min.
(Z)-3-allyl-5-(2,4-dihydroxybenzylidene)-2-thioxothiazolidin-4-one 40s
Reaction time: red solid; Purification: Filtration from ethanol; Yield: 65 mg of red solid
(0.22 mmol, 47 %); Yield: 30 mg of red solid (0.10 mmol, 35 %); 1H-NMR (400 MHz, MeOD)
δ= 4.69 (dt, 2 H, 3,4JH,H = 5.6, 1.3 Hz, CH2), 5.15-5.21 (m, 2 H, CH2), 5.85 (ddt, 1 H, 3JH,H =
17.4, 10.1, 5.6 Hz, CH), 6.34 (d, 1 H, 4JH,H = 2.3 Hz, 2-Ar-CH), 6.42 (dd, 1 H, 3,4JH,H = 8.7,
2.3 Hz, 4-Ar-CH), 7.20 (d, 1 H, 3JH,H = 8.7 Hz, 5-Ar-CH), 8.08 (s, 1 H, CH) ppm; 13C-NMR
(400 MHz, MeOD) δ= 47.1 (CH2), 103.4 (2-Ar-CH), 109.7 (4-Ar-CH), 114.2 (Ar-C), 117.6 (Ar-
C), 118.7 (CH2), 131.1 (CH), 131.4 (Allyl-CH), 132.7 (5-Ar-CH), 161.5 (Ar-C), 164.0 (Ar-C),
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169.1 (C=O), 195.0 (C=S) ppm; EI-MS m/z (%) = 293.1 [M]+ (100 %), 278.1 [fragment]+ (20 %),
194.1 [fragment]+ (75 %), 166.1 [fragment]+ (100 %); HR-MS m/z = 293.0172 [M]+ (calculated:
293.0180); HPLC-Analysis (Method B): 97 %, Rt = 14.6 min.
(Z)-3-allyl-5-(3,4-dihydroxybenzylidene)-2-thioxothiazolidin-4-one 40t
TLC Rf = 0.1 (DCM); Reaction time: 3 h; Purification: Re-crystallisation from DCM; Yield:
13 mg of yellow solid (0.04 mmol, 15 %); 1H-NMR (400 MHz, CDCl3) δ= 4.83-4.87 (m, 2 H,
CH2), 5.29-5.41 (m, 2 H, Allyl-CH2), 6.00-6.10 (m, 1 H, 3) 7.10 (d, 1 H, 3JH,H = 8.0 Hz, 5-Ar-CH),
7.25-7.29 (m, 1 H, Ar-CH), 7.43-7.50 (m, 1 H, Ar-CH), 7.87 (s, 1 H, CH), 9.74-10.38 (s(br), 2 H,
2xOH) ppm; ESI-MS m/z (%) = 1H-NMR (400 MHz, MeOD) δ= 4.68 (d, 2 H, 3JH,H = 5.5 Hz,
CH2), 5.15-5.21 (m, 2 H, Allyl-CH2), 5.84 (ddt, 1 H, 3JH,H = 17.3, 10.2, 5.5 Hz, Allyl-CH), 6.86
(d, 1 H, 3JH,H = 8.2 Hz, 5-Ar-CH), 6.96 (d, 1 H, 3JH,H = 8.2 Hz, 6-Ar-CH), 6.98 (s, 1 H, 3-Ar-
CH), 7.57 (s, 1 H, CH) ppm; 13C-NMR (400 MHz, MeOD) δ= 47.2 (CH2), 117.1 (5-Ar-CH),
117.9 (6-ArCH). 118.9 (Allyl-CH2), 119.6 (Ar-C). 126.4 (3-Ar-CH), 126.6 (Ar-C), 131.3 (Allyl-
CH), 135.3 (CH), 147.3 (Ar-C), 150.5 (C=O), 168.8 (C=O) 193.0 (C=S) ppm; ESI-MS m/z (%) =
292.0 [M−H]− (100 %), 585.0 [2M−H]− (20 %); HR-MS m/z = 292.0105 [M−H]− (calculated:
292.0108); HPLC-Analysis : 99.9 %, Rt = 32.2 min.
(5Z)-5-[(4-hydroxy-3,5- dimethoxyphenyl)methylidene]-3-(prop-2-en-1-yl)-2- sulfanylidene-1,3-
thiazolidin-4-one 40u
TLC Rf = 0.7 (DCM/MeOH 9:1); Reaction time: 4 h; Purification: Re-crystallisation from
ethanol; Yield: 280 mg of yellow solid (0.83 mmol, 78 %); Yield: 430 mg of yellow solid
(1.27 mmol, 92 %); 1H-NMR (400 MHz, DMSO-d6) δ= 3.83 (s, 6 H, 2xOCH3), 4.64 (d, 2 H,
3JH,H = 5.2 Hz, CH2), 5.11 (ddd, 1 H, 3,4JH,H = 17.2, 2.7, 1.1 Hz, E-Allyl-CHH), 5.18 (ddd,
1 H, 3,4JH,H = 10.4, 2.7, 1.1 Hz, Z-Allyl-CHH), 5.84 (ddt, 1 H, 3JH,H = 17.2, 10.4, 5.2 Hz, Allyl-
CH), 6.92 (s, 2 H, 2,6-Ar-CH), 7.74 (s, 1 H, CH) ppm; 13C-NMR (400 MHz, DMSO-d6) δ=
46.0 (CH2), 56.1 (2xOCH3), 108.8 (2,6-Ar-CH), 117.3 (Ar-C), 117.6 (Allyl-CH2), 122.7 (Ar-C),
130.4 (Allyl-CH), 134.6 (CH), 140.6 (Ar-C), 148.5 (2xAr-C), 166.5 (C=O), 192.6 (C=S), ppm;
ESI-MS m/z (%) = 338.1 [M+H]+ (100 %), 360.0 [M+Na]+ (23 %), 692.1 [2M+NH4]+ (28 %), 697.1
[2M+Na]+ (100 %); ESI-MS m/z (%) = 338.1 [M+H]+ (32 %), 360.0 [M+Na]+ (4 %), 692.1 [2M+H]+
(9 %), 697.1 [2M+Na]+ (10 %); HPLC-Analysis (Method B): 92 %, Rt = 19.3 min.
(Z)-3-allyl-5-(4-(methylsulfonyl)benzylidene)-2-thioxothiazolidin-4-one 40v
Reaction time: 4 h; Purification: Re-crystallisation from ethanol; Yield: 88 mg of orange
crystals (0.26 mmol, 42 %); 1H-NMR (400 MHz, CDCl3) δ= 3.09 (s, 3 H, SO2CH3), 4.74 (dt,
2 H, 3,4JH,H = 5.9, 1.2 Hz, CH2), 5.26 (ddd, 1 H, 3,4JH,H = 10.3, 2.3, 1.2H˙z, CHH), 5.30 (ddd,
1 H, 3,4JH,H = 17.2, 2.6, 1.3 Hz, CHH), 5.85 (ddt, 1 H, 3JH,H = 17.2, 10.3, 5.9 Hz, Allyl-CH), 7.66
(d, 1 H, 3JH,H = 8.4 Hz, 2xAr-CH), 7.72 (s, 1 H, CH), 8.04 (d, 1 H, 3JH,H = 8.4 Hz, 2xAr-CH)
ppm; 1H-NMR (400 MHz, DMSO-d6) δ= 3.29 (s, 3 H, CH3), 4.66 (dt, 2 H, 3,4JH,H = 5.2, 1.6 Hz,
CH2), 5.17 (ddd, 1 H, 3,4JH,H = 17.2, 2.9, 1.5 Hz, E-Allyl-CH2), 5.20 (ddd, 1 H, 3,4JH,H = 10.4,
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2.8, 1.4 Hz, Z-Allyl-CH2), 5.85 (ddt, 1 H, 3,4JH,H = 17.2, 10.4, 5.2 Hz, Allyl-CH), 7.91 (ddd, 2 H,
3,4JH,H = 8.6, 2.0, 2.0 Hz, 2,4-Ar-CH), 7.92 (s, 1 H, CH), 8.08 (ddd, 2 H, 3,4JH,H = 8.6, 2.0,
2.0 Hz, 1,5-Ar-CH); 13C-NMR (400 MHz, CDCl3) δ= 44.5 (SO2CH3), 46.7 (CH2), 119.9 (Allyl-
CH2), 127.2 (Ar-C), 128.4 (2xAr-CH), 129.3 (Allyl-CH), 130.0 (CH), 131.0 (2xAr-CH) 138.5
(Ar-C), 141.6 (Ar-C), 167.1 (C=O), 191.7 (C=S) ppm; ESI-MS m/z (%) = 340.0 [M+H]+ (100 %),
362.0 [M+Na]+ (60 %); HR-MS m/z = 340.0133 [M+H]+ (calculated: 340.0130); HPLC-Analysis
: 99.9 %, Rt = 31.7 min.
(Z)-4-((3-allyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)benzaldehyde 40w [296]
TLC Rf = 0.4 (DCM); Reaction time: 4 h; Purification: Flash-Chromatography DCM (Rf = 0.4);
Yield: 23 mg of yellow solid (0.08 mmol, 27 %); 1H-NMR (400 MHz, CDCl3) δ= 4.63-4.69 (m,
2 H, CH2), 5.17-5.26 (m, 2 H, CH2), 7.57 (d, 2 H, 3JH,H = 8.3 Hz, 2xAr-CH), 7.62 (s, 1 H, CH),
7.90 (d, 2 H, 3JH,H = 8.3 Hz, 2xAr-CH), 9.98 (s, 1 H, CHO) ppm; EI-MS m/z (%) = 288.9 [M]+
(100 %); APCI-MS m/z (%) = 290.0 [M+H]+ (100 %); HR-MS m/z = 290.0306 [M+H]+ (calculated:
290.0304); HPLC-Analysis (Method B): 91 %, Rt = 14.8 min.
(Z)-3-allyl-5-(3-(benzyloxy)benzylidene)-2-thioxothiazolidin-4-one 40x [300]
TLC Rf = 0.6 (DCM); Reaction time: 3 h; Purification: Re-crystallisation from methanol/
acetone; Yield: 25 mg of yellow crystals (0.07 mmol, 10 %); 1H-NMR (400 MHz, CDCl3) δ=
4.74 (dt, 2 H, 3,4JH,H = 5.8, 1.3 Hz, CH2), 5.13 (s, 2 H, Bn-CH2), 5.26 (ddd, 1 H, 3,4JH,H = 10.3,
2.4, 1.3 Hz, CHH), 5.30 (ddd, 1 H, 3,4JH,H = 17.2, 2.4, 1.3 Hz, CHH), 5.86 (ddt, 1 H, 3JH,H = 17.2,
10.3, 5.8 Hz, Allyl-CH), 7.05-7.13 (m, 3 H, 3xAr-CH), 7.33-7.47 (m, 6 H, 6xAr-CH), 7.69 (s, 1 H,
CH) ppm; 1H-NMR (400 MHz, DMSO-d6) δ= 4.62-4.67 (m, 2 H, CH2), 5.10-5.22 (m, 4 H, E(Z)-
Allyl-CH2, OCH2Ph), 5.80-5.90 (m, 1 H, Allyl-CH), 7.17-7.53 (m, 9 H, 9 x Ar-CH), 7.81 (s, 1 H,
C-H); 13C-NMR (400 MHz, CDCl3) δ= 46.5 (CH2), 70.3 (Bn-CH2), 116.2 (Ar-CH), 118.0 (Ar-
CH), 119.5 (Allyl-CH2), 123.4 (Ar-C), 123.7 (Ar-CH), 127.6 (Ar-CH), 128.4 (Ar-CH), 128.8 (Ar-
CH), 128.9 (Ar-CH), 129.6 (Allyl-CH), 130.5 (Ar-CH), 133.2 (CH), 134.7 (Ar-C), 136.4 (Ar-C),
159.4 (Ar-C), 167.5 (C=O), 193.0 (C=S) ppm; ESI-MS m/z (%) = 368.1 [M+H]+ (100 %), 385.1
[M+NH4]+ (35 %); HR-MS m/z = 368.0774 [M+H]+ (calculated: 368.0773). HPLC-Analysis
(Method B): 98 %, Rt = 21.9 min.
(Z)-3-allyl-5-(4-(benzyloxy)benzylidene)-2-thioxothiazolidin-4-one 40y [99]
Reaction time: 4 h; Purification: Re-crystallisation from ethanol; Yield: 154 mg of yellow
crystals (0.42 mmol, 69 %); 1H-NMR (400 MHz, DMSO-d6) δ= 4.64 (dt, 2 H, 3,4JH,H = 5.2,
1.6 Hz, CH2), 5.12 (ddd, 1 H, 3,4JH,H = 17.2, 2.9, 1.7 Hz, E-Allyl-CH2), 5.19 (ddd, 1 H, 3,4JH,H =
10.4, 2.7, 1.5 Hz, Z-Allyl-CH2), 5.21 (s, 2 H, OCH2), 5.84 (ddt, 1 H, 3,4JH,H = 17.2, 10.4, 5.2 Hz,
Allyl-CH), 7.21 (ddd, 2 H, 3,4,5JH,H = 8.9, 3.0, 2.0 Hz, 2,3-Ar-CH), 7.32-7.48 (m, 5 H, 5 x Ar-CH),
7.63 (ddd, 2 H, 3,4,5JH,H = 8.9, 3.0, 2.0 Hz, 1,4-Ar-CH), 7.81 (s, 1 H, CH) ppm; 1H-NMR (400
MHz, CDCl3) δ= 4.74 (dt, 2 H, 3,4JH,H = 5.8, 1.3 Hz, CH2), 5.13 (s, 2 H, Bn-CH2), 5.25 (ddd,
1 H, 3,4JH,H = 10.2, 2.3, 1.1 Hz, CHH), 5.30 (ddd, 1 H, 3,4JH,H = 17.2, 2.6, 1.3 Hz, CHH), 5.87
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(ddt, 1 H, 3JH,H = 17.2, 10.2, 5.8 Hz, Allyl-CH), 7.07 (d, 2 H, 3JH,H = 8.9 Hz, 2xAr-CH), 7.46 (d,
2 H, 3JH,H = 8.9 Hz, 2xAr-CH), 7.33-7.48 (m, 5 H, 5xAr-CH), 7.69 (s, 1 H, CH) ppm; 13C-NMR
(400 MHz, CDCl3) δ= 46.5 (CH2), 70.4 (Bn-CH2), 115.9 (2xAr-CH), 119.4 (Allyl-CH2), 120.2
(Ar/Bn-C), 126.4 (Ar/Bn-C), 127.6 (Bn-CH), 128.4 (Bn-CH), 128.9 (Ar/Bn-C), 129.7 (Allyl-CH),
132.9 (2xAr-CH), 133.4 (CH), 136.1 (Ar/Bn-C), 161.0 (Ar/Bn-C), 167.7 (C=O), 193.0 (C=S)
ppm; ESI-MS m/z (%) = 368.1 [M+H]+ (100 %), 390.1 [M+Na]+ (40 %), 406.0 [M+K]+ (10 %),
757.1 [2M+Na]+ (35 %), 1124.2 [3M+Na]+ (10 %); HR-MS m/z = 368.0773 [M+H]+ (calculated:
368.0773); HPLC-Analysis (Method B): 99 %, Rt = 22.5 min.
(Z)-3-allyl-5-(3,4-bis(benzyloxy)benzylidene)-2-thioxothiazolidin-4-one 40z
Reaction time: 4 h; Purification: Filtration from methanol; Yield: 138 mg of yellow solid
(0.29 mmol, 51 %); 1H-NMR (400 MHz, CDCl3) δ= 4.73 (dt, 2 H, 3,4JH,H = 5.8, 1.3 Hz, CH2),
5.23 (s, 2 H, Bn-CH2), 5.24 (s, 2 H, Bn-CH2), 5.23-5.31 (m, 2 H, Allyl-CH2), 5.85 (ddt, 1 H,
3JH,H = 17.1, 10.3, 5.8 Hz, CH), 6.99 (d, 1 H, 3JH,H = 8.5 Hz, 6-Ar-CH), 7.01 (d, 1 H, 4JH,H =
2.1 Hz, 3-Ar-CH), 7.07 (dd, 1 H, 3,4JH,H = 8.5, 2.1 Hz, 5-Ar-CH), 7.31-7.49 (m, 10 H, 10xBn-
CH), 7.60 (s, 1 H, CH) ppm; 1H-NMR (400 MHz, DMSO-d6) δ= 4.62-4.65 (m, 2 H, CH2), 5.12
(ddd, 1 H, 3,4JH,H = 17.2, 2.9, 1.7 Hz, E-Allyl-CH2), 5.19 (ddd, 1 H, 3,4JH,H = 10.4, 2.7, 1.5 Hz,
Z-Allyl-CH2), 5.23 (s, 2 H, OCH2Ph), 5.25 (s, 2 H, OCH2Ph), 5.84 (ddt, 1 H, 3,4JH,H = 17.2,
10.4, 5.2 Hz, Allyl-CH), 7.23-7.50 (m, 13 H, 13 x Ar-CH), 7.74 (s, 1 H, CH) ppm; 13C-NMR
(400 MHz, CDCl3) δ= 46.5 (CH2), 71.0 (Bn-CH2), 71.4 (Bn-CH2), 114.3 (6-Ar-CH), 116.0 (3-
Ar-CH), 119.4 (Allyl-CH2), 120.4 (Ar/Bn-C), 126.2 (5-Ar-CH), 126.7 (Ar/Bn-C or CH), 127.3
(Bn-CH), 127.4 (Bn-CH), 128.3 (2xBn-CH or Ar/Bn-C), 128.8 (Bn-CH), 128.9 (Bn-CH), 129.7
(Allyl-CH), 133.6 (CH), 136.4 (Ar/Bn-C), 136.6 (Ar/Bn-C), 149.1 (Ar/Bn-C), 151.6 (Ar/Bn-C),
167.6 (C=O), 193.0 (C=S) ppm; ESI-MS m/z (%) = 474.1 [M+H]+ (100 %), 491.1 [M+NH4]+
(60 %), HR-MS m/z = 474.1187 [M+H]+ (calculated: 474.1192); HPLC-Analysis (Method B):
99 %, Rt = 22.5 min.
Synthesis of N-allyl-thiazolidine-2,4-dione 41 and N-Propagyl-thiazolidine-2,4-dione 42
Synthesis of N-Allyl or N-Propagyl thiazolidine-2,4-dione via Mitsunobu reaction condi-
tions
PPh3 (2.56 mmol, 1.0 eq) was dissolved in anhydrous THF (20 mL) under a nitrogen atmo-
sphere. DEAD (2.56 mmol, 1.0 eq) were added at -78 ◦C over a time period of 5 min. The
thiazolidine-2,4-dione (2.56 mmol, 1.0 eq) and allyl or propagyl alcohol (2.56 mmol, 1.0 eq)
were added to the reaction mixture. The reaction mixture was stirred at -78 ◦C for another
15 min and was subsequently allowed to stir at rt. After TLC showed complete consumption
of starting material, the reaction mixture was concentrated and purified via flash column chro-
matography.
3-Allylthiazolidine-2,4-dione 41 [301]
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TLC Rf = 0.6 (Toluene/EtOAc 8:2); Reaction time: 12 h; Yield: 126 mg of clear oil (0.80 mmol,
84 %); Purification: Flash-Chromatography toluene/EtOAc 8:2 (Rf = 0.6); 1H-NMR (400 MHz,
CDCl3) δ= 3.93 (s, 2 H, CH2), 4.16 (dt, 2 H, 3,4JH,H = 5.9, 1.3 Hz, CH2), 5.17 (ddd, 1 H, 3,4JH,H =
10.3, 2.3, 1.3 Hz, CHH), 5.21 (ddd, 1 H, 3,4JH,H = 17.2, 2.3, 1.3 Hz, CHH), 5.74 (ddt, 1 H, 3JH,H =
17.2, 10.3, 5.9 Hz, CH) ppm; 13C-NMR (400 MHz, CDCl3) δ= 33.8 ((C=O)CH2S), 43.9 (CH2),
119.0 (Allyl-CH2), 130.0 (CH), 171.0 (C=O), 171.3 (C=O) ppm; 1H-NMR (400 MHz, CDCl3)
δ= 3.90 (s, 2 H, CH2), 4.10 (dt, 2 H, 3,4JH,H = 5.9, 1.4 Hz, CH2), 5.11 (ddd, 1 H, 3,4JH,H = 10.2,
2.3, 1.1 Hz, CHH), 5.15 (ddd, 1 H, 3,4JH,H = 17.2, 2.6, 1.4 Hz, CHH), 5.68 (ddt, 1 H, 3JH,H =
17.1, 10.2, 5.9 Hz, Allyl-CH) ppm; 13C-NMR (400 MHz, CDCl3) δ= 33.7 ((C=O)CH2S), 43.6
(CH2), 118.7 (Allyl-CH2), 130.0 (CH), 170.9 (C=O), 171.2 (C=O) ppm; 1H-NMR (400 MHz,
CDCl3) δ= 3.97 (s, 2 H, ) 4.22 (d, 2 H, 3JH,H = 5.9 Hz, CH2), 5.20-5.29 (m, 2 H, CH2), 5.73-5.84
(m, 1 H, CH) ppm;
3-(prop-2-yn-1-yl)thiazolidine-2,4-dione 42 [302]
TLC Rf = 0.1 (Hexane/EtOAc 8:2); Purification: Flash-Chromatography Hexane/EtOAc 8:2
(Rf = 0.1); Yield: 388 mg of clear oil (2.50 mmol, 98 %); 1H-NMR (400 MHz, CDCl3) δ= 2.23
(t, 1 H, 4JH,H = 2.5 Hz, CH), 4.00 (s, 2 H, 5-CH2), 4.36 (d, 2 H, 4JH,H = 2.5 Hz, CH2) ppm; 13C-
NMR (400 MHz, CDCl3) δ= 30.9 (CH2), 34.0 (5-CH2), 72.2 (CH), 76.1 (CCH), 170.2 (C=O),
170.6 (C=O) ppm;
Synthesis of N-allyl or N-Propagyl thiazolidine-2,4-dione via nucleophilic substitution
NaH (1.1 eq) was charged in a flask under N2 atmosphere. Thiazolidone-2,4-dione (1.0 eq) in
DMF (5 mL) were added at 0 ◦C. The reaction mixture was stirred for 5 min and allyl bromide
was added at 0 ◦C. The reaction mixture was allowed to subsequently stir at rt. After TLC
showed complete consumption of starting material, the reaction mixture was concentrated.
The crude was extracted between H2O (5 mL) and EtOAc (3x10 mL), dried over MgSO4, fil-
tered and concentrated. Purification by flash column chromatography afforded 41 as clear
oil.
3-(prop-2-en-1-yl)-1,3-thiazolidine-2,4-dione 41 [301]
TLC Rf = 0.3 (Hexane/EtOAc 8:2), Reaction time: 2 h; Purification: Flash-Chromatography
Hexane/EtOAc 8:2 (Rf = 0.3); Yield: 1161 mg of clear oil (7.39 mmol, 86 %); Yield: 251 mg
of clear oil (1.60 mmol, 62 %); Yield: 371 mg of clear oil (2.36 mmol, 84 %); Yield: 297 mg
of clear oil (1.89 mmol, 67 %); 1H-NMR (400 MHz, CDCl3) δ= 3.98 (s, 2 H, CH), 4.22 (d,
2 H, 3JH,H = 5.9 Hz, CH2), 5.23 (d, 1 H, 3JH,H = 10.3 Hz, CHH), 5.27 (d, 1 H, 3JH,H = 17.3 Hz,
CHH), 5.79 (ddt, 1 H, 3JH,H = 5.9, 10.3, 17.3 Hz, CH) ppm. EI-MS m/z (%) = 157.0 [M]+ (50 %),
129.0 [fragment]+ (25 %), 97.1 [fragment]+ (70 %), 46.0 [fragment]+ (100 %), 4.20 [fragment]+
(100 %).
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Knoevenagel condensation of 41 and 42 with various benzaldehydes
Compound 41 or 42 (1.0 eq), benzaldehyde derivative (1.1-1.5 eq) and sodium acetate (1.0 eq)
were dissolved in ethanol (5-10 mL). The reaction mixture was stirred at 80 ◦C until TLC
showed complete consumption of starting material. The compounds were purified as de-
scribed below.
(5Z)-3-(prop-2-en-1-yl)-5-[2-(trifluoromethyl)phenyl]methylidene-1,3-thiazolidine-2,4-dione 41a
TLC Rf = 0.6 (Hexane/EtOAc 8:2); Reaction time: 16 h; Purification: Flash-Chromatography
Hexane/EtOAc 95:5 (Rf = 0.3); Yield: 123 mg of white solid (0.39 mmol, 35 %); Purification:
Flash-Chromatography Cyclohexane/EtOAc 9:1 (Rf = 0.4); Yield: 49 mg of white solid (0.16
mmol, 46 %); 1H-NMR (400 MHz, CDCl3) δ= 4.36 (dt, 2 H, 3,4JH,H = 6.0, 1.3 Hz, CH2), 5.28
(ddd, 1 H, 3,4JH,H = 10.2, 2.2, 1.1 Hz, Allyl-CHH), 5.33 (ddd, 1 H, 3,4JH,H = 17.1, 2.4, 1.2 Hz,
Allyl-CHH), 5.87 (ddt, 1 H, 3JH,H = 17.1, 10.2, 6.0 Hz, Allyl-CH), 7.50-7.56 (m, 1 H, 4-Ar-CH),
7.61-7.69 (m, 2 H, 5,6-Ar-CH), 7.78 (d, 1 H, 3JH,H = 7.9 Hz, 3-Ar-CH), 8.18 (q, 1 H, 5JH,F =
1.9 Hz, CH) ppm; 13C-NMR (400 MHz, CDCl3) δ= 44.1 (CH2), 119.5 (Allyl-CH2), 123.7 (q,
1JC,F = 274.1 Hz, CF3), 126.4 (Ar-C), 126.8 (q, 3JC,F = 5.5 Hz, 3-Ar-CH), 129.0 (5 or 6-Ar-CH),
129.7 (q, 4JC,F = 1.9 Hz, CH), 129.8 (q, 2JC,F = 30.5 Hz, 2-Ar-C), 130.0 (4-Ar-CH), 130.1 (Allyl-
CH), 132.2 (q, 5JC,F = 1.7 Hz, Ar-C), 132.4 (5 or 6-Ar-CH) 165.1 (C=O), 167.2 (C=O) ppm;
HPLC-Analysis (Method B): 100 %, Rt = 19.2 min.
(Z)-3-allyl-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione 41b
TLC Rf = 0.3 (Hexane/EtOAc 9:1); Reaction time: 6 h; Purification: Re-crystallisation from
ethanol; Yield: 17 mg of white crystals (0.05 mmol, 14 %); 1H-NMR (400 MHz, CDCl3) δ=
4.37 (dt, 2 H, 3,4JH,H = 5.9, 1.3 Hz, CH2), 5.27 (ddd, 1 H, 3,4JH,H = 10.2, 2.1, 1.1 Hz, CHH), 5.31
(ddd, 1 H, 3,4JH,H = 17.0, 2.5, 1.4 Hz, CHH), 5.86 (ddt, 1 H, 3JH,H = 17.0, 10.2, 5.0 Hz, Allyl-cH),
7.60-7.72 (m, 3 H, 3xAr-CH), 7.75 (s, 1 H, Ar-CH), 7.92 (s, 1 H, CH) ppm; 13C-NMR (400 MHz,
CDCl3) δ= 44.2 (CH2), 119.4 (Allyl-CH2), 122.3 (Ar-C), 123.9 (Ar-C), 127.0 (2xAr-CH), 127.1
(Ar-C), 130.0 (Ar-CH), 130.1 (Allyl-CH), 132.0 (CH), 132.8 (Ar-CH), 134.2 (CF3), 165.7 (C=O),
166.9 (C=O) ppm; APCI-MS m/z (%) = 314.0 [M+H]+ (100 %); HR-MS m/z = 314.0452 [M+H]+
(calculated: 314.0457); HPLC-Analysis : 99.9 %, Rt = 33.8 min.
(Z)-3-allyl-5-(4-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione 41c
TLC Rf = 0.7 (hexane/EtOAc 8:2); Reaction time: 5 h; Purification: Re-crystallisation from
ethanol; Yield: 70 mg of white crystals (0.22 mmol, 66 %); 1H-NMR (400 MHz, CDCl3) δ=
4.37 (dt, 2 H, 3,4JH,H = 5.9, 1.3 Hz, CH2), 5.27 (ddd, 1 H, 3,4JH,H = 10.3, 2.2, 1.1 Hz, CHH), 5.32
(ddd, 1 H, 3,4JH,H = 17.2, 2.5, 1.4 Hz, CHH), 7.62 (d, 2 H, 3JH,H = 8.3 Hz, 2xAr-CH), 7.74 (d,
2 H, 3JH,H = 8.3 Hz, 2xAr-CH), 7.91 (s, 1 H, CH) ppm; 13C-NMR (400 MHz, CDCl3) δ= 44.2
(CH2), 119.5 (Allyl-CH2), 126.3 (2,6-ArCH), 130.1 (3,5-ArCH), 130.3 (ArC), 132.0 (CH), 165.7
(C=O), 167.0 (C=O); ppm; APCI-MS m/z (%) = 314.0 [M+H]+ (100 %); HR-MS m/z = 313.0380
[M]+ (calculated: 313.0379); HR-MS m/z = 314.0457 [M+H]+ (calculated: 314.0457); HR-MS
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m/z = 314.0454 [M+H]+ (calculated: 314.0457); HPLC-Analysis : 99.9 %, Rt = 34.1 min.
(Z)-3-allyl-5-(2,4-bis(trifluoromethyl)benzylidene)thiazolidine-2,4-dione 41e
TLC Rf = 0.7 (Cyclohexan/EtOAc 8:2); Reaction time: 30 min; Purification: Flash-Chroma-
tography Cyclohexan/EtOAc 95:5 (Rf = 0.2); Yield: 36 mg of white solid (0.09 mmol, 25 %);
1H-NMR (400 MHz, CDCl3) δ= 4.37 (dt, 2 H, 3,4JH,H = 6.0, 1.2 Hz, CH2), 5.27-5.31 (m, 1 H,
CHH), 5.31-5.37 (m, 1 H, CHH), 5.86 (dt, 1 H, 3JH,H = 17.1, 10.2, 6.0 Hz, Allyl-CH), 7.77 (d,
1 H, 3JH,H = 8.1 Hz, 3 o. 4-Ar-CH), 7.92 (d, 1 H, 3JH,H = 8.1 Hz, 3 o. 4-Ar-CH), 8.01 (s, 1 H,
6-Ar-CH), 8.13 (q, 1 H, 4JH,F = 1.5 Hz, CH) ppm; 13C-NMR (400 MHz, CDCl3) δ= 44.4 (CH2),
119.9 (Allyl-CH2), 123.0 (q, 1JC,F = 272.9 Hz, CF3), 123.1 (q, 2JC,F = 272.9 Hz, CF3), 124.1 (m,
6-Ar-CH), 127.9 (CH), 128.8 (Ar-C) 129.4 (CH) 129.7 (3 o. 4-Ar-CH), 129.9 (CH) 130.6 (q,
2JC,F = 31.6 Hz, Ar-C-CF3), 131.9 (q, 2JC,F = 34.0 Hz, Ar-C-CF3), 136.0 (Ar-C), 164.7 (C=O),
166.5 (C=O) ppm; APCI-MS m/z (%) = 382.0 [M+H]+ (100 %); HR-MS m/z = 382.0337 [M+H]+
(calculated: 382.0331); HPLC-Analysis (Method B): 98 %, Rt = 20.5 min.
(Z)-3-allyl-5-(2-hydroxybenzylidene)thiazolidine-2,4-dione 41f
TLC Rf = 0.2 (Cyclohexane/EtOAc 8:2); Reaction time: 12 h; Purification: Filtration from
Cyclohexane/EtOAc 8:2; Yield: 19 mg of white solid (0.07 mmol, 19 %); 1H-NMR (400 MHz,
MeOD) δ= 4.31 (dt, 2 H, 3,4JH,H = 5.6, 1.4 Hz, CH2), 5.19 (ddd, 1 H, 3,4JH,H = 10.3, 2.5, 1.2 Hz,
CHH), 5.20 (ddd, 1 H, 3,4JH,H = 17.1, 2.7, 1.4 Hz, CHH), 5.86 (ddt, 1 H, 3JH,H = 17.1, 10.3,
5.6 Hz, Allyl-CH), 6.88 (d, 1 H, 3JH,H = 8.3 Hz, 3-Ar-CH), 6.92 (at, 1 H, 3JH,H = 7.7, 7.8 Hz,
5-Ar-CH), 7.27 (dd, 1 H, 3JH,H = 8.3, 7.7 Hz, 4-Ar-CH), 7.40 (d, 1 H, 3JH,H = 7.8 Hz, 6-Ar-CH),
8.27 (s, 1 H, CH) ppm; 13C-NMR (400 MHz, MeOD) δ= 44.5 (CH2), 117.0 (3-Ar-CH), 118.4
(Allyl-CH2), 120.9 (5-Ar-CH), 121.0 (Ar-C), 121.8 (Ar-C), 130.0 (6-Ar-CH), 130.6 (CH), 132.1
(Allyl-CH), 133.5 (4-Ar-CH), 158.9 (Ar-C), 167.5 (C=O), 169.2 (C=O) ppm; ESI-MS m/z (%) =
262.1 [M+H]+ (100 %), 279.1 [M+NH4]+ (26 %), 284.0 [M+Na]+ (13 %), 523.1 [2M+H]+ (2 %),
540.1 [2M+NH4]+ (15 %), 545.1 [2M+Na]+ (30 %). HPLC-Analysis : 99.9 %, Rt = 30.0 min.
(5Z)-5-[(3-hydroxyphenyl)methylidene]-3-(prop-2-en-1-yl)-1,3-thiazolidine-2,4-dione 41g
TLC Rf = 0.1 (CHCl3/MeOH 1:0.01); Reaction time: 6 h; Purification: Filtration from Ethanol;
Yield: 144 mg of white crystals (0.55 mmol, 35 %); 1H-NMR (400 MHz, CDCl3) δ= 4.36 (d,
2 H, 3JH,H = 5.9 Hz, CH2), 5.21 (s(br), 1 H, OH), 5.26 (d, 1 H, 3JH,H = 10.2 Hz, CHH), 5.30 (d,
1 H, 3JH,H = 17.1 Hz, CHH), 5.80-5.91 (m, 1 H, Allyl-CH), 6.93 (dd, 1 H, 3,4JH,H = 1.4, 8.2 Hz,
4-Ar-CH), 6.99 (d, 1 H, 4JH,H = 1.4 Hz, 2-Ar-CH), 7.10 (d, 1 H, 3JH,H = 7.7 Hz, 6-Ar-CH), 7.35
(at, 1 H, 3JH,H = 7.7, 8.2 Hz, 5-Ar-CH), 7.85 (s, 1 H, CH) ppm; 13C-NMR (400 MHz, CDCl3) δ=
44.1 (CH2), 116.7 (2-Ar-CH), 118.0 (4-Ar-CH), 119.3 (Allyl-CH2), 122.0 (Ar-C), 123.1 (6-Ar-
CH), 130.2 (Allyl-CH), 130.7 (5-Ar-CH), 133.9 (CH), 134.8 (Ar-C), 156.3 (Ar-C), 166.1 (C=O),
167.7 (C=O) ppm; HPLC-Analysis (Method B): 97 %, Rt = 16.5 min.
(5Z)-5-[(4-hydroxyphenyl)methylidene]-3-(prop-2-en-1-yl)-1,3-thiazolidine-2,4-dione 41h
TLC Rf = 0.3 (Hexane/EtOAc 8:2); Reaction time: 16 h; Purification: Flash-Chromatogra-
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phy DCM (Rf = 0.1); Yield: 160 mg of white solid (0.61 mmol, 46 %); 1H-NMR (400 MHz,
CDCl3) δ= 1.25 (s(br), 1 H, OH), 4.35 (adt, 2 H, 3,4JH,H = 1.3, 5.8 Hz, 1-CH2), 5.24 (ddd, 1 H,
3,4JH,H = 1.1, 2.2, 10.2 Hz, Z-CHH), 5.29 (ddd, 1 H, 3,4JH,H = 1.4, 2.5, 17.1 Hz, E-CHH), 5.86
(ddt, 1 H, 3JH,H = 5.8, 10.2, 17.1 Hz, Alken-CH), 5.90 (s(br), 1 H, OH), 6.94 (d, 2 H, 3JH,H =
8.7 Hz, 2,6-Ar-CH), 7.43 (d, 2 H, 3JH,H = 8.7 Hz, 3,5-Ar-CH), 7.86 (s, 1 H, CH) ppm; 13C-
NMR (400 MHz, CDCl3) δ= 44.0 (CH2), 116.5 (2,6-Ar-CH), 118.4 (Ar-C), 119.0 (Allyl-CH2),
126.1 (Ar-C), 130.4 (Allyl-CH), 132.7 (3,5-Ar-CH), 134.2 (CH), 158.2 (Ar-C), 166.4 (C=O),
168.0 (C=O) ppm; APCI-MS m/z (%) = 262.1 [M+H]+ (100 %); HR-MS m/z = 262.0529 [M+H]+
(calculated: 262.0532); HPLC-Analysis (Method B): 98 %, Rt = 16.6 min.
(Z)-3-allyl-5-(3,4-dihydroxybenzylidene)thiazolidine-2,4-dione 41i
TLC Rf = 0.2 (toluene/EtOAc 7:3); Reaction time: 6 h; Purification: Flash-Chromatogra-
phy toluene/EtOAc 7:3 (Rf = 0.2); Yield: 8 mg of white solid (0.03 mmol, 13 %); 1H-NMR
(400 MHz, MeOD) δ= 4.29 (dt, 2 H, 3,4JH,H = 5.6, 1.4 Hz, CH2), 5.18 (m, 1 H, E-Allyl-CH2),
5.19 (m, 1 H, Z-Allyl-CH2), 5.85 (ddt, 1 H, 3JH,H = 17.2, 10.1, 5.5 Hz, Allyl-CH), 6.86 (d, 1 H,
3JH,H = 8.3 Hz, 6-Ar-CH), 6.96 (dd, 1 H, 3,4JH,H = 8.3, 2.2 Hz, 5-ArCH), 7.01 (d, 1 H, 4JH,H =
2.2 Hz, 3-ArCH), 7.74 (s, 1 H, CH), 13C-NMR (400 MHz, MeOD) δ= 44.54 (CH2), 116.9 (6-
ArCH), 117.5 (3-ArCH) 118.1 (C), 118.3 (Allyl-CH2), 132.1 (Allyl-C), 125.6 (5-ArCH), 126.4
(Ar-C), 132.1 (Ar-C), 135.6 (CH), 147.2 (ArC-OH), 150.1 (ArC-OH), 167.5 (C=O), 169.1 (C=O)
ppm; APCI-MS m/z (%) = 278.0 [M+H]+ (100 %); HR-MS m/z = 278.0480 [M+H]+ (calculated:
278.0482); HPLC-Analysis : 99.9 %, Rt = 27.2 min.
(Z)-3-allyl-5-(2,4-dihydroxybenzylidene)-2-thioxothiazolidin-4-one 41m
TLC Rf = 0.1 (Cyclohexane/EtOAc 7:3); Reaction time: 12 h; Purification: Flash-Chroma-
tography Cyclohexane/EtOAc 8:2 → 7:3 (Rf = 0.1); Yield: 13 mg of white solid (0.05 mmol,
15 %); 1H-NMR (400 MHz, MeOD) δ= 4.28 (dt, 2 H, 3,4JH,H = 5.6, 1.4 Hz, CH2), 5.17 (ddd,
1 H, 3,4JH,H = 10.1, 2.5, 1.3 Hz, CHH), 5.18 (ddd, 1 H, 3,4JH,H = 17.2, 2.8, 1.5 Hz, CHH), 5.84
(ddt, 1 H, 3JH,H = 17.2, 10.1, 5.6 Hz, Allyl-CH), 6.34 (d, 1 H, 4JH,H = 2.3 Hz, 2-Ar-CH), 6.39 (dd,
1 H, 3,4JH,H = 8.6, 2.3 Hz, 6-Ar-CH), 7.24 (d, 1 H, 3JH,H = 8.6 Hz, 5-Ar-CH), 8.23 (s, 1 H, CH)
ppm; 13C-NMR (400 MHz, MeOD) δ= 44.4 (CH2), 103.4 (2-Ar-CH), 109.2 (6-Ar-CH), 113.8
(Ar-C), 116.2 (Ar-C), 118.2 (Allyl-CH2), 131.0 (CH), 131.7 (5-Ar-CH), 132.2 (Allyl-CH), 161.1
(Ar-C-OH), 163.4 (Ar-C-OH), 167.9 (C=O), 169.5 (C=O), ppm; HPLC-Analysis (Method B):
97 %, Rt = 17.1 min.
(5Z)-5-[3-(benzyloxy)phenyl]-methylidene-3-(prop-2-en-1-yl)-1,3-thiazolidine-2,4-dione 41j
TLC Rf = 0.7 (Hexane/EtOAc 8:2); Reaction time: 6 h; Purification: Flash-Chromatography
Hexane/EtOAc 95:5 (Rf = 0.1); Yield: 490 mg of white solid (1.39 mmol, 88 %); 1H-NMR (400
MHz, CDCl3) δ= 4.32 (adt, 2 H, 3,4JH,H = 1.1, 1.4, 5.9 Hz, CH2), 5.09 (s, 2 H, CH2Ar), 5.24
(ddd, 1 H, 3,4JH,H = 1.0, 1.1, 10.2 Hz, CHH), 5.28 (ddd, 1 H, 3,4JH,H = 1.0, 1.4, 17.1 Hz, CHH),
5.84 (ddt, 1 H, 3JH,H = 5.9, 10.2, 17.1 Hz, Allyl-CH), 7.01-7.06 (m, 2 H, 2,6-Ar-CH), 7.08 (d,
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1 H, 3JH,H = 7.9 Hz, 4-Ar-CH), 7.30-7.45 (m, 6 H, 6xAr-CH), 7.83 (s, 1 H, CH) ppm; 13C-NMR
(400 MHz, CDCl3) δ= 43.9 (CH2CH), 70.2 (CH2Ar), 116.0 (2 or 6-Ar-CH), 117.6 (2 or 6-Ar-
CH), 119.1 (Allyl-CH2), 121.8 (Ar-C), 123.1 (4-Ar-CH), 127.5 (2xAr-CH), 128.3 (Ar-CH), 128.8
(2xAr-CH), 130.2 (Ar-CH), 130.3 (Allyl-CH), 133.9 (CH), 134.6 (Ar-C), 136.4 (Ar-C), 159.2 (Ar-
C), 165.9 (C=O), 167.5 (C=O) ppm; ESI-MS m/z (%) = 352.1 [M+H]+ (28 %), 369.1 [M+NH4]+
(16 %), 720.2 [2M+NH4]+ (11 %), 725.2 [2M+Na]+ (2 %); HPLC-Analysis (Method B): 99 %,
Rt = 21.1 min.
(5Z)-5-[4-(benzyloxy)phenyl]methylidene-3-(prop-2-en-1-yl)-1,3-thiazolidine-2,4-dione 41k
TLC Rf = 0.6 (Hexane/EtOAc 9:1); Reaction time: 16 h; Purification: Flash-Chromatogra-
phy Hexane/EtOAc 95:5 (Rf = 0.2), loaded in DCM; Yield: 492 mg of white solid (1.40 mmol,
88 %); 1H-NMR (400 MHz, CDCl3) δ= 4.33 (adt, 2 H, 3,4JH,H = 1.1, 1.4, 5.8 Hz, CH2), 5.11 (s,
2 H, CH2Ar), 5.23 (ddd, 1 H, 3,4JH,H = 1.1, 1.2, 10.2 Hz, CHH), 5.28 (ddd, 1 H, 3,4JH,H = 1.1,
1.4, 17.1 Hz, CHH), 5.85 (ddt, 1 H, 3JH,H = 5.8, 10.2, 17.1 Hz, Allyl-CH), 7.04 (d, 2 H, 3JH,H =
8.8 Hz, 3,5-Ar-CH), 7.31-7.42 (m, 5 H, 5xAr-CH), 7.45 (d, 2 H, 3JH,H = 8.8 Hz, 2,6-Ar-CH), 7.84
(s, 1 H, CH) ppm; 13C-NMR (400 MHz, CDCl3) δ= 43.8 (CH2CH), 70.3 (CH2Ar), 115.7 (3,5-
Ar-CH), 118.6 (Ar-C), 118.9 (Allyl-CH2), 126.2 (Ar-C), 127.6 (2xAr-CH), 128.4 (Ar-CH), 128.8
(2xAr-CH), 130.4 (Allyl-CH) 132.4 (2,6-Ar-CH), 133.8 (CH), 136.2 (Ar-C), 160.7 (Ar-C), 166.2
(C=O), 167.7 (C=O) ppm; ESI-MS m/z (%) = 352.1 [M+H]+ (54 %), 369.1 [M+NH4]+ (8 %), 720.2
[2M+NH4]+ (17 %), 725.2 [2M+Na]+ (3 %); HPLC-Analysis (Method B): 97 %, Rt = 19.3 min.
(5Z)-5-[3,4-bis(benzyloxy)phenyl]methylidene-3-(prop-2-en-1-yl)-1,3-thiazolidine-2,4-dione 41l
TLC Rf = 0.7 (Hexane/EtOAc 8:2); Reaction time: 6 h; Purification: Flash-Chromatography
DCM/CHCl3 9:1 (Rf = 0.4); Yield: 525 mg of white solid (1.15 mmol, 72 %); 1H-NMR (400
MHz, CDCl3) δ= 4.31 (dt, 2 H, 3,4JH,H = 5.8, 1.2 Hz, Allyl-CH2), 5.21 (s, 2 H, CH2Ar), 5.22 (s,
2 H, CH2Ar), 5.20-5.24 (m, 1 H, CHHCH), 5.27 (ddd, 1 H, 3,4JH,H = 17.1, 2.5, 1.5 Hz, CHH),
5.83 (ddt, 1 H, 3JH,H = 17.1, 10.3, 5.8 Hz, Allyl-CH), 6.97 (d, 1 H, 3JH,H = 8.3 Hz, 5-Ar-CH), 7.02
(d, 1 H, 4JH,H = 2.1 Hz, 2-Ar-CH), 7.05 (dd, 1 H, 3,4JH,H = 8.3, 2.1 Hz, 6-Ar-CH), 7.29-7.34 (m,
2 H, 2xAr-CH), 7.35-7.40 (m, 4 H, 4xAr-CH), 7.42-7.47 (m, 4 H, 4xAr-CH), 7.75 (s, 1 H, CH)
ppm; 13C-NMR (400 MHz, CDCl3) δ= 43.9 (Allyl-CH2), 71.0 (CH2Ar), 71.3 (CH2Ar), 114.2 (5-
Ar-CH), 115.9 (2-Ar-CH), 118.9 (CH-CH2), 125.3 (6-Ar-CH), 126.5 (Ar-C), 127.2 (4xAr-CH),
127.3 (Ar-CH), 128.2 (4xAr-CH), 128.8 (Ar-C), 130.4 (Allyl-CH), 134.0 (CH), 136.5 (Ar-C),
136.6 (Ar-C), 148.9 (Ar-C), 151.2 (Ar-C), 166.1 (C=O), 167.7 (C=O) ppm; HPLC-Analysis
(Method B): 99 %, Rt = 21.9 min.
Synthesis of heterocyclic modification on N-allyl rhodanine and thiazolidine-2,4-dione
derivatives; derivatives 43a–l, 44a–b, and 45a
N-Allyl rhodanine 40 or the corresponding thiazolidine-2,4-dione derivative 41 and 42 (1.0 eq),
the aldehyde (1.0-1.1 eq) and sodium acetate (1.0 eq) were dissolved in EtOH and stirred at
80 ◦C until TLC showed complete consumption of starting material. The products were purified
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as stated below.
(Z)-3-allyl-5-(pyridin-2-ylmethylene)-2-thioxothiazolidin-4-one 43a [303]
TLC Rf = 0.7 (DCM); Reaction time: 4 h; Purification: Re-crystallisation from methanol;
Yield: 155 mg of yellow crystals (0.59 mmol, 91 %); 1H-NMR (400 MHz, CDCl3) δ= 4.75 (dt,
2 H, 3,4JH,H = 5.8, 1.4 Hz, CH2), 5.24 (ddd, 1 H, 3,4JH,H = 10.3, 2.3, 1.2 Hz, CHH), 5.28 (ddd,
1 H, 3,4JH,H = 17.2, 2.6, 1.3 Hz, CHH), 5.87 (ddt, 1 H, 3JH,H = 17.2, 10.3, 5.8 Hz, CH), 7.28
(ddd, 1 H, 3,4JH,H = 7.7, 4.8, 1.0 Hz, 2-Pyr-CH), 7.54 (d(br), 1 H, 3JH,H = 7.7 Hz, 4-Pyr-CH),
7.62 (s, 1 H, CH), 7.77 (atd, 1 H, 3,4JH,H = 7.7, 1.8 Hz, 3-Pyr-CH), 8.77 (d(br), 1 H, 3JH,H =
4.8 Hz, 1-Pyr-CH) ppm; 1H-NMR (400 MHz, DMSO-d6) δ= 4.65 (dt, 2 H, 3,4JH,H = 5.2, 1.6 Hz,
CH2), 5.11 (ddd, 1 H, 3,4JH,H = 17.2, 2.8, 1.6 Hz, E-Allyl-CH2), 5.18 (ddd, 1 H, 3,4JH,H) = 10.4,
2.8, 1.6 Hz, Z-Allyl-CH2), 5.85 (ddt, 1 H, 3,4JH,H) = 17.2, 10.4, 5.2 Hz, Allyl-CH), 7.46 (ddd,
1 H, 3,4JH,H = 6.9, 4.8, 2.2 Hz, 4-Ar-CH), 7.86 (s, 1 H, CH), 7.94-7.99 (m, 1 H, 5-Ar-CH), 7.94-
8.00 (m, 1 H, 6-Ar-CH), 8.80-8.83 (m, 1 H, 3-Ar-CH); ppm; 13C-NMR (400 MHz, CDCl3) δ=
46.0 (CH2), 119.2 (Allyl-CH2), 123.6 (2-Pyr-CH), 127.5 (4-Pyr-CH), 128.0 (CH), 128.6 (Ar-C),
129.9 (Allyl-CH), 137.1 (3-Pyr-CH), 149.7 (1-Pyr-CH), 151.8 (Ar-C), 167.8 (C=O), 199.8 (C=S)
ppm; EI-MS m/z (%) = 262.1 [M]+ (100 %), 247.1 [fragment]+ (65 %), 135.1 [fragment]+ (100 %);
HR-MS m/z = 262.0231 [M]+ (calculated: 262.0235); HPLC-Analysis (Method B): 99 %, Rt =
19.7 min.
(Z)-3-allyl-5-(pyridin-3-ylmethylene)-2-thioxothiazolidin-4-one 43b [303]
TLC Rf = 0.1 (DCM); Reaction time: 4 h; Purification: Re-crystallisation from ethanol; Yield:
75 mg of yellow crystals (0.29 mmol, 47 %); 1H-NMR (400 MHz, DMSO-d6) δ= 4.65 (dt, 2 H,
3,4JH,H = 5.2, 1.6 Hz, CH2), 5.15 (ddd, 1 H, 3,4JH,H = 17.2, 2.9, 1.7 Hz, E-Allyl-CH2), 5.19 (ddd,
1 H, 3,4JH,H = 10.4, 2.7, 1.5 Hz, Z-Allyl-CH2), 5.85 (ddt, 1 H, 3,4JH,H = 17.2, 10.4, 5.2 Hz, Allyl-
CH), 7.59 (dddd, 1 H, 3,5JH,H = 8.0, 4.8, 0.8, 0.4 Hz, 4-Ar-CH), 7.89 (s, 1 H, CH),8.01 (dddd,
1 H, 3,4JH,H = 8.0, 2.4, 1.6, 0.6 Hz, 3-Ar-CH), 8.66 (dd, 1 H, 3,4JH,H = 5.4, 1.6 Hz, 5-Ar-CH),
8.89-8.90 (m, 1 H, 1-Ar-CH); ppm; 1H-NMR (400 MHz, CDCl3) δ= 4.75 (d, 2 H, 3,4JH,H = 5.9,
1.3 Hz, CH2), 5.27 (ddd, 1 H, 3,4JH,H = 10.3, 2.2, 1.1 Hz, CHH), 5.31 (ddd, 1 H, 3,4JH,H = 17.2,
2.5, 1.4 Hz, CHH), 5.86 (ddt, 1 H, 3JH,H = 17.2, 10.3, 5.9 Hz, Allyl-CH), 7.48 (dd, 1 H, 3JH,H =
8.0, 4.9 Hz, 5-Pyr-CH), 7.71 (s, 1 H, CH), 7.82 (adt, 1 H, 3,4JH,H = 8.0, 2.2, 1.5 Hz, 4-Pyr-CCH),
8.66 (dd, 1 H, 3,4JH,H = 4.9, 1.5 Hz, 6-Pyr-CCH), 8.79 (d, 1 H, 4JH,H = 2.2 Hz, 2-Pyr-CCH) ppm;
13C-NMR (400 MHz, CDCl3) δ= 46.7 (CH2), 119.9 (Allyl-CH2), 124.4 (5-Pyr-CH), 126.1 (Ar-C),
128.7 (CH), 129.4 (Allyl-CH), 129.8 (Ar-C), 136.9 (4-Pyr-CH), 150.4 (6-Pyr-CH), 151.4 (2-Pyr-
CH), 167.2 (C=O), 191.8 (C=S) ppm; ESI-MS m/z (%) = 263.0 [M+H]+ (100 %); HR-MS m/z =
263.0310 [M+H]+ (calculated: 263.0307) HPLC-Analysis (Method B): 98 %, Rt = 11.2 min.
(Z)-3-allyl-5-(pyridin-4-ylmethylene)thiazolidine-2,4-dione 43c [303]
TLC Rf = 0.3 (DCM); Reaction time: 2.5 h; Purification: Flash-Chromatography DCM (Rf = 0.3);
Yield: 128 mg of yellow solid (0.49 mmol, 42 %); Purification: Re-crystallisation from ethanol;
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Yield: 36 mg of orange crystals (0.14 mmol, 22 %); 1H-NMR (400 MHz, DMSO-d6) δ= 4.65
(dt, 2 H, 3,4JH,H = 5.9, 1.3 Hz, CH2), 5.15 (ddd, 1 H, 3,4JH,H) = 17.5, 2.7, 1.3 Hz, E-Allyl-CH2),
5.19 (ddd, 1 H, 3,4JH,H = 10.4, 2.7, 1.3 Hz, Z-Allyl-CH2), 5.85 (ddt, 1 H, 3JH,H = 17.5, 10.4,
5.9 Hz, Allyl-CH), 7.59 (d, 2 H, 3,5JH,H = 5.6 Hz, 2,6-Ar-CH), 7.81 (s, 1 H, CH), 8.75 (d, 2 H,
3,5JH,H = 5.6 Hz, 3,5-Ar-CH) ppm; 1H-NMR (400 MHz, CDCl3) δ= 4.75 (dt, 2 H, 3,4JH,H = 5.9,
1.3 Hz, CH2), 5.26-5.35 (m, 2 H, Allyl-CH2), 5.86 (ddt, 1 H, 3JH,H = 17.5, 10.4, 5.9 Hz, Allyl-
CH), 7.36 (d, 2 H, 3JH,H = 5.6 Hz, 2,6-Pyr-CH), 7.62 (s, 1 H, CH), 8.76 (d, 2 H, 3JH,H = 5.6 Hz,
3,5-Pyr-CH) ppm; 13C-NMR (400 MHz, CDCl3) δ= 46.7 (CH2), 120.0 (Allyl-CH2), 123.8 (2,6-
Pyr-CH), 128.6 (Allyl-CH), 129.2 (CH), 129.3 (Ar-C), 140.6 (Ar-C), 150.7 (3,5-Pyr-CH), 167.1
(C=O), 191.6 (C=S) ppm; APCI-MS m/z (%) = 263.0 [M+H]+ (100 %); ESI-MS m/z (%) = 263.0
[M+H]+ (100 %); HR-MS m/z = 263.0310 [M+H]+ (calculated: 263.0307); HR-MS m/z = 263.0306
[M+H]+ (calculated: 263.0307); HPLC-Analysis (Method B): 97 %, Rt = 13.5 min.
(Z)-3-allyl-5-((2-chloropyridin-4-yl)methylene)-2-thioxothiazolidin-4-one 43d
TLC Rf = 0.6 (DCM); Reaction time: 6 h; Purification: Re-crystallisation from ethanol; Yield:
75 mg of yellow solid (0.25 mmol, 44 %); 1H-NMR (400 MHz, CDCl3) δ= 4.75 (dt, 2 H, 3,4JH,H =
5.9, 1.3 Hz, CH2), 5.28 (ddd, 1 H, 3,4JH,H = 10.2, 2.3, 1.3 Hz, Z-Allyl-CH2), 5.32 (ddd, 1 H,
3,4JH,H = 17.1, 2.3, 1.3 Hz, E-Allyl-CH2), 5.85 (ddt, 1 H, 3JH,H = 17.1, 10.2, 5.9 Hz, Allyl-CH),
7.26 (ddd, 1 H, 3,4JH,H = 0.6, 1.6, 5.3 Hz, 4-Ar-CH), 7.38 (dd, 1 H, 3,4JH,H = 0.6, 1.6 Hz, 2-
Ar-CH), 7.55 (0, 1 H, ,J = CH, )8.52 (d, 1 H, 3JH,H = 5.3 Hz, 5-Ar-CH) ppm; ESI-MS m/z (%) =
297.0 [M+H]+ (100 %); HR-MS m/z = 296.9921 [M+H]+ (calculated: 296.9918); HPLC-Analysis
: 100 %, Rt = 34.4 min.
(Z)-3-allyl-5-((2-(benzylamino)pyridin-4-yl)methylene)-2-thioxothiazolidin-4-one 43f
TLC Rf = 0.2 (CHCl3/ EtOAc 9:1); Reaction time: 16 h; Purification: Flash-Chromatogra-
phy CHCl3/ EtOAc 9:1 (Rf = 0.2); Yield: 16 mg of orange solid (0.04 mmol, 54 %); 1H-NMR
(400 MHz, CDCl3) δ= 4.47 (d, 2 H, 3JH,H = 5.7 Hz, CH2Ph), 4.64 (dt, 2 H, 3,4JH,H = 5.8, 1.3 Hz,
CH2), 5.18 (ddd, 1 H, 3,4JH,H = 10.2, 2.3, 1.3 Hz, Z-Allyl-CH2), 5.22 (ddd, 1 H, 3,4JH,H = 17.1, 2.3,
1.3 Hz, E-Allyl-CH2), 5.76 (ddt, 1 H, 3JH,H = 17.1, 10.2, 5.8 Hz, Allyl-CH), 7.18-7.33 (m, 6 H,
5xAr-CH), 7.41 (s, 1 H, CH), 8.12 (d, 1 H, 3JH,H = 5.4 Hz, 5-Ar-CH) ppm; ESI-MS m/z (%) =
368.1 [M+H]+ (100 %), 391.3 [M+Na]+ (10 %); HR-MS m/z = 368.0890 [M+H]+ (calculated:
368.0886); HPLC-Analysis (Method B): 100 %, Rt = 20.5 min.
(Z)-3-allyl-5-((2-(4-methylbenzylamino)pyridin-4-yl)methylene)-2-thioxothiazolidin-4-one 43g
TLC Rf = 0.4 (Hexane/EtOAc 6:4); Reaction time: 6 h; Purification: Flash-Chromatogra-
phy hexane/EtOAc 8:2 (Rf = 0.2); Yield: 17 mg of yellow solid (0.04 mmol, 32 %); 1H-NMR
(400 MHz, CDCl3) δ= 2.35 (s, 3 H, CH3), 4.49 (d, 2 H, 3JH,H = 5.7 Hz, Bn-CH2), 4.72 (dt, 2 H,
3,4JH,H = 5.9, 1.3 Hz, CH2), 5.15 (t(br), 1 H, 3JH,H = 5.7 Hz, NH2), 5.26 (ddd, 1 H, 3,4JH,H = 10.3,
2.4, 1.2 Hz, CHH), 5.29 (ddd, 1 H, 3,4JH,H = 17.1, 2.4, 1.2 Hz, CHH), 5.84 (ddt, 1 H, 3JH,H =
17.1, 10.3, 5.9 Hz, CH), 6.32 (s, 1 H, 2-Pyr-CH), 6.63 (dd, 1 H, 3,4JH,H = 5.3, 1.2 Hz, 4-Pyr-CH),
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7.17 (d, 2 H, 3JH,H = 8.0 Hz, 2xAr-CH), 7.27 (d, 2 H, 3JH,H = 8.0 Hz, 2x-Ar-CH), 7.49 (s, 1 H,
CH), 8.19 (d, 1 H, 3JH,H = 5.3 Hz, 5-Pyr-CH) ppm; 13C-NMR (400 MHz, CDCl3) δ= 21.3 (CH3),
46.4 (Allyl-CH2), 46.6 (Bn-CH2), 106.9 (2-Pyr-CH), 113.1 (4-Pyr-CH), 119.8 (Allyl-CH2), 127.2
(Ar-C), 127.5 (2xAr-CH), 129.5 (Allyl-CH), 129.7 (2xAr-CH), 131.0 (CH), 135.4 (Ar-C), 137.4
(Ar-C), 141.8 (Ar-C), 149.6 (5-Pyr-CH), 159.4 (Ar-C), 167.3 (C=O), 192.5 (C=S), ppm; ESI-MS
m/z (%) = 382.1 [M+H]+ (100 %); HR-MS m/z = 382.1046 [M+H]+ (calculated: 382.1042); HPLC-
Analysis (Method B): 99 %, Rt = 19.1 min.
(Z)-3-allyl-5-((2-(benzylamino)pyridin-4-yl)methylene)-2-thioxothiazolidin-4-one 43g
TLC Rf = 0.3 (DCM/EtOAc 9:1); Reaction time: 6 h; Purification: Flash-Chromatography
DCM/EtOAc 9:1 (Rf = 0.3); Yield: 8.0 mg of yellow solid (0.02 mmol, 70 %); 1H-NMR (300 MHz,
CDCl3) δ= 2.35 (s, 3 H, Ar-CH3), 4.49 (d, 2 H, 3JH,H = 5.6 Hz, CH2Ar), 4.72 (dt, 2 H, 3,4JH,H =
5.8, 1.3 Hz, CH2), 5.23-5.32 (m, 2 H, E,Z-Allyl-CH2), 5.77-5.91 (m, 1 H, Allyl-CH), 6.32 (s, 1 H,
2-Ar-CH), 6.62-6.65 (m, 1 H, 4-Ar-CH), 7.17 (d, 2 H, 3JH,H = 8.0 Hz, 3’,5’-Ar-CH), 7.27 (d, 2 H,
3JH,H = 8.0 Hz, 2’,6’-Ar-CH), 7.49 (s, 1 H, CH), 8.19 (d, 1 H, 3JH,H = 5.4 Hz, 5-Ar-CH) ppm;
ESI-MS m/z (%) = 382.1 [M+H]+ (100 %), 763.2 [2M+H]+ (10 %); HR-MS m/z = 382.1043 [M+H]+
(calculated: 382.1042).
(5Z)-5-(3-[(4-methoxyphenyl)methoxy]phenylmethylidene)-3-(prop-2-en-1-yl)-2-sulfanylidene-1,3-
thiazolidin-4-one 43i
TLC Rf = 0.7 (Hexane/EtOAc 8:2); Reaction time: 4 h; Purification: Filtration from ethanol;
Yield: 317 mg of yellow crystals (0.80 mmol, 90 %); 1H-NMR (400 MHz, CDCl3) δ= 3.83 (s,
3 H, OCH3), 4.74 (dt, 2 H, 3,4JH,H = 5.8, 1.3 Hz, Allyl-CH2), 5.05 (s, 2 H, CH2Ar), 5.26 (ddd, 1 H,
3,4JH,H = 10.2, 2.3, 1.1 Hz, CHH), 5.30 (ddd, 1 H, 3,4JH,H = 17.2, 2.5, 1.3 Hz, CHH), 5.87 (ddt,
1 H, 3JH,H = 17.2, 10.2, 5.8 Hz, Allyl-CH), 6.94 (d, 2 H, 3JH,H = 8.7 Hz, 3’,5’-Ar-CH), 7.04-7.08
(m, 2 H, 2,4-Ar-CH), 7.10 (d, 1 H, 3JH,H = 7.7 Hz, 6-Ar-CH), 7.37 (d, 2 H, 3JH,H = 8.7 Hz, 2’,6’-
Ar-CH), 7.39 (at, 1 H, 3JH,H = 7.7 Hz, 5-Ar-CH), 7.69 (s, 1 H, CH) ppm; 13C-NMR (400 MHz,
CDCl3) δ= 46.5 (Allyl-CH2), 55.5 (OCH3), 70.2 (CH2Ar), 114.3 (3’,5’-Ar-CH), 116.2 (2-Ar-CH),
118.1 (4-Ar-CH), 119.6 (CH2CH), 123.4 (Ar-C), 123.7 (6-Ar-CH), 128.4 (Ar-C), 129.4 (2’,6’-
Ar-CH), 129.6 (Allyl-CH), 130.5 (5-Ar-CH), 133.4 (CH) 134.7 (Ar-C), 159.5 (Ar-C), 159.8 (Ar-
C), 167.6 (C=O), 193.1 (C=S) ppm; ESI-MS m/z (%) = 398.1 [M+H]+ (5 %); HPLC-Analysis
(Method B): 99 %, Rt = 22.6 min.
(5Z)-5-[(3-[3-azido-5-(azidomethyl)phenyl]methoxyphenyl)methylidene]-3-(prop-2-en-1-yl)-2-sulf-
anylidene-1,3 -thiazolidin-4-one 43j
TLC Rf = 0.7 (DCM); Reaction time: 4 h; Purification: Flash-Chromatography Hexane/EtOAc
1:1 (Rf = 0.2); Yield: 260 mg of red solid (0.56 mmol, 66 %); 1H-NMR (400 MHz, CDCl3) δ=
4.39 (s, 2 H, CH2), 4.72 (dd, 2 H, 3,4JH,H = 1.0, 5.8 Hz, Allyl-CH2), 5.10 (s, 2 H, CH2), 5.25
(d, 1 H, 3JH,H = 10.3 Hz, Z-Allyl-CH2), 5.29 (d, 1 H, 3JH,H = 17.3 Hz, E-Allyl-CH2), 5.85 (ddd,
1 H, 3JH,H = 5.8, 10.3, 17.3 Hz, Allyl-CH), 6.95 (s, 1 H, Ar-CH), 6.99 (s, 1 H, Ar-CH), 7.05 (d,
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1 H, 3JH,H = 8.3 Hz, 4-Ar-CH), 7.06-7.08 (m, 1 H, 2-Ar-CH), 7.10 (d, 1 H, 3JH,H = 7.6 Hz, 6-Ar-
CH), 7.17 (s, 1 H, CH), 7.39 (at, 1 H, 3JH,H = 7.6, 8.3 Hz, 5-Ar-CH), 7.65 (s, 1 H, CH) ppm;
HPLC-Analysis (Method B): 97 %, Rt = 18.8 min.
(5Z,5’Z)-5,5’-(1,4-phenylenebis(methan-1-yl-1-ylidene))bis(3-allyl-2-thioxothiazolidin-4-one) 43l
Reaction time: 4 h; Purification: Re-crystallisation from ethanol; Yield: 41 mg of red crys-
tals (0.09 mmol, 32 %); 1H-NMR (400 MHz, DMSO-d6) δ= 4.65-4.68 (m, 4 H, CH2), 5.12-
5.22 (m, 4 H, E(Z)-Allyl-CH2), 5.79-5.91 (m, 2 H, Allyl-CH), 7.82-7.84 (m, 3 H, CH,2 x Ar-CH),
7.87-7.88 (m, 2 H, 2 x Ar-CH); EI-MS m/z (%) = 444.0 [M]+ (80 %), 429.0 [fragment]+ (70 %),
317.0 [fragment]+ (45 %), 221.0 [fragment]+ (65 %), 190.0 [fragment]+ (100 %); HR-MS m/z =
444.0094 [M]+ (calculated: 444.0095); HPLC-Analysis (Method B): 64 %, Rt = 23.9 min.
(Z)-3-allyl-5-(pyridin-4-ylmethylene)thiazolidine-2,4-dione 44a
TLC Rf = 0.2 (Toluene/EtOAc 7:3); Reaction time: 6 h; Purification: Flash-Chromatography
toluene/EtOAc 7:3 (Rf = 0.2); Yield: 18 mg of white solid (0.07 mmol, 23 %); 1H-NMR (400
MHz, CDCl3) δ= 4.36 (dt, 2 H, 3,4JH,H = 6.0, 1.2 Hz, CH2), 5.27 (ddd, 1 H, 3,4JH,H = 10.3,
2.5, 1.3 Hz, CHH), 5.31 (ddd, 1 H, 3,4JH,H = 17.1, 2.5, 1.3 Hz, CHH), 5.85 (ddt, 1 H, 3JH,H =
17.1, 10.3, 6.0 Hz, Allyl-CH), 7.34 (dd, 2 H, 3,4JH,H = 6.1, 1.6 Hz, 2xPyr-CH), 7.79 (s, 1 H, CH),
8.74 (dd, 1 H, 3,4JH,H = 6.1, 1.6 Hz, 2xPyr-CH) ppm; 13C-NMR (400 MHz, CDCl3) δ= 44.3
(CH2), 119.6 (Allyl-CH2), 123.5 (2xPyr-CH), 126.8 (Ar-C), 129.9 (Allyl-CH), 130.6 (CH), 140.4
(Ar-C), 150.9 (2xPyr-CH), 165.4 (C=O), 166.5 (C=O) ppm; ESI-MS m/z (%) = 247.1 [M+H]+
(100 %); APCI-MS m/z (%) = 247.1 [M+H]+ (100 %); HR-MS m/z = 247.0533 [M+H]+ (calculated:
247.0536); HR-MS m/z = 247.0538 [M+H]+ (calculated: 247.0536); HPLC-Analysis : 99.9 %,
Rt = 18.9 min.
(Z)-3-(prop-2-yn-1-yl)-5-(pyridin-4-ylmethylene)thiazolidine-2,4-dione 44b
TLC Rf = 0.4 (Hexane/EtOAc 1:1); Reaction time: 2 h; Purification: Re-crystallisation from
ethanol; Yield: 40 mg of white crystals (0.16 mmol, 26 %); 1H-NMR (400 MHz, CDCl3) δ=
2.29 (t, 1 H, 4JH,H = 2.5 Hz, CCH), 4.51 (d, 2 H, 4JH,H = 2.5 Hz, CH2), 7.34 (d, 2 H, 3JH,H =
5.6 Hz, 2,6-Pyr-CH), 7.83 (s, 1 H, CH), 8.74 (d, 2 H, 3JH,H = 5.6 Hz, 3,5-Pyr-CH) ppm; 13C-
NMR (400 MHz, CDCl3) δ= 31.1 (CH2), 72.7 (CCH), 75.8 (CCH), 123.4 (2,6-Pyr-CH), 126.3
(Ar-C), 131.3 (CH), 140.2 (Ar-C), 151.0 (3,5-Pyr-CH), 164.6 (C=O), 165.8 (C=O) ppm;
9.11 Reduction of compound 41h
Compound 41h (124 mg, 0.47 mmol) was dissolved in 20 mL dioxane. Pd/C (300 mg, 2.02 mmol)
was added and the hydrogenation was carried out under 30 psi H2 atmosphere. After H2 pres-
sure stabilisation, the reaction mixture was filtered through celite and washed with EtOAc. The
crude was purified by flash column chromatography (CHCl3/EtOAc 100:5, Rf 0.2). The product
was afford as a white solid (130 mg, 0.49 mmol).
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5-[(4-hydroxyphenyl)methyl]-3-propyl-1,3-thiazolidine-2,4-dione 46a
TLC Rf = 0.1 (CHCl3/EtOAc 100:5); Reaction time: 16 h; Purification: Flash-Chromatogra-
phy CHCl3/EtOAc 100:5 (Rf = 0.1); Yield: 130 mg of white solid (0.49 mmol, 100 %); 1H-NMR
(400 MHz, CDCl3) δ= 0.80 (t, 3 H, 3JH,H = 7.4 Hz, γ-CH3), 1.51 (tq, 2 H, 3JH,H = 7.4, 7.2 Hz,
β-CH2), 3.07 (dd, 1 H, 2,3JH,H = 8.9, 14.1 Hz, cis-CHH), 3.39 (dd, 1 H, 2,3JH,H = 3.9, 14.1 Hz,
anti-CHH), 3.50 (td, 2 H, 2,3JH,H = 3.5, 7.2 Hz, α-CH2), 4.41 (dd, 1 H, 3JH,H = 3.9, 8.9 Hz, CH),
6.25 (s(br), 1 H, OH), 6.77 (d, 2 H, 3JH,H = 8.5 Hz, 2,6-Ar-CH), 7.06 (d, 2 H, 3JH,H = 8.5 Hz,
3,5-Ar-CH) ppm; 13C-NMR (400 MHz, CDCl3) δ= 11.1 (CH3) 20.9 (β-CH2), 37.8 (CH2), 43.5
(α-CH2), 51.7 (CH), 115.7 (2,6-Ar-CH), 127.3 (Ar-C), 130.8 (3,5-Ar-CH), 155.5 (Ar-C), 171.8
(C=O), 174.5 (C=O) ppm; ESI-MS m/z (%) = 264.1 [M−H]− (85 %), 529.1 [2M−H]− (100 %);
HR-MS m/z = 264.0702 [M−H]− (calculated: 264.0700); HPLC-Analysis (Method B): 98 %,
Rt = 16.6 min.
9.12 Synthesis of derivatives 36a–ag, 48a–v, 54a–ab, and 55a–z
The starting rhodanine or thiazolidine-2,4-dione 36, 48, 54, and 55 (1.0 eq), the corresponding
aldehyde (1.1-1.5 eq) and sodium acetate (1.0 eq) were dissolved in methanol or ethanol (5-
10 mL). The reaction mixture was stirred at 80 ◦C until TLC showed complete consumption
of starting material. The products were afforded after filtration, re-crystallisation or column
chromatography as stated below.
(Z)-5-benzylidene-2-thioxothiazolidin-4-one 36b [304]
TLC Rf = 0.1 (DCM); Reaction time: 2 h; Purification: Filtration from methanol; Yield: 43
mg of yellow solid (0.19 mmol, 25 %); 1H-NMR (400 MHz, DMSO-d6) δ= 7.48-7.64 (m, 5 H,
5 x Ar-CH), 7.67 (s, 1 H, CH) ppm; 13C-NMR (400 MHz, DMSO-d6) δ= 129.5 (Ar-CH), 130.5
(Ar-CH), 131.3 (Ar-C), 131.6 (CH), 133.0 (Ar-C), 202.5 (C=S) ppm; EI-MS m/z (%) = 221.0
[M]+ (100 %), 134.0 [fragment]+ (100 %). HR-MS m/z = 220.9962 [M]+ (calculated: 220.9969);
HPLC-Analysis (Method B): 100 %, Rt = 18.2 min.
(Z)-5-(2-methylbenzylidene)-2-thioxothiazolidin-4-one 36c [305]
TLC Rf = 0.1 (DCM); Reaction time: 4 h; Purification: Filtration from methanol; Yield: 41
mg of yellow solid (0.17 mmol, 23 %); 1H-NMR (400 MHz, DMSO-d6) δ= 2.42 (s, 3 H, CH3),
7.34-7.42 (m, 4 H, 4 x Ar-CH), 7.74 (s, 1 H, CH) ppm; 13C-NMR (400 MHz, DMSO-d6) δ=
19.4 (CH3), 126.9 (Ar-CH), 127.6 (Ar-CH), 129.3 (CH), 130.7 (Ar-CH), 131.1 (Ar-CH), 132.0
(Ar-C), 139.1 (Ar-C), 169.1 (Ar-C), 196.1 (C=O), 206.5 (C=S) ppm; EI-MS m/z (%) = 235.1
[M]+ (100 %), 221.1 [fragment]+ (65 %), 147.1 [fragment]+ (100 %); HR-MS m/z = 235.0122 [M]+
(calculated: 235.0126); HPLC-Analysis (Method B): 98 %, Rt = 17.1 min.
(5Z)-5-[(3-methylphenyl)methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one 36d [295]
TLC Rf = 0.1 (Hexane/EtOAc 8:2); Reaction time: 16 h; Purification: Flash-Chromatography
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Hexane/EtOAc 8:2 (Rf = 0.1); Yield: 400 mg of yellow solid (1.70 mmol, 90 %); 1H-NMR (400
MHz, DMSO-d6) δ= 2.37 (s, 3 H, CH3), 7.33 (d, 1 H, 3JH,H = 7.1 Hz, Ar-CH), 7.38-7.46 (m,
3 H, 3xAr-CH), 7.60 (s, 1 H, CH) ppm; 13C-NMR (400 MHz, DMSO-d6) δ= 20.9 (CH3), 125.4
(Ar-C), 127.7 (Ar-CH), 129.4 (Ar-CH), 130.9 (Ar-CH), 131.6 (Ar-CH) 131.8 (CH), 133.0 (Ar-C),
138.9 (Ar-C), 169.4 (C=O), 195.8 (C=S) ppm; APCI-MS m/z (%) = 236.0 [M+H]+ (100 %); HR-
MS m/z = 236.0199 [M+H]+ (calculated: 236.0198); HPLC-Analysis (Method B): 93 %, Rt =
19.4 min.
(5Z)-5-[(4-methylphenyl)methylidene]-2-sul-fanylidene-1,3-thiazolidin-4-one 36e [268]
TLC Rf = 0.2 (Hexane/EtOAc 8:2); Reaction time: 12 h; Purification: Flash-Chromatography
Hexane/EtOAc 8:2 (Rf = 0.2), dry loaded on SiO2; Yield: 380 mg of yellow solid (1.61 mmol,
86 %); 1H-NMR (400 MHz, DMSO-d6) δ= 2.35 (s, 3 H, CH), 7.33 (d, 2 H, 3JH,H = 8.2 Hz, 3,5-
Ar-CH), 7.47 (d, 2 H, 3JH,H = 8.2 Hz, 2,6-Ar-CH), 7.58 (s, 1 H, CH) ppm; 13C-NMR (400 MHz,
DMSO-d6) δ= 21.2 (CH3), 124.4 (Ar-C), 130.1 (3,5-Ar-CH), 130.3 (Ar-C), 130.6 (2,6-Ar-CH),
131.7 (CH), 141.2 (Ar-C), 169.6 (C=O), 195.7 (C=S) ppm; ESI-MS m/z (%) = 236.0 [M+H]+
(7 %), 253.0 [M+NH4]+ (3 %), 488.1 [2M+NH4]+ (3 %), 493.0 [2M+Na]+ (2 %); HPLC-Analysis
(Method B): 99 %, Rt = 21.9 min.
(Z)-2-thioxo-5-(2-(trifluoromethyl)benzylidene)thiazolidin-4-one 36f [306]
TLC Rf = 0.1 (DCM); Reaction time: 4 h; Purification: Filtration from methanol; Yield: 205
mg of yellow solid (0.71 mmol, 73 %); 1H-NMR (400 MHz, DMSO-d6) δ= 7.65-7.73 (m, 3 H,
2,3-Ar-CH, CH), 7.86 (t, 1 H, 3JH,H = 7.7 Hz, 4-Ar-CH), 7.91 (d, 1 H, 3JH,H = 7.7 Hz, 5-Ar-
CH), 14.01 (s(br), 1 H, NH) ppm; 13C-NMR (400 MHz, DMSO-d6) δ= 125.4 (Ar-C), 126.9 (q,
3JC,F = 5.6 Hz, 5-Ar-CH), 127.8 (q, 2JC,F = 29.8 Hz, 6-Ar-CCF3), 129.4 (Ar-CH), 130.6 (Ar-CH),
131.0 (Ar-C), 131.2 (CH), 133.6 (4-Ar-CH) 168.9 (C=O), 195.7 (C=S) ppm; EI-MS m/z (%) =
289.0 [M]+ (100 %), 202.0 [fragment]+ (60 %), 85.1 [fragment]+ (70 %), 71.1 [fragment]+ (90 %),
57.0 [fragment]+ (100 %); HR-MS m/z = 288.9831 [M]+ (calculated: 288.9843); HPLC-Analysis
: 100 %, Rt = 32.6 min;
(5Z)-2-sulfanylidene-5-[3- (trifluoromethyl)phenyl]methylidene-1,3- thiazolidin-4-one 36g [307]
TLC Rf = 0.1 (DCM); Reaction time: 4 h; Purification: Flash-Chromatography DCM (Rf = 0.1);
Yield: 113 mg of yellow solid (0.39 mmol, 42 %); 1H-NMR (400 MHz, DMSO-d6) δ= 7.76 (s,
1 H, CH), 7.76-7.80 (m, 1 H, 5-Ar-CH), 7.85 (d, 2 H, 3JH,H = 7.8 Hz, 4,6-Ar-CH), 8.00 (s, 1 H, 2-
Ar-CH), 13.95 (s(br), 1 H, NH); 13C-NMR (400 MHz, DMSO-d6) δ= 123.8 (q, 1JC,F = 272.5 Hz,
CF3), 126.7 (q, 3JC,F = 3.7 Hz, 4-Ar-CH), 127.3 (q, 3JC,F = 3.9 Hz, 2-Ar-CH), 128.0 (Ar-C), 129.5
(CH), 130.0 (q, 2JC,F = 32.3 Hz, 3-Ar-CCF3), 130.6 (5-Ar-CH), 133.1 (6-Ar-CH), 134.2 (Ar-C)
169.6 (C=O), 195.5 (C=S) ppm; 1H-NMR (400 MHz, CDCl3) δ= 7.61-7.66 (m, 2 H, 2xAr-
CH), 7.68 (s, 1 H, CH), 7.69-7.73 (m, 2 H, 2xAr-CH), 9.59 (s(br), 1 H, NH) ppm; EI-MS
m/z (%) = 289.0 [M]+ (100 %), 202.0 [fragment]+ (100 %); HR-MS m/z = 288.9834 [M]+ (cal-
culated: 288.9843); HPLC-Analysis : 98 %, Rt = 34.1 min.
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(5Z)-2-sulfanylidene-5-[4- (trifluoromethyl)phenyl]methylidene-1,3- thiazolidin-4-one 36h [308]
TLC Rf = 0.1 (DCM); Reaction time: 4 h; Purification: Flash-Chromatography DCM (Rf = 0.1);
Yield: 82 mg of yellow solid (0.28 mmol, 37 %); 1H-NMR (400 MHz, CDCl3) δ= 7.59 (d, 2 H,
3JH,H = 8.2 Hz, 2xAr-CH), 7.66 (s, 1 H, CH), 7.75 (d, 2 H, 3JH,H = 8.2 Hz, 2xAr-CH), 9.30 (s(br),
1 H, NH) ppm; 1H-NMR (400 MHz, DMSO-d6) δ= 7.71 (s, 1 H, CH), 7.81 (d, 2 H, 3JH,H =
8.3 Hz, 2,6-Ar-CH), 7.88 (d, 2 H, 3JH,H = 8.3 Hz, 3,5-Ar-CH), 13.95 (s(br), 1 H, NH) ppm; 13C-
NMR (400 MHz, DMSO-d6) δ= 123.9 (q, 1JC,F = 272.4 Hz, CF3), 126.2 (q, 3JC,F = 3.7 Hz, 2,6-
Ar-H), 128.6 (Ar-C), 129.5 (CH), 129.8 (q, 2JC,F = 32.2 Hz, Ar-CCF3), 130.9 (3,5-Ar-CH), 136.9
(Ar-C), 169.3 (C=O), 195.5 (C=S) ppm; EI-MS m/z (%) = 289.0 [M]+ (100 %), 202.0 [fragment]+
(100 %); HR-MS m/z = 288.9834 [M]+ (calculated: 288.9843); HPLC-Analysis (Method B):
98 %, Rt = 21.7 min.
(Z)-5-(4-chlorobenzylidene)-2-thioxothiazolidin-4-one 36i [268]
TLC Rf = 0.3 (DCM); Reaction time: 3 h; Purification: Flash-Chromatography DCM (Rf = 0.3);
Yield: 61 mg of yellow solid (0.24 mmol, 63 %); 1H-NMR (400 MHz, CDCl3) δ= 7.41 (d, 2 H,
3JH,H = 8.5 Hz, 3,5-Ar-CH), 7.47 (d, 2 H, 3JH,H = 8.5 Hz, 2,6-Ar-CH), 7.61 (s, 1 H, CH), 9.13
(s(br), 1 H, NH) ppm; ESI-MS m/z (%) = 254.0 [M−H]− (100 %); HR-MS m/z = 253.9504 [M−H]−
(calculated: 253.9507); HPLC-Analysis : 99.9 %, Rt = 34.3 min.
mixture of Z to E 5:1 (Z)-4-((4-oxo-2-thioxothiazolidin-5-ylidene)methyl)benzonitrile 36j [296]
Reaction time: 16 h; Purification: Filtration from methanol; Yield: 28 mg of yellow solid (0.11
mmol, 30 %); 1H-NMR (400 MHz, DMSO-d6) δ= 7.56 (s, 1 H, E-CH), 7.70 (s, 1 H, Z-CH), 7.78
(d, 2 H, 3JH,H = 8.4 Hz, Z-3,5-Ar-CH), 7.89 (d, 2 H, 3JH,H = 8.4 Hz, E-3,5-Ar-CH), 7.99 (d, 2 H,
3JH,H = 8.4 Hz, Z-2,6-Ar-CH), 8.03 (d, 2 H, 3JH,H = 8.4 Hz, E-2,6-Ar-CH), 13.94 (s(br), 1 H,
NH) ppm; 13C-NMR (400 MHz, DMSO-d6) δ= 111.9 (Ar-C), 112.2 (Ar-C), 118.4 (Ar-C), 129.1
(Z-CH), 129.4 (Ar-C), 130.8 (Z-3,5-Ar-CH), 131.3 (E-2,6-Ar-CH), 131.9 (E-3,5-Ar-CH), 133.1
(Z-2,6-Ar-CH), 133.7 (E-CH), 137.4 (Ar-C), 169.5 (C=O), 195.4 (C=S) ppm; EI-MS m/z (%) =
246 [M]+ (100 %), 202.0 [fragment]+ (30 %), 159.0 [fragment]+ (100 %); HR-MS m/z = 245.9914
[M]+ (calculated: 245.9916); HPLC-Analysis (Method B): 97 %, Rt = 18.7 min.
(Z)-5-(3-bromo-4-fluorobenzylidene)-2-thioxothiazolidin-4-one 36k
TLC Rf = 0.2 (DCM); Reaction time: 4 h; Purification: Filtration from methanol; Yield: 84 mg
of yellow solid (0.26 mmol, 24 %); 1H-NMR (400 MHz, DMSO-d6) δ= 7.51 (s, 1 H, CH), 7.54
(t, 1 H, 3JH,H(F) = 8.6 Hz, 5-Ar-CH), 7.61 (ddd, 1 H, 3,4JH,H(F) = 8.6, 4.7, 2.2 Hz, 6-Ar-CH), 7.96
(dd, 1 H, 4JH,F(H) = 6.7, 2.2 Hz, 2-Ar-CH) ppm; 13C-NMR (400 MHz, DMSO-d6) δ= 109.0 (d,
3JC,F = 21.7 Hz, 3-Ar-C), 117.6 (d, 3JC,F = 23.1 Hz, 5-Ar-CH), 125.7 (CH), 129.1 (Ar-C), 130.8
(d, JC,F = 8.1 Hz, 6-Ar-CH), 132.4 (Ar-C), 135.2 (2-Ar-CH), 158.5 (d, 1JC,F = 250.3 Hz, 4-Ar-
CF), 181.6 (C=O), 198.1 (C=S) ppm; EI-MS m/z (%) = 318.9 [M]+ (100 %), 231.9 [fragment]+
(100 %), 151.0 [fragment]+ (40 %), 107.0 [fragment]+ (70 %); HR-MS m/z = 316.8978 [M]+ (cal-
culated: 316.8980); HPLC-Analysis (Method B): 100 %, Rt = 32.6 min.
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(Z)-5-(3-bromo-4-methoxybenzylidene)-2-thioxothiazolidin-4-one 36l [309]
TLC Rf = 0.5 (DCM); Reaction time: 3 h; Purification: Filtration from methanol; Yield: 20
mg of yellow solid (0.06 mmol, 16 %); 1H-NMR (400 MHz, DMSO-d6) δ= 3.93 (s, 3 H, OCH3),
7.30 (d, 1 H, 3JH,H = 8.8 Hz, 4-Ar-CH), 7.60 (dd, 1 H, 3,4JH,H = 2.3, 8.8 Hz, 3-Ar-CH), 7.61 (s,
1 H, CH), 7.88 (d, 1 H, 4JH,H = 2.3 Hz, 6-Ar-CH) ppm; EI-MS m/z (%) = 330.9 [M]+ (100 %),
243.9 [fragment]+ (100 %), 228.9 [fragment]+ (50 %); HR-MS m/z = 328.9177 [M]+ (calculated:
328.9180); HPLC-Analysis (Method B): 99 %, Rt = 18.3 min.
(Z)-N-(4-((4-oxo-2-thioxothiazolidin-5-ylidene)methyl)phenyl)acetamide 36m [310]
TLC Rf = 0.1 (DCM); Reaction time: 2 h; Purification: Filtration from methanol; Yield: 23 mg
of yellow solid (0.08 mmol, 22 %); 1H-NMR (400 MHz, DMSO-d6) δ= 2.08 (s, 3 H, CH3), 7.56
(d, 2 H, 3JH,H = 8.7 Hz, 3,5-Ar-CH), 7.57 (s, 1 H, CH), 7.75 (d, 2 H, 3JH,H = 8.7 Hz, 2,6-Ar-CH),
10.31 (s(br), 1 H, NHAc) ppm; EI-MS m/z (%) = 278.0 [M]+ (100 %), 191.0 [fragment]+ (60 %),
149.0 [fragment]+ (95 %); HR-MS m/z = 278.0180 [M]+ (calculated: 278.0184); HPLC-Analysis
: 99 %, Rt = 37.6 min.
(Z)-5-(4-(dimethylamino)benzylidene)-2-thioxothiazolidin-4-one 36n [268]
TLC Rf = 0.6 (DCM/EtOAc 9:1); Reaction time: 5 h; Purification: Filtration from methanol;
Yield: 10 mg of red solid (0.04 mmol, 10 %); 1H-NMR (400 MHz, DMSO-d6) δ= 3.04 (s, 6 H,
N(CH3)2), 6.83 (d, 2 H, 3JH,H = 8.8 Hz, 3,5-Ar-CH), 7.44 (d, 2 H, 3JH,H = 8.8 Hz, 2,6-Ar-CH),
7.53 (s, 1 H, CH) ppm; ESI-MS m/z (%) = 265.0 [M+H]+ (100 %), 529.1 [2M+H]+ (30 %); HR-
MS m/z = 265.0468 [M+H]+ (calculated: 265.0464); HPLC-Analysis (Method B): 86 %, Rt =
18.6 min.
(Z)-5-(3-nitrobenzylidene)-2-thioxothiazolidin-4-one 36o [268]
Z to E 10:1 ratio; Reaction time: 3 h; Purification: Filtration from methanol; Yield: 35 mg of
yellow solid (0.13 mmol, 35 %); 1H-NMR (400 MHz, DMSO-d6) δ= 7.61 (s, 1 H, E-CH), 7.71 (at,
1 H, 3JH,H = 8.2, 7.9 Hz, E-5-Ar-CH), 7.79 (s, 1 H, Z-CH), 7.82 (at, 1 H, 3JH,H = 8.2, 7.9 Hz, Z-5-
Ar-CH), 7.99 (d, 1 H, 3JH,H = 7.9 Hz, Z-6-Ar-CH), 8.21 (d, 1 H, 3JH,H = 7.9 Hz, E-6-Ar-CH), 8.25
(dd, 1 H, 3,4JH,H = 8.2, 2.1 Hz, E-4-Ar-CH), 8.30 (dd, 1 H, 3,4JH,H = 8.2, 2.1 Hz, Z-4-Ar-CH), 8.43
(at, 1 H, 4JH,H = 2.1 Hz, Z-2-Ar-CH), 8.91 (at, 1 H, 4JH,H = 2.1 Hz, Z-2-Ar-CH), 13.95 (s(br), 1 H,
NH) ppm; 13C-NMR (400 MHz, DMSO-d6) δ= 124.7 (4-Ar-CH), 124.8 (2-Ar-CH), 128.6 (Ar-C),
129.0 (CH) 131.0 (5-Ar-CH), 134.7 (Ar-C), 135.7 (6-Ar-CH), 148.3 (Ar-C), 169.2 (C=O), 195.2
(C=S) ppm; EI-MS m/z (%) = 266.0 [M]+ (100 %), 179.0 [fragment]+ (100 %), 133.0 [fragment]+
(35 %), 89.0 [fragment]+ (40 %); HR-MS m/z = 265.9813 [M]+ (calculated: 265.9820); HPLC-
Analysis (Method B): 94 %, Rt = 17.6 min.
(Z)-5-(4-(methylsulfonyl)benzylidene)-2-thioxothiazolidin-4-one 36p [309]
TLC Rf = 0.4 (DCM/EtOAc 9:1); Reaction time: 6 h; Purification: Re-crystallisation from
ethanol; Yield: 14 mg of yellow crystals (0.05 mmol, 12 %); 1H-NMR (400 MHz, DMSO-d6)
δ= 3.28 (s, 3 H, SO2CH3), 7.73 (s, 1 H, CH), 7.86 (d, 2 H, 3JH,H = 8.5 Hz, 3,5-Ar-CH), 8.05
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(d, 2 H, 3JH,H = 8.5 Hz, 2,6-Ar-CH) ppm; ESI-MS m/z (%) = 317.0 [M+NH4]+ (100 %); HR-MS
m/z = 317.0087 [M+NH4]+ (calculated: 317.0083); HPLC-Analysis (Method B): 99 %, Rt =
19.8 min.
(Z)-4-((4-oxo-2-thioxothiazolidin-5-ylidene)methyl)benzaldehyde 36q [311]
Reaction time: 3 h; Purification: Filtration from methanol; Yield: 30 mg of red solid (0.12
mmol, 32 %); 1H-NMR (400 MHz, DMSO-d6) δ= 7.67 (s, 1 H, CH), 7.81 (d, 2 H, 3JH,H = 8.0 Hz,
3,5-Ar-CH), 8.03 (d, 2 H, 3JH,H = 8.0 Hz, 2,6-Ar-CH) ppm; APCI-MS m/z (%) = 245.0 [M+H]+
(100 %); HR-MS m/z = 249.9991 [M+H]+ (calculated: 249.9995); HPLC-Analysis (Method B):
97 %, Rt = 16.1 min.
(Z)-5-(2-hydroxybenzylidene)-2-thioxothiazolidin-4-one 36r [268]
TLC Rf = 0.3 (DCM/EtOAc 9:1); Reaction time: 4 h; Purification: Filtration from H2O; Yield:
60 mg of yellow solid (0.25 mmol, 67 %); 1H-NMR (400 MHz, CD3OD) δ= , 6.87-6.98 (m, 2 H,
2xAr-CH), 7.27-7.35 (m, 2 H, 2xAr-CH), 8.00 (s, 1 H, CH) ppm; 1H-NMR (400 MHz, DMSO-
d6) δ= 6.93-6.98 (m, 2 H, 2xAr-CH), 7.29-7.35 (m, 2 H, 2xAr-CH), 7.84 (s, 1 H, CH), 10.65
(s(br), 1 H, OH), 13.74 (s(br), 1 H, NH) ppm; 13C-NMR (400 MHz, DMSO-d6) δ= 116.2 (Ar-
CH), 120.0 (Ar-CH), 124.3 (Ar-C), 126.9 (CH), 129.2 (Ar-CH), 132.7 (Ar-CH) 157.5 (C=O),
196.3 (C=S) ppm; ESI-MS m/z (%) = 236.0 [M−H]− (100 %); HR-MS m/z = 235.9840 [M−H]−
(calculated: 235.9845); HPLC-Analysis : 99.9 %, Rt = 30.6 min.
(5Z)-5-[(3-hydroxyphenyl)methylidene]-2- sulfanylidene-1,3-thiazolidin-4-one 36s [312]
TLC Rf = 0.6 (DCM/MeOH 9:1); Reaction time: 3h˙; Purification: Flash-Chromatography
DCM→ DCM/MeOH 9:1 (Rf = 0.1,0.6); Yield: 102 mg of yellow solid (0.43 mmol, 68 %); 1H-
NMR (400 MHz, MeOD) δ= 6.84 (dd, 1 H, 3,4JH,H = 8.1, 2.3 Hz, 4-Ar-CH), 6.89-6.91 (m, 1 H,
2-Ar-CH), 6.96 (d, 1 H, 3JH,H = 7.6 Hz, 6-Ar-CH), 7.27 (at, 1 H, 3JH,H = 8.1, 7.6 (7.9) Hz, 5-Ar-
CH), 7.47 (s, 1 H, CH) ppm; 1H-NMR (400 MHz, DMSO-d6) δ= 6.89 (dd, 1 H, 3,4JH,H = 8.1,
2.4 Hz, 4-Ar-CH), 6.97 (at, 1 H, 4JH,H = 1.9 Hz, 2-Ar-CH), 7.05 (d, 1 H, 3JH,H = 7.7 Hz, 6-Ar-
CH), 7.33 (at, 1 H, 3JH,H = 8.1, 7.7 (7.9) Hz, 5-Ar-CH), 7.53 (s, 1 H, CH), 9.87 (s(br), 1 H, OH),
13.82 (s(br), 1 H, NH) ppm; 13C-NMR (400 MHz, DMSO-d6) δ= 116.2 (2-Ar-CH), 118.1 (4-Ar-
CH), 121.9 (5-Ar-CH), 125.4 (Ar-C), 130.5 (5-Ar-CH), 131.8 (CH), 134.2 (Ar-C), 158.0 (Ar-C),
169.5 (C=O), 195.9 (C=S) ppm; EI-MS m/z (%) = 237.1 [M]+ (100 %), 150.2 [fragment]+ (80 %),
121.2 [fragment]+ (40 %), 59.2 [fragment]+ (100 %); ESI-MS m/z (%) = 236.0 [M−H]− (100 %);
238.0 [M+H]+ (80 %), 260.0 [M+Na]+ (30 %), 734.0 [3M+Na]+ (100 %); ESI-MS m/z (%) = 236.0
[M−H]− (100 %); HR-MS m/z = 235.9843 [M−H]− (calculated: 235.9845). HR-MS m/z =
236.9913 [M]+ (calculated: 236.9918). HR-MS m/z = 237.9981 [M+H]+ (calculated: 237.9991);
HR-MS m/z = 235.9843 [M−H]− (calculated: 235.9845); HPLC-Analysis (Method B): 26.3 %,
Rt = 100 min.
(Z)-5-(4-hydroxybenzylidene)-2-thioxothiazolidin-4-one 36t [268]
Reaction time: 2 h; Purification: Filtration from methanol; Yield: 51 mg of yellow solid (0.21
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mmol, 25 %); 1H-NMR (400 MHz, DMSO-d6) δ= 6.93 (d, 2 H, 3JH,H = 8.5 Hz, 3,5-Ar-CH),
7.47 (d, 2 H, 3JH,H = 8.5 Hz, 2,6-Ar-CH), 7.57 (s, 1 H, CH), 10.43 (s(br), 1 H, OH), 13.70
(s)br), 1 H, NH) ppm; 13C-NMR (400 MHz, DMSO-d6) δ= 116.6 (3,5-Ar-CH), 120.9 (Ar-C),
124.0 (Ar-C), 132.5 (CH), 133.1 (2,6-Ar-CH), 160.4 (Ar-C), 169.5 (C=O), 195.6 (C=S) ppm;
ESI-MS m/z (%) = 238.0 [M+H]+ (100 %), 497.0 [2M+Na]+ (95 %), 734.0 [3M+Na]+ (100 %),
971.0 [4M+Na]+ (15 %); HPLC-Analysis : 97 %, Rt = 28.3 min; EI-MS m/z (%) = 237.2 [M]+
(100 %), 150.1 [fragment]+ (100 %), 121.2 [fragment]+ (50 %), 59.2 [fragment]+ (100 %); HR-
MS m/z = 236.9913 [M]+ (calculated: 236.9918); HR-MS m/z = 237.9981 [M+H]+ (calculated:
237.9991); HPLC-Analysis (Method B): 100 %, Rt = 18.2 min.
(Z)-5-(2,4-dihydroxybenzylidene)-2-thioxothiazolidin-4-one 36u [268]
TLC Rf = 0.1 (DCM/EtOAc 9:1); Reaction time: 2.5 h; Purification: Filtration from methanol;
Yield: 14 mg of red solid (0.06 mmol, 15 %); 1H-NMR (400 MHz, CD3OD) δ= 6.35 (d, 1 H,
4JH,H = 2.4 Hz, 2-Ar-CH), 6.42 (dd, 1 H, 3,4JH,H = 2.4, 8.6 Hz, 4-Ar-CH), 7.18 (d, 1 H, 3JH,H =
8.6 Hz, 5-Ar-CH), 7.97 (s, 1 H, CH) ppm; EI-MS m/z (%) = 253.0 [M]+ (100 %); HPLC-Analysis
(Method B): 99 %, Rt = 21.2 min.
(5Z)-5-[(3,4-dihydroxyphenyl)methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one 36a [93]
TLC Rf = 0.7 (DCM/MeOH 9:1); Reaction time: 16 h; Purification: Filtration from methanol;
Yield: 15 mg of yellow solid (0.06 mmol, 14 %); 1H-NMR (400 MHz, DMSO-d6) δ= 6.88 (d,
1 H, 3JH,H = 8.8 Hz, 5-Ar-CH), 6.97-7.01 (m, 2 H, 2,6-Ar-CH), 7.47 (s, 1 H, CH), 9.54 (s(br),
1 H, OH), 9.96 (s(br), 1 H, OH), 13.67 (s(br), 1 H, NH) ppm; 13C-NMR (400 MHz, DMSO-d6)
δ= 116.5 (5-Ar-CH), 116.6 (2- or 6-Ar-CH), 120.8 (Ar-C), 124.4 (Ar-C), 124.9 (2- or 6-Ar-CH),
132.8 (CH), 146.1 (Ar-C), 149.2 (Ar-C), 169.7 (C=O), 195.7 (C=S) ppm; EI-MS m/z (%) = 253.0
[M]+ (100 %), 166.0 [fragment]+ (100 %). HR-MS m/z = 252.9859 [M]+ (calculated: 252.9867);
HPLC-Analysis (Method B): 99 %, Rt = 21.0 min.
(5Z)-5-[(4-hydroxy-3,5- dimethoxyphenyl)methylidene]-2-sulfanylidene-1,3- thiazolidin-4-one 36v [313]
TLC Rf = 0.5 (DCM/EtOAc 9:1); Reaction time: 4 h; Purification: Filtration from ethanol;
Yield: 460 mg of yellow solid (1.55 mmol, 93 %); 1H-NMR (400 MHz, DMSO-d6) δ= 3.81 (s,
6 H, 2xOCH3), 6.80 (s, 2 H, 2,6-Ar-CH), 7.16 (s, 1 H, CH), 9.00 (s(br), 1 H, NH) ppm; 13C-
NMR (400 MHz, DMSO-d6) δ= 56.0 (2xOCH3), 107.4 (2,6-Ar-CH), 125.4 (CH), 131.5 (Ar-C),
136.9 (Ar-C), 148.1 (2xAr-C), 182.6 (C=O), 201.9 (C=S) ppm; ESI-MS m/z (%) = 298.0 [M+H]+
(100 %), 320.0 [M+Na]+ (75 %), 617.0 [2M+Na]+ (100 %); HR-MS m/z = 298.0207 [M+H]+ (cal-
culated: 298.0202); HPLC-Analysis (Method B): 98 %, Rt = 15.5 min.
4-[(5Z)-4-oxo-2-sulfanylidene-1,3-thiazolidin-5- ylidene]methylbenzaldehyde 104 [311]
Reaction time: 3 h; Purification: Filtration from EtOH; Yield: 30 mg of red solid (0.12 mmol,
32 %); ESI-MS m/z (%) = 250.0 [M+H]+ (100 %); HR-MS m/z = 249.9995 [M+H]+ (calculated:
249.9991).
(Z)-5-(3-(benzyloxy)benzylidene)-2-thioxothiazolidin-4-one 36w [110]
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TLC Rf = 0.2 (DCM); Reaction time: 2 h; Purification: Re-crystallisation from methanol;
Yield: 160 mg of yellow crystals (0.49 mmol, 44 %); 1H-NMR (400 MHz, DMSO-d6) δ= 5.18
(s, 2 H, OCH2), 7.08-7.24 (m, 3 H, 3xAr-CH), 7.29-7.53 (m, 7 H, 7xAr-CH), 7.62 (s, 1 H, CH),
13.84 (s(br), 1 H, NH) ppm; 13C-NMR (400 MHz, DMSO-d6) δ= 69.40 (CH2), 116.4 (Ar-CH),
117.6 (Ar-CH), 122.7 (Ar-CH), 125.9 (Ar-C), 127.8 (2xAr-CH), 128.0 (Ar-CH), 128.5 (2xAr-CH),
130.6 (Ar-CH), 131.5 (CH), 134.3 (Ar-C), 136.7 (Ar-C), 158.8 (Ar-C), 169.3 (C=O), 195.7 (C=S)
ppm; ESI-MS m/z (%) = 328.1 [M+H]+ (25 %), 350.0 [M+Na]+ (15 %), HR-MS m/z = 328.0460
[M+H]+ (calculated: 328.0460); HPLC-Analysis (Method B): 99 %, Rt = 21.4 min.
(Z)-5-(4-(benzyloxy)benzylidene)-2-thioxothiazolidin-4-one 36y [110]
TLC Rf = 0.2 (DCM); Reaction time: 2 h; Purification: Filtration from methanol; Yield: 123
mg of yellow solid (0.38 mmol, 41 %); 1H-NMR (400 MHz, DMSO-d6) δ= 5.20 (s, 2 H, OCH2),
7.19 (d, 2 H, 3JH,H = 8.9 Hz, 3,5-Ar-CH), 7.32-7.48 (m, 5 H, 5xAr-CH), 7.58 (d, 2 H, 3JH,H =
8.9 Hz, 2,6-Ar-CH), 7.62 (s, 1 H, CH); 13C-NMR (400 MHz, DMSO-d6) δ= 69.6 (CH2), 115.9
(3,5-Ar-CH), 122.5 (Ar-C), 125.7 (Ar-C), 127.8 (2xAr-CH) 128.1 (Ar-CH), 128.5 (2xAr-CH),
131.7 (CH), 132.7 (2,6-Ar-CH), 136.4 (Ar-C), 160.4 (Ar-C), 169.6 (C=O), 195.6 (C=S) ppm;
ESI-MS m/z (%) = 328.0 [M+H]+ (100 %), 345.1 [M+NH4]+ (50 %), 350.0 [M+Na]+ (55 %), 672.1
[2M+NH4]+ (25 %), 677.1 [2M+Na]+ (25 %), 999.2 [3M+NH4]+ (15 %); HR-MS m/z = 328.0464
[M+H]+ (calculated: 328.0460); HPLC-Analysis (Method B): 85 %, Rt = 20.6 min.
(Z)-5-(3,4-bis(benzyloxy)benzylidene)-2-thioxothiazolidin-4-one 36z [314]
TLC Rf = 0.3 (Hexane/DCM 2:8); Reaction time: 4 h; Purification: Flash-Chromatogra-
phy Hexane/DCM 2:8 (Rf = 0.3); Yield: 38 mg of yellow solid (0.09 mmol, 23 %); 1H-NMR
(400 MHz, CDCl3) δ= 5.24 (d, 4 H, 2JH,H = 6.8 Hz, 2xCH2), 6.98 (s, 1 H, 1-Ar-CH), 6.99 (d, 1 H,
3JH,H = 8.1 Hz, 3-Ar-CH), 7.05 (d, 1 H, 3JH,H = 8.1 Hz, 4-Ar-CH), 7.31-7.49 (m, 10 H, 10xAr-
CH), 7.52 (s, 1 H, CH), 9.33 (s(br), 1 H, NH) ppm; 13C-NMR (300 MHz, CDCl3) δ= 70.9 (CH2),
71.2 (CH2), 114.1 (Ar-C or Ar-CH), 115.8 (Ar-C or Ar-CH), 126.0 (Ar-C or Ar-CH), 127.1 (Ar-C
or Ar-CH), 127.2 (Ar-C or Ar-CH), 128.1 (Ar-C or Ar-CH), 128.2 (Ar-C or Ar-CH), 128.7 (Ar-C
or Ar-CH), 133.7 (CH) ppm; ESI-MS m/z (%) = 434.1 [M+H]+ (60 %), 451.1 [M+NH4]+ (100 %);
HR-MS m/z = 451.1144 [M]+NH4 (calculated: 451.1145); HPLC-Analysis (Method B): 99 %,
Rt = 22.0 min.
(5Z)-5-(phenylmethylidene)-1,3-thiazolidine-2,4- dione 48o [315]
TLC Rf = 0.4 (Toluene/EtOAc 8:2); Reaction time: 16 h; Purification: Re-crystallisation from
ethanol; Yield: 81 mg of white crystals (0.39 mmol, 42 %); 1H-NMR (400 MHz, MeOD) δ=
7.29-7.59 (m, 5 H, ,)7.90-7.951m0Ar-CH ppm; 1H-NMR (400 MHz, DMSO-d6) δ= 7.29 (s,
1 H, CH), 7.42 (at, 2 H, 3JH,H = 7.7 Hz, 2xAr-CH), 7.52 (d, 2 H, 3JH,H = 7.6 Hz, 2xAr-CH),
7.87-7.92 (m, 1 H, Ar-CH) ppm; 13C-NMR (400 MHz, DMSO-d6) δ= 122.0 (Ar-CH), 127.5
(CH) 127.7 (Ar-CH), 128.7 (Ar-CH), 129.0 (Ar-CH), 129.1 (Ar-CH), 135.9 (Ar-C), 136.4 (Ar-
C), 175.6 (C=O), 182.9 (C=O) ppm; EI-MS m/z (%) = 205.0 [M]+ (100 %), 133.9 [fragment]+
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(100 %); HR-MS m/z = 205.0192 [M]+ (calculated: 205.0192); HPLC-Analysis : 100 %, Rt =
29.9 min;
(Z)-5-(2-methylbenzylidene)thiazolidine-2,4-dione 48a [316]
Reaction time: 16 h; Purification: Re-crystallisation from Ethanol/PE; Yield: 37 mg of white
crystals (0.17 mmol, 31 %); 1H-NMR (400 MHz, CDCl3) δ= 2.45 (s, 3 H, Ar-CH3), 7.27-7.36
(m, 3 H, 3xAr-CH), 7.42-7.45 (m, 1 H, 6-Ar-CH), 8.07 (s, 1 H, CH) ppm; 1H-NMR (400 MHz,
DMSO-d6) δ= 2.39 (s, 3 H, CH3), 7.32-7.38 (m, 3 H, 3xAr-CH), 7.39-7.43 (m, 1 H, Ar-CH), 7.89
(s, 1 H, CH), 12.63 (s(br), 1 H, NH) ppm; 13C-NMR (400 MHz, DMSO-d6) δ= 19.4 (CH3), 125.2
(Ar-C), 126.6 (Ar-CH), 127.1 (Ar-CH), 129.6 (CH), 130.3 (Ar-CH), 131.0 (Ar-CH), 132.1 (Ar-C),
138.7 (Ar-C) 167.1 (C=O), 168.2 (C=O) ppm; ESI-MS m/z (%) = 237.1 [M+NH4]+ (100 %), 456.1
[2M+NH4]+ (25 %); HR-MS m/z = 237.0692 [M+NH4]+ (calculated: 237.0692); HPLC-Analysis
(Method B): 96 %, Rt = 30.2 min.
(Z)-5-(3-methylbenzylidene)thiazolidine-2,4-dione 48b [317]
Reaction time: 16 h; Purification: Re-crystallisation from PE; Yield: 58 mg of white crystals
(0.26 mmol, 45 %); 1H-NMR (400 MHz, CDCl3) δ= 2.41 (s, 3 H, Ar-CH3), 7.25-7.41 (m, 4 H,
4xAr-CH), 7.84 (s, 1 H, CH), 8.45 (s(br), 1 H, NH) ppm; ESI-MS m/z (%) = 237.1 [M+NH4]+
(100 %), 456.1 [2M+NH4]+ (50 %), 675.1 [3M+NH4]+ (10 %); HR-MS m/z = 237.0696 [M+NH4]+
(calculated: 237.0692); HPLC-Analysis : 92 %, Rt = 30.7 min.
(Z)-5-(4-methylbenzylidene)thiazolidine-2,4-dione 48c [318]
TLC Rf = 0.5 (DCM/EtOAc 9:1); Reaction time: 16 h; Purification: Filtration from ethanol;
Yield: 37 mg of white solid (0.17 mmol, 24 %); 1H-NMR (400 MHz, CD3OD) δ= 2.31 (s, 3 H,
Ar-CH3), 7.22 (d, 2 H, 3JH,H = 8.1 Hz, 2,6-Ar-CH), 7.38 (d, 2 H, 3JH,H = 8.1 Hz, 3,5-Ar-CH),
7.54 (s, 1 H, CH) ppm; ESI-MS m/z (%) = 237.1 [M+NH4]+ (100 %), 242.0 [M+Na]+ (10 %),
456.1 [2M+NH4]+ (50 %), 461.1 [2M+Na]+ (30 %); HR-MS m/z = 237.0694 [M+NH4]+ (calcu-
lated: 237.0692); HPLC-Analysis : 99.9 %, Rt = 31.1 min; HPLC-Analysis (Method B): 99 %,
Rt = 12.4 min.
(Z)-5-(2-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione 48d
TLC Rf = 0.2 (CHCl3/EtOAc 9:1); Reaction time: 4 h; Purification: Re-crystallisation from
petroleum ether; Yield: 20 mg of white solid (0.07 mmol, 16 %); 1H-NMR (400 MHz, CDCl3)
δ= 7.55 (at, 1 H, 3JH,H = 7.6 Hz, Ar-CH), 7.61 (d, 1 H, 3JH,H = 7.6 Hz, Ar-CH), 7.64-7.69 (m, 1 H,
Ar-CH), 7.79 (d, 1 H, 3JH,H = 7.9 Hz, 6-Ar-CH), 8.13 (s, 1 H, CH), 8.23 (s(br), 1 H, NH) ppm; 1H-
NMR (400 MHz, DMSO-d6) δ= 7.65-7.74 (m, 2 H, 2xAr-CH), 7.82-7.88 (m, 2 H, Ar-CH, CH),
7.90 (d, 1 H, 3JH,H = 7.8 Hz, 3-Ar-CH), 12.83 (s(br), 1 H, NH) ppm; 13C-NMR (400 MHz, DMSO-
d6) δ= 123.9 (q, 1JC,F = 273.9 Hz, CF3), 126.1 (Ar-CH), 126.8 (q, 3JC,F = 5.6 Hz, 3-Ar-CH),
127.6 (Ar-C), 127.8 (Ar-C), 129.0 (Ar-CH), 130.4 (Ar-CH), 131.4 (Ar-C), 133.5 (CH), 166.8
(C=O), 167.6 (C=O) ppm; APCI-MS m/z (%) = 274.0 [M+H]+ (100 %); HR-MS m/z = 274.0144
[M+H]+ (calculated: 274.0139); HPLC-Analysis : 96 %, Rt = 30.2 min.
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(Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione 48e [317]
TLC Rf = 0.2 (CHCl3/EtOAc 9:1); Reaction time: 6.5 h; Purification: Flash-Chromatography
DCM/EtOAc 9:1 (Rf = 0.4); Yield: 58 mg of white solid (0.21 mmol, 45 %); 1H-NMR (400 MHz,
CDCl3) δ= 7.61-7.72 (m, 3 H, 3xAr-CH), 7.74 (s, 1 H, CH), 7.87 (s, 1 H, 2-CH) ppm; 1H-NMR
(400 MHz, DMSO-d6) δ= 7.70-7.85 (m, 3 H, 3xAr-CH), 7.87 (s, 1 H, 2-Ar-CH), 7.93 (s, 1 H,
CH) 12.71 (s(br), 1 H, NH) ppm; 13C-NMR (400 MHz, DMSO-d6) δ= 123.8 (q, 1JC,F = 272.5 Hz,
CF3), 125.9 (Ar-CH), 126.7 (q, 3JC,F = 32.9 Hz, 2-Ar-CH), 130.0 (q, JC,F = 32.1 Hz, 4-Ar-C)
130.0 (CH), 130.5 (Ar-CH), 132.8 (Ar-CH) 134.2 (Ar-C), 167.1 (C=O), 167.5 (C=O) ppm;
APCI-MS m/z (%) = 274.0 [M+H]+ (100 %), 547.0 [2M+H]+ (15 %); HR-MS m/z = 274.0144
[M+H]+ (calculated: 274.0141); HPLC-Analysis (Method B): 100 %, Rt = 20.4 min.
(Z)-5-(4-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione 48f [317]
Reaction time: 16 h; Purification: Re-crystallisation from PE; Yield: 23 mg of white crystals
(0.08 mmol, 15 %); 1H-NMR (400 MHz, CDCl3) δ= 7.61 (d, 2 H, 3JH,H = 8.2 Hz, 3,5-Ar-CH),
7.74 (d, 2 H, 3JH,H = 8.2 Hz, 2,6-Ar-CH), 7.87 (s, 1 H, CH), 8.37 (s(br), 1 H, NH) ppm; 1H-NMR
(400 MHz, DMSO-d6) δ= 7.81 (d, 2 H, 3JH,H = 8.2 Hz, 3,5-Ar-CH), 7.87 (s, 1 H, CH), 7.89 (d,
2 H, 3JH,H = 8.2 Hz, 2,6-Ar-CH), 12.76 (s(br), 1 H, NH) ppm; 13C-NMR (400 MHz, DMSO-d6) δ=
123.9 (q, 1JC,F = 272.4 Hz, CF3), 126.1 (q, 3JC,F = 3.9 Hz, 2,6-Ar-CH), 126.7 (Ar-C), 129.5 (Ar-
C), 129.8 (CH), 130.5 (3,5-Ar-CH), 137.1 (Ar-C), 167.2 (C=O), 167.6 (C=O) ppm; APCI-MS
m/z (%) = 274.0 [M+H]+ (100 %); HR-MS m/z = 274.0147 [M+H]+ (calculated: 274.0144); HR-MS
m/z = 274.0143 [M+H]+ (calculated: 274.0144); HPLC-Analysis : 99.9 %, Rt = 32.0 min.
(Z)-5-(2-hydroxybenzylidene)thiazolidine-2,4-dione 48g [319]
TLC Rf = 0.1 (DCM/EtOAc 9:1); Reaction time: 16 h; Purification: Filtration from DCM;
Yield: 50 mg of white solid (0.23 mmol, 38 %); 1H-NMR (400 MHz, CD3OD) δ= 6.83 (dd, 1 H,
3,4JH,H = 1.2, 8.2 Hz, 3-Ar-CH), 6.88 (ddd, 1 H, 3,4JH,H = 1.2, 7.4, 8.2 Hz, 5-Ar-CH), 7.22 (ddd,
1 H, 3,4JH,H = 1.6, 7.4, 8.2 Hz, 4-Ar-CH), 7.34 (dd, 1 H, 3,4JH,H = 1.6, 8.2 Hz, 6-Ar-CH) 8.13 (s,
1 H, CH) ppm; 1H-NMR (400 MHz, DMSO-d6) δ= 6.92-6.99 (m, 2 H, 2xAr-CH), 7.28-7.35 (m,
2 H, 2xAr-CH), 8.02 (s, 1 H, CH), 10.51 (s, 1 H, OH), 12.51 (s(br), 1 H, NH) ppm; 13C-NMR
(400 MHz, DMSO-d6) δ= 116.1 (Ar-CH), 119.7 (Ar-CH), 119.9 (Ar-C), 121.9 (Ar-C), 127.0
(CH), 128.3 (Ar-CH), 132.3 (Ar-CH) 157.3 (Ar-C), 167.5 (C=O), 168.2 (C=S) ppm; APCI-MS
m/z (%) = 222.0 [M+H]+ (100 %), 239.0 [M+NH4]+ (5 %); HR-MS m/z = 222.0213 [M+H]+ (calcu-
lated: 222.0219); HPLC-Analysis (Method B): 99 %, Rt = 13.0 min.
(Z)-5-(3-hydroxybenzylidene)thiazolidine-2,4-dione 48h [320]
TLC Rf = 0.3 (DCM/EtOAc 9:1); Reaction time: 16 h; Purification: Filtration from ethanol;
Yield: 38 mg of white solid (0.17 mmol, 31 %); 1H-NMR (400 MHz, CD3OD) δ= 6.76 (dd,
1 H, 3,4JH,H = 8.2, 2.4 Hz, 4-Ar-CH), 6.92-6.94 (m, 1 H, 2-Ar-CH), 6.96 (d, 1 H, 3JH,H = 7.8 Hz,
6-Ar-CH), 7.21 (at, 1 H, 3JH,H = 7.8 Hz, 5-Ar-CH), 7.50 (s, 1 H, CH) ppm; 1H-NMR (400 MHz,
DMSO-d6) δ= 6.79 (dd, 1 H, 3,4JH,H = 8.2, 2.4 Hz, 4-Ar-CH), 6.95-6.97 (m, 1 H, 2-Ar-CH), 6.98
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(d, 1 H, 3JH,H = 7.8 Hz, 6-Ar-CH), 7.26 (at, 1 H, 3JH,H = 7.8 Hz, 5-Ar-CH), 7.43 (s, 1 H, CH),
9.68 (s(br), 1 H, NH) ppm; 13C-NMR (400 MHz, DMSO-d6) δ= 115.6 (2-Ar-CH), 116.4 (4-Ar-
CH), 120.9 (6-Ar-CH), 127.2 (CH), 130.0 (5-Ar-CH), 135.7 (Ar-C), 157.7 (Ar-C), 172.0 (C=O),
175.2 (C=O) ppm; APCI-MS m/z (%) = 222.0 [M+H]+ (100 %); HR-MS m/z = 222.0216 [M+H]+
(calculated: 222.0219); HPLC-Analysis (Method B): 99 %, Rt = 13.0 min.
(Z)-5-(4-hydroxybenzylidene)thiazolidine-2,4-dione 48i [321]
Reaction time: 16 h; Purification: Filtration from ethanol; Yield: 19 mg of white solid (0.09
mmol, 15 %); 1H-NMR (400 MHz, CD3OD) δ= 6.81 (d, 2 H, 3JH,H = 8.6 Hz, 3,5-Ar-CH), 7.35
(d, 2 H, 3JH,H = 8.6 Hz, 2,6-Ar-CH), 7.52 (s, 1 H, CH) ppm; APCI-MS m/z (%) = 222.0 [M+H]+
(100 %), 239.0 [M+NH4]+ (5 %); HR-MS m/z = 222.0216 [M+H]+ (calculated: 222.0219); HPLC-
Analysis (Method B): 99 %, Rt = 12.4 min.
(5Z)-5-[(3,4-dihydroxyphenyl)methylidene]-1,3-thiazolidine-2,4-dione 48p [322]
TLC Rf = 0.2 (CHCl3/MeOH 95:5); Reaction time: 16 h; Purification: Flash-Chromatography
CHCl3/MeOH 95:5 (Rf = 0.2); Yield: 502 mg of white solid (2.12 mmol, 46 %); 1H-NMR (400
MHz, DMSO-d6) δ= 6.76 (d, 1 H, 3JH,H = 8.2 Hz, 5-Ar-CH), 6.81 (dd, 1 H, 3JH,H = 1.9, 8.2 Hz,
6-Ar-CH), 6.96 (d, 1 H, 4JH,H = 1.9 Hz, 2-Ar-CH), 7.11 (s, 1 H, CH) ppm; 13C-NMR (400 MHz,
DMSO-d6) δ= 115.8 (2,5-Ar-CH), 121.8 (6-Ar-CH), 123.1 (CH), 127.2 (Ar-C), 132.1 (Ar-C),
145.3 (Ar-C), 145.9 (Ar-C), 176.0 (C=O), 182.9 (C=O) ppm; ESI-MS m/z (%) = 236.0 [M−H]−
(100 %), 473.0 [2M−H]− (60 %); HR-MS m/z = 236.0023 [M−H]− (calculated: 236.0023).
(5Z)-5-[(4-hydroxy-3,5- dimethoxyphenyl)methylidene]-1,3-thiazolidine-2,4- dione 48k [322]
TLC Rf = 0.4 (DCM/EtOAc 9:1); Reaction time: 4 h; Purification: Filtration from ethanol;
Yield: 130 mg of white solid (0.46 mmol, 47 %); 1H-NMR (400 MHz, DMSO-d6) δ= 3.78 (s,
6 H, 2xOCH3), 6.82 (s, 2 H, 2,6-Ar-CH), 7.21 (s, 1 H, CH), 8.72 (s(br), 1 H, NH) ppm; 13C-
NMR (400 MHz, DMSO-d6) δ= 55.9 (2xOCH3) 106.8 (2,6-Ar-CH), 123.2 (CH), 126.4 (Ar-C),
133.0 (Ar-C), 135.9 (Ar-C), 148.0 (2xAr-C), 175.8 (C=O), 183.1 (C=O) ppm; HPLC-Analysis
(Method B): 99 %, Rt = 12.7 min.
(Z)-5-(3-(benzyloxy)benzylidene)thiazolidine-2,4-dione 48l [323]
TLC Rf = 0.4 (DCM/EtOAc 9:1); Reaction time: 7 h; Purification: Filtration from ethanol;
Yield: 290 mg of white solid (0.93 mmol, 76 %); 1H-NMR (400 MHz, CD3OD) δ= 5.08 (s, 2 H,
CH2), 6.95-6.98 (m, 1 H, Ar-CH), 7.06-7.09 (m, 2 H, 2xAr-CH), 7.22-7.34 (m, 4 H, 4xAr-CH),
7.38-7.41 (m, 2 H, 2xAr-CH), 7.52 (s, 1 H, CH) ppm; 1H-NMR (400 MHz, DMSO-d6) δ= 5.14
(s, 2 H, CH2), 6.99 (dd, 1 H, 3JH,H = 8.2, 2.5 Hz, 4-Ar-CH) 7.12 (d, 1 H, 3JH,H = 7.7 Hz, 6-Ar-
CH), 7.15-7.18 (m, 1 H, 2-Ar-CH), 7.35 (s, 1 H, CH), 7.30-7.42 (m, 4 H, 4xAr-CH), 7.45-7.48
(m, 2 H, 2xAr-CH) ppm; 13C-NMR (400 MHz, DMSO-d6) δ= 69.2 (CH2), 115.0 (4-Ar-CH),
115.2 (2-Ar-CH), 121.8 (6-Ar-CH), 123.9 (5-Ar-CH), 127.8 (2xAr-CH), 127.9 (Ar-CH), 128.5
(2xAr-CH), 129.9 (CH), 134.3 (Ar-C), 136.8 (Ar-C), 136.9 (Ar-C), 158.5 (Ar-C), 172.1 (C=O),
180.0 (C=O) ppmESI-MS m/z (%) = 329.1 [M+NH4]+ (100 %), 640.2 [2M+NH4]+ (60 %), 645.1
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[2M+Na]+ (15 %); HR-MS m/z = 329.0959 [M+NH4]+ (calculated: 329.0954); HPLC-Analysis
(Method B): 94 %, Rt = 17.0 min.
(Z)-5-(4-(benzyloxy)benzylidene)thiazolidine-2,4-dione 48m [320]
TLC Rf = 0.4 (DCM/EtOAc 9:1); Reaction time: 8 h; Purification: Filtration from ethanol;
Yield: 112 mg of white solid (0.36 mmol, 38 %); Yield: 1189 mg of white solid (3.82 mmol,
89 %); 1H-NMR (400 MHz, CD3OD) δ= 5.07 (s, 2 H, CH2), 7.01 (d, 2 H, 3JH,H = 8.9 Hz, 3,5-
Ar-CH), 7.22-7.45 (m, 5 H, 5xAr-CH), 7.43 (d, 2 H, 3JH,H = 8.9 Hz, 2,6-Ar-CH) ppm; 1H-NMR
(400 MHz, DMSO-d6) δ= 5.19 (s, 2 H, CH2), 7.18 (d, 2 H, 3JH,H = 8.9 Hz, 3,5-Ar-CH), 7.31-
7.37 (m, 1 H, 4’-Ar-CH), 7.38-7.43 (m, 2 H, 3,5-Ar-CH), 7.44-7.48 (m, 2 H, 2’,6’-Ar-CH), 7.56
(d, 2 H, 3JH,H = 8.9 Hz, 2,6-Ar-CH), 7.74 (s, 1 H, CH), 12.53 (s(br), 1 H, NH) ppm; 13C-
NMR (400 MHz, DMSO-d6) δ= 69.5 (CH2), 115.7 (3,5-Ar-CH), 125.8 (Ar-C), 127.9 (2’,6’-Ar-
CH), 128.0 (4’-Ar-CH), 128.5 (3,5-Ar-CH), 131.1 (CH), 132.0 (2,6-Ar-CH), 136.5 (Ar-C), 160.0
(C=O), 168.2 (C=O) ppm; ESI-MS m/z (%) = 329.1 [M+NH4]+ (100 %), 334.1 [M+Na]+ (20 %),
640.2 [2M+NH4]+ (100 %), 645.1 [2M+Na]+ (55 %); HR-MS m/z = 329.0958 [M+NH4]+ (calcu-
lated: 329.0954); HPLC-Analysis (Method B): 99 %, Rt = 19.1 min.
(Z)-5-(3,4-bis(benzyloxy)benzylidene)thiazolidine-2,4-dione 48n [324]
TLC Rf = 0.3 (DCM/EtOAc 9:1); Reaction time: 6 h; Purification: Flash-Chromatography
DCM/EtOAc 9:1 (Rf = 0.3); Yield: 94 mg of white solid (0.23 mmol, 29 %); 1H-NMR (400 MHz,
CDCl3) δ= 5.23 (s, 2 H, CH2), 5.25 (s, 2 H, CH2), 6.98 (d, 1 H, 3JH,H = 8.5 Hz, 6-Ar-CH), 7.00
(d, 1 H, 4JH,H = 2.1 Hz, 3-Ar-CH), 7.05 (dd, 1 H, 3,4JH,H = 2.1, 8.5 Hz, 5-Ar-CH), 7.30-7.47 (m,
10 H, 10xAr-CH), 7.70 (s, 1 H, CH), 8.22 (s(br), 1 H, NH) ppm; 13C-NMR (400 MHz, CDCl3)
δ= 71.0 (CH2), 71.4 (CH2), 114.2 (Ar-CH), 115.9 (Ar-CH), 119.7 (Ar-C), 125.5 (Ar-CH), 126.2
(Ar-C), 127.3 (2xAr-CH), 128.3 (2xAr-CH), 128.8 (2xAr-CH), 134.6 (CH), 136.4 (Ar-C), 136.6
(Ar-C), 148.9 (Ar-C), 151.4 (Ar-C), 166.8 (C=O), 167.4 (C=O) ppm; ESI-MS m/z (%) = 435.1
[M+NH4]+ (100 %), 852.2 [2M+NH4]+ (35 %), 858.2 [2M+Na]+ (10 %); HR-MS m/z = 435.1372
[M+NH4]+ (calculated: 435.1373); HPLC-Analysis : 100 %, Rt = 31.1 min.
(5Z)-3-amino-5-(phenylmethylidene)-2-sulfanylidene-1,3-thiazolidin-4-one 54a [85]
TLC Rf = 0.3 (DCM/EtOAc 10:1); Reaction time: 4 h; Purification: Re-crystallisation from
methanol; Yield: 629 mg of orange crystals (2.66 mmol, 79 %); 1H-NMR (400 MHz, DMSO-
d6) δ= 5.95 (s, 2 H, NH2), 7.50-7.59 (m, 3 H, 3 x Ar-CH), 7.63-7.68 (m, 2 H, 2 x Ar-CH), 7.86
(s, 1 H, C-H) ppm; 13C-NMR (300 MHz, DMSO-d6) δ= 120.4 (C), 129.6 (2 x Ar-CH), 130.9 (2
x Ar-CH), 131.1 (Ar-CH), 133.1 (Ar-C), 133.5 (CH), 163.9 (C=O), 188.0 (C=S) ppm; ESI-MS
m/z (%) = 237.0 [M+H]+ (55 %), 259.0 [M+Na]+ (45 %), 495.0 [2M+Na]+ (100 %), HR-MS m/z =
237.0153 [M+H]+ (calculated: 237.0151), 495.0043 [2M+Na]+ (calculated: 495.0048); HPLC-
Analysis (Method B): 97 %, Rt = 16.4 min.
(Z)-3-amino-5-(2-methylbenzylidene)-2-thioxothiazolidin-4-one 54b
TLC Rf = 0.8 (DCM/MeOH 90:5); Reaction time: 4 h; Purification: Filtration from methanol;
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Yield: 56 mg of yellow solid (0.22 mmol, 32 %); 1H-NMR (400 MHz, DMSO-d6) δ= 2.43 (s,
3 H, CH3), 5.95 (s, 2 H, NH2), 7.35-7.45 (m, 4 H, 4xAr-CH), 7.93 (s, 1 H, CH) ppm; 13C-NMR
(400 MHz, DMSO-d6) δ= 19.4 (CH3), 121.8 (Ar-C), 126.9 (Ar-CH), 127.8 (Ar-CH), 130.9 (Ar-
CH), 131.1 (Ar-CH), 131.2 (CH), 132.0 (Ar-C), 139.3 (Ar-C), 163.4 (C=O), 188.4 (C=S) ppm;
ESI-MS m/z (%) = 251.0 [M+H]+ (75 %), 273.0 [M+Na]+ (50 %), 523.0 [2M+Na]+ (100 %). HR-
MS m/z = 251.0310 [M+H]+ (calculated: 251.0307); HPLC-Analysis (Method B): 99 %, Rt =
17.3 min.
(Z)-3-amino-5-(3-methylbenzylidene)-2-thioxothiazolidin-4-one 54c
TLC Rf = 0.8 (DCM/MeOH 90:5); Reaction time: 20 min; Purification: Filtration from methanol;
Yield: 125 mg of yellow solid (0.50 mmol, 70 %); 1H-NMR (400 MHz, DMSO-d6) δ= 2.38 (0,
3 H, ,J = 0, CH3 Hz, ) 5.95 (s, 2 H, NH2), 7.30-7.51 (m, 4 H, 4xAr-CH), 7.81 (s, 1 H, C-H)
ppm; 13C-NMR (400 MHz, DMSO-d6) δ= 20.9 (CH3), 120.1 (Ar-C), 128.0 (Ar-CH), 129.4 (Ar-
CH), 131.1 (Ar-CH), 131.8 (Ar-CH), 133.0 (Ar-C), 133.5 (CH), 138.9 (Ar-C) 163.7 (C=O), 187.8
(C=S) ppm; ESI-MS m/z (%) = 251.0 [M+H]+ (100 %), 268.1 [M+NH4]+ (45 %), 518.1 [2M+NH4]+
(70 %), 523.0 [2M+Na]+ (50 %), HR-MS m/z = 251.0309 [M+H]+ (calculated: 251.0307); HPLC-
Analysis (Method B): 99 %, Rt = 17.3 min.
(5Z)-3-amino-5-[(4-methylphenyl)methylidene]-2- sulfanylidene-1,3-thiazolidin-4-one 54d [85]
TLC Rf = 0.8 (DCM/MeOH 90:5); Reaction time: 20 min; Purification: Filtration from methanol;
Yield: 124 mg of yellow solid (0.50 mmol, 74 %); 1H-NMR (400 MHz, DMSO-d6) δ= 2.35 (s,
3 H, CH3), 5.93 (s, 2 H, NH2), 7.36 (d, 2 H, 3JH,H = 8.0 Hz, 3,5-Ar-CH), 7.54 (d, 2 H, 3JH,H =
8.0 Hz, 2,6-Ar-CH), 7.81 (s, 1 H, CH) ppm; 13C-NMR (400 MHz, DMSO-d6) δ= 21.2 (CH3),
119.0 (Ar-C), 130.2 (3,5-Ar-CH), 130.3 (Ar-C), 130.9 (2,6-Ar-CH), 133.5 (CH), 141.6 (Ar-C),
163.8 (C=O), 187.6 (C=S) ppm; ESI-MS m/z (%) = 251.0 [M+H]+ (100 %), 268.1 [M+NH4]+
(45 %), 518.1 [2M+NH4]60 (; %) HR-MS m/z = 251.0309 [M+H]+ (calculated: 251.0307); HPLC-
Analysis (Method B): 99 %, Rt = 17.8 min.
(Z)-3-amino-2-thioxo-5-(2-(trifluoromethyl)benzylidene)thiazolidin-4-one 54e
TLC Rf = 0.6 (Cyclohexane/EtOAc 7:3); Reaction time: 16 h; Purification: Flash-Chroma-
tography Cyclohexane/EtOAc 7:3 (Rf = 0.6); Yield: 12 mg of orange solid (0.04 mmol, 12 %);
1H-NMR (300 MHz, CD3OD) δ= 6.89 (d, 1 H, 3JH,H = 8.1 Hz, 2-Ar-CH), 6.94 (at, 1 H, 3JH,H =
7.6, 8.1 Hz, 3-Ar-CH), 7.28 (at, 1 H, 3JH,H = 7.6, 8.1 Hz, 4-Ar-CH), 7.40 (d, 1 H, 3JH,H = 8,1 Hz,
5-Ar-CH), 8.19 (s, 1 H, CH) ppm; HPLC-Analysis (Method B): 99 %, Rt = 11.5 min.
(5Z)-3-amino-2-sulfanylidene-5-[3-(trifluoromethyl)phenyl]methylidene-1,3-thiazolidin-4-one 54f
TLC Rf = 0.3 (Hexane/EtOAc 6:4); Yield: 250 mg of yellow solid (0.82 mmol, 78 %); Reac-
tion time: 12 h Purification: Flash-Chromatography Hexane/EtOAc 7.5:2.5 (Rf = 0.2); 1H-
NMR (400 MHz, DMSO-d6) δ= 5.96 (s, 2 H, NH2), 7.77-7.82 (m, 1 H, Ar-CH), 7.83-7.93 (m,
2 H, 2xAr-CH), 7.98 (s, 1 H, CH), 8.06 (s, 1 H, Ar-CH) ppm; 13C-NMR (400 MHz, DMSO-d6)
δ= 122.6 (Ar-CH), 123.8 (q, 1JC,F = 272.7 Hz, CF3), 127.1 (q, 3JC,F = 3.7 Hz, Ar-CH), 127.7
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(q, 3JC,F = 3.8 Hz, Ar-CH), 130.1 (q, 2JC,F = 32.3 Hz, Ar-C), 130.7 (Ar-CH), 131.4 (CH) 163.7
(C=O), 187.6 (C=S) ppm; ESI-MS m/z (%) = 305.0 [M+H]+ (6 %); HPLC-Analysis (Method B):
100 %, Rt = 18.2 min.
(Z)-3-amino-2-thioxo-5-(4-(trifluoromethyl)benzylidene)thiazolidin-4-one 54g
TLC Rf = 0.1 (CHCl3); Reaction time: 4 h; Purification: Flash-Chromatography CHCl3
(Rf = 0.1); Yield: 50 mg of yellow solid (0.16 mmol, 41 %); 1H-NMR (400 MHz, CDCl3) δ=
5.24 (s(br), 1 H, NH2), 7.62 (d, 2 H, 3JH,H = 8.1 Hz, 3,5-Ar-CH), 7.75 (d, 2 H, 3JH,H = 8.1 Hz,
2,6-Ar-CH), 7.82 (s, 1 H, CH) ppm; 13C-NMR (400 MHz, CDCl3) δ= 123.1 (Ar-C or Ar-CH),
126.3 (2J1−ArC,CF3=3.8 Hz, 1-ArC), 130.7 (Ar-C or Ar-CH), 132.0 (Ar-C or Ar-CH), 132.1 (Ar-C
or Ar-CH), 136.3 (Ar-C or Ar-CH), 163.3 (C=O), 186.1 (C=S) ppm; ESI-MS m/z (%) = 322.0
[M+NH4]+ (100 %); HR-MS m/z = 322.9936 [M+NH4]+ (calculated: 322.0290); HPLC-Analysis
: 99.9 %, Rt = 32.1 min; HPLC-Analysis (Method B): 100 %, Rt = 21.1 min.
(Z)-3-amino-5-(4-chlorobenzylidene)-2-thioxothiazolidin-4-one 54h [325]
Reaction time: 4 h; Purification: Filtration from methanol; Yield: 227 mg of yellow solid (0.84
mmol, 50 %); 1H-NMR (400 MHz, DMSO-d6) δ= 5.95 (s, 2 H, NH2), 7.60-7.64 (m, 2 H, 2 x Ar-
CH), 7.66-7.70 (m, 2 H, 2 x Ar-CH), 7.86 (s, 1 H, CH), ppm; 13C-NMR (300 MHz, DMSO-d6)
δ= 121.2 (C), 129.7 (2 x Ar-CH), 132.0 (CH), 132.5 (2 x Ar-CH), 135.8 (Ar-C), 164.0 (C=O),
187.8 (C=S) ppm; ESI-MS m/z (%) = 293.0 [M+na]+ (100 %), 562.9 [2M+Na]+ (100 %); EI-MS
m/z (%) = 270.2 [M]+ (100 %), 170.2 [fragment]+ (40 %), 168.2 [fragment]+ (100 %); HR-MS m/z =
292.9586 [M+Na]+ (calculated: 292.9581); HPLC-Analysis (Method B): 98 %, Rt = 18.5 min.
(5Z)-3-amino-5-[(3-bromo-4-fluorophenyl)methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one 54i
Reaction time: 4 H; Purification: Filtration from methanol; Yield: 444 mg of yellow solid
(1.33 mmol, 79 %); 1H-NMR (400 MHz, DMSO-d6) δ= 5.95 (s, 2 H, NH2), 7.56 (t, 1 H, 3JH,H =
8.7 Hz, 5-Ar-CH), 7.67 (ddd, 1 H, 3,4JH,H(F) = 8.7, 4.7, 2.3 Hz, 6-Ar-CH), 7.85 (s, 1 H, CH),
8.05 (dd, 1 H, 4JH,H(F) = 6.7, 2.3 Hz, 2-Ar-CH); ppm; 13C-NMR (300 MHz, DMSO-d6) δ= 117.9
(Ar-C or Ar-CH), 121.7 (Ar-C or Ar-CH), 130.8 (Ar-C or Ar-CH), 131.6 (CH), 136.3 (Ar-C or
Ar-CH), 163.7 (C=O), 187.6 (C=S), ppm; ESI-MS m/z (%) = 330.9 [M−H]− (100 %), 664.8
[2M−H]− (40 %); EI-MS m/z (%) = 334.1 [M]+ (100 %); HR-MS m/z = 332.9096 [M−H]− (cal-
culated: 332.8994), 664.8066 [2M−H]− (calculated: 664.8084); HR-MS m/z = 331.9085 [M]−
(calculated: 331.9089); HPLC-Analysis (Method B): 98 %, Rt = 18.5 min.
(Z)-3-amino-5-(3-bromo-4-methoxybenzylidene)-2-thioxothiazolidin-4-one 54j
TLC Rf = 0.2 (DCM); Reaction time: 4 h; Purification: Flash-Chromatography DCM →
DCM/MeOH 9:0.01 (Rf = 0.2, 0.3); Yield: 201 mg of yellow solid (0.58 mmol, 34 %); 1H-NMR
(400 MHz, DMSO-d6) δ= 3.94 (s, 3 H, OCH3), 5.95 (s, 2 H, NH2), 7.31 (d, 1 H, 3JH,H = 8.6 Hz,
5-Ar-CH), 7.65 (dd, 1 H, 3,4JH,H = 8.6, 2.3 Hz, 6-Ar-CH), 7.82 (s, 1 H, C-H), 7.93 (d, 1 H, 3JH,H =
2.3 Hz, 2-Ar-CH) ppm; 13C-NMR (400 MHz, DMSO-d6) δ= 56.8 (OCH3), 111.6 (Ar-C), 113.4
(5-Ar-CH), 118.6 (Ar-C), 127.0 (Ar-C), 131.5 (6-Ar-CH), 132.0 (CH), 135.7 (2-Ar-CH), 157.4
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(Ar-C), 163.7 (C=O), 187.2 (C=S) ppm; EI-MS m/z (%) = 344.1 [M]+ (100 %), 242.1 [fragment]+
(80 %), 120.2 [fragment]+ (50 %), 74.1 [fragment]+ (100 %); HR-MS m/z = 343.9279 [M]+ (cal-
culated: 343.9289); HPLC-Analysis (Method B): 95 %, Rt = 18.0 min.
(Z)-3-amino-5-(4-ethynylbenzylidene)-2-thioxothiazolidin-4-one 54k
TLC Rf = 0.3 (DCM/MeOH 1:0.01); Reaction time: 4 h; Purification: Flash-Chromatogra-
phy DCM/MeOH 1:0.01 (Rf = 0.3); Yield: 123 mg of red solid (0.47 mmol, 28 %); 1H-NMR
(400 MHz, DMSO-d6) δ= 4.48 (s, 1 H, Alkyne-CH), 5.95 (s, 2 H, NH2), 7.64 (d, 2 H, 3JH,H =
8.4 Hz, 2,6-Ar-CH), 7.67 (d, 2 H, 3JH,H = 8.4 Hz, 3,5-Ar-CH), 7.86 (s, 1 H, CH) ppm; 13C-
NMR (400 MHz, DMSO-d6) δ= 83.0 (CCH), 84.0 (CCH), 121.4 (Ar-C), 123.9 (Ar-C), 130.9
(3,5-Ar-CH), 132.1 (CH), 132.6 (2,6-Ar-CH), 133.3 (Ar-C), 163.7 (C=O), 187.6 (C=S) ppm;
ESI-MS m/z (%) = 261.0 [M+H]+ (100 %), 278.0 [M+NH4]+ (50 %), 283.0 [M+Na]+ (25 %), 538.0
[2M+NH4]+ (45 %), 798.0 [3M+NH4]+ (10 %); HR-MS m/z = 261.0148 [M]+ (calculated: 261.0151);
HPLC-Analysis (Method B): 100 %, Rt = 17.2 min.
4-[(5Z)-3-amino-4-oxo-2-sulfanylidene-1,3-thiazolidin-5-ylidene]methylbenzonitrile 54l [85]
TLC Rf = 0.1 (DCM); Reaction time: DCM; Purification: Flash-Chromatography DCM (Rf = 0.1);
Yield: 187 mg of orange solid (0.72 mmol, 42 %); 1H-NMR (400 MHz, DMSO-d6) δ= 5.95
(s, 2 H, NH2), 7.80-7.86 (m, 2 H, 2xAr-CH), 7.90 (s, 1 H, C-H), 7.98-8.03 (m, 2 H, 2xAr-CH)
ppm; 13C-NMR (400 MHz, DMSO-d6) δ= 112.4 (Ar-C), 118.3 (Ar-C), 124.0 (Ar-C), 130.9
(CH), 131.0 (2xAr-CH), 133.2 (2xAr-CH), 137.0 (Ar-C), 163.6 (C=O), 187.6 (C=S) ppm; EI-MS
m/z (%) = 261.1 [M]+ (30 %), 159.1[fragment]+ (100 %), 148.1 [fragment]+ (30 %), 74.1 [fragment]+
(100 %); HR-MS m/z = 261.0022 [M]+ (calculated: 261.0197); HPLC-Analysis (Method B):
95 %, Rt = 14.2 min.
(Z)-3-amino-5-(3-nitrobenzylidene)-2-thioxothiazolidin-4-one 54m [85]
TLC Rf = 0.1 (DCM); Reaction time: 4 h; Purification: Flash-Chromatography DCM (Rf = 0.1);
Yield: 327 mg of orange solid (1.16 mmol, 69 %); 1H-NMR (400 MHz, DMSO-d6) δ= 5.97 (s,
2 H, NH2), 7.84 (at, 1 H, 3JH,H = 8.1 Hz, 5-Ar-CH), 8.04 (s, 1 H, C-H), 8.06 (d, 1 H, 3JH,H =
8.1 Hz, 6-Ar-CH), 8.32-8.36 (m, 1 H, 4-Ar-CH), 8.51-8.53 (m, 1 H, 2-Ar-CH) ppm; EI-MS
m/z (%) = 281.0 [M]+ (100 %), 179.0 [fragment]+ (100 %), 133.0 [fragment]+ (30 %), 89.0 [fragment]+
(40 %); HR-MS m/z = 280.9919 [M]+ (calculated: 280.9929); HPLC-Analysis (Method B):
98 %, Rt = 15.7 min.
N-(4-[(5Z)-3-amino-4-oxo-2-sulfanylidene-1,3-thiazolidin-5-ylidene]methylphenyl)acetamide 54n
Reaction time: 4 h; Purification: Filtration from methanol; Yield: 335 mg of red solid (1.14
mmol, 68 %); 1H-NMR (400 MHz, DMSO-d6) δ= 2.08 (s, 3 H, CH3), 5.93 (s, 2 H, NH2), 7.58
(d, 2 H, 3JH,H = 8.6 Hz, 2 x Ar-CH), 7.73-7.78 (m, 3 H, 2 x Ar-CH, CH), 10.31 (s, 1 H, NH)
ppm; 13C-NMR (300 MHz, DMSO-d6) δ= 24.1 (CH3), 117.8 (C), 119.3 (2 x Ar-CH), 127.5
(Ar-C), 132.2 (2 x Ar-CH), 133.4 (CH), 142.1 (Ar-C), 163.9 (C=O), 169.1 (C=O Ac), 187.5
(C=S), ppm; ESI-MS m/z (%) = 294.0 [M+H]+ (100 %), 316.0 [M+Na]+ (80 %), 609.0 [2M+Na]+
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(65 %), 902.1 [3M+Na]+ (10 %); HR-MS m/z = 294.0369 [M+H]+ (calculated: 294.0365); HPLC-
Analysis (Method B): 97 %, Rt = 16.4 min.
(Z)-3-amino-5-(4-(dimethylamino)benzylidene)-2-thioxothiazolidin-4-one 54o [85]
Reaction time: 4 h; Purification: Filtration from methanol; Yield: 20 mg of red solid (0.07
mmol, 21 %); 1H-NMR (400 MHz, DMSO-d6) δ= 3.05 (s, 6 H, N(CH3)2), 5.96 (s, 2 H, NH2),
6.85 (d, 2 H, 3JH,H = 9.0 Hz, 3,5-Ar-CH), 7.50 (d, 2 H, 3JH,H = 9.0 Hz, 2,6-Ar-CH), 7.74 (s,
1 H, CH) ppm; 13C-NMR (400 MHz, DMSO-d6) δ= 39.6 (N(CH3)2), 111.7 (Ar-C), 112.3 (3,5-
Ar-CH), 119.9 (Ar-C), 133.4 (2,6-Ar-CH), 135.0 (CH), 152.0 (Ar-C) 163.7 (C=O), 186.0 (C=S)
ppm; ESI-MS m/z (%) = 280.1 [M+H]+ (100 %), 302.0 [M+Na]+ (15 %); HR-MS m/z = 280.0576
[M+H]+ (calculated: 280.0573); HPLC-Analysis (Method B): 92 %, Rt = 17.2 min.
(5Z)-3-amino-5-[(2-hydroxyphenyl)methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one 54p [305]
TLC Rf = 0.8 (DCM/EtOAc 9:1); Reaction time: 4 h; Purification: Filtration from ethanol;
Yield: 276 mg of yellow solid (1.09 mmol, 65 %); 1H-NMR (400 MHz, DMSO-d6) δ= 4.32 (s,
2 H, NH2), 6.96 (at, 1 H, 3JH,H = 7.8, 7.3 Hz, 5-Ar-CH), 6.99 (d, 1 H, 3JH,H = 8.4 Hz, 3-Ar-CH),
7.47 (ddd, 1 H, 3,4JH,H = 8.4, 7.3, 1.7 Hz, 4-Ar-CH), 7.83 (dd, 1 H, 3,4JH,H = 7.8, 1.7 Hz, 6-Ar-
CH), 8.96 (s, 1 H, CH), 10.69 (s, 1 H, OH) ppm; 13C-NMR (400 MHz, DMSO-d6) δ= 116.8 (3-
Ar-CH), 117.7 (Ar-C), 119.7 (5-Ar-CH), 128.6 (6-Ar-CH), 134.8 (4-Ar-CH), 158.7 (CH), 167.1
(Ar-C), 169.8 (C=O), 197.2 (C=S) ppm; ESI-MS m/z (%) = 270.0 [M+NH4]+ (100 %); HR-MS
m/z = 270.0369 [M+NH4]+ (calculated: 270.0365); HPLC-Analysis (Method B): 100 %, Rt =
18.7 min.
(5Z)-3-amino-5-[(3-hydroxyphenyl)methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one 54q
Reaction time: 4 H; Purification: Re-crystallisation from methanol; Yield: 136 mg of orange
crystals (0.54 mmol, 32 %); 1H-NMR (400 MHz, DMSO-d6) δ= 5.94 (s, 2 H, NH2), 6.92 (dd,
1 H, 3,4JH,H = 8.1, 1.7 Hz, Ar-CH), 7.01-7.04 (m, 1 H, Ar-CH), 7.09 (d, 1 H, 3JH,H = 7.8 Hz, Ar-
CH), 7.34 (at, 1 H, 3JH,H = 7.8 Hz, Ar-CH), 7.74 (s, 1 H, C-H), 10.26 (s, 1 H, OH) ppm; 13C-NMR
(300 MHz, DMSO-d6) δ= 116.5 (C), 118.5 (Ar-C o. Ar-CH), 120.2 (Ar-C o. Ar-CH), 122.3 (Ar-
C o. Ar-CH), 130.7 (Ar-CH), 133.7 (CH), 134.3 (Ar-C o. Ar-CH), 158.2 (3-Ar-C), 163.9 (C=O),
188.0 (C=S) ppm; ESI-MS m/z (%) = 251.0 [M−H]− (75 %), 503.0 [2M−H]− (100 %), 755.0
[3M−H]− (20 %); HR-MS m/z = 250.9950 [M−H]− (calculated: 250.9954); HPLC-Analysis
(Method B): 98 %, Rt = 15.7 min.
(5Z)-3-amino-5-[(4-hydroxyphenyl)methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one 54r [305]
Reaction time: 4 h; Purification: Re-crystallisation from methanol; Yield: 134 mg of red
crystals (0.53 mmol, 31 %); 1H-NMR (400 MHz, DMSO-d6) δ= 5.94 (s, 2 H, NH2), 6.89 (d, 2 H,
3JH,H = 8.7 Hz, 2 x Ar-CH), 7.49 (d, 2 H, 3JH,H = 8.7 Hz, 2 x Ar-CH), 7.74 (s, 1 H, C-H) ppm;
13C-NMR (300 MHz, DMSO-d6) δ= 114.2 (Ar-CH or Ar-C), 117.1 (C), 123.5 (Ar-CH or Ar-C),
133.7 (CH), 133.9 (Ar-CH or Ar-C), 134.5 (Ar-CH or Ar-C), 134.8 (Ar-CH or Ar-C), 162.0 (4-
Ar-C), 163.9 (C=O), 187.1 (C=S) ppm; EI-MS m/z (%) = 252.0 [M]+ (100 %), 150.0 [fragment]+
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(100 %); HPLC-Analysis (Method B): 97 %, Rt = 13.9 min.
(5Z)-3-amino-5-[(2,4-dihydroxyphenyl)methylidene]-2- sulfanylidene-1,3-thiazolidin-4-one 54s
Reaction time: 4 h; Purification: Filtration from methanol; Yield: 251 mg of red solid (0.94
mmol, 55 %); 1H-NMR (400 MHz, DMSO-d6) δ= 5.93 (s, 2 H, NH2), 6.42-6.43 (m, 1 H, 3-Ar-
CH), 6.43 (dd, 1 H, 3,4J6,5(3) = 2.3, 7.5 Hz, 6-Ar-CH), 7.22 (dd, 1 H, 3,4J5,6(3) = 7.5, 2.1 Hz,
5-Ar-CH), 7.97 (s, 1 H, C-H), 10.48 (s, 1 H, OH), 10.69 (s, 1 H, OH) ppm; 13C-NMR (300 MHz,
DMSO-d6) δ= 102.6 (3-Ar-CH), 109.1 (6-Ar-CH), 112.1 (1-Ar-C o. C), 113.4 (1-Ar-C o. C),
130.0 (CH), 131.9 (5-Ar-CH), 160.2 (2- o. 4-Ar-C), 163.0 (2- o. 4-Ar-C), 164.1 (C=O), 187.2
(C=S) ppm; ESI-MS m/z (%) = 267.0 [M−H]− (100 %), 535.0 [2M−H]− (85 %), 803.0 [3M−H]−
(10 %), 269.0 [M+H]+ (100 %), 559.0 [2M+Na]+ (30 %); HR-MS m/z = 266.9900 [M−H]− (cal-
culated: 266.9904), HR-MS m/z = 269.0051 [M+H]+ (calculated: 269.0049); HPLC-Analysis
(Method B): 98 %, Rt = 16.2 min.
(Z)-3-amino-5-(3,4-dihydroxybenzylidene)-2-thioxothiazolidin-4-one 54t
TLC Rf = 0.2 (DCM/MeOH 9:1); Purification: Filtration from methanol; Yield: 13 mg of yellow
solid (0.05 mmol, 14 %); 1H-NMR (400 MHz, CD3OD) δ= 6.89 (d, 1 H, 3JH,H = 8.1 Hz, 5-Ar-
CH), 7.01 (dd, 1 H, ,JH,H = 2.1, 8.1 Hz, 3,4) 7.03 (d, 1 H, 4JH,H = 2.1 Hz, 3-Ar-CH), 7.67 (s,
1 H, CH) ppm; EI-MS m/z (%) = 268.0 [M]+ (100 %), 166.0 [fragment]+ (100 %); HR-MS m/z =
267.9971 [M]+ (calculated: 267.9976); HPLC-Analysis : 99 %, Rt = 32.3 min.
(5Z)-3-amino-5-[(4-methoxyphenyl)methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one 54u [85]
Reaction time: 4 h; Purification: Filtration from methanol; Yield: 277 mg of yellow solid (1.04
mmol, 62 %); 1H-NMR (400 MHz, DMSO-d6) δ= 3.84 (s, 3 H, OCH3), 5.94 (s, 2 H, NH2), 7.10-
7.15 (m, 2 H, 2,6-Ar-CH), 7.60-7.65 (m, 2 H, 3,5-Ar-CH), 7.82 (s, 1 H, C-H) ppm; 13C-NMR
(300 MHz, DMSO-d6) δ= 55.6 (OCH3), 115.3 (2,6-Ar-CH), 117.0 (C), 125.7 (1-Ar-C), 133.2
(3,5-Ar-CH), 133.7 (CH), 161.8 (4-Ar-C), 164.0 (C=O), 187.4 (C=S) ppm; ESI-MS m/z (%) =
284.1 [M+NH4]+ (40 %), 550.1 [2M+NH4]+ (100 %); HR-MS m/z = 284.0524 [M+NH4]+ (calcu-
lated: 284.0522), 550.0701 [2M+NH4]+ (calculated: 550.0706); HPLC-Analysis (Method B):
100 %, Rt = 17.2 min.
(5Z)-3-amino-5-[3-(benzyloxy)phenyl]methylidene-2- sulfanylidene-1,3-thiazolidin-4-one 54v
TLC Rf = 0.3 (DCM/EtOAc 10:1); Reaction time: 1 h; Purification: Flash-Chromatography
DCM/EtOAc 10:1 (Rf = 0.3); Yield: 22 mg of yellow solid (0.06 mmol, 10 %); 1H-NMR (400
MHz, CDCl3) δ= 3.97 (s(br), 1 H, NH2), 5.08 (s, 2 H, CH2), 6.97-7.52 (m, 10 H, 10xCH) ppm;
ESI-MS m/z (%) = 343.1 [M+H]+ (100 %), 365.0 [M+Na]+ (30 %), 702.1 [2M+NH4]+ (100 %),
707.1 [2M+Na]+ (50 %), 1044.2 [3M+NH4]+ (25 %), 1049.1 [3M+Na]+ (85 %); HR-MS m/z =
343.0573 [M+H]+ (calculated: 343.0569); HPLC-Analysis (Method B): 19.6 %, Rt = 94 min.
(5Z)-3-amino-5-[4-(benzyloxy)phenyl]methylidene-2-sulfanylidene-1,3-thiazolidin-4-one 54w
TLC Rf = 0.5 (DCM/EtOAc 10:1); Reaction time: 30 min; Purification: Filtration from methanol;
Yield: 145 mg of yellow solid (0.42 mmol, 63 %); 1H-NMR (400 MHz, DMSO-d6) δ= 5.21 (s,
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2 H, CH2), 5.94 (s, 2 H, NH2), 7.18-7.23 (m, 2 H, 2,6-Ar-CH), 7.32-7.49 (m, 5 H, Ar-CH), 7.61-
7.66 (m, 2 H, 3,5-Ar-CH), 7.82 (s, 1 H, C-H) ppm; 13C-NMR (300 MHz, DMSO-d6) δ= 69.6
(CH2), 100.1 (Ar-C), 116.1 (2,6-Ar-underlineCH), 117.2 (C), 125.9 (Ar-C), 128.0, 128.2, 128.6
(5 x Ar-CH), 133.2 (3,5-Ar-CH), 133.7 (CH), 136.6 (Ar-C), 160.9 (4-Ar-C), 164.0 (C=O), 187.5
(C=S) ppm; EI-MS m/z (%) = 342.2 [M]+ (100 %); ESI-MS m/z (%) = 343.1 [M+H]+ (100 %), 365.0
[M+Na]+ (50 %), 707.1 [2M+Na]+ (100 %), 1049.1 [3M+Na]+ (40 %); HR-MS m/z = 343.0573
[M+H]+ (calculated: 343.0569); HR-MS m/z = 365.0393 [M+Na]+ (calculated: 365.0389), 707.0889
[2M+Na]+ (calculated: 707.0892); HPLC-Analysis (Method B): 94 %, Rt = 19.6 min.
(Z)-3-amino-5-(4-(methylsulfonyl)benzylidene)-2-thioxothiazolidin-4-one 54z
Reaction time: 20 min; Purification: Filtration from EtOH; Yield: 76 mg of yellow solid (0.24
mmol, 32 %); 1H-NMR (400 MHz, DMSO-d6) δ= 3.29 (s, 3 H, SO2CH3), 8.07 (d, 2 H, 3JH,H =
8.5 Hz, 3,5-Ar-CH), 8.15 (d, 2 H, 3JH,H = 8.5 Hz, 2,6-Ar-CH), 8.85 (s, 1 H, CH) ppm.
(Z)-3-amino-5-(3,4-bis(benzyloxy)benzylidene)-2-thioxothiazolidin-4-one 54x
TLC Rf = 0.9 (DCM/MeOH 90:5); Reaction time: 20 min; Purification: Filtration from methanol;
Yield: 202 mg of yellow solid (0.45 mmol, 31 %); 1H-NMR (400 MHz, DMSO-d6) δ= 5.23
(s, 2 H, CH2), 5.25 (s, 2 H, CH2), 5.93 (s, 2 H, NH2), 7.23-7.51 (m, 13 H, 13xAr-CH), 7.76
(s, 1 H, CH) ppm; 13C-NMR (400 MHz, DMSO-d6) δ= 69.9 (CH2), 70.0 (CH2), 114.2 (Ar-
CH), 116.0 (Ar-CH), 117.3 (Ar-C), 125.4 (Ar-C), 125.9 (Ar-CH), 127.5 (Ar-CH), 127.6 (Ar-CH),
127.9 (Ar-CH), 128.0 (Ar-CH), 128.5 (Ar-CH), 133.7 (CH), 136.6 (Ar-C), 136.7 (Ar-C), 148.3
(Ar-C), 150.9 (Ar-C), 163.7 (C=O), 187.2 (C=S) ppm; ESI-MS m/z (%) = 449.1 [M+H]+ (100 %),
471.1 [M+Na]+ (20 %), 914.2 [2M+NH4]+ (20 %); HR-MS m/z = 449.0991 [M+H]+ (calculated:
449.0988); HPLC-Analysis (Method B): 99 %, Rt = 17.8 min.
(Z)-5-benzylidene-3-phenyl-2-thioxothiazolidin-4-one 55a [326]
TLC Rf = 0.5 (DCM); Reaction time: 55 min; Purification: Filtration from methanol; Yield:
80 mg of yellow solid (0.27 mmol, 60 %); 1H-NMR (400 MHz, DMSO-d6) δ= 7.41-7.77 (m,
10 H, Ar-CH), 7.86 (s, 1 H, C-H) ppm; 1H-NMR (400 MHz, CDCl3) δ= 7.27-7.32 (m, 2 H, 2xAr-
CH), 7.44-7.61 (m, 8 H, 8xAr-CH), 7.80 (s, 1 H, CH) ppm; 13C-NMR (400 MHz, CDCl3) δ=
123.5 (Ar-C), 128.5 (2xAr-CH), 129.5 (2xAr-CH), 129.7 (2xAr-CH), 129.9 (Ar-CH), 130.8 (2xAr-
CH), 131.0 (Ar-CH), 133.5 (Ar-C), 133.6 (CH), 135.0 (Ar-C), 167.7 (C=O), 193.6 (C=S) ppm;
ESI-MS m/z (%) = 298.0 [M+H]+ (100 %), 320.0 [M+Na]+ (30 %), 336.0 [M+K]+ (25 %), 617.0
[2M+Na]+ (60 %); HR-MS m/z = 298.0358 [M+H]+ (calculated: 298.0355); HPLC-Analysis
(Method B): 99 %, Rt = 20.2 min.
(Z)-5-(2-methylbenzylidene)-3-phenyl-2-thioxothiazolidin-4-one 55b
TLC Rf = 0.7 (DCM); Reaction time: 5 h; Purification: Filtration from methanol; Yield: 13 mg
of yellow solid (0.04 mmol, 17 %); 1H-NMR (400 MHz, CDCl3) δ= 2.49 (s, 3 H, CH3), 7.28-7.37
(m, 5 H, 5xAr-CH), 7.47-7.59 (m, 4 H, 4xAr-CH), 8.02 (s, 1 H, CH) ppm; 13C-NMR (400 MHz,
CDCl3) δ= 20.2 (CH3), 124.8 (Ar-C), 126.9 (Ar-CH) 128.2 (Ar-CH), 128.5 (2xAr-CH), 129.7
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(2xAr-CH), 129.9 (Ar-CH), 131.0 (Ar-CH), 131.4 (CH), 131.6 (Ar-CH) 132.6 (Ar-C), 135.0
(Ar-C), 139.7 (Ar-C) ppm; ESI-MS m/z (%) = 312.1 [M+H]+ (100 %), 329.1 [M+NH4]+ (20 %),
334.0 [M+Na]+ (10 %), 645.1 [2M+Na]+ (100 %); HR-MS m/z = 312.0515 [M+H]+ (calculated:
312.0511); HPLC-Analysis (Method B): 99 %, Rt = 20.9 min.
(Z)-5-(3-methylbenzylidene)-3-phenyl-2-thioxothiazolidin-4-one 55c [327]
Reaction time: 5 h; Purification: Filtration from ethanol; Yield: 24 mg of yellow solid (0.08
mmol, 32 %); 1H-NMR (400 MHz, CDCl3) δ= 2.44 (s, 3 H, CH3), 7.27-7.31 (m, 3 H, 3xAr-CH),
7.35-7.43 (m, 3 H, 3xAr-CH), 7.50-7.60 (m, 3 H, 3xAr-CH), 7.78 (s, 1 H, CH) ppm; 13C-NMR
(400 MHz, CDCl3) δ= 21.6 (CH3), 123.1 (Ar-C), 128.1 (Ar-CH), 128.5 (2xAr-CH), 129.4 (Ar-
CH), 129.7 (2xAr-CH), 129.9 (Ar-CH), 131.5 (Ar-CH), 131.9 (Ar-CH), 133.4 (Ar-C), 133.9 (CH),
135.0 (Ar-C), 139.4 (Ar-C), 167.8 (C=O), 193.8 (C=S) ppm; ESI-MS m/z (%) = 312.1 [M+H]+
(100 %), 329.1 [M+NH4]30 (, %) 645.1 [2M+Na]+ (20 %), 956.1 [3M+Na]+ (5 %); HR-MS m/z =
312.0515 [M+H]+ (calculated: 312.0511); HPLC-Analysis (Method B): 99 %, Rt = 20.9 min.
(Z)-5-(4-methylbenzylidene)-3-phenyl-2-thioxothiazolidin-4-one 55d [328]
Z to E ratio 1:17 Reaction time: 4.5 h; Purification: Filtration from methanol; Yield: 35
mg of yellow solid (0.11 mmol, 47 %); 1H-NMR (400 MHz, CDCl3) δ= 2.38 (s, 3 H, E-CH3)
2.43 (s, 3 H, Z-CH3), 7.16 (s, 1 H, E-CH), 7.20 (d, 2 H, 3JH,H = 8.0 Hz, E-3,5-Ar-CH), 7.30 (d,
2 H, 3JH,H = 8.0 Hz, 3,5-Ar-CH), 7.28-7.34 (m, 2 H, 2xAr-CH), 7.45 (d, 2 H, 3JH,H = 8.0 Hz,
2,6-Ar-CH), 7.48-7.59 (m, 8 H, 8xAr-CH), 7.78 (s, 1 H, CH), 7.97 (d, 2 H, 3JH,H = 8.0 Hz, E-2,6-
Ar-CH) ppm; 13C-NMR (400 MHz, CDCl3) δ= 21.8 (CH3), 122.2 (Ar-C), 128.5 (3,5-Ar-CH),
129.7 (2xAr-CH), 129.8 (Ar-CH), 130.3 (2xAr-CH), 130.8 (Ar-C), 131.0 (2,6-Ar-CH), 133.9
(CH), 135.1 (Ar-C), 142.0 (Ar-C), 167.9 (C=O), 193.7 (C=S) ppm; ESI-MS m/z (%) = 312.1
[M+H]+ (100 %), 329.1 [M+NH4]+ (25 %), 640.1 [2M+NH4]+ (15 %); HR-MS m/z = 312.0513
[M+H]+ (calculated: 312.0511); HPLC-Analysis (Method B): 99 %, Rt = 21.0 min.
(Z)-5-(4-chlorobenzylidene)-3-phenyl-2-thioxothiazolidin-4-one 55e [329]
TLC Rf = 0.7 (DCM); Reaction time: 2 h; Purification: Filtration from methanol; Yield: 37 mg
of yellow solid (0.11 mmol, 46 %); 1H-NMR (400 MHz, CDCl3) δ= 7.29 (d, 2 H, 3JH,H = 7.6 Hz,
3,5-Ar-CH), 7.47-7.60 (m, 5 H, 5xAr-CH), 7.56 (d, 2 H, 3JH,H = 7.6 Hz, 2,6-Ar-CH), 7.74 (s, 1 H,
CH) ppm; 13C-NMR (400 MHz, DMSO-d6) δ= 124.1 (Ar-C) 128.8 (2xAr-CH), 129.4 (2xAr-CH),
129.5 (Ar-C), 129.7 (2xAr-CH), 131.2 (Ar-CH), 132.0 (Ar-CH), 132.2 (2xAr-CH), 135.2 (Ar-C),
135.6 (Ar-C), 166.9 (C=O), 193.7 (C=S) ppm; ESI-MS m/z (%) = 332.0 [M+H]+ (100 %), 685.0
[2M+Na]+ (50 %); HR-MS m/z = 331.9969 [M+H]+ (calculated: 331.9965); HPLC-Analysis
(Method B): 99 %, Rt = 21.1 min.
(Z)-5-(4-ethynylbenzylidene)-3-phenyl-2-thioxothiazolidin-4-one 55f
TLC Rf = 0.8 (DCM); Reaction time: 3 h; Purification: Flash-Chromatography CHCl3 (Rf = 0.5);
Yield: 14 mg of yellow solid (0.04 mmol, 18 %); 1H-NMR (400 MHz, CDCl3) δ= 3.27 (s, 1 H,
Alkyne-CH), 7.27-7.32 (m, 2 H, 2xAr-CH), 7.51 (d, 2 H, 3JH,H = 8.4 Hz, 2,6-Ar-CH), 7.50-7.60
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(m, 3 H, 3xAr-CH), 7.61 (d, 2 H, 3JH,H = 8.4 Hz, 3,5-Ar-CH), 7.76 (s, 1 H, CH) ppm; EI-MS
m/z (%) = 321.0 [M]+ (100 %), 158.0 [fragment]+ (100 %); HR-MS m/z = 321.0277 [M]+ (calcu-
lated: 321.0282); HPLC-Analysis (Method B): 99 %, Rt = 18.8 min.
(Z)-4-((4-oxo-3-phenyl-2-thioxothiazolidin-5-ylidene)methyl)benzonitrile 55g [112]
TLC Rf = 0.7 (DCM); Reaction time: 3 h; Purification: Filtration from ethanol; Yield: 44 mg
of yellow solid (0.14 mmol, 57 %); 1H-NMR (400 MHz, CDCl3) δ= 7.27-7.30 (m, 2 H, 2xAr-CH),
7.51-7.60 (m, 3 H, 3-Ar-CH), 7.64 (d, 2 H, 3JH,H = 8.4 Hz, 3,5-Ar-CH), 7.75 (s, 1 H, CH), 7.79
(d, 2 H, 3JH,H = 8.4 Hz, 2,6-Ar-CH) ppm; EI-MS m/z (%) = 322.0 [M]+ (100 %), 159.0 [fragment]+
(100 %); HR-MS m/z = 322.0228 [M]+ (calculated: 322.0235); HPLC-Analysis (Method B):
99 %, Rt = 18.8 min.
(Z)-5-(3-bromo-4-methoxybenzylidene)-3-phenyl-2-thioxothiazolidin-4-one 55h [112]
TLC Rf = 0.6 (DCM); Reaction time: 4 h; Purification: Filtration from methanol; Yield: 35 mg
of yellow solid (0.09 mmol, 36 %); 1H-NMR (400 MHz, CDCl3) δ= 3.99 (s, 3 H, OCH3), 7.02 (d,
1 H, 3JH,H = 8.6 Hz, 4-Ar-CH), 7.27-7.31 (m, 2 H, 2xAr-CH), 7.48-7.59 (m, 3 H, 3xAr-CH), 7.54-
7.57 (m, 1 H, 3-Ar-CH), 7.67 (s, 1 H, CH), 7.76 (d, 1 H, 4JH,H = 2.3 Hz, 6-Ar-CH) ppm; ESI-MS
m/z (%) = 408.0 [M+H]+ (100 %), 425.0 [M+NH4]+ (50 %), 829.9 [2M+NH4]+ (100 %), 1241.8
[3M+Na]+ (10 %); HR-MS m/z = 405.9563 [M+H]+ (calculated: 405.9566); HPLC-Analysis
(Method B): 99 %, Rt = 21.2 min.
(Z)-N-(4-((4-oxo-3-phenyl-2-thioxothiazolidin-5-ylidene)methyl)phenyl)acetamide 55i [330]
TLC Rf = 0.1 (DCM); Reaction time: 3 h; Purification: Filtration from methanol; Yield: 29
mg of yellow solid (0.08 mmol, 34 %); 1H-NMR (400 MHz, DMSO-d6) δ= 2.10 (s, 3 H, CH3),
7.40-7.43 (m, 2 H, 2xAr-CH), 7.49-7.59 (m, 3 H, 3xAr-CH), 7.66 (d, 2 H, 3JH,H = 8.8 Hz, 3,5-Ar-
CH), 7.77 (s, 1 H, CH), 7.79 (d, 2 H, 3JH,H = 8.8 Hz, 2,6-Ar-CH), 10.35 (s(br), 1 H, NHAc) ppm;
13C-NMR (400 MHz, DMSO-d6) δ= 24.2 (CH3) 119.3 (2,6-Ar-CH), 120.7 (Ar-C), 127.5 (Ar-
C), 128.8 (2xAr-CH) 129.3 (2xAr-CH), 129.4 (Ar-CH), 132.0 (3,5-Ar-CH), 132.6 (CH), 135.3
(Ar-C), 141.8 (Ar-C), 167.1 (C=O), 169.0 (C=O), 193.9 (C=S) ppm; ESI-MS m/z (%) = 355.1
[M+H]+ (100 %), 709.1 [2M+H]+ (15 %), 1085.1 [3M+Na]+ (5 %); HR-MS m/z = 355.0573 [M+H]+
(calculated: 355.0569); HPLC-Analysis (Method B): 99 %, Rt = 18.3 min; HPLC-Analysis :
100 %, Rt = 33.9 min.
(Z)-5-(4-(dimethylamino)benzylidene)-3-phenyl-2-thioxothiazolidin-4-one 55j [329]
mixture of Z to E 4:1 ratio Reaction time: 5 h; Purification: Filtration from methanol; Yield:
8 mg of red solid (0.02 mmol, 10 %); 1H-NMR (400 MHz, CDCl3) δ= 3.08 (s, 6 H, E-N(CH3)2),
3.11 (s, 6 H, Hz, ,)6.732dH,H9.0 HzE-3,5-Ar-CH3, 6.80 (d, 2 H, 3JH,H = 9.0 Hz, Z-3,5-Ar-CH),
7.03 (s, 1 H, E-CH), 7.28-7.31 (m, 2 H, 2xAr-CH), 7.46 (d, 2 H, 3JH,H = 9.0 Hz, Z-2,6-Ar-CH),
7.49-7.58 (m, 3 H, 8xAr-CH), 7.73 (s, 1 H, CH), 8.16 (d, 2 H, 3JH,H = 9.0 Hz, E-2,6-Ar-CH)
ppm; 13C-NMR (400 MHz, CDCl3) δ= 40.5 (CH3) 112.6 (Z-3,5-Ar-CH), 128.6 (Ar-CH), 129.6
(Ar-CH), 133.4 (Z-2,6-Ar-CH), 134.9 (Z-CH) ppm; ESI-MS m/z (%) = 341.1 [M+H]+ (100 %),
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681.1 [2M+H]+ (30 %); HR-MS m/z = 341.0781 [M+H]+ (calculated: 341.0777); HPLC-Analysis
(Method B): 83 %, Rt = 18.4 min.
(Z)-5-(3-nitrobenzylidene)-3-phenyl-2-thioxothiazolidin-4-one 55k
Reaction time: 4 h; Purification: Filtration from methanol; Yield: 16 mg of yellow solid (0.05
mmol, 19 %); 1H-NMR (400 MHz, CDCl3) δ= 7.27-7.32 (m, 2 H, 2xAr-CH), 7.52-7.61 (m, 3 H,
3xAr-CH), 7.72 (at, 1 H, 3JH,H = 8.0 Hz, 5-Ar-CH), 7.81 (s, 1 H, CH), 7.86 (d, 1 H, 3JH,H =
8.0 Hz, 4-Ar-CH), 8.32 (d, 1 H, 3JH,H = 8.0 Hz, 6-Ar-CH), 8.41 (s, 1 H, 2-Ar-CH) ppm; EI-MS
m/z (%) = 342.0 [M]+ (100 %), 179.0 [fragment]+ (100 %); HR-MS m/z = 342.0129 [M]+ (calcu-
lated: 342.0133); HPLC-Analysis (Method B): 99 %, Rt = 19.8 min.
(Z)-5-(2-hydroxybenzylidene)-3-phenyl-2-thioxothiazolidin-4-one 55l [331]
TLC Rf = 0.5 (DCM); Reaction time: 3 h; Purification: Filtration from DCM; Yield: 9 mg of
yellow solid (0.03 mmol, 12 %); 1H-NMR (400 MHz, CD3OD) δ= 6.93 (d, 1 H, 3JH,H = 8.4 Hz,
3-Ar-CH), 6.99 (at, 1 H, 3JH,H = 7.6 Hz, 5-Ar-CH), 7.29-7.37 (m, 3 H, 3xAr-CH), 7.42-7.45 (m,
1 H, Ar-CH), 7.48-7.60 (m, 3 H, 3xAr-CH), 8.17 (s, 1 H, CH) ppm; EI-MS m/z (%) = 313.0 [M]+
(100 %), 178.0 [fragment]+ (90 %), 150.0 [fragment]+ (100 %). HR-MS m/z = 313.0224 [M]+
(calculated: 313.0231); HPLC-Analysis (Method B): 98 %, Rt = 19.9 min.
(Z)-3-amino-2-thioxo-5-(3-(hydroxy)benzylidene)thiazolidin-4-one 55m [112]
TLC Rf = 0.2 (DCM); Reaction time: 3 h; Purification: Flash-Chromatography DCM (Rf = 0.2);
Yield: 11 mg of yellow solid (0.04 mmol, 15 %); 1H-NMR (400 MHz, CDCl3) δ= 5.22 (s(br), 1 H,
OH), 6.95 (dd, 1 H, 3,4JH,H = 2.1, 8.1 Hz, 6-Ar-CH), 7.01 (s, 1 H, 2-Ar-CH), 7.14 (d, 1 H, 3JH,H =
8.1 Hz, 4-Ar-CH), 7.27-7.31 (m, 2 H, 2-Ar-CH), 7.38 (t, 1 H, 3JH,H = 8.1 Hz, 5-Ar-CH), 7.49-
7.59 (m, 3 H, 3xAr-CH), 7.73 (s, 1 H, CH) ppm; ESI-MS m/z (%) = 314.0 [M+H]+ (100 %), 331.1
[M+NH4]+ (30 %), 649.0 [2M+Na]+ (80 %), 962.1 [3M+Na]+ (20 %); HR-MS m/z = 314.0307
[M+H]+ (calculated: 314.0304); HPLC-Analysis (Method B): 98 %, Rt = 18.7 min.
(Z)-5-(4-hydroxybenzylidene)-3-phenyl-2-thioxothiazolidin-4-one 55n [112]
Reaction time: 2 h; Purification: Filtration from methanol; Yield: 17 mg of yellow solid (0.05
mmol, 23 %); 1H-NMR (400 MHz, DMSO-d6) δ= 6.97 (d, 2 H, 3JH,H = 8.4 Hz, 3,5-Ar-CH), 7.40
(d, 2 H, 3JH,H = 8.4 Hz, 2,6-Ar-CH), 7.49-7.60 (m, 5 H, 5 x Ar-CH), 7.76 (s, 1 H, CH), 10.52
(s, 1 H, OH) ppm; ESI-MS m/z (%) = 312.0 [M−H]− (100 %); HR-MS m/z = 312.0155 [M−H]−
(calculated: 312.0158); ESI-MS m/z (%) = 314.0 [M+H]+ (100 %), 649.0 [2M+Na]+ (60 %); HR-
MS m/z = 314.0308 [M+H]+ (calculated: 314.0304); HPLC-Analysis : 100 %, Rt = 34.3 min.
(5Z)-5-[(3,4-dihydroxyphenyl)methylidene]-3-phenyl-2- sulfanylidene-1,3-thiazolidin-4-one 55o [332]
TLC Rf = 0.3 (DCM/EtOAc 9:1); Reaction time: 4 h; Purification: Filtration from ethanol;
Yield: 190 mg of yellow solid (0.58 mmol, 78 %); 1H-NMR (400 MHz, DMSO-d6) δ= 6.91
(d, 1 H, 3JH,H = 8.8 Hz, 5-Ar-CH), 7.07-7.12 (m, 2 H, 2,6-Ar-CH), 7.36-7.43 (m, 2 H, 2xAr-
CH), 7.46-7.59 (m, 3 H, 3xAr-CH), 7.66 (s, 1 H, CH), 9.80 (s(0), 2 H, 2xOH) ppm; 13C-NMR
(400 MHz, DMSO-d6) δ= 116.6 (Ar-CH), 124.4 (Ar-C), 125.4 (Ar-CH), 128.8 (Ar-CH), 129.3
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(Ar-CH), 133.9 (CH), 135.4 (Ar-CH), 137.9 (Ar-C), 146.2 (Ar-CH), 167.0 (C=O), 193.8 (C=S),
ppm; ESI-MS m/z (%) = 330.0 [M+H]+ (100 %), 347.1 [M+NH4]+ (27 %), 676.1 [2M+NH4]+ (32 %),
681.0 [2M+Na]+ (10 %); HPLC-Analysis (Method B): 92 %, Rt = 17.4 min.
(Z)-5-(3-(benzyloxy)benzylidene)-3-phenyl-2-thioxothiazolidin-4-one 55p
TLC Rf = 0.3 (Hexane/DCM 2:8); Reaction time: 4 h; Purification: Flash-Chromatogra-
phy Hexane/DCM 2:8 (Rf = 0.3); Yield: 90 mg of yellow solid (0.23 mmol, 93 %); 1H-NMR
(400 MHz, CDCl3) δ= 5.15 (s, 2 H, CH2), 7.08-7.12 (m, 2 H, 2xAr-CH), 7.14-7.17 (m, 1 H,
1xAr-CH), 7.27-7.59 (m, 11 H, 11xAr-CH), 7.75 (s, 1 H, CH) ppm; 13C-NMR (300 MHz, CDCl3)
δ= 46.5 (CH2), 100.4 (Ar-C or Ar-CH), 116.7 (Ar-C or Ar-CH), 119.5 (Ar-C or Ar-CH), 129.9
(Ar-C or Ar-CH), 133.2 (CH), 158.3 (C=O), 193.3 (C=S) ppm; ESI-MS m/z (%) = 404.1 [M+H]+
(100 %), 824.2 [2M+NH4]+ (75 %), 1232.2 [3M+Na]+ (25 %), 1636.3 [4M+Na]+ (10 %); HR-
MS m/z = 404.0774 [M]+H (calculated: 404.0773); HPLC-Analysis (Method B): 99 %, Rt =
22.0 min.
(Z)-5-(4-(benzyloxy)benzylidene)-3-phenyl-2-thioxothiazolidin-4-one 55q
TLC Rf = 0.6 (DCM); Reaction time: 1 h; Purification: Re-crystallisation from DCM/ethanol;
Yield: 41 mg of yellow solid (0.10 mmol, 21 %); 1H-NMR (400 MHz, DMSO-d6) δ= 5.22 (s,
2 H, CH2Ph), 7.23 (d, 2 H, 3J3(5),2(6) = 9.0 Hz, 3,5-Ar-CH), 7.33-7.45 (m, 5 H, 5xAr-CH), 7.46-
7.59 (m, 5 H, 5xAr-CH), 7.68 (d, 2 H, 3J2(6),3(5) = 9.0 Hz, 2,6-Ar-CH), 7.82 (s, 1 H, C-H) ppm;
1H-NMR (400 MHz, CDCl3) δ= 4.15 (s, 2 H, CH2), 7.10 (d, 2 H, 3JH,H = 8.6 Hz, 3,5-Ar-CH),
7.27-7.31 (m, 2 H, 2xAr-CH), 7.33-7.47 (m, 5 H, 5xAr-CH), 7.51 (d, 2 H, 3JH,H = 8.6 Hz, 2,6-
Ar-CH), 7.53-7.59 (m, 3 H, 3xAr-CH), 7.75 (s, 1 H, CH) ppm; 13C-NMR (400 MHz, CDCL3)
δ= 70.4 (CH2), 100.1 (Ar-C), 109.2 (Ar-C) 116.0 (3,5-Ar-CH), 120.5 (Ar-C), 126.4 (Ar-CH),
127.6 (Ar-CH), 128.5 (2xAr-CH), 128.9 (Ar-CH), 129.7 (Ar-CH), 129.8 (Ar-CH), 133.0 (2,6-
Ar-CH), 133.6 (CH), 135.1 (Ar-C), 136.2 (Ar-CH), 161.1 (Ar-C), 167.9 (C=O), 193.6 (C=S)
ppm; ESI-MS m/z (%) = 404.1 [M+H]+ (100 %), 426.1 [M+Na]+ (70 %), 442.0 [M+K]+ (10 %),
HR-MS m/z = 404.0774 [M+H]+ (calculated: 404.0773); HPLC-Analysis (Method B): 99 %,
Rt = 20.2 min.
(Z)-5-(3,4-bis(benzyloxy)benzylidene)-3-phenyl-2-thioxothiazolidin-4-one 55r [314]
TLC Rf = 0.9 (DCM); Reaction time: 1 h; Purification: Filtration from methanol; Yield: 144
mg of yellow solid (0.28 mmol, 60 %); 1H-NMR (400 MHz, DMSO-d6) δ= 5.25 (s, 2 H, CH2Ph),
5.27 (s, 2 H, CH2Ph), 7.27-7.58 (m, 18 H, Ar-CH), 7.75 (s, 1 H, C-H) ppm; 1H-NMR (400 MHz,
CDCl3) δ= 5.19 (s, 4 H, 2xCH2), 6.90-7.06 (m, 3 H, 3xAr-CH), 7.14-7.51 (m, 15 H, 15xAr-CH),
7.59 (s, 1 H, CH) ppm; 13C-NMR (400 MHz, CDCl3) δ= 71.1 (CH2), 71.4 (CH2), 114.3 (Ar-CH),
116.1 (Ar-CH), 120.8 (Ar-C), 126.2 (Ar-CH), 126.7 (Ar-C), 127.3 (Ar-CH) 127.4 (Ar-CH), 128.3
(Ar-CH), 128.5 (Ar-CH), 128.8 (Ar-CH), 128.9 (Ar-CH), 129.7 (Ar-CH), 129.8 (Ar-CH), 133.8
(CH), 135.1 (Ar-C), 136.4 (Ar-C), 136.6 (Ar-C), 149.1 (Ar-C), 151.6 (Ar-C), 167.8 (C=O), 193.5
(C=S) ppm; ESI-MS m/z (%) = 510.1 [M+H]+ (100 %), 532.1 [M+Na]+ (30 %), 548.1 [M+K]+
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(10 %); HR-MS m/z = 510.1185 [M+H]+ (calculated: 510.1192); ESI-MS m/z (%) = 510.1 [M+H]+
(100 %), 527.1 [M+NH4]+ (8 %), 532.6 [M+Na]+ (12 %); HPLC-Analysis (Method B): 89 %,
Rt = 20.8 min.
9.13 Synthesis of heterocyclic modified rhodanine,
thiazolidine-2,4-dione, N-amino rhodanine and N-phenyl rhodanine
derivatives 56a–d, 57a–d, 58a–i, and 59a–c
(Z)-5-(pyridin-4-ylmethylene)-2-thioxothiazolidin-4-one 36ag [333]
Reaction time: 4-16 h; TLC Rf = 0.1 (hexane/EtOAc 6:4); Purification: Filtration from methanol;
Yield: 93 mg of yellow solid (0.42 mmol, 50 %); Yield: 400 mg of green solid (1.80 mmol,
96 %); 1H-NMR (400 MHz, DMSO-d6) δ= 7.55 (d, 2 H, 3JH,H = 6.2 Hz, 2,6-Pyr-CH), 7.60
(s, 1 H, CH), 8.73 (d, 2 H, 3JH,H = 6.2 Hz, 3,5-Pyr-CH) ppm; ESI-MS m/z (%) = 223.0 [M+H]+
(100 %), 445.1 [2M+H]+ (4 %), 462.2 [2M+NH4]+ (5 %); HPLC-Analysis (Method B): 92 %,
Rt = 16.7 min.
(Z)-5-(pyridin-3-ylmethylene)-2-thioxothiazolidin-4-one 36af [334]
TLC Rf = 0.4 (DCM); Reaction time: 4 h; Purification: Filtration from methanol; Yield:
97 mg of yellow solid (0.44 mmol, 52 %); 1H-NMR (400 MHz, DMSO-d6) δ= 7.56 (dd, 1 H,
3JH,H = 4.7, 7.9 Hz, 4-Ar-CH), 7.61 (s, 1 H, CH), 7.93 (d, 1 H, 3JH,H = 7.9 Hz, 3-Ar-CH),
8.61 (dd, 1 H, 3,4JH,H = 4.7, 1.0 Hz, 5-Ar-CH), 8.82 (d, 1 H, 4JH,H = 1.7 Hz, 1-Ar-CH) ppm;
13C-NMR (400 MHz, DMSO-d6) δ= 124.2 (4-Ar-CH), 125.7 (CH), 129.8 (Ar-C), 130.8 (Ar-C),
136.1 (3-Ar-CH), 150.1 (5-Ar-CH), 151.5 (1-Ar-CH), 172.0 (C=O), 197.3 (C=S) ppm; EI-MS
m/z (%) = 222.0 [M]+ (100 %), 135.0 [fragment]+ (100 %); HR-MS m/z = 221.9916 [M]+ (calcu-
lated: 221.9922); HPLC-Analysis (Method B): 98 %, Rt = 11.2 min.
(Z)-5-(pyridin-2-ylmethylene)-2-thioxothiazolidin-4-one 36ad [335]
TLC Rf = 0.1 (DCM); Reaction time: 4 h; Purification: Re-crystallisation from methanol;
Yield: 145 mg of yellow crystals (0.65 mmol, 59 %); 1H-NMR (400 MHz, DMSO-d6) δ= 7.44
(ddd, 1 H, 3,4J2-Ar-CH,1(3,4)Ar-CH = 4.8, 7.2, 1.3 Hz, 4-Ar-CH), 7.68 (s, 1 H, C-H), 7.90 (dd, 1 H,
3,4JH,H = 7.5, 0.5 Hz, 6-Ar-CH), 7.94 (ddd, 1 H, 3,4JH,H = 7.5, 7.2, 1.3 Hz, 5-Ar-CH), 8.79 (ddd,
1 H, 3,4JH,H = 4.8, 0.5, 0.5 Hz, 3-Ar-CH), 13.67 (s(br), 1 H, NH) ppm; 13C-NMR (400 MHz,
DMSO-d6) δ= 124.0 (4-Ar-CH), 127.5 (CH), 128.2 (6-Ar-CH), 129.7 (Ar-C), 137.6 (5-Ar-CH),
149.5 (3-Ar-CH), 151.1 (Ar-C), 169.4 (C=O), 202.0 (C=S) ppm; ESI-MS m/z (%) = 222.9 [M+H]+
(100 %), 445.0 [2M+H]+ (10 %); HR-MS m/z = 222.9996 [M+H]+ (calculated: 222.9994); HPLC-
Analysis (Method B): 99 %, Rt = 16.2 min.
(5Z)-5-[(4-tert-butylphenyl)methylidene]-2- sulfanylidene-1,3-thiazolidin-4-one 36ab [336]
TLC Rf = 0.8 (DCM/EtOAc 9:1); Reaction time: 4 h; Purification: Filtration from ethanol;
Yield: 380 mg of yellow solid (1.37 mmol, 78 %); 1H-NMR (400 MHz, DMSO-d6) δ= 1.29
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(s, 9 H, 3xCH3), 7.51 (d, 2 H, 3JH,H = 8.6 Hz, 3,5-Ar-CH), 7.52 (s, 1 H, CH), 7.55 (H,H, 2 H,
,J8.6 Hz = 2,6-Ar-CH, 3) 13.80 (s(br), 1 H, NH) ppm; 13C-NMR (400 MHz, DMSO-d6) δ= 30.8
(3xCH3), 34.8 (C(CH3)3) 125.4 (Ar-C), 126.3 (2,6-Ar-CH), 129.2 (Ar-C), 130.0 (Ar-C), 130.3
(3,5-Ar-CH), 130.7 (CH), 153.4 (C=O), 197.1 (C=S) ppm; ESI-MS m/z (%) = 278.1 [+HM+]100
(, %) 295.1 [+NH4M+]45 (; %) HR-MS m/z = 278.0672 [M+H]+ (calculated: 278.0668); HPLC-
Analysis (Method B): 84 %, Rt = 21.4 min.
(5Z)-5-(3-[(4- methoxyphenyl)methoxy]phenylmethylidene)-2- sulfanylidene-1,3-thiazolidin-4-one
36x
TLC Rf = 0.8 (DCM/EtOAc 9:1); Reaction time: 4 h; Purification: Filtration from ethanol;
Yield: 380 mg of yellow solid (1.06 mmol, 85 %); 1H-NMR (400 MHz, DMSO-d6) δ= 3.75
(s, 3 H, OCH3), 5.08 (s, 2 H, CH2), 6.95 (d, 2 H, 3JH,H = 8.7 Hz, 3’,5’-Ar-CH), 7.12-7.17 (m,
2 H, 4,6-Ar-CH), 7.19-7.21 (m, 1 H, 2-Ar-CH), 7.40 (d, 2 H, 3JH,H = 8.7 Hz, 2’,6’-Ar-CH), 7.45
(at, 1 H, 3JH,H = 8.0 Hz, 5-Ar-CH), 7.59 (s, 1 H, CH), 13.85 (s(br), 1 H, NH) ppm; 13C-NMR
(400 MHz, DMSO-d6) δ= 55.1 (OCH3), 69.2 (CH2), 113.9 (3’,5’-Ar-CH), 116.4 (2-Ar-CH),
117.6 (4 or 6-Ar-CH), 122.6 (4 or 6-Ar-CH), 126.3 (Ar-C), 128.5 (Ar-C), 129.6 (2’,6’-Ar-CH),
130.6 (5-Ar-CH), 131.3 (CH), 134.4 (Ar-C), 158.8 (Ar-C), 159.1 (C=O), 196.0 (C=S) ppm;
ESI-MS m/z (%) = 358.1 [M+H]+ (100 %), 375.1 [M+NH4]+ (75 %), 380.0 [M+Na]+ (80 %), 732.1
[2M+NH4]+ (100 %), HR-MS m/z = 358.0571 [M+H]+ (calculated: 358.0566); HPLC-Analysis
(Method B): 100 %, Rt = 20.7 min.
(5Z)-5-(3-[(4- methoxyphenyl)methoxy]phenylmethylidene)-1,3- thiazolidine-2,4-dione 48t
TLC Rf = 0.5 (Hexane/EtOAc 8:2); Reaction time: 4 h; Purification: Filtration from ethanol;
Yield: 440 mg of white solid (1.29 mmol, 91 %); 1H-NMR (400 MHz, DMSO-d6) δ= 3.75 (s,
3 H, OCH3), 5.06 (s, 2 H, CH2), 6.95 (d, 2 H, 3JH,H = 8.5 Hz, 3’,5’-Ar-CH), 7.02 (d, 1 H, 3JH,H =
7.7 Hz, 4-Ar-CH), 7.13 (d, 1 H, 3JH,H = 7.5 Hz, 6-Ar-CH), 7.17 (s, 1 H, 2-Ar-CH), 7.35-7.42 (m,
1 H, 5-Ar-CH), 7.39 (d, 2 H, 3JH,H = 8.5 Hz, 2’,6’-Ar-CH), 7.50 (s, 1 H, CH) ppm; 13C-NMR
(400 MHz, DMSO-d6) δ= 55.1 (OCH3), 69.0 (CH2Ar), 113.9 (3’,5’-Ar-CH), 115.6 (2-Ar-CH),
115.8 (4-Ar-CH), 121.8 (6-Ar-CH), 126.8 (CH), 128.7 (Ar-C), 129.6 (2’,6’-Ar-CH), 130.1 (5-Ar-
CH), 135.9 (Ar-C), 158.6 (C=O), 159.1 (C=O) ppm; HPLC-Analysis (Method B): 88 %, Rt =
19.1 min.
(Z)-5-(pyridin-4-ylmethylene)thiazolidine-2,4-dione 48s [315]
Reaction time: 16 h; Purification: Filtration from ethanol; Yield: 70 mg of white solid (0.34
mmol, 48 %); 1H-NMR (400 MHz, DMSO-d6) δ= 7.53 (dd, 2 H, 3,5JH,H = 1.5, 4.6 Hz, 3,5-Ar-
CH), 7.67 (s, 1 H, CH), 8.70 (dd, 2 H, 3,5JH,H = 1.5, 4.6 Hz, 2,6-Ar-CH) ppm; ESI-MS m/z (%) =
207.0 [M+H]+ (100 %); HR-MS m/z = 207.0223 [M+H]+ (calculated: 207.0223); HPLC-Analysis
(Method B): 97 %, Rt = 2.7 min.
(Z)-5-(pyridin-3-ylmethylene)thiazolidine-2,4-dione 48q [315]
Reaction time: 16 h; Purification: Filtration from ethanol; Yield: 51 mg of white solid (0.25
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mmol, 53 %); 1H-NMR (400 MHz, DMSO-d6) δ= 7.51 (dd, 1 H, 3JH,H = 8.1, 4.8 Hz, 5-Pyr-CH),
7.56 (s, 1 H, CH), 7.93 (adt, 1 H, 3,4JH,H = 8.1, 2.0 Hz, 6-Pyr-CH), 8.54 (dd, 1 H, 3,4JH,H = 4.8,
1.6 Hz, 4-Pyr-CH), 8.78 (d, 1 H, 4JH,H = 2.1 Hz, 2-Pyr-CH) ppm; 13C-NMR (400 MHz, DMSO-
d6) δ= 123.3 (CH), 124.0 (5-Pyr-CH), 130.6 (Ar-C), 135.4 (6-Pyr-CH), 149.3 (4-Pyr-CH), 150.9
(2-Pyr-CH), 171.3 (C=O), 175.0 (C=O) ppm; ESI-MS m/z (%) = 207.0 [M+H]+ (100 %); HR-
MS m/z = 207.0223 [M+H]+ (calculated: 207.0223); HPLC-Analysis (Method B): 99 %, Rt =
11.5 min.
(Z)-5-(pyridin-2-ylmethylene)thiazolidine-2,4-dione 48r [315]
Reaction time: 16 h; Purification: Filtration from ethanol; Yield: 26 mg of brown solid (0.13
mmol, 24 %); 1H-NMR (400 MHz, DMSO-d6) δ= 7.31 (ddd, 1 H, 3,4JH,H = 1.2, 4.8, 7.5 Hz, 4-
Ar-CH), 7.54 (s, 1 H, CH), 7.69 (dd, 1 H, 3JH,H = 1.2, 7.8 Hz, 2-Ar-CH), 7.85 (ddd, 1 H, 3,4JH,H =
1.8, 7.5, 7.8 Hz, 3-Ar-CH), 8.69 (d, 1 H, 3JH,H = 4.8 Hz, 5-Ar-CH) ppm; ESI-MS m/z (%) = 207.0
[M+H]+ (100 %); HR-MS m/z = 207.0223 [M+H]+ (calculated: 207.0223); HPLC-Analysis :
99.9 %, Rt = 24.8 min; HPLC-Analysis (Method B): 99 %, Rt = 11.5 min.
(Z)-3-amino-5-(pyridin-2-ylmethylene)-2-thioxothiazolidin-4-one 54ab
TLC Rf = 0.1 (DCM); Reaction time: 4 h; Purification: Filtration from methanol; Yield:
105 mg of yellow solid (0.44 mmol, 57 %); 1H-NMR (400 MHz, DMSO-d6) δ= 5.91 (s, 2 H,
NH2), 7.46 (ddd, 1 H, 3,4JH,H = 4.8, 6.8, 1.9 Hz, 4-Ar-CH), 7.87 (s, 1 H, C-H), 7.94 (dd, 1 H,
3,4JH,H = 7.8, 1.9 Hz, 6-Ar-CH), 7.96 (ddd, 1 H, 3,4JH,H = 7.8, 6.8, 1.7 Hz, 5-Ar-CH), 8.79-8.81
(m, 1 H, 3-Ar-CH) ppm; 13C-NMR (400 MHz, DMSO-d6) δ= 124.2 (4-Ar-CH), 124.8 (Ar-C),
128.3 (6-Ar-CH), 128.8 (CH), 137.7 (5-Ar-CH), 149.5 (3-Ar-CH), 151.3 (Ar-C), 163.8 (C=O),
194.2 (C=S) ppm; ESI-MS m/z (%) = 238.0 [M+H]+ (100 %), 260.0 [M+Na]+ (10 %); HR-MS m/z
= 238.0104 [M+H]+ (calculated: 238.0103); HPLC-Analysis : 99.9 %, Rt = 27.2 min; HPLC-
Analysis (Method B): 99 %, Rt = 16.2 min.
(Z)-3-phenyl-5-(pyridin-2-ylmethylene)-2-thioxothiazolidin-4-one 55z [337]
TLC Rf = 0.7 (DCM); Reaction time: 4 h; Purification: Filtration from methanol; Yield: 97
mg of yellow solid (0.33 mmol, 72 %); 1H-NMR (400 MHz, DMSO-d6) δ= 7.23-7.77 (m, 6 H,
6 x Ar-CH), 7.81-8.10 (m, 3 H, 3xAr-CH), 8.85 (s, 1 H, CH) ppm; ppm; 13C-NMR (400 MHz,
DMSO-d6) δ= 124.1 (Ar-CH), 127.7 (Ar-C), 128.3 (2xAr-CH), 128.8 (2xAr-CH), 129.2 (2xAr-
CH), 129.4 (Ar-CH) 135.2 (Ar-C), 137.7 (Ar-CH), 149.6 (CH), 151.3 (Ar-C), 167.0 (C=O), 200.4
(C=S) ppm; ESI-MS m/z (%) = 299.1 [M+H]+ (100 %); HR-MS m/z = 299.0310 [M+H]+ (calcu-
lated: 299.0307); HPLC-Analysis (Method B): 99 %, Rt = 19.7 min.
9.14 Reduction of the rhodanine derivative 36b
Sodium borohydrite (10 mg, 0.27 mmol) was dissolved in pyridine (0.2 mL). The mixture was
stirred at 30 ◦C for 15 min, then the temperature was increased to 65 ◦C and lithium chlo-
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rid (17.2 mg, 0.41 mmol) in pyridine (0.2 mL) was added. After 2 h, THF (2 mL) was added
and the reaction mixture was heated under reflux for 30 min. After the reaction mixture has
reached ambient temperature 36b (20 mg, 0.09 mmol) was added in 3 portions. The mixture
was heated to reflux for 2.5 h, until TLC (DCM/EtOAc 9:1, Rf 0.9) showed complete consump-
tion of starting material. The cooled crude was quenched with 1 N HCl (pH 6), extracted with
EtOAc (3x5 mL), dried over MgSO4, filtered and concentrated. Purification by flash chromatog-
raphy (DCM, Rf 0.6) afforded 36ac (11.0 mg, 55 %) as a yellow oil.
5-benzyl-2-thioxothiazolidin-4-one 36ac [338]
TLC Rf = 0.3 (Cyclohexane/EtOAc 8:2); Reaction time: 2.5 h; Purification: Flash-Chroma-
tography DCM (Rf = 0.4); Yield: 11 mg of white solid (0.05 mmol, 55 %); 1H-NMR (400 MHz,
CDCl3) δ= 3.07 (dd, 1 H, ,JH,H = 9.7, 14.0 Hz, 2,3) 3.49 (dd, 1 H, ,JH,H = 3.9, 14.0 Hz, 2,3)
4.38 (dd, 1 H, JH,H = 3.9, 9.7 Hz, CH), 7.59 (dd, 2 H, 3,4JH,H = 6.6, 7.6 Hz, 3,5-Ar-CH), 8.05
(ddd, 1 H, 3,4JH,H = 1.5, 7.7 Hz, 4-Ar-CH), 8.76 (dd, 2 H, 3,4JH,H = 1.5, 6.6 Hz, 2,3-Ar-CH)
ppm; ESI-MS m/z (%) = 222.0 [M−H]− (100 %); HR-MS m/z = 222.0054 [M−H]− (calculated:
222.0053); HPLC-Analysis (Method B): 64 %, Rt = 18.4 min.
pyridine-borane 73
1H-NMR (400 MHz, CDCl3) δ= 2.56 (q, 3 H, 1JB,H = 92.3 Hz, BH3), 7.45-7.52 (m, 2 H, 3,5-Pyr-
CH), 7.86-7.99 (m, 1 H, 4-Pyr-CH), 8.57 (d, 2 H, 3JH,H = 5.7 Hz, 2,6-Pyr-CH) ppm.
Reduction of Compound 36y using Hantzsch ester reduction
The general procedure is as described for 27a.
5-[4-(benzyloxy)phenyl]methyl-2-sulfanylidene-1,3-thiazolidin-4-one 75a
TLC Rf = 0.3 (Hexane/EtOAc 8:2); Reaction time: 16 h; Purification: Flash-Chromatography
Hexane/EtOAc 8:2 (Rf = 0.3); Yield: 122 mg of yellow solid (0.37 mmol, 46 %); 1H-NMR (400
MHz, CDCl3) δ= 3.10 (dd, 1 H, 2,3JH,H = 14.2, 9.8 Hz, E-CHH), 3.44 (dd, 1 H, 2,3JH,H = 14.2,
4.0 Hz, Z-CHH), 4.56 (dd, 1 H, 3JH,H = 9.8, 4.0 Hz, CH), 5.03 (s, 2 H, CH2), 6.92 (d, 2 H, 3JH,H =
8.6 Hz, 3,5-Ar-CH), 7.13 (d, 2 H, 3JH,H = 8.6 Hz, 2,6-Ar-CH), 7.29-7.44 (m, 5 H, 5xAr-CH) 9.89
(s(br), 1 H, NH) ppm; 13C-NMR (400 MHz, CDCl3) δ= 37.5 (E,Z-CH2), 57.1 (CH), 70.1 (CH2Ar)
115.3 (3,5-Ar-CH), 127.6 (Ar-CH), 127.9 (Ar-C), 128.1 (Ar-CH) 128.7 (Ar-CH), 130.3 (2,6-Ar-
CH), 136.8 (Ar-C), 158.4 (Ar-C), 176.9 (C=O), 200.4 (C=S) ppm; HPLC-Analysis (Method
B): 98 %, Rt = 16.3 min.
3,5-diethyl 2,6-dimethylpyridine-3,5-dicarboxylate 74 [339]
TLC Rf = 0.3 (Hexane/EtOAc 8:2); 1H-NMR (400 MHz, CDCl3) δ= 1.42 (t, 6 H, 3JH,H = 7.1 Hz,
2xCH3), 2.85 (s, 6 H, 2xCH3), 4.40 (q, 4 H, ,JH,H = 7.1 Hz, 2xCH2CH3) 8.68 (s, 1 H, Ar-CH)
ppm; ESI-MS m/z (%) = 252.1 [M+H]+ (100 %).
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9.15 Reduction of thiazolidine-2,4-dione derivatives 48p and 48m
The procedure is as described for 27b and 27c.
5-[(3,4-dihydroxyphenyl)methyl]-1,3-thiazolidine-2,4-dione 48v [340]
TLC Rf = 0.2 (CHCl3/MeOH 95:5); Reaction time: 16 h; Purification: Flash-Chromatography
CHCl3/MeOH 95:5 (Rf = 0.2); Yield: 201 mg of white solid (0.84 mmol, 100 %); 1H-NMR (400
MHz, DMSO-d6) δ= 2.91 (dd, 1 H, 2,3JH,H = 9.3, 14.1 Hz, anti-CHH), 3.19 (dd, 1 H, 2,3JH,H =
4.2, 14.1 Hz, syn-CHH), 4.78 (dd, 1 H, 3JH,H = 4.2, 9.3 Hz, CH), 6.47 (dd, 1 H, 3,4JH,H = 2.1,
8.0 Hz, 6-Ar-CH), 6.60 (d, 1 H, 4JH,H = 2.1 Hz, 2-Ar-CH), 6.64 (d, 1 H, 3JH,H = 8.0 Hz, 5-Ar-CH),
8.83 (s(br), 1 H, OH), 8.87 (s(br), 1 H, OH), 11.98 (s(br), 1 H, NH) ppm; 13C-NMR (400 MHz,
DMSO-d6) δ= 36.7 (CH2), 53.3 (CH), 115.5 (5-Ar-CH), 116.5 (2-Ar-CH), 119.9 (6-Ar-CH),
127.5 (Ar-C), 144.3 (Ar-C), 145.1 (Ar-C), 172.0 (C=O), 175.9 (C=O) ppm; ESI-MS m/z (%) =
238.0 [M−H]− (100 %), 477.0 [2M−H]− (40 %); HR-MS m/z = 238.0177 [M−H]− (calculated:
238.0180).
5-[4-(benzyloxy)phenyl]methyl-1,3-thiazolidine- 2,4-dione 48u [341]
Reaction time: 4 h; Yield: 63 mg of white solid (0.20 mmol, 100 %); 1H-NMR (400 MHz,
CDCl3) δ= 3.08 (dd, 1 H, 2,3JH,H = 14.2, 9.6 Hz, E-CHH), 3.45 (dd, 1 H, 2,3JH,H = 14.2, 3.9 Hz,
Z-CHC), 3.71 (s, 1 H, NH), 4.49 (dd, 1 H, 3JH,H = 9.6, 3.9 Hz, CH), 5.03 (s, 2 H, CH2), 6.92 (d,
2 H, 3JH,H = 8.6 Hz, 3,5-Ar-CH), 7.14 (d, 2 H, 3JH,H = 8.6 Hz, 2,6-Ar-CH), 7.30-7.44 (m, 5 H,
5xAr-CH) ppm; 13C-NMR (400 MHz, CDCl3) δ= 37.9 (E,ZCH2), 53.9 (CH), 70.1 (CH2), 115.3
(3,5-Ar-CH), 127.6 (2xAr-CH), 128.1 (Ar-C), 128.2 (Ar-CH), 128.7 (2xAr-CH), 130.5 (2,6-Ar-
CH), 136.9 (Ar-C), 158.4 (Ar-C), 171.1 (C=O), 174.8 (C=O) ppm; ESI-MS m/z (%) = 331.1
[M+NH4]+ (13 %); HPLC-Analysis (Method B): 64 %, Rt = 17.3 min.
9.16 Alkylation of the thiocarbonyl in rhodanine derivatives
Representative procedure for the alkylation of the thiocarbonyl in rhodanine
derivatives
Rhodanine (666 mg, 5 mmol, 1.0 eq) were dissolved in NaOH(aq) (2 %, 12 mL). Ethyl-iodide 63
(342 mg, 5.5 mmol, 1.1 eq) were added and the reaction mixture was stirred at rt for 16 h. The
crude was extracted with DCM (3x15 mL). The combined organic fractions were washed with
NaHCO3 (sat, 10 mL), dried over MgSO4, filtered and concentrated. Re-crystallisation from
methanol yields the substituted thiocarbonyl 63a as yellow solid.
2-(ethylsulfanyl)-5H-1,3-thiazol-4-one 67a [342]
TLC Rf = 0.3 (Hexane/EtOAc 8:2); Purification: Re-crystallisation from methanol; Yield: 726
mg of yellow solid (4.50 mmol, 90 %); 1H-NMR (400 MHz, MeOD) δ= 1.48 (t, 3 H, 3JH,H =
7.4 Hz, CH3), 3.37 (q, 2 H, 3JH,H = 7.4 Hz, CH2CH3), 4.18 (s, 2 H, CH2) ppm.
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Alkylating agent: iodo-acetic acid sodium salt: [(4-oxo-5H-1,3-thiazol-2-yl)sulfanyl]acetic acid
64a [343]
TLC Rf = 0.2 (DCM/MeOH 7:3); Reaction time: 12 h; Purification: Filtration from methanol;
Yield: 638 mg of white solid (3.34 mmol, 33 %); 1H-NMR (400 MHz, DMSO-d6) δ= 3.78 (s,
2 H, CH2), 4.18 (s, 2 H, CH2) ppm; 13C-NMR (400 MHz, DMSOd6) δ= 33.8 (CH2), 45.0 (CH2),
168.1 (C), 171.9 (C=O), 172.1 (C=O) ppm;
Finkelstein reaction to iodo-acetic acetate 66: To a solution of NaI (7683 mg, 51.26 mmol,
1.2 eq) in acetone (150 mL) was added ethyl 2-bromoacetate 65 (4.83 mL, 42.78 mmol, 1.0 eq).
The reaction mixture was stirred 12 h in the dark. After 12 h, sodium bromide was filtered and
the filtrate was concentrated. The crude was extracted between H2O (40 mL) and EtOAc
(3x50 mL). The combined organic fraction were washed with Na2S2O3 (sat, 20 mL), brine
(20 mL) and was dried over MgSO4, filtered and concentrated. The changed NMR shift and
mass spec confirmed the product.
Ethyl iodoacetate 66 [344]
TLC Rf = 0.5 (Hexane/EtOAc 9:1); Reaction time: 12 h; Yield: 8988 mg of clear oil (42.01
mmol, 98 %); 1H-NMR (400 MHz, CDCl3) δ= 1.27 (t, 3 H, 3JH,H = 7.1 Hz, CH3), 3.67 (s, 2 H,
CH2), 4.19 (q, 2 H, 3JH,H = 7.1 Hz, CH2CH3) ppm; APCI-MS m/z (%) = 215.0 [M+H]+ (100 %),
428.9 [2M+H]+ (45 %), HR-MS m/z = 214.9561 [M+H]+ (calculated: 214.9563).
Procedure as describes for 105a with iodo-acetic acetate 66 as alkylating agent.
(4-oxo-5H-1,3-thiazol-2-yl)sulfanyl acetic acid 67b [343]
TLC Rf = 0.1 (Hexane/EtOAc 95:5); Yield: 1012 mg of white solid (5.29 mmol, 53 %); Reac-
tion time: 16 h; Purification: Flash-Chromatography Hexane/EtOAc 95:5 (Rf = 0.1); 1H-NMR
(400 MHz, DMSO-d6) δ= 3.78 (s, 2 H, CH2), 4.18 (s, 2 H, CH2) ppm; 13C-NMR (400 MHz,
DMSO-d6) δ= 33.8 (CH2), 45.0 (CH2), 168.1 (C), 171.9 (C=O), 172.1 (C=OOH) ppm; ESI-MS
m/z (%) = 190.0 [M−H]− (100 %), 380.9 [2M−H]− (15 %); HR-MS m/z = 189.9638 [M−H]− (cal-
culated: 189.9638).
(4-oxo-5H-1,3-thiazol-2-yl)sulfanide TEAH salt 68 [345]
Rhodanine 36 (6.65 g, 0.05 mol, 1.0 eq) was dissolved in iso-propanol (25 mL). NEt3 (7 mL,
0.05 mol, 1.0 eq) was added to the reaction mixture. The yellow mixture was stirred at 100 ◦C
for 15 min. Upon cooling, yellow crystals were forming. The crystals were filtered and re-
crystallised from toluene to afford 68 as purple crystals. Reaction time: 15 min; Purification:
Re-crystallisation from isopropanol, toluene; Yield: 8006 mg of purple crystals (34.16 mmol,
68 %); 1H-NMR (400 MHz, DMSO-d6) δ= 1.14 (t, 9 H, 3JH,H = 7.3 Hz, 3xCH3), 3.02 (q, 6 H,
3JH,H = 7.3 Hz, 3xCH2), 3.82 (s, 2 H, CH2) ppm; 13C-NMR (400 MHz, CDCl3) δ= 9.0 (3xCH3),
42.3 (CH2), 45.6 (3xCH2) ppm; ZQ-Nano-EI-MS m/z (%) = 131.9 [M] (100 %); HR-MS m/z =
131.9587 [M] (calculated: 131.9583).
Ethyl 2-[(4-oxo-5H-1,3-thiazol-2-yl)sulfanyl] acetate 69 [346]
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Compound 68 (4.00 g, 0.02 mol, 1.0 eq) and ethyl 2-bromoacetate 65 (1.9 mL, 0.02 mol, 1.0 eq)
were dissolved in acetone (20 mL) and stirred at 70 ◦C for 2 h. A white solid precipitated from
the mixture and was filtered and washed with acetone. The filtrate was concentrated and re-
crystallised from iso-propanol or acetone to afford 67c. TLC Rf = 0.1 (Hexane/EtOAc 9:1);
Reaction time: 2 h; Purification: Re-crystallisation from acetone; Yield: 3465 mg of pink
crystals (15.80 mmol, 93 %); Yield: 901 mg of orange solid (4.11 mmol, 97 %); 1H-NMR (400
MHz, DMSO-d6) δ= 1.20 (t, 3 H, 3JH,H = 7.1 Hz, CH3), 4.15 (q, 2 H, 3JH,H = 7.1 Hz, CH2),
4.25 (s, 2 H, CH2), 4.28 (s, 2 H, CH2) ppm; 13C-NMR (400 MHz, DMSO-d6) δ= 14.0 (CH3),
35.1 (CH2), 40.4 (CH2), 61.6 (CH2CH3), 167.2 (C=O), 187.4 (C=N), 200.3 (COOEt) ppm;
ESI-MS m/z (%) = 220.0 [M+H]+ (100 %), 237.0 [M+NH4]+ (15 %), 242.0 [M+Na]+ (25 %), 461.0
[2M+Na]+ (15 %); HR-MS m/z = 220.0099 [M+H]+ (calculated: 220.0097).
Synthesis of S-modified analogues 69
The alkylated analogue 69 (1.0 eq), various cyclic aldehydes (1.1 eq) and sodium acetate
(1.0 eq) were dissolved in ethanol (5 mL) and stirred at 70 ◦C until TLC showed complete con-
sumption of starting material.
Ethyl 2-[(5Z)-5-[(2-methylphenyl)methylidene]-4- oxo-1,3-thiazol-2-yl]sulfanylacetate 69a
TLC Rf = 0.4 (Toluene/MeOH 8:2); Reaction time: 1 h; Purification: Re-crystallisation from
isopropanol; textbfHR-MS APCI m/z = 322.0557 [M+H]+ (calculated: 322.0566) ; HPLC-Analysis
(Method B): 67 %, Rt = 19.0 min.
Ethyl 2-[(5Z)-5-[(3-methylphenyl)methylidene]-4-oxo-1,3-thiazol-2-yl]sulfanylacetate 69b
TLC Rf = 0.1 (Toluene/MeOH 9:1); Reaction time: 2 h; Purification: Flash-Chromatography
Toluene/MeOH 9:1 (Rf = 0.1); Yield: 110 mg of yellow solid (0.34 mmol, 30 %); 1H-NMR (400
MHz, CDCl3) δ= 1.31 (t, 3 H, 3JH,H = 7.1 Hz, CH3), 2.44 (s, 3 H, Ar-CH3), 4.22 (s, 2 H, CH2),
4.25 (q, 2 H, 3JH,H = 7.1 Hz, CH2CH3), 7.26-7.42 (m, 4 H, 4xAr-CH), 7.81 (s, 1 H, CH) ppm;
13C-NMR (400 MHz, CDCl3) δ= 14.2 (CH3), 21.6 (Ar-CH3), 35.5 (CH2), 62.7 (CH2CH3), 118.4
(Ar-C), 127.3 (Ar-CH), 129.4 (Ar-CH), 131.0 (Ar-CH), 132.0 (Ar-CH), 134.6 (CH), 139.4 (Ar-C),
147.5 (Ar-C), 165.9 (C=O), 167.2 (C=N), 184.7 (COOEt) ppm; HPLC-Analysis (Method B):
100 %, Rt = 18.7 min.
Ethyl 2-[(5Z)-5-[(4-methylphenyl)methylidene]-4-oxo-1,3-thiazol-2-yl]sulfanylacetate 69c [346]
TLC Rf = 0.1 (Toluene/MeOH 95:5); Reaction time: 2 h; Purification: Flash-Chromatogra-
phy Toluene/MeOH 95:5 (Rf = 0.1); Yield: 120 mg of yellow solid (0.37 mmol, 33 %); 1H-NMR
(400 MHz, CDCl3) δ= 1.30 (t, 3 H, 3JH,H = 7.1 Hz, CH3), 2.42 (s, 3 H, Ar-CH3), 4.21 (s, 2 H,
CH2), 4.24 (q, 2 H, 3JH,H = 7.1 Hz, CH2CH3), 7.30 (d, 2 H, 3JH,H = 8.1 Hz, 3,5-Ar-CH), 7.42 (d,
2 H, 3JH,H = 8.1 Hz, 2,6-Ar-CH), 7.80 (s, 1 H, CH) ppm; 13C-NMR (400 MHz, CDCl3) δ= 14.2
(CH3), 21.8 (Ar-CH3), 35.5 (CH2), 62.7 (CH2CH3), 117.4 (C), 130.3 (4xAr-CH), 134.4 (CH),
142.0 (Ar-C), 147.6 (Ar-C), 167.2 (C=O), 178.2 (C=N), 184.6 (COOEt) ppm; HPLC-Analysis
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(Method B): 98 %, Rt = 19.1 min.
Ethyl 2-[(5Z)-5-[3-(benzyloxy)phenyl]methylidene-4-oxo-1,3-thiazol-2-yl]sulfanylacetate 69d
TLC Rf = 0.4 (Toluene/MeOH 8:2); Reaction time: 1 h; Purification: Filtration from ethanol;
Yield: 97 mg of yellow solid (0.23 mmol, 21 %); 1H-NMR (400 MHz, DMSO-d6) δ= 1.21 (t,
3 H, 3JH,H = 7.1 Hz, CH3), 4.15 (q, 2 H, 3JH,H = 7.1 Hz, CH2CH3), 4.19 (s, 2 H, CH2), 5.17 (s,
2 H, OCH2-Ar), 7.03 (dd, 1 H, 3,4JH,H = 2.2, 8.1 Hz, 6-Ar-CH), 7.21 (d, 1 H, 3JH,H = 7.8 Hz, 4-
Ar-CH), 7.24 (d, 1 H, 4JH,H = 2.2 Hz, 2-Ar-CH), 7.32 (s, 1 H, CH), 7.32-7.36 (m, 1 H, 4’-Ar-CH),
7.38-7.44 (m, 3 H, 3’,5’,5-Ar-CH), 7.50 (d, 2 H, 3JH,H = 7.7 Hz, 2’,6’-Ar-CH) ppm; 13C-NMR
(400 MHz, DMSO-d6) δ= 14.0 (CH3), 33.9 (CH2), 61.4 (CH2), 69.3 (CH2), 114.9 (Ar-C or
CH), 115.9 (Ar-C or CH), 121.8 (Ar-C or CH), 126.2 (Ar-C or CH), 127.9 (2xAr-CH), 128.5
(2xAr-CH), 130.0 (Ar-C or CH), 131.7 (Ar-C or CH), 136.8 (Ar-C or CH), 136.9 (Ar-C or CH),
158.6 (Ar-C or CH), 164.5 (Ar-C or CH), 167.8 (Ar-C or CH), 176.4 (C=O), 177.1 (C=N), 180.0
(COOEt) ppm; ESI-MS m/z (%) = 513.1 [M+99]+ (100 %); HPLC-Analysis (Method B): 98 %,
Rt = 20.8 min.
Ethyl 2-[(5Z)-5-[4-(benzyloxy)phenyl]methylidene-4-oxo-1,3-thiazol-2-yl]sulfanylacetate 69e
TLC Rf = 0.7 (Toluene/MeOH 8:2); Reaction time: 1 h; Purification: Filtration from ethanol;
Yield: 49 mg of yellow solid (0.12 mmol, 10 %); 1H-NMR (400 MHz, DMSO-d6) δ= 1.22 (t,
3 H, 3JH,H = 7.1 Hz, CH3), 4.15 (q, 2 H, 3JH,H = 7.1 Hz, CH2CH3), 4.18 (s, 2 H, CH2), 5.17 (s,
2 H, CH2Ar), 7.16 (d, 2 H, 3JH,H = 8.8 Hz, 2,6-Ar-CH), 7.33 (s, 1 H, CH), 7.32-7.37 (m, 1 H,
4’-Ar-CH), 7.39 (d, 1 H, 3JH,H = 7.5 Hz, 3’,5’-Ar-CH), 7.48 (d, 1 H, 3JH,H = 7.5 Hz, 2’,6’-Ar-CH),
7.57 (d, 1 H, 3JH,H = 8.8 Hz, 3,5-Ar-CH) ppm; 13C-NMR (400 MHz, DMSO-d6) δ= 14.0 (CH3),
33.9 (CH2), 61.4 (CH2CH3), 69.4 (CH2Ar), 115.4 (2,6-Ar-CH), 126.4 (CH), 127.9 (2’,6’-Ar-CH),
128.5 (3’,5’-Ar-CH), 131.1 (3,5-Ar-CH), 136.8 (Ar-C), 158.6 (Ar-C), 164.9 (Ar-C), 167.9 (Ar-C),
175.7 (C=O), 176.9 (C=N), 180.3 (COOEt) ppm; ESI-MS m/z (%) = 414.1 [M+H]+ (90 %); HR-
MS m/z = 414.0829 [M+H]+ (calculated: 414.0828); HPLC-Analysis (Method B): 98 %, Rt =
20.8 min.
Ethyl 2-[(5Z)-5-[3,4-bis(benzyloxy)phenyl]methylidene-4-oxo-1,3-thiazol-2-yl]sulfanylacetate 69f
TLC Rf = 0.8 (Hexane/EtOAc 6:4); Reaction time: 1.5 h; Purification: Filtration from ethanol;
Yield: 84 mg of yellow solid (0.16 mmol, 14 %); 1H-NMR (400 MHz, DMSO-d6) δ= 1.22 (t, 3 H,
3JH,H = 7.1 Hz, CH3), 4.15 (q, 2 H, 3JH,H = 7.1 Hz, CH2CH3), 4.18 (s, 2 H, CH2), 5.20 (s, 4 H,
2xCH2), 7.17 (dd, 1 H, 3,4JH,H = 1.9, 8.5 Hz, 6-Ar-CH), 7.22 (d, 1 H, 3JH,H = 8.5 Hz, 5-Ar-CH)
7.27 (s, 1 H, CH), 7.30 (d, 1 H, 4JH,H = 1.9 Hz, 2-Ar-CH), 7.29-7.35 (m, 2 H, 2xAr-CH), 7.36-
7.42 (m, 4 H, 4x-Ar-CH), 7.46-7.53 (m, 4 H, 4xAr-CH) ppm; 13C-NMR (400 MHz, DMSO-d6) δ=
14.0 (CH3), 33.9 (CH2), 61.4 (CH2CH3), 70.0 (CH2Ar), 70.1 (CH2Ar), 114.4 (5-Ar-CH), 115.9
(2-Ar-CH), 122.7 (6-Ar-CH), 127.7 (CH), 127.8 (Ar-CH), 127.9 (Ar-CH), 128.4 (Ar-CH), 128.5
(ArCH), 129.1 (Ar-CH), 137.0 (Ar-C), 137.1 (Ar-C), 148.1 (Ar-C), 164.8 (Ar-C), 167.9 (Ar-C),
173.6 (Ar-C), 175.8 (C=O), 176.9 (C=N), 180.2 (COOEt) ppm; HPLC-Analysis (Method B):
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69 %, Rt = 20.5 min.
Ethyl 2-[(5Z)-5-[(3-hydroxyphenyl)methylidene]-4-oxo-1,3-thiazol-2-yl]sulfanylacetate 69g
TLC Rf = 0.3 (Hexane/EtOAc 6:4); Reaction time: 1 h; Purification: Filtration from ethanol;
Yield: 59 mg of yellow solid (0.18 mmol, 16 %); 1H-NMR (400 MHz, DMSO-d6) δ= 1.22 (t, 3 H,
3JH,H = 7.1 Hz, CH3), 4.15 (q, 2 H, 3JH,H = 7.1 Hz, CH2CH3), 4.19 (s, 2 H, CH2), 6.74-6.78 (m,
1 H, 6-Ar-CH), 7.00-7.05 (m, 2 H, 4-Ar-CH.CH), 7.25-7.30 (2,5-Ar-CH, 2 H, 9.73J = „ ) (s, 1 H,
OH) ppm; 13C-NMR (400 MHz, DMSO-d6) δ= 14.0 (CH3), 33.9 (CH2), 61.4 (CH2CH3), 115.3
(4-Ar-CH), 115.9 (6-Ar-CH), 121.0 (CH), 126.6 (5 or 2-Ar-CH), 129.9 (5 or 2-Ar-CH), 136.5
(Ar-C), 157.8 (Ar-C), 167.9 (Ar-C) 176.2 (C=O), 177.0 (C=N), 180.1 (COOEt) ppm; ESI-MS
m/z (%) = 421.0 [M+99]− (100 %), 423.0 [M+99]+ (100 %); HPLC-Analysis (Method B): 46 %,
Rt = 14.5 min.
Ethyl 2-([(5Z/E)-5-[(4-hydroxyphenyl)methylidene]-4-oxo-1,3-thiazol-2-yl]sulfanyl) acetate 69h [346]
1:1 ratio E to Z
TLC Rf = 0.1 (Toluene/MeOH 8:2); Reaction time: 2 h; Purification: Filtration from ethanol;
Yield: 103 mg of yellow solid (0.16 mmol, 14 %); 1H-NMR (400 MHz, DMSO-d6) δ= 1.21 (t,
6 H, 3JH,H = 7.1 Hz, 2xCH3), 4.15 (q, 4 H, 3JH,H = 7.1 Hz, 2xCH2CH3), 4.18 (s, 2 H, CH2), 4.36
(s, 2 H, CH2), 6.89 (d, 2 H, 3JH,H = 8.6 Hz, 2,6 or 2’,6’-Ar-CH), 6.93 (d, 2 H, 3JH,H = 8.6 Hz,
2,6 or 2’,6’-Ar-CH), 7.29 (s, 1 H, E-CH), 7.46 (d, 2 H, 3JH,H = 8.6 Hz, 3,5- or 3’,5’-Ar-CH),
7.53 (d, 2 H, 3JH,H = 8.6 Hz, 3,5- or 3’,5’-Ar-CH), 7.79 (s, 1 H, Z-CH), 9.97 (s(br), 2 H, 2xOH)
ppm; 13C-NMR (400 MHz, DMSO-d6) δ= , 13.9 (CH3), 14.0 (CH3), 33.9 (CH2), 34.8 (CH2),
61.4 (CH2CH3), 61.7 (CH2CH3), 116.0, 116.5 (2,6 or 2’,6’-Ar-CH), 121.6 (Ar-C), 124.0 (Ar-
C), 126.3 (Ar-C), 127.0 (E-CH), 131.3 (3,5 or 3’,5’-Ar-CH), 133.1 (3,5 or 3’,5’-Ar-CH), 136.5
(Z-CH), 138.8 (Ar-C), 158.1 (Ar-C), 160.7 (Ar-C), 167.1 (C=O), 167.9 (C=O), 176.8 (C=N),
178.8 (C=N), 189.0 (COOEt), 189.9 (COOEt) ppm; HPLC-Analysis (Method B): 46 %, Rt =
14.5 min; HPLC-Analysis (Method B): 55 %, Rt = 15.3 min.
Ethyl 2-[(5Z)-5-[(2,4-dihydroxyphenyl)methylidene]-4-oxo-1,3-thiazol-2-yl]sulfanylacetate 69i
TLC Rf = 0.2 (Toluene/MeOH 7:3); Reaction time: 1 h; Purification: Filtration from ethanol;
Yield: 210 mg of red solid (0.62 mmol, 54 %); 1H-NMR (400 MHz, MeOD) δ= 1.29 (t, 3 H,
3JH,H = 7.1 Hz, CH3), 4.22 (q, 2 H, 3JH,H = 7.1 Hz, CH2CH3), 6.33 (d, 1 H, 4JH,H = 2.4 Hz, 3-Ar-
CH), 6.41 (dd, 1 H, 3,4JH,H = 2.4, 8.6 Hz, 4-Ar-CH), 7.52 (d, 1 H, 3JH,H = 8.6 Hz, 6-Ar-CH), 8.05
(s, 1 H, CH) ppm;
Ethyl 2-[(5Z)-5-[(3,4-dihydroxyphenyl)methylidene]-4-oxo-1,3-thiazol-2-yl]sulfanylacetate 69j
TLC Rf = 0.1 (Hexane/EtOAc 6:4); Reaction time: 2 h; Purification: Filtration from ethanol;
Yield: 46 mg of red solid (0.14 mmol, 12 %); 1H-NMR (400 MHz, DMSO-d6) δ= 1.22 (t, 3 H,
3JH,H = 7.1 Hz, CH3), 4.15 (q, 2 H, 3JH,H = 7.1 Hz, CH2CH3), 4.18 (s, 2 H, CH2), 6.78 (d, 1 H,
3JH,H = 8.2 Hz, 5-Ar-CH), 6.90 (d, 1 H, 3,4JH,H = 2.1, 8.2 Hz, 6-Ar-CH), 7.04 (d, 1 H, 4JH,H =
2.1 Hz, 2-Ar-CH), 7.20 (s, 1 H, CH) ppm; 13C-NMR (400 MHz, DMSO-d6) δ= 14.0 (CH3), 33.9
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(CH2), 61.4 (CH2CH3), 116.1 (2,5-Ar-CH), 122.9 (6-Ar-CH), 126.3 (Ar-C), 127.9 (CH), 146.0
(Ar-C), 165.4 (Ar-C), 167.9 (Ar-C), 175.0 (C=O), 176.7 (C=N), 180.6 (COOEt) ppm; HPLC-
Analysis (Method B): 93 %, Rt = 21.5 min.
Ethyl 2-[(5Z)-5-(furan-2-ylmethylidene)-4-oxo-1,3-thiazol-2-yl]sulfanylacetate 69l [347]
TLC Rf = 0.4 (Hexane/EtOAc 7:3); Reaction time: 4 h; Purification: Filtration from ethanol;
Yield: 285 mg of yellow solid (0.96 mmol, 84 %); 1H-NMR (400 MHz, DMSO-d6) δ= 1.21
(t, 3 H, 3JH,H = 7.1 Hz, CH3), 4.17 (q, 2 H, 3JH,H = 7.1 Hz, CH2CH3), 4.35 (s, 2 H, CH2), 6.79
(dd, 1 H, 3JH,H = 1.8, 3.5 Hz, 4-Ar-CH), 7.22 (d, 1 H, 3JH,H = 3.5 Hz, 3-Ar-CH), 7.71 (s, 1 H,
CH), 8.11 (d, 1 H, 3JH,H = 1.8 Hz, 5-Ar-CH) ppm; 13C-NMR (400 MHz, DMSO-d6) δ= 14.0
(CH3), 34.8 (CH2), 61.7 (CH2CH3), 114.1 (4-Ar-CH), 120.5 (3-Ar-CH), 121.6 (CH), 122.9 (Ar-
C), 148.4 (5-Ar-CH), 149.2 (Ar-C), 167.2 (C=O), 178.4 (C=N), 191.2 (COOEt) ppm; ESI-MS
m/z (%) = 296.0 [M−H]− (22 %), 298.0 [M+H]+ (100 %), 595.0 [2M+H]+ (3 %), 612.1 [2M+NH4]+
(3 %); HPLC-Analysis (Method B): 84 %, Rt = 15.1 min.
Substitution of thio-alkyl group in 67c
Thio-alkyl 69 (250 mg, 1.14 mmol, 1.0 eq), glycine methyl ester (143 mg, 1.14 mmol, 1.0 eq,
HCl salt) and DIPEA (397µL, 2.28 mmol, 2.0 eq) were dissolved in ethanol (4 mL). The reaction
mixture was stirred at 80 ◦C. After 24 h, TLC showed complete consumption of starting 67c.
The crude was concentrated and purified by flash column chromatography to afford 70 as
white solid.
Ethyl 2-[(4-oxo-5H-1,3-thiazol-2-yl)amino] acetate 70
TLC Rf = 0.2 (Hexane/EtOAc 1:9); Reaction time: 16 h; Purification: Flash-Chromatography
Hexane/EtOAc 1:9 (Rf = 0.2); Yield: 202 mg of white solid (1.00 mmol, 88 %); Yield: 892 mg
of white solid (4.41 mmol, 93 %); 1H-NMR (400 MHz, MeOD) δ= 1.28 (t, 3 H, 3JH,H = 7.2 Hz,
CH3), 4.03 (s, 2 H, CH2), 4.21 (q, 2 H, 3JH,H = 7.2 Hz, CH2CH3), 4.28 (s, 2 H, CH2) ppm; 13C-
NMR (400 MHz, MeOD) δ= 14.4 (CH3), 40.3 (CH2), 46.9 (CH2), 62.6 (CH2CH3), 169.9 (C=0),
185.1 (C=N), 190.7 (COOEt) ppm.
The amino-derivative 67d (250 mg, 1.24 mmol, 1.0 eq), 4-chloro-benzaldehyde (209 mg, 1.48
mmol, 1.2 eq) and sodium acetate (101 mg, 1.24 mmol, 1.0 eq) were dissolved in methanol.
The reaction mixture was stirred at 80 ◦C, until TLC showed complete consumption of starting
67d.
Methyl 2-[(5Z)-5-[(4-chlorophenyl)methylidene]-4-oxo-1,3-thiazol-2-yl]aminoacetate 70a
TLC Rf = 0.2 (Hexane/EtOAc 4:6); Reaction time: 16 h; Purification: Flash-Chromatogra-
phy Hexane/EtOAc 4:6 (Rf = 0.2); Yield: 267 mg of white solid (0.86 mmol, 70 %); 1H-NMR
(400 MHz, DMSO-d6) δ= 3.70 (s, 3 H, OCH3), 4.38 (s, 2 H, CH2), 7.59 (as, 4 H, 4xAr-CH),
7.63 (s, 1 H, CH), 10.12 (s(br), 1 H, NH) ppm; 13C-NMR (400 MHz, DMSO-d6) δ= 45.3 (CH2),
52.3 (CH3), 128.7 (Ar-C), 129.3 (2xAr-CH or CH), 131.2 (2xAr-CH or CH), 132.9 (Ar-C), 134.2
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(Ar-C), 169.0 (C=O), 174.6 (C=N), 179.2 (C=OMe) ppm; ESI-MS m/z (%) = 309.0 [M−H]−
(100 %), 311.0 [M+H]+ (100 %), 333.0 [M+Na]+ (58 %); HPLC-Analysis (Method B): 81 %,
Rt = 15.5 min.
One-pot reaction sequence to compounds of the class 70
Rhodanine 36 (499 mg, 3.75 mmol, 1.0 eq), benzaldehyde (1.042 mL, 7.50 mmol, 2.0 eq) and
piperidine (408µL, 4.13 mmol, 1.1 eq) were dissolved in ethanol (3 mL). Glacial acetic acid
(21µL, 0.38 mmol, 0.1 eq) was added to the reaction mixture and stirring was continued at
80 ◦C until TLC showed complete consumption of starting 36. Upon cooling, a white crystalline
solid was forming. The solid was filtered and washed with ethanol and dried in vacuo.
(5Z)-5-(phenylmethylidene)-2-(piperidin-1-yl)-1,3-thiazol-4-one 70b [348]
TLC Rf = 0.3 (Hexane/EtOAc 8:2); Reaction time: 5 h; Purification: Filtration from ethanol;
Yield: 691 mg of white solid (2.54 mmol, 68 %); 1H-NMR (400 MHz, DMSO-d6) δ= 1.57-1.71
(m, 6 H, 3xCH2), 3.60-3.64 (m, 2 H, CH2), 3.88-3.92 (m, 2 H, CH2), 7.41-7.54 (m, 3 H, 3xAr-
CH), 7.61-7.65 (m, 3 H, 2xAr-CH, CH) ppm; 13C-NMR (400 MHz, DMSO-d6) δ= 23.4 (CH2),
25.1 (CH2), 25.8 (CH2), 49.1 (CH2), 49.9 (CH2), 128.8 (Ar-C), 129.2 (2xAr-CH), 129.5 (3xAr-
CH) 129.7 (Ar-CH) 133.9 (Ar-C), 173.3 (C=O), 179.4 (C=N), ppm; ESI-MS m/z (%) = 273.1
[M+H]+ (100 %), 545.2 [2M+H]+ (25 %); HPLC-Analysis (Method B): 82 %, Rt = 16.3 min.
(5Z)-5-[(3,4-dihydroxyphenyl)methylidene]-2-(piperidin-1-yl)-1,3-thiazol-4-one 70c
TLC Rf = 0.2 (Hexane/EtOAc 7:3); Reaction time: 5 h; Purification: Filtration from ethanol;
Yield: 312 mg of white solid (1.03 mmol, 27 %); 1H-NMR (400 MHz, DMSO-d6) δ= 1.57-1.63
(m, 2 H, CH2), 1.63-1.69 (m, 4 H, 2xCH2), 3.56-3.60 (m, 2 H, CH2), 3.85-3.90 (m, 2 H, CH2),
6.85 (d, 1 H, 3JH,H = 8.2 Hz, 5-Ar-CH), 6.96 (dd, 1 H, 3,4JH,H = 2.2, 9.2 Hz, 6-Ar-CH), 7.04
(d, 1 H, 4JH,H = 2.2 Hz, 2-Ar-CH), 7.44 (s, 1 H, CH), 9.50 (s(br), 2 H, 2xOH) ppm; 13C-NMR
(400 MHz, DMSO-d6) δ= 23.5 (CH2), 25.2 (CH2), 25.7 (CH2), 48.9 (CH2), 49.8 (CH2), 116.2
(2,5-Ar-CH), 122.9 (6-Ar-CH), 124.5 (Ar-C), 125.2 (Ar-C), 130.5 (CH), 145.8 (Ar-C), 147.8 (Ar-
C), 173.4 (C=O), 179.8 (C=N) ppm; ESI-MS m/z (%) = 305.1 [M+H]+ (96 %), 609.2 [2M+H]+
(41 %); HPLC-Analysis (Method B): 99 %, Rt = 12.6 min.
General Procedure for methylation/ Benzylation of 36f, 36g, and 36h
The rhodanine derivative (1.0 eq), iodo methane or benzyl bromide (1.4 eq) and NaOH (1.2 eq)
were dissolved in ethanol (10 mL). The reaction mixture was stirred at rt for 2 h. After 2 h, the
products were afforded by filtration.
(5Z)-2-(methylsulfanyl)-5-[2- (trifluoromethyl)phenyl]methylidene-1,3-thiazol-4- one 62a
Reaction time: 2 h; Purification: Filtration from ethanol Yield: 24 mg of white solid (0.08
mmol, 48 %); only Z-isomer: 1H-NMR (400 MHz, CDCl3) δ= 2.83 (s, 3 H, CH3), 7.49-7.55 (m,
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1 H, 4-Ar-CH), 7.61-7.67 (m, 2 H, 5,6-Ar-CH), 7.76 (d, 1 H, 3JH,H = 7.8 Hz, 3-Ar-CH), 8.14 (q,
1 H, 5JH,F = 2.0 Hz, CH) ppm; 13C-NMR (400 MHz, CDCl3) δ= 16.3 (CH3), 100.1 (Ar-C), 126.8
(q, 3JC,F=5.5 Hz, 3-Ar-CH), 129.3 (5(6)-Ar-CH), 130.0 (4-Ar-CH), 131.2 (CH), 132.4 (5(6)-CH),
178.6 (C=O), 193.8 (C=N) ppm; ESI-MS m/z (%) = 304.0 [M+H]+ (100 %), 607.0 [2M+H]+ (2 %);
HR-MS m/z = 304.0072 [M+H]+ (calculated: 304.0072); HPLC-Analysis (Method B): 96 %,
Rt = 17.7 min.
(5E/Z)-2-(methylsulfanyl)-5-[3- (trifluoromethyl)phenyl]methylidene-1,3-thiazol-4- one 62b
Reaction time: 2 h; Purification: Filtration from ethanol; Yield: 21 mg of white solid (0.07
mmol, 46 %); 4:3 Z to E isomer ratio: 1H-NMR (400 MHz, CDCl3) δ= 2.69 (s, 3 H, CH3), 2.79
(s, 3 H, CH3), 5.25 (s, 1 H, E-CH), 6.79 (d, 1 H, 3JH,H = 8.0 Hz, E-Ar-CH), 7.00 (s, 1 H, E-2-
Ar-CH), 7.30 (at, 1 H, 3JH,H = 7.8 Hz, E-Ar-CH), 7.43-7.47 (m, 1 H, Ar-CH), 7.43-7.47 (m, 1 H,
Ar-CH), 7.52-7.57 (m, 1 H, Ar-CH), 7.59-7.65 (m, 2 H, 2xZ-Ar-CH), 7.69 (s, 1 H, Z-2-Ar-CH),
7.81 (s, 1 H, Z-CH) ppm; ESI-MS m/z (%) = 304.0 [M+H]+ (100 %), 607.0 [2M+H]+ (100 %),
624.0 [2M+NH4]+ (50 %), 910.0 [3M+H]+ (100 %), 932.0 [3M+Na]+ (60 %), 1213.0 [4M+H]+
(30 %), 1230.0 [4M+NH4]+ (45 %); HR-MS m/z = 304.0070 [M+H]+ (calculated: 304.0072);
HPLC-Analysis (Method B): 96 %, Rt = 17.7 min.
(5Z)-2-(methylsulfanyl)-5-[4- (trifluoromethyl)phenyl]methylidene-1,3-thiazol-4- one 62c
Reaction time: 2 h Purification: Filtration from ethanol; Yield: 25 mg of white solid (0.08
mmol, 48 %); 1H-NMR (400 MHz, DMSO-d6) δ= 2.84 (s, 3 H, E-CH3), 2.85 (s, 3 H, Z-CH3)
4.96 (s, 1 H, E-CH), 6.87 (d, 2 H, 3JH,H = 8.2 Hz, E-3,5-Ar-CH), 7.77 (d, 2 H, 3JH,H = 8.2 Hz,
E-2,6-Ar-CH) 7.86-7.93 (m, 4 H, 4xZ-Ar-CH), 7.94 (s, 1 H, Z-CH) ppm; 13C-NMR (400 MHz,
DMSO-d6) δ= 16.5 (CH3), 54.0 (CH), 72.2 (Ar-C), 125.9 (2,6-Ar-CH), 127.3 (3,5-Ar-CH), 186.6
(C=O), 201.2 (C=N) ppm; ESI-MS m/z (%) = 304.0 [M+H]+ (100 %), 607.0 [2M+H]+ (100 %),
624.0 [2M+NH4]+ (10 %), 629.0 [2M+Na]+ (20 %); HR-MS m/z = 304.0075 [M+H]+ (calculated:
304.0072); HPLC-Analysis (Method B): 87 %, Rt = 20.5 min.
(5Z)-2-(benzylsulfanyl)-5-[2- (trifluoromethyl)phenyl]methylidene-1,3-thiazol-4- one 62d
Reaction time: 3 h Purification: Filtration from ethanol; Yield: 36 mg of white solid (0.09
mmol, 46 %); only Z-isomer: 1H-NMR (400 MHz, CDCl3) δ= 4.67 (s, 2 H, CH2), 7.26-7.40
(m, 5 H, 5xAr-CH), 7.46-7.52 (m, 1 H, 4-Ar-CH), 7.58-7.62 (m, 2 H, 5,6-Ar-CH), 7.73 (d, 1 H,
3JH,H = 7.8 Hz, 3-Ar-CH), 8.13 (q, 1 H, 5JH,F = 2.1 Hz, CH) ppm; 13C-NMR (400 MHz, CDCl3)
δ= 38.2 (CH2), 126.8 (q, 4JC,F=5.5 Hz, 3-Ar-CH), 128.5 (Ar-CH), 129.1 (Ar-CH), 129.3 (5(6)-
Ar-CH), 129.5 (Ar-CH), 129.8 (Ar-C), 130.1 (4-Ar-CH), 131.5 (q, 4JC,F=2.2 Hz, CH), 131.7 (Ar-
C), 132.4 (5(6)-Ar-CH), 133.2 (Ar-C), 134.7 (Ar-C), 178.7 (C=O), 192.7 (C=N) ppm; ESI-MS
m/z (%) = 380.0 [M+H]+ (100 %), 402.0 [M+Na]+ (15 %), 759.1 [2M+H]+ (30 %); HR-MS m/z =
380.0384 [M+H]+ (calculated: 380.0385).
(5Z)-2-(benzylsulfanyl)-5-[3- (trifluoromethyl)phenyl]methylidene-1,3-thiazol-4- one 62e
Reaction time: 3 h; Purification: Filtration from ethanol; Yield: 42 mg of white solid (0.11
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mmol, 54 %); only Z-isomer: 1H-NMR (400 MHz, CDCl3) δ= 4.68 (s, 2 H, CH2), 7.28-7.41
(m, 5 H, 5xAr-CH), 7.54-7.70 (m, 3 H, 3xAr-CH), 7.72 (s, 1 H, 2-Ar-CH), 7.85 (s, 1 H, CH)
ppm; 13C-NMR (400 MHz, CDCl3) δ= 38.3 (CH2), 126.9 (2-Ar-CH), 127.1 (4-Ar-CH), 128.5
(Ar-CH), 128.6 (Ar-C), 129.2 (Ar-CH), 129.5 (Ar-CH), 130.0 (Ar-CH), 130.1 (Ar-C), 133.3
(Ar-CH), 133.9 (CH), 134.6 (q, 4JC,F=3.1 Hz, 5-Ar-CH), 179.7 (C=O), 192.1 (C=N), ppm;
ESI-MS m/z (%) = 380.0 [M+H]+ (100 %), 402.0 [M+Na]+ (20 %), 759.1 [2M+H]+ (100 %), 781.1
[2M+Na]+ (100 %), 797.0 [2M+K]+ (40 %); HR-MS m/z = 380.0388 [M+H]+ (calculated: 380.0385).
(5Z)-2-(benzylsulfanyl)-5-[4- (trifluoromethyl)phenyl]methylidene-1,3-thiazol-4- one 62f
Z to E 1:1 mixture Reaction time: 3 h; Purification: Filtration from ethanol; Yield: 52 mg
of white solid (0.14 mmol, 57 %); 1H-NMR (400 MHz, DMSO-d6) δ= 4.61 (s, 2 H, CH2), 4.75
(s, 2 H, CH2), 5.46 (s, 1 H, E-CH), 7.27-7.42 (m, 10 H, 10xAr-CH), 7.48-7.52 (m, 2 H, 2xAr-
H), 7.72 (d, 2 H, 3JH,H = 8.2 Hz, 2xAr-CH), 7.87 (d, 2 H, ,J8.6 Hz = 2xAr-CH, 3) 7.90 (d, 2 H,
,J8.6 Hz = 2xAr-CH, 3) 7.96 (s, 1 H, Z-CH) ppm; 13C-NMR (400 MHz, DMSO-d6) δ= 36.9 (CH2),
37.0 (CH2), 57.5 (E-CH), 125.3 (q, 4JC,F = 4.1 Hz, 2xAr-CH), 126.2 (q, 4JC,F = 3.8 Hz, 2xAr-CH),
128.0 (2xAr-CH), 128.7 (Ar-CH), 128.8 (Ar-CH), 128.9 (Ar-CH), 129.2 (Ar-CH), 129.3 (Ar-CH),
129.4 (Ar-CH), 130.9 (2xAr-CH), 133.3 (CH), 135.2 (Ar-C), 135.5 (Ar-C), 178.7 (C=O), 186.9
(C=O), 192.0 (C-S), 200.2 (C-S) ppm; ESI-MS m/z (%) = 380.0 [M+H]+ (100 %), 402.0 [M+Na]+
(15 %), 418.0 [M+K]+ (10 %), 759.1 [2M+H]+ (85 %), 781.1 [2M+Na]+ (100 %), 797.0 [2M+K]+
(40 %); HR-MS m/z = 380.0388 [M+H]+ (calculated: 380.0385); HPLC-Analysis (Method B):
48 %, Rt = 20.9 min.
9.17 Synthesis of photo-label affinity probe
Synthesis of phosphorochloridate 31
Prior to reaction, phosphoryl trichloride (8.75 mL, 94 mmol) was distilled. The clear solution
of phosphoryl trichloride was subjected to 2,4-dichlorophenol (24.45 g, 150 mmol) and mag-
nesium turnings (80 mg, 3.3 mmol). The reaction mixture was slowly heated to 120 ◦C. HCl
fumes were collected in a cooling trap and neutralised with concentrated NaOHaq. After 3 h,
the reaction temperature was increased to 160 ◦C and stirring was continued for another 3 h.
The product was afforded via fractionated destillation (bp 200 ◦C, 0.02 mm Hg). The first
fraction of the destination (bp 180 ◦C, 0.02 mm Hg) was the dichloro-mono-ester and this frac-
tion was recovered and subjected to fresh 2,4-dichlorophenol and magnesium turnings (same
equivalents as described above). The combined yield and product characterisation is stated
below.
Bis(2,4-dichlorophenyl) chlorophosphonate 31a [182]
Purification: Fractionated destilation of product. Yield: 15230 mg of white solid (37.50 mmol,
80 %); Yield: 34000 mg of white solid (83.66 mmol, 89 %); 1H-NMR (400 MHz, CDCl3) δ=
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7.27 (dd, 2 H, 3,4JH,H = 2.4, 8.9 Hz, 5,5’-Ar-CH), 7.46-7.49 (m, 2 H, 3,3’-Ar-CH), 7.49 (dd, 2 H,
3,4JH,H = 1.2, 8.9 Hz, 6,6’-Ar-CH) ppm; 31P-NMR (400 MHZ, CDCl3) δ= 18.84 (P=OCl) ppm;
13C-NMR (400 MHz, CDCl3) δ= 122.4 (6-Ar-CH) 122.5 (6’-Ar-CH), 126.7 (Ar-C), 126.8 (Ar-C),
128.3 (5,5’-Ar-CH), 130.8 (3,3’-Ar-CH), 132.0 (Ar-C), 145.0 (Ar-C), 145.1 (Ar-C) ppm;
2,4-dichlorophenoxyphosphonoyl dichloride 31b [182]
1H-NMR (400 MHz, CDCl3) δ= 7.21 (dd, 1 H, 3,4JH,H = 1.6, 8.8 Hz, 5-Ar-CH), 7.33 (dd, 1 H,
3,4JH,H = 2.2, 8.8 Hz, 6-Ar-CH), 7.41-7.43 (m, 1 H, 3-Ar-CH) ppm; 31P-NMR (400 MHZ, CDCl3)
δ= 4.38 (P=OCl) ppm;
Representative procedure for the synthesis of diol-amine 33b
Dimethyl 5-aminoisophthalate (10 g, 47.8 mmol) was dissolved in THF (anhydrous, 200 mL)
under a nitrogen gas atmosphere. LiAlH4 (4.9 g, 143 mmol) was added in small portions
at 0 ◦C. The reaction mixture was stirred 8 h at rt and then cooled to 0 ◦C. The reaction
was quenched with NaOHaq (w/v %: 20 %, 20 mL). The crude was filtered through cellite,
washed with EtOAc and concentrated. Purification by flash column chromatography (EtOAc
→ EtOAc/MeOH 9:1, Rf 0.2) afforded the product (6.45 g, 88 %) as a yellow solid.
[3-amino-5-(hydroxymethyl)phenyl]methanol [349]
TLC Rf = 0.2 (EtOAc); Purification: Flash-Chromatography EtOAc → EtOAc/MeOH 9:1
(Rf = 0.2); Yield: 695 mg of yellow solid (4.54 mmol, 95 %) (1 g scale); Yield: 717 mg of
yellow solid (4.68 mmol, 98 %) (1 g scale); Yield: 6454 mg of yellow solid (42.13 mmol, 88 %)
(10 g scale); 1H-NMR (400 MHz, DMSO-d6) δ= 4.32 (d, 4 H, 3JH,H = 5.8 Hz, CH2), 4.94 (s(br),
2 H, NH2), 4.96 (t, 2 H, 3JH,H = 5.8 Hz, OH), 6.40 (s, 3 H, 3xAr-CH) ppm; 13C-NMR (400 MHz,
DMSO-d6) δ= 63.3 (CH2), 110.6 (2,6-Ar-CH) 112.4 (4-Ar-CH), 142.8 (Ar-C), 148.3 (Ar-C)
ppm; 1H-NMR (400 MHz, MeOD) δ= 4.48 (s, 4 H, 2xCH2), 6.63 (s, 2 H, 2,6-Ar-CH), 6.67 (s,
1 H, 4-Ar-CH) ppm; 13C-NMR (400 MHz, MeOD) δ= 65.4 (CH2), 114.2 (2,6-Ar-CH), 116.6
(4-Ar-CH), 143.7 (Ar-C), 148.9 (Ar-C) ppm.
Representative protocol for the synthesis of azido-diol 33c
The amino-diol 33b (1.00 g, 6.53 mmol, 1.0 eq) and t-BuONO (815µL, 7.69 mmol, 1.2 eq) were
dissolved in anhydrous acetonitrile (20 mL) under a N2 gas atmosphere. TMS-N3 (1110µL,
9.23 mmol, 1.4 eq) was added in five portions to the reaction mixture. The mixture was stirred
2 h at rt. The crude was concentrated and purified by flash column chromatography. Condi-
tions, yields and analytical data below.
[3-azido-5-(hydroxymethyl)phenyl]methanol 33c [349]
TLC Rf = 0.3 (Hexane/EtOAc 3:7); Purification: Flash-Chromatography Hexane/EtOAc 3:7
(Rf = 0.3); Yield: 1150 mg of yellow solid (6.42 mmol, 98 %); Yield: 2170 mg of yellow solid
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(12.11 mmol, 98 %); 1H-NMR (400 MHz, MeOD) δ= 4.58 (s, 4 H, 2xCH2), 6.95 (s, 2 H, 2,6-Ar-
CH), 7.10 (s, 1 H, 4-Ar-CH) ppm; 13C-NMR (400 MHz, MeOD) δ= 64.5 (CH2), 116.9 (2,6-Ar-
CH), 122.7 (Ar-C), 141.6 (4-Ar-CH), 145.2 (Ar-C-N3) ppm.
Representative reaction for the synthesis of the di-azido alcohol 33d
[3-azido-5-(azidomethyl)phenyl]methanol 33d [349]
TLC Rf = 0.4 (Hexane/EtOAc 7:3); Purification: Flash-Chromatography Hexane/EtOAc 7:3
→ 1:1 (Rf = 0.4); Yield: 843 mg of yellow oil (4.13 mmol, 74 %); Yield: 1481 mg of yellow oil
(7.26 mmol, 65 %); Yield: 943 mg of yellow oil (4.62 mmol, 75 %); Yield: 634 mg of yellow
oil (3.11 mmol, 54 %); Yield: 388 mg of yellow oil (1.90 mmol, 73 %); 1H-NMR (400 MHz,
CDCl3) δ= 2.57 (s(br), 1 H, OH), 4.32 (s, 2 H, CH2N3), 4.65 (s, 2 H, CH2OH), 6.87 (s, 1 H,
6-Ar-CH), 6.98 (s, 1 H, 2-Ar-CH), 7.05 (s, 1 H, 4-Ar-CH) ppm; 13C-NMR (400 MHz, CDCl3)
δ= 54.3 (CH2), 64.3 (CH2), 117.0 (Ar-CH), 117.7 (Ar-C), 122.7 (Ar-CH), 137.7 (Ar-C), 141.0
(Ar-C), 143.6 (Ar-CH) ppm; 1H-NMR (400 MHz, MeOD) δ= 4.33 (s, 2 H, CH2), 4.59 (s, 2 H,
CH2), 6.89 (s, 1 H, Ar-CH), 7.01 (s, 1 H, Ar-CH), 7.10 (s, 1 H, Ar-CH) ppm.
Installation of the tosyl-leaving group, synthesis of
The azido-alcohol 33d (500 mg, 2.45 mmol, 1.0 eq) was dissolved in DCM (20 mL). NEt3 (849µL,
6.09 mmol, 2.5 eq) was added to the reaction mixture, followed by TsCl (529 mg, 2.78 mmol,
1.1 eq) at 0 ◦C. The reaction mixture was maintained at 0 ◦C until TLC (hexane/EtOAc 7:3, Rf
0.6) showed complete consumption of 33d. The reaction mixture was quenched with water
(20 mL). The crude was extracted with DCM (3x30 mL), washed with brine (10 mL), dried over
MgSO4, filtered and concentrated. Purification by flash column chromatography afforded the
tosylated di-azido compound 33e.
[3-azido-5-(azidomethyl)phenyl]methyl 4-methylbenzenesulfonate 33e [349]
TLC Rf = 0.6 (Hexane/EtOAc 7:3); Purification: Flash-Chromatography Hexane/EtOAc 9:1→
7:3 (Rf = 0.2), DCM; Yield: 396 mg of yellow oil (1.10 mmol, 45 %) (500 mg scale); Yield: 1533
mg of yellow oil (4.28 mmol, 76 %)(1150 mg scale); Yield: 402 mg of yellow oil (1.12 mmol,
35 %)655.1 mg scale); 1H-NMR (400 MHz, CDCl3) δ= 2.45 (s, 3 H, CH3), 4.31 (s, 2 H, CH2),
5.03 (s, 2 H, CH2), 6.82 (s, 1 H, Ar-CH), 6.91 (s, 1 H, Ar-CH), 6.97 (s, 1 H, Ar-CH), 7.34 (d, 2 H,
3JH,H = 8.3 Hz, 3,5-Ts-CH), 7.80 (d, 2 H, 3JH,H = 8.3 Hz, 2,6-Ts-CH) ppm; 13C-NMR (400 MHz,
CDCl3) δ= 21.8 (CH3), 54.1 (CH2), 70.8 (CH2), 118.5 (Ar-CH), 119.0 (Ar-CH), 124.2 (Ar-CH),
128.1 (2,6-Ts-CH), 130.1 (3,5-Ts-CH), 133.1 (Ar-C), 136.2 (Ar-C), 138.2 (Ar-C), 141.4 (Ar-C),
145.3 (Ar-C) ppm;
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Synthesis of modified photo-affinity aldehyde 33f
3-Hydroxybenzaldehyde (151 mg, 1.23 mmol, 1.1 eq) and potassium carbonate (346 mg, 2.50
mmol, 2.2 eq) were dissolved in DMF (10 mL). Tosyl derivative 33f (402 mg, 1.12 mmol, 1.0 eq)
was added to the reaction mixture. The mixture was stirred at 50 ◦C for 4 h. The reaction mix-
ture was concentrated and purified by flash column chromatography. See below for conditions,
yields and analytical details.
3-[3-azido-5-(azidomethyl)phenyl]methoxybenzaldehyde 33f
TLC Rf = 0.7 (Hexane/EtOAc 7:3); Reaction time: 2-4 h; Purification: Flash-Chromatogra-
phy Hexane/EtOAc 9:1 → 7:3 (Rf = 0.2), DCM; Yield: 267 mg of clear oil (0.87 mmol, 86 %)
(396 mg of 33f scale); Yield: 262 mg of clear oil (0.85 mmol, 69 %) (402 mg of 33f scale); 1H-
NMR (400 MHz, CDCl3) δ= 4.34 (s, 2 H, CH2), 5.06 (s, 2 H, CH2), 6.92 (s, 1 H, Ar-CH), 7.05
(s, 1 H, Ar-CH), 7.14 (s, 1 H, Ar-CH), 7.21-7.24 (m, 1 H, Ar-CH), 7.41-7.48 (m, 3 H, 3xAr-CH)
ppm; 13C-NMR (400 MHz, CDCl3) δ= 54.1 (CH2), 69.2 (CH2), 113.1 (Ar-CH), 117.5 (Ar-CH),
118.1 (Ar-CH), 122.0 (Ar-CH), 123.1 (Ar-CH), 124.0 (Ar-CH), 130.2 (Ar-CH), 137.9 (Ar-C),
138.0 (Ar-C), 139.1 (Ar-C), 141.1 (Ar-C), 158.9 (Ar-C), 191.8 (CHO) ppm;
Synthesis of rhodanine-N-acetic ethyl ester photo-affinity probe 34
Rhodanine-N-acetic ethyl ester 14 (189 mg, 0.86 mmol, 1.0 eq), the aldehyde 33f (266 mg,
0.86 mmol, 1.0 eq) and sodium acetate (71 mg, 0.86 mmol, 1.0 eq) were dissolved in EtOH
(10 mL) and stirred at 50 ◦C for 2 h. The reaction mixture was concentrated and purified by
flash column chromatography.
Ethyl 2-[(5Z)-5-[(3-[3-azido-5-(azidomethyl)phenyl]methoxyphenyl) methylidene] 4-oxo-2-sul-
fanylidene-1,3-thiazolidin-3-yl] acetate 34
TLC Rf = 0.5 (Hexane/EtOAc 8:2); Reaction time: 2 h; Purification: Flash-Chromatography
Hexane/EtOAc 95:5 → 9:1 (Rf = 0.3), DCM; Yield: 168 mg of red solid (0.33 mmol, 38 %);
1H-NMR (400 MHz, CDCl3) δ= 1.29 (t, 3 H, 3JH,H = 7.1 Hz, CH3), 4.23 (q, 2 H, 3JH,H = 7.1 Hz,
CH2CH3), 4.39 (s, 2 H, CH2), 4.83 (s, 2 H, CH2), 5.10 (s, 2 H, CH2), 6.95 (s, 1 H, Ar-CH),
6.98-7.01 (m, 1 H, Ar-CH), 7.04-7.08 (m, 2 H, 2,4-Ar-CH), 7.11 (d, 1 H, 3JH,H = 7.8 Hz, 6-
Ar-CH), 7.17 (s, 1 H, Ar-CH), 7.39 (at, 1 H, 3JH,H = 7.8, 8.0 Hz, 5-Ar-CH), 7.69 (s, 1 H, CH)
ppm; 13C-NMR (400 MHz, CDCl3) δ= 14.2 (CH3), 44.9 (CH2), 54.2 (CH2), 62.2 (CH2CH3),
69.4 (CH2), 115.8 (Ar-CH), 117.5 (2-Ar-CH), 118.2 (4-Ar-CH), 118.3 (Ar-CH), 123.1 (Ar-CH),
123.2 (Ar-C), 124.2 (6-Ar-CH), 130.6 (5-Ar-CCH), 133.7 (CH), 134.6 (Ar-C), 138.2 (Ar-C),
139.2 (Ar-C), 141.3 (Ar-C), 158.9 (Ar-C), 165.9 (C=O), 167.0 (COOEt), 192.9 (C=S) ppm;
ESI-MS m/z (%) = 527.1 [M+NH4]+ (100 %), 532.1 [M+Na]+ (50 %), 548.1 [M+K]+ (25 %), 1036.2
[2M+NH4]+ (100 %), 1041.2 [2M+Na]+ (100 %) 1057.2 [2M+K]+ (75 %); HR-MS m/z = 527.1275
[M+NH4]+ (calculated: 527.1278); HPLC-Analysis (Method B): 90 %, Rt = 18.8 min.
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9.18 Synthesis of pyrazole derivatives
Synthesis of Pyrazole derivatives using traditional heating and NaOAc/HOAc
Representative procedure for the synthesis of N-phenyl-pyrazole precursor 80 for Kno-
evenagel reaction
Phenylhydrazine (200µL, 2.03 mmol), ethyl 3-oxobutanoate (260µL, 2.03 mmol) were dis-
solved in glacial HOAc (5 mL). The reaction mixture was stirred at 100-110 ◦C for 12 h or until
TLC showed complete consumption of starting material.
edaravone 80 [350]
TLC Rf = 0.3 (Hexane/EtOAc 1:1); Reaction time: 12 h; Purification: Flash-Chromatogra-
phy Cyclohexan/EtOAc 7:3 (Rf = 0.1); Yield: 343 mg of white solid (1.97 mmol, 97 %) (scale:
2.03 mmol); Yield: 650 mg of white solid (3.73 mmol, 92 %) (scale: 4.06 mmol); 1H-NMR (400
MHz, CDCl3) δ= 2.26 (s, 3 H, CH3), 3.49 (s, 2 H, CH2), 7.27-7.32 (m, 1 H, 1xAr-CH), 7.48-7.54
(m, 2 H, 2xAr-CH), 7.96-8.01 (m, 2 H, 2xAr-CH) ppm; 13C-NMR (400 MHz, CDCl3) δ= 16.9
(CH3), 43.0 (CH2), 118.8 (2x-Ar-CH), 125.0 (Ar-CH), 128.8 (2x-Ar-CH), 138.0 (Ar-C), 156.4
(Ar-C), 170.6 (C=O) ppm; HPLC-Analysis (Method B): 96 %, Rt = 8.2 min.
Representative procedure for the synthesis of N-(3-benzoic-acid)-pyrazole precursor 81
for Knoevenagel reaction
3-Hydrazinylbenzoic acid (128 mg, 0.84 mmol), ethyl 3-oxobutanoate (108µL, 0.84 mmol) were
dissolved in glacial HOAc (6 mL). The orange reaction mixture was stirred at 100-110 ◦C until
TLC showed complete consumption of starting material.
3-(3-methyl-5-oxo-4H-pyrazol-1-yl)benzoic acid 81 [351]
TLC Rf = 0.1 (Toluene/MeOH 8:2); TLC Rf = 0.5 (DCM/MeOH 9:1); Reaction time: 16 h
Purification: Flash-Chromatography Toluene/MeOH 8:2 (Rf = 0.1); Yield: 150 mg of white
solid (0.69 mmol, 81 %); Yield: 23 mg of white solid (0.11 mmol, 20 %); 1H-NMR (400 MHz,
MeOD) δ= 2.24 (s, 3 H, ) 7.56 (at, 1 H, 3JH,H = 8.0 Hz, 5-Ar-CH), 7.89-7.95 (m, 2 H, 4,6-Ar-
CH), 8.30 (at, 1 H, 4JH,H = 1.9 Hz, 2-Ar-CH) ppm; 1H-NMR (400 MHz, DMSO-d6) δ= 2.46 (d,
3 H, 4JH,H = 1.0 Hz, CH3), 5.98 (q, 1 H, 4JH,H = 1.0 Hz, CH), 7.71 (at, 1 H, 3JH,H = 8.1, 7.8 Hz,
5-Ar-CH), 7.93-7.96 (m, 1 H, 6-Ar-CH), 8.06 (ddd, 1 H, 3,4JH,H = 8.1, 2.2, 0.9 Hz, 4-Ar-CH),
8.37 (at, 1 H, 4JH,H = 1.9, 1.8 Hz, 2-Ar-CH), 13.32 (s(br), 1 H, COOH) ppm; HPLC-Analysis
(Method B): 99 %, Rt = 8.6 min.
Knoevenagel reaction with N-phenyl pyrazole 80 and benzaldehyde derivatives
N-phenyl pyrazole 80 (0.29 mmol, 1.0 eq)), benzaldehyde derivative (0.58 mmol, 2.0 eq) and
NaOAc (0.29 mmol, 1.0 eq) were dissolved in EtOH (5 mL) and stirred at 100 ◦C until TLC
showed complete consumption of starting material.
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(4Z)-3-methyl-4-[(3-nitrophenyl)methylidene]-1-phenyl-4,5-dihydro-1H-pyrazol-5-one 80a [352]
TLC Rf = 0.6 (Hexane/EtOAc 7:3); Reaction time: 4 h; Purification: Filtration from methanol;
Yield: 17 mg of red solid (0.55 mmol, 13 %); NOESY (CH3,CH → Z) 1H-NMR (400 MHz,
CDCl3) δ= 2.38 (s, 3 H, CH3), 7.21 (at, 1 H, 3JH,H = 7.5 Hz, 4-Ar-CH), 7.39-7.45 (m, 3 H, 2xAr-
CH, CH), 7.70 (dd, 1 H, 3JH,H = 8.1, 7.9 Hz, 5’-Ar-CH), 7.91-7.96 (m, 2 H, 2,6-Ar-CH), 8.37
(ddd, 1 H, 3,4JH,H = 8.1, 2.0, 1.0 Hz, 4’-Ar-CH), 8.95 (d, 1 H, 3JH,H = 7.9 Hz, 6’-Ar-CH), 9.18
(at, 1 H, 4JH,H = 2.0 Hz, 2’-Ar-CH) ppm; 1H-NMR (400 MHz, DMSO-d6) δ= 2.36 (s, 3 H, CH3),
7.22 (at, 1 H, 3JH,H = 7.5 Hz, 4-Ar-CH), 7.46 (dd, 2 H, 3JH,H = 7.5, 7.8, 3,5-Ar-CH), 7.84 (at,
1 H, 3JH,H = 7.9 Hz, 5’-Ar-CH), 7.88 (d, 2 H, 3JH,H = 7.8 Hz, 2,6-Ar-CH), 8.02 (s, 1 H, CH), 8.43
(dd, 1 H, 3,4JH,H = 8.2, 1.8 Hz, 4’-Ar-CH), 8.84 (d, 1 H, 3JH,H = 7.9 Hz, 6’-Ar-CH), 9.61 (dd, 1 H,
4JH,H = 1.8 Hz, 2’-Ar-CH) ppm; 13C-NMR (400 MHz, DMSO-d6) δ= 13.1 (CH3), 118.5 (2,6-
Ar-CH), 124.9 (4-Ar-CH), 126.9 (4’-Ar-CH), 127.4 (2’-Ar-CH), 128.8 (3,5-Ar-CH), 128.9 (5’-
Ar-CH), 130.2 (Ar-C), 134.1 (Ar-C), 137.9 (Ar-C), 139.4 (6’-Ar-CH), 145.4 (CH), 147.8 (Ar-C),
151.8 (Ar-C), 161.3 (C=O) ppm; ESI-MS m/z (%) = 308.1 [M+H]+ (80 %), 340.1 [M+CH3OH+H]+
(100 %); HR-MS m/z = 308.1032 [M+H]+ (calculated: 308.1030); HPLC-Analysis (Method B):
66 %, Rt = 19.7 min.
(4Z)-5-methyl-4-[(3-methylphenyl)methylidene]-2- phenylpyrazol-3-one 80b [353]
Reaction time: 4 h Purification: Filtration from EtOAc Yield: 26 mg of yellow solid (0.09
mmol, 14 %); 1H-NMR (400 MHz, DMSO-d6) δ= 2.35 (s, 3 H, CH3), 2.40 (s, 3 H, CH3), 7.18-
7.23 (m, 1 H, Ar-CH), 7.41-7.48 (m, 4 H, 4xAr-CH), 7.80 (s, 1 H, CH), 7.88-7.92 (m, 2 H, 2xAr-
CH), 8.41-8.45 (m, 2 H, 2xAr-CH) ppm.
5-methyl-2-phenyl-4-[2- (trifluoromethyl)phenyl]methylidenepyrazol-3-one 80c
1:1 mixture of E to Z
TLC Rf = 0.5 (Hexane/EtOAc 8:2); Reaction time: 20 min; Purification: Flash-Chromatogra-
phy Hexane/EtOAc 95:5 (Rf = 0.1); Yield: 30 mg of red solid (0.08 mmol, 15 %); 1H-NMR (400
MHz, CDCl3) δ= 1.80 (s, 3 H, CH3), 2.29 (s, 3 H, CH3), 7.08-7.16 (m, 2 H, 2xAr-CH), 7.29-7.39
(m, 5 H, 5xAr-CH), 7.50-7.61 (m, 4 H, 4xAr-CH), 7.69-7.75 (m, 3 H, Z-CH, 2xAr-CH), 7.81-7.84
(m, 2 H, 2xAr-CH), 7.86-7.89 (m, 2 H, 2xAr-CH), 8.11 (q, 1 H, 5JH,F = 1.8 Hz, E-CH), 8.42 (d,
1 H, 3JH,H = 7.7 Hz, Ar-CH) ppm.
(Z)-4-(2,4-dihydroxybenzylidene)-3-methyl-1-phenyl-1H-pyrazol-5(4H)-one 80d [354]
TLC Rf = 0.1 (Hexane/EtOAc 7:3); Reaction time: 1 h; Purification: Filtration from HOAc;
Yield: 60 mg of red solid (0.20 mmol, 31 %); 1H-NMR (400 MHz, DMSO-d6) δ= 2.28 (s, 3 H,
CH3), 6.39 (dd, 1 H, 3,4JH,H = 2.4, 8.9 Hz, 4-Ar-CH), 6.43 (d, 1 H, 4JH,H = 2.4 Hz, 2-Ar-CH),
7.16 (at, 1 H, 3JH,H = 7.5 Hz, 4’-Ar-CH), 7.41 (at, 2 H, 3JH,H = 7.9 Hz, 3’,5’-Ar-CH), 7.93 (d, 2 H,
3JH,H = 7.7 Hz, 2’,6’-Ar-CH), 7.96 (s, 1 H, CH), 9.35 (d, 1 H, 3JH,H = 8.9 Hz, 5-Ar-CH), 10.88 (s,
2 H, 2xOH) ppm; 13C-NMR (400 MHz, DMSO-d6) δ= 13.2 (CH3), 101.8 (2-Ar-CH), 108.5 (4-
Ar-CH), 113.1 (Ar-C), 118.2 (2’,6’-Ar-CH), 119.8 (Ar-C), 124.2 (4’-Ar-CH), 128.7 (3’,5’-Ar-CH),
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132.3 (Ar-C), 135.8 (5-Ar-CH), 138.7 (Ar-C), 141.3 (CH), 151.8 (Ar-C), 162.3 (Ar-C), 162.6
(Ar-C), 165.9 (Ar-C) ppm; ESI-MS m/z (%) = 293.1 [M−H]− (100 %); HR-MS m/z = 293.0928
[M−H]− (calculated: 293.0932); HPLC-Analysis (Method B): 92 %, Rt = 17.0 min.
(4Z)-4-[3,4-bis(benzyloxy)phenyl]methylidene-5- methyl-2-phenylpyrazol-3-one 80e
TLC Rf = 0.3 (Hexane/EtOAc 8:2); Reaction time: 30 min; Purification: Re-crystallisation
from ethanol; Yield: 130 mg of red crystals (0.27 mmol, 46 %); NOESY (CH3,CH → Z) 1H-
NMR (400 MHz, DMSO-d6) δ= 2.32 (s, 3 H, CH3), 5.22 (s, 2 H, CH2), 5.30 (s, 2 H, CH2), 7.19
(at, 1 H, 3JH,H = 7.6 Hz, 4-Ar-CH), 7.28 (d, 1 H, 3JH,H = 8.6 Hz, 6’-Ar-CH), 7.30-7.52 (m, 12 H,
12xAr-CH), 7.73 (s, 1 H, CH), 7.93 (d, 2 H, 3JH,H = 7.6 Hz, 3,5-Ar-CH), 8.12 (dd, 1 H, 3,4JH,H =
1.9, 8.6 Hz, 5’-Ar-CH), 8.90 (d, 1 H, 4JH,H = 1.9 Hz, 3’-Ar-CH), 13C-NMR (400 MHz, DMSO-d6)
δ= 13.2 (CH3), 69.9 (CH2), 70.1 (CH2), 113.3 (6’-Ar-CH), 118.4 (3,5-Ar-CH or 3’-Ar-CH), 188.5
(3,5-Ar-CH or 3’-Ar-CH), 123.9 (Ar-C), 124.5 (4-Ar-CH), 126.5 (Ar-C), 127.7 (Ar-CH), 128.0
(Ar-CH), 128.5 (Ar-CH), 128.9 (Ar-CH), 130.7 (5’-Ar-CH), 136.5 (Ar-C), 136.7 (Ar-C), 138.4
(Ar-C), 147.4 (Ar-C), 148.5 (CH), 151.8 (Ar-C), 153.1 (Ar-C), 161.9 (C=O) ppm; APCI-MS
m/z (%) = 475.2 [M+H]+ (100 %); HR-MS m/z = 475.2008 [M+H]+ (calculated: 475.2016); HPLC-
Analysis (Method B): 90 %, Rt = 22.5 min.
(Z)-4-(4-hydroxybenzylidene)-3-methyl-1-phenyl-1H-pyrazol-5(4H)-one 80f [355]
TLC Rf = 0.3 (Hexane/EtOAc 6:4); Purification: Filtration from Cyclohexan/EtOAc 9:1; Yield:
65 mg of red solid (0.23 mmol, 80 %); NOESY (CH3,CH→ Z) 1H-NMR (400 MHz, DMSO-d6)
δ= 2.32 (s, 3 H, CH3), 6.94 (d, 2 H, 3JH,H = 8.9 HZ, 3,5-Ar-CH), 7.18 (at, 1 H, 3JH,H = 7.4 Hz, 4’-
Ar-CH), 7.43 (dd, 2 H, 3JH,H = 7.4, 8.4 Hz, 3,5-’Ar-CH), 7.70 (s, 1 H, CH), 7.93 (dd, 2 H, 3JH,H =
7.4, 8.4 Hz, 2,6-’Ar-CH), 8.64 (d, 2 H, 3JH,H = 8.9 Hz, 2,6-Ar-CH) 10.84 (s(br), 1 H, OH), ppm;
13C-NMR (400 MHz, DMSO-d6) δ= 13.2 (CH3), 115.9 (3,5-Ar-CH), 118.3 (2,6’-Ar-CH), 122.5
(Ar-C), 124.4 (4’-Ar-CH), 124.9 (Ar-C), 128.8 (3,5’-Ar-CH), 137.5 (2,6-Ar-CH), 138.5 (Ar-C),
148.5 (CH), 151.8 (Ar-C), 162.0 (Ar-C), 163.2 (Ar-C), ppm; ESI-MS m/z (%) = 277.1 [M−H]−
(100 %); HR-MS m/z = 277.0985 [M−H]− (calculated: 277.0983); HPLC-Analysis (Method
B): 94 %, Rt = 17.5 min.
(4Z)-4-[(2-hydroxyphenyl)methylidene]-5-methyl-2- phenylpyrazol-3-one 80an [356]
ESI-MS m/z (%) = 279.1 [M+H]+ (65 %), 557.2 [2M+H]+ (36 %), 579.2 [2M+Na]+ (2 %).
Synthesis of pyrazole derivatives using microwave-assisted three-component one-pot
reaction
Aryl hydrazine (0.30 mmol, 1.0 eq), ethyl-aceto-acetate (0.45 mmol, 1.5 eq) and benzaldehyde
derivative (0.3 mmol) were placed in microwave proof glass tube and heated 5 min at 400 W.
Ethylacetate was added to the cooled reaction mixture and the products were afforded after
simple filtration.
3-[(4Z)-4-[3,4-bis(benzyloxy)phenyl]methylidene-3- methyl-5-oxopyrazol-1-yl] benzoic acid 81a
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TLC Rf = 0.1 (Toluene/MeOH 9:1); Reaction time: 5 min (MWI, 400 W); Purification: Filtra-
tion from EtOAc; Yield: 37 mg of red solid (0.07 mmol, 13 %); NOESY (CH3,CH→ Z) 1H-NMR
(400 MHz, DMSO-d6) δ= 2.34 (s, 3 H, CH3), 5.23 (s, 2 H, CH2), 5.30 (s, 2 H, CH2), 7.27-7.60
(m, 12 H, 12xAr-CH), 7.75 (s, 1 H, CH), 7.73-7.78 (m, 1 H, ) 8.16 (d, 1 H, 3JH,H = 8.5 Hz, Ar-
CH), 8.21 (d, 1 H, 3JH,H = 8.5 Hz, Ar-CH), 8.54 (s, 1 H, Ar-CH), 8.84 (s, 1 H, Ar-CH), 13.11
(s(br), 1 H, COOH) ppm; 13C-NMR (400 MHz, DMSO-d6) δ= 13.2 (CH3), 70.1 (2xCH2), 113.3
(Ar-CH), 118.5 (Ar-CH), 118.8 (Ar-CH), 122.1 (Ar-CH), 123.6 (Ar-C or Ar-CH), 125.1 (Ar-C or
Ar-CH), 126.5 (Ar-C or Ar-CH), 127.7 (Ar-CH), 127.9 (Ar-CH), 128.0 (Ar-CH), 128.1 (Ar-CH),
128.4 (Ar-CH), 128.5 (Ar-CH) 129.2 (Ar-CH), 130.7 (Ar-CH), 136.4 (Ar-C or Ar-CH), 136.7
(Ar-C or Ar-CH), 138.5 (Ar-C or Ar-CH), 147.4 (Ar-C or Ar-CH), 148.9 (CH), 152.3 (Ar-C or Ar-
CH), 153.2 (Ar-C or Ar-CH), 162.1 (Ar-C), 167.1 (C=O), ppm; ESI-MS m/z (%) = 517.2 [M−H]−
(100 %), 1035.4 [2M−H]− (20 %); HR-MS m/z = 517.1775 [M−H]− (calculated: 517.1769);
HPLC-Analysis (Method B): 74 %, Rt = 21.5 min.
3-[(4Z)-4-[(3-bromo-4-methoxyphenyl)methylidene]-3- methyl-5-oxopyrazol-1-yl] benzoic acid
81b
TLC Rf = 0.5 (DCM/MeOH 9:1); Reaction time: 5 min (MWI, 400W); Purification: Filtration
from ethanol; Yield: 53 mg of red solid (0.13 mmol, 24 %); 1H-NMR (400 MHz, DMSO-d6) δ=
2.33 (s, 3 H, CH3), 3.99 (s, 3 H, OCH3), 7.33 (d, 1 H, 3JH,H = 8.8 Hz, 5-Ar-CH), 7.56 (at, 1 H,
3JH,H = 8.2, 7.7 Hz, 5’-Ar-CH), 7.76 (adt, 1 H, 3,4JH,H = 7.7, 1.3 Hz, 4’-Ar-CH), 7.79 (s, 1 H, CH),
8.18 (ddd, 1 H, 3,4JH,H = 8.2, 2.3, 1.1 Hz, 6’-Ar-CH), 8.53 (at, 1 H, 4JH,H = 1.9 Hz, 2’-Ar-CH),
8.57 (dd, 1 H, 3,4JH,H = 8.8, 2.1 Hz, 6-Ar-CH), 9.23 (d, 1 H, 4JH,H = 2.1 Hz, 2-Ar-CH), 13.09
(s(br), 1 H, COOH) ppm; 13C-NMR (400 MHz, DMSO-d6) δ= 13.1 (CH3), 56.9 (OCH3), 110.8
(Ar-C), 112.6 (5-Ar-CH), 118.7 (2’-Ar-CH), 122.1 (6’-Ar-CH), 124.7 (Ar-C), 125.2 (4’-Ar-CH),
127.3 (Ar-C), 129.3 (5’-Ar-CH), 131.4 (Ar-C), 136.7 (6-Ar-CH), 138.1 (2-Ar-CH), 138.4 (Ar-C),
147.0 (CH), 152.3 (Ar-C), 159.3 (Ar-C), 161.9 (C=O), 167.0 (COOH) ppm; ESI-MS m/z (%) =
413.0 [M−H]− (100 %), 829.0 [2M−H]− (25 %); HR-MS m/z = 413.0151 [M−H]− (calculated:
413.0142); HR-MS m/z = 413.0148 [M−H]− (calculated: 413.0142); HPLC-Analysis (Method
B): 73 %, Rt = 19.0 min.
3-[(4Z/E)-4-[3-(benzyloxy)phenyl]methylidene-3- methyl-5-oxopyrazol-1-yl] benzoic acid 81c
TLC Rf = 0.1 (DCM/MeOH 9:1); Reaction time: 5 min (MWI, 400 W); Purification: Filtration
from EtOAc; Yield: 56 mg of red solid (0.14 mmol, 25 %); 1H-NMR (400 MHz, DMSO-d6) δ=
2.36 (s, 3 H, CH3), 5.20 (s, 2 H, CH2), 7.30 (dd, 1 H, 3,4JH,H = 2.4, 8.0 Hz, Ar-CH), 7.32-7.37 (m,
1 H, Ar-CH), 7.39-7.44 (m, 2 H, 2xAr-CH), 7.46-7.53 (m, 3 H, 3xAr-CH), 7.57 (at, 1 H, 3JH,H =
8.0 Hz, Ar-CH), 7.77 (ddd, 1 H, 3,4JH,H = 1.3, 7.8 Hz, Ar-CH), 7.84 (s, 1 H, CH), 8.09 (d, 1 H,
3JH,H = 8.0 Hz, Ar-CH), 8.18 (ddd, 1 H, 3,4JH,H = 1.0, 2.2, 8.2 Hz, Ar-CH), 8.51-8.53 (m, 2 H,
2,2’-Ar-CH), 13.07 (s(br), 1 H, COOH) ppm; 13C-NMR (400 MHz, DMSO-d6) δ= 13.2 (CH3),
69.5 (CH2), 118.8 (2 or 2’-Ar-CH), 119.0 (2 or 2’-Ar-CH), 120.3 (Ar-CH) 122.2 (Ar-CH) 125.3
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(Ar-CH) 126.7 (Ar-CH), 127.0 (Ar-C), 128.0 (2xAr-CH) 128.5 (Ar-CH) 129.3 (Ar-CH) 129.8 (Ar-
CH) 131.5 (Ar-C), 134.1 (Ar-C), 136.7 (Ar-C), 138.3 (Ar-C), 148.7 (CH), 152.3 (Ar-C), 158.2
(Ar-C), 161.6 (Ar-C=O), 167.0 (COOH) ppm; ESI-MS m/z (%) = 411.1 [M−H]− (100 %); HR-
MS m/z = 411.1352 [M−H]− (calculated: 411.1350); HPLC-Analysis (Method B): 73 %, Rt =
19.0 min.
3-[(4Z)-4-[(4-cyanophenyl)methylidene]-3-methyl-5- oxopyrazol-1-yl] benzoic acid 81d
5:1 mixture with starting aldehyde Reaction time: 5 min Purification: Filtration from EtOAc
Yield: 46 mg of red solid (0.14 mmol, 45 %); 1H-NMR (400 MHz, DMSO-d6) δ= 2.37 (s, 3 H,
CH3), 7.34-7.40 (m, 2 H, 2xAldehyde-Ar-CH) 7.57 (at, 1 H, 3JH,H = 8.0 Hz, Ar-CH), 7.75-7.80
(m, 1 H, Ar-CH), 7.83 (s, 1 H, CH), 7.90-7.95 (m, 1 H, Ar-CH), 8.03 (d, 2 H, 3JH,H = 8.5 Hz, 2xAr-
CH), 8.06-8.17 (m, 2 H, 2xAldehyde-Ar-CH), 8.51-8.53 (m, 1 H, Ar-CH) 8.64 (d, 2 H, 3JH,H =
8.5 Hz, 2xAr-CH), 13.10 (s(br), 1 H, COOH) ppm.
3-[(4Z)-4-[(4-hydroxyphenyl)methylidene]-3-methyl-5-oxo-4,5-dihydro-1H-pyrazol-1-yl] benzoic
acid 81e
TLC Rf = 0.5 (DCM/MeOH 9:1); Reaction time: 5min under MWI (400 W); Purification: Filtra-
tion from EtOAc; Yield: 111 mg of red solid (0.34 mmol, 64 %); 1H-NMR (400 MHz, DMSO-d6)
δ= 2.33 (s, 3 H, CH3), 6.92-6.98 (m, 2 H, 3,5-Ar-CH), 7.52-7.58 (m, 1 H, 5’-Ar-CH), 7.69-7.77
(m, 1 H, Ar-CH), 7.71 (s, 1 H, ), 8.13-8.20 (m, 1 H, 6’-Ar-CH), 8.59 (s, 1 H, 2’-Ar-CH), 8.60-
8.66 (m, 1 H, 2,6-Ar-CH), 10.91 (s(br), 1 H, OH), 13.06 (s(br), 1 H, COOH), ppm; 13C-NMR
(400 MHz, DMSO-d6) δ= 13.2 (CH3), 99.6 (Ar-C or Ar-CH), 115.9 (Ar-C or Ar-CH), 118.6 (Ar-
C or Ar-CH), 121.9 (Ar-C or Ar-CH), 122.4 (Ar-C or Ar-CH), 124.9 (Ar-C or Ar-CH), 124.9 (Ar-C
or Ar-CH), 129.2 (Ar-C or Ar-CH), 131.4 (Ar-C or Ar-CH), 137.6 (Ar-C or Ar-CH), 138.6 (Ar-C
or Ar-CH), 149.0 (Ar-C or Ar-CH), 152.3 (Ar-C or Ar-CH), 162.2 (Ar-C or Ar-CH), 163.3 (C=O),
167.1 (COOH) ppm; ESI-MS m/z (%) = 321.1 [M−H]− (100 %), 365.1 [M+FA−H]− (10 %); HR-
MS m/z = 321.0878 [M−H]− (calculated: 321.0881); HPLC-Analysis (Method B): 89 %, Rt =
16.5 min.
3-[(4Z)-4-[4-(benzyloxy)phenyl]methylidene-3- methyl-5-oxopyrazol-1-yl] benzoic acid 81f
TLC Rf = 0.6 (DCM/MeOH 9:1); Reaction time: 10min, MWI (400 W); Purification: Filtra-
tion from EtOAc; Yield: 160 mg of red solid (0.39 mmol, 72 %); NOESY (CH3,CH → Z) 1H-
NMR (400 MHz, DMSO-d6) δ= 2.35 (s, 3 H, CH3), 5.26 (s, 2 H, CH2), 7.22 (d, 2 H, 3JH,H =
8.8 Hz, 3,5”-Ar-CH), 7.35-7.51 (m, 5 H, 5xAr-CH), 7.55 (H,H, dd H, ,J7.8, 8.1 Hz = 5’-Ar-CH, 3)
7.75 (d, 1 H, 3JH,H = 7.8 Hz, 4’-Ar-CH), 7.79 (s, 1 H, CH), 8.18 (d, 1 H, 3JH,H = 8.1 Hz, 6’-
Ar-CH), 8.57 (s, 1 H, 2’-Ar-CH), 8.71 (d, 2 H, 3JH,H = 8.8 Hz, 2,6”-Ar-CH), 13.08 (s(br), 1 H,
COOH) ppm; 13C-NMR (400 MHz, DMSO-d6) δ= 13.2 (CH3), 69.7 (CH2), 115.1 (3,5”-Ar-CH),
118.7 (CH), 122.0 (6’-Ar-CH), 123.6 (Ar-C), 125.0 (4’-Ar-CH), 126.3 (Ar-C), 128.0 (”’Ar-CH),
128.2 (”’Ar-CH), 128.5 (”’-Ar-CH), 129.2 (”’-Ar-CH), 131.4 (Ar-C), 136.3 (Ar-C), 136.9 (2,6”-Ar-
CH), 138.5 (Ar-C), 148.5 (2’-Ar-CH), 152.3 (Ar-C), 162.0 (Ar-C), 162.8 (Ar-C), 167.1 (C=O),
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185.1 (COOH) ppm; ESI-MS m/z (%) = 411.1 [M−H]− (100 %), 823.3 [2M−H]− (11 %); HPLC-
Analysis (Method B): 89 %, Rt = 16.5 min.
3-[(4Z)-4-[4-(dimethylamino)phenyl]methylidene-3- methyl-5-oxopyrazol-1-yl] benzoic acid 81g [357]
TLC Rf = 0.5 (DCM/MeOH 9:1); Reaction time: 5 min (MWI, 400 W); Purification: Filtration
from EtOAc; Yield: 151 mg of red solid (0.43 mmol, 80 %); NOESY (CH3,CH → Z) 1H-NMR
(400 MHz, DMSO-d6) δ= 2.31 (s, 3 H, CH3), 3.13 (s, 6 H, N(CH3)2), 6.85 (d, 2 H, 3JH,H =
9.2 Hz, 2,6-Ar-CH), 7.53 (at, 1 H, 3JH,H = 7.9, 8.2 Hz, 5’-Ar-CH), 7.60 (s, 1 H, CH), 7.72 (adt,
1 H, 3,4JH,H = 1.2, 7.9 Hz, 4’-Ar-CH), 8.22 (ddd, 1 H, 3,4JH,H = 1.2, 2.0, 8.2 Hz, 6’-Ar-CH), 8.61
(m, 1 H, 2’-Ar-CH), 8.65 (d, 2 H, 3JH,H = 9.2 Hz, 3,5-Ar-CH), 13.02 (s(br), 1 H, COOH) ppm;
13C-NMR (400 MHz, DMSO-d6) δ= 13.2 (CH3), 39.6 (N(CH3)2), 111.4 (2,6-Ar-CH), 118.5 (Ar-
C), 118.6 (2’-Ar-CH), 121.2 (6’-Ar-CH), 121.8 (Ar-C), 124.5 (4’-Ar-CH), 129.1 (5’-Ar-CH), 131.3
(Ar-C), 137.6 (3,5-Ar-CH), 139.1 (Ar-C), 148.6 (CH), 152.1 (Ar-C), 154.0 (Ar-C). 162.6 (C=O),
167.2 (COOH) ppm; ESI-MS m/z (%) = 348.1 [M−H]− (100 %), 697.3 [2M−H]− (60 %); HR-
MS m/z = 348.1356 [M−H]− (calculated: 348.1354); HPLC-Analysis (Method B): 99 %, Rt =
14.9 min.
2-[(1Z)-[2-(3-carboxyphenyl)hydrazin-1- ylidene]methyl] benzoic acid 81j [358]
TLC Rf = 0.3 (DCM/MeOH 9:1); Reaction time: 5 min (MWI, 400 W); Purification: Flash-
Chromatography CHCl3/MeOH 9:1 (Rf = 0.1); Yield: 70 mg of red solid (0.25 mmol, 46 %);
1H-NMR (400 MHz, DMSO-d6) δ= 6.69 (s(br), 1 H, NH), 7.52-7.66 (m, 4 H, 4xAr-CH), 7.75-
7.82 (m, 2 H, 2xAr-CH), 7.90 (d, 1 H, 3JH,H = 7.6 Hz, Ar-CH), 7.99 (dd, 1 H, 3,4JH,H = 8.1, 1.3 Hz,
Ar-CH), 8.29 (s, 1 H, Ar-CH) ppm.
3-[(E)-2-[(3-nitrophenyl)methylidene]hydrazin-1-yl] benzoic acid 81k [359]
TLC Rf = 0.1 (Hexane/EtOAc 8:2); Reaction time: 10 min (MWI, 400 W); Purification: Flash-
Chromatography DCM/MeOH 9:1 (Rf = 0.3); Yield: 52 mg of ; (0.18 mmol, 34 %) 1H-NMR
(400 MHz, DMSO-d6) δ= 7.34-7.40 (m, 3 H, 3xAr-CH), 7.67-7.71 (m, 2 H, 2xAr-CH), 8.00
(s, 1 H, CH), 8.09-8.15 (m, 2 H, 2xAr-CH), 8.46 (at, 1 H, 4JH,H = 1.8 Hz, Ar-CH), 10.87 (s,
1 H, NH), 12.91 (s(br), 1 H, COOH) ppm; 13C-NMR (400 MHz, DMSO-d6) δ= 112.9 (Ar-
CH), 116.5 (Ar-CH), 119.8 (Ar-CH), 120.3 (Ar-CH), 122.3 (Ar-CH), 129.5 (Ar-CH), 130.3 (Ar-
CH), 131.7 (Ar-CH), 131.7 (Ar-CH), 134.9 (Ar-CH), 137.6 (Ar-C), 145.0 (Ar-C), 148.3 (Ar-
C), 167.5 (Ar-COOH), ppm; ESI-MS m/z (%) = 284.1 [M−H]− (100 %), 320.0 [M+Cl]− (10 %),
569.1 [2M−H]− (70 %); HR-MS m/z = 284.0675 [M−H]− (calculated: 284.0677); HR-MS m/z =
284.0679 [M−H]− (calculated: 284.0677); HPLC-Analysis (Method B): 74 %, Rt = 21.5 min.
(Z)-4-(4-hydroxybenzylidene)-3-methyl-1-phenyl-1H-pyrazol-5(4H)-one 80f [360]
TLC Rf = 0.3 (Hexane/EtOAc 6:4); Purification: Filtration from Cyclohexan/EtOAc 9:1; Yield:
50 mg of red solid (0.18 mmol, 60 %); NOESY (CH3,CH→ Z); 1H-NMR (400 MHz, DMSO-d6)
δ= 2.32 (s, 3 H, CH3), 6.94 (d, 2 H, 3JH,H = 8.9 HZ, 3,5-Ar-CH), 7.18 (at, 1 H, 3JH,H = 7.4 Hz, 4’-
Ar-CH), 7.43 (dd, 2 H, 3JH,H = 7.4, 8.4 Hz, 3,5-’Ar-CH), 7.70 (s, 1 H, CH), 7.93 (dd, 2 H, 3JH,H =
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7.4, 8.4 Hz, 2,6-’Ar-CH), 8.64 (d, 2 H, 3JH,H = 8.9 Hz, 2,6-Ar-CH) 10.84 (s(br), 1 H, OH), ppm;
13C-NMR (400 MHz, DMSO-d6) δ= 13.2 (CH3), 115.9 (3,5-Ar-CH), 118.3 (2,6’-Ar-CH), 122.5
(Ar-C), 124.4 (4’-Ar-CH), 124.9 (Ar-C), 128.8 (3,5’-Ar-CH), 137.5 (2,6-Ar-CH), 138.5 (Ar-C),
148.5 (CH), 151.8 (Ar-C), 162.0 (Ar-C), 163.2 (Ar-C), ppm; ESI-MS m/z (%) = 277.1 [M−H]−
(100 %); HR-MS m/z = 277.0985 [M−H]− (calculated: 277.0983).
Synthesis of pyrazole derivatives with improved sequential one-pot reaction
Phenylhydrazine or 3-hydrazinylbenzoic acid (2.03 mmol, 1.0 eq), ethyl aceto-acetate (2.03
mmol, 1.0 eq) were dissolved in 5 mL HOAc. The reaction mixture was stirred at 110 ◦C for
16 h. Benzaldehyde derivative (2.44 mmol, 1.2 eq) was added to the yellow reaction mixture.
The reaction mixture was continued to stir at 110 ◦C, until TLC showed complete consumption
of intermediate formed pyrazole precursor. The reaction mixture was cooled and the product
was isolated by simple filtration or column chromatography.
(Z)-4-(4-methoxybenzylidene)-3-methyl-1-phenyl-1H-pyrazol-5(4H)-one 80w [361]
TLC Rf = 0.1 (Hexane/EtOAc 8:2); Reaction time: 17 h; Purification: Re-crystallisation from
ethanol; Yield: 40 mg of red crystals (0.14 mmol, 15 %); NOESY (CH3,CH → Z) 1H-NMR
(400 MHz, DMSO-d6) δ= 2.33 (s, 3 H, CH3), 3.89 (s, 3 H, OCH3), 7.14 (d, 2 H, 3JH,H = 9.0 Hz,
3,5-Ar-CH), 7.19 (att, 1 H, 3,4JH,H = 7.4, 1.2 Hz, 4’-Ar-CH), 7.43 (at, 2 H, 3JH,H = 7.6, 7.4 Hz,
3’,5’-Ar-CH), 7.77 (s, 1 H, CH), 7.92 (dd, 2 H, 3,4JH,H = 7.6, 1.2 Hz, 2’,6’-Ar-CH), 8.71 (d, 2 H,
3JH,H = 9.0 Hz, 2,6-Ar-CH) ppm; 13C-NMR (400 MHz, DMSO-d6) δ= 13.2 (CH3), 55.8 (OCH3),
114.4 (3,5-Ar-CH), 118.3 (2’,6’-Ar-CH), 123.8 (Ar-C), 124.5 (4’-Ar-CH), 126.2 (Ar-C), 128.8
(3’,5’-Ar-CH), 136.9 (2,6-Ar-CH), 138.4 (Ar-C), 148.2 (CH), 151.9 (Ar-C), 161.9 (Ar-C), 163.7
(C=O) ppm; ESI-MS m/z (%) = 293.1 [M+H]+ (100 %), 585.2 [2M+H]+ (20 %); HR-MS m/z =
293.1286 [M+H]+ (calculated: 293.1285); HPLC-Analysis (Method B): 98 %, Rt = 19.2 min.
(4Z)-5-methyl-2-phenyl-4-[(4-phenylphenyl)methylidene]pyrazol-3-one 80x [362]
TLC Rf = 0.1 (Hexane/EtOAc 9:1); Reaction time: 17 h; Purification: Filtration from HOAc;
Yield: 113 mg of red solid (0.33 mmol, 16 %); 1H-NMR (400 MHz, CDCl3) δ= 2.38 (s, 3 H,
CH3), 7.20 (att, 1 H, 3,4JH,H = 1.0, 7.4 Hz, 4’-Ar-CH), 7.39-7.45 (m, 4 H, 3’,5,4”-Ar-CH, CH),
7.49 (at, 2 H, 3JH,H = 7.4 Hz, 3”,5”-Ar-CH), 7.66-7.69 (m, 2 H, 2”,6”-Ar-CH), 7.75 (d, 2 H, 3JH,H =
8.5 Hz, 3,5-Ar-CH), 7.98 (d, 2 H, 3JH,H = 7.7 Hz, 2’,6’-Ar-CH), 8.61 (d, 2 H, 3JH,H = 8.5 Hz, 2,6-
Ar-CH) ppm; 13C-NMR (400 MHz, CDCl3) δ= 13.5 (CH3), 119.3 (2’,6’-Ar-CH), 125.0 (4’-Ar-
CH), 127.4 (2”,6”,3,5-Ar-CH), 127.6 (Ar-C) 128.6 (Ar-CH), 128.9 (Ar-CH) 129.2 (Ar-CH) 132.1
(Ar-C), 134.5 (2,6-Ar-CH), 138.5 (Ar-C), 139.9 (Ar-C), 145.8 (Ar-C), 146.5 (CH), 151.0 (Ar-
C), 162.1 (C=O) ppm; ESI-MS m/z (%) = 339.1 [M+H]+ (100 %), 677.3 [2M+H]+ (5 %); HPLC-
Analysis (Method B): 96 %, Rt = 21.5 min.
4-[(4Z)-3-methyl-5-oxo-1-phenylpyrazol-4-ylidene]methylbenzonitrile 80y [363]
TLC Rf = 0.1 (Hexane/EtOAc 8:2); Reaction time: 20 h; Purification: Filtration from HOAc;
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Yield: 126 mg of red solid (0.44 mmol, 22 %); 1H-NMR (400 MHz, DMSO-d6) δ= 2.34 (s, 3 H,
CH3), 7.18-7.24 (m, 1 H, 4’-Ar-CH), 7.40-7.46 (m, 2 H, 3’,5’-Ar-CH), 7.85-7.90 (m, 3 H, CH,
2’,6’-Ar-CC), 7.99-8.04 (m, 2 H, 3,5-Ar-CH), 8.61-8.65 (m, 2 H, 2,6-Ar-CH) ppm; 13C-NMR
(400 MHz, DMSO-d6) δ= 13.1 (CH3), 114.1 (CN), 118.4 (2’,6’-Ar-CH), 124.9 (4’-Ar-CH), 128.9
(3’,5’-Ar-CH), 129.1 (Ar-C), 132.3 (2,6-Ar-CH), 133.4 (3,5-Ar-CH), 136.7 (Ar-C), 137.9 (Ar-C),
145.5 (CH), 151.7 (C=N), 161.1 (C=O) ppm; APCI-MS m/z (%) = 288.1 [M+H]+ (100 %); HR-
MS m/z = 288.1134 [M+H]+ (calculated: 288.1131); HPLC-Analysis (Method B): 82 %, Rt =
16.3 min.
(4Z)-4-[(4-chlorophenyl)methylidene]-5-methyl-2-phenylpyrazol-3-one 80z [353]
TLC Rf = 0.6 (Hexane/EtOAc 8:2); Reaction time: 17 h; Purification: Re-crystallisation from
ethanol; Yield: 144 mg of red crystals (0.49 mmol, 24 %); 1H-NMR (400 MHz, DMSO-d6)
δ= 2.33 (s, 3 H, CH3), 7.20 (at, 1 H, 3JH,H = 1.0, 7.4 Hz, 4’-Ar-CH), 7.44 (dd, 2 H, 3JH,H =
7.4, 8.6 Hz, 3’,5’-Ar-CH), 7.64 (d, 2 H, 3JH,H = 8.6 Hz, 3,5-Ar-CH), 7.83 (s, 1 H, CH), 7.89
(dd, 2 H, 3,4JH,H = 1.0, 8.6 Hz, 2’,6’-Ar-CH), 8.61 (d, 2 H, 3JH,H = 8.6 Hz, 2,6-Ar-CH) ppm;
13C-NMR (400 MHz, DMSO-d6) δ= 13.1 (CH3), 118.4 (2’,6’-Ar-CH), 124.7 (4’-Ar-CH), 127.1
(Ar-C), 128.8 (2,6-Ar-CH), 128.9 (3’,5’-Ar-CH), 131.8 (Ar-C), 135.3 (3,5-Ar-CH), 137.9 (Ar-
C), 138.0 (Ar-C), 146.7 (CH), 151.8 (Ar-C), 161.4 (C=O) ppm; APCI-MS m/z (%) = 297.1
[M+H]+ (100 %); HR-MS m/z = 297.0796 [M+H]+ (calculated: 297.0789); H-Jresqf-Experiment:
3JCH,C=O = 5.7 Hz; HPLC-Analysis (Method B): 98 %, Rt = 18.1 min.
(4Z)-4-[(4-methanesulfonylphenyl)methylidene]-5-methyl-2-phenylpyrazol-3-one 80aa
TLC Rf = 0.1 (DCM); Reaction time: 20 h; Purification: Filtration from ethanol; Yield: 306
mg of red solid (0.90 mmol, 44 %); 1H-NMR (400 MHz, DMSO-d6) δ= 2.36 (s, 3 H, CH3), 3.31
(s, 3 H, SO2CH3), 7.21 (att, 1 H, 3,4JH,H = 1.0, 7.4 Hz, 4’-Ar-CH), 7.45 (dd, 2 H, 3JH,H = 7.4,
8.8 Hz, 3’,5’-Ar-CH), 7.88 (dd, 2 H, 3,4JH,H = 8.8, 1.0 Hz, 2’,6’-Ar-CH), 7.95 (s, 1 H, CH), 8.08
(d, 2 H, 3JH,H = 8.6 Hz, 3,5-Ar-CH), 8.68 (d, 2 H, 3JH,H = 8.6 Hz, 2,6-Ar-CH) ppm; 13C-NMR
(400 MHz, DMSO-d6) δ= 13.1 (CH3), 43.2 (SO2CH3), 118.4 (2’,6’-Ar-CH), 124.9 (4’-Ar-CH),
126.9 (3,5-Ar-CH), 128.9 (3’,5’-Ar-CH), 129.1 (Ar-C), 133.6 (2,6-Ar-CH), 137.0 (Ar-C), 137.9
(Ar-C), 143.3 (Ar-C), 145.7 (CH), 151.8 (Ar-C), 161.1 (C=O) ppm; ESI-MS m/z (%) = 341.1
[M+H]+ (87 %), 358.1 [M+NH4]+ (4 %); HPLC-Analysis (Method B): 96 %, Rt = 21.5 min.
(4Z)-4-[(3-bromo-4-methoxyphenyl)methylidene]-5-methyl-2-phenylpyrazol-3-one 80ab
TLC Rf = 0.2 (Hexane/EtOAc 8:2); Reaction time: 20 h; Purification: Filtration from HOAc;
Yield: 346 mg of red solid (0.93 mmol, 46 %); NOESY (CH3,CH → Z) 1H-NMR (400 MHz,
DMSO-d6) δ= 2.31 (s, 3 H, CH3), 3.98 (s, 3 H, O-CH3), 7.20 (at, 1 H, 3JH,H = 7.4 Hz, 4’-Ar-CH),
7.31 (d, 1 H, 3JH,H = 8.8 Hz, 5-Ar-CH), 7.43 (at, 2 H, 3JH,H = 7.4, 7.6 Hz, 3’,5’-Ar-CH), 7.75
(s, 1 H, CH), 7.91 (d, 2 H, 3JH,H = 7.6 Hz, 2’,6’-Ar-CH), 8.55 (dd, 1 H, 3JH,H = 1.7, 8.8 Hz, 6-
Ar-CH), 9.24 (d, 1 H, 4JH,H = 1.7 Hz, 2-Ar-CH) ppm; 13C-NMR (400 MHz, DMSO-d6) δ= 13.1
(CH3), 56.9 (OCH3), 110.8 (Ar-C), 112.6 (5-Ar-CH), 118.4 (2’,6’-Ar-CH), 124.6 (Ar-C), 124.9
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(4’-Ar-CH), 127.3 (Ar-C), 128.9 (3’,5’-Ar-CH), 136.6 (6-Ar-CH), 138.1 (Ar-C or 2-Ar-CH), 138.2
(Ar-C or 2-Ar-CH), 146.6 (CH), 151.8 (Ar-C), 159.2 (Ar-C), 161.8 (C=O) ppm; ESI-MS m/z (%) =
372.0 [M+H]+ (22 %), 743.1 [2M+H]+ (8 %); HPLC-Analysis (Method B): 90 %, Rt = 18.0 min.
(4Z)-5-methyl-2-phenyl-4-[2-(trifluoromethyl)phenyl]methylidenepyrazol-3-one 80ac
TLC Rf = 0.1 (Hexane/EtOAc 95:5); Reaction time: 20 h; Purification: Flash-Chromatogra-
phy Hexane/EtOAc 95:5 (Rf = 0.1); Yield: 320 mg of red solid (0.97 mmol, 48 %); 1H-NMR
(400 MHz, CDCl3) δ= 2.20 (s, 3 H, CH3), 7.05 (att, 1 H, 3,4JH,H = 1.1, 7.4 Hz, 4’-Ar-CH), 7.26
(at, 2 H, 3JH,H = 7.4, 8.7 Hz, 3’,5’-Ar-CH), 7.44 (at, 1 H, 3JH,H = 7.6 Hz, 5-Ar-CH), 7.52 (at,
1 H, 3JH,H = 7.6, 8.1 Hz, 4-Ar-CH), 7.62-7.65 (m, 2 H, CH, 6-Ar-CH), 7.80 (dd, 2 H, 3,4JH,H =
1.1, 8.7 Hz, 2’,6’-Ar-CH), 8.37 (d, 1 H, 3JH,H = 8.1 Hz, 3-Ar-CH) ppm; 13C-NMR (400 MHz,
CDCl3) δ= 13.0 (CH3), 118.9 (2’,6’-Ar-CH), 124.1 (q, 1JC,F = 273.9 Hz, CF3), 125.0 (4’-Ar-
CH), 126.0 (q, 4JC,F = 5.5 Hz, 6-Ar-CH), 128.8 (3’,5’-Ar-CH), 129.4 (q, 3JC,F = 30.2 Hz, Ar-C)
130.4 (q, 2JC,F = 66.1 Hz,Ar-C) 131.3 (5-Ar-CH), 131.5 (4-Ar-CH), 132.7 (3-Ar-CH), 138.1 (Ar-
C), 141.3 (CH), 150.5 (ArC), 161.0 (C=O) ppm; ESI-MS m/z (%) = 331.1 [M+H]+ (100 %), 348.1
[M+NH4]+ (8 %), 661.2 [2M+H]+ (3 %); APCI-MS m/z (%) = 331.1 [M+H]+ (100 %); HR-MS m/z =
331.1058 [M+H]+ (calculated: 331.1053); HPLC-Analysis (Method B): 98 %, Rt = 19.8 min.
(Z)-4-(3-bromo-4-fluorobenzylidene)-3-methyl-1-phenyl-1H-pyrazol-5(4H)-one 80ad
TLC Rf = 0.6 (Hexane/EtOAC 7:3); Reaction time: 2 h; Purification: Filtration from HOAc/
ethanol; Yield: 189 mg of red solid (0.53 mmol, 57 %); NOESY (CH3,CH→ Z) 1H-NMR (400
MHz, DMSO-d6) δ= 2.33 (s, 3 H, ) 7.21 (at, 1 H, 3JH,H = 7.4 Hz, 4’-Ar-CH), 7.45 (at, 2 H, 3JH,H =
7.4, 7.6 Hz, 3’,5’-Ar-CH), 7.60 (at, 1 H, 3JH,H(F) = 8.7 Hz, 6-Ar-CH), 7.84 (s, 1 H, CH), 7.89 (d,
2 H, 3J7.6 Hz = H,H, 2’,6’-Ar-CH), 8.57 (ddd, 1 H, 3,4JH,H(F) = 2.1, 5.0, 8.7 Hz, 5-Ar-CH), 9.20 (dd,
1 H, 3,4JH,H(F) = 2.1, 7.0 Hz, 3-Ar-CH), 13C-NMR (400 MHz, DMSO-d6) δ= 13.1 (CH3), 117.1
(d, 2JC,F = 22.8 Hz, 6-Ar-CH) 118.5 (2’,6’-Ar-CH), 124.8 (4’-Ar-CH), 127.3 (Ar-C), 128.9 (3’,5’-
Ar-CH), 131.2 (Ar-C), 136.0 (d, 2JC,F = 8.6 Hz, 5-Ar-CH), 138.0 (Ar-C), 138.4 (3-Ar-CH), 145.4
(CH), 151.8 (Ar-C), 161.4 (C=O) ppm; 1H-NMR (400 MHz, CDCl3) δ= 2.23 (s, 3 H, CH3), 3.02
(s, 6 H, 2xCh3), 6.62 (d, 2 H, 3JH,H = 9.0 Hz, 3,5-Ar-CH), 7.07 (at, 1 H, 3JH,H = 7.4 Hz, 4’-Ar-CH),
7.15 (s, 1 H, CH), 7.32 (at, 2 H, 3JH,H = 7.4, 7.9 Hz, 3’,5’-Ar-CH), 7.93 (d, 2 H, 3JH,H = 7.9 Hz,
2’,6’-Ar-CH), 8.48 (d, 2 H, 3JH,H = 9.0 Hz, 2,6-Ar-CH) ppm; 13C-NMR (400 MHz, CDCl3) δ=
13.5 (CH3), 40.1 (2xCH3), 111.4 (3,5-Ar-CH), 119.2 (2’,6’-ArCH), 121.0 (Ar-C), 121.9 (Ar-C),
124.4 (4’-Ar-CH), 128.7 (3’,5’-Ar-CH), 137.4 (2,6-Ar-CH), 139.1 (Ar-C), 147.4 (CH), 151.3 (Ar-
C), 153.7 (Ar-C), 163.0 (C=O) ppm; ESI-MS m/z (%) = 359.0 [M+H]+ (100 %), 719.0 [2M+H]+
(45 %); HR-MS m/z = 359.0195 [M+H]+ (calculated: 359.0190); HPLC-Analysis (Method B):
66 %, Rt = 18.4 min.
(4Z)-5-methyl-2-phenyl-4-[3- (trifluoromethyl)phenyl]methylidenepyrazol-3-one 80ae
TLC Rf = 0.1 (Hexane/EtOAc 9:1); Reaction time: 4 h; Purification: Re-crystallisation from
ethanol; Yield: 416 mg of red crystals (1.26 mmol, 62 %); NOESY (CH3,CH → Z) 1H-NMR
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(400 MHz, DMSO-d6) δ= 2.30 (s, 3 H, CH3), 7.18 (at, 1 H, 3JH,H = 7.4 Hz, Ar-CH), 7.39-
7.46 (m, 2 H, 2xAr-CH), 7.72 (d, 1 H, 3JH,H = 8.6 Hz, Ar-CH), 7.76 (d, 1 H, 3JH,H = 7.9 Hz,
Ar-CH), 7.85-7.89 (m, 3 H, 2xAr-CH, CH), 7.92 (d, 1 H, 3JH,H = 7.7 Hz, Ar-CH), 8.69 (d, 1 H,
3JH,H = 7.9 Hz, Ar-CH), 9.07 (s, 1 H, 2-Ar-CH) ppm; 13C-NMR (400 MHz, DMSO-d6) δ= 13.0
(CH3), 118.4 (2xAr-CH), 120.5 (Ar-CH), 123.9 (q, 1JC,F = 272.6 Hz, CF3), 128.2 (Ar-CH), 128.8
(2xAr-CH), 128.9 (Ar-CH), 129.7 (2-Ar-CH), 133.5 (Ar-C), 137.1 (Ar-CH), 137.9 (Ar-C) 146.0
(CH), 151.6 (Ar-C), 161.2 (C=O) ppm; ESI-MS m/z (%) = 331.1 [M+H]+ (83 %); HPLC-Analysis
(Method B): 88 %, Rt = 18.5 min.
(E/Z)-4-(3-(benzyloxy)benzylidene)-3-methyl-1-phenyl-1H-pyrazol-5(4H)-one 80af
ratio 5.5 to 1 (Z to E) not isolated
TLC Rf = 0.4 (Hexane/EtOAc 9:1); Reaction time: 4 h; Purification: Flash-Chromatogra-
phy Hexane/EtOAc 95:5 (Rf = 0.3); Yield: 192 mg of yellow solid (0.52 mmol, 62 %); NOESY
(CH3,CH→ Z); 1H-NMR (400 MHz, CDCl3) δ= 2.05 (s, 3 H, Z-CH3), 2.22 (s, 3 H, E-CH3), 5.01
(s, 2 H, E-CH2), 5.09 (s, 2 H, Z-CH2), 6.98-7.02 (m, 2 H, ) 7.05-7.11 (m, 2 H, ) 7.15 (s, 1 H, E-
CH), 7.22 (s, 1 H, Z-CH), 7.22-7.35 (m, 6 H, ) 7.37-7.41 (m, 2 H, 2xZ-Ar-CH), 7.60-7.63 (m, 1 H,
) 7.67 (d, 1 H, 3JH,H = 7.7 Hz, 6-Z-Ar-CH), 7.85-7.89 (m, 2 H, 2xE-Ar-CH), 7.85-7.89 (m, 3 H, )
8.54 (at, 1 H, 4JH,H = 1.9 Hz, 2-Z-Ar-CH) ppm; 13C-NMR (400 MHz, CDCl3) δ= 13.4 ((E)-CH3),
17.6 ((Z)-CH3), 70.3 ((E,Z)-CH2), 116.3 (Ar-CH), 117.9 ((E)-2-Ar-CCH), 118.7 (Ar-C), 119.3
(2xAr-CH), 121.2 (Ar-CH), 121.8 (Ar-CH), 123.2 (Ar-CH), 125.0, 127.3, 127.5, 127.6, 127.9,
128.0, 128.2, 128.3, 128.7, 2x128.8, 128.9, 129.0, 129.6, 129.9 (Ar-CH or Ar-C), 134.3, 134.5,
136.5, 136.8, 138.3, 138.5, 145.5 (Ar-C), 147.0 ((E)-CH), 147.6, 150.9, 158.8, 159.0, 161.9,
163.8 (Ar-C), ppm; ESI-MS m/z (%) = 369.2 [M+H]+ (100 %), 391.3 [M+Na]+ (35 %); HR-MS m/z
= 369.1599 [M+H]+ (calculated: 369.1598); HPLC-Analysis (Method B): 98 %, Rt = 19.2 min.
(4Z)-4-[(4-hydroxy-3,5-dimethoxyphenyl)methylidene]-5-methyl-2-phenylpyrazol-3-one 80ag [364]
TLC Rf = 0.1 (Hexane/EtOAc 6:4); Reaction time: 16 h; Purification: Filtration from ethanol;
Yield: 496 mg of red crystals (1.47 mmol, 72 %); NOESY (CH3,CH→ Z); 1H-NMR (400 MHz,
DMSO-d6) δ= 2.32 (s, 3 H, CH3), 3.87 (s, 6 H, 2xAr-CH3), 7.19 (att, 1 H, 3,4JH,H = 1.0, 7.4 Hz,
4’-Ar-CH), 7.44 (dd, 1 H, 3JH,H = 7.4, 8.7 Hz, 3’,5’-Ar-CH), 7.72 (s, 1 H, CH), 7.92 (dd, 1 H,
3,4JH,H = 1.0, 8.7 Hz, 2’,6’-Ar-CH), 8.29 (s, 2 H, 2,6-Ar-CH) ppm; 13C-NMR (400 MHz, DMSO-
d6) δ= 13.2 (CH3), 56.1 (2xOCH3), 112.7 (2,6-Ar-CH), 118.5 (2’,6’-Ar-CH), 122.8 (4’-Ar-CH),
124.0 (Ar-C), 124.5 (Ar-C), 128.8 (3’,5’-Ar-CH), 138.5 (Ar-C), 142.3 (Ar-C), 147.5 (Ar-C), 149.4
(CH), 151.8 (Ar-C), 162.1 (C=O) ppm; ESI-MS m/z (%) = 339.1 [M+H]+ (100 %), 677.3 [2M+H]+
(24 %); HPLC-Analysis (Method B): 95 %, Rt = 17.8 min.
(4Z/E)-5-methyl-2-phenyl-4-(phenylmethylidene)pyrazol-3-one 80ah [365]
Is a mixture of E to Z of 1 to 6 TLC Rf = 0.1 (Hexane/EtOAc 9:1); Reaction time: 16 h;
Purification: Flash-Chromatography hexane/EtOAc 9:1 (Rf = 0.1); Yield: 438 mg of yellow
solid (1.67 mmol, 82 %); NOESY (CH3,CH → Z); NOESY (CH3,ArCH → E); 1H-NMR (400
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MHz, CDCl3) δ= 2.12 (s, 3 H, E-CH3), 2.24 (s, 3 H, Z-CH3), 7.09 (att, 1 H, 3,4JH,H = 1.0,
7.4 Hz, 4’-(E+Z)-Ar-CH), 7.27 (s, 1 H, Z-CH), 7.32 (dd, 2 H, 3JH,H = 7.4, 8.6 Hz, 3’,5’-(E+Z)-
Ar-CH), 7.37-7.47 (m, 3 H, 3,4,5-Z-Ar-CH), 7.37-7.47 (m, 5 H, 2,3,4,5,6-E-Ar-CH), 7.88 (dd,
2 H, 3,4JH,H = 1.0, 8.6 Hz, 2’,6’-(E+Z)-Ar-CH), 7.92 (s, 1 H, E-CH), 8.37-8.41 (m, 2 H, 2,6-Z-Ar-
CH) ppm; 13C-NMR (400 MHz, CDCl3) δ= 13.4 (Z-CH3), 17.7 (E-CH3), 118.7 (2’,6’-E-Ar-CH),
119.2 (2’,6’-Z-Ar-CH), 125.0 (4’-(E+Z)-Ar-CH), 127.8 (Ar-C), 128.7, 128.8, 128.9, 129.0 (3,4,5-
Z-Ar and 2-6-E-Ar and 3’,5’-(E+Z)-Ar-CH), 130.5 (Ar-C or Ar-CH), 131.2 (Ar-C), 133.0, 133.1
(3,4,5-Z-Ar- and 2-6-Ar-CH), 133.8 (2,6-Z-Ar-CH), 138.4 (Ar-C), 145.8 (E-CH), 147.0 (Z-Ar-
CH), 147.6 (Ar-C), 150.9 (Ar-C), 161.9 (C=O) ppm; ESI-MS m/z (%) = 263.1 [M+H]+ (100 %),
280.1 [M+NH4]+ (3 %); HPLC-Analysis (Method B): 88 %, Rt = 18.5 min.
(4Z)-4-[(3-hydroxyphenyl)methylidene]-5-methyl-2- phenylpyrazol-3-one 80ai [366]
TLC Rf = 0.2 (CHCl3/MeOH/HOAc 96:3:1); Reaction time: 16 h; Purification: Flash-Chroma-
tography CHCl3/MeOH/HOAc 97:2:1 (Rf = 0.1); Yield: 501 mg of red solid (1.80 mmol, 89 %);
1H-NMR (400 MHz, CDCl3) δ= 2.34 (s, 3 H, CH3), 7.07 (dd, 1 H, 3,4JH,H = 8.2, 1.8 Hz, 6-Ar-
CH), 7.19 (at, 1 H, 3JH,H = 7.4 Hz, 4’-Ar-CH), 7.33-7.43 (m, 4 H, 3’,5,5’-Ar-CH, CH), 7.60 (d,
1 H, 3JH,H = 7.7 Hz, 4-Ar-CH), 7.90 (d, 2 H, 3JH,H = 7.6 Hz, 2’,6’-Ar-CH), 8.52 (s, 1 H, 2-Ar-CH)
ppm; 13C-NMR (400 MHz, CDCl3) δ= 13.4 (CH3), 119.2 (2-Ar-CH), 119.7 (2’,6’-Ar-CH), 121.1
(6-Ar-CH), 125.4 (4’-Ar-CH), 127.2 (4-Ar-CH), 127.8 (Ar-C), 129.0 (3’,5’-Ar-CH), 129.1 (Ar-C),
130.0 (5-Ar-CH), 134.2 (Ar-C), 138.2 (Ar-C), 147.5 (CH) 151.3 (Ar-C), 156.2 (C=O), 161.9
(C=O) ppm; ESI-MS m/z (%) = 279.1 [M+H]+ (100 %), 296.1 [M+NH4]+ (4 %), 557.2 [2M+H]+
(2 %); HPLC-Analysis (Method B): 95 %, Rt = 17.3 min.
(4Z)-4-[(3,4-dihydroxyphenyl)methylidene]-5-methyl-2- phenylpyrazol-3-one 80ak
Reaction time: 20 h; Purification: Filtration from HOAc; Yield: 310 mg of red solid (1.05
mmol, 87 %); NOESY (CH3,CH→ Z); 1H-NMR (400 MHz, CDCl3) δ= 2.33 (s, 3 H, CH3), 6.96
(d, 1 H, 3JH,H = 8.3 Hz, 5-Ar-CH), 7.19-7.24 (m, 1 H, 4’-Ar-CH), 7.33 (dd, 1 H, 3,4JH,H = 8.3,
2.1 Hz, 6-Ar-CH), 7.34 (s, 1 H, CH), 7.40 (at, 2 H, 3JH,H = 7.9 Hz, 3’,5’-Ar-CH), 7.78-7.81 (m,
2 H, 2’,6’-Ar-CH), 9.19 (d, 1 H, 4JH,H = 2.1 Hz, 2-Ar-CH) ppm; 13C-NMR (400 MHz, CDCl3) δ=
13.4 (CH3), 115.2 (5-Ar-CH), 119.3 (2-Ar-CH), 120.5 (2’,6’-Ar-CH), 123.8 (Ar-C), 125.8 (4’-
ArCH), 126.4 (Ar-C), 128.9 (3’,5’-Ar-CH), 131.7 (6-Ar-CH), 138.0 (Ar-C), 143.8 (Ar-C), 149.6
(CH), 151.2 (Ar-C), 152.0 (Ar-C), 162.4 (C=O) ppm; ESI-MS m/z (%) = 295.1 [M+H]+ (92 %),
589.2 [2M+H]+ (17 %); HPLC-Analysis (Method B): 87 %, Rt = 16.3 min.
(4Z)-4-[4-(dimethylamino)phenyl]methylidene-5- methyl-2-phenylpyrazol-3-one 80am [361]
Reaction time: 20 h; Purification: Filtration from HOAc; Yield: 85 mg of yellow solid (0.28
mmol, 56 %); 1H-NMR (400 MHz, CDCl3) δ= 2.23 (s, 3 H, CH3), 3.02 (s, 6 H, 2xCH3), 6.62
(d, 2 H, 3JH,H = 9.0 Hz, 3,5-Ar-CH), 7.07 (at, 1 H, 3JH,H = 7.4 Hz, 4’-Ar-CH), 7.15 (s, 1 H, CH),
7.32 (at, 2 H, 3JH,H = 7.9, 7.4 Hz, 3’,5’-Ar-CH), 7.93 (d, 2 H, 3JH,H = 7.9 Hz, 2’,6’-Ar-CH), 8.48
(d, 2 H, 3JH,H = 9.0 Hz, 2,6-Ar-CH) ppm; 13C-NMR (400 MHz, CDCl3) δ= 13.5 (CH3), 40.1
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(2xCH3), 111.4 (3,5-Ar-CH), 119.2 (2’,6’-Ar-CH), 121.0 (Ar-C), 121.9 (Ar-C), 124.4 (4’-Ar-CH),
128.7 (3’,5’-Ar-CH), 137.4 (2,6-Ar-CH), 139.1 (Ar-C), 147.4 (CH), 151.3 (Ar-C), 153.7 (Ar-C),
163.0 (C=O) ppm; ESI-MS m/z (%) = 306.2 [M+H]+ (100 %), 611.3 [2M+H]+ (30 %), 1238.6
[3M+NH4]+ (10 %); HR-MS m/z = 306.1602 [M+H]+ (calculated: 306.1601); HPLC-Analysis
(Method B): 66 %, Rt = 18.4 min.
(4Z)-5-methyl-2-phenyl-4-[4-(trifluoromethyl)phenyl]methylidenepyrazol-3-one 80aj
TLC Rf = 0.1 (Hexane/EtOAc 9:1); Reaction time: 4 h; Purification: Flash-Chromatography
Hexane/EtOAc 9:1 (Rf = 0.1), DCM; Yield: 621 mg of red solid (1.88 mmol, 93 %); 1H-NMR
(400 MHz, CDCl3) δ= 2.08 (s, 3 H, CH3), 7.02 (at, 1 H, 3JH,H = 7.4 Hz, 4’-Ar-CH), 7.07 (s, 1 H,
CH), 7.24 (at, 2 H, 3JH,H = 7.4, 8.5 Hz, 3’,5’-Ar-CH), 7.52 (d, 2 H, 3JH,H = 8.2 Hz, 3,5-Ar-CH),
7.78 (d, 2 H, 3JH,H = 8.5 Hz, 2’,6’-Ar-CH), 8.31 (d, 2 H, 3JH,H = 8.2 Hz, 2,6-Ar-CH), ppm; 13C-
NMR (400 MHz, CDCl3) δ= 13.1 (CH3), 118.8 (2’,6’-Ar-CH), 120.4 (q, 1JC,F =393.1 Hz, CF3),
125.0 (4’-Ar-CH), 125.4 (q, 3JC,F = 3.7 Hz, 3,5-Ar-CH) 128.8 (3’,5’-Ar-CH), 129.5 (Ar-C), 133.3
(q, 2JC,F =32.8 Hz, 4-Ar-CCF3), 133.4 (2,6-Ar-CH), 135.7 (Ar-C), 138.1 (Ar-C), 144.2 (CH),
150.6 (Ar-C), 161.2 (C=O) ppm; ESI-MS m/z (%) = 331.1 [M+H]+ (100 %), 348.1 [M+NH4]+
(1 %); HPLC-Analysis (Method B): 98 %, Rt = 19.8 min.
3-[(4Z)-4-[(2-hydroxyphenyl)methylidene]-3-methyl-5-oxopyrazol-1-yl] benzoic acid 81m [367]
TLC Rf = 0.5 (CHCl3/MeOH 8:2); Reaction time: 16 h; Purification: Flash-Chromatography
CHCl3/MeOH 95:5 (Rf = 0.3); Yield: 22 mg of red solid (0.07 mmol, 13 %); 1H-NMR (400 MHz,
DMSO-d6) δ= 2.34 (s, 3 H, CH3), 6.93 (at, 1 H, 3JH,H = 7.3, 8.0 Hz, 5-Ar-CH), 7.01 (dd, 1 H,
3,4JH,H = 0.7, 8.6H˙z, 3-Ar-CH), 7.47 (ddd, 1 H, 3,4JH,H = 1.6, 7.3, 8.6 Hz, 4-Ar-CH), 7.55 (at,
1 H, 3JH,H = 8.0 Hz, 5’-Ar-CH), 7.74-7.77 (m, 1 H, 6’-Ar-CH), 8.07 (s, 1 H, CH), 8.14-8.18 (m,
1 H, 4’-Ar-CH), 8.55 (at, 1 H, 4JH,H = 1.8 Hz, 2’-Ar-CH), 9.07 (dd, 1 H, 3,4JH,H = 1.6, 8.0 Hz,
6-Ar-CH) ppm; 13C-NMR (400 MHz, DMSO-d6) δ= 13.1 (CH3), 116.0 (3-Ar-CH), 118.9 (2’-
Ar-CH), 119.8 (5-Ar-CH), 122.0 (4’-Ar-CH), 124.4 (Ar-C), 125.1 (6’-Ar-CH), 129.3 (5’-Ar-CH),
133.0 (6-Ar-CH), 136.1 (Ar-C), 138.5 (Ar-C), 142.2 (CH), 152.3 (Ar-C), 159.4 (Ar-C), 162.0
(Ar-C), 167.1 (C=O), 184.6 (COOH) ppm.
3-[(4Z)-4-[(3-bromo-4-fluorophenyl)methylidene]-3- methyl-5-oxopyrazol-1-yl] benzoic acid 81o
TLC Rf = 0.1 (Hexane/EtOAc 7:3); Reaction time: 2 h; Purification: Filtration from HOAc;
Yield: 126 mg of red solid (0.31 mmol, 58 %); NOESY (CH3,CH → Z); 1H-NMR (400 MHz,
DMSO-d6) δ= 2.35 (s, 3 H, CH3), 7.57 (at, 1 H, 3JH,H = 7.8, 8.2 Hz, 5-Ar-CH), 7.61 (at, 1 H,
3JH,H(F) = 8.7 Hz, 5’-Ar-CH), 7.77 (adt, 1 H, 3,4JH,H = 1.3, 7.8 Hz, 4-Ar-CH), 7.86 (s, 1 H, CH),
8.15 (ddd, 1 H, 3,4JH,H = 1.3, 1.9, 8.2 Hz, 6-Ar-CH), 8.52 (at, 1 H, 4JH,H = 1.9 Hz, 2-Ar-CH),
8.59 (ddd, 1 H, 3,4JH,H(F) = 2.1, 4.9, 8.7 Hz, 6’-Ar-CH), 9.17 (dd, 1 H, 3,4JH,H(F) = 2.1, 7.0 Hz, 3’-
Ar-CH), 13.13 (s(br), 1 H, COOH) ppm; 13C-NMR (400 MHz, DMSO-d6) δ= 13.1 (CH3), 117.3
(5’-Ar-CH), 118.8 (6’-Ar-CH), 122.2 (6-Ar-CH), 125.4 (4-Ar-CH), 127.2 (Ar-C), 129.3 (5-Ar-
CH), 131.2 (Ar-C), 131.5 (Ar-C), 136.1 (2-Ar-CH), 138.2 (Ar-C), 138.5 (3’Ar-CH), 145.8 (CH)
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152.3 (Ar-C), 161.6 (Ar-C), 167.0 (C=O) ppm; ESI-MS m/z (%) = 401.0 [M−H]− (20 %), 436.0
[M+Cl−H]− (100 %), 460.0 [M+HAc−H]− (55 %), HR-MS m/z = 400.9935 [M−H]− (calculated:
400.9943); HPLC-Analysis (Method B): 92 %, Rt = 17.0 min.
3-[(4Z)-3-methyl-5-oxo-4- (phenylmethylidene)pyrazol-1-yl] benzoic acid 81p [368]
Reaction time: 6 h; Purification: Filtration from HOAc; Yield: 173 mg of yellow solid (0.56
mmol, 78 %); NOESY (CH3,CH → Z); 1H-NMR (400 MHz, DMSO-d6) δ= 2.35 (s, 3 H, CH3),
7.52-7.65 (m, 4 H, 3,4,5,5’-Ar-CH), 7.76 (d, 1 H, 3JH,H = 7.7 Hz, 4’-Ar-CH), 7.84 (s, 1 H, CH),
8.13-8.17 (m, 1 H, 6’-Ar-CH), 8.55 (at, 1 H, 4JH,H = 1.8 Hz, 2’-Ar-CH), 8.58 (d, 2 H, 3JH,H =
7.5 Hz, 2,6-Ar-CH), 13.07 (s(br), 1 H, COOH) ppm; 13C-NMR (400 MHz, DMSO-d6) δ= 13.1
(CH3), 118.7 (2’-Ar-CH), 122.0 (6’-Ar-CH), 125.2 (4’-Ar-CH), 126.5 (Ar-C), 128.7 (3,5-Ar-CH),
129.2 (4, 5’-Ar-CH), 131.4 (Ar-C), 132.9 (Ar-C), 133.3 (4 or 5’-Ar-CH), 133.8 (2,6-Ar-CH),
138.3 (Ar-C), 148.7 (CH), 152.3 (Ar-C), 161.6 (C=O), 167.0 (COOH) ppm; HPLC-Analysis
(Method B): 82 %, Rt = 17.7 min.
3-[(4Z)-4-[4-(benzyloxy)phenyl]methylidene-3- methyl-5-oxopyrazol-1-yl] benzoic acid 81n
Reaction time: 18 h Purification: Filtration from HOAc Yield: 176 mg of yellow solid (0.43
mmol, 64 %); 1H-NMR (400 MHz, DMSO-d6) δ= 1.91 (s, 3 H, CH3), 5.25 (s, 2 H, CH2), 7.20-
7.24 (m, 2 H, 2xAr-CH), 7.34-7.58 (m, 7 H, 7xAr-CH), 7.73-7.77 (m, 1 H, 1xAr-CH), 7.78 (s,
1 H, CH), 8.57 (at, 1 H, 4JH,H = 2.0 Hz, Ar-CH), 8.70 (d, 2 H, 3JH,H = 9.0 Hz, 2xAr-CH), 12.62
(s(br), 2 H, 2xOH) ppm; 13C-NMR (400 MHz, DMSO-d6) δ= 21.1 (CH3), 69.7 (CH2), 115.1
(Ar-CH), 115.3 (Ar-CH), 118.7 (Ar-CH), 122.0 (Ar-CH), 123.6 (Ar-C), 125.0 (Ar-CH), 126.3
(Ar-CH), 127.9 (Ar-CH), 128.0 (Ar-CH), 128.1 (Ar-CH), 128.5 (Ar-CH), 129.2 (Ar-CH), 136.3
(Ar-C), 136.9 (2xAr-CH), 138.5 (Ar-C), 148.5 (CH), 152.3 (Ar-C), 162.0 (Ar-C), 162.8 (Ar-C),
167.1 (C=O), 172.0 (COOH) ppm; ESI-MS m/z (%) = 411.1 [M−H]− (53 %) HPLC-Analysis
(Method B): 46 %, Rt = 20.1 min.
3-[(4Z)-4-[(3,4-dihydroxyphenyl)methylidene]-3- methyl-5-oxopyrazol-1-yl] benzoic acid 81q [369]
ESI-MS m/z (%) = 337.1 [M−H]− (100 %), 675.2 [2M−H]− (22 %).
Synthesis of phenyl-furanyl-carbaldehyde 86
5-Bromofuran-2-carbaldehyde (100 mg, 0.57 mmol), phenyl-boronic acid (105 mg, 0.86 mmol),
Pd(PPh3)4 (13 mg, 0.01 mmol) and potassium carbonate (197 mg, 1.425 mmol) were dissolved
in DMF under a N2-gas protection atmosphere. H2O (0.5 mL) were added so the suspension
and the reaction mixture was heated to 110 ◦C. After 4 h, TLC showed complete consump-
tion of starting material and the reaction mixture was concentrated and subjected to column
chromatography.
5-phenylfuran-2-carbaldehyde 86 [370]
TLC Rf = 0.5 (Hexane/EtOAc 8:2); Reaction time: 4 h Yield: 38 mg of yellow oil (0.22 mmol,
39 %); Purification: Flash-Chromatography Cyclohexan/EtOAc 95:5 (Rf = 0.1); 1H-NMR (400
347
9 Methods
MHz, CDCl3) δ= 6.58 (d, 1 H, 3JH,H = 3.7 Hz, Furan-CH), 7.06 (d, 1 H, 3JH,H = 3.7 Hz, Furan-
CH), 7.11-7.21 (m, 3 H, 3xAr-CH), 7.54-7.58 (m, 2 H, 2xAr-CH), 9.39 (s, 1 H, CHO).
Reduction of double bond in pyrazole derivatives
The pyrazole derivative 80ak (253 mg, 0.86 mmol) was dissolved in 25 mL dioxane and Pd/C
(360 mg) was added. The reaction mixture was placed in a hydrogenation chamber and the
hydrogenation was carried out at 30 psi H2 under gently shaking. The crude was filtered,
washed with EtOAc and concentrated to afford the reduced analogue 85a as a white solid.
4-[(5-hydroxy-3-methyl-1-phenylpyrazol-4- yl)methyl]benzene-1,2-diol 85a
Reaction time: 4 h; Purification: Filtration from EtOAc; Yield: 255 mg of white solid (0.86
mmol, 100 %); 1H-NMR (400 MHz, MeOD-d4) δ= 2.10 (s, 3 H, CH3), 3.51 (s, 2 H, CH2), 6.56
(dd, 1 H, 3,4JH,H = 8.1, 2.0 Hz, 6-Ar-CH), 6.64-6.71 (m, 2 H, 2,5-Ar-CH), 7.25 (at, 1 H, 3JH,H =
7.4 Hz, 4’-Ar-CH), 7.42 (at, 2 H, 3JH,H = 7.9, 7.4 Hz, 3’,5’-Ar-CH), 7.62 (d, 2 H, 3JH,H = 7.9 Hz,
2’,6’Ar-CH) ppm; 13C-NMR (400 MHz, MeOD-d4) δ= 11.2 (CH3), 27.8 (CH2), 106.9 (Ar-C),
116.2 (2(5)-Ar-CH), 116.3 (2(5)-Ar-CH), 120.4 (6-Ar-CH), 122.1 (2’,6’-Ar-CH), 127.2 (4’-Ar-
CH), 130.1 (3’,5’-Ar-CH), 133.4 (Ar-C), 137.8 (Ar-C), 144.4 (Ar-C), 146.2 (Ar-C), 148.7 (Ar-C)
ppm; ESI-MS m/z (%) = 297.1 [M+H]+ (100 %).
Synthesis of heterocyclic modified pyrazole derivatives
The Phenylhydrazine or the 3-hydrazinyl benzoic acid (2.03 mmol, 1.0 eq), ethyl 3-oxobutanoate
(2.03 mmol, 1.0 eq) were dissolved in 5 mL HOAc. The reaction mixture was stirred at 110 ◦C
for 16 h. The heterocyclic modified aldehyde (2.44 mmol, 1.2 eq) was added to the yellow reac-
tion mixture. The reaction mixture was continued to stir at 110 ◦C, until TLC showed complete
consumption of intermediate formed pyrazole precursor. The reaction mixture was cooled and
the product was isolated by simple filtration or column chromatography.
(4Z)-4-(furan-2-ylmethylidene)-5-methyl-2-phenylpyrazol-3-one 88a [353]
TLC Rf = 0.3 (Hexane/EtOAc 8:2); Reaction time: 4 h; Purification: Flash-Chromatography
Hexane/EtOAc 8:2 (Rf = 0.3); Yield: 472 mg of red solid (1.87 mmol, 92 %); 1H-NMR (400
MHz, DMSO-d6) δ= 2.33 (s, 3 H, CH3), 6.94 (dd, 1 H, 3JH,H = 1.6, 3.7 Hz, 4-Furan-CH), 7.19
(at, 1 H, 3JH,H = 7.4 Hz, 4’-Ar-CH), 7.41-7.47 (m, 2 H, 3’,5’-Ar-CH), 7.71 (s, 1 H, CH), 7.90-7.93
(m, 2 H, 2’,6’-Ar-CH), 8.27 (d, 1 H, 3JH,H = 1.6 Hz, 5-Furan-CH), 8.64 (d, 1 H, 3JH,H = 3.7 Hz,
3-Furan-CH) ppm; 13C-NMR (400 MHz, DMSO-d6) δ= 12.8 (CH3), 115.0 (4-Furan-CH), 117.8
(2’,6’-Ar-CH), 118.2 (Ar-C), 121.4 (4’-Ar-CH or 3-Furan-CH), 124.5 (4’-Ar-CH or 3-Furan-CH),
128.9 (3’,5’-Ar-CH), 130.5 (CH), 138.3 (Ar-C), 150.2 (Ar-C). 150.5 (Ar-C), 161.6 (C=O) ppm;
HPLC-Analysis (Method B): 99 %, Rt = 12.6 min.
348
9 Methods
Synthesis of N-1-modified pyrazole derivatives
Synthesis of N-1-unsubstituted precursor 89
Ethyl 3-oxobutanoate (1275µL, 10 mmol) was added to ethanol and hydrazine (973µL, 20 mmol)
was added drop wise to the reaction mixture. The temperature was maintained at 60 ◦C with
ice-cooling. After complete addition of hydrazine the reaction mixture was continued to stir for
1 h until TLC showed complete consumption of starting ethyl-aceto-acetate. Upon cooling the
product crystallised from the ethanol solution and was filtered and washed with ethanol.
5-methyl-2H-pyrazol-3-ol 89 [371]
TLC Rf = 0.1 (DCM/MeOH 9:1); Reaction time: 1 h; Purification: Filtration from ethanol;
Yield: 1066 mg of white solid (10.87 mmol, 100 %); Yield: 791 mg of white solid (8.06 mmol,
81 %); 1H-NMR (400 MHz, DMSO-d6) δ= 2.08 (s, 3 H, CH3), 5.21 (s, 1 H, CH), 10.28 (s)br),
1 H, OH) ppm; 13C-NMR (400 MHz, DMSO-d6) δ= 11.2 (CH3), 88.9 (CH), 139.3 (Ar-C), 161.0
(C=O) ppm; HPLC-Analysis (Method B): 100 %, Rt = 1.9 min.
Synthesis of N-1-acetic ester pyrazole precursor 90
Compound 89 (250 mg, 2.55 mmol) in DMF (5 mL) was added to NaH (102 mg, 2.55 mmol)
under ice-cooling at 0 ◦C and N2 gas atmosphere. The reaction mixture was stirred for 10 min
and ethyl 2-bromoacetate (283µL, 2.55 mmol) was added drop wise. The reaction mixture
was continued to stir at rt until TLC showed complete consumption of starting materials. The
reaction was quenched with water (20 mL), extracted with EtOAc (3x20 mL), dried over MgSO4,
filtered and concentrated. The crude was purified by flash column chromatography.
Ethyl 2-(5-hydroxy-3-methylpyrazol-1-yl) acetate 90 [372]
TLC Rf = 0.1 (CHCl3/MeOH 1:0.02); Reaction time: 6 h; Purification: Flash-Chromato-
graphy CHCl3/MeOH 1:0.02 → 1:0.05 (Rf = 0.1, 0.3) Purification: Flash-Chromatography
CHCl3/MeOH 1:0.02 (Rf = 0.1); Yield: 140 mg of white solid (0.76 mmol, 30 %); 1H-NMR
(400 MHz, CDCl3) δ= 1.25 (t, 3 H, 3JH,H = 7.1 Hz, CH2CH3), 2.14 (s, 3 H, CH3), 4.19 (q, 2 H,
3JH,H = 7.1 Hz, CH2CH3), 4.55 (s, 2 H, CH2), 5.44 (s, 1 H, CH), 10.99 (s(br), 1 H, OH) ppm;
13C-NMR (400 MHz, CDCl3) δ= 11.2 (CH3), 14.2 (CH2CH3) 49.6 (CH2), 61.9 (CH2CH3), 92.1
(CH) 141.7 (Ar-C), 162.0 (C=O), 167.8 (COOEt) ppm;
9.19 Synthesis of CQ-HPO conjugated iron chelators
Synthesis of amino-quinoline precursor 96
4,7-dichloroquinoline 95 (5 g, 0.025 mmol) and 1,4-diaminobutane (11.02 g, 0.125 mol) was
heated to reflux for 18 h at 160-180 ◦C until TLC showed complete consumption of 95. DMF
was added to the reaction mixture and a white solid was filtered and washed with chloroform.
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Recrystallization from MeOH/Et2O gave 3.85 g of the amino-quinoline 96 as white crystals
(62 % yield).
N-(4-aminobutyl)-7-chloroquinolin-4-amine 96 [373]
TLC Rf = 0.3 (Toluene/MeOH 7:3); Purification: Flash-Chromatography Toluene/MeOH 8:2
(Rf = 0.2); Yield: 3246 mg of white solid (13.00 mmol, 52 %) (column chromatography); Yield:
3850 mg of white solid (15.42 mmol, 62 %) (precipitation and recrystallisation); Melting point:
242.2-244.8 ◦C; 1H-NMR (400 MHz, DMSO-d6) δ= 1.49-1.57 (m, 2 H, β-CH2), 1.61-1.70 (m,
2 H, γ-CH2), 3.11-3.16 (m, 2 H, δ-CH2), 3.24-3.30 (m, 2 H, α-CH2), 6.48 (d, 1 H, 3JH,H = 5.5 Hz,
3-Ar-CH), 7.37 (t(br), 1 H, 3JH,H = 5.1 Hz, NH), 7.77 (d, 1 H, 4JH,H = 2.2 Hz, 8-Ar-CH), 7.97-8.05
(m, 2 H, NH2), 8.28 (d, 1 H, 3JH,H = 9.0 Hz, 5-Ar-CH), 8.39 (d, 1 H, 3JH,H = 5.5 Hz, 2-Ar-CH)
ppm; 13C-NMR (400 MHz, DMSO-d6) δ= 25.2 (γ-CH2), 26.7 (β-CH2), 36.8 (δ-CH2), 42.0 (α-
CH2), 98.7 (3-Ar-CH), 117.4 (Ar-C), 124.1 (6-Ar-CH), 124.2 (5-Ar-CH), 127.3 (8-Ar-CH), 133.5
(Ar-C), 150.2 (Ar-C), 151.7 (2-Ar-CH), 161.0 (Ar-C), ppm; HPLC-Analysis (Method B): 81 %,
Rt = 16.6 min.
Synthesis of HPO-CQ-conjugated iron chelators
Synthesis following Route A: Installation of amino-linker prior to Michael addition reac-
tion
Benzyl protected maltol 92b (1.300 g, 0.006 mol) was dissolved in EtOH (83 % v/v, 30 mL).
The amino-quinoline 96 (1.000 g, 0.004 mol) was added, followed by NaOH (2N) until pH 13
was reached. The reaction mixture was stirred at 100 ◦C until TLC showed complete con-
sumption of starting materials. The crude was concentrated, extracted between water (20 mL)
and EtOAc (3x50 mL). The combined organic fractions were dried over MgSO4, filtered and
concentrated. Purification by flash chromatography (CHCl3/MeOH 8:2 + 0.25-0.30 % aq. NH3)
afforded 0.9 g of the protected iron-chelator 97 as a yellow-orange solid. This material was dis-
solved in aq. HCl (6 N, 30 mL) and the solution was heated to reflux until TLC showed complete
consumption of starting material to remove the protecting group. The reaction mixture was
concentrated in vacuo, and the resulting precipitate was recrystallized from ethanol/acetone,
to give the title compound 98a as a white solid.
3-(benzyloxy)-1-(4-((7-chloroquinolin-4-yl)amino)butyl)-2-methylpyridin-4(1H)-one 97
TLC Rf = 0.4 (CHCl3/MeOH/NH3 8:2:0.25); Purification: Flash-Chromatography CHCl3/ MeOH/
NH3 (Rf = 0.4); Yield: 188 mg of white solid (0.42 mmol, 74 %) (Route A); Yield: 900 mg of
yellow-orange solid (2.01 mmol, 50 %) (Route A); Yield: 200 mg of white solid (0.45 mmol,
20 %) (Route B); 1H-NMR (400 MHz, DMSO-d6) δ= 1.61-1.74 (m, 4 H, β,γ-CH2), 2.16 (s, 3 H,
) 3.38-3.44 (m, 2 H, δ-CH2), 3.94 (t, 2 H, 3JH,H = 6.8 Hz, α-CH2), 5.00 (s, 2 H, CH2), 6.16 (d,
1 H, 3JH,H = 7.4 Hz, 3-HPO-CH), 6.65 (d, 1 H, 3JH,H = 6.3 Hz, 3-Ar-CH), 7.29-7.39 (m, 5 H,
5xAr-CH), 7.56 (dd, 1 H, 3,4JH,H = 2.2, 9.0 Hz, 6-Ar-CH), 7.68 (d, 1 H, 3JH,H = 7.4 Hz, 2-HPO-
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CH), 7.91-7.97 (m, 1 H, 8-Ar-CH), 8.45 (d, 1 H, 3JH,H = 6.3 Hz, 2-Ar-CH), 8.58 (d, 1 H, 3JH,H =
9.0 Hz, 5-Ar-CH), 8.69-8.74 (m, 1 H, ) ppm; 13C-NMR (400 MHz, DMSO-d6) δ= 11.9 (CH3),
24.4, 27.7 (β,γ-CH2), 42.2 (δ-CH2), 52.4 (α-CH2), 71.8 (CH2), 98.6 (3-Ar-CH), 116.0 (3-HPO-
CH), 116.5 (Ar-C), 123.1 (8-Ar-CH), 125.3 (5-Ar-CH), 125.4 (6-Ar-CH), 127.8 (Ar-CH), 128.2
(Ar-CH), 128.4 (Ar-CH), 135.7 (Ar-C), 137.7 (Ar-C), 139.6 (2-HPO-CH), 140.8 (Ar-C), 143.7
(Ar-C), 145.3 (Ar-C), 147.1 (2-Ar-CH), 152.8 (Ar-C), 171.8 (C=O) ppm; ESI-MS m/z (%) = 447.1
[M−H]− (50 %), HR-MS m/z = 447.0729 [M−H]− (calculated: 447.1714).
1-(4-((7-chloroquinolin-4-yl)amino)butyl)-3-hydroxy-2-methylpyridin-4(1H)-one 98a
TLC Rf = 0.1 (CHCl3/MeOH 8:2); Purification: Re-crystallisation from EtOH/Acetone; Yield:
47 mg of white solid (0.13 mmol, 59 %); 1H-NMR (400 MHz, DMSO-d6) δ= 1.68-1.79 (m, 2 H,
γ-CH2), 1.83-1.92 (m, 2 H, β-CH2), 2.53 (s, 3 H, CH3), 3.54-3.61 (m, 2 H, δ-CH2), 4.38 (t, 2 H,
3JH,H = 7.4 Hz, α-CH2), 6.89 (d, 1 H, 3JH,H = 7.2 Hz, 3-HPO-CH), 7.18 (d, 1 H, 3JH,H = 7.0 Hz,
3-Ar-CH), 7.77 (dd, 1 H, 3,4JH,H = 2.1, 9.1 Hz, 6-Ar-CH) 8.07 (d, 1 H, 4JH,H = 2.1 Hz, 8-Ar-CH),
8.26 (d, 1 H, 3JH,H = 7.0 Hz, 2-Ar-CH), 8.55 (d, 1 H, 3JH,H = 7.2 Hz, 2-HPO-CH), 8.77 (d, 1 H,
3JH,H = 9.1 Hz, 5-Ar-CH) 9.56 (t, 1 H, 3JH,H = 5.4 Hz, NH), 14.27 (s(br), 1 H, OH) ppm; 1H-NMR
(400 MHz, D2O) δ= 1.76-1.84 (m, 2 H, γ-CH2), 1.94-2.02 (m, 2 H, β-CH2), 2.45 (s, 3 H, CH3),
3.55-3.60 (m, 2 H, δ-CH2), 4.35 (t, 2 H, JH,H = 7.0 Hz, α-CH2), 6.69 (d, 1 H, 3JH,H = 7.2 Hz, 3-Ar-
HPO-CH), 6.91 (d, 1 H, 3JH,H = 7.0 Hz, 3-Ar-CH), 7.64 (dd, 1 H, 3,4JH,H = 1.9, 9.0 Hz, 6-Ar-CH),
7.86 (d, 1 H, 4JH,H = 1.9 Hz, 8-Ar-CH), 7.95 (d, 1 H, 3JH,H = 7.0 Hz, 2-Ar-CH), 8.08 (d, 1 H,
3JH,H = 9.0 Hz, 5-Ar-CH), 8.22 (d, 1 H, ppmJH,H = 7.2 Hz, 2-Ar-HPO-CH); 13C-NMR (400 MHz,
DMSO-d6) δ= 12.5, 24.2, 26.9, 42.5, 55.3, 98.6, 110.7, 115.5, 119.1, 125.9, 126.9, 138.0,
138.5, 142.9, 143.2, 155.4 () ppm; IR (cm-1): 2500-3300 (OH, NH); EI-MS m/z (%) = 358.0
[M]+ (100 %), 233.0 [fragment]+ (75 %), 154 [fragment]+ (38 %); HPLC-Analysis : 99.9 %, Rt =
20.6 min.
Synthesis following Route B: Double Michael addition prior to quinoline conjugation
Maltol (50 g, 0.397 mol) was dissolved in methanol (450 mL). NaOH( 8.7 M, 50 mL) was added,
followed by benzylbromide (74.66 g, 0.437 mmol). The reaction mixture was heated to 100 ◦C
for 6 h.The crude was concentrated, extracted between NaOH(aq) (5 %, 400 mL) and DCM
(2x200 mL). The combined organic fractions were washed with water (190 mL) and dried over
MgSO4, filtered and concentrated. Recrystallisation from Et2O gave 69.9 g of 92b as colour-
less needles (81 % yield). The benzyl protected maltol (346 mg, 1.60 mmol) was dissolved in
EtOH(aq) (50 %, 15 mL) and 1,4-diaminobutane (141 mg, 1.60 mmol) was added. The pH of the
reaction mixture was adjusted to pH 13 with aq. sodium hydroxide (10N) and stirring was con-
tinued at 100 ◦C for 18 h. The reaction mixture was concentrated and the crude was extracted
between water (10 mL) and CHCl3 (3x10 mL). The combined organic fractions were dried over
MgSO4, filtered and concentrated. The amino-HPO 99 was obtained after column chromatog-
raphy (CHCl3/MeOH/NH3 8:2:0.01, Rf 0.1) as white solid (230 mg, 50 %). The amino-HPO
351
9 Methods
(1.00 g, 3.50 mmol) and 4,7-dichloroquinoline (693 mg, 3.50 mmol) were dissolved in DMSO
(10 mL) and heated to 100 ◦C for 16 h. The reaction mixture was concentrated and purified as
described in chapter 9.19. The protected iron chelator was obtained in 20 % yield. The pro-
tected reaction product 97 (22 mg, 0.05 mmol) was dissolved in ethanol, the pH was adjusted
to 1 with HCl(aq), and hydrogenation was carried out in the presence of 5 % Pd/C to give the
title compound 98b as a white solid.
2-Methyl-3-benzyloxy-4-(4H)-pyranone 92b [261]
Reaction time: 6 h; Purification: Re-crystallisation from Et2O; Yield: 69.9 mg of colourless
neddles (0.32 mmol, 81 %); 1H-NMR (400 MHz, DMSO-d6) δ= 1.99 (s, 3 H, CH3), 5.00 (s, 2 H,
CH2), 6.14-6.24 (m, 1 H, Ar-CH), 7.20 (m, 5 H, 5xAr-CH), 7.39-749 (m, 1 H, Ar-CH) ppm.
1-(4-aminobutyl)-3-(benzyloxy)-2-methylpyridin-4(1H)-one 99 [374]
TLC Rf = 0.1 (CHCl3/MeOH/NH3 8:2:0.01); Reaction time: 18 h; Purification: Flash-Chroma-
tography CHCl3/MeOH/NH3 8:2:0.01 (Rf = 0.1); Yield: 230 mg of white solid (0.80 mmol,
50 %); 1H-NMR (400 MHz, MeOD) δ= 1.36-1.47 (m, 2 H, β-CH2), 1.55-1.64 (m, 2 H, γ-
CH2), 2.65 (t, 2 H, 3JH,H = 7.3 Hz, α-CH2), 3.87 (t, 2 H, 3JH,H = 7.4 Hz, δ-CH2), 4.98 (s, 3 H,
CH3), 6.39 (d, 1 H, 3JH,H = 7.4 Hz, 3-HPO-CH), 7.23-7.33 (m, 5 H, 5xAr-CH), 7.61 (d, 1 H,
3JH,H = 7.4 Hz, 2-HPO-CH) ppm; 13C-NMR (400 MHz, MeOD) δ= 12.8 (CH3), 28.8 (CH2),
41.3 (CH2), 54.9 (CH2), 74.4 (CH2), 117.3 (Ar-C or Ar-underlineCH), 129.4 (Ar-C or Ar-
underlineCH), 129.4 (Ar-C or Ar-underlineCH), 130.3 (Ar-C or Ar-underlineCH), 138.3 (Ar-C
or Ar-underlineCH), 141.2 (Ar-C or Ar-underlineCH), 144.0 (Ar-C or Ar-underlineCH), 146.9
(Ar-C or Ar-underlineCH), 174.6 (C=O) ppm;
4-((4-(3,4-dihydroxy-2-methylpyridin-1-ium-1-yl)butyl)amino)quinolin-1-ium 98b
Reaction time: 4 h Purification: Filtration from EtOH; Yield: 15 mg of white solid (0.05 mmol,
100 %); 1H-NMR (400 MHz, D2O) δ= 1.80-1.89 (m, 2 H, CH2), 1.98-2.06 (m, 2 H, CH2), 2.50
(s, 3 H, CH3), 3.58 (t, 2 H, 3JH,H = 6.6 Hz, CH2), 4.38 (t, 2 H, 3JH,H = 6.9 Hz, CH2), 6.65 (d, 1 H,
3JH,H = 7.0 Hz, 3-HPO-Ar-CH), 6.93 (d, 1 H, 3JH,H = 6.9 Hz, 3-Ar-CH), 7.65 (at, 1 H, 3JH,H = 7.6,
8.4 Hz, 7-Ar-CH), 7.75 (d, 1 H, 3JH,H = 8.4 Hz, 5-Ar-CH), 7.90 (at, 1 H, 3JH,H = 7.6, 8.4 Hz, 6-Ar-
CH), 7.99 (d, 1 H, 3JH,H = 6.9 Hz, 2-Ar-CH), 8.03 (d, 1 H, 3JH,H = 8.4 Hz, 8-Ar-CH), 8.21 (d, 1 H,
3JH,H = 7.0 Hz, 2-HPO-Ar-CH), ppm; 13C-NMR (400 MHz, D2O) δ= 15.1 (CH3), 26.1 (CH2),
29.3 (CH2), 45.1 (CH2), 59.2 (CH2), 100.8 (3-HPO-Ar-CH), 113.6 (3-Ar-CH), 119.4 (Ar-C),
122.8 (5-Ar-CH), 124.7 (8-Ar-CH), 130.0 (7-Ar-CH), 136.6 (6-Ar-CH), 140.1 (Ar-C), 141.5 (2-
Ar-CH), 144.2 (2-HPO-Ar-CH), 145.7 (Ar-C), 158.5 (Ar-C), 161.6 (C=O), ppm; EI-MS m/z (%) =
324.0 [M]+ (45 %), 233.0 [fragment]+ (100 %); HPLC-Analysis : 100 %, Rt = 20.6 min.
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Synthesis of CatL inhibitor CAA0225
Synthesis of building block A
2-(tert-butoxycarbonylamino)-3-phenylpropanoic acid 106 (500 mg, 1.88 mmol) was dissolved
in DCM and TBTU (605 mg, 1.88 mmol) was added. After 5 min, DIPEA (445µL, 1.88 mmol)
and benzyl-amine (206µL, 1.88 mmol) were added subsequently. The reaction mixture was
stirred for 16 h at rt. The mixture was diluted with DCM and washed with brine. The organic
phase was further washed with 1 N HCl (2 x 5 mL), dried over MgSO4, filtered and concen-
trated. Purification by flash chromatography (cyclohexane/EtOAc 6:4, Rf 0.5) afforded tert-
butyl 1-(benzylamino)-1-oxo-3-phenylpropan-2-ylcarbamate 107a (662 mg, 99 %) as a white
solid. The Boc protected amide 107a (100 mg, 0.28 mmol) was dissolved in DCM (5 mL) and
TFA (408 mg, 4.21 mmol) was subsequently added. The reaction mixture was allowed to stir
for another 2 h and was concentrated. The crude mixture was redissolved in DCM and cooled
to 0C, while it was neutralised with Na2CO3 solution. The organic layer was washed with
conc. NaHCO3 solution (3 x 5 mL) and dried over MgSO4, filtered and dried in vacuo to afford
2-amino-N-benzyl-3-phenylpropanamide 107b (69 mg, 98 %) as a white solid.
tert-Butyl 1-(benzylamino)-1-oxo-3-phenylpropan-2-ylcarbamate 107a [375]
TLC Rf = 0.5 (Cyclohexane/EtOAc 6:4); Purification: Flash-Chromatography Cyclohexane/
EtOAc 6:4 (Rf = 0.5); Yield: 662 mg of white solid (1.87 mmol, 99 %); 1H-NMR (400 MHz,
CDCl3) δ= 1.39 (s, 9 H, (CH3)3Boc), 3.02-3.15 (m, 2 H, CH2CH), 4.35,4.36 (2xs, 3 H, CH2NH,
HC, NH), 5.05 (s(br), 1 H, NHBoc), 6.06 (s(br), 1 H, NHCO), 7.05-7.30 (m, 10 H, 10xAr-CH)
ppm; 13C-NMR (400 MHz, CDCl3) δ= 28.3 (3xCH3), 38.8 (CH2), 43.4 (CH2), 56.1 (CH), 80.2
(CtBu), 126.9 (Ar-CH), 127.4 (Ar-CH), 127.7 (Ar-CH), 128.6 (Ar-CH), 128.7 (Ar-CH), 129.4
(Ar-CH), 136.8 (Ar-C), 137.8 (Ar-C), 155.6 (C=O), 171.3 (COOtBu) ppm; ESI-MS m/z (%) =
355.2 [M+H]+ (100 %), 377.2 [M+Na]+ (10 %), 709.4 [2M+H]+ (15 %), 731.4 [2M+Na]+ (10 %);
HR-MS m/z = 355.2020 [M+H]+ (calculated: 355.2016); HPLC-Analysis (Method B): 87 %,
Rt = 17.5 min.
2-amino-N-benzyl-3-phenylpropanamide 107b [375]
Reaction time: 2 h; Yield: 69 mg of white solid (0.27 mmol, 98 %); 1H-NMR (400 MHz, CDCl3)
δ= 1.53 (s(br), 2 H, NH2), 2.74 (dd, 1 H, 3JH,H = 9.1, 13.7 Hz, CH2CH), 3.28 (dd, 1 H, 3JH,H =
4.2, 13.7 Hz, CH2CH), 3.59-3.69 (m, 1 H, αH), 4.40 (dd, 1 H, 3JH,H = 6.1, 14.8 Hz, CH2NH),
4.45 (dd, 1 H, 3JH,H = 6.1, 14.8 Hz, CH2NH), 7.12-7.33 (m, 10 H, 10xAr-CH), 7.58 (s(br), 1 H,
NH) ppm. ESI-MS m/z (%) = 255.1 [M+H]+ (100 %), 277.1 [M+Na]+ (35 %), 509.3 [2M+H]+
(25 %), 531.3 [2M+Na]+ (85 %), HR-MS m/z = 255.1495 [M+H]+ (calculated: 255.1492); HR-
MS m/z = 255.1496 [M+H]+ (calculated: 255.1492).
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Synthesis of CAA0225, assembly of building blocks
(2S,3S)-diethyl oxirane-2,3-dicarboxylate 108a (99 mg, 0.53 mmol) in EtOH (0.5 mL) was cooled
to 4 ◦C and KOH (5.25 mL, 0.1 M) was added over a period of 3 h. The mixture was then
stored over night in the freezer. After warming to rt, the mixture was concentrated, the
residue was taken up between NaHCO3 (aqueous, 50 mM) and EtOAc. The aqueous layer
was extracted with EtOAc (2 x 2 mL). The pH of the aqueous layer was adjusted to 2.5 using
NaHSO4 (50 mM) and was extracted with EtOAc (5 x 5 mL). The combined of organic layers
of the second extraction were dried over MgSO4, filtered and concentrated to afford (2S,3S)-
3-(ethoxycarbonyl)oxirane-2-carboxylic acid 108b (60 mg, 70 %) as a clear oil. To a solution of
cmpdepoxy.oh (53 mg, 0.33 mmol), tyramine (55 mg, 0.40 mmol) and HOBt (51 mg, 0.33 mmol)
in CHCl3 (1 mL) at 0 ◦C was added EDC (57 mg, 0.36 mmol) slowly in 5 portions. The reaction
mixture was stirred for 1 h at 0 ◦C and then subsequently at rt for 24 h. The mixture was con-
centrated, and the residue was taken up between EtOAc and water. The organic layer was
washed with 0.5 N HCl (2 x 5 mL) and saturated NaHCO3 (2 x 5 mL), dried over MgSO4, filtered
and concentrated. Purification by flash chromatography (Cyclohexane/EtOAc 1:1, Rf 0.1)
afforded (2S,3S)-ethyl 3-(4-hydroxyphenethylcarbamoyl)oxirane-2-carboxylate 109a (30 mg,
33 %) as a white solid. Compound 109a was dissolved in EtOH (2 mL) and KOH (1.3 mL,
0.1 M) was added over a period of 3 h. The mixture was then stored over night in the freezer.
After warming to rt, the mixture was concentrated, the residue was taken up between NaHCO3
(aqueous, 50 mM) and EtOAc. The aqueous layer was extracted with EtOAc (2 x 2 mL). The
pH of the aqueous layer was adjusted to 2.5 using NaHSO4 (50 mM) and was extracted with
EtOAc (5 x 5 mL). The combined of organic layers of the second extraction were dried over
MgSO4, filtered and concentrated to afford (2S,3S)-3-(4-hydroxyphenethylcarbamoyl)oxirane-
2-carboxylic acid 109b (15 mg, 54 %) as a white solid. Compound 109b (19 mg, 0.07 mmol),
107b (15 mg, 0.06 mmol) and HOBt (10 mg, 0.06 mmol) were dissolved in CHCl3 (1 mL) and
NMM (9µL) was added. The reaction mixture was cooled to 0 ◦C and EDC (11 mg, 0.07 mmol)
was added in 5 small portions. The mixture was stirred for 16 h subsequently at rt. The crude
reaction mixture was diluted with DCM and washed with 1 N HCl (2 x 1 ml) and NaHCO3 (conc,
2 x 1 mL). The organic phase was dried over MgSO4, filtered and concentrated. Purification by
flash chromatography (DCM/MeOH 1:0.05, Rf 0.1) afforded (2S,3S)-N2-(1-(benzylamino)-1-
oxo-3-phenylpropan-2-yl)-N3-(4-hydroxyphenethyl)oxirane-2,3-dicarboxamide CAA0225 (5 mg,
17 %) as a white solid.
(2S,3S)-3-(ethoxycarbonyl)oxirane-2-carboxylic acid 108b [375]
TLC Rf = 0.1 (DCM/MeOH 9:1); Purification: The crude was dissolved in NaHCO3aq (4 mL,
50 mM), extracted with EtOAc (2x4 mL). The pH of the aqueous layer was adjusted to 2.5
using KHSO4 (2 M) and was extracted with EtOAc (5x3 mL). The combined organic fractions
from the 2nd extraction were dried over MgSO4, filtered and concentrated. Yield: 60 mg of
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clear oil (0.37 mmol, 71 %); 1H-NMR (400 MHz, DMSO-d6) δ= 1.22 (t, 3 H, 3JH,H = 7.1 Hz,
CH2CH3), 3.61 (d, 1 H, 3JH,H = 1.8 Hz, CH), 3.70 (d, 1 H, 3JH,H = 1.8 Hz, CH), 4.17 (q, 2 H,
3JH,H = 7.1 Hz, CH2CH3) ppm; ESI-MS m/z (%) = 159.0 [M−H]− (100 %), 177.0 [M+H2O−H]−
(30 %), 319.1 [2M−H]− (50 %), 337.1 [2M+H2O−H]− (10 %); HR-MS m/z = 159.0302 [M−H]−
(calculated: 159.0299).
(2S,3S)-ethyl 3-(4-hydroxyphenethylcarbamoyl)oxirane-2-carboxylate 109c [375]
TLC Rf = 0.4 (Cyclohexane/EtOAc 1:1); Reaction time: 16 h; Purification: Flash-Chromato-
graphy Cyclohexane/EtOAc 1:1 (Rf = 0.4); Yield: 60 mg of white solid (0.21 mmol, 65 %); 1H-
NMR (400 MHz, CDCl3) δ= 1.28 (t, 3 H, 3JH,H = 7.1 Hz, CH2CH3), 2.69-2.75 (m, 2 H, NHCH2),
3.35 (d, 1 H, 3JH,H = 1.8 Hz, CH), 3.42-3.53 (m, 2 H, CH2), 3.64 (d, 1 H, 3JH,H = 1.8 Hz, CH),
4.18-4.27 (m, 2 H, CH2), 6.20 (t(br), 1 H, 3JH,H = 5.7 Hz, NHCH2), 6.39 (s(br), 1 H, Ar-OH), 6.78
(d, 2 H, 3JH,H = 8.5 Hz, 3,5-Ar-CH), 6.99 (d, 2 H, 3JH,H = 8.5 Hz, 2,6-Ar-CH) ppm.
(2S,3S)-3-(4-hydroxyphenethylcarbamoyl)oxirane-2-carboxylic acid 109b
TLC Rf = 0.1 (Cyclohexane/EtOAc 1:1); Yield: 15 mg of white solid (0.06 mmol, 54 %); Re-
action time: 3 h; 1H-NMR (400 MHz, CD3OD) δ= 2.63 (t, 2 H, 3JH,H = 7.4 Hz, CH2CH2Ar),
3.27-3.35 (m, 2 H, CH2CH2Ar), 3.37 (d, 1 H, 3JH,H = 1.8 Hz, CH), 3.45 (d, 1 H, 3JH,H = 1.8 Hz,
CH), 6.64 (d, 2 H, 3JH,H = 8.5 Hz, 3,5-Ar-CH), 6.95 (d, 2 H, 3JH,H = 8.5 Hz, 2,6-Ar-CH), 8.19
(t(br), 1 H, 3JH,H = 5.5 Hz, NH) ppm. ESI-MS m/z (%) = 367.1 [M−H]− (100 %); HR-MS m/z =
367.1300 [M−H]− (calculated: 367.1299).
(2S,3S)-N2-(1-(benzylamino)-1-oxo-3-phenylpropan-2-yl)-N3-(4-hydroxyphenethyl)oxirane-2,3-
dicarboxamide CAA0225 [375]
TLC Rf = 0.1 (DCM/MeOH 100:5); Reaction time: 16 h; Purification: Flash-Chromatography
DCM/MeOH 100:5 (Rf = 0.1); Yield: 5 mg of white solid (0.01 mmol, 17 %); 1H-NMR (400 MHz,
CD3OD) δ= 2.64 (t, 2 H, 3JCH2,CH2 = 7.4 Hz, tyramine-CH2), 2.89 (dd, 1 H,
2,3JβH,βH(αH) = 8.5,
13.7 Hz, βH), 3.09 (dd, 1 H, 2,3JβH,βH(αH) = 6.8, 13.7 Hz, βH), 3.25 (d, 1 H, JH,H = 1.9 Hz, CH),
3.32 (dt, 2 H, 3JH,H = 1.5, 7.4 Hz, tyramine-NHCH2), 3.43 (d, 1 H, JH,H = 1.9 Hz, CH), 4.24 (d,
1 H, 2JH,H = 15.0 Hz, CH2Ph), 4.31 (d, 1 H, 2JH,H = 15.0 Hz, CH2Ph), 4.61 (dd, 1 H, 3JαH,βH =
6.8, 8.5 Hz, αH), 6.66 (d, 2 H, 3JH,H = 8.5 Hz, tyramine-3,5-Ar-CH), 6.97 (d, 2 H, 3JH,H = 8.5 Hz,
tyramine-2,6-Ar-CH), 7.06-7.25 (m, 10 H, 10xAr-CH) ppm; APCI-MS m/z (%) = 488.2 [M+H]+
(100 %); HR-MS m/z = 488.2168 [M+H]+ (calculated: 488.2180).
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Table 72: Reagents for Baltz-Media preparation
Reagent Supplier Order-No CAS-No Molecular Formula FW [ gmol ]
HEPES Sigma H3375-100G 7365-45-9 C8H18N2O4S 238.30
D-(+)-Glucose Sigma G8270-1006 50-99-7 C6H12O6 180.16
L-Glutamine Sigma G8540-25G 56-85-9 C5H10N2O3 146.15
Hypoxanthine Sigma H9636-1G 68-94-0 C5H4N4O 136.11
Thymidine Sigma T1895-1G 50-89-5 C10H14N2O5 242.23
BCDS Sigma B-1125 C26H18N2O6S2Na2 564.50
Sodium pyruvate Sigma P-5280-25G 113-24-6 C3H3NaO3 110.04
Adenosine Sigma A4036-5G 58-61-7 C10H13N5O4 267.25
MEM GIBCO 51200-087
NEAA Sigma M7145
Table 73: Reagents for Baltz-Media-completion
Reagent Supplier Order-No
Fetal Bovine Serum (heat inactivated) Sigma F4135-500ML
Penicillin-Streptomycin Sigma P4333-100ML
β-ME Sigma 63689-25ML-F
9.20 Preparation of media
Preparation of incomplete-Baltz-Media
HEPES (3.00 g), glucose (0.45 g), glutamine (146.00 mg), sodium pyruvate (100.00 mg), hy-
poxanthine (7.00 mg), thymidine (2.00 mg), adenosine (10.70 mg) and Bathocuproinedisulfonic
acid disodium salt (Na-BCDS, 14.10 mg) were dissolved in Earls’ medium without phenol red
(50 mL). The solution was stirred 15 min at rt and the pH was adjusted to 7.5 using NaOH
(1aq, 1 M). The neutralised solution was sterile filtered and transferred back to the remaining
450 mL of media. The media was supplemented with 5 mL non-essential amino acid solution
(NEAA).
Preparation of complete-Baltz-Medium
In order to prepare complete-Baltz-Medium for the culturing of T. brucei, 100 mL of incomplete-
Baltz-medium was supplemented with 20 mL heat-inactivated FBS, 1 mL β-mercapto-ethanol
(β-ME) solution (14.1µL β-ME in 10 mL dd-H2O) and 1 mL of PenStrep (1000 UmL ).
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Table 74: Reagents for RPMI-media
Reagent Supplier Order-No
Fetal Bovine Serum (heat inactivated) Sigma F4135-500ML
Penicillin-Streptomycin Sigma P4333-100ML
L-Glutamine solution (200 mM) Sigma G7513-100ML
Preparation of RPMI-1640 media
RPMI-1640 media was prepared by adding heat-inactivated FBS (20 mL), PenStrep (1 mL)
and L-glutamine (2 mL) to 100 mL RPMI 1640 media.
9.21 Culturing of parasites and mammalian cells
Culturing of T. brucei
T. brucei bloodstream form 427-221a was cultured in Baltz-medium (complete) at 37 ◦C and
5 % CO2. The parasite density was adjusted to not exceed 106 cellsml .
[189]
Culturing of T. cruzi
The trypomastigotes forms of Trypanosoma cruzi (Y strain) were grown in LLC-MK2 cells in
RPMI-1640 supplemented with 2 % FBS, at 37 ◦C in an incubator with 5 % CO2 . [136,376]
Culturing of L. infantum
Promastigotes of Leishmania (Leishmania) infantum chagasi (MHOM/BR/1972/LD) were cul-
tured in M-199 supplemented with 10 % FCS and 0.25 % hemine, without addition of antibiotics
in an incubator at 24 ◦C. Amastigotes of L. infantum were obtained by infection of golden ham-
sters (Mesocricetus auratus). All animals were obtained from the vivarium of the Adolfo Lutz
Institute in Sao Paulo and kept in sterile boxes with absorbent material, receiving food and wa-
ter ad libitum. All procedures performed on animals were previously approved by the Research
Ethics Committee (CEP) of the Adolfo Lutz Institute. [136]
Amastigotes of L. (L.) infantum chagasi were purified from the spleen of golden hamsters by
differential centrifugation and the number of parasites was determined by weight of the infected
spleen and counting of a representative sample 60 to 70 days after infection. [377]
Culturing of HL-60 cells
Human Caucasian promyelocytic leukaemia cells were obtained from European Collection
of Cell Cultures (ECACC, Catalogue No: 98070106) HL-60 cells were propagated in RPMI-
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medium, supplemented with L-glutamine (2mM) and FBS (20 %) at 37 ◦C and 5 % CO2. The
cells were obtained at passage P+8 and were first frozen in 10 % DMSO in FBS after P+10.
Toxicity assays were performed with cells with a passage number of lower P+20. HL60 cells
grow in suspension and cells were suspended at 100-150xg in a centrifuge for maximum 5 min.
Cultures were maintained between 1-9x105 cellsmL . Cells were counted with the aid of tryphan
blue in a Neubauer counting chamber (20µL sample and 20µL tryphanblue).
9.22 Anti-parasitic activity and toxicity assays
AlamarBlue assay for T. brucei activity and HL-60 cell toxicity
The AlamarBlue assay was performed in a 24 well plate (Figure 78). The columns (1-6) repre-
sent different concentrations of inhibitor, with the highest concentration of 100µM in column 1.
A1 contains 995.5µL of media and 5.5µL of inhibitor (20 mM in DMSO). For the next dilution
in A2, 100µL of A1 were given to 900µL of media (0.5 % DMSO). This procedure was re-
peated for all subsequent columns, so that 1:10 dilutions were achieved. B1 would represent
the next drug tested in this assay. To each well with the exception of wells C6 and D6, 100µL
of T. brucei 105 cellsmL were added, so that the final parasite concentration in each well was 10
4
cells
ml . The positive controls contained only media with 0.5 % DMSO and T. brucei, there as
the negative controls constituted of media (0.5 % DMSO) alone. The cells were incubated for
24 h, at 37 ◦C and 5 % CO2, before 100µL AlamarBlue (11.11 mg resazurin in 100 mL PBS)
were added. The colour reaction was allowed to proceed for another 48 h and the plates were
read at 570 nm with 630 nm as the reference wavelength. MIC values were obtained after vi-
sual inspection of the wells after 72 h of incubation. In order to keep the DMSO concentration
throughout the assay constant, the media was prepared with a concentration of 0.5 % DMSO
(110.6µL DMSO in 20 mL media). Melarsoprol was used as positive control for T. brucei.
The toxicity assay with HL-60 cells was performed analogues to the T. brucei activity assay.
The final cell density was adjusted to 105 cellsmL and all other steps were as described above.
Alternatively, the HL-60 toxicity assay was performed in a 96 well plate (Figure 79). Here,
the inhibitors were arranged in the columns 1-12. Each inhibitor was tested in duplicate on
each plate (inhibitor 1: column 1+2). The rows represent the tested concentrations. The
highest concentration was 100µM (row A). This concentration was diluted 1:1 with media in
each subsequently row, till the lowest concentration of 0.78125µM was reached. H9 and
H10 represented the positive control with T. brucei in media only, there as H11 and H12
represented the negative controls with only media. In detail, each well in row A was loaded with
198µL media, followed by 2µL of inhibitor (20 mM in DMSO) to give a starting concentration of
200µM. Rows B-H were charged with 100µL of media. 100µL of row A were taken from each
well and mixed with 100µL of media from the well below (red arrows, Figure 79). This was
358
9 Methods
Figure 78: Pipette scheme for AlamarBlue assay in 24 well plate
repeated for all the wells and the last 100µL were discarded. To each well, except the negative
control, 100µL of 2·105 cellsmL HL60 cells were added. The negative control, was supplemented
with 100µL of media. While in the 24 well plate assay the DMSO concentration was constant,
here the DMSO concentration decreased from row to row. However, both methods did not have
any effect on parasitic or mammalian cell growth. After 44 h, 20µL AlamarBlue (11.11 mg
in 100 mL PBS) was added and incubation was continued for another 4 h. The emission at
585 nm (excitation wavelength 570 nm) was read and the cell viability was estimated.
The cell densities for both the 24 and 96 well plate assay were estimated by counting of a
representative culture sample in a Neubauer counting chamber. In detail, each side of the
neubauer counting chamber was filled with 10µL of T. brucei culture solution prior to mixing.
All 20 middle squares were counted under a light microscope and averaged for both side of
the counting chamber. The cell density was calculated according to the volume of the counting
chamber (2). HL60-cells were visualised with tryphan blue solution prior to counting. 20µL
of HL60-cell culture were added to 20µL of tryphan blue. The cells were counting similarly to
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Figure 79: Pipette scheme for AlamarBlue/MTT assay in 96 well plate
T. brucei, but the individual counts were not average, because of the 1:1 dilution in the initial
preparation step.
viable cell count[
cells
mL
] =
Number of living cells counted
Number of counted squares ·2 (from 1:1 dilution) · 10
4 (2)
For the 24 well plate assay, the density of the cells was adjusted by dilution of the T. brucei
or HL60 cell culture. In the case of the 96 well assay format, the cells were concentrated
by centrifugation (T. brucei 3000 rpm for 5 min; HL60 1000 rpm for 5-10 min). The volume of
media to resuspend the cells was estimated by calculating the dilution factor from the first
count (3).
Dilution factor =
initial cell count
2 · 105 (3)
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MTT activity assay for T. cruzi and L. chagasi
Inhibitors were dissolved in DMSO, diluted in culture medium and incubated with parasites
at different concentrations in order to determine its GI50. The solvent concentration did not
exceed 0.5 % to avoid damage of parasites. The GI50 of different compounds was determined
using promastigotes of L. infantum, applied to 1x106 cellswell for 48 hours (in BOD incubator at
24 ◦C) in 96 well plates. After an incubation period of of 24 h, the viability of the promastigotes
was verified by mitochondrial oxidative activity using th colorimetric viability dye MTT (3 - (4,5
- dimethiltiazol-2-yl)-bromide 2,5-di-fenoltetrazolio). Therefore, 20µl of MTT were added and
the cells were incubated for 4 h, followed by the addition of 80µL of sodium dodecyl sulphate
(SDS). After 24 or 48 hours, the supernatant was read at 550nm on a plate reader (Multiskan
reader 30). The drug amphotericin B was used as the assay positive control. Trypomastigotes,
taken on the first day of culture LLC-MK2 cells were applied at a concentration of 1x106 cellswell
in 96-well plates containing the various compounds in RPMI-1640 medium supplemented with
2 % fetal bovine serum. The plates were incubated at 37 ◦C and 5 % CO2 for 24 hours and vi-
ability of trypomastigotes was determined by the MTT as previously described for Leishmania.
The drug benznidazole was used as the assay positive control.
Amastigote assay for L. infantum
Macrophages were collected from the peritoneal cavity of BALB/c mice by washing with RPMI-
1640 medium supplemented with 10 % FCS and were incubated at 37 ◦C at 5 % CO2. Macro-
phages were seeded to 4x105 cellsmL in 16-well Nunc plates and were incubated at 37¡C for
24 hours. Amastigotes of L. infantum were extracted from the spleen of an infected golden
hamster and were separated by differential centrifugation. [377] Amastigotes were added to the
macrophages in a ratio of 10:1 (amastigotes/macrophage), and incubated with inhibitors at
37¡C and 5 % CO2 for 120 h. Following, staining of the slides with Giemsa and microscopi-
cally inspection. The EC50 was determined by counting 200 macrophages/well, evaluating the
number of infected macrophages, using as positive control (100 % infected) and macrophages
treated with glucantime as negative control (0 % infected).
9.23 Metabolic labelling of GPI-anchor proteins with myristate
analogues
T. brucei was pre-incubated with various inhibitors over a course of 24 h. The concentrations of
the inhibitors were chosen based on the minimum inhibitory concentration (MIC). The parasites
for the labelling experiment should be cultured at a concentration of inhibitor which inhibits
growth but does not show any toxic effects. To determine the effective doses, T. brucei was
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Table 75: P: parasitaemia count; %-P: percent parasitaemia; AB-%-P: Alamar Blue; seeding
concentration of T. brucei : 5·105 cells/mL
# c [µM] P ·105 cells/mL %-P AB-%-P
40x
50.0 17.5 56 74
25.0 31.5 100 93
40c
50.0 27.5 93 72
25.0 29.5 100 98
14v
50.0 11.0 40 36
25.0 18.5 67 41
14a
5.0 25.0 63 83
0.5 40.0 100 100
Table 76: P: parasitaemia count; Plabel : cell density for labelling experiment with YNC12; seed-
ing concentration of T. brucei : 1·106 cells/mL
# c [µM] P24 h Plabel
105 cells/mL 105 cells/mL
40x 75.0 9.35 37.4
40c 100 0.50 excluded
14v 50 8.30 37.4
14a 7.5 31.7 37.4
incubated at concentrations below the MICs of inhibitors over a time course of 24 h (Table 75).
Following this initial time course experiment T. brucei was incubated at the estimated effective
dose over a course of 24 h. After the incubation period the parasites were counted and the cell
density adapted to the lowest growth density after 24 h (Table 76). The effective doses for 14v
and 40c were too high and therefore showed increased toxicity against T. brucei. However
there were sufficient amounts of parasites to continue with the labelling with YnC12. YnC12
and the corresponding inhibitor were added to T. brucei at a final concentration of 100µM for
an incubation period of 4 h. After 4 h, the cells were lysed in ice-cold RIPA buffer (50 mM Tris
pH 7.4, 1 % (v/v) NP-40, 1 % (w/v) sodium deoxycholate, 150 mM NaCl, 0.5 % (w/v) SDS and
1 x EDTA-free Complete protease inhibitor cocktail (Roche)), sonicated, then centrifuged at
15,000 g for 30 minutes at 4¡C. [378] A total of 25µg protein from each sample were diluted to
1 mg/mL with lysis buffer. Then 4 volumes of ice-cold acetone (stored at -20) were added,
vortexed and left at -20 ¡C for 1 hour. Pelleted by centrifugation at 15,000 x g for 10 mins and
acetone was removed and the pellet was air-dried. The pellet was resuspended in 25µL 2 %
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P: parasitaemia count; seeding concentration of HL60 cells: 2.5·105 cells/mL
# c [µM] P24 h
105 cells/mL
40x 75.0 4.1
40c 100 2.4
14a 7.5 4.4
14v 50 4.5
SDS in PBS to give a 1 mgmL solution. For the click chemistry reaction, premix the click reagents
before use. Therefore 0.25µL 38 reagent (100µL final concentration, 10 mM stock in DMSO),
0.5µL CuSO4 (1 mM final concentration, 50 mM stock in water), 0.5µL TCEP (1 mM final
concentration, 50 mM stock in water), 0.25µL TBTA (100µL final concentration, 10 mM stock
in DMSO). The reagents were vortexes between each addition and after addition of the TCEP
solution, 2 min incubation were performed prior to addition of the TBTA solution. Add 1.5µL
premix solution to each protein (25µg protein) sample and shake for 1 h at rt. To stop the
reaction, 5µL of 100 mM EDTA stock (in water) were added to each sample, giving a 10 mM
final concentration. 2xSDS Page sample loading buffer was added (10µL) and the mixture
was vortexted. 10µg crude protein were loaded on a SDS gel and run at 80 V. The gel was
fixed with 50 % aqueous methanol solution (10 % AcOH, 40 % MeOH; this helps clean up the
gel and fixes it) for 10 min to 1 h and imaged using TAMRA-settings. Next the gel was stained
with Coomassie to confirm equal loading with protein sample.
The labelling with YnC15 was carried out at a final concentration of 100µM for 4 h. The
proteins were labelled with TB-Az as described for YnC12. The crude proteins were subjected
to a SDS gel.The overall efficiency of the labelling with YNC15 was lower than for YNC12.
GPI-Labelling with myristate analogue YNC12 HL-60
The GPI-anchored VSG proteins in HL-60 cells were labelled analogues to T. brucei. The
inhibitors 40x, 40c, 14a and 14v were incubated at the same concentrations as used for the
T. brucei settings (??). Compound 40c did show some toxicity in HL60 cells, while all the
other compounds did not have any influence on HL60 cell growth. In contrast to the previous
protocol, the cell density was not adjusted prior addition of YnC12. YnC12 was added at a
final concentration of 100µM. After a further 4 h, the cells were lysed and the proteins purified.
The proteins were subjected to TB-Az (38) in the following Click-chemistry reaction. According
to there cell density after 24 h equal amounts of 10µg protein sample was loaded onto a SDS
gel.
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P: parasitaemia count; Plabel ; seeding concentration of T. brucei : 1·106 cells/mL
# c [µM] P24 h Pstarvation
105 cells/mL 105 cells/mL
40x 75.0 10.6 20.3
40c 50 20.4 20.3
14a 7.5 36.2 20.3
14v 25 4.05 20.3
9.24 Transferrin uptake after iron starvation
Trypanosomes (5·105 cellsml ) were incubated with 50µM 100a, 25µM Deferoxamine or DMSO
in Baltz medium supplemented with 16.7 % heat-inactivated FBS. After 24 h incubation, try-
panosomes were harvested and washed three times with Baltz medium supplemented with
2 % BSA. The cells were incubated with 50 µgml fluorescein-labelled transferrin in Baltz medium
with 2 % BSA and 100µM benzyloxycarbonyl-phenylalanyl-arginyl-diazomethyl ketone (Z-FA-
DMK) for 2 h. After washing twice with PBS/1 % glucose, cells were fixed with 2 % formalde-
hyde/0.05 % glutaraldehyde, and analysed by flow cytometry using a DB Accuri C6 flow cy-
tometer
9.25 Flow cytometry
In order to study the effect on FITC-conjugated transferrin of compounds 14v, 14a, 40x and
40c, T. brucei was pre incubated for 24 h in the presence of the inhibitors (??). [379] After 24 h,
the parasites were starved on transferrin for 2 h, before the FITC-conjugated transferrin was
added. Pre-incubation with the inhibitor 14a resulted only in a minor change on the mean
fluorescent intensity. The fluorescence microscopy pictures show that there is still fluorescent
signal for the FITC conjugated transferrin (Figure Figure 41).
T. brucei (1x106 cellsmL ) were subjected to FITC-labelled transferrin in Baltz-Media containing 2 %
BSA and 100µM benzyloxycarbonyl-phenylalanyl-arginyl-diazomethyl ketone (Z-FA-DMK). Af-
ter 2 h of incubation, the parasites were washed two times with PBS supplemented with 1 %
glucose. Lastly, the cells were fixed with with 2 % formaldehyde/0.05 % glutaraldehyde in PBS.
The cells were analysed by flow cytometry using a BD Accuri C6 flow cytometer. The exci-
tation wavelength was set to 488 nm (Filter 530±30 nm). The gates were set to exclude cell
fragments and debris from the analysis, if possible 50.000 events were counted.
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9.26 Fluorescence microscopy
FITC-labelled cells were applied to poly-L-lysine-coated microscope slides, and treated with
0.0001 % 4,6-diamidino-2-phenylindole (DAPI) in PBS. The slides were washed 6 times with
PBS and imaged with a Zeiss Axioplan 2 fluorescence microscope using a Plan-Apochromat
100x/1.4 oil objective. [379]
9.27 Photo-labelling of T. brucei proteins
Lysis of parasites: 1 % Triton X-100 sodiumphosphate pH 8, 0.1 % DSD, 1 % NP40, 50 mM
Tris pH 7.4, 150 mM NaCl and 1xEDTA-free protease inh
365
Abbreviations
Abbreviations
L. infantum Leishmania infantum spp.
T. brucei Trypanosoma brucei spp..
T. cruzi Trypanosoma cruzi spp..
AD Alzheimer’s disease.
ADME absorption, distribution, metabolism, and excretion.
CHCl3 chloroform.
CNS central nervous system.
CQ chloroquine.
DAPI 4’,6-diamidino-2-phenylindole.
DCC N’,N’-dicyclohexylcarbodiimide.
DCU dicyclohexylurea.
DEAD di-tert-butylazodicarboxylate.
DIPEA N,N-Diisopropylethylamine.
DMAP 4-dimethylaminopyridine.
DMF dimethylformamide.
DMSO dimethyl sulfoxide.
Dol-P dolicholphosphate.
DPMS dolichol phosphate mannnose synthase.
DTNB 5,5’-dithiobis-(2-nitrobenzoic acid).
DTT dithiothreitol.
ESI electron spray ionisation.
EtOAc ethyl acetate.
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Abbreviations
EtOH ethanol.
FBS foetal bovine serum.
FITC fluorescein isothiocyanate.
GDP guanosine diphosphate.
GI50 (growth inhibition)50.
GPI Glycosyl Phosphatidyl Innositol.
HAT Human african trypanosomiasis.
HCl hydrochloric acid.
HCV hepatitis C virus.
HOAc acetic acid.
HOMO highest occupied molecular orbital.
HPO hydroxypyridin-4-one.
HPTLC high performance thin layer chromatography.
LiAlH4 lithium aluminium hydride.
MIC minimum inhibitory concentration.
MMFF94x Merck molecular force field 94x.
MPGS mannosyl-3-phosphoglycerate synthase.
MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide.
NAD(P)H nicotinamide adenine dinucleotide phosphate.
NaH sodium hydride.
NaN3 sodium azide.
NaOAc sodium acetate.
NaOH sodium hydroxide.
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Abbreviations
NEt3 triethylamine.
NMR Nuclear magnetic resonance.
NOESY nuclear overhauser effect spectroscopy.
PBS phosphate buffered saline.
RPMI Roswell Park Memorial Institute.
rt room temperature.
SCC side scatter.
SDS sodium dodcyle sulphate.
TAMRA tetramethylrhodamine.
tBuONO tert-butyl nitrite.
TLC thin layer chromatography.
TsCl tosyl chloride.
UGM UDP-galactopyranose mutase.
UV ultraviolet.
VSG variant surface glycoprotein.
WHO world health organisation.
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Figure 80: SDS gel visualised with Tamra-Channel settings; lane 1:SB, lane 2: SD, lane 3:
SB, lane 4: DMSO, lane 5: 40x, lane 6: 14v, lane 7: 40c, lane 8: 14a, lane 9+10:
SB
Figure 81: SDS gel visualised with Coomassie stain; lane 1:SB, lane 2: SD, lane 3: SB, lane
4: DMSO, lane 5: 40x, lane 6: 14v, lane 7: 40c, lane 8: 14a, lane 9+10: SB
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Figure 82: in-gel fluorescence after 24 h incubation with inhibitors and 4 hYnC12 labelling us-
ing TAMRA settings; lane 1: SB, lane 2: SB, lane 3: SD, lane 4: SB, lane 5:
negative control (-YnC12), lane 6: positive control (DMSO), lane 7: 40x, lane 8:
14a, lane 9: 14v, lane 10: SB.
Figure 83: Coomassie stain after 24 h incubation with inhibitors and 4 hYnC12 labelling using
TAMRA settings; lane 1: SB, lane 2: SB, lane 3: SD, lane 4: SB, lane 5: negative
control (-YnC12), lane 6: positive control (DMSO), lane 7: 40x, lane 8: 14a, lane
9: 14v, lane 10: SB.
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Figure 84: in-gel fluorescence: Tamra settings; lane 1: SB, lane 2: SD, lane 3: SB, lane 4:
negative control, lane 5: DMSO, lane 6: 40x, lane 7: 14a, lane 8: 40c, lane 9: SB,
lane 10: SB.
Figure 85: Coomassie staining; lane 1: SB, lane 2: SD, lane 3: SB, lane 4: negative control,
lane 5: DMSO, lane 6: 40x, lane 7: 14a, lane 8: 40c, lane 9: SB, lane 10: SB.
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Figure 86: in-gel fluorescence: Tamra setting; lane 1: SB, lane 2: SD, lane 3: SB, lane 4:
negative control (absence of YnC15), lane 5: DMSO, lane 6: 14a, lane 7: 14v,
lane 8: 40x, lane 9: 40c, lane 10: SB.
Figure 87: Coomassie stain; lane 1: SB, lane 2: SD, lane 3: SB, lane 4: negative control
(absence of YnC15), lane 5: DMSO, lane 6: 14a, lane 7: 14v, lane 8: 40x, lane 9:
40c, lane 10: SB.
395
11 Appendices
Figure 88: HPTLC of GPI synthesis radio-label assay (Plate 1); lane 1: control; lane 2 54v;
lane 3: 54w; lane 4: 54a; lane 5: 54i; lane 6: 54h; lane 7: 54q; lane 8: 54r; lane 9:
54u; lane 10: 54s; lane 11: 54c; lane 12: 54x (failed).
Figure 89: HPTLC of GPI synthesis radio-label assay (Plate 2); lane 1: control; lane 2 54l;
lane 3: 54ab; lane 4: 54b; lane 5: 54d; lane 6: unknown; lane 7: unknown; lane 8:
unknown.
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Figure 90: HPTLC of GPI synthesis radio-label assay (Plate 3); lane 1: control; lane 2: 55r;
lane 3: 55z; lane 4: 55q; lane 5: 36c; lane 6: 36k; lane 7: 36af; lane 8: 36ad; lane
9: 36w; lane 10: 36f; lane 11: 36t; lane 12: 36y.
Figure 91: HPTLC of GPI synthesis radio-label assay (Plate 4); lane 1: 43c; lane 2: 43b; lane
3: 40v; lane 4: 40f; lane 5: 40y; lane 6: 40z; lane 7: 40g; lane 8: 40x; lane 9: 40h;
lane 10: 43a; lane 11: 40i.
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Figure 92: HPTLC of GPI synthesis radio-label assay (Plate 5); lane 1: control; lane 2: 40e;
lane 3: 40m; lane 4: 2a; lane 5: 2b; lane 6: 2c; lane 7: 2e; lane 8: 2g; lane 9: 2f.
Figure 93: HPTLC of GPI synthesis radio-label assay (Plate 6); lane 1: 2q; lane 2: 2p; lane 3:
2o; lane 4: 2r; lane 5: 2m; lane 6: 2h; lane 7: 26d; lane 8: 26c; lane 9: 2u; lane
10: 2s; lane 11: 2n.
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